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Now 30 years have passed since Francis Crick and I
discovered the double helix. We knew from the mo-
ment we first put together our two-stranded model
for the precise arrangement of the atoms in DNA
that we had found a uniquely wonderful molecule,
the knowledge of which would transform the nature
of biological research, if not of man's perception of
his own meaning within our universe. Our spring of
1953 thus was filled with the exhilaration that came
from the winning of a very big race as well as the
thrill that came from the realization that we were
the first to perceive the key secret of the gene that
gave it the power of accurate self-replication.
Soon we moved on to worrying about how the
key features of the double helix could be definitive-
ly proved correct and then how we might determine
the way in which the genetic information within it
was used to order the amino acids within polypep-
tides. Solving these problems was clearly not going
to be easy, and never did we see the need to fan-
tasize as to where DNA research might take us over
the long haul. The genetic engineering tricks of to-
day were beyond our wildest imagination, with
neither Francis nor I having the slightest addiction
to science fiction when our science itself could be
so immensely rewarding.
Now I can only feel very fortunate to have lived
during the era that already by its 20th birthday
(1973) had given us an elegant, practical way to
make recombinant DNA and through it a virtually
unlimited power to probe the remaining key
mystery of life. What has been learned about DNA
in just 30 years perhaps only has a parallel in the in-
tellectual achievements that marked the revolution
in atomic physics which began with Rutherford and
Bohr in 1912 and culminated with the building by
Fermi and Szilard of the first atomic pile in 1942.
And like with that grand era of physics, the early
days of DNA involved the participation of a small
group of highly perceptive scientists. For the most
part, they were close friends and took real pleasure
in the accomplishments of their peers even when at
times it meant that another had first achieved the
objective they had also keenly wanted.
Fortunately, there were so many good discoveries
to be made that virtually all the pioneers with DNA
did experiments of great importance, and I do not
remember the first decade of the double helix as a
period of happy winners and unlucky losers. Of
course, here I am referring only to those scientists
who, after the double helix was found, stopped
thinking about whether DNA was important, know-
ing that from 1953 on the only sensible way to at-
tack genetics was to start with the base pairs of
DNA. There was, of course, a small coterie of
malcontents who disliked the double helix from the
start. Given that bias, they had little chance for
future success, and to judge by their later bitter ob-
jections, first to the general validity of the central
dogma (DNA-RNA-protein) and then much later
to any use of recombinant DNA, they must have
known that real science was passing them by.
And while the fundamental significance of many
newly reported experiments was often debatable,
the experimental facts themselves were seldom that
controversial. To be sure, certain results were
misinterpreted long enough to reach the print of a
respectable journal, but such errors were few and
far between and through them the course of DNA
research has probably not suffered more than a
month or two delay.
Of even less consequence has been actual fabri-
cation of false data. For the most part, these
forgeries were reported as semi-anticipated exten-
sions of the conventional scientific wisdom of the
moment. For example, the recent claim that a pro-
tein kinase cascade gives rise to the cancerous
phenotype built upon the prior discovery that the
oncogenic protein coded by the Rous sarcoma virus
was a protein kinase. But almost from the moment
the cascade was proposed, an undercurrent of
rumors arose that no graduate student, much less
mature scientist, had ever accomplished that much
science in such a short time. And when the trou-
bling fact became known that key experiments
could not be repeated in other labs, the burden of
proof quickly passed back to the lab making the sen-
sational claims. To be sure, the protein kinase
cascade dominated the conversations of retro-
virologists for several months, but the only real sci-
entist seriously harmed was the supervisor of the
now revealed to be long-term compulsive faker.
Massive fakeries of the protein kinase cascade
variety have been very rare occurrences in the
world of molecular biology. The most sensational of
these soon generated skepticism from labs doing
similar research which desired independent confir-
mation before accepting the claims at face value. In
each such case the putative facts were too important
to be ignored, and of necessity other labs began to
repeat the experiments. On the other hand, when
only marginally interesting claims are made, no one
is likely to repeat them. Scientifically irrelevant
fakes, however, could be more common occur-
rences, since advancement in many academic in-
stitutions depends upon the number of published
papers. Unfortunately, libraries, like our own, all
too often subscribe to many effectively unread
periodicals which serve as sitting ducks for inven-
tors of irrelevant data. By so subscribing, we keep in
existence journals whose only honest justification is
their availability for the occasional important article
that has been mistakenly rejected by the major jour-
nals of the moment.
It has thus made good sense to accept as correct
the facts that we read in journals like Nature, Cell,
or the Journal of Molecular Biology. To be sure, we
may sometimes reject the way some of these facts
are interpreted, and it is often by such questioning
that we move science forward. But we should not
make too much of a point about where we have oc-
casionally gone wrong. The past 30 years of DNA
research have not been dominated by frequent
reversals of scientific direction. Instead, it has been
an era of decisive experiments that rightfully have
virtual immediate acceptance.
During the early days of DNA research there was
no way to guarantee that practical benefits for
mankind would emerge, and there were indeed
well-known scientists, like the celebrated Australian
immunologist Macfarlane Burnet, who wrote with
almost passionate conviction as late as 1962 that the
worlds of molecular genetics and medicine would
never meaningfully come together. In his view, we
had no more to offer society than a group of high-
powered philosophers worried about the meaning
of life or the nature of free will. Then I might also
have predicted that our one day knowing the com-
plete sequence of the DNA of a human chromo-
some was an even less likely event than my witness-
ing a genie arise out of a bottle in the Arabian
Desert. Fortunately, I had the good sense never to
put in print what I thought the future would bring.
Nowadays we hear much more often the opposite
complaint that because of the recombinant DNA
procedures that promise to bring about great ad-
vances in medicine, agriculture, and possibly the
chemical industry itself, we shall be forced to sur-
render our highly valued academic freedom for the
nasty bustle of the competitive market place. To
those like me brought up in a depression era when a
scientist choosing a career in biology could look for-
ward to a life of almost monkish austerity, it is still a
shock to see friends driving cars that in the past
were totally off limits to any academic, save those
few either born rich or fortunate enough to be a
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highly paid consultant to the chemical or securities
industries.
We must take care, however, not to be dominated
by petty jealousy of our new breed of molecular
biologist-entrepreneur. I am not among those who
believe that poverty enriches the soul and re-
member well how my American fellowship in a still
impoverished, just post-war Europe let me virtually
commute between the best labs in England and on
the continent. My scientific career was thus greatly
advanced. At worst I anticipate that my now much
more affluent peers will at least share the costs of a
joint dinner and at best dream that they will soon
sense the virtues of enlightened philanthropy and
see the Cold Spring Harbor Laboratory which
helped shape their scientific careers as the obvious
institution for buildings that bear their names.
I also do not believe we should be that much con-
cerned about the fact that a large number of senior
academic molecular biologists will be spending a
noticeable fraction of their time consulting with in-
dustry. Such arrangements have for decades been
the norm with chemists, and I have never heard the
argument convincingly made that chemistry would
be a more exciting subject if it could be divorced
from industry. That chemistry today lacks much of
the excitement that it had 30 years ago more likely
reflects the fact that important new discoveries in
chemistry are much harder now to make. As a con-
sequence, many of the better graduate students who
in the past would have gone into chemistry now opt
for careers in molecular biology-biochemistry.
We should, moreover, take note of the fact that
much, if not the majority, of high-quality science
teaching is done by younger scientists not yet
known to the outside world. It is this younger group
who, furthermore, does much of the incisive re-
search that outsiders normally credit to the senior
faculty. And those individuals who do annoy us by
their excessive outside advising are seldom those
still capable of either inspiring or teaching well our
better youth. It is not that academics are absent for a
day or even a week of talks with industry that really
bothers their peers. Instead, it is usually the fact
that this absence comes on top of their inability
(disinclination?) to teach well, a trait long notice-
able before they began to consult and which
shunted them away from maintrack teaching
assignments.
Of course, there are other scientists who both
teach and consult well, and we are better off for
their existence. There may, in fact, be little correla-
tion between being a consultant and the quality of
teaching. So, I would be surprised if the quality of
academic life were to rise perceptibly if we were to
stop all consulting arrangements with industry.
Thus, given the increasingly eroding scientific
salaries, even within our major universities, it may
be a blessing to all concerned that consulting ar-
rangements make possible family incomes for
selected senior faculty that actually relate to the
financial requirements of full-time intellectuals
colon and lung cancer cell lines. Why such large
genes are used to code for such relatively small pro-
teins is most unclear. Whether still other RNA genes
exist is not yet known, nor do we have any idea as
to the differences in function between the H.RAS,
N.RAS, and K.RAS genes. It is tempting to follow
Jim Feramisco's hunch that they may be involved in
the modulation of signals initiated when specific
receptor proteins recognize their respective
agonists. Until, however, real biochemistry is done
with the RAS proteins, we shall have no way to test
such speculations.
The Cassette Model Moves to
the Level of Enzymology
Over the past several years our Yeast Group has
provided crucial molecular evidence for the con-
cept that the silent mating-type cassettes at the
storage sites HML and HMR donate copies of
themselves that move to and replace functional
cassettes at the MAT site. But how this happens at
the molecular level was until very recently a total
mystery. Then, Jeff Strathern, working with other
members of the Yeast Group, observed a unique
double-stranded cut within the MAT DNA in strains
frequently switching mating type (homothallic
strains) but no such breaks in DNA from non-
switching strains. This result suggested the presence
within switching cells of a specific endonuclease
that recognizes a sequence found at the MAT locus.
Such an enzyme was looked for and found by
Richard Kostriken working with Fred Heffron in
Demerec Lab. They call their enzyme YZ endo. The
finding that double-stranded cuts initiate cassette
movements closely followed upon new data from
John Szostak's lab at the Sidney Farber Center
which indicated ordinary genetic recombination in
yeast also largely proceeds with double-stranded
cuts. When we better understand both processes at
the molecular level, we may well find that they
share many common steps.
The First of Our Exxon Scientists Arrives
The agreement we concluded in May of 1982 with
Exxon specified that up to six Exxon scientists will
work here at Cold Spring Harbor over the next
several years doing research of joint interest to
ourselves and Exxon. Early in the fall, Susan Bonitz,
the first of those appointments, joined the Yeast
Group. Prior to her arrival here, Susan was for a year
with Genentech, after finishing her Ph.D. at Colum-
bia University on the structure of the yeast mitchon-
drial genome. Within Delbr{ick Lab Susan will ini-
tially work on RNA splicing mechanisms in yeast
mitochondria.
Key to our being able to provide adequate research
facilities for the Exxon scientists is the construction
of a badly needed new addition to Demerec Lab.
Work on this addition began in the fall of 1982,
with a target finishing date of July 1, 1983. This
6000 sq. ft. addition will let us initiate major new ef-
forts in protein chemistry, in vitro mutagenesis, and
genetic recombination at the DNA level. The equip-
ment for these labs, as well as the funds needed for
the addition, are being funded largely through our
agreement with Exxon. Soon our scientists will have
the opportunity to work with equipment commen-
surate with the doing of the most sophisticated
forms of recombinant DNA research.
Dedication of the Reginald G. Harris
Research Building
On May 27, 1982 we dedicated the Reginald G.
Harris Building, a most attractive new facility that at
long last gives us adequate holding space for the
mice, rats, rabbits, and guinea pigs that we utilize in
our cancer research as well as facilities for the
breeding of those unique mouse strains used by Lee
Silver in his studies on the T locus. The opening
ceremony was held on the lawn below Davenport
House before a large audience which included the
Demerec Laboratory extension under construction
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unable to moonlight on weekends say as taxi drivers
or security guards.
So, instead of focusing on the imputed evil
tradeoffs of the salary supplements given to in-
dividual scientists by industry, our academic institu-
tions might best see how they themselves might be
recipients of equally invaluable industrial largesse.
Just as with consulting, we should not expect a one-
way flow of benefits; it only makes sense for in-
dustry to ask how it can direct help to those who
might in return benefit them. Here molecular
biology occupies a privileged position since this is
still a discipline almost totally lacking at the high
levels, if not the middle levels, of management.
While there now exist many chemists in the top
ranks of industry, there are virtually no molecular
biologists so sited. High-level advice as to how to
properly utilize their techniques has to come from
the outside. And instituional help per se, as op-
posed to assistance from individuals, may often be
required to let the benefit of the recombinant
DNA-hybridoma revolutions be rapidly assimilated
by our industries so that they can remain competi-
tive with the outside world.
The arrangement we concluded a year ago with
Exxon may, in fact, serve as a model for such pro-
grams of mutual help. We saw the imperative to
radically expand our facilities for protein chemistry
and nucleic acid chemistry at the micro level, both
to let us probe even deeper the nature of the genes
that cause cancer, as well as to begin to explore the
genes that control the development of nervous
systems. But we saw no immediate way to obtain
the funds to add the new space to Demerec, our
laboratory best suited for such work. At the same
time, Exxon, seeing the long-term need to have a
first-rate research group in biotechnology, needed
help in moving into a field with which they had no
previous practical experience. We thus agreed on a
joint program of research in which we help Exxon
recruit a number of promising young molecular
biologists who will first come to CSH and use our
Highlights of the Year
Cancer Gene Research Becomes
Even More Exciting
Last year I reported successes in the cloning of a
DNA segment, isolated from a human bladder
cancer cell line, which has the capacity to convert
the mouse cell line NIH3T3 into its transformed
cancerous equivalent. This research done in Dem-
erec Laboratory by Michael Wig ler and his associ-
ates was soon followed by similar feats at MIT and
NIH. Each of these labs isolated the same 5.6-kb
gene called Hu-H.RAS. Hu-H.RAS is closely homol-
ogous to the oncogene of the Harvey sarcoma virus
that Ed Scolnick and his group at NCI have shown to
be a GTP binding protein located at the cytoplasmic
surface of the plasma membrane. Subsequent DNA
sequence analysis revealed that Hu-H.RAS codes
new facilities for recombinant DNA research and
then move on to the modern, new research labs that
soon will be completed for Exxon in Clinton, New
Jersey.
While here, the Exxon scientists will also be
members of our scientific staff and will work on
problems of joint interest to both Exxon and this
Laboratory. No product-oriented research will be
carried on here, the main emphasis being the
development of recombinant DNA procedures that
may someday hasten the development of commer-
cially useful genetically engineered enzymes. We in
no way see our academic freedom or potential for
excellence threatened; just the opposite, we now
have the funds not only to add a major new addition
to Demerec Lab, but also to obtain the equipment
and additional staff and postdocs that will let recom-
binant DNA research proceed here at the rapid pace
that necessarily characterizes the best of the recom-
binant DNA world.
At Cold Spring Harbor we can thus anticipate
with great pleasure the next decade of DNA re-
search. It would be most surprising, indeed, if it
does not also dazzle us with the unexpected and
produce much well-deserved satisfaction for those
who combine optimism with the capacity for sus-
tained intelligent hard work. I am, of course, assum-
ing that the federal government will continue to pro-
vide the main support for our research as well as
that of other leading institutions. Here I believe that
there is no way that our nation can continue to help
lead the world without the exploiting of science to
the fullest extent. And given that of all the fields of
science, molecular biology now shows the greatest
promise of development for the public good, I
believe we would be virtually silly to worry exces-
sively as to whether our scientific endeavors might
suddenly be downgraded to the back burner. We
are thus in the position of a front runner who has the
capacity of staying ahead. This is an opportunity we
must not squander.
for a 189-amino acid protein that differs from its
homolog found in normal cells by only a single
amino acid replacement, glycine to valine at posi-
tion 12. Somehow this single change converts a nor-
mal protein into one that makes its respective cell
cancerous. How this happens is still a total mystery
since no one has any idea of the function of Hu-
H. RAS.
Recently, two additional members of the human
RAS gene family have been cloned by the Wigler
group. Each codes for a protein very similar to Hu-
H.RAS. One, called Hu-N.RAS, isolated from a
human neuroblastoma cell line, is 13.5-kb in length
and contains much longer introns than found in the
Hu-H.RAS. Even larger is the 45-kb DNA segment
that codes for the third RAS gene, Hu-K.RAS, whose
cancerous equivalents are found in several human
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attendees of our annual RNA Tumor Virus Meeting.
Speaking first was Harry Eagle of the Albert Einstein
College of Medicine, who in the past has served us
so well as Chairman of our Board of Trustees. Giv-
ing the main speech was Vincent De Vita, Director
of the National Cancer Institute, who related the
problems he faced in attempting to fund increasing
numbers of first-class research proposals while fac-
ing a static level of federal support for the National
Cancer Institute.
After solving several teething problems with the
air-conditioning and heating systems, the Harris
Building works very well indeed. Over the past
month we have been modifying still unoccupied
first-floor rooms into a laboratory for mouse em-
bryology that shall first be used for a course on the
Molecular Embryology of the Mouse to be held in
July of 1983. Afterward, we shall use these new lab
facilities for introducing new forms of recombinant
DNA vectors into early mouse embryos, with the
expectation that many of their respective genes will
be functionally integrated into the chromosomes of
the host embryos. Thus, through possession of the
Harris facility, we cannot only extend our efforts
toward understanding cancer, but perhaps also play
a leading role in the development of procedures for
the genetic engineering of the mouse.
A First-class Symposium on
The Structures of DNA"
The realization in 1979 that certain segments of
DNA might twist to the left as well as to the right
brought increased attention to the exact molecular
conformations of DNA and to the physical and
chemical techniques used in their study. The time
had thus arrived for a fruitful interaction between
those physicists and chemists concerned with the
precise arrangements of atoms within DNA and
those scientists concerned with its replication and
transcription. So we decided to hold our 47th Sym-
posium on "The Structures of DNA." The opening
address was given by Alex Rich, the discoverer of
left-handed DNA, and Aaron Klug provided a most
perceptive summary of the major advances reported
during the seven information-packed days of the
Symposium. By the end of the meeting we realized
that our expectations for much intellectual en-
lightenment were more than exceeded, and many
participants told us that the 1982 Symposium was
the best meeting they had ever attended. Few con-
ferences now extend as long as the Symposium, and
the fact that so many participants attended all the
sessions reaffirms our belief that the Symposium
continues to be a major asset toward the advance-
ment of modern biology.
The Past Summer Brings Almost 3000
Scientists to Cold Spring Harbor
In no past year have so many persons come to Cold
Spring Harbor for our various meetings and courses.
Our spring set of meetings was dominated by
recombinant DNA, starting with the first meeting
ever devoted to the increasingly important subject
of Heat Shock. Then successive weeks witnessed
meetings on In Vitro Mutagenesis, RNA Processing,
and RNA Tumor Viruses. Our nine-week period of
summer courses commenced as soon as our Sym-
posium ended. Then our late-summer set of
meetings started up. These were dominated by vari-
ous sets of viruses-SV40, Polyoma and Adeno-
viruses, Phage, Herpes, Papilloma, and Poxvirus-
into which was interposed our Cell Proliferation
meeting on Teratocarcinoma Stem Cells.
Our six courses on Molecular Genetics and Cells,
held in James and Delbruck Labs, all represented
continuation of courses given in previous years.
Most of our courses in Neurobiology also continued
successfully. One brand-new offering, a combined
workshop/course on Molecular Neurobiology, was
Oh 11l)1Wil
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initiated through funds provided by the Sloan Foun-
dation. It was organized by Ron McKay of our staff
and Jeremy Brockes, then still at Caltech. The ex-
citement that had emerged by its conclusion led to
the obvious suggestion that we focus the 1983 Sym-
posium on this subject.
Financing such a large number of summer
courses over the future now seems problematical.
We find that even when we obtain firm federal
study section support, administrative decisions fre-
quently greatly reduce the monies we finally
receive. Now it appears that substantial help from
private foundations will be essential if we are to
help provide a continuing flow of highly trained in-
dividuals into science. Already I must express our
great indebtedness to the Klingenstein Fund for their
positive response to my frantic last-minute cries for
help when the National Institute of Mental Health
did not provide the support we had expected.
LIBA Initiates a Fund Drive for
a New Auditorium
In the fall, LIBA committed itself to a fund drive to
raise $500,000 toward the estimated $2,000,000
cost of a 360-seat auditorium building to be sited
across Bungtown Road from our Bush Lecture Hall.
Toward this end, Edward Pulling assembled and
distributed to all LIBA members a most appealing
brochure outlining the plans for the building as well
as the ways in which it will be used. Not only has
the brochure been very effective in mobilizing LIBA
members who already have pledged over 60% of
their goal, but it also led one of our neighbors who
wishes now to remain anonymous to pledge a fur-
ther million-dollar gift toward the construction
costs. We have thus commenced working drawings
for the auditorium, with the goal of starting con-
struction by the late fall of 1983 so that it will be
ready for dedication at the start of the 50th Cold
Spring Harbor Symposium in 1985.
In looking forward to what promises to be a
marvelous new addition to our facilities, we can
again take comfort in the fact that our LIBA
neighbors remain such effective and devoted cham-
pions of our efforts. Here we should note that Ed-
ward Pulling, the Chairman of LIBA, has now pro-
vided extraordinarily effective leadership for 15
straight years.
Continued Upgrading of Our Physical Plants
This past year witnessed replacement of totally in-
adequate heating and air-conditioning equipment
within Demerec Lab by a series of heat pumps that
now perform both heating and cooling functions.
Not only was the original equipment out of date,
but it represented planning for labs containing
many fewer scientists and very few heat-producing
machines. Equally important was the complete re-
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Mouse House lab
building of the Demerec labs now occupied by
Richard Roberts and Dave Kurtz, as well as partial
reworking of Michael Wigler's lab. In McClintock
lab, the rooms renovated 12 years ago for neuro-
physiological experiments have been greatly up-
graded to permit hybridoma and recombinant DNA
research. In addition, a dark room and a new micro-
scopy room have been created on the second floor.
The former sheep shed, a storage space for Sym-
posium volumes when I became director 15 years
ago and more recently our Mouse House, has been
completely renovated again into most attractive of-
fice and mini-lab space for neurobiology. It pro-
vides Ron McKay and Susan Hockfield a semi-
civilized retreat when the summer courses force
them to vacate their labs in McClintock and Jones
Labs.
Urey Cottage, formerly a tiny summer house con-
structed by unemployed carpenters during the
depression and since added onto several times in
the process of becoming a year-round residence,
was effectively gutted in the fall as the first step in its
transformation into the new home for our publica-
tions department now housed in Nichols. During
the winter a wing was built facing the hill on its west
side, a shed extension added to the south, and a
porch constructed on the east side that overlooks
the harbor. The final renovations and refurnishings
should be completed by late summer, thereby giv-
ing our crowded Nichols administration the addi-
tional space they so badly need.
A dignified new look was also given to the main
reading room of the Library building through the
placement of greatly expanded shelves for our
periodicals and serials collections.
Firm Decisions Made to Construct a North
Addition to James Lab and a Squash Court-
Exercise Facility near the Tennis Court
Our tentative plans last year for a major new addi-
tion to James Lab have now solidified into firm
working drawings approved by the National Cancer
Institute which shall provide partial funding. When
Urey Cottage under renovation
its new north wing is completed, James Lab will at
last have a year-round hybridoma facility as well as
sufficient lab space so that each year's commence-
ment of summer courses does not automatically set
back the research of the year-round James staff.
Happily, our architects correctly estimated what the
addition would cost, and the low bid of $1, 297,000
was within our committed resources. A contract has
already been signed which shall allow construction
to start in late June of this year (1983).
Our trustees also approved the plans for a squash
court that will be partially built into the hill leading
up to the tennis court. Originally conceived solely
as a squash court, it is now planned to contain also
a separate room for an exercise machine as well as
appropriate shower and rest room facilities. Work-
ing drawings are now being made, and we an-
ticipate using an outside contractor so as not to fur-
ther overburden our buildings and grounds person-
nel. Construction is planned to begin by early fall,
so that, with luck, the much-needed addition will be
available for use by lab personnel in late winter.
Planning Commences for Expanded
Facilities for Plant Molecular Biology
Already two scientists (Russell Malmberg and
Stephen Dellaporta) in DelbrUck Lab are working
full-time with plants, and both Jim Hicks and Jeff
Strathern are devoting smaller parts of their efforts to
research with plants. Concurrently, we have ini-
tiated a very successful summer course on Plant
Molecular Biology that will be given for the third
time in 1983. Unfortunately, we see no way to ex-
pand Delbruck into a building large enough to per-
mit the Yeast Group to continue flourishing as well
as to establish an equally effective research team
focused on plants and their potential for genetic en-
gineering.
For the moment, we have a small, satellite, plant
molecular biology lab located at Uplands Farm, a
former dairy farm that belonged to Mrs. George
Nichols and which was willed to the Nature Con-
servancy upon her death in late 1981. We are using
for plant research her former greenhouses, as well
as a field where Barbara McClintock and Stephen
Dellaporta can grow corn during the coming sum-
mer (1983). We have also applied for funds from
the National Science Foundation to convert the
Uplands Farm garage, in which we now store and
ship our books, into a lab for six to eight scientists.
Hopefully, we shall start by early January the
renovations needed to transform this solidly built
brick building into a functional lab-office facility.
We realize that these plans are very ambitious, if
not audacious, considering the currently low fund-
ing level for plant molecular biology within the
United States. There are signs, however, that our
governmental agencies are seriously considering
rapidly expanding their support for this area. In ad-
dition, the possibility exists that we might be able to
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fund much of this research through arrangements
with large corporations that see recombinant DNA
procedures as major future tools for agricultural
research.
Our Molecular Cloning Manual Has
Already Sold 18,000 Copies
Publication of "Molecular Cloning," a manual for
genetic engineering by Tom Maniatis, Edward
Fritsch, and Joe Sambrook occurred in June 1982.
Prior to its appearance we had orders for more than
5000 copies and were assured of a best seller. But
we did not in any way anticipate the broadly based
appreciation it would quickly receive and its rapid
adoption by many, many university courses. Al-
ready (late June 1983) over 18,000 copies have
been sold, almost twice the number of any previous
book published by us, and it seems likely that at
least 25,000 copies of the first edition will be pur-
chased. We have plans for a revised edition to ap-
pear in 1984, and hopefully we can maintain much
of the student market that we have captured.
This year also marked the publication of many
other fine books, including the massive 1400-page
"RNA Tumor Viruses" edited by Robin Weiss,
Natalie Teich, Harold Varmus, and John Coffin.
Because of its size it could not be priced cheaply,
but nonetheless it has already sold nearly 1500
copies. We should also note the rapid publication,
in a most-handsome form, of "Heat Shock," a
volume arising out of a meeting on this topic and
which appeared in print only 51/2 months after the
meeting. Such speedy publication owes much to a
major editing effort by Alfred Tissieres who re-
mained in Cold Spring Harbor for the month follow-
ing the May meeting. We have also been most
pleased by the strong, positive reception accorded
to "Readings in Developmental Neurobiology"
Molecular Cloning Manual
12
Nancy Ford
edited with critical comments by Paul Patterson and
Dale Purves. And we note with great satisfaction the
appearance of our 1981 Symposium volume "The
Organization of the Cytoplasm" and the ninth
volume in our Cell Proliferation series "Growth of
Cells in Hormonally Defined Media." Both sets of
books represent major editing efforts by our publi-
cations staff.
The number of volumes sold in 1983 was 37,337
compared to 16,056 in 1981. Although much of this
increase reflects the spectacular sales of the
"Molecular Cloning" manual, subtraction of its
1982 sales of 13,103 still leaves 24,234 sales, a
most substantial advance over 1981. We should
note that 1982 represents the tenth year that our
Publications Office has been headed by Nancy
Ford, who deserves much credit for the loyal, in-
telligent way she has efficiently guided our publish-
ing effort to its current state as a major supplier of
advanced books in molecular biology.
More Major Changes in Our Scientific Staff
Departing in August of 1982 after 12 years at Cold
Spring Harbor was David Zipser. David came here
from a tenured position at Columbia University to
help reestablish genetics as a major focus in our in-
tellectual life. Since then his lab has welcomed
many younger scientists whose careers first began
to flourish here at Cold Spring Harbor. Over the past
several years David's main interests have switched
to the brain and how computer modeling may help
us understand how information is processed by in-
tegrated sets of nerve cells. Through moving as a
Research Professor to a Cognitive Science Group at
the University of California, La Jolla, David will be
able to interact with other scientists of similar
interests.
Leaving for an Assistant Professorship at the
University of Alabama Medical School was Jeffrey
David Zipser
Engler who first as a Postdoc and then as a Staff In-
vestigator worked so effectively on adenovirus
DNA. Also moving to a medical school environ-
ment was Manuel Perucho who has joined the
Microbiology Department at the Stony Brook
Medical School. Manuel played a key role in the
isolation of the human bladder cancer cell gene.
We shall also miss Jim Stringer who has moved on
from a Staff Investigator position in James Lab to the
University of Cincinnati Medical School where he
will be an Assistant Professor of Microbiology.
Departing at the end of the year to help found
California Biotechnology, Inc., was John Fiddes
who as a Senior Staff Investigator in James Lab great-
ly advanced our capacity to do high-level recombi-
nant DNA research.
In the spring of 1983 Maggie So and Fred Heffron
left their positions as Senior Staff Investigators to
join the scientific staff of the Scripps Research In-
stitute in La Jolla. Likewise moving to Scripps
Research Institute was Rasika Harshey who as a Staff
Investigator associated with Ahmad Bukhari's Lab
did many imaginative experiments on phage
Leaving their Postdoctoral slots here were Bruce
Anderson to run a lab at Fairfield Hospital in
Australia, Marilyn Anderson to join a Plant Cell
Biology Group at the University of Melbourne,
Hans Engeser to return to Germany, Maria Goradia
to do research at the College of Physicians and
Surgeons of Columbia University, Margaret High-
tower to move to the Population Council Center for
Biomedical Research in New York City, Deborah
and Theodore Kwoh to join the teaching staff at the
Veterinary Microbiology Department of the Univer-
sity of Saskatchewan, Sandra Le Master to move with
her husband Jim Stringer to Cincinnati, Sam Silbers-
tein to return to his position at the National Bureau
of Standards in Washington, Joseph Sorge to join
the staff at the Scripps Research Institute in La Jolla,
and Nikos Vamvakopoulos to return to Greece.
Promoted to Staff Investigator from their Post-
doctoral positions here were Russell Malmberg,
Fumio Matsumura, Earl Ruley, and Paul Thomas.
Likewise joining our staff as Staff Investigators were
Fevzi Daldal, a Turkish citizen who after receiving
his Ph.D. in France was a postdoc at Harvard
Medical School with Dan Frankel, and Ed Harlow
who did his Ph.D. at Imperial Cancer Research
Fund with Lionel Crawford. And moving up to
Senior Staff Investigator positions were Bruce
Stillman, Jim Lin, and Ron McKay. Also newly ap-
pointed as Senior Staff Investigator was Mary-Jane
Gething, who also comes to us from the Imperial
Cancer Research Fund where she was on the scien-
tific staff after completing her Ph.D. in her native
Australia.
Three new Additions to Our Senior
Scientist Ranks
At their spring meeting our Trustees approved the
promotion of Yakov Gluzman, Amar Klar, and
Jeffrey Strathern to the rank of Senior Scientist
beginning July 1, 1982. Each position carries a roll-
ing commitment of five years of salary support, pro-
viding the closest approximation to tenure that we
can honestly offer considering our limited endow-
ment funds. So promoting them signifies our belief
that they have the capacity for continued highly
creative research.
Our Ability to Grow Intellectually
Continues to Depend Upon Our
Research Funds
This year marks the tenth anniversary of Charles S.
Robertson's major gift to us that established in 1973
the Robertson Research Fund. Now it is virtually im-
possible to conceive the healthy functioning of our
Lab without the funds that it provides to renovate
and equip our major laboratories as well as to pro-
vide much-needed fellowship support for younger
scientists. The Robertson Research Fund Fellows
during this year were Kenji Shimizu and Masao
Yamada, both from Japan, and David Beach from
England. Robertson money was also essential in
permitting Robert Franza to join Jim Garrels' group
to use its sophisticated technology for 2-D protein
gels to examine the unique features of cancer cells.
A Very Successful Year for Our
Banbury Center
When Charles S. Robertson donated his Banbury
Lane estate to us, he did so with the knowledge that
we would use it as a center for advanced teaching in
neurobiology as well as for the holding of high-level
conferences in biology. Last year, the fifth year the
Banbury Center has been in full operation, was in-
deed most successful, witnessing a wide variety of
meetings that collectively brought some 400
leading scientists to discuss problems ranging from
the feasibility for the genetic engineering of man
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and the risks we face from exposure to DNA damag-
ing agents to the nature of senile dementias like
Alzheimer's disease. In virtually every case we were
able to fund these meetings adequately, and so the
Banbury Center had nearly a balanced budget. Our
early fears that we might not be able to put on
outstanding small conferences without a virtually
hemorrhagic drain on the Laboratory's general
funds have thus happily receded, at least temporari-
ly, from our thoughts.
Succeeding Victor McElheny as Director of the
Banbury Center is Michael Shodell. After obtaining
his Ph.D. from Berkeley, Mike was for five years on
the staff at the Imperial Cancer Research Fund in
London. Upon returning to the States he combined
teaching at nearby C.W. Post College with a free-
lance career in science journalism. His strong
background in cancer research fits in nicely with
our aim to maintain the Banbury Center as a site for
small meetings on Cancer Risk Assessment. Equally
valuable is his interest in journalism, given our
desire to also use our Banbury facilities to promote
the better understanding and use of science by the
general public.
We Decide to Explain Ourselves Better
to the Outside World
As we grow larger, to a size that soon will encom-
pass more than 100 scientists and over 300
employees in total, it no longer makes sense to act
as if the outside world is not interested in us and that
no harm comes from many Long Island residents
believing that we are a small, marine biology-
oriented annex to the Cold Spring Harbor Fish
Hatchery located across 25A. Not only do we do
science that the general public would take pleasure
in knowing, we are still not very known to the major
executives of the many large companies whose
corporate headquarters are in the New York region.
We thus initiated a search for a new staff member to
function as an Information Officer as well as to com-
mence a more organized effort to raise monies for
specialized projects. The person we eventually
recruited, David Mick los, fills neatly all the qualifi-
cations we were seeking. He was trained as a bi-
ologist, spent two years teaching science in
Botswana as a member of the Peace Corps, has pro-
fessional teaching experience as a photojournalist,
and has held a position with the major Public Rela-
tions firm, Hill and Knowlton.
For his first task David has prepared a most attrac-
tive brochure on our history and purposes that is not
burdened down with the necessarily dense tech-
nical vocabulary found in the scientific sections of
this Annual Report. Now he is working closely with
Mike Shodell of our Banbury Center to initiate both
a Corporate Sponsor Program aimed at bringing us
into closer contact with companies actually engaged
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in recombinant DNA research and a Corporate Af-
filiate Program that should help major corporations
not directly involved in recombinant DNA research
appreciate the changes that biotechnology is likely
to bring to both our individual lives and the ways
our industries must function to maintain com-
petitive positions on the world-wide scene.
Our Administrative Staff Continues
to Function Well Under Trying
Physical Conditions
Nichols Building, currently the center of our ad-
ministrative activities as well as our publishing ef-
forts, will get a major internal renovation when our
Publishing Department moves up to their new, ex-
panded Urey Cottage headquarters. The inherently
dingy entrance hallway of Nichols will be opened
up and many of the offices rearranged to handle
much more efficiently our Accounting, Grants
Management, and Personnel sections. Already we
have fixed up new space for a business-oriented
computer (Basic 4) which soon will record all of our
accounting and grant management actions.
The fact that despite there being so little space
now devoted to administration we still are in con-
trol of an operating budget that will grow to 17
million dollars in 1983 reflects the loyal, intelligent
devotion to our purposes by our Comptroller Bill
Keen and Administrative Director Bill Udry. Now
newly promoted to the key role of Assistant Ad-
ministrative Director is John Maroney, who former-
ly served us so well as Purchasing Director. Ap-
pointed as our Purchasing Agent was Peter Rice.
We now miss Pat Hickey who recently resigned as
Personnel Director, and we are now engaged in a
search for his replacement. Grants Management
continues to be very well handled by Steve Kron,
ably assisted by Susan Schultz.
We Must Soon Acquire a Much Larger
Computer to Aid Our DNA Research
The ability now to sequence very long DNA seg-
ments has created the need for both a means to
store this sequence information as well as pro-
cedures for scanning such sequences for biologi-
cally important signals and for comparing given
DNA segments to other such sequences. Now we
use a modestly small DEC PDP 11/44 microcom-
puter for these tasks. Increasingly, however, we find
this computer inadequate for our needs which by
now would best be handled by the much higher-
capacity VAX computer, also a DEC product, for
which many newly developed DNA sequence
analysis programs are available. We are already ac-
tively seeking the $500,000 sum needed to pur-
chase our own VAX. When available, it will be
located in a specially designed space for computers
on the ground floor of the new auditorium building
that we plan to have ready by June 1985.
We should note that our current PDP 11/44
machine also now handles 34 data processing ter-
minals located in many offices in all our major
scientific buildings. The availability of these data
processing terminals has greatly expanded our abili-
ty to speedily turn out manuscripts and grant ap-
plications, and we have already passed the point
where we would ever consider existing without the
availability of centralized computer facilities. Here I
should mention the key role played by Rich Roberts
in bringing a workable computer to the aid of our
staff and of the great skills that our resident com-
puter expert Mike Balamuth brings to those who
need his help.
Our Buildings and Grounds Department
Performs Beyond the Call of Duty
Unlike most institutions where the Buildings and
Grounds Department largely handles routine main-
tenance and grounds upkeep, we run in a very dif-
ferent way. Before coming here, Jack Richards, our
Superintendent of Buildings and Grounds, was a
successful contractor and so has the skills needed to
let the Lab itself often supervise major lab renova-
tions as well as the construction of new buildings.
We thus have not used an outside contractor for the
south addition to Demerec, with Jack directly deal-
ing with sub-contractors of known reputation for
careful workmanship. Such procedures can save us
much needed monies as well as insuring more rapid
completion of badly needed facilities.
Likewise, most impressive has been the profes-
sional way Hans Trede and his grounds staff have
landscaped our newly completed labs as well as the
new parking lot next to the Harris Building. I note
also with great satisfaction the clearing and planting
of grass in the great field to the north of Nichols. In
this process a small, spring-fed pond has been
created which already has attracted our resident
mallards and barn swallows.
Continued Leadership from Our
Board of Trustees
All major decisions such as the go-ahead signal for a
new laboratory reflect lengthy deliberations by our
Board of Trustees. We are indeed fortunate that we
have a Board on which both distinguished scientists
and lay persons serve. This mixed composition can
let us move rapidly, for around one table the key
scientific, esthetic, and financial inputs can be ob-
tained. Until now, most such decisions were easy to
reach since new research and teaching labs could
be generated by the renovation of older, effectively
unused buildings. Now we can no longer move this
way, and to increase further our research and
teaching capabilities we must construct new build-
ings. The new and almost finished south extension
of Demerec and the about to be started north exten-
sion of James Lab represent the new way we must
act. But in so expanding our physical plant we risk
changing our quiet whaling-era appearance to that
of the more ordinary research university. So we
have been more than careful to instruct our archi-
tects to see that their new designs will still let us take
delight in walking down Bungtown Road.
At the same time, we have to realize that the
generation of new lab benches automatically must
lead to new parking slots as well as to new dwelling
places for the scientists who use them. An Ad Hoc
Infrastructure Committee chaired by Bayard Clark-
son has just been set up by our Board to examine
these problems. They have a target date of October
1983 to come up with practical solutions for park-
ing and housing that will improve the way of life for
our staff as well as reassure our local community
that we have no intention, in any way, of losing the
bucolic feeling that since our founding has enriched
the scientific life at Cold Spring Harbor.
Retiring from our Board at the conclusion of their
statutory six-year terms were Bache Bleecker, Emilo
Collado, and Mrs. Franz Schneider. All functioned
most effectively in our behalf, and we trust that we
can count on their continued support. Returning to
our Board to again represent the Wawepex Society
is Townsend Knight, a lawyer for the New York law
firm of Curtis, Mallet-Prevost, Colt and Mosle. New-
ly elected for the first time as Individual Trustees are
Oliver R. Grace of Cove Neck, a distinguished in-
vestor who has long served the world of medical
research so well by his leadership of the Cancer
Research Institute of New York, and Ralph Landau,
one of our nation's most noted chemical engineers,
vice president of the National Academy of Engineer-
ing, founder of the Halcon Corporation, and who
for 30 years has maintained a home nearby on Long
Island Sound at Asharoken.
This is My 15th Consecutive Annual Report
In January of 1968 the trustees designated me as the
new director, with my duties actively to commence
in June of that year upon the completion of the
spring term at Harvard. It was a momentous period
of my life-I was about to turn 40, my book the
Double Helix was to be published in the USA in
February, coming out in April in London, and in late
March I entered married life with Elizabeth Lewis,
then a student at Radcliffe.
The Cold Spring Harbor Laboratory I took my
young bride to that summer of 1968 was very dif-
ferent from today. It was physically run down,
underfunded, and badly in need of staff. Even then,
however, I never felt the Lab's future in doubt. Our
site was beautiful, our traditions so great, and our
friends and admirerers numerous.
Since those first days I have worked steadily to
promote our causes. That we are now proclaimed a
very visible success story owes much to many,
many special people and institutions. I here men-
tion only those closest to me. First I must ac-
knowledge Harvard University for letting me start
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out as director while retaining the security of a Har-
vard professorship. For eight years I tried to serve
well both worlds, and my leaving of Harvard in no
way reflected any lack of respect or affection for that
great institution. I must also credit the perceptive
support and friendship I have received from Bentley
Glass, the late Robert Olney, Harry Eagle, and
Walter Page, the four chairmen of our Board of
Trustees that I have had the privilege to serve under.
Equally important has been the assistance of Ed-
ward Pulling and his late wife Lucy in introducing
me and Liz into the warm, civilized world of the
Long Island North Shore. I have also profited greatly
from my 14-year association with our now Assistant
Director Joe Sambrook. Together we have worked
hard to make the Lab a world-class participant in
cancer research. We would not have succeeded
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nearly so well without the astute financial know-
how of our Administrative Director Bill Udry. He
has helped generate the steady positive cash flow
that has given us the ability to provide the modern
laboratories and equipment needed to do important
science. And with pleasure I acknowledge the
steady leadership and good taste of Jack Richards,
whose feeling for buildings has been a key ingre-
dient in giving us a physical environment that
delights not only our eyes but our intellect.
But most of all I am indebted to my wife Liz for
the supportive and stylish way she has played the
necessarily difficult role of the Director's wife while
simultaneously giving me the family life I deeply
cherish.
June 24, 1983 J.D. Watson
YEAR-ROUND RESEARCH
TUMOR VIRUSES
Molecular Biology of Tumor Viruses
Nucleic Acid Chemistry
Electron Microscopy
Protein Synthesis
DNA Synthesis
MOVABLE GENETIC ELEMENTS
Insertion Elements and Plasm ids
Yeast and Plant Genetics
Molecular Genetics of
Pathogenic and Virulence Factors
Bacterial Transposition
VERTEBRATE GENE STRUCTURE
AND EXPRESSION
Mammalian Cell Genetics
Hormonal Control of Gene Expression
Genes for the Major Structural Proteins
Structure and Expression of
Eukaryotic Genes
Molecular Genetics of the Mouse
Mammalian Cell Genetics
CELL BIOLOGY
Mammalian Stress Response
Biology of the Cytoskeleton
Quest 2-D Gel Laboratory
NEUROBIOLOGY
Leech Neurobiology
Anatomical Studies with
Monoclonal Antibodies
Molecular Studies of the Nervous System
First row: M. Mathews; M. Yamada, S. Hughes, D. Hellman, T. Kost
Second row: W. Osheroff; J.-Z Li; C. Bray, E. Waldvogel, J. Johansen; D. O'Loane
Third row: W. Boorstein, D. Pascucci; Yeast Group
Fourth row: B. Stillman, P. Lalik, M. Walsh; M.A. Ruley, E. Taparowsky; G. Binns, W. Welch
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First row: S. Hinton, G. Penzi, A. Bukhari, T. Patterson, B. Vogel; M. Manos, K. Van Doren
Second row: S. Hockfield; M. Costa; Y. Katoh; L. Ed lund; K. O'Neill
Third row: C. Schley; B. Vogel; B. Zipser; Z. Manzoor
Fourth row: M. Rossini; M. Goldfarb, D. Birnbaum; G. Blose, S. Blose, N. Haffner, B. Daniels
Fifth row: W. Huse, M. Deluca; P. Meyer; C. Deal, E. Bi Ilyard; I. Emanuele, L. Cascio
TUMOR VIRUSES
For many years, adenoviruses and SV40 have been the central obsession of the Tumor Virus Group. From
time to time we discuss the possibility of switching to other topics but always we are drawn back to the
DNA tumor viruses. They remain objects of extraordinary intellectual interest and they continue to serve as
the major source of ideas that enliven studies of the molecular biology of eukaryotic organisms in general.
MOLECULAR BIOLOGY OF TUMOR VIRUSES
J. Sambrook, J. Fiddes, M.-J. Gething, Y. Gluzman, T. Grodzicker, E. Harlow, E. Ruley, J. Stringer,
W. Topp, B. Anderson, M. Anderson, J. Brandsma, M. Hightower, M. Roth, M. Yamada, B. Ahrens,
P. Barkley, M. Cahn, R. Chisum, M. DeLuca, M. Dermody-Weisbrod, A. Devine, C. Doyle, L. Garbarini,
M. Goodwin, R. Greene, D. Hanahan, D. Keller, R. McGuirk, M. Manos, M. Merle, D. Moll, M. Ramundo,
L. Rodgers, J. Scal, D. Smith, C. Stephens, L. van der Wal, K. Van Doren, J. Wiggins
Transformation and Viral Tumor Induction
W.C. Topp, M.J. Hightower, M.B. Ramundo, D.M.
Smith, M. Dermody-Weisbrod, M. Cahn
This past year the research in the group again
centered about two projects, the induction of breast
fibroadenomas in female rats by group-D adeno-
viruses and the alteration in nutritional re-
quirements for cellular proliferation that accom-
pany oncogenic transformation by DNA viruses.
In collaboration with John Shanley and Claire
Shellabarger at Brookhaven, we have determined
that the inducibility of breast fibroadenomas by
human adenovirus type 9 is hormone dependent,
the virus being nononcogenic in ovariectomized
female animals. Reimplantation of diethylstilbestrol
(DES) does not restore oncogenicity and castration
of males does not render them susceptible. The ex-
act nature of this hormone dependence is under ac-
tive investigation, and preliminary results suggest
that the tumors themselves lack cytoplasmic
estrogen receptors. Specific experiments are de-
signed to determine the status of progesterone
receptors and the progesterone dependence of
tumor induction.
From a genetic standpoint, two interesting facts
have been determined. First, although unusually
similar one to another by the criteria of DNA/DNA
heteroduplex analysis or restriction mapping, very
few of the group-D viruses are active for
fibroadenoma induction. Both Ad9 and Ad10 in-
duce fibroadenomas in virtually 100% of female
animals injected at birth but at least 10 other group-
D viruses we have tested fail to do so. So far there is
nothing about either the structure or the pathology
of these various serotypes that could provide a clue
to explain this variability, and experiments are
underway to isolate in vitro recombinants (in col-
laboration with Tom Shenk) between oncogenic
and nononcogenic group-D viruses. Mapping of the
relevant sequences in this way will help us to iden-
tify the gene products and allow us to begin to study
mechanisms.
The second interesting phenomenon is the
variability in susceptibility to viral fibroadenoma in-
duction amongst inbred strains of rats. To date
Wistar/Furth, Long-Evans, Buffalo, and Brown Nor-
way rats have been found to respond to viral injec-
tion whereas Fisher, Lewis, and ACI rats are resis-
tant. There is an apparent correlation between
susceptibility and MHC haplotype with the a and I
haplotypes being resistant and the u, b, and n
haplotypes sensitive. The F, generation of a cross
between ACI (a) and W/Fu (u) is 100% resistant and
an N2 backcross to the W/Fu parent is now in prog-
ress. The hypothesis that susceptibility to viral
fibroadenoma is linked to MHC will be tested in
three ways. First, the N2 generation will be MHC
typed using monoclonal reagents provided by Abe
Fuks and a correlation sought between MHC type
and fibroadenoma appearance. Second, two more
strains of a supposed sensitive haplotype and two of
a supposed resistant will be tested. Finally, Lewis in-
breds which are congenic to either ACI or W/Fu at
MHC will be challenged. Other possible explana-
tions for the apparent genetic dominance of resis-
tance include interferon inducibility, and experi-
ments along these lines will be conducted in paral-
lel.
Significant advances in our understanding of the
altered growth requirements of transformed cells
have been achieved in collaboration with Don
McClure in the Cancer Center at the University of
California, San Diego. Our experiments are de-
signed around viral transformation of an established
rat cell line, REF52. In addition to nutritional factors
such as insulin, transferrin, hydrocortisone, and fat-
ty acid, this line requires two mitogens, epidermal
growth factor/vasopressin and the apoproteins of
the high-density lipoprotein complex. SV40 trans-
formation is accompanied by the obviation of the
requirement of one of the two mitogenic factors for
serum-free cellular proliferation. The phenotype of
the transformants is only partially transformed, with
most lines growing only poorly in soft agar. Selec-
tion of soft agar subclones produces lines that have
obviated the requirement for both mitogens and
these lines are tumorigenic. Nutritional requirements
do not further change upon selection of tumor-
derived sublines. The soft agar sublines are not
highly tumorigenic, tumors appearing only after 3
months, so it is of interest that the complete obvia-
tion of requirement for mitogenic stimulation pre-
cedes the acquisition of oncogenic growth potential
and is not coincidental with it. In the past, cloning
efficiency in serum-containing soft agar has been
found to be the most reliable correlate of cellular
tumorigenicity, and the acquisition of this property
also precedes oncogenicity in our system. How-
ever, only the highly oncogenic tumor-derived lines
give good growth in serum-free soft agar in the
absence of added mitogens, suggesting that it is this
property that may be closely linked.
In a parallel set of experiments, we examined the
loss of the actin cable bundles that has often been
said to accompany the acquisition of anchorage-
independent growth potential. Here again, we
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found that cable loss preceded the appearance of
oncogenic growth potential; however, in nonon-
cogenic lines, the cables returned when the cells
were cultured serum free. Only oncogenic lines
were found to lack cables in serum-free monolayer
cultures. It would appear that, on the basis of these
results, SV40 transformation results in the acquired
sensitivity to serum factors that produce anchorage -
independent growth and loss of actin cables.
However, this is not sufficient alteration to allow
tumor growth and it is only those cells that exhibit
these properties in the absence of added serum
factors.
Infectivity of a Plasmid Clone of
Adenovirus 5
D. Hanahan, Y. Gluzman
A full-length copy of an EcoRl-resistant variant of
Ad5 has been cloned in Escherichia colt by linkage
to the plasmid pXf3. The remnants of the Ad ter-
minal protein were removed with NaOH, and the
duplex molecule reformed by annealing. RI linkers
were added to the flush ends. Following ligation to
RI-cleaved pXf3, the recombinant was used to
transform E. colt DH1. The clone that arose (pxAd5)
contained full-length Ad5, which was releasable
from the plasmid with EcoRl. No sign of rear-
rangements was detected.
The clone was examined for its ability to infect
human cell lines (HeLa and 293). The cloned cir-
cular plasmid was not infectious. The RI-cleaved
recombinant produced plaques when transfected
into 293 cells, which carry and express adenovirus
early proteins from regions 1A and 1B. Viral DNA
was prepared and was shown to be RI resistant,
which is not a characteristic of either the control
viral DNAs used in the transfections or of other Ad5
virus used in the laboratory. The 3' ends of Ad5 and
the XAd viral DNA were labeled using T4 polymer-
ase, cleaved with Hhal, and analyzed on a 20%
polyacrylamide gel, using a sequencing ladder to
provide markers differing by 1 bp. The ends of the
XAd virus were precisely the size of wild-type virus.
Thus, in the course of establishing an infection, the
cloned virus DNA was relieved of the extra
nucleotides on its ends and restored to its original
configuration.
The specific infectivity of RI-cloned pXAd is about
5% of normal Pronased viral DNA. In vitro, RI ends
are - 50% as efficient as ends carrying the terminal
protein (Tamanoi and Stillman, Proc. Natl. Acad.
Sci. 79: 2221 [1982]). Since the RI ends can func-
tion as origins of replication, the low infectivity may
result from a competition between replication and
degradation. When a bona fide Ad end (the 700-bp
CIaB fragment) is ligated onto linearized pXAd, and
the ligated DNA transfected into cells, the virus that
appear carry the extra CIaB fragment on the right
end, along with the original RI end embedded about
700 by into the new end. This is consistent with
other data that indicate that the Ad origin of replica-
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tion is in part a free end, and if embedded, it is not
active. The observation that initiation of RI-linked
ends produces wild-type ends in virus bears on
possible mechanisms of initiation.
Cloning of cDNA of SV40 Large T Antigen
and Its Propagation as SV40 Virus
Y. Gluzman, J. Fiddes, B. Ahrens
The early region of SV40 codes for two early pro-
teins (large T and small t antigens). The single
transcript produced from the early region serves as a
splicing template to originate two different messa-
ges. These messages, which have the same acceptor
but two different donor sites, are translated into
large T and small t antigens. The role of large T an-
tigen in the initiation of viral DNA replication and
initiation of transformation is well established. Us-
ing mutants with a deletion in the small t region, it
was found that the complete integrity of small t an-
tigen is not absolutely required in either lytic
growth of SV40 or for transformation of some cells
in vitro. However, most of these deletion mutants
produced a truncated small t antigen. The influence
of the altered proteins remains unclear. To bypass
this problem, we cloned a complete cDNA copy of
the SV40 large T antigen mRNA and placed it under
the control of the bona fide SV40 regulatory region.
The cloning of the cDNA was synthesized from
SV40 early mRNA produced during infection of 293
cells with a helper-free Ad5 vector carrying the
SV40 early region under control of the late Ad2 pro-
motor. The cDNA was reconstructed to be colinear
with the early SV40 region and was reconstructed
with the SV40 late region. This construction resul-
ted in production of the complete SV40 genome,
with the exception that the early region has the
cDNA for large T antigen. This DNA was used to
transfect COS-1 cells to propagate a virus popula-
tion containing the altered early region. Very slow
growth was also observed after direct transfection
on CV-1 cells, although plaques appeared after 20
days. The virus population grown on COS-1 cells
was infectious and could replicate SV40 DNA on
CV-1 cells, although with greatly reduced efficien-
cy. The preliminary marker-rescue experiments lo-
cated deficiency in the cDNA construct to HindlIl B
fragment which spans the splicing region. At pres-
ent, we are investigating the role of small t antigen
in complementing the growth of SV40 cDNA virus,
the transforming potential of cDNA, and transcrip-
tional controls of messages, produced from cDNA
template.
Helper-free Adenovirus-5 Vectors
Y. Gluzman, K. VanDoren, D. Hanahan
In the last annual report, we reported the construc-
tion of helper-independent adenovirus-5 (Ad5) vec-
tors. Since then, we have cloned and propagated
several different genes of interest as recombinant
helper-independent viruses. These genes include:
(1) SV40 T antigen-coding region under control of
late Ad2 promoter; (2) wild-type SV40 early region
with its own promoter and origin of DNA replica-
tion; (3) SV40 early region with its promoter but
mutated origin of DNA replication; and (4)
neomycin resistance gene from TN 5 under control
of the SV40 promoter.
The biological functions of these genes were
evaluated in a variety of assays. The vector contain-
ing the SV40 T antigen-coding region under control
of the major Ad2 late promoter was examined for
the production of T antigen. This construct pro-
duced large amounts of T antigen during lytic in-
fection of 293 cells as judged by polyacrylamide gel
electrophoresis with or without immunoprecipi-
tation. The wild-type early region with its own
promoter produced T antigen during nonlytic infec-
tions in a variety of cells as judged by immunofluo-
rescence. Vectors containing the early region of
SV40 with and without a functional origin of
replication were assayed for their ability to trans-
form Rat 2 or HS74BM (human fibroblast) cells.
SV40 inserts lacking a functional origin of replica-
tion transformed cells as efficiently as the wild-type
early region. These cells formed foci on monolayers
of cells and efficiently expressed T antigen as judg-
ed by immunofluorescence. Several lines of
HS74BM-transformed cells have been established
and analysis of the DNA integrated into the genome
is underway. A similar vector containing the
neomycin resistance gene of TN 5 under control of
the 5V40 early promoter was assayed on Rat 2 and
CV-1 cells. Cells were efficiently transformed to
resistance to the drug G418 (neomycin analog). Pre-
liminary results on the integration of this DNA into
the genome of Rat 2 cells indicate that there are
multiple insertions of the viral DNA as well as
amplification of the integrated sequences. Further
analysis of these DNAs as well as the DNAs isolated
from neomycin-resistant CV-1 colonies is currently
in progress.
SV40 Mutants That Differentiate the Lytic
and Transforming Functions of T Antigen
Y. Gluzman, M. Manos, B. Ahrens
Mutant SV40 DNA insertions have been rescued
from a variety of permissive cells transformed by
UV-irradiated SV40. Viral DNA was rescued by fu-
sion of these lines with COS-1 cells. Fusion with
COS-1 cells provides a functional T antigen in trans
that allows SV40 insertions in transformed cells to
excise and replicate in the heterokaryons formed.
The rescued 5V40 inserts were cloned into the
plasmid vector pK1. This cloning procedure restores
a complete 5V40 genome containing the early
region (Bgli-BamHI) from the mutant inserts. These
DNAs were analyzed by marker-rescue analysis,
and some of them by DNA sequencing. A total of
seven mutants were isolated (C6-1, C6-2, C2, C8,
C11, T22, and BSC-SV1). The mutants contain le-
sions in different parts of T antigen that render the
protein incompetent in viral DNA replication but
functional in transforming cells in vitro. The muta-
tions in C6-1 and C6-2 were determined by se-
quence analysis and found to be: nucleotide
numbers 5074 and 5011 in C6-1 and nucleotide
number 4360 in C6-2, which is 277 nucleotides
away from the mRNA splice joint. Mutations in
C6-1 affect both large T and small t antigens, while
the mutation in C6-2 lies in the unique part of large
T antigen. The mutations in C2 and C11 were
mapped to the C-terminal part of T antigen encoded
between nucleotides 3373 and 2848. The T22
mutation resides in the aminoterminal third of the
protein. C2 and C6 (containing both the C6-1 and
C6-2 mutations) appear to have an enhanced tumor-
igenicity in hamsters.
Illegitimate Recombination between
Adenovirus and SV40 Genomes
L. Ling, M. Manos, Y. Gluzman
Different mechanisms of DNA recombination might
lead to different final products. Analysis of the final
products of recombination has been useful in study-
ing the mechanisms of transposition and insertions
of different movable elements. We have chosen to
analyze junctions of adenovirus-SV40 recom-
binants because these junctions are the final results
of illegitimate recombination occurring between
two nonhomologous viruses: adenovirus 2 and
SV40. The nucleotide sequences of six Ad2-SV40
junctions from three Ad2-SV40 hybrid viruses
(Ad2"HEY, Ad2"LEY, and Ad21)1) were deter-
mined. Comparison of parental adenovirus 2 and
SV40 DNA sequences with the sequence at the
Ad2-SV40 junctions revealed that five out of six
junctions are abrupt transitions from Ad2 to SV40
DNA, and in one case (Ad2++LEY, right junction)
there is an additional nucleotide at the junction,
which cannot be ascribed to either DNA. Ad2"HEY
and Ad2+1D1 right junctions are identical and
Ad2"LEY and Ad2+ND4 left junctions are identical,
a result that strongly suggests these Ad2-SV40
hybrids arose by recombination between the linear
Ad2 DNA and circular SV40 DNA, followed by
recombination between Ad2 DNA and SV40 DNA
present in the Ad2 -5V40 hybrid DNA. The unam-
biguous transition of Ad2 DNA into SV40 DNA at
the junction sites is an example of recombination
events that have apparently occurred without any
homology at the recombination site.
Transformation of Escherichici coli
D. Hanahan
During the last year, a study on plasmid transforma-
tion of Escherichia coli was continued both in James
Laboratory and at Harvard University. The influence
of the conditions under which DNA and cells are
combined on the efficiency with which plasmid
molecules produce transformed cells was examined
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in considerable detail. Multivalent cations are
necessary for transformation, and an extensive com-
parison of different combinations of cations has pro-
duced one set that is very effective in facilitating
transformation by plasmids. About one in 500
plasmid molecules effects a transformed cell. This
represents about a 100 x improvement over the
classical method of Mandel and Higa, which
employs Ca" alone.
Plasmid transformation can be loosely divided in-
to two stages-uptake across the cell envelope and
establishment as an autonomously replicating
genetic element. DNA competition and plasmid
cotransformation experiments suggest that uptake is
efficient under these conditions and that multiple
plasmids can be taken up with independent prob-
ability. Establishment may now be the rate-limiting
step. Higher eukaryotic DNA inhibits transforma-
tion in cis but not in trans, and this inhibition is seen
both in transformation by naked DNA or following
in vitro packaging of recombinant cosmids and this
subsequent injection into cells. Since two unrelated
ways of putting plasmids into cells produce similar
responses, it seems likely that this restrictionlike ef-
fect is manifested during establishment. Genetic
studies in progress suggest that it may be possible to
release this inhibition. The improvements in trans-
formation efficiency are already enjoying wide
application in the cloning of cDNAs (see reports by
Hughes and Fiddes, for example), where efficient
transformations are essential to maximize the yields
of precious cDNA preparations.
Expresssion of SV40 Tumor Antigens from
Adenovirus Promoters and Controlling
Elements
T. Grodzicker, M. Yamada, M. Merle, C. Stephens
In an effort to study regulation of adenoviral
transcription, processing, and translation, we have
constructed a series of adenovirus-SV40 hybrid
viruses that contain the SV40 A gene downstream
from different adenovirus promoters. The SV40
DNA used contains the SV40 T antigen-coding
region but is missing the SV40 early promoter and T
antigen-binding sites. Thus, expression of T antigen
is under the control of adenovirus regulatory
elements. The SV40 A gene is a useful marker be-
cause reagents exist that allow the accurate quan-
titation of SV40 T antigen mRNA and protein in in-
fected cells. Furthermore, the entire SV40 sequence
and the adenoviral sequences in the region of in-
terest are known (see Tooze, DNA tumor viruses
[1980]; Gingeras et al., Biol. Chem. 257: 13475
[1982]). We also wanted to construct viruses that
would produce large quantities of SV40 T antigen
that could be easily purified and used in
biochemical studies. These studies were conducted
in collaboration with Dr. R. Tjian and C. Thummel
at the University of California at Berkeley.
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Precise POsitioning of SV40 T Antigen-coding
Sequences in Preselected Regions of the
Adenoviral Genome
To place the SV40 A gene at several positions
around the adenoviral major late promoter and late
leaders, a combination of in vitro and in vivo
recombination was used (see Fig. 1). The starting
material was a series of plasmids containing
adenoviral DNA linked to the SV40 A gene. These
plasmids were constructed by S.-L. Hu at Cold
Spring Harbor Laboratory. The joint between the
Ad2 and SV40 DNA was located at a position on the
adenoviral genome where we wanted the SV40 A
gene to be located in the hybrid virus to be con-
structed. This Ad2-SV40 insert was ligated to a Bam-
digested adenoviral DNA-protein complex. The
product created would be a virus with a duplication
of adenoviral DNA (in the insert and the left arm of
the vector). Homologous recombination (see Fig.
1 B) would excise the intervening DNA and produce
a virus with the SV40 insert positioned at the
desired location. We have found that the internal
adenoviral fragment of the vector can be present or
absent depending on the size of the insert. A
favorable packing size for the final virus is probably
selected. By using an adenoviral vector with Ad5 se-
quences in the left arm and Ad2 sequences in the
plasmid insert, we can determine where recombina-
tion took place in the virus constructs to yield the
final hybrid virus. We have found that recombina-
tion can occur very close to (within 200 bp) the
SV40 insert.
The construct DNAs were cotransfected with
human 293 cells with helper wild-type DNA and
the resulting virus grown through two cycles of in-
fection in simian CV-1 cells to select viruses that ex-
press SV40 T antigen. The SV40 helper function that
enables human adenoviruses to grow in monkey
cells is encoded by the carboxyterminal end of
SV40 T antigen. The final viruses produced are
shown in Figure 2. Viruses exist that have the SV40
A gene in the third segment of the tripartite leader
(Ad-SVR284), and in the i leader (Ad-SVR274). The i
leader is an auxiliary leader found frequently on
mRNAs initiated at the major late promoter at early
and intermediate times after infection, in the intron
between the first and second segments of the tripar-
tite leader (Ad-SVR26), in the intron between the
second and third segments of the late leader (Ad-
SVR280), and in the intron distal to the third seg-
ment of the late leader (R289).
Transcription and Processing of SV40 mRNAs in
Cells Infected with the Hybrid Viruses
All of the hybrid viruses that contain the SV40 A
gene in the region of the adenoviral major late pro-
moter make very large amounts of T mRNA. They
are made in the same high amounts as adenoviral
late mRNAs. All of the virus make SV40 T mRNAs
that are spliced and terminated at the position as
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Figure 1
Construction of adenovirus-SV40 hybrid viruses. (A) Inserts of viral DNA in plasmids p6B, p8B, p9B, and p1 0B. On top
is depicted a segment of the adenoviral genome, including the late promoter (1)1d1e), three late leader regions (small dark
boxes), and early i leader segment (hatched box). Below are the four Barn inserts that contain different lengths of
adenoviral DNA fused to the SV40 A gene (open box). (8) An example of in vitro/in vivo recombination: the construction
of Ad-SVR274. Above is depicted the 1 x 51i adenovirus vector with the Bcll sites marked by arrows. Replacement of the
internal 1 x Sli Bc11 fragment with the p6B Barn insert results in the proposed precursor to Ad-SVR274. The duplication
of adenoviral DNA from map positions 15.4 to 22.6 is emphasized by the open boxes with arrows, and the SV40 A gene
is represented by the dark box. Intramolecular recombination between the duplicated regions of adenoviral DNA, shown
in the intermediate, would result in the formation of Ad-SVR274, shown at the bottom. Alternatively, recombination
could proceed via an intramolecular intermediate.
authentic SV40 T mRNA. Analyses of SV40 mRNA adenoviral major late promoter. (2) If the SV40 is in-
by Si nuclease treatment, Northern hybridization, serted distal to any segments of the late leader, they
and sandwich hybridization lead to the following are spliced together normally and found at the 5'
conclusions: (1) All T mRNA5 are initiated at the end of SV40 T mRNA (see, for example, Fig. 3).
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Figure 2
Genome structures of the adenovirus-SV40 hybrid viruses. The genome structure of Ad-SVR26, one of our previous con-
structions (Thummel et al., I. Mol. Appl. Genet. 1: 435 [19821), is depicted above. The genome structures of five recom-
binant viruses: Ad-SVR26, Ad-SVR274, Ad-SVR280, AdSVR284, and Ad-SVR289 are shown. The late leader regions
(small black boxes), early i leader (small open box), deleted adenovirus DNA (triangles), and SV40 sequences (large open
box) are shown. The numbers are adenoviral map units (1 map unit = 360 bp).
When SV40 is in the intron between the first and se- time. Instead the transcript is continuous past the
cond leaders (Ad-SVR26), splicing does not occur at first leader into the intron and the SV40 sequences.
the first leader donor splice site about 50% of the (3) When SV40 is in the i leader segment, large
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Figure 3
A schematic representation of splicing and translation at the 5' ends of the Ad-SVR274- and Ad-SVR284-encoded hybrid
mRNA5. Portions of the Ad-SVR274 and Ad-SVR284 genomes are depicted. The open boxes represent leader regions, the
hatched boxes represent SV40 DNA, and the normal SV40 T antigen-coding region is marked with an open arrow. All
AUG triplets in the DNA are marked; they are numbered in the Ad-SVR274 genome so that they can be matched to their
appropriate termination codons. The SV40 AUG codons (3 and 4) are both in frame with the T antigen-coding region
(Tooze DNA tumor viruses [1981]). The two adenoviral AUG triplets (1 and 2) are both out of frame with the T antigen-
coding region and are also out of frame with each other (Gingeras et al., I. Biol. Chem. 257: 13475 [1982]). The dark
lines below the genomes represent the predominant hybrid T mRNA5 encoded by each virus. The AUG codons used for
T antigen translation are shown above each of the messages.
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amounts of T mRNA contain i sequences even
though they are normally present at low levels at
late times after infection in adenoviral late mRNAs.
(4) Several cryptic splice acceptor sites in SV40 se-
quences are used with reasonable efficiency. For ex-
ample, there is a very strong splice acceptor at the
5' end of the SV40 sequences near the AUG initia-
tion codon for T antigen. Presumably this is not
used in authentic SV40 mRNAs because there is no
donor splice site preceding it. Two other strong
SV40 cryptic splice acceptor sites in the 3' region of
the gene are used to produce hybrid mRNAs. These
sites are seen in all hybrid SV40 mRNA populations
and not in SV40-infected cells. Thus, fhere is some
feature of an adenovirus-infected monkey cell that
differs from SV40-infected cells and influences the
splicing pattern. (5) Very low amounts of small t
mRNA are seen in hybrid-infected cells. Since large
T and small t mRNAs differ only in the splice donor
sites used to make the mRNA, it is likely that the
adenovirus-infected cell is influencing the splicing
pattern of mRNAs. However we have not ruled out
that t mRNA is particularly unstable.
Translation Control of T mRNAs in
Hybrid-infected Cells
In all hybrid-infected cells, the same large amounts
of T mRNAs are produced. However different
amounts of T protein are made. In Ad-SVR284-
infected cells, for example, protein is overproduced
to the same level as the mRNA. At least 5% of newly
made protein is T antigen and one can isolate at
least 2 mg of T antigen from 1 liter of infected cells.
T antigens are detected by [35S]methionine labeling
of infected cell extracts. Proteins are analyzed on
polyacrylamide gels before and after immunopre-
cipitation with various anti-T antibodies. Proteins
are detected by autoradiography or Coomassie blue
staining. Cells infected with the other hybrid viruses
(see Fig. 2) make about 20-fold less T antigen
although the protein is equally stable. However,
when T mRNAs produced by different viruses are
translated in vitro in reticulocyte lysates, the same
amounts of T antigen are synthesized. Thus, there is
some translational control in the infected cell that is
not present in vitro.
Novel AUG Codons Can Be Used To Produce T
Antigen
In some cases, T antigen synthesis does not begin at
the normal AUG initiation codon. In Ad-SVR26 (see
Fig. 2), a large proportion of T mRNAs carry se-
quences from the first leader and the intron between
the first and second leader before the SV40 se-
quences. Two AUG codons are located in the intron
RNA and are in the same frame as T antigen-coding
sequences. Use of one of these AUG codons would
produce a T protein about 5K larger than SV40 T an-
tigen, and this is, in fact, found. The first AUG
codon has a G at position -3 (GGCATGA) and an
A at position +4 and thus falls into the category of
efficient starts as proposed by Kozak (Nucleic Acids
Res. 9: 5233 [1981]). Why translation of this mRNA
does not produce as much protein as mRNA in
which translation is initiated at the normal T AUG is
not clear. The intron AUG may be intrinsically a
weaker start sequence, the adenoviral leaders may
play an important role, or more sequences than
those immediately surrounding the AUG may be
important for efficient translation initiation in vivo.
In addition, mRNAs that have been produced by
splicing at the SV40 cryptic splice acceptor site at
the beginning of the SV40 sequences (see Fig. 3, for
example) have had the normal T AUG removed by
splicing. There is another internal AUG located 13
codons downstream that is in frame with the T
AUG. Thus, T antigen initiated at this AUG codon
would be close in size to wild-type SV40 T antigen
but would differ at the N terminus. In cells infected
with hybrid virus that contain T mRNAs with this
new splice point, one can find, by immunoprecipi-
tation, T proteins that comigrate with SV40 T an-
tigen. They are efficiently immunoprecipitated with
polyclonal T antisera or monoclonal antibodies that
recognize determinants in the middle or carboxyl
terminus of the molecule. However, they are not
immunoprecipitated by monoclonal antibodies that
recognize determinants at the amino terminus of the
molecule. (Monoclonal antibodies were obtained
from D. Lane and E. Harlow.) Thus, these T antigens
have the properties predicted for T antigen initiated
at the second AUG found in the T antigen-coding
sequence.
Efficiency of Translation of T Antigen When the
SV40 A Gene Is Transcribed as the Second Gene
in a Dicistronic mRNA
There are two hybrid viruses in which the SV40 A
gene is preceded by coding sequences for part of an
adenoviral gene that contains an AUG start codon,
coding sequences, and a translation termination
codon. In Ad-SVR274 (see Fig. 1), the A gene is in-
serted into the middle of the i leader in the protein-
coding sequences (C. Anderson et al., unpubl.). The
reading frames of the i protein and T antigen are dif-
ferent so that a termination codon is introduced into
the i coding sequence at the beginning of the SV40
insert. In Ad-SVR6 (Thummel et al., Cell 23: 825
[1981]; T. Grodzicker et al., unpubl.), the A gene is
located in the adenoviral early 1B transcription unit
about 200 by downstream from the El b 15K AUG
codon. The 5' end of the SV40 insert introduces a
translation termination codon into the 15K reading
frame (see Tooze, DNA tumor viruses [1981] for
adenoviral sequence). Analyses of SV40 T mRNA
by S1 nuclease analysis, R-loop mapping (in col-
laboration with L. Chow), and Northern blotting
have shown that the SV40 sequences are preceded
by the truncated adenoviral gene coding sequences
in both Ad-SVR6- and Ad-SVR274-infected cells.
27
Analysis of T antigen protein by labeling with
[3'S]methionine and immunoprecipitation with a
variety of anti-T sera and monoclonal antibodies has
shown that Ad-SVR274 produces low levels of a
wild-type T antigen. Thus, when the SV40 A gene is
the second gene in the mRNA, it is translated, albeit
inefficiently. In Ad-SVR6-infected cells, T antigen is
produced in large amounts and at levels quite com-
mensurate with the levels of T mRNA. Thus, it is
translated efficiently when it is the second gene on
this mRNA. This situation is unusual for eukaryotic
mRNAs where distal coding sequences on a
message are not usually translated. The El b
transcription unit is unusual in itself because it
codes for two proteins whose AUG starts are 300 by
distant from each other, although the mRNAs for
these proteins have common 5' ends (see Tooze,
DNA tumor viruses [1980]; Bos et al., Cell 27: 121
[1981]). Clearly positioning a foreign gene as the
second coding sequence in this transcription unit
allows for its efficient translation.
Integration of Other Foreign Genes into
Adenovirus
T. Grodzicker
Plasmids had been constructed containing the
human j3-globin gene (either with or without its pro-
moter) coupled to T antigen-coding sequences. The
inserts were excised with Bam and ligated to Bam-
digested Ad2/Ad5 1 x 51 DNA. This Ad2/Ad5
recombinant virus contains only two Bam sites and
is the most common vector that we use. After
transfection into 293 cells along with wild-type
helper virus, progeny were grown in CV monkey
cells to select viruses that express T antigen. Among
the progeny were viruses that contained the 13-
globin gene and expressed 13-globin mRNA. We are
presently trying to quantitate the levels of mRNA
and determine their 5' ends.
Based on our previous work with T antigen, we
can now position foreign DNA precisely in adeno-
virus and have found that insertion of the SV40 A
gene into the third leader gives the highest levels of
T mRNA translation. We are now constructing
plasmids to be used for inserting foreign genes into
adenovirus based on these results. First, we have
modified p9B (see Fig. 1) so that the SV40 insert car-
ries its own promoter. Second, there are sites be-
tween the adenoviral and SV40 DNA into which
foreign DNA can be inserted. Several genes are be-
ing inserted into this plasmid. We have also inserted
the human a-chorionic gonadotropin gene with and
without its poly(A) addition site into the plasmid
pALE. This plasmid is similar to that shown in Figure
1, except that adenovirus and SV40 sequences are
joined at position 17 on the adenoviral genome. All
of these inserts are being put into adenovirus by a
combination of in vivo and in vitro recombination
and will be analyzed as to what sequences they con-
tain.
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Foreign Proteins Expressed on Eukaryotic
Cell Surfaces
J. Sambrook, M.-J. Gething
During the past year, we have continued studies on
the molecular genetics of cell-surface proteins. Most
of our work has involved the gene of influenza virus
that codes for the hemagglutinin (HA). This
glycoprotein is the major antigen of the influenza
viral particle and it is inserted into the lipid mem-
brane that envelops the virion. Apart from its impor-
tance to man as a mutable antigen, HA is involved
in the penetration of the host cell by the virus, being
responsible not only for the initial attachment of the
virus to cellular receptors, but also for the fusion of
viral and cellular membranes that marks the onset of
infection.
The natural form of the HA gene is an RNA
molecule of negative polarity. However, in recent
years, the gene has been converted into a double-
stranded DNA form, cloned and propagated in pro-
karyotic vectors, and sequenced. In this way, the
complete amino acid sequences of the HAs of a
large number of strains of influenza virus have been
established. Furthermore, a large number of
monoclonal antibodies have been raised against HA
and these have allowed a detailed analysis of the
antigenic structure of HA. Finally, about 5 years
ago, the glycoprotein spike of HA was crystallized
and its three-dimensional structure was recently
determined at the 3-A level using X-ray crystallog-
raphy. The culmination of all this work has been a
detailed description of the physical domains of the
molecule, the location of its major antigenic sites,
the points at which it is glycosylated, its organiza-
tion into trimeric structures, and its orientation with
respect to the membrane. At the present time,
therefore, HA is the best characterized of all
eukaryotic membrane proteins.
The crucial interactions between HA and mem-
branes are mediated by the three separate
hydrophobic regions of the molecule: (1) the
aminoterminal, hydrophobic signal draws the nas-
cent polypeptide chain into contact with the in-
tracellular membrane system; (2) the carboxyter-
minal region anchors the completed molecule in
the external membranes of both virus and infected
cell; and (3) the amino terminus of HA2 subunit of
HA which appears to be involved in penetration of
the cell membrane during infection.
Because the biosynthesis of HA involves host en-
zymes and processes during translation, membrane
transport, glycosylation, and maturation, it appears
to be a profitable model for the study of the integral
membrane proteins of eukaryotic cells. One ap-
proach to the further analysis of HA, and of integral
membrane proteins in general, is to introduce
alterations in their amino acid sequences and to
analyze the subsequent effects on the biosynthesis,
structure, and function of the molecules. It would
be of particular interest to determine the effects of
alterations in the hydrophobic sequences on the in-
teractions of the protein with membranes, par-
ticularly those involving translocation of the nascent
polypeptide strand. The first stage in this process is
to synthesize HA from a cloned gene; and much of
our work this year has been concerned with the
construction and use of recombinant viral genomes
consisting of both SV40 and influenza virus se-
quences that direct the expression of large amounts
of HA at the surface of eukaryotic cells.
The clones of the HA gene used in our work were
derived from RNA extracted from influenza viral
particles using methods that are standardly em-
ployed to clone cellular RNAs. The only extra step
was the addition of a tract of polyadenylic acid to
the 3' end of the virion RNA to provide a binding
site for the oligo(dT) used to prime reverse transcrip-
tase (see Gething et al., Nature 287: 301 [1980]).
Double-stranded cDNA was inserted into the Pstl
site of the plasmid pAT153 by dG:dC homopoly-
meric tailing. Following transfection of E. coli,
plasmids containing copies of the Japan HA gene
were identified by in situ hybridization to colonies
and to virion RNAs immobilized on DBM paper.
The DNA sequence of the cloned inserts was car-
ried out using the procedures of Maxam and
Gilbert. Using these methods, a cDNA copy of the
complete Japan HA was obtained (except for 11
nucleotides of the 3' untranslated region). The exo-
nuclease BAL31 was used to remove both of the sets
of homopolymeric C:G and A:T tails used in the
construction and also the 5' untranslated region of
the gene. Hindlll linkers were added to the ends of
the resected molecules, which were then recloned
in pAT153. The resulting population of clones was
scanned to identify an individual in which the
nucleotide immediately following the HindlIl linker
was the A of the initiating AUG codon of the HA-
coding sequence. Cleavage of such a clone with
Hindlll and BamHI yielded a fragment containing
the entire coding sequence of HA in an orientation
suitable for insertion into the various vectors
described below.
Vector Systems
Because the HA gene occurs naturally in the form of
negatively stranded RNA, it contains none of the
controlling elements, such as promoters and
enhancers, that are required for efficient transcrip-
tion of conventional DNA genes. Thus, the vectors
all were designed so that the HA-coding region was
placed under the control of either the SV40 early
promoter/enhancer or the SV40 late promoters.
Vectors in Which the HA-coding Sequence
Replaces the SV40 Early Genes
As mentioned above, the cloned HA had been
reconstructed so that the A residue immediately
following the HindlIl linker would correspond to
the A of the initiating AUG of the protein. This
allowed the HA gene to be inserted into the early
region of the SV40 genome (between the HindlIl
site at nucleotide 5171 and the BamHl site at
nucleotide 2533 so that its initiation codon was
almost exactly in the position normally occupied by
the initiation codon of large and small T antigens. In
addition, at the time that these experiments were
undertaken, there were indications from other
workers that foreign genes inserted into SV40
recombinant vectors were expressed more efficient-
ly when splice donor and acceptor sites were pro-
vided. We therefore built into the original a se-
quence of DNA containing the intron of the SV40
gene coding for small t antigen. Finally, to ensure
that transcripts of the HA gene would be terminated
efficiently, the HA sequences were always inserted
so that they lay upstream of a poly(A) additional
signal (also derived from SV40). It should be noted
that the untranslated 3' region of the HA gene con-
tains the sequence (AAUUAA), closely related to
the consensus poly(A) addition signal (AAUAAA),
that is believed to function during natural infections
with influenza virus. However, it was not clear
whether this signal would work efficiently in the
form of double-stranded DNA, and a conventional
poly(A) addition signal was therefore included in
the construct.
The HA gene should therefore be transcribed
under the control of the upstream SV40 pro-
moter/enhancer to yield an mRNA that (1) initiates
at the usual site, (2) contains a 5' untranslated
region that apart from the last 5 nucleotides is iden-
tical to that of conventional SV40 early mRNAs, (3)
carries a coding region specifying an HA molecule
whose sequence is identical to that of the natural
form of the molecule, (4) has the opportunity to be
spliced at the donor/acceptor sequences provided
by the downstream intron, and (5) terminates at
either the poly(A) addition site within the HA gene
or at the SV40 site further downstream.
This recombinant viral genome contains the
origin of SV40 replication and an intact set of late
genes. However, the SV40 early genes have been
replaced by the influenza virus HA gene and the
recombinant therefore cannot replicate in simian
cells unless functional T antigen is supplied. This
was done by using as a permissive host the COS-1
line of SV40-transformed simian cells that carry an
endogenously expressed copy of the SV40 T an-
tigen gene.
Vectors in Which the HA-coding Sequence
Replaces the SV40 Late Genes
To place the HA-coding sequences under the con-
trol of the SV40 late promoter(s), the HA gene was
inserted into the late region of the SV40 genome
between the Hpall site at nucleotide 346 and the
BamHl site at nucleotide 2533. The resulting
recombinant viral genome contains the origin of
SV40 replication and an intact set of SV40 early
genes. The HA-coding sequences are joined to the
noncoding sequences of SV40 that would normally
be transcribed into the untranslated 5' region of
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SV40 late mRNAs. At late times during lytic infec-
tion of permissive simian cells, this recombinant
genome should express an unspliced, hybrid mRNA
consisting of untranslated SV40 sequences at its 5'
end and an intact set of HA-coding sequences.
Polyadenylation could occur either at the site within
the 3' untranslated sequences of the HA gene or at
the normal site for late SV40 mRNAs at nucleotide
2674. Translation of this RNA should begin at the
first AUG, which is located at the beginning of the
HA-coding sequences. Because the late-replace-
ment vector contains a functional origin of DNA
replication and an intact set of SV40 early genes, it
will replicate its DNA efficiently in permissive si-
mian cells. However, the late genes of SV40 have
been deleted and production of infectious virions
containing the recombinant genome therefore re-
quires that SV40 capsid proteins be supplied by a
complementing helper virus such as dll 055, an ear-
ly deletion mutant of SV40.
The late-replacement vector is similar to those
used previously by many other workers to express
cloned genes derived from a variety of different
organisms; and more recently, to express cloned
HA genes from other strains of influenza virus.
Production of Viral Particles Carrying
SV40-influenza Recombinant Genomes
All the intermediate constructions were carried out
in bacterial plasmids of various sorts: The final
recombinant viral genomes also were propagated in
bacterial plasmids until their structures had been
verified. They were then excised from the plasmids
(by cleavage with BamHI), purified by gel elec-
trophoresis, and ligated at low concentrations of
DNA to generate closed circular molecules, which
were then introduced into the appropriate host cells
using DEAE-dextran as a facilitator. The early-
replacement vectors were introduced into COS-1
cells in the absence of a helper viral DNA: The late-
replacement vector was introduced into CV-1 cells
together with an equal amount of the DNA of the
SV40 deletion mutant d/1055. Only a small propor-
tion of cultured mammalian cells are competent at
any one time to take up DNA, so that very few cells
of the population are infected initially. However,
during the next several days, each of these cells
undergoes a lytic infection and produces over a
million viral particles that are able to spread into
neighboring cells and infect them with high efficien-
cy. Usually, the lysate obtained from the first set of
infected cells needs to be passed serially once or
twice to obtain a high-titer virus stock. In the case of
the early-replacement vector, this virus stock con-
sists exclusively of recombinant genomes encap-
sidated in SV40 coat proteins; in the case of the late-
replacement vector, it consists of approximately
equal numbers of helper virus particles (d11055)
and recombinants. Both virus stocks can be used to
infect permissive cells with high efficiency and to
induce in them a lytic cycle of virus growth. During
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such productive infections, the viral genomes are
transported to the nucleus where they are liberated
from their capsids. The early promoter soon
becomes active and genes under its control are ex-
pressed. By 12 hours after infection, viral DNA
replication is under way and genes begin to be ex-
pressed from the late promoter with high efficiency.
By 36-48 hours after infection, the newly synthe-
sized viral genomes begin to be assembled into
progeny viral particles-a process that continues for
another 24 hours, when the cells detach from their
substrate and die.
HA Is Expressed Efficiently from Both the Early
and the Late SV40 Promoters
The simplest way to measure the quantity of HA
synthesized in cells infected with the early- or the
late-replacement vectors is by solid-phase radioim-
mune assay. In this test, extracts of the infected cells
are allowed to react with HA-specific polyclonal an-
tibody that has been adsorbed onto a polyvinyl
chloride surface. HA is known to have several dif-
ferent epitopes, so it would be expected that a given
molecule of HA might bind to the adsorbed an-
tibody through one antigenic site, leaving the others
available for reaction. The number of these
available sites (and hence the number of HA
molecules) can then be titrated with radiolabeled
antibody.
When this test was applied to extracts made from
cells infected with either the early- or the late-
replacement vector, it was found that the amount of
HA detected increased as the course of infection
proceeded. By 62 hours, when the lytic infection
was in its terminal phase, cells infected with the
late-replacement vector contained approximately
6 x 108 molecules of HA per cell, while those in-
fected with the early-replacement vector contained
approximately 2.5 x 106 molecules of HA per cell.
For comparison, a simian cell at a late stage during
infection with influenza virus will contain about
5 x 107 molecules of HA
. These results show that
the influenza virus HA gene is expressed with high
efficiency when it is coupled to either the early or
the late SV40 promoters.
Originally, the fact that COS-1 cells infected with
the early-replacement vector synthesized 10-fold
less HA than CV-1 cells infected with the late-
replacement vector was thought to be simply a
reflection of the relative strengths of the early and
late SV40 promoters. However, we now know that
other factors are involved that play a much more im-
portant role in determining the amount of HA that is
synthesized by these recombinant viruses. Chief
amongst these is the presence or absence from the
early-replacement vector of the small DNA frag-
ment that carries the intron of small t antigen.
The Small t Intron Leads to Genetic Instability of
the Early-replacement Vector
It was clear from the studies described above that
splicing of mRNA is not required for expression of
the HA gene from the late-replacement vector. To
test whether the intron sequence built into the early-
replacement vector was necessary for expression of
HA, we constructed a derivative that is identical to
the original early-replacement vector in every
respect except that it lacks the intron. A virus stock
containing this new recombinant was raised and
propagated in COS-1 cells in the absence of helper
virus. When its ability to express functional HA was
compared with that of the original, intron' recombi-
nant virus, we found that the intron virus stock was
of a much higher titer, so that it could infect more
cells of the population. Furthermore, each of these
infected cells produced more HA than cells infected
with the intron' virus.
Analysis of the recombinant DNA molecules
isolated from cells infected with sequential passages
of the intron' virus showed a rapid increase in the
proportion of rearranged genomes. By the fourth
and fifth passage, the stock was essentially nonin-
fectious and contained a preponderance of mole-
cules shorter than that of the original construct. A
number of the rearranged DNA molecules from the
fourth-passage intron' stock were cloned into the
bacterial plasmid Xf3, analyzed by restriction en-
zyme digestion, and sequenced by the Maxam-
Gilbert procedure. The results showed that many
forms of rearrangement had occurred, including (1)
simple deletions, 50 by to 1 kb in length, both
within the HA gene and across both of the SV40-HA
junctions, (2) deletion of a segment of the HA gene,
together with an insertion of a similar-sized piece of
SV40 DNA, derived from a distant region of the
viral genome, (3) deletion of the SV40-HA junction
downstream of the HA-coding region, together with
an inversion of the sequence of SV40 DNA lying
immediately downstream from the junction. These
changes are reminiscent of the sorts of rearrange-
ment that were shown several years ago to occur in
the SV40 genome when the virus was serially
passaged many times in succession at high
multiplicity. The genome of the intron' recombinant
however, -seems to be particularly vulnerable to
such rearrangements. By contrast, the recombinant
genome lacking an intron is completely stable. No
rearrangement of its genome could be detected by
restriction analysis and Southern hybridization after
six sequential passages at high multiplicity; the
intron- virus stock showed no reduction in infectivi-
ty with increasing passage number, and it continued
to direct the synthesis of large quantities of HA.
We therefore conclude that the provision of splice
junctions is not required for efficient expression of
influenza virus HA cloned within either the early- or
the late-replacement vectors. The functional,
unspliced mRNA for HA is apparently synthesized
with great efficiency no matter whether the HA
gene is presented to the cell in the form of double-
stranded DNA or as negatively stranded RNA. It
might be tempting to argue that the presence of the
intron in the early-replacement vector is actually
detrimental to the expression of the HA gene.
However, the rapid accumulation of rearrange-
ments in the recombinant genome suggests that the
deleterious effects of the intron are mediated more
at the level of DNA than RNA. Why genomic in-
stability should be correlated with the presence of
the intron remains to be elucidated.
The HA Synthesized by 5V40-HA Recombinants Is
Biologically Active
To establish that the HA expressed by the 5V40-HA
recombinants was authentic both in structure and
biological activity, a series of assays were per-
formed on cells infected with either the early- or the
late-expression vectors. These included immuno-
precipitation, cytoplasmic and cell-surface immuno-
fluorescence, and erythrocyte binding. By all these
and other tests, the protein was indistinguishable
from HA produced naturally in influenza virus-
infected cells. These results have been described in
detail previously and will be discussed only briefly
here.
Immunoprecipitation. Extracts of cells infected
with the recombinant 5V40 HA viruses contained a
protein that was specifically precipitated by an HA
antiserum and was indistinguishable in size from
authentic, glycosylated HA precipitated from ex-
tracts of cells infected with influenza virus. So much
of this protein did the recombinant cells contain that
it was not necessary to use immunoprecipitation to
detect it; HA could be seen either as a band stained
with Coomassie blue after the extracts of infected
cells had been analyzed by SDS-polyacrylamide gel
electrophoresis, or as a prominent radioactive
species when extracts were prepared from infected
cells that had been labeled with [35S]methionine.
Cell-free Translation of mRNA. HA-specific
mRNAs isolated from authentic, influenza virus-
infected cells and from cells infected with SV40-HA
recombinants can be translated in lysates of rabbit
reticulocytes into a protein of molecular weight
63,000 that is the nonglycosylated form of HA.
When the translation was carried out in the
presence of dog pancreas membranes, the apparent
molecular weight of both HA products increased to
that of the in vitro, glycosylated form of HA
(75,000). Thus, the two forms of HA synthesized in
vitro from recombinant mRNA are identical to the
corresponding forms synthesized from authentic
HA mRNA.
Immunofluorescence. Cells infected with the
5V40-HA vectors displayed bright, cytoplasmic
fluorescence with the Golgi apparatus staining with
particular intensity. The surface of the cells also
stained specifically with a uniform, dimmer
fluorescence. The distribution of fluorescence in
cells infected with influenza virus was similar to that
displayed by recombinant-infected cells, but of
lower intensity.
Binding of Erythrocytes. Cells infected with the
early- or the late-replacement vector adsorbed a
dense carpet of erythrocytes onto their surfaces.
It is clear from these studies that both types of
recombinant viruses express large quantities of HA,
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which appears normal in all respects; its molecular
weight is indistinguishable from that of authentic
HA and it is displayed on the infected cell's surface
in a glycosylated form that is both antigenically and
biologically active. Thus, a protein that is normally
encoded by a negative-strand RNA genome can be
expressed in copious amounts when double-
stranded DNA copies of its coding sequences are
harnessed to strong SV40 promoters. To our
knowledge, influenza virus HA is the first integral
membrane protein to be expressed in eukaryotic
cells from recombinant DNA vectors. It is therefore
possible to begin to think of using site-directed
mutagenesis to dissect those parts of the molecule
that are important in its structure, function, and
biosynthesis and have been inaccessible to genetic
analysis until now.
Removing the Carboxyterminal Hydrophobic
Sequence Converts HA from an Integral
Membrane Protein into a Secreted Protein
As discussed above, HA is normally anchored in the
plasma membrane of the infected cell or in the
envelope of influenza virus by a tract of nonpolar
amino acids that are coded by the distal sequences
of the HA gene. These sequences were removed
from the standard late-replacement vector to create
a new vector that differs from its parent in only one
significant way: It lacks the DNA sequences coding
for the 38 amino acids that normally are found at
the C-terminus of HA. Substituting for them is a
stretch of 11 amino acids, largely polar in nature,
that is encoded by the dG:dC homopolymer tail, a
synthetic BamHI linker, and a short sequence of
SV40 DNA.
This "anchor-minus" mutant synthesizes as much
HA as the standard late-replacement vector.
However, instead of being entirely cell-associated
(in the Golgi or on the cell surface), the mutant HA
is found largely in the medium. The synthesis and
secretion of the anchor-minus HA is so efficient that
it is the only labeled protein that can be detected in
the medium after labeling the infected cells for
1 hour with esSimethionine. The most straightfor-
ward explanation of the mutant 's properties is that
the removal of the C-terminal hydrophobic se-
quences results in a loss of anchoring function, so
that the nascent polypeptide, instead of remaining
attached to the luminal face of the rough en-
doplasmic reticulum, passes completely through
the membrane. Once free in the lumen, the mutant
form of HA is treated by the cell as if it were an
authentic secretory protein and is discharged into
the medium.
The secreted form of HA differs from the mem-
brane-bound form in only one major respect-its
rate of glycosylation. The complex oligosaccharides
that are added to membrane and secretory proteins
are composed of "core" and "terminal" regions
that are added in the rough endoplasmic reticulum
and the Golgi apparatus, respectively. The inner
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core region, linked to asparagine, contains a
minimum of two N-acetylglucosamine and three
mannose residues. While fewer in number than
those originally added, all of these core sugars are
donated as a part of a preformed group from an ac-
tivated donor molecule-dolichol. As far as is
known, all secretory and integral membrane pro-
teins share the same asparagine-linked oligosac-
charide core. However, the final pattern of
glycosylation differs greatly from protein to protein.
Most of these differences are generated during the
passage of the protein through the Golgi apparatus,
as a consequence of the activity of a series of
specific mannosidase and glycosyl transferase en-
zymes. Since, in general, all copies of a particular
protein show the same pattern of glycosylation,
there must be information contained in either the
sequence or the folding of the polypeptide chain
that determines what alterations are to be made to
the original precursor oligosaccharide. It is therefore
interesting that the anchor-minus and the wild-type,
which differ so little in primary amino acid se-
quence, should show differences in the rates at
which they become glycosylated. The core-glyco-
sylated form of wild-type HA (M, = 73,000), which
can be detected after a short period of labeling
(-10 min), is chased completely into its final
glycosylated form within a matter of minutes. By
contrast, the population of anchor-minus molecules
takes up to 2 hours to become completely glyco-
sylated. Even though the rate of glycosylation of
anchor-minus HA is comparatively slow, its pattern
of labeling with radioactive sugars is very similar to
that of wild-type HA and it therefore appears that
final composition of the oligosaccharides attached
to the two proteins is not significantly different.
These results lead to the following conclusions:
(1) The hydrophobic amino acid sequence at the C-
terminus of HA is required to anchor the protein in
the outer membrane of the cell. Removal of this se-
quence converts HA from an integral membrane
protein into a secretory protein. It therefore follows
that signal sequences apart, there is no unique se-
quence of amino acids common to all secretory pro-
teins that automatically confers on them the ability
to be secreted. (2) The slow rate of glycosylation of
the anchor-minus HA indicates that secretory pro-
teins in general may be processed more slowly than
integral membrane proteins. This difference may lie
at the level of transport to the Golgi apparatus or
passage through it. (3) The signals governing the
pattern of glycosylation of HA cannot lie in the 38
amino acids that normally comprise the carboxyl
terminus of the molecule.
Future Work
During the next year, we intend to extend this work
in several directions. First, we would like to develop
cell lines that constitutively synthesize HA in large
quantities, and we are exploring a variety of ways
(1) to establish stable cell lines that contain multiple
copies of the HA gene and (2) to place the HA-
coding sequences under the control of inducible
promoters. Second, we would like to refine our
analysis of the functional domains of the HA
molecule by synthesizing forms of the protein that
contain single amino acid substitutions in the
crucial hydrophobic regions. Finally, we would like
to analyze the properties of chimeric molecules in
which the hydrophobic regions of HA have been
replaced by those of another integral membrane
protein.
Recognition Signals for Sorting Surface
Proteins
M. Roth, C. Doyle, M. -J. Gething
A fundamental principle of cell architecture is the
segregation of cell functions into distinct subcellular
regions. This partitioning requires a directed trans-
port of structural and enzymatic components, since
molecules are not synthesized everywhere in the
cell. The best-understood system of directional
transport is the pathway by which secretory and
cell-surface proteins reach the plasma membrane
(Sabatini et al., I. Cell Biol. 92: 1 [1983]). In cells
that form selective barriers, such as kidney distal
tubule epithilia, the plasma membrane is itself po-
larized into at least two surface domains. Each do-
main contains a subset of surface proteins, indicat-
ing that some mechanism for sorting surface pro-
teins is active in these cells (Louvard, Proc. Natl.
Acad. Sci.72: 4132 [1980]). We have been in-
vestigating this sorting process, taking advantage of
the observation that certain viral glycoproteins are
directionally transported to either the apical or
basolateral surface domains in polarized epithelial
cells (Rodriguez-Boulan and Sabatini, Proc. Natl.
Acad. Sci. 75: 5071 [1978]). Glycosylation does not
play a role in this process (Roth et al., Proc. Natl.
Acad. Sci. 76: 6430 [1979]; Green et al., I. Cell Biol.
89: 230 [1981]), and recently we have determined
that influenza virus hemagglutinins (HAs) are sorted
to the apical surface of polarized AGMK cells in-
fected with recombinant SV40 viruses. Thus, some
feature of the HA polypeptide serves as a recogni-
tion signal for cell-sorting mechanisms.
To determine the location of this "sorting signal"
on HA, we have begun construction of both deleted
and chimeric HA molecules using the cloned HA
gene inserted into SV40 vectors (Gething and Sam-
brook, Nature 293: 620 [1981]). As a first approach,
we wish to determine on which side of the
membrane-spanning region of HA the sorting signal
resides. HA molecules with the extreme carboxyter-
minal "tail" either truncated or extended have been
constructed. Construction is underway of a chi-
meric HA with sequences coding for the external
HA spike spliced in frame to sequences coding for
the hydrophobic membrane spanning region and
cytoplasmic "tail" of the HSV-I gC glycoprotein. In
addition, the HSV gC glycoprotein gene has been
inserted into an SV40 expression vector. The
biological properties of each of these recombinant
molecules will be studied in CV-1 cells and in
polarized AGMK primary epithelial cell cultures. In
collaboration with E. Ruley, we are preparing a
polyoma expression vector that may be of great use
for studies of the sorting of chimeric glycoproteins
in the polarized continuous mouse epithelial cell
line, MME (Roth et al., J. Virol. 45: 1065 [1983]).
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NUCLEIC ACID CHEMISTRY
R.J. Roberts, T.R. Gingeras, I.E. Brooks, N. D'Anna, 1. Dellaporta, G. Freyer, Y. Katoh, C. Keller, P.M. Lin,
P.A. Myers, D. O'Loane, K. O'Neil, B. Parsons, M. Wallace
During the past year, the Nucleic Acid Chemistry
group has continued to accumulate data toward the
elucidation of the Ad2 DNA sequence. In addition,
we have begun characterizing mRNA splice points
in early region-IV mRNAs. The development of
computer programs to analyze these sequences has
continued and is now focusing on computer-
graphic routines. Our long-standing interest in
restriction endonucleases and methylases has been
maintained, and a major effort is being directed
towards the characterization of the PaeR7 retric-
tion-modification system, which we have cloned in-
to Escherichia coli.
Adenovirus-2 Genomic Sequence
R.J. Roberts, K. O'Neill, B. Parsons
At the present time, two main blocks of sequence
have been collected. The first segment consists of
16,000 nucleotides located between 0% and 43%
of the genome, of which 0-36% is in final form, and
confirmatory data is being collected between coor-
dinates 36% and 43%. The second main block of
sequence is located at the right end of the genome
and consists of 4000 nucleotides of completed se-
quence between genome coordinates 89% and
100%. In addition, all but a few nucleotides of the
region between genome coordinates 66% and 70%
have been obtained. As a result of the information
available from this laboratory and from others, most
notably the groups of F. Galibert (Hopital Saint-
Louis, Paris), U. Pettersson (University of Uppsala,
Sweden), and J. Sussenbach (University of Utrecht,
Holland), more than 95% of the complete sequence
is now available. As soon as an uninterrupted se-
quence for the Ad2 genome is obtained by combin-
ing our data with the data from these other
laboratories, the remaining task will be to identify
and confirm those differences that occur between
our strain and the strains used in these other
laboratories. Because we already have a great deal
of data corresponding to regions sequenced in other
laboratories, we know that these strain differences
are rather limited and so far number less than 10.
From the analysis of the sequences that are
presently available in final form, it is apparent that
the information content of the Ad2 genome is ex-
traordinarily high. There are numerous examples of
overlapping genes. This can occur through the use
of different reading frames on the same strand and
also by the use of overlapping reading frames on
complementary strands. Nowhere is this more pro-
nounced than within the region between genome
coordinates 14% and 30%, which at one time was
considered the silent region of the Ad2 genome! It is
now almost certain that one long open reading
34
frame, located on the I strand between coordinates
14.2% and coordinate 23%, encodes the main
body of the Ad2 DNA polymerase. At both the C
terminus and the N terminus of this gene, there are
overlapping reading frames on the same strand.
One of these, which overlaps the C terminus, is
known to encode the N terminus of the IVa2 poly-
peptide. Within the main body of the gene, there
are two other reading frames that are open on the
r strand. Recent evidence from C. Anderson (Brook-
haven) and J. Lewis (Seattle) indicates that poly-
adenylated mRNAs, from which these reading
frames can be translated in vitro, are present in
Ad2-infected cells. In one case, the corresponding
mRNA is entirely contained within the intron that is
removed during the splicing of the first and second
leaders of late mRNA, whereas the second is con-
tained within thoSe mRNAs that carry the i leader,
which was first identified by T. Broker et al. (Elec-
tron Microscopy Section). Other significant stretches
of open reading frame also exist within this region,
however so far there is no information to suggest
that they are used. The sequences in this region also
contain other biological information. Both the late
promoter and the promoter for the IVa2 mRNA lie
within it, as do the signals that direct the splicing of
the first, second, and i leaders of late mRNAs.
Computer Program Development
T.R. Gingeras, C. Keller, R.J. Roberts
For several years now, we have been developing
computer software designed to aid both in the
assembly of DNA sequences and in the subsequent
analysis of the data. These programs are written in
FORTRAN, a language that is relatively transport-
able to other computers, and copies of the programs
have been widely distributed.
During the course of the last year, we have made
considerable improvements in many of our pro-
grams that are concerned with the assembly of DNA
sequences. In particular, we have streamlined the
two main programs that handle the data base of in-
formation about the various M13 clones that we ob-
tain together with the sequence reactions that have
been carried out on these clones. We have also
streamlined the procedure by which primary pieces
of sequence data that overlap are joined together.
Finally, a new program, SCROLL, has been devel-
oped in collaboration with M. Corcoran and
P. Rice. This program takes a main segment of com-
pleted sequence and extracts from the master data
base of primary sequence all of those segments that
were used to deduce the complete sequence. These
segments are then aligned with respect to the main
sequence in such a way that the accuracy of that se-
quence, as judged by the number of times that an
individual base has been determined independent-
ly, can be readily visualized. The output from this
program is extremely useful during the final stages
of the sequencing project when it is desired to
recheck those regions that may be most susceptible
to error.
We have also made considerable progress in
writing software that gives a graphic representation
of the information content of a sequence using a
high-resolution graphics terminal. Thus, we have
developed programs that will accurately display
restriction enzyme maps and open translational
reading frames. In addition, we have programs that
will allow graphic display of searches, either for
specific nucleotide sequences or for information
about specific peptides. It is already clear to us that
the use of computer graphics in an interactive mode
provides a powerful tool with which to access the
information content of a long sequence.
Restriction Endonucleases
I.E. Brooks, P.M. Lin, P.A. Myers
The list of restriction endonucleases continues to
grow, and at the present time 398 different enzymes
have been found with at least 91 different
specificities represented. For the last 2 years, we
have been involved in a joint project with D. Comb
and I. Schildkraut (New England Biolabs) during
which we have examined more than 170 strains for
restriction endonucleases. So far a total of 47 type-II
enzymes have been found and 11 new specificities
identified. The 15 enzymes discovered during the
last year are listed in Table 1. In addition, we have
also determined recognition sequences for the
previously described enzymes BstXI and Bsp1286.
BstXI recognizes the sequence CCANNNNNSNTGG
and is only the second example of an enzyme that
recognizes this rather unusual sequence pattern.
Bspl 286 recognizes the sequence
G C
GA GC AC
T T
Table 1
and is identical in specificity with two bther enzymes
(Sdul and Nsp[7524] Ill that have recently been
described by other laboratories.
Early Region IV of Adenovirus 2
C. Freyer, Y. Katoh
Early region IV of Ad2 maps between coordinates
91.3% and 100% on the viral genome and is express-
ed early in infection. Transcription of this region has
been studied extensively by electron microscopy and
is known to be complex. Some of the polypeptides
derived from this region have been partially charac-
terized; however, this region's role in the Ad2 life
cycle is not well understood. We have been study-
ing the splicing patterns of the mRNAs produced
from this region at the sequence level by cloning
cDNAs corresponding to early region-IV mRNAs.
Initially, a cDNA library was constructed in the con-
ventional way using mRNA isolated early during Ad2
infection of HeLa cells. Eighty early region-IV clones
were isolated, and sequence analysis of a represen-
tative selection enabled us to identify donor and ac-
ceptor splice sites for several of the known mRNAs. In
addition, two of the cDNAs that we have sequenced
correspond to mRNAs that had not previously been
reported. One surprising finding was that the large in-
tron lying between coordinates 92% and 95%, which
is common to several early region-IV mRNAs, did not
contain unique donor and acceptor splice sites. Unfor-
tunately, most of the clones that we isolated were not
full length and, in particular, were lacking the 5'
leader sequence. Since the mRNAs that arise from ear-
ly region IV fall into families based upon the particular
acceptor splice site to which this 5' leader sequence
is joined, we were not able to discover whether the
heterogeneity in the large intron correlated with
specific families of mRNA, or whether all families
would show this heterogeneity.
To answer this question, we have devised a new
strategy for the construction of a cDNA library that
leads to an increase in the frequency of full-length
cDNA clones. To this end, we synthesized a short
oligonucleotide of 15 bases that exactly matches a
Strain
Actinomadura madurae
Halococcus agglomeratus
Nocardia brasiliensis
Nocardia brasiliensis
Nocardia dassonvillei
Nocardia minima
Nocardia otitidis caviarum
Rhodococcus rhodochrous
Rhodococcus species
Rhodococcus species
Rhodococcus species
Streptomyces dysgalactiae
Vibrio harveyi
Enzyme
Amal (Nrul)
Hagl
Nbrl (Nael)
Nbal (Nael)
Ndal (Narl)
Nmil (Kpnl)
Nocl (Pstl)
Rrhl (Sall)
RrhIl
Rhsl (BamHI)
Rhpl (Sall)
Rhpll
Rhel (Sall)
Sdyl (Sau96I)
Vhal (Haell1)
Recognition sequence
TCGCGA
unknown
GCCGGC
GCCGGC
GGCGCC
GGTACC
CTGCAG
GTCGAC
unknown
GGTACC
GTCGAC
unknown
GTCGAC
GGNCC
GGCC
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portion of the early region-IV leader sequence. The
four 5' nucleotides were complementary to the 5' ex-
tension that is left when DNA is cut with Sall (TCGA).
This single-stranded oligonucleotide was then ligated
onto the Sail end of a pBR322 vector that had been
prepared by digestion with Hindlll and Sail. Poly(A)
plus mRNA isolated from Ad2-infected He La cells was
then used to make cDNA using oligo(dT) priming.
This mixed population of cDNAs was then annealed
to the vector and second-strand synthesis carried out,
such that the oligonucleotide that had been ligated to
the vector could serve as a primer for its synthesis.
This was followed by ligation and transformation. A
large number of early region -IV cDNA clones have
been isolated from this library. Plasmid DNA from
these clones was sequenced directly using the original
oligonucleotide as a primer, and more than 80% of
the clones examined were found to contain the 5'
leader sequence. Since the first leader is extremely
short, these sequence reactions also reveal the posi-
tion of the first splice in each cDNA. A second syn-
thetic oligonucleotide that maps close to the junction
sequences of the large intron will be used to finish the
characterization of these clones.
The method that we have used for the production of
these early region -IV cDNAs containing an intact 5'
leader sequence was remarkably successful. To test its
more general applicability, we plan to employ a
similar strategy for the cloning of early region-I1B
cDNAs where the mRNAs are present in much lower
amounts.
A Substrate for In Vitro Splicing
G. Freyer
Despite a great deal of work, there has so far been lit-
tle success in the characterization of a good in vitro
system able to accomplish mRNA splicing. One pro-
blem in this area is the difficulty of isolating large
quantities of a suitable substrate with which to assay
splicing activity because the nuclear precursors of
these mRNAs are present in exceedingly low quan-
tities. In an attempt to overcome this difficulty, we
have constructed a recombinant plasmid that is
designed to produce an accurate Ad2 late transcript
under the control of an E. coli promoter. The scheme
for the construction of the clone was as follows. A
restriction fragment containing the Ad2 major late start
site was cloned into pBR322. A strong terminator from
phage fd was then inserted downstream at the BamHl
site of pBR322. The leftwards lambda promoter (PO
was then inserted next to the Ad2 sequences such that
the Pribnow box lay approximately the same number
of nucleotides away from the Ad2 late start as it does
for the lambda leftwards start site. The Ad2 HindIIIB
fragment was then inserted so as to reconstruct a con-
tinuous section of Ad2 sequence beginning at the ma-
jor late start site at 16.6% on the Ad2 genome and
continuing out to 31.5%. Finally, a poly(dA)-poly(dT)
stretch was added so that transcripts ending in poly(A)
could be produced by in vitro transcription with E.
coli RNA polymerase.
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Initial studies have shown that in vitro the E. coli
RNA polymerase can make a specific transcript con-
taining Ad2 sequences which can be easily purified
by virtue of its poly(A) tail. Direct RNA sequence
analysis of the transcript produced in vitro shows that
it initiates to the left of the normal Ad2 late transcript
start site. Furthermore, the level of transcripts pro-
duced in vitro are lower than those usually ob-
served with lambda P1. We are currently attempting
to remove two bases from the region between the
Pribnow box and the transcription start site so as to
ensure that the in vitro transcript exactly matches, at
its 5' end, the in vivo Ad2 transcript. Once that is
completed, we will then attempt to use this RNA as
a substrate with which to assay in vitro mRNA
splicing.
Cloned Restriction-modification Genes
I.E. Brooks, T.R. Gingeras
We have continued our work on the cloning and
characterization of type-II restriction-modification
systems. The proteins encoded by these systems are of
interest, not only as invaluable tools to the molecular
biologist, but also as a means of studying specific
DNA-protein interactions. During the past year, we
have concentrated on two plasmid-borne systems,
PaeR7 and EcoRII. The PaeR7 system was isolated
from a plasmid of Pseudomonas aeruginosa. We have
succeeded in transferring these genes into a pBR322
vector and propagating them in E. coli (Gingeras and
Brooks, Proc. Natl. Acad. Sci. 80: 402 [1983]). By a
series of BAL31 nuclease digestions, we have been
able to clone separately the restriction endonuclease
and modification methylase genes. Clones containing
only the endonuclease gene are of particular interest
because extracts of these clones display restriction en-
donuclease activity, although there is no apparent
restriction of the growth of infecting phages. Further-
more, chromosomal and phage DNAs isolated from
these host cells are not protected against cleavage by
PaeR7 in vitro.
The subclones obtained by BAL31 deletion have
been examined for their levels of expression of the en-
donuclease and/or methylase both in vivo and in vitro
(Table 2). In addition, restriction maps of these
subclones have been obtained and in several cases
deletion end points have been sequenced. From this
analysis, it appears that both genes are under the con-
trol of a common promoter with the methylase gene
lying proximal to the promoter and the restriction en-
donuclease gene lying distal to it. In collaboration
with G. Theriault, this controlling region has been se-
quenced and contains a sequence identical to that of
the E. coil arac promoter. Clones that are endo-
nuclease*, methylase (restriction- in vivo) have
deleted either part or all of this region and charac-
teristically show low endonuclease levels (Table 2).
The determination of the complete nucleotide se-
quence of the PaeR7 system, as well as efforts to
isolate and identify the protein products made by
this system, are now in progress.
Table 2
Properties of Clones Containing the PaeR7 Restriction-modification System
Phenotypeb
in vitro in vivo Endonuclease
levels`
Stability upon
retransformationdClones' R M R M
1. RM 3.8
2. A1.4
to-5
o-5
1.0
1.0
1
10-2-10'
3. A 1.3 1.0 0.1 10-3-10-2
4. R 2.3 1.0 0 10'3-10-2
5. R 1.9 1.0 0 <10-3
6. M 2.7 0 1.0 NA' +
'A clones are deletion mutants formed after treatment of the RM3.8 clone with BAL31 nuclease.
bin vitro phenotype refers to restriction endonuclease and modification methylase activity, respectively, on Ad2 DNA
substrates by crude extracts; in vivo phenotype refers to restriction and modification, respectively, of 580 phage used to
infect the various host clones.
`A pBR322 derivative plasmid containing one PaeR7 site is linearized at a distal site and used as a substrate on which
to measure endonuclease activity. The endonuclease activity of RM3.8 is standardized to 1.0.
dStability of these constructs is measured as their ability to maintain initially measured level of phage restriction after
two or three rounds of retransformation.
eNA, not applicable.
E. coli also carries plasmid-borne restriction-
modification systems. We have been characterizing
the EcoRII restriction-modification system. This system
differs from the Pae system in that modification is bas-
ed on cytosine rather than adenine methylation and its
recognition site is CMG (the internal cytosine is
modified). This is also the recognition sequence for
the Eco dcm methylase found in E. coli strains, and
such sites are reported to be "hot spots" of recom-
bination in E. coli (Coulondre et al., Nature 274: 775
[1978]). We have now isolated the EcoRII restriction-
modification genes on a 5-kb fragment and have
begun BAL31 deletion experiments to characterize
the order and position of the genes. Comparative
studies involving PaeR7, EcoRII, and EcoRl systems
(Newman et al., J. Biol. Chem. 256: 2131 [1981];
Greene et al., J. Biol. Chem. 256: 2143 [1981]) have
been initiated to see if plasmid-borne systems share
common features of organization and control of ex-
pression, as well as to explore their possible sequence
homology, which might indicate that they have a
common evolutionary origin. Additionally, we are in
the process of exploring the role that the Eco dcm
methylase gene plays in E.coli. This will be done by
introducing clones expressing EcoRII methylase into
dcm- cells. In addition to being identical in its en-
zymatic specificity, preliminary evidence shows
EcoRII and dcm to be homologous in DNA sequence,
as assayed by Southern blot analysis.
As we noted in last year's report, the availability of
cloned DNA methylase genes recognizing a variety of
site-specific nucleotide sequences presents the
possibility of investigating the effect of DNA modifica-
tion on the control of gene expression in eukaryotic
cells. Recently, there has been accumulating evidence
that DNA methylation is important in eukaryotic gene
regulation. Because it has been technically impossible
to isolate eukaryotic DNA methylase genes and dif-
ficult to study their protein products, we have con-
structed eukaryotic expression vectors containing a
variety of DNA methylation genes from prokaryotic
cells. Development of these heterologous systems will
make it possible to study the role of site-specific DNA
modification during eukaryotic gene expression. We
have begun by transferring the M Eco dam gene in-
to Saccharomyces cerevisiae using the yeast-E. col/
shuttle vector YEP228. This was accomplished after
we had isolated and sequenced this gene (Brooks et
al., Nucleic Acids Res. [1983, in press]) which
methylates the sequence G°ATC. Knowing the
complete sequence of this gene enabled us, in col-
laboration with R. Kostriken and F. Heffron
(Mechanism of Transposition Section), to obtain ex-
pression in yeast cells. We have found that all of the
GrnATC sequences are modified in yeast cells con-
taining this recombinant plasmid.
Although adenine or cytosine methylation does
not occur normally in the yeast genome (D. Swinton
and S. Hattman, pers. comm.), the appearance of
such significant levels of DNA modification does
not appear to affect any of 12 different metabolic
pathways tested nor does it affect the rate of growth
of these cells. dam* yeast clones are now being used
to study nucleosome structure of the genome by
digesting chromatin with restriction endonucleases
that recognize GATC and either require (Dpnl) or
are blocked (Mbol) by dam expression.
The dam gene has also been transferred into
another eukaryotic expression vector pXKH (D.
Hanahan) and, in collaboration with D. Kurtz (Hor-
monal Control of Gene Expression Section), has
been transformed into cultured mouse L cells. The
results from these experiments appear positive for
expression of dam and are currently being ana-
lyzed.
More in line with the type of DNA modification
that is normally found in eukaryotic cells (5-methyl-
cytosine), we have begun work on transferring two
cytosine methylase genes (from type-II restriction-
modification systems) into eukaryotic host cells.
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These methylase genes are the EcoRII methylase
gene from E. coli ('"CMG) and the Boll methyl-
ase gene from Bacillus centrosporus (CrnqGG). In
general, we are fusing these prokaryotic methylase
genes to an inducible eukaryotic promoter so that it
will be possible to control expression of these
modification processes. In collaboration with D.
Kurtz, we wish to determine if modification at
CpmCpG or mCpCpG will affect the levels of gene
expression of specific gene products made within
the host cells.
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ELECTRON MICROSCOPY
T.R. Broker, L.T. Chow, J.A Engler, M. Rossini, R.A. Guilfoyle, M.S. Hoppe, R. Galli, W. Osheroff,
Al.. Pelletier, D. Campanelli, M. Hallaran
We have concentrated on four major research pro-
jects during the past year: (1) transcription of and
cellular transformation by human papilloma virus
DNA contained in a variety of shuttle-expression
vectors; (2) completion of the DNA sequence of
group-B human adenovirus type 7 (Ad7) between
chromosomal map coordinates 8.8 and 31.5, inter-
pretation of the RNA regulatory and processing
signals and coding regions, and comparison with
the analogous DNA sequences of the group-C
adenovirus types 2 and 5 (Ad2, Ad5); (3) analysis of
regulatory interactions of adenovirus early regions
1A and 2A using a combination of site-directed
mutagenesis of cloned DNAs, DNA sequencing and
microinjection, and indirect immunofluorescent
detection of protein products of the cloned genes;
and (4) characterization of the structures and se-
quence relations of four chicken (3-tubulin genes.
Each of these systems and the results obtained are
discussed below in detail.
Dr. Peter Howley of the National Cancer Institute
and T.R.B. co-organized a Papilloma Virus Meeting,
which was held'at Cold Spring Harbor Laboratory
from September 14-18, 1982. The conference at-
tracted 120 molecular geneticists, cell biologists,
and clinicians, as described in detail elsewhere in
this Annual Report.
Human Papilloma Virus RNA Transcription
L. Chow, T. Broker, R. Galli, D. Campanelli,
A. Pelletier
We initiated the study of HPV-1 transcription in the
fall of 1981 before the viral DNA was sequenced.
We chose pBR322 derivative vectors pSVO8 and
pSV010 (from R. Myers and T. Tjian, Proc. Natl.
Acad. Sci. 77: 6491 [1980]). These vectors are
deleted for the pBR322 poison sequence which in-
hibits DNA replication in eukaryotic cells. They
contain the SV40 origin of replication but no major
cap sites of SV40 early or late mRNAs. Neither vec-
tor has a complete copy of the SV40 72-bp en-
hancer sequence necessary for SV40 early RNA
transcription (Banerji et al., Cell 27: 299 [1981];
Benoist and Chambon, Nature 290: 304 [1981]). At
the time, they were felt to be SV40 promoter-minus,
with little likelihood of interference with the expres-
sion of the inserted genes. The recombinant
plasmids are able to replicate in COS cells (SV40-
transformed monkey CV-1 cells; Gluzman, Cell
23: 182 [1981]). For lack of information on the
genomic organization of HPV-1, we cloned full-
length chromosomes (extracted from viruses iso-
lated from deep plantar warts) opened in a number
of different circular permutations using the BamHl
restriction site, both of the EcoRl restriction sites,
and three of the four Bglll restriction sites (Fig. 1).
We anticipated that transcription units would be
uninterrupted in at least one of the constructs.
Recombinant plasmids were transfected into COS
cells using a calcium phosphate precipitation pro-
cedure. Cytoplasmic RNAs were isolated 48 hours
posttransfection and examined by electron micro-
scopy after hybridization to linearized HPV-1
recombinant DNA (Figs. 2 and 3; Chow and Broker
1983). The results can be summarized briefly as
follows:
(1) The HPV-containing plasmids were replicated
to very high copy number in the COS cells.
(2) The activity of the HPV-1 promoter(s) is ex-
tremely low. This was quite unexpected because of
the high gene dosage. Rare transcripts comprising
less than 0.001% of the poly(A)-containing mRNAs
originated from minor SV40 early or late cap sites,
depending on the orientation of HPV-1 in the clone
relative to SV40. The transcripts extended over
40-80% of one and the same strand of HPV-1, with
none complementary to the other strand.
(3) Two spliced RNAs were observed (Figs. 2 and
3). The main body of the major species corresponds
to the predominant species seen in BPV-1-trans-
formed mouse cells (Heilman et al., Virology 119:
22 [1982]). The main body of the minor species cor-
responds to the BPV-1 mRNA encoding the major
capsid protein (L. Engel, C. Heilman, and P. How-
ley, pers. comm.). Each has a 5' leader sequence
spliced to the main body. Both species correlate
well with the open reading frames of the HPV-1
DNA sequence subsequently published (Danos et
al., EMBO J. 1: 231 [19821) (Fig. 1). The 3' ends of
the RNA as mapped by electron microscopy (EM) also
correspond to the locations of AATAAA signals
for cleavage and polyadenylation found in the DNA
sequence at the ends of the two gene blocks (Fig. 1).
(4) Splice acceptor sites of the main message body
remain the same irrespective of whether the 5' ends
of the RNAs were derived from the early or late
SV40 promoter and cap site.
(5) Primary transcripts initiated from the SV40
minor early promoter extend completely through
the pBR322 vector sequences and on to one or the
other HPV poly(A) site. During their processing, two
donor and one acceptor splice sites (and one leader
segment) were derived from the antisense se-
quences of the ampicillin gene in pBR322.
(6) Indirect immunofluorescence assays for the
HPV capsid protein using antibodies directed
against disrupted HPV-1 virions gave negative
results in these transfected cells, consistent with the
low amount of viral RNA.
We also transfected the plasmids into HeLa cells
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Figure 1
Organization and expression of human papilloma virus type-la. (i) HPV-1 RNA transcripts generated from a surrogate SV40
late RNA promoter in an expression vector transfected into COS cells (Chow and Broker 1983) (see Fig. 2). (ii) Human
papilloma virus type 1 a, sequenced by Danos et al. (EMBOLI: 231 [1982]; I. Virol. 46: 557 [19831). The circular genome
is represented as a linear molecule opened at a site upstream of the transformation genes. Selected restriction endo-
nuclease cleavage sites are indicated. Significant open translation regions in each of the three reading frames of the
sense strand are shown. Dashed bars in open frames mark the positions of the first potential AUG initiation codon. Open
translation frames are labeled by T (transformation region) or M (morphogenesis region). The locations of promoters
and the DNA replication origins are not known. Splicing of primary RNA transcripts (see Fig. 3) potentially would join
open translation frames in presently undefined combinations. Vertical arrows indicate the positions of AATAAA
sequences, potential signals for 3' cleavage and polyadenylation of transcripts. Dots above the axis indicate 1000-bp
intervals from the index position.
because transcription of some genes has been
reported to be better in HeLa than in COS cells,
even though they will not replicate and amplify.
Again, HPV-1 mRNAs remained extremely rare, as
assayed by EM analysis of RNA:DNA hetero-
duplexes. In another attempt to increase the activity
of the HPV-1 promoter, we treated the transfected
HeLa or COS cells with a low dose of azacytidine.
This base analog inhibits cytidine methylation,
which has been shown to be associated with tran-
scriptionally inactive genes. Still we saw no im-
provement of HPV-1 transcription.
A drawback in trying to study gene expression by
transient expression in transfected cells is the low
percentage of cells that successfully take up DNA
(typically 5-20%). We have tried other protocols
that have produced high (>70%) efficiency of
transfection in certain cell types. Again, there was
hardly any HPV-1 RNA in the cytoplasm. We con-
clude that transcription of HPV-1 is unusually
restricted in otherwise successful expression vec-
tors, as it also is in warts in situ.
Transformation of tk-Cells by Cloned Human
Papilloma Viral DNA
One way to ensure that each cell in a culture has
many copies of the HPV-1 DNA sequence is to
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isolate transformed cells containing HPV-1 DNA.
We elected to use the herpes simplex virus type-1
thymidine kinase (tk) gene as a selectable marker.
The tk gene (without a promoter) can initiate tran-
scription from within the coding region (apparently
from an adventitious "TATA" sequence and 5' cap
site), and the shortened RNA is translated from an
internal, in-phase AUG initiation codon into a
somewhat defective protein (Zipser et al., Proc.
Natl. Acad. Sci. 78: 6276 [1981]; Roberts and Axel,
Cell 29: 109 [1982]). Cells can become successfully
transformed and HAT-resistant with such a defective
tk gene only when it is highly expressed from
amplified tk genes present at several hundred
copies (ibid). Long stretches of DNA next to the tk
gene are also amplified in the process. Therefore,
we chose to make HPV-1 recombinants containing
a promoterless tk gene. The recombinants were
transfected into mouse Ltk- cells and human 143 tk-
cells using a calcium phosphate precipitation pro-
cedure, and the cells were put under HAT selection.
We expected that each surviving cell would have
several hundred copies of the HPV-1 DNA.
Two major types of tk* HPV-1 recombinants were
constructed. Four recombinants were in a pBR322
vector and four in a pBR322 derivative, .13SVAPH,
a vector that we modified from plasmid pSVAPH
(Treisman et al., in Eukaryotic Viral Vectors, p. 63,
Cold Spring Harbor Laboratory [1982]). Two of the
Figure 2
Electron micrographs of RNA transcripts of HPV-1. (a) Total cytoplasmic RNA was isolated 48 hr posttransfection of
COS-1 cells with HPV-1:pSVO8 plasmid D2 (cf. Fig. 3A). It was annealed to plasmid 6.3 DNA, which consists of HPV-1
DNA opened at the Bg111 site at nucleotide 594 and inserted into the pSV010 WI site in the polylinker. Plasmid 6.3
was linearized prior to R-loop formation at its Clal site in the polylinker on the side of the vector (near SV40 cf. Fig. 3A).
The RNA is annealed to a terminal fork in the partially denatured DNA. lb) RNA from the same preparation was annealed
to plasmid 55.2 DNA, which consists of HPV-1 DNA opened at the Bglll site at HPV-1 nucleotide 5581 and inserted into
the pSV010 4111 site in the polylinker in the same orientation as plasmid 6.3. Plasmid 55.2 was linearized at the
Clal site in the polylinker prior to R-loop formation. The 5' and 3' ends of the RNAs are labeled with arrows and
the DNA deletion loop corresponding to the single intervening sequence in each RNA is marked with a large arrow-
head. (c) and (c') RNA from the same COS cell extract was annealed to plasmid 6.3 DNA, as in a. The RNA termini
and the two DNA deletion loops corresponding to the two intervening sequences removed from the RNA are in-
dicated as in a and b. In the interpretive tracing, RNA is depicted with the dashed line. The locations of the 5' ends of
both species of RNA (cf. schematic illustration in Fig. 3A) suggest they were initiated from an SV40 late promoter in
the vector. (d) and (d') Total cytoplasmic RNA isolated 48 hr posttransfection of COS-1 cells with HPV-1:pSV010
plasmid B38 (cf. Fig. 3B) was annealed to plasmid 6.3 DNA to form R loops. The DNA deletion loop correspond-
ing to the first intervening sequence (IVS) encoded by the pSV010 vector is indicated with an arrowhead. The DNA
was linearized at the Xorll site in the vector, which is within the second IVS, as reflected by the short and long duplex
DNA tails, also marked by large arrowheads. In the interpretive tracing, RNA is depicted with the dashed line. (See
Fig. 3B for a graphic representation.)
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Figure 3
Human papilloma virus RNA transcripts (Chow and Broker 1983). The spliced RNAs generated from A, an SV40 late pro-
moter in the vector pSV08, or B, an SV40 early promoter in vector pSV010 transfected into COS cells, were mapped by
electron microscopical analyses of heteroduplexes or R loops formed between cytoplasmic RNAs and linearized cloned
DNAs. In B, note the use of cryptic donor and acceptor splice sites derived from pBR322 sequences in the vector, and the
RNA "leader segment equivalent to part of the antisense strand of the amp gene. The SV40 and the pBR322 replication
origins are marked. The conserved HPV-1-specific sequences of the hybrid transcripts from the two plasmids are iden-
tical. The alignments of the RNAs derived from the late SV40 late promoter in A with the open translation frames are
shown in Fig. 1. The nucleotide numbering system was recently altered so that the BamHl restriction site is at nucleotide
3538.
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recombinants are shown in Figure 4, A and B.
*pSVAPH lacks the pBR322 poison sequence; it
contains one copy of the SV40 enhancer and the
SV40 origin of replication and, due to a deletion in
the 21-bp repetition in the SV40 segment, lacks
SV40 promoter activity. In these recombinants, the
HPV-1 viral DNA was linearized at the EcoRI site at
nucleotide 7777, which is upstream from both a
"TATA"-like sequence in the putative HPV pro-
moter region (Danos et al., EMBO J. 1: 231 [1982])
and all open reading frames. The HPV was inserted
into the vector in different locations and orienta-
tions, relative to the transcription direction of the tk
gene as well as the SV40 enhancer sequence. Very
few tk+ colonies were recovered from cells trans-
formed with clones containing pBR322 as a vector
(about 30 transformants /µg DNA). When the pBR322
derivative lacking the poison sequence was used as
the vector (see Fig. 4B), tk+ colonies were readily
recovered (about 3000 transformants /µg DNA). A
large number of transformants were isolated and
grown up under HAT selection. Southern blot
analyses of both low-molecular-weight and total
cellular DNA of the tk+ transformants confirmed the
presence of HPV-1 DNA. To our surprise, the copy
number in each transformed cell was fewer than 10,
indicating the recombinants were not amplified.
Therefore, unlike in previous reports, the attenuated
tk gene was sufficient to confer HAT resistance. It is
possible that the SV40 enhancer had an effect on the
cryptic tk promoter and stimulated its activity suffi-
ciently without requiring high gene dosage. Simi-
larly, in the few tic' colonies that arose in cultures
transformed by recombinants of poison sequence-
containing pBR322-tk-HPV1 that had no SV40 se-
quences (see Fig. 4A), the input DNA was not
amplified. This suggests that an HPV enhancer-like
effect on the transcription of the truncated tk gene
has occurred. An enhancer sequence has been
located in the BPV-1 sequence which stimulates tk
transformation by the intact HSV-1 tk gene (Lusky et
al., in Eukaryotic Virol Vectors, p. 99, Cold Spring
Harbor Laboratory [1982]).
HPV-1 recombinants in some of the transformants
have integrated. But some apparently exist as
plasmids, as demonstrated by Southern blotting ex-
periments. A number of plasmids have been recov-
ered from Hirt lysates of the transformed cells into E.
coli bacteria using ampicillin selection. Some have
small DNA rearrangements and others have gross
deletions; they are now being mapped by EM
analysis of DNA:DNA heteroduplexes.
We have isolated cytoplasmic RNAs from tk+
transformants where the DNA rearrangements did
not involve HPV-1 sequences. Unfortunately, no
HPV-1-specific RNA was found, even when the
transformants were treated with 10-7 M 12-0-
tetradecanoylphorbal-13-acetate (TPA), a phorbol
ester known to increase the transcription of BPV-1
viral sequences in BPV-1-infected mouse embryo
fibroblast cells (Amtmann and Sauer, J. Virol. 43: 59
[1982]). These HPV-1-tk-SV Ori recombinant plas-
mids were also transfected into COS and HeLa cells.
The level of HPV-1 RNA transcription was not
higher than in our original experiments. Therefore,
the SV40 enhancer had no detectable effect on the
HPV promoter(s).
Transformation of Primary Rat Cells
Recombinant plasmid 1-24 is an HPV-1 recombinant
we have cloned using *pSVAPH as a vector without
including the tk gene (Fig. 4C). It was used to
transform primary baby rat kidney cells. Mor-
phological transformants (foci) appeared in 10-14
days. Southern blot experiments showed that
HPV-1 recombinant DNA existed in these cells as
plasmids with fewer than 10 copies per cell. Plas-
mids were rescued from Hirt lysates of the
transformed cells into E. coli HB101 via ampicillin
selection. The majority of the recovered plasmids
were identical to the input DNA, as judged by three
different restriction endonuclease digestions (EcoRI,
Bg/II, and HindlIl).
Cytoplasmic RNA was isolated from TPA (phorbol
ester) treated or untreated transformants. Despite
the successful expression of the HPV transformation
genes, our preliminary results indicate the level of
HPV-1-specific mRNA remains miniscule. 1-24 plas-
mid was also used to transfect COS and HeLa cells
to no avail. Again, it appeared that the SV40
enhancer has little effect in this system.
In summary, the results from all our experiments
indicate that the transcriptional promoter(s) of HPV-1
is very inefficient. Although we can not rule out
that part or all of it has been separated from the rest
of the transcription unit during DNA cloning, it
clearly can not be the only cause of inactivity. We
conclude this because, in two of the recombinants
we made, HPV-1 was linearized with BglIl cleavage
in the morphogenesis region M, (see Fig. 1), well
upstream from the segment in which the promoter
is suspected to be located (between M, and T6).
Cells transfected with these clones did not produce
more HPV-1 RNA than those cloned at the EcoRl
site at nucleotide 7777.
Adenovirus-7 DNA Sequence and
Interpretation
J. Engler, M. Hoppe
In the 1981 Annual Report, many of the features of
the Ad7 DNA sequence between map coordinates
8.8 and 31.5 were discussed. Resolution of the few
remaining uncertainties allowed the preparation of
the complete sequence analysis shown in Figure 5.
The protein IX and IVa2 coding regions were
described in detail in previous reports. The longest
open translation frame (map coordinates 23.0-13.8)
encodes a 140-kD protein, which has recently been
shown to be a DNA polymerase (Enomoto et al.,
Proc. Natl. Acad. Sci. 78: 6779 [1981]; Stillman and
Tamanoi, Cold Spring Harbor Symp. Quant. Biol.
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Figure 4
Shuttle-expression vectors for HPV-1. HPV-1 virion DNA
from a single plantar wart was linearized by partial diges-
tion with EcoRl restriction endonuclease and inserted into
vectors we constructed from elements available from others,
as described below. The clones selected for con-
tinued study were those in which the HPV-1 was opened
at the EcoRl site at nucleotide 7777, presumably upstream
from the promoter for the T region. (A) A pBR322 clone of
a truncated herpes simplex virus type-1 thymidine kinase
(tk) gene was obtained from Zipser et al. (Proc. Natl. Acad.
Sci. 78: 6276 [1981]). The truncated tk gene apparently is
transcribed from an adventitious TATA "promoterlike" se-
quence within the coding region of the gene, and transla-
tion of the mRNA utilizes an in-phase AUG initiation
codon, as indicated. We removed the EcoRl site in
pBR322 by restricting, filling in the cohesive ends, and
religating the blunt ends. The HPV-1 was then recombined
into the EcoRl site downstream of the tk gene. (B) pSVAPH
was obtained from Dr. Michael Green (see Treisman et al.,
in Eukaryotic viral vectors, p. 63. Cold Spring Harbor
Laboratory [1982]). A deletion in the SV40 sequences
removes the "21-bp repetitions" and part of one of the
72-bp "enhancer sequences" to eliminate SV40 early pro-
moter activity. The vector retains enhancer activity from
the remaining intact 72-bp repetition. The plasmid also
has a deletion of one of the three T antigen binding sites
constituting the replication origin but retains a diminished
capacity for amplification in COS cells. The poison se-
quence in pBR322 that inhibits replication in eukaryotic
cells is deleted. We first excised the globin gene from
pSVAPH. The BamHl site in the pBR322 sequences of
this vector was then converted to an EcoRl site via linker
addition (vpSVAPH). The EcoRl -Sall fragment containing
the HSV-1 tk gene described in A was used to replace
the EcoRl -Sall fragment of *pSVAPH. Finally, the HPV-1
genome was inserted into the EcoRl site of the composite
vector. (C) The BamHl site in the pSVAPH (as in 8) was
converted to an EcoRl site, and HPV-1 was inserted into
this site.
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Figure 5
Adenovirus-7 (Ad7) DNA sequence analysis between coordinates 9.5 and 31 (Engler et al. 1983). (A) The distance from the left end of Ad7 is given in base pairs and in chromosome coor-
dinates. Thin lines designate early mRNAs from region E2B of Ad2; thick lines show the positions of the promoter and leader segments for the latemRNAs for proteins IX, IVa2, the i leader,
the viral-associated (VA) RNA genes, and the 5' end of the main body for late region 1 (the gene for the 52-kD-55-kD protein). (B) Vertical lines show the positions of stop codons in each
potential translation frame. The first ATG in each major reading frame is shown with a triangle and the first stop codon with a filled circle. Frames that are thought to encode proteins are
shown as open or filled rectangles; those that are highly conserved between Ad7 and Ad2 and Ad5 are shown as filled rectangles. The hatched rectangleshows the position of the 13.6-kD
polypeptide encoded by the i and third leaders equivalent to that identified in Ad2 by Virtanen et al. (Nucleic Acids Res. 10: 2539 [1982]). The 13.5-kD protein-coding region (Lewis and
Mathews, Cell 21: 303 [1980]; C.W. Anderson and J.B. Lewis, pers. comm.) is at the same position and of the same length in Ad2 and Ad7, and is generally conserved in sequence except
for a significantly higher number of arginine residues in Ad7.
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47: 741 [1983]). On the basis of DNA-negative
mutations mapping within the gene, the polymerase
is essential for viral replication. As reported last
year, the coding sequences for the carboxyl ter-
minus of the polymerase overlap those for the
amino terminus of the IVa2 protein. Ad2 DNA se-
quence over this same region was concurrently
determined by Gingeras et al. (I. Biol. Chem.
257: 13475 [1982]) and by Alestrbm et al. (J. Biol.
Chem. 257: 13492 [1982]). The few sequence dif-
ferences between Ad7 and Ad5 or Ad2 in this
region suggest that the greater selective pressure has
been on the polymerase; most differences are in the
degenerate positions of the codon triplets of the
polymerase, where they make little or no difference
in the specified amino acids, but they do alter the
IVa2 protein, which is translated in a different
phase. The splice junctions of the mRNA for the
polymerase have not yet been determined; hence, it
is not clear whether translation starts in the
upstream leader segment (map coordinates 39.5-
39.0) or at the first AUG initiation codon in the
main body of the RNA at coordinate 21.4. As shown
by the solid black bar in Figure 5, the region
of close homology in the Ad7 and the Ad2 genes for
the polymerase extends to coordinate 22.3, well
upstream from the first AUG codon. This and the
large size of the polymerase lend support to the
speculation that the amino terminus of the poly-
merase is encoded in the leader.
The coding region for the 87-kD protein, which is
covalently linked to the 5' termini of the DNA and
essential for the initiation of DNA replication (Chall-
berg et al., Proc. Natl. Acad. Sci. 77:1510511980]);
Stillman et al., Cell 23: 497 [1981]), is also
transcribed from the leftward-transcribed strand,
between coordinates 28.5 and 23.0. As with the
polymerase genes and mRNAs, it is not yet known
whether translation of the spliced messages begins
in the common leader from coordinate 39.5-39.0
or in the main body of the message. The 5' end se-
quences of the open translation frame of Ad7 are
not very similar to those of Ad2 between coor-
dinates 29.8 and 28.8. The overall nucleotide se-
quence homology of Ad7 and Ad2 within the (-
strand- coding regions is 80%.
A 13.6-kD protein (Lewis and Mathews, Cell
21: 303[1980]) specified at early to intermediate
times after infection by the i leader of the r-strand
mRNAs originating from the major late promoter at
16.6 (Chow et al., 1. Mol. Biol. 134: 265 [1979]).
Part or most of its coding sequences overlap the
coding region for the polymerase on the opposite
strand, a novel situation among eukaryotes. By
analogy to the Ad2 13.6-kD gene, the message for
which has been sequenced as a cDNA (Virtanen et
al., Nucleic Acids Res. 10: 2539 [1982]), the ter-
mination codon for the Ad7 13.6-kD protein is prob-
ably introduced after the splice of the i leader to the
third leader segment of the r-strand transcripts in
which it is included. The only place the three leader
segments of the late messages are not strictly co-
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linear is near the beginning of the third leader,
where Ad2 has an extra triplet codon (for the
13.6-kD protein) compared with Ad7. The carboxy-
terminal halves of the Ad7 and Ad2 13.6-kD pro-
teins differ significantly, unlike the entire remainder
of this genetic interval. The inferred sequences of
the amino termini of the Ad7 and Ad2 genes for the
52-kD-55-kD genes are very similar, but long in-
phase open reading frames just upstream of the
known splice site (Akusjarvi and Persson, Nature
292: 420 [1981]) are not similar. Nonetheless, these
may encode proteins from late messages with splice
acceptors for the third leader near coordinate 29
(Chow and Broker, Cell 15: 497 [1978]).
Comparison of unassigned open translation
frames of Ad7 and Ad2 suggest that only two, both
on the r strand, are reasonably homologous: One
appears to encode a 13.5-kD protein between coor-
dinates 16.9 and 17.9. Direct evidence for such a
protein has been found by Drs. J.B. Lewis and C.W.
Anderson (pers. comm.) using cell-free translation
of selected mRNA, but the RNA itself has not been
mapped. The second open frame spans the third
leader segment and suggests that the "long third
leaders" occasionally seen (Kilpatrick et al., J. Virol.
30: 899 [1979]; Chow et al., Cold Spring Harbor
Symp. Quant. Biol. 44: 401 [1980]) in r-strand
messages at intermediate times after infection might
encode minor proteins.
Following a very productive and interactive five
years at Cold Spring Harbor Laboratory, Jeff Engler
accepted a position as an Assistant Professor of
Biochemistry at the University of Alabama-Birming-
ham School of Medicine.
Adenoviral Early Gene Regulation
M. Rossini, R. Cuilfoyle, J. Engler, W. Osheroff,
M. Hoppe
We have continued to study the regulatory interac-
tion between human adenoviral genes expressed at
early times after infection by combining site-direc-
ted mutagenesis and microinjection techniques. We
have determined that the products of early region
lA (El A) differentially regulate the two primary pro-
moters for the single-stranded DNA binding protein
(DBP), one active at early times and the other at late
times. By microinjecting different E2A clones con-
taining the DBP gene in association with its early
promoter (at map coordinate 75), with its late pro-
moter (at coordinate 72) or with both the early and
the late promoters, we have shown that coinjection
of a plasmid that expresses early region 1A
stimulates the expression of the DBP mRNA tran-
scribed from its early promoter and inhibits the
production of the DNA binding protein (DBP) from
its late promoter (Table 1) (M. Rossini, in prep.). A
modulation of the inhibitory effect on the E2A
plasmid with the late promoter has been obtained by
varying the El A DNA concentration, providing more
Table 1
Expression of the 72-kD DNA Binding Protein after Microinjection of E2A Clones into Tk-ts 13 Cell Nuclei
Plasmid
injected
Ad DNA insert E2A promoter Percent nuclei positive
coordinates present for 72-kD protein
pAd207 + buffer
pAd207 + HE4a
pBR730 + buffer
pBR730 + HE4a
pFAG5 + buffer
pFAG5 + HE4a
pAd15.1 + buffer
pAd15.1 + HE4.
59.5-70.7
59.5-75.9
59.5-75.9b
50.7-72.8
none
early + late
early
late
3
2
15
81
20
87
53
16
About 10-11 ml of solution containing plasmid DNAs at a final concentration of 250 µg /ml were injected into
100-200 cell nuclei in each experiment. The average percentage of positive nuclei has been calculated from 5 to 10
separate experiments. The 72-kD protein was visualized by indirect immunofluorescence 20-24 hr after microinjection
using a hamster anti 72-kD serum (c-783 provided by A. Lewis) as the first antibodies.
'Plasmid HE4 includes adenovirus DNA sequences from coordinates 0-4.5. Similar results were obtained when an
E1A + E1B Be5 (coordinates 0-9.1) was coinjected.
'The DNA segment between coordinates 68.4 and 72.8 containing the late promoter has been deleted.
evidence that the inhibition is a direct function of El A
products. A primary objective of the past year has
been the determination of which El A products are
responsible for the interactions with the E2A pro-
moters.
From microinjection tests using El A plasmids
with short deletions introduced by site-directed mu-
tagenesis into different parts of the gene (N. Stow, I.
Virol. 37: 171 [1981]), we suggested last year that
the carboxyl terminus of the El A proteins includes
control functions that lead to the activation or
repression of the DBP gene. More detailed under-
standing has been achieved recently through the
use of two additional El A mutant plasmids, pEK
pm975 and phrl. The pEK pm975 (obtained from
Dr. A. Berk, University of California, Los Angeles), a
single base-pair transversion at the donor splice site
of the 12S mRNA, eliminates its production, but
does not alter the synthesis of 13S mRNA or its pro-
tein product (Montell et al., Nature 295: 380
[1982]). Reciprocally, the mutation in adenovirus
type 5 (Ad5) hrl introduces a termination codon in-
to the 13S mRNA but leaves the 12S mRNA intact
(Esche et al., J. Mol. Biol. 142: 399 [1980]; Ricciardi
et al., Proc. Natl. Acad. Sci. 78: 6121 [1981]). Coin-
jection of an El A clone derived from hrl failed to
activate the E2A early promoter clone, but this El A
mutant (with the intact 12S mRNA) is still able to
inhibit the production of the DBP from its late
promoter (Table 2). Conversely, the El A plasmid pEK
pm975, which generates only the 13S mRNA, main-
tains the ability to stimulate the expression of the
DBP early promoter clone (pFAG5), but no longer
inhibits the expression of the DBP late promoter
clone (pAd 15.1) (Table 2). These results indicate
that early region 1A encodes two distinct functions
controlling the expression of the DBP. The stimu-
latory factor for the early DBP promoter encoded by
the 13S mRNA was previously demonstrated in vivo
(Montell et al., Nature 295: 380 [1982]). The inac-
tivity of the late promoter for DBP in pBR730
(which also contains the early promoter) in the ab-
sence of El A plasmid suggests there is interaction
between the two promoters.
On the assumption that stimulation is a conse-
quence of activation of a transcriptional promoter
and that inhibition results from repression of a pro-
moter, experiments were designed to identify the
exact location and sequence feature for each of the
region-2A promoter sites. Sets of deletions in the
E2A early and late promoter regions have been con-
structed by site-directed mutagenesis using BAL31
Table 2
Expression of the 72-kD DNA Binding Protein Gene from Its Early or Late Promoter
after Coinjection of the E2A Plasmids with Mutated EtA Plasmids DNAs
EtA plasmid
coinjected
None
HE4 (wt)
phrl
pEKpm975.
E2A plasmid:
E2A promoter:
pFAG5 pAd15.1
early late
EtA mRNA produced percent of nuclei positive
125 135 for the 72-kD protein
20 84
+ 85 35
truncated
protein
18 36
86 83
Cell nuclei were injected and analyzed as described in Table 1.
aMontell, C., E.F. Fisher, M.H. Caruthers, and A.). Berk, Nature 295: 380 (1982).
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exonuclease. These mutants are derivatives of two
newly constructed E2A clones containing the DBP
gene associated with the early promoter (E252.1) or
with the late promoter (L251.1) that have been
shown to behave in microinjection experiments like
the other E2A clones (described in Table 1) in
response to coinjection with region Et A. DNA se-
quence analyses of these mutants have shown that
these deletions extend to different positions be-
tween nucleotides - 132 and - 3, upstream from
both the early and late mRNA cap sites.
The mutants deleted in the late promoter region
have been tested recently in the microinjection
system in the presence or in the absence of the wild-
type E1A plasmid. The sequences located between
- 51 and - 87 by upstream from the late transcrip-
tional RNA cap site appear to contain at least part of
the E1A regulatory interaction site (Fig. 6). Inspec-
tion of the DNA sequence within this region has
revealed an interesting feature that consists of a
duplicated GCGG sequence flanking a potential
stem-loop structure, which can also be regarded as
a partial inverted sequence repetition (Fig. 7).
Perhaps the binding of an E1A protein to this region
blocks entry of RNA polymerase II or its transloca-
tion to the preferred initiation site. Alternatively,
binding may induce a change in the DNA or
chromatin conformation that renders this region
transcriptionally inactive. Additional deletions be-
tween -87 and - 51 are now being created to map
more precisely the primary sequence involved in
the repressor function. Similar coinjection experi-
ments are underway using deletions of various por-
tions of the sequences upstream from the E2A early
promoter to study the effect on E1A stimulation of
DBP expression.
Two approaches are now in progress to analyze
the E2A transcription products directly. One in-
volves the use of cell-free extracts, prepared from
HeLa cell suspension cultures, which contain RNA
polymerase II and cellular factors required for
faithful transcription in vitro from the E2A early and
late promoters (Mathis et al., Proc. Natl. Acad. Sci.
78: 7383 [1981]). The parental plasmid, L251.1 and
E252.1, have been tested for their template ac-
tivities in this system and compared to clone p41
(obtained from N. Fraser), which contains the major
late promoter of Ad2 (coordinate 16.45). Our results
indicate that transcription from the E2A early and
late promoters is extremely inefficient relative to the
Ad2 major late promoter (30-50-fold reduced), as
also observed by others. To facilitate 5' end anal-
ysis of these transcripts by S1 nuclease mapping pro-
cedures, it will be necessary to increase these weak
signals. To this end, calf thymus RNA polymerase II
will be added to supplement the extracts in the
transcription reactions.
The second approach we are undertaking to
analyze early region 2A transcription directly is by
transient expression of the early and late promoter
clones transfected into cell monolayers. Experi-
ments are in progress to optimize conditions for the
uptake and expression of the E2A plasmids added to
hamster cells as calcium-phosphate precipitates.
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Figure 6
The structures of an Ad5 DBP clone containing just the late DBP promoter region and deletion mutant derivatives affect-
ing the promoter. The sequences upstream of the cap site that are deleted and substituted by pBR322 (broken lines) are
illustrated. The nucleotide corresponding to the end point of deletion in each mutant clone is indicated to the right side
of each diagram the 5' capped nucleotide of the mRNA being at nucleotide position + 1). On the far right are the results
obtained after microinjection of these clones in the presence or the absence of E1A plasmid reported as percentages of
nuclei positive for the DNA-binding protein.
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Figure 7
The DNA sequence between nucleotide -88 and -40
located upstream from the E2A late transcription initiation
site (Gabbed et al., Gene 6: 1 [1979]). The dyad axis of
near symmetry found in this region is shown diagramati-
cally as a hairpin structure. The nucleotides substituted
with pBR322 sequences in deletion mutants Ld15 -87 and
Ldl 5 -51 are indicated. The deletion 5' to nucleotide
-51, but not the deletion 5' to nucleotide - 87, reduces
the E2 late-promoter repression by the Et A product, as in-
dicated in Fig. 6.
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The 72-kD DBP is being analyzed by im-
munofluorescence and by immunoprecipitation of
transfected cell extracts.
Electron Microscopic Heteroduplex Analysis
of Chicken )3- Tubulin Genes
L.T. Chow
Microtubules are major cytoskeletal structures that
participate in the formation of spindles used for
chromosomal segregation during cell division. They
also are present in the cilia and flagella involved in
cellular motion and form some of the cytoplasic
fibers that confer cell shape and permit anchorage
and locomotion. They are composed of various
types of a- and 0-tubulin polypeptides, which have
been rather highly conserved during evolution.
Nonetheless, small but important differences within
the a- and 0-tubulin gene families dictate subtle
structural and functional distinctions; their regulated
expression plays a basic role in cellular differentia-
tion.
In a previous collaborative study with Dr. Nich-
olas Cowan at Princeton, I investigated the struc-
tures of some of the human a- and (3-tubulin
genes (Cowan et al., Proc. Natl. Acad. Sci. 78: 4877
[1981]; Wilde et al., Proc. Natl. Acad. Sci. 79: 96
[1982]). More recently, in collaboration with Drs.
Don Cleveland, Margaret Lopata, and Jane Haver-
craft of The Johns Hopkins University of Medicine,
the structures of the four different 0-tubulin genes of
chicken were studied. Each of the genes, cloned in
pBR322, was characterized by electron microscopic
analyses of heteroduplexes formed with a (3-tubulin
cDNA clone prepared from mature mRNA. Repre-
sentative heteroduplexes, and interpretative trac-
ings, are presented in Figure 8, a-e. The 0-1 and
0-2 genes had three intervening sequences (IVS) at
similar sites relative to the conserved regions. The
IVS ranged from 160 to 500 nucleotides long and
were separated from each other by conserved se-
quences homologous to the pT2 cDNA of about
130 nucleotides each (Fig. 8, a and b). The interven-
ing sequences were located near the 5' end of each
gene, as concluded from the asymmetrical disposi-
tion of the pBR322 sequence relative to the cDNA
insertion in pT2 DNA in the heteroduplexes (e.g., Fig.
8d). About 250 nucleotides proximal to the 3' end
of the cDNA in pT2 correspond to the untranslated
region of the mRNA (Valenzuela et al., Nature
284: 650 [1981]). They did not hybridize to the
0-1 genomic DNA, indicating sequence divergence
in the 3' untranslated region (Fig. 8a). In contrast,
the /3 -2 clone hybridized to the entire cDNA in pT2
(Fig. 8b). This observation suggests that the cDNA is
derived from a message transcribed from the
3-2 gene. The 0-1 and (3-2 genes appear highly
homologous in all the other conserved coding seg-
ments, since the heteroduplexes with pT2 were
formed at fairly stringent conditions.
The 0-3 genomic DNA clone hybridized to pT2
DNA at lower frequency than did 0-1 or 0-2, sug-
gesting some sequence divergence. 0-3 appeared to
have three or four small intervening sequences of
80-500 nucleotides clustered at the 5' end of the
gene; three of these were located at sites similar to
those in the /3-1 and 0-2 genes (Fig. 8c). Occasional-
ly, an additional homologous sequence was detect-
ed at the 5' end and was possibly followed by a small
intervening sequence, as diagramed in Figure 8f. The
first two conserved segments hybridized to pT2
only in some of the heteroduplexes at a nonstringent
condition. This is most likely due to sequence
divergence. About 250 nucleotides in the 3' un-
translated region in the cDNA did not hybridize to
3-3 DNA.
The /3 -4 gene and the pT2 cDNA formed two
related heteroduplexes that had three or four small
intervening sequences, respectively, near the 5'
end of the gene (Fig. 8, d and e). The first large IVS
in the heteroduplexes with three IVS apparently
contained sequences redundant to, but separate
from, the 3' half of the first conserved segment.
Branch migration led to the formation of a fourth
IVS in the heteroduplexes. Consequently, the first
conserved region was split into two shorter seg-
ments. In fact, most heteroduplexes had four IVS,
suggesting a better sequence homology to pT2 in
this configuration. Interestingly, of the four chicken
/3- tubulin genes, only the /3 -4 gene appears to en-
code two mRNAs of slightly different lengths,
perhaps due to different splicing associated with the
apparent duplication of a conserved segment.
Again, the 3' untranslated region in pT2 cDNA did
not hybridize to the (3-4 DNA.
The arrangement of conserved and intervening
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segments in the chicken and human /3- tubulin genes
is diagramatically summarized in Figure 8f. In-
terestingly, all three IVS in 13 -1 and i3 -2 and the latter
three IVS in 0-3 and 0-4 were located at sites similar
to one another and to those detected in a human /3-
tubulin gene (Cowan et al., Proc. Natl. Acad. Sci.
78: 4877 [1981]). Moreover, the pT2 cDNA is more
homologous to the human i3 gene than it is to f3 -3
and (3-4. It is possible that i3 -3 and 0-4 genes may en-
code polypeptides of substantial sequence diver-
gence from the (3-2 polypeptide.
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Figure 8
The structure of chicken i3- tubulin genes. (a-c) Electron micrographs of heteroduplexes between the linearized cDNA
clone pT2 and, respectively, the 0-1, 13 -2, and 13 -3 inserts released from pBR322 with restriction endonucleases. (d-e)
Micrographs of two related heteroduplexes between pT2 and linearized 13 -4 DNA showing different structures near the
5' end. In a-c, pBR322 released from the 13 tubulin clones has also hybridized to the linearized pT2 DNA causing it to
circularize. The 5' and 3' ends of each gene were determined by the asymmetrical lengths of the pBR322 sequences in
pT2 DNA in the heteroduplexes (as seen in 3D) and are marked with large and small arrowheads in the tracing, respec-
tively. Large and small arrowheads in the electron micrographs point to DNA deletion loops corresponding to the in-
tervening sequences in the four i3- tubulin genes. Each micrograph is accompanied by an interpretative tracing: (-) genomic
DNA; I. . .) cDNA in pT2; (- - -) vector pBR322 DNA. (f) Diagram summarizing the structures of the four chicken
clones as well as a human 13- tublin gene 0-5 (Cowan et al., Proc. Natl. Acad. Sci. 78: 4877 [19811). The first conserved
segment and first intervening sequence in 0-3 were seen only infrequently. The regions hybridized to pT2 DNA are
represented by the solid bars. The redundant sequence in 0-4 that did not hybridize to pT2 is represented as an open box.
The hatched box in 13 -2 represents the untranslated region which hybridizes to pT2 but has no homology to the other 13-
gene clones. The 3' untranslated regions of 0-1, 13 -3, and )3 -4 cannot be deduced by this analysis. The corresponding con-
served segments in different clones are connected with dashed lines.
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PROTEIN SYNTHESIS
M.B. Mathews, B.W. Stillman, F. Tamanoi, A.M. Francoeur, N.K. Gural, C.H. Herrmann, C. Jackson,
P.H. Lalik, S.L. Lemaster, D. Pascucci, P.A. Reichel, D.R. Taylor, G.P. Thomas, E.H. Woodruff
In 1982 the work of the Protein Synthesis laboratory
continued along the lines set out in last year's
report. The three main areas of research covered
were the adenoviral early proteins, ribonucleopro-
tein particle (RNP) synthesis, and the stress (heat-
shock) response of human cells.
Proteins Required in Adenoviral DNA
Synthesis
B.W. Stillman, F. Tamanoi, M.B. Mathews
In annual reports over the last several years, we
described analysis of the protein-coding properties
of both the late and the early genes of adenovirus 2
(Ad2). Standing in stark contrast with the impres-
sively detailed mapping data, outlined in Fig. 1, is
the dearth of information on the roles of these protein
species. Of the roughly two dozen early proteins that
have been observed, biochemical functions have
been ascribed to only three, and it is no coincidence
that these all participate in DNA replication, for
which we now have a powerful assay system. The
three proteins are products of early region E2,
which has two major domains. The upstream,
promoter-proximal E2A domain codes for the
72,000-dalton DNA binding protein (DBP), a
multifunctional protein that is involved in DNA
chain elongation and was discussed extensively in
last year's report. We now know that the down-
stream portion, region E2B, encodes at least two
proteins-the terminal protein precursor (pTP) and
adenoviral DNA polymerase-that are required for
DNA chain initiation.
The first step in the initiation reaction is the forma-
tion of a covalent complex between the first nucleo-
tide, dCMP, and the terminal protein precursor,
pTP. This remains attached to the growing DNA
chain and persists on mature viral DNA in the form
of a shorter (55,000-dalton) terminal protein that is
derived by specific cleavage of the 80,000-dalton
precursor. The cleavage is carried out by a virus-
encoded protease during maturation of infectious
viral particles (see 1980 and 1981 reports). Several
laboratories have demonstrated that the initiating
complex can be formed in crude extracts of Ad2
infected He La cells supplemented with ATP, Mg++,
and template DNA. We have fractionated this ex-
tract to study the enzymology of the initiation reac-
tion and to determine the functional domains of the
pTP protein.
We had previously mapped the gene encoding
pTP to the E2B region, a 6.5-kb span that specifies
multiple mRNA and protein species. Recently, the
DNA sequence of this region was completed by the
Nucleic Acid Chemistry Section. In collaboration
with Dr. J.E. Smart (Protein Chemistry Section), the
location of the sequence coding for pTP was
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established through partial sequence analysis of the
protein. Comparison of this data with the amino
acid sequence predicted from the DNA sequence
showed that the majority of the coding region for
pTP lies between coordinates 23.4 and 28.9 on the
viral genome. From this work, we also learned that
the mature terminal protein corresponds to the C-
terminal portion of pTP, as does an intermediate
62,000-dalton cleavage product. Furthermore, the
serine residue that is covalently bound to dCMP or
to viral DNA was located at a site near the common
C terminus of the three proteins.
On the other hand, the pTP- coding region did not
overlap the region that, on genetic grounds, was
believed to specify a protein involved in DNA
replication and also in cell transformation. Mutants
of the adenovirus N group, such as Ad5ts149, are
defective for replication at the restrictive temper-
ature and had been mapped to a stretch of the viral
genome between coordinates 18 and 22.5. This
span neighbors that encoding pTP and is included
in the E2B region. We therefore postulated that the
E2B region encodes an additional protein involved
in replication, and we set out to test this idea.
Extracts were prepared from Ad5ts149-infected
cells grown at either the permissive or restrictive
temperature and were tested for their ability to sup-
port DNA synthesis. The extracts prepared at the
permissive temperature were active for DNA
replication and could not be inactivated by incuba-
tion at the restrictive temperature (39.5°C). How-
ever, Ad5ts149 extracts prepared from cells grown
at the restrictive temperature were inactive for both
DNA synthesis and pTP-dCMP complex formation.
These results suggested that the mutation in
Ad5ts149 causes a defect in a protein that functions
in the initiation of DNA replication. We purified this
protein in functional form from cells infected with
wild-type virus using an assay in which protein frac-
tions were tested for their ability to complement
defective extracts for DNA replication. The purified
protein can restore both pTP-dCMP complex forma-
tion and full-length DNA synthesis. It has an ap-
parent molecular weight of 140,000 daltons, is
tightly bound to pTP, and-most strikingly-
contains DNA polymerase activity. These results
demonstrated a defect in the 140,000-dalton DNA
polymerase of cells infected with Ad5ts149, but did
not formally prove that the polymerase is virus-
encoded. To establish this point, we reexamined the
coding potential of the E2B region. RNA isolated
from infected cells at 8 hours postinfection was
shown to contain mRNA complementary to viral (-
strand DNA in the region containing the N-group
mutants. This mRNA, when translated in a cell-free
system, produces proteins of 140,000 daltons and
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Topography of the adenoviral genome. The diagram shows the distribution of the main early (stippled), intermediate (filled
in), and late (open) gene blocks along the viral DNA. Also indicated are the protein products of some of the early genes
and their functions. Square brackets and narrow boxes mark the positions of promoters and leader segments.
80,000 daltons; the latter had previously been iden-
tified as pTP. The mRNA encoding the 140,000-
clalton protein was mapped more closely by hy-
bridization to small segments of viral DNA cloned
into M13 phage DNA. The results showed that
the protein maps to the left of coordinate 24,
leaving little room to doubt that the 140K protein is
the virus-encoded DNA polymerase. Corroborating
evidence comes from the DNA sequence of this
region, which shows an open reading frame
capable of accommodating a protein in excess of
120,000 daltons.
Other proteins are also produced from the E2B
region (75K and 105K) and there seems to be tem-
poral control of the synthesis of mRNAs for these
proteins. These features raise the possibility that ad-
ditional viral factors may be involved in replication.
Furthermore, the purified Ad-DNA polymerase and
pTP do not support a significant amount of pTP-
dCMP complex formation when incubated with
Ad2 DNA-protein complex as template, but full ac-
tivity is restored when extracts of uninfected HeLa
cell nuclei are included in the reaction. This finding
does not support the idea that additional viral prod-
ucts, including the E2A DBP, are essential; rather, it
suggests that a cellular factor is required for pTP-
dCMP complex formation and initiation of DNA
replication. The nature of this factor, as well as of
the adenoviral DNA template about the origin of
replication, is addressed in the report of the DNA
Synthesis Section which was instituted in the mid-
dle of the year to pursue these questions in more
detail.
In summary, three viral proteins are required for
the synthesis of adenoviral DNA: the 72,000-dalton
single-strand DBP, the 80,000-dalton terminal protein
precursor, and the newly discovered 140,000 - Balton
DNA polymerase activity. These proteins are syn-
thesized from a single complex transcription unit or
gene family on the adenoviral genome. How the
process is regulated during the infection cycle, and
how the Ad-DNA polymerase is related to cell
transformation are intriguing open questions.
Small viral RNAs and RNPs
A.M. Francoeur, M.B. Mathews
In previous reports, we have described our studies
of the structure and properties of the two small
(-160-nucleotide) noncoding adenoviral VA-RNAs.
Interest in these species has quickened with the
discovery that they interact with viral mRNA, on the
one hand, and with a host cell protein on the other.
We have continued to characterize these interac-
tions as an approach to the function of the species
involved.
Sera from patients with the autoimmune disease
systemic lupus erythematosus often contain an-
tibodies that react with cellular RNPs. One such an-
tibody specificity, the anti-La class, recognizes par-
ticles from adenovirus-infected HeLa cells that con-
tain the VA-RNAs (Fig. 2). These particles can
assemble in vitro in a cell-free transcription system
from HeLa cells that also acts as source of the La an-
tigen. Using variant forms of the gene for VA-RNA,
as transcription template, we have examined the
RNA requirements for particle formation. Develop-
ment of a reconstitution assay, in which preformed
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and fragmented VA-RNA can bind the antigen,
allowed further refinement of the analysis. To-
gether, these experiments define the termini of
the VA-RNAs as the site of La antigen binding. Since
the termini of RNAs (such as the VA-RNAs) that are
synthesized by RNA polymerase Ill present com-
mon features, it is not surprising that the La antigen
also recognizes other molecules-such as 5S RNA
and tRNA-which are also made by the same poly-
merase.
The antigen binds to the VA-RNAs at the time of
transcription or very soon afterward, but does not
seem to be required for transcription. Neither addi-
tion of antibody to the transcription system, nor use
of immobilized antibody to deplete the extract of
the La antigen, had any effect on synthesis of VA-
RNA (or other polymerase III products), although, as
expected, the RNAs failed to assemble into RNPs in
these conditions as no La antigen was available.
This result implies that the role of the antigen is
subsequent to RNA synthesis.
To explore its role further, we have begun to
characterize and purify the protein. We have per-
formed immunoprecipitation experiments with
several independent human anti-La sera and 355- or
32P-labeled He La cell extracts, and have examined
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the proteins by both one-dimensional and two-
dimensional gel electrophoresis (some of the latter
in collaboration with Dr. J. Garrels). These results
identify the La antigen as a family of cellular
phosphoproteins of apparent molecular weight
45,000 daltons. This conclusion is supported by
data obtained with the Western gel transfer tech-
nique. Using a recently developed rapid assay for
RNP formation in concert with conventional
chromatographic methods, we have succeeded in
purifying the La antigen about 1000-fold. The
enriched fractions have been injected into animals
for antibody production, and in parallel are being
analyzed for enzymic activities.
Turning to the mRNA-binding properties of the
VA-RNAs, we have begun to characterize in detail
the sites of interaction between the two RNA
species with methods similar to those employed in
studies of the La antigen-VA-RNA interaction.
Preliminary findings suggest involvement of the 5'
ends of the mRNA and VA-RNA molecules, but fur-
ther work is needed to define the nucleotide se-
quences precisely.
The Stress Response of Mammalian Cells
G.P. Thomas, M.B. Mathews
Human cells, and cells of most organisms, respond
to metabolic stress of various kinds in a way that is
closely akin to the heat-shock response first studied
in Drosophila. Having established the kinetics and
some of the mechanistic requirements of the induc-
tion of stress proteins in He La cells by amino acid
analogs, our attention this year has been focused
primarily in two areas: the isolation and construc-
tion of suitable gene probes and their characteriza-
tion, and investigation of the translational controls
operating in stressed cells.
Last year we described the isolation of bacterio-
phage clones containing some or all of the gene for
the 90,000-dalton (90K) stress protein. We have
since then begun to analyze the organization of
coding sequences using both S1 nuclease analysis
and hybridization selection. As a first step, an unam-
biguous restriction map was derived using frag-
ments subcloned into pBR322 as probes for
Southern blots of restricted phage DNA. By hybrid-
ization selection, two noncontiguous regions of the
DNA were found to select the 90K mRNA and to
make nuclease-resistant hybrids with RNA from
stressed cells. This presumably implies that the
mRNA for the 90K protein is spliced, as is its
homolog, the 83K protein mRNA in Drosophila,
where it has been found to be the only heat-shock
protein mRNA that is spliced. More intriguing is the
finding that all regions of the 90K clone also select
the mRNA encoding the 72K stress protein, the
other major induced protein of mammalian cells, if
hybridization is conducted at higher tempera-
ture. This is true whether hybrids are formed in
solution or on filters, and whether the complete
phage DNA or plasmid subclones from it are used.
The possibility that these two genes contain com-
mon sequences is under investigation. From a
cDNA library constructed using stressed-cell RNA, a
number of clones displayed preferential hybridiza-
tion to a stressed-cell probe as against an unstressed-
cell probe. Of these, a small number also hybridized
with a probe for the Drosophila 70K stress protein
(the homolog of the mammalian 72K stress protein).
These clones have proven capable of selecting the
mRNA for the human 72K stress protein, as have
other clones that failed to hybridize with the insect
probe. Two of the 72K cDNAs have different restric-
tion patterns, although we do not yet know whether
they are copies of different mRNAs or of parts of the
same mRNA. These are currently being used to
isolate genomic clones to determine how many
genes exist in human cells (in Drosophila there are
many copies of the 70K gene as well as multiple
related but not inducible genes) and to obtain pure
preparations of 72K mRNA for use in translational
control experiments.
Our earlier studies had indicated that preexisting
mRNAs are rendered nonfunctional in stressed
cells, yet retain both their polysomal location and
the ability to be translated in cell-free systems. We
interpret this as an indication of translational control
at the level of polypeptide elongation, a situation for
which no obvious precedents are available. The
normal mRNAs can be released from polysomes by
treatment with either EDTA or puromycin, but are
not utilized for translation when polysomes are in-
cubated intact in a rabbit reticulocyte system. Thus,
the discrimination between the normal and stress
protein is rather stable, implying that some integral
or tightly associated component of the ribosomes or
mRNPs is responsible.
Immediate goals for the future include the de-
velopment of initiating cell-free systems with which
to assess utilization of particular classes of mRNA
and comparisons of the protein components of the
various RNP and ribosomal structures. In addition,
we are presuming a more detailed analysis of the re-
quirement for RNA synthesis during establishment
of the response.
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DNA SYNTHESIS
F. Tamanoi, B.W. Stillman, M. Dermody-Weisbrod, P. Lalik, D. Taylor, M. Walsh, E. Woodruff
The DNA Synthesis laboratory came into existence
during the past year; its major interest is to under-
stand the enzymatic mechanism of DNA replication
in eukaryotes. The recent development of cell-free
extracts that are capable of replicating DNA has
greatly facilitated such studies. Our work on DNA
replication, which grew from the study of adeno-
viral DNA replication that was begun in the Protein
Synthesis Section, has already contributed to the
discovery of a novel DNA polymerase and a new
mechanism for the priming of DNA synthesis at the
origin of replication. We intend to exploit the.
adenoviral DNA replication system further and also
to expand the work to cellular DNA replication.
Virus-encoded Proteins Required for
DNA Replication
As described in last year's report (Protein Synthesis
Section), we have characterized two virus-encoded
proteins that are required for DNA replication in
vitro: the E2A single-stranded DNA binding protein
(DBP) (72,000-dalton [72K]) and the E2B terminal
protein precursor (pTP). By aligning the partial
amino acid sequence of pTP (performed in col-
laboration with the Protein Chemistry Section) to
the DNA sequence of the E2B region (determined
by the Nucleic Acid Chemistry Section), it was
demonstrated that the coding region for pTP was
between 28.9 and 23.4 map units on the genome.
Gatos et al. (Cell 17: 945 [1979]) had previously
mapped the N complementation group of adeno-
virus type-5 (Ad5) temperature-sensitive mutants to
18.0-22.5 map units on the viral genome, which
lies outside the region encoding pTP. These mutants
are defective for replication of viral DNA in vivo
and also for transformation of rat embryo cells.
These combined results suggested that a third virus-
encoded protein, other than pTP and the 72K DBP,
was involved in the replication of adenoviral DNA
and that this protein was also encoded by region
E2B.
As a first approach to identify the gene product
defined by the N complementation mutants (e.g.,
Ad5ts149), nuclear extracts were prepared from
wild-type Ad2- and Ad5ts149-infected He La cells
grown at the nonpermissive temperature of 39.5°C.
The extracts prepared from wild-type-infected cells
supported adenoviral DNA synthesis, whereas ex-
tracts prepared from Ad5ts149-infected cells did
not. Furthermore, the Ad5ts149 extracts were also
defective for the formation of a covalent linkage be-
tween pTP and dCMP, which is the proposed initial
step in the priming of DNA synthesis at the replica-
tion origin. By complementation of the defective
Ad5ts149 extracts with fractions derived from wild-
type Ad2-infected He La cell extracts, a 140,000-dal-
ton (140K) protein was purified and shown to con-
tain DNA polymerase activity. The 140K DNA poly-
merase activity copurified with the pTP, and both
proteins were required for the pTP-dCMP complex
formation (also demonstrated by Enomoto et al.,
Proc. Natl. Acad. Sci. 78: 6779 [19811; Lichy et al.,
Proc. Natl. Acad. Sci. 79: 5225 [19821).
The purified 140K DNA polymerase and pTP
were unable to link dCMP covalently (which is the
first nucleotide in the nascent DNA chain) to the
pTP when Ad2 DNA-protein complex was used as a
template DNA. However, the activity could be fully
restored by addition of either nuclear extracts
prepared from Ad5ts149-infected or uninfected
He La cells. Thus, at least one cellular factor is re-
quired for the initiation of adenoviral DNA replica-
tion in vitro. Recently, Nagata et al. (Proc. Natl.
Acad. Sci. 79: 6438 [1982]) have purified a nuclear
factor that stimulates the initiation reaction, but they
have not yet assigned any enzymatic function to this
protein.
The Ad5ts149 mutation maps within the E2B
region of the genome (Gatos et al., Cell 17: 945
[1979]), and we had previously shown that this
region encodes proteins of 105K and 75K, in addi-
tion to pTP (1980 Annual Report). However, since
the DNA sequence of the E2B region of the genome
shows a large open translational reading frame that
might encode the DNA polymerase, we reexamined
the coding potential of the E2B region. In collabora-
tion with M. Mathews (Protein Synthesis Section),
RNA was prepared from Ad2-infected cells at
various times postinfection and selected by hy-
bridization to cloned fragments of adenoviral DNA,
followed by translation in vitro. Substantial amounts
of a 140K protein, as well as three- to fourfold
higher amounts of the 80K pTP were synthesized
from mRNA isolated at 8 hours postinfection, after
addition of 10 kdv1 anisomycin 3 hours after infec-
tion. At this time postinfection, very little mRNA
synthesizing the 75K and 105K proteins was ob-
served. RNAs for the 140K and 80K proteins were
selected by all cloned DNAs tested that originated
from the region between 18 and 24.5 map units.
However, only the 80K pTP mRNA, and not the
140K mRNA, hybridized to cloned DNA fragments
that lie to the right of 25 map units. In addition, both
proteins were translated from mRNA selected by
M13 bacteriophage DNAs containing cloned /-
strand DNA but not r-strand DNA, demonstrating
that these proteins are indeed encoded by early
region 2B on the viral genome.
The 140K protein synthesized by cell-free transla-
tion of mRNA migrated on SDS-polyacrylamide gels
with [35S]methionine-labeled 140K DNA poly-
merase that had been purified from wild-type
Ad2-infected He La cells. The combined data de-
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scribed above support the conciusion that
adenovirus encodes a 140K DNA polymerase from
early region 2B on the genome that is required for
the initiation of DNA replication by formation of a
protein (pTP)-deoxynucleotide primer. It remains to
be determined whether the adenoviral DNA
polymerase catalyzes complete synthesis of viral
DNA or whether a cell DNA polymerase is also
required.
Thus, adenovirus encodes at least three proteins
that are required for DNA replication, all of which
are synthesized from early region 2 on the viral
genome. The adenoviral single-strand DBP (72K) is
encoded by early region E2A (Fig. 1) and is required
for elongation of DNA replication. The mRNA for
this protein is synthesized at both early and late
times from two promoters active at the respective
times after infection. The pTP and DNA polymerase
are both encoded by early region E2B, and mRNA
for these proteins appears to be synthesized from
the early promoter. Since these latter proteins are re-
quired for initiation of DNA synthesis, the rate of
DNA synthesis in adenovirus-infected cells may be
regulated at the level of transcription or processing
of E2B RNA.
The addition of purified single-stranded DBP,
pTP, and the adenoviral DNA polymerase to
nuclear extracts prepared from uninfected HeLa
cells promotes specific initiation and elongation of
adenoviral DNA synthesis in vitro. This suggested
that these three virus-coded proteins are the only
such proteins directly required for DNA replication
in vivo. However, Martin et al. (1. Gen. Virol. 41: 303
[1978]) have reported the isolation of a temperature-
sensitive mutant of Ad2 that could complement
mutants in the DBP (Ad5ts125) and the DNA poly-
merase IN complementation-group mutants). The
mutant, Ad2ts111, maps within the left 30% of the
adenoviral genome (D'Halluin et al., I. Virol.
41: 401 [1982]) and is defective for the replication
of viral DNA in vivo as well as causing degradation of
both cell and viral DNA at the nonpermissive temper-
ature (D'Halluin et al., J. Virol. 32: 61 [1978]).
We have prepared nuclear extracts from
Ad2ts111-infected HeLa cells grown at 39.5°C
(nonpermissive temperature) and demonstrated that
these extracts are defective for the replication of
added adenoviral DNA. The block to replication in
vitro is not at the stage of initiation of DNA replica-
tion, since the Ad2ts111 nuclear extracts are
capable of forming the covalent linkage between
pTP and dCMP. This latter result indicates that these
extracts contain functional pTP and 140K DNA
polymerase activity. Complete DNA synthesis can
be restored to Ad2ts111-defective extracts by addi-
tion of the purified single-strand DBP isolated from
wild-type-infected cells. Since the mutation in
Ad2ts111 maps outside the gene for the DBP, this
result suggests that another adenoviral protein af-
fects the activity of the DBP in vivo. We are current-
ly investigating the biochemical nature of this block
to DNA synthesis and its possible link to the DNA
degradation phenotype of this mutant, as well as
precisely mapping the mutation (in collaboration
with T. Grodzicker, Tumor Virus Section).
HeLa Cell Proteins
For the identification of the virus-encoded proteins
that are necessary for DNA replication in vitro, the
use of mutants that affect DNA replication in vivo
has been invaluable. Unfortunately, such a genetic
approach is not practical for the identification of
cellular enzymes required for the replication of
adenoviral DNA, therefore we have begun to frac-
tionate extracts prepared from uninfected HeLa
cells and have identified three fractions derived
from nuclear extracts that are either necessary for,
or stimulate the rate of adenoviral DNA synthesis in
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A map of adenovirus early region 2 showing the structure of the mRNAs. The DNA replication proteins encoded by this
region are shown, as is the map location of the Ad5ts149 mutation used to identify the virus-encoded DNA polymerase.
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vitro. One such factor that is currently under in-
vestigation is required for completion of full-length
DNA chains. As mentioned above, another nuclear
factor is required for initiation of DNA synthesis in
vitro and has been purified by Nagata et al. (Proc.
Natl. Acad. Sci. 79: 6438 [1982]). It is hoped that in
the near future, the replication of adenoviral DNA
will be accomplished with purified proteins and
that we can then learn the precise nature of
eukaryotic DNA synthesis.
Origin of Adenoviral DNA Replication
In many systems, specific DNA sequences define
the region where initiation of DNA replication takes
place. This has been demonstrated by constructing
small deletions or base changes at the origin that
destroy the initiation of replication. From the study
of prokaryotic systems, especially that of the small
single-stranded DNA phages, it has become clear
that the origin serves as a site where enzymes in-
volved in initiation form a complex, or a so called
replisome.
In last year's report, we described the develop-
ment of an in vitro system to search for DNA se-
quences required for the initiation of adenoviral
DNA synthesis. Briefly, the initiation is carried out
on a cloned origin of adenoviral DNA replication
using a partially purified enzyme fraction. The
cloned DNA has to be linearized in such a way that
the adenoviral DNA sequence is located at the end
of the linear DNA molecule. The initiation on such
a linear DNA occurs at the correct initiation site as
well as at an additional site four nucleotides from
the correct site. This system has been exploited to
search DNA sequences that are required for the for-
mation of the pTP-dCMP primer complex.
First, a set of deletions beginning from an internal
Pvull site at 453 nucleotides and extending toward
the terminus was created by nuclease BAL31 diges-
tion. Also, exonuclease III and S1 nuclease were used
to create fine deletions. Examination of their tem-
plate activity has shown that all the plasmid DNAs
that contain adenoviral DNA longer than 20 nucleo-
tides support the pTP-dCMP complex formation,
whereas those that contain 14 nucleotides or less
did not. Second, a set of mutants was constructed
that created deletions from the end of adenoviral
DNA. However, this time, the template activity was
lost completely, even when a few nucleotides were
removed. A plasmid DNA containing 20 nucleo-
tides of adenoviral DNA was capable of supporting
a limited amount of DNA chain elongation. There-
fore, the terminal 20 nucleotides define a minimum
sequence required for the initiation in vitro (Fig. 2).
Comparison of the terminal sequence of different
serotypes of adenovirus has revealed conserved se-
quences (see 1981 Annual Report). The inverted ter-
minal repeat could be divided into a terminal A.T-
rich domain and a C-rich domain and within the
terminal AT-rich domain, the first 22 nucleotides
are highly conserved. Within this region, there is a
perfectly conserved sequence that extends from
bases 9 to 18 from the end of the DNA.
We have begun to make base changes within the
origin of adenoviral DNA replication using chem-
ically synthesized DNA (see below and Fig. 3). As a
first trial, oligonucleotides corresponding to the ter-
minal 20 nucleotides of both the I and r strands of
adenoviral DNA have been chemically synthesized.
The DNA contained base changes in the perfectly
conserved region: GG instead of TA. The single-
stranded oligonucleotides were annealed, linkers
EcoRI and Sall were ligated to the ends, and the
DNA was then cloned into the EcoRl and Sall sites
of pAT DNA. DNA sequencing of the resulting
plasmid DNAs confirmed the mutant sequence.
When the template activity of this mutant DNA was
examined, the activity was reduced to less than
30% of the wild-type DNA. This indicated that the
conserved sequence is playing an important role in
the initiation of adenoviral DNA replication. We
plan to use this method further to create mutations
at other locations within the origin.
5 ICATCATCAATAATATACC TTIATTTTGGATTGAAGCCAATA... Templateactivity
Figure 2
The nucleotide sequence of the 40 bases at the 5' end of adenoviral DNA and the position of deletions created within
the origin. The ability of each cloned DNA to act as a template for the initation of DNA replication in vitro is also in-
dicated. The boxed area shows those nucleotides that constitute the minimum origin of DNA replication.
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Figure 3
Oligonucleotides (20-mer) were chemically synthesized
de novo by the phosphite triester method and then
separated by electrophoresis in a polyacrylamide-urea gel.
The photograph shows the oligonucleotides identified by
the UV shadowing technique that contained base changes
within the terminal 20 bases of each strand of adenoviral
DNA. They are used for site-directed mutagenesis of the
adenoviral origin of DNA replication.
Oligonucleotide Synthesis
The ultimate aim in investigating regulatory se-
quences such as replication origins is to find out
how proteins recognize specific DNA sequences
and whether this involves the recognition by the
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protein of a subset of bases in the DNA sequence.
The most straightforward approach to this problem
is to synthesize DNA chemically with base altera-
tions. The functional origin of adenoviral DNA
replication defined by us is 20 nucleotides, which is
in a range that can easily be synthesized. Therefore,
during the last year we have set up a system to syn-
thesize DNA chemically.
Phosphite triester and phosphate triester methods
are the two most common methods for chemically
synthesizing DNA. However, each method has
some drawbacks. The phosphite triester synthesis is
fast and time saving, but the reaction is very sen-
sitive to moisture and some phosphoramidites used
as building blocks are unstable. On the other hand,
the phosphate triester synthesis is less sensitive to
moisture but it is time consuming. We have tried to
solve the stability problem of the phosphoramidites
by using different derivatives. Diethyl, morpholino,
and di-isopropyl derivatives were tested and it was
found that the di-isopropyl derivatives provided the
best results. For the phosphate triester method, we
have been examining a modified method recently
reported by Efimov et al. (Nucleic Acids Res. 10 6675
[1982]). This method is very attractive since the
reaction is rapid and uses acetonitrile as the only
solvent.
We now have the capability to produce several
hundred micrograms of oligomer in a matter of hours
and these oligomers have become important tools for
mutagenizing DNA, priming DNA sequencing reac-
tions, and for the synthesis and screening of cDNA
libraries.
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Movable Genetic Elements
This section is comprised of scientists who are interested in mechanisms by which genetic rearrangements
occur and affect gene expression. Studies on transposable genetic elements have led to the establishment
of two basic principles: (1) DNA can undergo rearrangements at a frequency higher than DNA replication
errors in all organisms. (2) In many cases, unstable phenotypes result from DNA rearrangements. Perhaps
within the next few years many of the interesting genetic mysteries noticed by geneticists for decades will
be explained on the basis of these two principles.
Our section is devoted to two main research activities: Work on prokaryotic transposable genetic
elements, with bacteriophage Mu as a model system, and work on DNA transposition in eukaryotic systems
with mating type genes in yeast as a model system. Other research projects involving various microbial,
plant, or mammalian systems are added to this section when necessary and appropriate. During the past
year, this section included studies on transposition of Tn3 (a transposon for ampicillin resistance) and the
DNA rearrangements that affect the pilus antigen expression in Neisseria gonorrhoeae.
The two main model systems under study in our section represent two fundamental aspects of the biology
of movable genetic elements. Mu DNA transposition represents DNA rearrangements and genetic variation
at the population level (the underlying principle being that genetic variation can occur abruptly and at a
high frequency in a population). Switching of mating-type genes represents DNA rearrangements at the
developmental level (the underlying principle being that a change in gene organization at a given stage
may alter gene expression and thus affect developmental patterns). These two aspects are at the center of
genetics today, and we hope that by concentrating on the two model systems we can advance our
knowledge of the causes and effects of genetic variation.
INSERTION ELEMENTS AND PLASMIDS
A.I. Bukhari, R. Harshey, L. Dalessandro, M. Coradia, Z. Manzoor, C. Monaghan, C. Penzi, S. Silberstein,
B. Vogel
During the past year, we continued our studies on
the mechanisms by which bacteriophage Mu DNA
undergoes transposition and causes various DNA
rearrangements. We also studied the expression of
the DNA modification function, mom, of Mu.
Products of Mu DNA Transposition
R. Harshey
Studies on the transposable bacteriophage Mu have
demonstrated that, upon induction of a Mu pro-
phage, replication is associated with transposition.
Similar conclusions have been reached from studies
of other transposable elements. Different elements
differ in the nature of the final product of transposi-
tion. Some give cointegrates (replicon fusions) in
which two circular genomes fuse to generate a
structure containing two copies of the element, one
at each junction of the two fused replicons. Others
give simple insertions in which the donor and recip-
ient genomes are not found joined (Fig. 1). In some
transposons, such as Tn3, cointegrates appear to be
intermediate products that are resolved into sepa-
rate replicons by a site-specific recombination event
mediated by a resolvase that acts on a site within the
element after replication and transposition. Other
transposons do not appear to have internal resolu-
tion systems, but curiously one still observes that
these transposons give both kinds of products. The
A and B genes of bacteriophage Mu code for func-
tions that mediate its transposition. The A function
is absolutely required for transposition and related
DNA rearrangements. The 8' mutants can promote
DNA rearrangements but at greatly reduced fre-
quencies. There appear to be two pathways for Mu
transposition-one that normally operates during
prophage induction and lytic growth and produces
cointegrates and a second that operates during the
events leading to lysogeny and gives simple inser-
tions.
Since integration of Mu during lysogenv is not
dependent on B function, we decided to de:ermine
the nature of transposition products in its apsence.
We find that under these conditions the majority of
end products of transposition are simple insertions.
This is in striking contrast to the situation in which
the majority of the products are cointegrates in the
presence of both A and B gene products. There are
three possible relationships between simple inser-
tions and cointegrates: (1) Simple insertions arise by
a resolution of cointegrates after completion of
replication, as in the case of Tn3. (2) Simple inser-
tions and cointegrates are alternative products of a
replication pathway that diverges before replication
is complete. (3) There are two mechanistically dif-
ferent pathways for transposition-one involves
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replication of the transposable element and always
generates cointegrates, the other may involve exci-
sion of the element before or after replication with
subsequent integration of this excised DNA into a
new target site to give simple insertions. This
scheme is reminiscent of the suicide models pro-
posed for transposition. The first possibility was
tested by looking for a recombination event be-
tween the two direct repeats of a mini-Mukan
cointegrate carried on an F pro'lac episome in the
presence of large amounts of the A protein. It was
found that the cointegrate did not resolve to give
simple insertions. The other two possibilities remain
to be tested. Since we now have conditions for
generating simple insertions almost exclusively, we
can begin to study the actual mechanism involved
in their formation.
The developmental regulation of the transposition
proteins A and B is unclear. From our results
reported here, it is tempting to speculate that during
lysogenization only the A protein is synthesized.
Alternately, an early abundance of A protein could
be ensured if the A protein were packaged into
phage particles and injected along with the DNA.
Infecting Bacteriophage Mu DNA Forms of a
Circular DNA-Protein Complex
R. Harshey
Upon superinfection of immune (lysogenic) cells
with bacteriophage Mu, a form of Mu DNA ac-
cumulates that sediments about twice as fast as the
linear phage DNA marker in neutral sucrose gra-
dients. This form is also detected upon infection of
sensitive cells with Mu. We have purified it and ex-
amined its physical nature. Under the electron
2
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Figure 1
Alternate pathways of transposition. 1. Simple transposi-
tion without the intermediate step of cointegrate forma-
tion. 2. Cointegrate formation. 3. Resolution of cointe-
grates to give transposition products.
Figure 2
Electron micrographs of Mu DNA-protein complex. (a-d) Supertwisted molecules:0, (e-g) partially supertwisted
molecules with open ends; (h-i) open circular molecules.
microscope, it appears circular and supertwisted.
Upon treatment with Pronase, phenol, or SDS,
however, it is converted to a linear Mu-length form,
indicating that the circle is not covalently closed.
The linear DNA still has heterogeneous host se-
quences at its termini. The circular DNA is resistant
to the action of E. coli exonuclease Ill and T7 exo-
nuclease, but becomes sensitive to these nucleases
after treatment with Pronase showing the presence
of a protein that binds noncovalently to the ends of
the DNA to circularize it as well as protect it from
digestion with exonucleases. The complex is resis-
tant to high salt (up to 6 M NaCI), but can undergo
transitions between forms that are partially open,
open circular, linear and circular dimers, and
trimers. Examination of DNA from mature phage
particles reveals that a circular DNA species is pres-
ent in at least 0.1-1% of the population. The
purified complex is extremely efficient in transfec-
tion of E. coli speroplasts. We estimate the molec-
ular weight of the protein in this DNA-protein com-
plex to be approximately 64,000 daltons and sug-
gest that this complex might represent the in-
tegrative precursor of infecting Mu DNA.
Integration of Infecting Mu DNA
G. Chaconas, D. Evans
We have previously presented evidence that during
both the lysogenic and the lytic cycle, but not after
prophage induction, the integration of Mu follows
the simple insertion mode rather than cointegrate
formation (Chaconas et al., I. Mol. Biol. 150: 341
[1981]).
E. Ljungquist, while at Cold Spririg Harbor Lab-
oratory, had previously shown that 32P-labeled Mu
DNA gets integrated into the host DNA after infec-
tion. G. Chaconas, now at the University of Western
Ontario, extended these studies by showing that
both strands of infecting Mu DNA are integrated in-
to the host DNA. His experiments involved separa-
tion of Mu DNA strands by agarose gel electro-
phoresis in the presence of poly(UG). 32P- labeled
Mu DNA integrated into the host DNA was isolated
and hybridized to the separated Mu DNA strands.
Both strands hybridized with the integrated Mu
DNA. These studies were completed by George
Chaconas in his new laboratory at Western Ontario.
He used X phages carrying various regions of Mu to
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conclude that there is no strand preference in the in-
tegration process and there is no site-specific resolu-
tion site in Mu. The simple insertions that are the
end products of Mu DNA integration following in-
fection appear to be generated independently rather
than by the resolution of cointegrate structures.
The mom Function of Mu
C. Monaghan, M. Goradia
Transcription of the mom gene apparently requires
an active dam' function of the host. We have shown
that this requirement for dam* can be circumvented
by manipulating sequences upstream from the mom
gene. Apparently, dam' methylation of a specific
region is required for transcription. It also seems
that the regulatory sequences of the mom gene
overlap the gin gene, and alterations in this region
have a dramatic effect on the dam* requirement for
gene expression. Under normal circumstances
dam* methylation is necessary, but not sufficient
for, mom gene expression. This follows from the
observation that mom is not expressed in plasmids
containing a cloned mom gene. However, infection
with a mom' phage results in transactivation of the
mom gene present on the plasmid. Our results on in
vitro transcription with methylated Mu DNA and
purified RNA polymerase (a gift of Dr. John Dunn)
have shown that whereas the gin gene is transcribed
at a low efficiency in the in vitro system, the mom
gene transcript is not detectable at all. Evidently,
this result reflects the requirement for the trans-
acting function for synthesis of a mom transcript.
We have now identified the mom gene product as
a 27,000-dalton protein encoded in the iS segment
of Mu. This protein cannot ordinarily be detected in
minicells; it can be seen only if the mom gene is ex-
pressed under the control of a different promoter,
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such as the lac promoter or the Mu early promoter.
It is for this reason that the mom protein was not
identified earlier. These studies have also revealed a
24-25K protein that was previously identified as the
R gene product and then as the gin gene product
(Giphart-Gassler et al., I. Mol. Biol. 145:139 [19811).
However, our speculation is that it is the trans-
acting function.
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YEAST AND PLANT GENETICS
J. Hicks, A.J.S. Klar, J.N. Strathern, R. Malmberg, S. Bonitz, J. Abraham, D. Beach, P. Creatura,
S. Dellaporta, I. Ivy, M. Kelly, C. LoFranco, C. McGill, I. Mclndoo, D. Prudente, R. Schwarz, C. Stephens,
S. Weisbrod, I. Wood
Two new staff members joined the Yeast/Plant
Genetics Group in 1982, each bringing a new pro-
ject to expand further the range of genetics studies
in the Delbriick Building. Dr. David Beach, who
had previously developed a DNA transformation
system in the fission yeast Schizosaccharomyces
pombe while at the University of Sussex, England,
initiated a molecular study of the mating-type switch-
ing system in that organism. Later in the year, Dr.
Susan Bonitz joined the group as a visiting staff
scientist employed by Exxon Research and En-
gineering Company as part of our joint research
program. Dr. Bonitz will continue her work on the
processing of mRNA species in the yeast mitochon-
drion. These projects now coexist with our ongoing
studies of mating type in Saccharomyces cerevisiae
and our expanding plant genetic studies, which
now include tomato as well as tobacco cell culture
and transposable elements in corn.
Control of Mating Type in saccharonigues
Yeasts
Strathern, C. McGill, A. Klar, D. Prudente,
I. Abraham, M. Kelly, S. Weisbrod, I. Hicks
Changes of mating type in Saccharomyces involve
the activation of a regulatory gene (either the MATa
or MAT« allele of the mating- type locus) by a
transposition from storage sites at which they are
not expressed to a unique site, MAT. The copy of
the donor is substituted for the resident allele,
which is lost. The end-product description of this
process is well documented both in terms of genetic
and physical proofs. This simple statement of the
mechanism of mating-type differentiation suggests
several questions: What are the cell-type-specific
genes that are regulated by MATa and MAT«? What
are the products of the MAT alleles and how do they
control the expression of cell-type-specific genes?
How are the silent genes kept from being expressed?
How are copies of the donor loci made, transposed,
and substituted into MAT? We and others have
made substantial progress in each of these areas.
The specific DNA rearrangement associated with
mating-type switching in S. cerevisiae is the best-
characterized example of such a mechanism regu-
lating cell type in a eukaryote. The high efficiency
with which it occurs, the availability of mutants
defective in switching, the fact that the donor and
recipient loci have been cloned (and work on
plasmids), and the amenability of yeast to bio-
chemical as well as genetic manipulation all suggest
that research in this area will continue to contribute
to basic knowledge about how such mechanisms
can be used for differentiation.
Cloning and molecular characterization of the
mating-type cassettes led to the elucidation of the
physical structure diagramed in Figure 1. Each
transcription unit consists of homologous DNA
segments common to all three loci flanking a se-
quence specifying the a gene or a gene transcripts.
In homothallic switching, this sex-specific sequence
is transposed from one of the silent loci to the MAT
locus where it is then expressed.
One of the most novel aspects of the mating-type
regulatory scheme is the mechanism by which the
normally silent storage cassettes at the HML and
HMR loci are controlled (see Fig. 1). Each silent
cassette contains a fully functional set of mating-
type information that is under negative transcrip-
tional control through the action of the MAR/SIR
gene products. As described in last year's report, we
have identified sites present at the silent loci (and
not present at MAT) that are necessary in cis for
MAR/SIR control to be exerted. These sites differ in
their activity and have been designated E (for Essen-
tial) and I (for Important), because deletion of the E
site results in complete loss of control (and, thus,
full expression of the cassette) whereas deletion of
the I site results in only partial expression of the af-
fected locus. that the
E and I sites are coincident with sites allowing au-
tonomous replication of plasmid DNA molecules.
The role of these autonomous replication sites (ARS)
in gene control, or even chromosomal DNA replica-
tion, is not yet clear. However, possible interactions
between the replication activity and the action of
the MAR/SIR regulatory genes are under exami-
nation.
Chromatin Structure of the Cassettes
Last year we also reported that the regulation of the
silent loci was reflected in changes in the chromatin
structure of these loci. By probing the chromatin of
the mating-type loci with the enzymes DNase I and
micrococcal nuclease, Kim Nasmyth found that
some of the sites within HML and HMR that are
hypersensitive to cleavage by these nucleases shift
in location and intensity when the nuclease
cleavage patterns of chromatin from Mar./Sir' and
Mar cells were compared. No such shift was seen
in the chromatin of the MAT locus isolated from the
two types of cells. The differences seen in the
chromatin at the silent loci appear to be confined to
the sequences lying between the E and I regions,
which suggests that Mar/Sir regulation may involve
the creation of a "domain" of altered chromatin
structure that is bounded by E and I. Nasmyth also
found that regulation is associated with a change in
65
W X Ya ZI Z2
HMLo<
TRANSPOSITION
MARI
-.----SIRI
-.---
SIR3
-..---
SIR4
<JVVVV1 ZI Z2H H
To,
X Yo Z I
MATot HMRa
W X Apive
W X Ar,
MATS
TRANSPOSITION
Figure 1
Diagram of the mating-type casettes on chromosome III. W, X, Y, Z1, and Z2 represent regions defined by homology be-
tween MAT and the HML, or HMR loci. The W region is 723 bases in length and is found at MAT and HML; the X region
is 704 bases in length and is found at MAT, HML, and HMR; MAT, HML, and HMR can have either the a-specific se-
quence, Ya (642 bases), or the a-specific sequence, Ya (747 bases); Z1 is 239 bases in length and is found at MAT, HML,
and HMR; finally, Z2 is 88 bases in length and is found only at MAT and HML. The HML and HMR copies of the mating-
type genes are normally kept silent by the MAR and SIR genes. Interconversion of MATa and MATa involves a unidirec-
tional transposition-substitution event from HML or HMR to MAT and is regulated and/or catalyzed by the HO gene
product.
the linking number of the DNA, in that plasmids
carrying HML or HMR are more negatively super-
coiled when purified from a Mar/Sir' strain than
when isolated from a Mar- strain. Nasmyth and Judy
Abraham have demonstrated that, at HMR, the
supercoil shift requires the presence of the E
regulatory region; deletion of the I region does not
appear to alter the shift substantially (see Fig. 2). The
cause of the change in linking number, and the role
that the change plays in the regulation process, has
not yet been determined.
In Strains Undergoing Switching, A Double-
stranded Cut Exists in the MAT DNA
As part of our investigations of how the actual
replication-transposition-substitution process oc-
curs, we have identified intermediates in the
pathway. We looked for DNAs that do not corre-
spond to normal genomic fragments and that are
unique to strains undergoing homothallic switch-
ing. These studies did not identify any candidate for
a diffusible copy of the donor cassette unattached to
the chromosomal DNA. We did find that about 2%
of the MAT DNA has a double-stranded cut, and we
localized this switching-specific cut to the YZ junc-
tion.
To determine the role of this double-stranded cut
in homothallic switching, we asked two questions:
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(1) Is this cut associated with initiation or resolution
of the switching process? Because we observed cut-
ting at MAT in strains that do not have HML or
HMR, we conclude that the cutting does not reflect
a resolution process. (2) Is the ability to make this
double-stranded cut essential to homothallic switch-
ing? We addressed this question by in vitro mu-
tagenesis of the MAT locus and then testing the
variants for their activity as substrates for switching.
We reported that deletion of most of the Y region
does not affect the ability of the plasmids to be
switched (mats to MATa). However, deletions that
cross the YZ boundary abolish switching. These
observations established that there is a site near the
YZ boundary that is required for switching, and sug-
gest that an endonuclease specific to homothallical-
ly switching cells cuts at a site near the YZ boundary
as an initiation step in switching. These studies have
identified no unique site other than the YZ junction
required for switching.
A more general technique for the examination of
mutations has been made available by the observa-
tion that transformation of yeast with a linear, gapped
molecule results in repair of the gap (Orr-Weaver et
al., Proc. Natl. Acad. Sci. 78: 6354 [1981]). An in-
tegrating yeast cloning vector was cut in such a way
as to remove a piece of yeast DNA. The resulting
linearized, gapped plasmid was then used to
transform yeast. Orr-Weaver et al. (Proc. Natl.
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Figure 2
Comparison of supercoil densities of plasmids isolated
from a Mar' /Sir' strain (+ lanes and a Mar-strain (-
lanes). Plasmids were subjected to electrophoresis through
a 0.7% agarose gel containing 2.5 gg/mIchloroquine, and
the gel was then blotted to nitrocellulose and probed with
32P-labeled pBR322 DNA. The first two lanes show the
results for a plasmid carrying a wild-type copy of HMR, the
middle two lanes show the same plasmid except contain-
ing a deletion of the E region, and the last two lanes show
the results for an I deletion plasmid. The dark band near
the top of each lane is presumed to be nicked open-circle
DNA.
Acad. Sci. 78: 6354 [1981]) reported that the
transformation rate was higher than for circular
plasmids and the transformants had an integrated
copy of the clone in which the gap had been
repaired by duplicating host sequences. Obviously,
if this procedure were applied to transformation of a
mutant strain with a gapped wild-type clone, the
result would be an integrated vector in which mu-
tant host sequences have replaced wild type. The
mutant allele can then be isolated from this struc-
ture as described above.
We used a related gapped molecule technique to
recover alleles of MAT. Starting with the MAT Hindi!l
fragment in YEp213, we constructed a deletion of
the cassette that left only unique DNA from each
side of MAT separated by a Xhol site. Transforma-
tion of a MATa strain with this plasmid linearized by
Xhol restriction resulted in repair of the gap to yield
YEp213:MATa. This replicating plasmid was readily
recovered from a DNA preparation by transforma-
tion of E. coli without restriction or ligation. With
this tool, we can quite simply recover MAT alleles
from any transformable leu2- strain. We have desig-
nated this MAT recovery plasmid the "golden
retriever" and have used it to recover a series of
mutations affecting cassette switching, as described
in a subsequent section.
Introduction of Mutant Alleles into the Genome
A particularly useful feature of the properties of
transformation of yeast with linear DNA is that it
provides the opportunity to isolate or generate mu-
tant alleles and to replace the wild-type loci in the
genome with those mutant alleles. Thus, the be-
havior of in vitro-manipulated precise mutations
can readily be tested in vivo. For recessive muta-
tions generated in vitro, it is important to be able to
replace the wild-type allele with the new mutation.
Several methods may be used to "transplace" wild-
type loci with the mutant variants. One such
method, first suggested by Rodney Rothstein
(Methods Enzymol. 101: 202 [1983]), is based on
the recombinogenic property of cut DNA (Orr-
Weaver et al., Proc. Natl. Acad. Sci. 78: 6354
[1981]). In one approach, a selectable yeast marker
is inserted into the cloned mutant allele. The hybrid
yeast fragment is then cut out of the vector and
transformed into yeast selecting for the marker. For
example, we transformed yeast with the HML
BamHl fragment in which an internal restriction
fragment carrying the HML cassette was replaced by
LEU2. The Let,* cells produced by transformation
with this linear DNA had HML deleted and replaced
by LEU2 (A. Klar, unpubl.). Likewise, an inverted
HML locus has been placed on the chromosome.
Another variation of this scheme circumvents the
need for insertion of the selectable marker into the
mutant allele. Instead, the cells are transformed with
a mixture of linear yeast DNA containing the mutant
allele and a circular replicating plasmid that can be
selected. The transformants containing the repli-
cating plasmid are screened for "cotransformants"
that exhibit the mutant phenotype. We successfully
used this procedure to introduce deletion mutations
into MAT. We observed that nearly 1% of the
transformants with the selectable plasmid (YEpl 3)
had undergone a transplacement event replacing
the wild-type MAT allele with the deletion variant.
The Pedigree of Death
Last year we described the "pedigree of death" that
results from the introduction of the HO-dependent
double-strand cut in strains that cannot complete
the switching process because they are deleted for
both donor (HML and HMR) cassettes (Fig. 3). These
strains (genotype hmlA [deletion] MATa [or MATa]
hmrA HO) produce dead cells nonrandomly in a
cell lineage (Fig. 3). This pedigree of death follows
the rules defined for MAT switching in standard
strains (Hicks and Herskowitz, Genetics 83: 245
[1976]; Strathern and Herskowitz, Cell 17: 371
[1979]).
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Figure 3
Pedigree of death. Strains with deletions of HML and HMR
produce dead cells in a predictable fashion.
The competent (mother) cells, those that would
have normally switched in standard strains, produce
two dead cells. The incompetent (daughter) cells
always produce a pair of healthy cells. Therefore,
we presume that MAT in these strains is efficiently
cut in cells competent to switch, thus causing
lethality. Clearly, lethality results from break at MAT
since the control hm1.6, MATa-inc hmrS HO and
hmiS mats hmrS HO strains do not produce dead
cells. Because this lethality occurs in the absence of
the HM loci, it is therefore likely that the MAT cut is
the initiating event of transposition. Thus, every
time a switch occurs, it does so by making a break.
Since only about 2% of the DNA is cut in exponen-
tially growing cells, the cut must be transient and
should be "healed" by switching in standard strains.
Selection of Mutations
Because the competent (mother) cells efficiently
produce dead cells in the hmiS MATa hmrS HO
strains, such strains grow slowly, essentially in a
linear fashion. This growth pattern provides a novel
genetic selection scheme for isolating mutations in
Wild Type
Mutants d 2 8 4
Mutant 4 17
Mutant d 13
Mutant 0 10
the switching pathway. Any mutation that blocks
switching would allow the cells to grow logarith-
mically, and therefore can be easily identified
because of the larger colony size on the solid
medium. At least two classes of mutants, those af-
fecting the MAT site and those affecting the activity
that catalyzes the break are expected to arise. One
class of these mutations isolated (9 of 15 indepen-
dent isolates) resulted from mutations mapping at
MAT and the other (6 of 15) mapped at HO. The
mutants characterized thus far that map at MAT fall
into two categories. One mutant, which has an a-
like mating phenotype, resulted from large deletion
of MAT, whereas the other eight mutants are sterile
but exhibit no gross changes at the DNA level.
Several of the mutants have been shown to be
defective as substrates for cutting in vivo. Since the
cut site falls within the al gene-coding region and
the al - mutants are sterile, it is likely that these
sterile mutants represent mutations of the cut site.
We have cloned the mutant loci and have sequenced
across the YZ junction. The sequences of these mu-
tant loci are shown in Figure 4 and coincide with
the site of cutting defined by Kostriken and Heffron
using an in vitro assay for cutting at the YZ junction.
Knowledge gained from the analysis of these, and
additional mutants presently being isolated, will
help us define precisely the MAT sequences re-
quired for cutting.
The Pedigree of "Lingering Death"
In standard strains the transposition of mating-type
cassettes is unidirectional: Only MAT switches
while the HM loci act as donors. The HM loci
themselves remain unaltered. In Mar* strains, the
same YZ junction sequence is not cut. However, we
have shown previously that the HM loci switch as
efficiently as MAT in Mar strains (Klar et al., Cell
25: 517 [1981]). If presence of the double-strand
break defines the recipient locus, then, in Mar cells
the HM loci should also experience the double-
strand break.
To test this prediction, cell lineage studies were
conducted on a strain with the genotype HMLa mats
Hhal
TCGICGCAACA_IGTAIAATTT 1 Al AAACCCTGG
AGCGCGITTG 1 CATA,TTAAAATATTTGGGACC
A
A
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A A C A G T A 1 A A T T 1 TA 1 ATTG 1 CAlATTAAAATAT
Figure 4
Sequence change of "fast growing" MAT-Inc mutants.
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hmrS marl HO. This genotype allows us to focus on
the behavior of a single HM locus during switching.
Because of the expression of the HMLa information,
this strain expresses an a phenotype. This strain pro-
duces a-like cells in a cell lineage that follow the same
rules defined for MAT switching. The a-like cells we
presume result from a double-strand break at the
HMLa locus. Such cells in the absence of any func-
tional MAT information are supposed to behave as a-
like. Interestingly enough, these a-like cells grow to
make a microcolony containing about 20-32 cells,
which are all dead at that stage. No essential genetic
loci exist distal to HML. We rationalize that the
double-strand break at HML in HMLa mats hmrS
marl HO cells is not lethal immediately, the "linger-
ing death" may ensue from the broken end (which
lacks a telomere) during subsequent rounds of growth.
DNA isolated from a strain with the genotype HMLa
mats hmrS marl HO was shown to contain a cut at
the YZ junction of HML.
Cell-cycle Enrichment
Although we have been interested in the timing and
cell-cycle regulation of the switching process for many
years, we will dwell here only on its usefulness as a
potential means of enriching for or trapping switching
intermediates that would be undetectable in exponen-
tially growing cultures. The observation that switches
occur in pairs led to the suggestion that it was an
event that affects both strands of the DNA prior to
DNA synthesis, and then was replicated and
segregated into both daughter cells. The ability to
detect the double-stranded cut at MAT YZ does not
depend on mating (a G, event) and hence can be
monitored throughout the cell cycle.
Our published studies have shown that saturated
cultures in which most cells are in the G, phase of
the cell cycle do not exhibit the HO cut. We have ex-
tended these studies to show that cells arrested in G,
by a-factor also lack the cut, whereas cells allowed
to proceed into the DNA synthetic phase before be-
ing arrested by treatment with hydroxyurea have en-
hanced levels of cut chromosomal DNA (Fig. 5).
Isolation and Characterization of HMLa
Minichromosomes
Differences in chromatin conformation of the silent
mating-type cassettes have also been observed, in this
case in superhelical density (K. Nasmyth and J.
Abraham, in prep.) and nuclease digestion patterns
(Nasmyth, Cell 30: 567 [1982]). These differences
have been shown to be mediated through the action
(directly or indirectly) of MAR/SIR. Thus, it seems
reasonable that the MAR/SIR gene products them-
selves, or proteins that MAR/SIR regulate or add
specificity to, interact with the chromatin structure
to repress transcription of the silent genes. This can
best be investigated by purifying the MAR/SIR gene
products and isolating the silent cassettes as repressed
chromatin. This would enable us (1) to deter-
lAyarbxyu reap.
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Figure 5
Southern blot of yeast DNA digested with HindIII.
Fragments (MAT left, MAT right), derived by HO-cutting in
addition to the restriction digest. Note that HO-cutting is
enhanced in the strain treated with hydroxyurea.
mine if the MAR/SIR product(s) directly interact
with the silent genes, and (2) to provide information
on the effect of regulatory proteins on chromatin
conformation.
When a plasmid is introduced into a cell by trans-
formation, the DNA is assembled into a nucleo-
some conformation that is indistinguishable from
normal chromatin (Livingston and Hahn, Proc. Natl.
Acad. Sci. 76: 3727 [1979]; Nelson and Fangman,
Proc. Natl. Acad. Sci. 76:6515 [1979]), resulting in
a minichromosome. When a silent cassette contain-
ing the a allele is introduced in this fashion into a
MAR /SIR' heterothallic a cell, the resulting mini-
chromosome is regulated (repressed), as judged by
a mating-type test, at nearly the same level as the
chromosomal gene. In one case, a plasmid (Bam26)
containing the HMLa cassette on a 6.5-kb BamH1
fragment, the LEU2 gene and pBR322 when
transformed into a cell (DC67) lacking the en-
dogenous plasmid 2/,, results in a plasmid copy
number of approximately 150 per cell, all of which
are regulated. The mechanism responsible for this
extremely high copy number is not clear and is
under investigation. Two chromosomal ARS
elements are present at both the HML and HMR loci
and are coincident with the E and I control sites. The
Bam26 minichromosome can be extracted by gen-
tle lysis of Ficoll-purified nuclei followed by
sedimentation on a 10-30% linear sucrose gradient
with 0.2 mm EDTA. The gradients are easily
assayed by dot blotting for the presence of the
plasmid DNA, and the proteins on the mini-
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Figure 6
Sucrose gradient purification of HMLa minichromosomes from wild-type yeast.
chromosome can be visualized on an SDS acryl-
amide gel (Fig. 6). The material sedimenting at ap-
proximately 75S contains 90-95% of the mini-
chromosomes (plus ribosomal complexes as the
major nonchromatin contaminant). Greater than
90% of the proteins associated with the minichro-
mosome are the four inner histones, H3, H4, H2a,
and H2b. Topoisomerase I can be enzymatically
detected cosedimenting with the peak of the mini-
chromosomes. A number of standard techniques
(see below) are presently being used to compare the
proteins associated with the HML minichromo-
somes in wild-type and Mar-/Sir- strains.
CVO3Bam26 has been introduced into two mutant
strains, carrying either a marl or a sir4 defect. In
marl-, the plasmid also remains episomal and has a
high copy number but is mitotically unstable and
segregates at a rate of approximately 25% per genera-
tion. However, when minichromosomes are prepared
from the marl- strain by techniques similar to those
used for the wild-type strain, a very poor yield is ob-
tained (less than 5% compared with the wild type). To
try to increase the yield, increasing amounts of non-
ionic detergents and NaCI were added at the chro-
mosome-releasing step. Using 2 M NaCI and 1%
Triton X-100, the minichromosome is still pelleted
with the bulk of the nuclear DNA. It can be released
with 1.0% SDS or by nicking with DNase I. This
behavior satisfied the operation definition of attach-
ment to the nuclear matrix in marl- strains. The in-
ability to release the CVO3Bam26 plasmid from the
nuclear scaffold in marl strains posed a problem in
that it seemed impossible to compare minichromo-
somes from wild-type and mutant strains.
Evidence from a number of other labs (Robinson et
al., Cell 28: 99 11982]) suggests that transcribed genes
are more closely associated with the nuclear scaffold
than transcriptionally inert genes. That is, after the
histones are removed with 2 M NaCI and the histone-
depleted nucleoid is purified, the active genes are less
accessible to digestion by DNase I than are the inac-
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tive genes. Preliminary results indicate that this is also
true for the yeast mating-type genes. The silent copies
of mating type are more easily digested with DNase I
in wild-type cells than is the transcribed MAT locus,
while the digestion rates are indistinguishable in
marl- cells.
The proposal that the reason for the inability to
release the minichromosome in marl- strains has to
do with its expression suggested that a general in-
hibitor of transcription would result in the release of
CVO3Bam26 in these strains. Recently, it has been
demonstrated that the heat-shock response in yeast is
tightly controlled at the transcription level (McAlister
and Finkelstein, I. Bacteriol. 143: 603[1980]). During
heat shock, the predominant heat-shock messages are
transcribed at a high rate to the detriment of most
other messages coding for non-life-threatening func-
tions. We found that when the marl- stain containing
CVO3Bam26 is grown for 3 hours at 40°C, the
minichromosome can be released from lysed nuclei
and can be isolated in the same manner as in the
wild-type case, indicating that transcription control
during heat shock in yeast may involve release from
the nuclear matrix (S. Weisbrod, unpubl.).
Fission Yeast Mating-type Switching
A. Klar, D. Beach
To determine generalities of the principles discovered
in the MAT switching system of S. cerevisiae, we have
begun studies on an unrelated fission yeast, Schizo-
saccharomyces pombe. This organism, although mor-
phologically and genetically distinct, switches its
mating type at high frequency in a manner analogous
to that in S. cerevisiae. Previous work on the fission
yeast mating-type switching has been limited to
genetic analysis, but with the development of transfor-
mation in this organism it has become possible to
clone S. pombe genes easily and to proceed with a
molecular investigation of the many interesting
genetic phenomena found in this system.
Haploid fission yeast grows by division in rich
medium, but as this is depleted, particularly of a
nitrogen source, cells cease division and conjugate
with those of opposite mating type, h' or h-. The
diploid thus formed directly enters a round of meiotic
division that leads to the formation of a four-spored
ascus. Although expression of sexual functions is ap-
parently limited to conditions of nutritional depriva-
tion, switching of mating-type occurs during exponen-
tial growth.
Using techniques analogous to those employed in
the isolation of the mating-type cassettes from S.
cerevisiae, we have cloned the mating-type informa-
tion from S. pombe and found it to be arranged in
three distinct copies. We presume that these elements
are functionally similar to the three cassettes in S.
cerevisiae but there is no evidence for DNA sequence
homology.
Isolation of DNA fragments containing the mating-
type genes has allowed the structure of the locus to be
investigated in wild-type strains and in the many
mutants that arise at high frequency as the result of ab-
normal switching events. Figure 7 shows the three
copies of mating-type information; the expressed copy
at MAT1 and the store of silent-plus information
MAT2-P and silent-minus information MAT3-M. The
mating type of the cell is determined by which of P
(for Plus) or M (for Minus) information is the tem-
porary resident at MAT1. Unlike in S. cerevisiae,
MAT1, MAT2, and MAT3 in S. pombe are a tightly
linked cluster of genes. The cassettes are flanked in
each case by two regions of homology, H1 (-90 bp)
and H2 ( -240 bp), detected by means of hetero-
duplex analysis (Fig. 8). Interestingly, a surprisingly
large percentage of the chromosome ( -25%) is
found to contain a double-stranded cut in the H1
region at MAT1. This cut is much reduced in switch-
ing defective (swi-) strains and is probably involved
in initiation of the recombination event of a switch.
The presence of such a high percentage of broken
chromosome suggests the existence of a special
mechanism stabilizing the cut ends.
Switching gives rise to many abnormal events
such as deletions and insertions. Deletions fusing
MAT2-P with MAT3-M generate a stable minus
strain (h-s), whereas transposition of both MAT2-P
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and MAT3-M, and the sequences in between, into
MAT1 generates heterothallic h*" and h-u strains.
The latter strains, at frequencies less than 10-4,
revert back to homothallic strains. The MAT2-P and
MAT3-M information can be activated in situ by fu-
sions to MAT1 resulting in deletions of the internal
sequences. This property allowed us to orient and
order these determinants on chromosome II.
Northern blots have been used to analyze the
transcripts of the mating-type locus. Neither MAT2-P
nor MAT3-M produce transcripts. MAT1-M has one
constitutive transcript, whereas MAT1-P has two
transcripts. One of these is constitutively expressed
but the other is induced only during conditions of
nitrogen deprivation.
Future work on the fission yeast mating-type system
will be twofold. First, it will provide a model system in
which to study eukaryotic recombination. The recom-
bination event takes place at almost every cell division
and is initiated and resolved in precisely known
regions (H1 and H2). Furthermore, there are now
numerous mutants affecting switching; these may
allow analysis of intermediate steps in the process of
recombination.
The second area of interest is the role of the mating-
type gene products in the control of mating and
sporulation. Use will be made of mutants that
derepress the cell for the normal requirement of
heterozygosity at the mating-type locus for sporula-
tion. Such mutations may lie in genes acting just
downstream of the mating-type genes in the control of
the transition from mitotic growth to meiosis.
Mutant Selection in Nicotiana
R.L. Malmberg, I. Mclndoo
Our major results for this year derive from selection
and characterization of a number of new Nicotiana
tabacum (tobacco) cell culture mutants. The goals of
this project have been (1) to increase the number of
characterized, selectable mutants, and (2) to per-
form a mutational analysis of the polyamine syn-
thesis pathway. We have done this by developing a
UV light mutagenesis procedure and a selection
system based on specific inhibitors of the pathway.
The polyamine synthesis pathway was chosen
MAT 2-P
Eco Eco
Sst I \ Boa I Born Xbo
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Figure 7
Restriction map of the S. pombe mating-type genes. Open and solid blocks represent regions of DNA homology. SMT is
a site where a double-stranded DNA break is found in vivo.
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MAT1-P x MAT3-M heteroduplex.
because mutants we had previously obtained in the
pathway showed a developmental switch in flower
morphology in regenerated plants. This posed the
questions of whether or not the mutation in the
polyamine pathway was directly correlated with the
developmental phenotype, or if the switch was the
result of some ill-defined pleiotropic interaction.
We have now isolated a number of new mutants
resistant to polyamine synthesis inhibitors. One of
these has a developmental switch in flower mor-
phology related to, but even more dramatic than,
the lesions observed in our first temperature-
sensitive line.
The original mutant, ts4, was isolated in a negative
selection for temperature-sensitive growth from a
haploid tobacco cell line. A second-site revertant, Rt1,
was obtained is amphidiploid
in origin, the reversion could have come from some
event at the homologous locus to ts4. These mutants
have been shown to be defective in polyamine
biosynthesis, and to have low intracellular levels of
spermidine and spermine, although we have not been
able to assign a structural gene to either. The ts4 mu-
tant also has the property that it produces a polypep-
tide of M, 30,000 and pl 5.3 which is not found in
either wild-type or Rt1 protein preparations. While
analyzing the effects of a polyamine synthesis in-
hibitor on wild-type cells, we noticed that the same
polypeptide is overproduced. Blocking the wild-type
pathway with the inhibitor produces a phenocopy of
the ts4 protein. The inhibitor used was methylglyoxal-
bis(guanylhydrazone) (MGBG, a spermidine analog)
which affects S-adenosylmethionine decarboxylase,
the second and third enzymes of the pathway. This ef-
fect is not seen with difluormethylornithine (DFMO,
an ornithine analog) an inhibitor of ornithine decar-
boxylase, the first enzyme in the pathway. Subse-
quently, we have shown that the polypeptides from
induced wild type and from mutant are identical by
analyzing peptide maps resolved by HPLC. In col-
laboration with John Smart (Biogen, Cambridge,
Mass.) we are sequencing the polypeptide.
The mutants ts4 and Rt1 had previously been
regenerated from cell cultures into whole plants. The
ts4 plants are very small, grow poorly, are light green,
and never flower. In contrast, Rt1 plants are dark
green, compact, and flower with the switch of anthers
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into petals. Approximately once per leaf on Rt1
plants, a light green sector appears, which can be ex-
cised and cultured and shown to be temperature sen-
sitive. A mitotic event is occurring at high frequency
on these leaves to separate the two mutants, revealing
ts4. The major question posed by the existence of
these mutants is thus, Is the switch from anthers into
petals a direct consequence of the lesions in poly-
amine synthesis?
Because of the phenocopy effect, this year we
concentrated on selection and analysis of MGBG-
resistant tobacco lines, after UV light mutagenesis;
more recently, we have also obtained some DFMO-
resistant lines. These mutants were mostly selected
from a diploid line of cultivar Xanthi; partway
through the selection process, we developed a
haploid line, and some selections have been per-
formed with it. From the MGBG diploid selection,
we obtained roughly 190 colonies, from which it
now appears that about 24 will prove resistant,
representing about 20 independent events. The mu-
tagenesis protocol was highly successful. Plants
have been regenerated from several of the MGBG-
resistant cell lines, and two of these strongly resem-
ble the Rt1 plants-they are normal colored but
dwarfed. The dwarfism exhibited may be a direct
consequence of the polyamine phenotype, since I.
Bernal-Lugo, J. Varner, and D. Ho (pers. comm.)
have shown that gibberellic acid treatment of tissues
causes pronounced increases in polyamine levels,
even prior to the well-documented a-amylase in-
duction; of course, dwarfism can be a consequence
of lack of gibberellic acid. Thus, the short internode
length of the new MGBG-R mutants with the same
effect in the Rtl-ts4 mutants may be a strong confir-
mation of the role of polyamines in the gibberellic
acid response of plants.
One of the MGBG-resistant lines, Mgr3, has flow-
ered, revealing an extraordinary developmental
change in flower morphology. The flowers appear
normal at first, but then the ovary swells greatly,
bursting the corolla and killing the five anthers. The
stigma elongates until it exerts from the corolla as
much as 5 mm. The stigma surface is divided into
quadrants instead of halves, and after a short period
of time, the surface turns black. Dissection of the
ovaries reveals the source of the dramatic swelling.
In a normal tobacco plant, there are usually found
hundreds of ovules, white discs, implanted on the
placental wall. In Mgr3, almost all of the ovules are
converted into anthers. Upon dissecting the ovary
wall, one is suddenly confronted with hundreds of
anthers, appearing like green spaghetti (Fig. 9). This
is a female-to-male developmental-switch mutant.
The implications of this are that polyamine syn-
thesis is intimately involved with flower mor-
phology, specifically anther development, since the
two regenerated mutants, RI? and now Mgr3, both
have altered gametogenesis.
The ovules-to-anthers phenotype is surprising, even
given that a female-to-male switch would occur.
Ovules and anthers are not equivalently advanced
Figure 9
Dissected ovaries of wild-type Nicotiana tabacum (left)
and mutant Mgr3 (right). The ovaries were removed from
the flower and then a triangular flap of the ovary wall was
removed. (Photomicrography performed with the assis-
tance of Sue Hockfield and Jorgen Johansen.)
structures. The female equivalent of the anther is the
whole ovary/stigma structure. Thus, this mutant
reveals that a developmental switch can occur that
does not just replace the ovule with the homologous
male organ, but also resets the developmental pro-
gram to an earlier stage.
Critical experiments to perform in the future must
include discovering the nature of the biochemical le-
sion of the Mgr3 mutant, as well as meiotic genetic
analysis. Mgr3 happens to be the first of the mutants
selected to be regenerated into a plant and flower. We
are eagerly awaiting the regeneration of more of the
MGBG- and DFMO-resistant lines.
Transposable Elements Associated with
Aberrant Ratio in Zest mays
S.L. Dellaporta, I.B. Hicks, Wood
This year our attention focused on the isolation and
characterization of Zea mays (maize) transposable
elements. In collaboration with Dr. John Mottinger
(University of Rhode Island), we have been working
on the molecular characterization and cloning of
elements that are activated by viral infection,
specifically, seven spontaneous mutations at the
shrunken locus in maize that were obtained by Dr.
Mottinger. These mutations were found in an F,
population of 346,201 kernels in the following
genetic cross:
sh bz wx/sh bz wx x Sh Bz Wx/Sh Bz Wx
where the male parents were the advanced pro-
geny of stocks that were originally infected with barley
stripe mosaic virus (BSMV) by Sprague and McKinney
(Genetics 54: 1287 [1966]). The virus infection
resulted in phenotypic ratio distortions of colored
and colorless kernels among exceptional ears in F2
progeny segregating for the anthrocyanin factor A/a
which they termed aberrant ratio or AR. These
distortions found in F2 populations were associated
with BSMV, wheat streak mosaic virus, or lily corn
fleck virus infection of a male parent homozygous
dominant for aleurone color loci crossed to an
uninfected female homozygous recessive for a.
Subsequently, AR was described in F2 populations
segregating for Pr/pr and Su/su that have in common
a virus-infected male progenitor. Genetic studies by
others have since demonstrated that many of the ap-
parent ratio distortions at Al can be explained by
segregation of alleles at complementary loci such as
A2, C, C2, and R. However, the apparent transposi-
tion of AR from one locus to another and the ap-
parent ability to induce mutations at epistatic loci
suggested that spontaneous mutations in AR lines
could be directly or indirectly virally related.
Our investigation began by examining the DNA of
the original seven sh* mutants by Southern hybridiza-
tion analysis and has continued with isolating ge-
nomic clones of progenitor and mutant alleles. This
work has identified three different isoalleles of Sh,
distinguished by restriction site polymorphisms,
that were segregating in the progenitor and tester
strains used in these experiments. After characteriz-
ing the progenitor alleles, we were able to show that
all of the shrunken mutations isolated in the AR
stocks were associated with DNA rearrangements,
which in two cases have been identified as DNA in-
sertions. We have begun to clone both ShA and ShB
progenitor and mutant alleles for a detailed molec-
ular analysis. At the time of this writing, one pro-
genitor ShB and two mutant alleles, sh-5586 and
sh-5582, have been cloned from genomic X libraries
in EMBL4. Most of the information we have is on
sh-5586, its progenitor ShB allele, and sh-5582.
An 11-kb R1 fragment containing the ShB structural
gene and a 14.3-kb R1 fragment containing the mu-
tant ShB allele sh-5586 have been obtained. Restric-
tion mapping of both fragments has confirmed that
the sh-5586 mutation is the result of an insertion of
3.3 kb of DNA into the 0.7-kb Hindlll fragment of
ShB. This region is covered by the cDNA probe,
and therefore, the insertion most likely resides
within the Sh structural gene.
By hybridization analysis of internal and junction
fragment probes of insertion 86 to maize genomic
DNA, we have concluded that: (1) the terminal
regions of insertion 86 contain a highly repetitive
sequence found in all stocks tested; (2) internal
regions of insertion 86 vary in copy number from
two to three per genome to highly repetitive; (3) the
highly repetitive internal regions of the transposon
are highly dispersed in size and do not show com-
mon restriction sites; (4) a repetitive internal region
of insertion 86 does not hybridize to the insertion
element found in the sh-5582 allele.
Insertion 86 is thus a member of a family of
dispersed repetitive elements and probably not
related to the viral genome. Sequences homologous
to insertion 86 are found in three maize lines ex-
amined, suggesting that it is a normal constituent of
the genome. The lack of homology to the insert at
sh-5582 indicates that more than one family of
transposons was activated in the AR stocks.
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MOLECULAR GENETICS OF PATHOGENIC AND VIRULENCE
FACTORS
M. So, E. Bi Ilyard, C. Deal, C.H. Lee, K. Messina, E. Segal
Our laboratory is interested in studying the com-
ponents contributing to pathogenesis and virulence
at the molecular and genetic levels. At the moment,
we are concentrating on two bacterial systems:
enterotoxigenic Escherichia coli and Neisseria
gonorrhoeae.
Enterotoxigenic E. coli causes diarrheal disease in
both humans and animals. The clinical syndrome of
the disease-diarrhea due to an electrolyte im-
balance in the upper bowels-is due to the action of
one or more toxins produced by the invading
bacteria. Two types of toxins are known to exist: (1)
LT, a heat-labile toxin immunologically and genet-
ically related to cholera toxin and (2) ST, a heat-
stable protein less than 5000 daltons in size. There
are two classes of ST toxins: (1) STI or STA is
methanol soluble and is assayed in suckling mice
and (2) STII or STB is methanol insoluble and
assayed in jejuna! loops of weaned rabbits or
piglets.
STI is well characterized genetically and chemi-
cally. The gene encoding STI is part of a transposon
flanked by inverted or direct repeats of Si.1 The
amino acid sequence of STI, deduced from the
DNA sequence, indicates that it is synthesized
within the cell as a prepeptide with a signal se-
quence and contains a cysteine-rich region at the
carboxyterminal end. Comparison of this and subse-
quent sequence work by several other laboratories
suggests that the Cys-rich region comprises the ac-
tive moiety. Synthetic peptide work (RA. Noughton,
pers. comm.) indicates that the terminal 18 amino
acids are required for full toxin activity. The precise
mechanism by which STI induces electrolyte im-
balance is still poorly understood. STI has been
shown to stimulate guanylate cyclase in vitro, and a
model based on the last 18-amino sequence bears
striking resemblance to an ionophore (M. Gill, pers.
comm.).
The precise role played by STII in pathogenesis is
not known. This is due in large part to the cumber-
some assay required to detect its activity. Some E.
coli isolates from diseased piglets produce STII but
not LT or STI. However, these strains are unable to
cause disease in experimentally infected piglets. E.
coli isolates from humans were thought to produce
STII only. Southern blotting experiments subse-
quently showed most of them also contain the LT
and/or STI gene(s). We have shown that STI and STII
are genetically distinct. To understand better the
contribution of STII to pathogenesis and virulence,
we have cloned an 806-bp fragment of DNA en-
coding STII from a 60 x 106-dalton plasmid into a
genetically characterized K-12 strain of E. coli. This
K-12 recipient now produces STII as assayed in the
jejunal loops of weaned pigs. Through subcloning
and mutation analysis, we have identified the
coding region of the STII insert.
The nucleotide sequence of STII is quite different
from that of STI, as our previous work had sug-
gested. The deduced protein sequence is 71 amino
acids in length with a signal peptidelike sequence at
the aminoterminal end and a series of hydrophobic
amino acids at the carboxyterminal end; like STI, it
is Cys-rich, although the cysteines are not arranged
in as striking a manner.
Our previous work had indicated that the STI
gene may be disseminated by transposition. The im-
mediate areas flanking STII do not contain any
direct or inverted sequences that are hallmarks of
transposable elements. However, the original
plasmid from which the STII gene was cloned does
contain a 600-bp inverted repeat. This sequence
does not appear to be related to I51, and its relation-
ship to the transposability of STII is now under in-
vestigation.
We have used the STII gene as a probe in a set of
preliminary colony hybridizations and the data in-
dicate that all STII and only STII producing enter-
otoxigenic E. coil are detected. This observation
makes the task of epidemiology of enterotoxigenic
E. coli easier.
Recently, we have also been studying the genetic
regulation of pilin expression in N. gonorrhoeae.
Pill, comprised of identical 18,000-dalton subunits,
are surface proteins that function in colonization.
There is no animal model for gonorrhea since man
is the only host for this disease. At least 100
serotypically distinct pili are known to exist. The
protein sequences of three different pilin subunits
indicate that they all share a region of homology
located at the aminoterminal end. In addition, any
N. gonorrhoeae clinical isolate can switch from a
pilus* (P*) to pilus (P-) phenotype and back again to
P. at frequencies higher than can be explained by
random mutation. We have cloned two expressing
pilus genes into E. coli K-12; by using them as pro-
bes, we were able to show that transcription stops
when the cell switches from the P* to the P- state. In
addition, genomic rearrangement is involved in this
switching process.
Subcloning experiments localized the pilus-
coding region to a 1-kb fragment in each of the two
inserts of 2 kb and 4 kb. We have completed the se-
quence of the 2-kb insert. The structural gene con-
tains promoter sequences similar to those known for
E. coil and other bacterial species such as S.
pneumoniae. The noncoding region contains in-
teresting direct and indirect repeated sequences, in
addition to an extra copy of the region of the pilus
structural gene corresponding to the variable region
of the protein. We are now sequencing the clones
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from a P- genome derived from the original P*
isolate, which contains the "expression site," pro-
vided us by T.F. Meyer (Max Planck Institute). These
experiments should elucidate the sites important in
the rearrangement process.
In other experiments, we are also examining the
genetic potential of each cell to generate im-
munologically distinct pili subunits by a detailed set
of lineage studies. We have a set of subclones con-
taining only the constant and variable regions and
noncoding sequences and are using them as probes
to map the region of the N. gonorrhoeae genome
that functions in pilus expression. Last, we are
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generating a set of mutants of N. gonorrhoeae that
fail to switch from p4 P- and from P-- P.
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BACTERIAL TRANSPOSITION
F. Heffron, A. Bhagwat, R. Kostriken, C.-H. Lee
In the last year, my laboratory has focused on two
problems:
I. A large amount of data supports the idea that
recombination in yeast (and perhaps other organ-
isms) proceeds via an intermediate containing a
double-strand break (Orr-Weaver et al., Proc. Natl.
Acad. Sci. 78: 6354 [1981]; Szostak et al., Cell
[1982, in press]). Yeast endonucleases are therefore
likely to play a role in recombination. Strathern et
al. (Cell 31: 183 [1982]) have identified a double-
strand break at the mating-type locus in yeast cells
that are switching mating type. We have established
a sensitive endonuclease assay that allowed us to
identify an endonuclease (YZ endo) with the proper-
ties one would predict. YZ endo makes a double-
strand break within MAT (the mating-type locus) at a
site that corresponds closely to that mapped in vivo
by Strathern et al. (Cell 31: 183 [1982]). Further-
more, mutations at MAT that cannot switch mating
type were found to be resistant to digestion by the
endonuclease in vitro. YZ endo makes a double-
strand break at the sequence
CGCAACA1GTAAA
GCGTTGTCATTT
to generate a four-base 3' extension terminating in
a 3' hydroxyl in the Z region of the MAT locus. Based
on deletion studies and studies with synthetic DNA
substrates, the enzyme recognizes a short specific
sequence contained within the 12 nucleotides shown
above. YZ endo makes a concerted double-strand
break and does not remain attached to the DNA. It
appears to purify as a single protein (or tightly
bound complex) as judged by its purification as a
single peak of activity on DNA cellulose, DEAE
Sephacel, and phosphocellulose column chromo-
tography.
The sequence shown above occurs at least three
times in the yeast genome, i.e., once in each
cassette of mating-type information; yet, during
mating-type interconversion, the double-strand
break is observed only at MAT and not at either
HML or HMR. Therefore, we were interested in
testing if HML and HMR were not cut by the en-
donuclease in vivo because the DNA had been
covalently modified at the silent cassettes or
whether the sites at HML and HMR were protected
by chromatin. We isolated yeast DNA and treated it
in vitro with the endonuclease. We found that the
two silent cassettes are cut equally as well as MAT,
thus ruling out covalent modification.
In addition to YZ endo, we have identified a sec-
ond endonuclease that makes a double-strand break
within pBR322 at nucleotide 1330. Like YZ endo,
this enzyme cleaves DNA to leave a 4-bp (or 5) 3'
extension; but unlike YZ endo, it is present in all
strains of yeast we have tested. We are currently
looking for other endonucleases in yeasts and at-
tempting to determine their role in recombination.
II. Tn3 is a 5-kb bacterial transposon that encodes
three genes: (1) a resolvase/repressor, (2) a trans-
posase, and (3) a 0-lactamase. In addition to these
three genes, it encodes three sites required for its
transposition, it is terminated at either end by 38-bp
perfect inverted repeats that are required for Tn3
transposition, and it encodes a resolution site.
Transposition of Tn3 appears to take place by a two-
step process; in the first step, the donor and recip-
ient molecules become joined via a direct repeat of
Tn3 (the transposase and terminal repeats are ab-
solutely required for this step). In a second step, the
cointegrate is resolved. This step requires the
resolvase/repressor and the internal resolution site.
Transposons related to Tn3 exhibit a phenom-
enon called transposition immunity first described
by Robinson et al. (J. Bacteriol. 129: 407 [1977]). A
plasmid containing a copy of Tn3 is immune to fur-
ther insertions of Tn3. It is a particularly interesting
phenomenon to study because it works only in cis.
That is, a plasmid containing Tn3 is immune to in-
sertion of Tn3, but transposition occurs normally to
other plasmids in the same cell. Immunity must
block some step in transposition because plasmids
containing two copies of Tn3 can be constructed
and these are perfectly stable (Robinson et al., J.
Bacteriol. 129: 407 [1977[1. Last of all, we know
that transposition immunity is highly specific to the
transposon, that is, a plasmid containing Tn501 and
therefore immune to Tn501 is not immune to Tn3
(Grinsted et al., Mol. Gen. Genet. 166: 313 [1978]).
We have determined that tnpR is not required for
transposition immunity. By extensive deletion
analysis, as well as the chemical synthesis of the ter-
minal 38-bp repeat, we have determined that only
the terminal repeat need be present to confer im-
munity to Tn3. In most instances no other part of
Tn3 is required in cis for immunity. (We are current-
ly investigating the few exceptions to this rule.)
We believe that transposition immunity can be
accounted for by a tracking model. During trans-
position, the actual integration event in the recip-
ient molecule may be slow or inefficient. As a con-
sequence, an integration complex composed of the
transposase joined to the ends of Tn3 may have a
long half life. If the integration complex tracks along
a recipient molecule, it would thus have a high prob-
ability of scanning the entire recipient molecule
before integration. Such a model is supported by
transposition specificity studies (Grinsted et al.,
Mol. Gen. Genet. 166: 313 [1978]). A model for im-
munity could then be that the integration complex
dissociates itself when it encounters an immunity
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Vertebrate Gene Structure and Expression
Until recombinant DNA techniques were developed, the structure of vertebrate genes at the DNA level was
effectively a black box incapable of being opened up for intelligent dissection. Now virtually any gene can
be cloned if we have a trick to select for its presence or if we know a fragment of the amino acid sequence
of its protein product or if we can generate an antibody that specifically reacts with the desired protein. The
concept that a gene is isolatable and the actual cloning of it, however, are not the same. Much persistent in-
telligence and experimental skills are more often than not required. To take on the nature of vertebrate
genes, we have created a number of research groups of complementary objectives that can fruitfully in-
teract through the sharing of ideas, techniques, and equipment.
This past year saw the six different labs of this section first developing and then exploiting several power-
ful new general ways for gene cloning. Key to many of our successes was the assistance, both intellectual
and practical, given to all by John Fiddes, who for two and a half years led a group focusing on Polypeptide
Hormone Genes. Thus, his departure at the year end to help form the new recombinant DNA company,
California Biotechnology, Inc., left a gap not easily filled. David Zipser, who for 12 years headed our
Molecular Genetics Section, also moved to California where he will be part of a Cognitive Science group at
the University of California in La Jolla.
MAMMALIAN CELL GENETICS
M. Wig ler, M. Goldfarb, K. Shimizu, E. Taparowsky, 0. Fasano, Y. Suard, D. Birnbaum, L. Edlund,
M.A. Ruley, C. Fraser, M. Riggs
The use of DNA-mediated gene transfer led to the
discovery of dominant-acting transforming genes in
nonvirally transformed cells (Shih et al., Proc. Natl.
Acad. Sci. 76: 5714 [1979]). For the past year, our
major effort has been the isolation and characteriza-
tion of transforming genes we previously identified
in human neuroblastoma and bladder, lung, and
colon carcinoma cell lines (Perucho et al., Cell
27: 467 [1981]). Considerable progress has been
achieved in isolating the transforming gene com-
mon to lung and colon carcinomas. The transform-
ing gene from a neuroblastoma cell line and its nor-
mal counterpart from placental DNA have both
been fully cloned. Finally, the transforming gene of
the bladder carcinoma cell line T24 and its normal
counterpart have been cloned, sequenced, and
compared, and we understand at the nucleotide
level the difference between them. The transform-
ing gene encodes a protein that differs at one amino
acid from that encoded by the normal gene
(Taparowsky et al., Nature 300: 762 [1982]). This
difference accounts for its biological activity in the
NIH-3T3 focus assay system. How this change in
protein structure leads to cellular transformation is
now our major concern.
Isolation and Characterization of the
Transforming Gene of T24 Bladder
Carcinoma Cells
M. Goldfarb, E. Taparowsky, 0. Fasano, Y. Suard,
M. Wig ler
Last year, we reported isolating the transforming
gene of T24, a human cell line derived from a blad-
der carcinoma (Goldfarb et al., Nature 296: 404
[1982]). The method of isolation was the tRNA sup-
pressor method developed here by Kenji Shimizu.
Hybridization studies of this gene indicated that it
was human in origin and that its chromosomal locus
displayed a high frequency of restriction fragment
length polymorphisms (RFLPs) (Goldfarb et al.,
Nature 296: 404 [1982]). From this observation and
blotting to human DNAs, we have been able to infer
that this gene is present just once per haploid
chromosome complement. This gene has been used
as a probe by Ray White and colleagues (Howard
Hughes Medical Institute in Salt Lake City, Utah) to
demonstrate that hereditary predisposition to colon
cancer is not linked to this gene (Barker et al. [1983,
in prep.]).
Workers from other labs demonstrated that the
T24 gene was the human homolog to the viral on-
cogene v-Ha-ras, encoding a 21,000-dalton protein
(p21) (Der et al., Proc. Natl. Acad. Sci. 79: 3637
[1982]); Parada et al., Nature 297: 474 [1982]; Santos
80
et al., Nature 298: 343 [1982]). This result has been
confirmed by us (Shimizu et al., Proc. Natl. Acad.
Sci. [1983, in press]) and provided the first instance
of a gene, previously identified by its presence in
oncogenic retroviruses, implicated in human
cancer.
Our initial work on this gene has been to deter-
mine why it has transforming activity. The suppres-
sor-rescued gene was used as probe to isolate the in-
tact gene from both T24 DNA and placental DNA X
L47.1 libraries. No isolates from the placental DNA
were capable of inducing foci on NIH-3T3 cells,
whereas all isolates from the T24 library were effi-
cient at focus induction in NIH-3T3. This indicated
that the difference between the normal and transfor-
ming genes was indeed at the DNA level. By con-
structing chimeric genes-recombinants between
the normal and tranforming genes-we were able to
determine that a small 224-bp Mstll /Xbal fragment
of the transforming gene contained the functionally
altered sequence. Sequencing this region for the tran-
forming gene, the normal gene, and a cDNA copy to
the transforming gene transcript indicated only one
significant base change occurring in the coding por-
tion of the first coding exon whereby the 12th N-
terminal amino acid was changed from glycine in the
normal to valine in the transforming ras p21
(Taparowsky et al., Nature 300: 762 [1982]). These
sequence changes were also reported by others (Red-
dy et al., Nature 300: 149 [1982]; Tabin et al. Nature
300: 143 [1982]). Cotransformation into NIH-3T3
cells of either the normal or transforming gene in-
dicated that indeed the ras p21 of T24 was 100-1000
times more efficient than the normal ras p21 at induc-
ing the transformed phenotype in NIH-3T3 cells
(Taparowsky et al., Nature 300: 762 [1982]). Taken
together, at the DNA level, the molecular changes
resulting in a cancer gene have been defined. Most
importantly, these results indicate that, by a very
minor alteration, a normal cellular protein can be con-
verted to a transforming protein. Curiously, alterations
in the 12th amino acid are also found in the viral ras
oncogenes, suggesting this amino acid residue plays a
critical role in the normal function of this protein.
(Similar lesions were found in this gene isolated from
the human bladder carcinoma cell line El. However,
in collaboration with Jorgen Fogh and colleagues at
the Sloan Kettering Cancer Research Institute in Rye,
New York, we demonstrated that the cell line called El
probably arose as a subline of T24.)
A complete cDNA to the T24 Ha-ras transcript
was cloned and sequenced and compared with the
genomic Ha-ras gene. The human Ha-ras gene has
at least five exons, and the complete coding se-
quence is contained in four of these. We have not
yet identified the promoter of the Ha-ras gene nor
have we located the 5' untranslated sequences of
the mature message. By making genomic/cDNA
chimeras, we have established that introns are re-
quired for the efficient expression of this gene.
We made comparisons of the complete nucleo-
tide sequence of the human Ha-ras gene with the
viral Ha-ras gene, previously published by others
(Dahr et al., Science 217: 934 [1982]). This resulted
in discovering a remarkable conservation in amino
acid sequence (Fasano et al., J. Mol. Appl. Genet.
[1982, in press]). Although 30% divergence in
neutral base positions was observed, only 3 amino
acids out of 189 were different. In particular, there
was complete conservation at the carboxyl end of
the proteins, the regions where the viral Ki-ras,
another gene in the ras family, and the viral Ha-ras
diverge markedly (Dahr et al., Science 217: 934
[1982]; Tsuchida et al., Science 217: 937 [1982]).
We conclude that this region may distinguish the
physiologic functions of the ras genes.
Isolation and Characterization of the Lung
and Colon Carcinoma Transforming Gene
K. Shimizu, M.A. Ruley, M. Goldfarb,
D. Birnbaum, M. Wig ler
Previous work identified a large gene of human
origin with transforming activity present in several
lung and colon carcinoma cell lines (Perucho et al.,
Cell 27: 467 [1981]). Identification was made based
on the presence of conserved EcoRI digest frag-
ments containing human repeat sequences in
NIH-3T3 cells transformed with DNA from these
donors. The first fragment of this gene was cloned
by screening X Charon 4A libraries of NIH-3T3
secondary transformants derived from Ca lu-1, a
human lung carcinoma cell line, with blur 8, a cloned
representative of the Alu family of human repeat se-
quences (Shimizu et al., Proc. Natl. Acad. Sci.
[1983, in press]). Subsequent fragments of this gene
were obtained by chromosomal walking (Shimizu
et al., and work in progress). The resulting isolation
and mapping of over 20 overlapping phage inserts
have led to the construction of a composite restric-
tion map. Der et al. (Proc. Natl. Acad. Sci. 79: 3637
[1982]) demonstrated that another lung carcinoma
cell line, LX-1, carried a transforming gene that was
closely homologous to the viral Kirsten ras (Ki-ras)
gene. The Ki-ras and Ha-ras genes are related
members of a diverged family. They encode im-
munologically cross-reactive 21,000-dalton pro-
teins and share considerable nucleotide homology.
Hybridization studies on our cloned gene also in-
dicated its close relation to Ki-ras, and its identity to
the transforming gene of LX-1. Southern blotting
with cloned viral Kirsten sequences as probe has
identified the potential coding blocks of this gene.
Although the gene product is the same size as the
Ha-ras gene product, the human Ki-ras is 20 times
the size (40 kbp) of the human Ha-ras gene and con-
tains one more coding block. Preliminary sequence
data indicates considerable homology between the
second and third coding blocks of human Ki-ras and
Ha-ras. Indeed, they appear to utilize the same
splice site. We predict, therefore, that the human Ki-
ras gene contains either a pseudo-exon or that exon
choice exists, possibly in a developmentally
regulated fashion, with an alternate third or fourth
coding exon. As indicated from our previous
studies, we believe these last two exons contain the
protein determinants of physiologic specificity.
We have also begun to isolate the human Ki-ras
gene from a placental DNA library but have not yet
done sequence comparison of the normal and
transforming genes to determine the potential can-
didate sites of functionally significant biological
alteration.
Work from other labs has implicated this gene in
pancreatic carcinoma and osteosarcomas (Pulciani
et al., Nature 300: 539 [1982]).
Isolation and Characterization of the
Transforming Gene of a Human
Neuroblastoma Cell Line
K. Shimizu, E. Taparowsky, M. Goldfarb,
M. Wig ler
Transforming activity was found in the DNA deriv-
ed from SK-N-SH, a human neuroblastoma cell line
(Perucho et al., Cell 27: 467 [1981]). This past year,
we succeeded in cloning the gene responsible for
this activity (Shimizu et al., Proc. Natl. Acad. Sci.
80: 383 [1983]) using the methodology of tRNA
suppressor rescue that had been developed here by
Kenji Shimizu (see last year's report). Hybridization
studies indicated that this gene was of human
origin, since it had a normal counterpart in the DNA
of all human material we examined. Further hybrid-
ization studies showed that the transforming gene of
SK-N-SH was related to both the Ha-ras and Ki-ras
genes. It encodes an immunologically cross-reactive
19.5-kD protein. Indeed, it constitutes a third mem-
ber of the ras gene family, and all three ras genes are
about equidistant in nucleotide divergence from
each other. We have termed this gene N-ras. It is in-
termediate in size between Ha-ras and Ki-ras, a
biologically active fragment being less than 12 kb
and probably less than 9 kb. Its intron/exon struc-
ture has not yet been determined nor has sequence
comparison to the other ras genes begun.
In contrast to T24, SK-N-SH contains both normal
and transforming copies of this gene. The homolog
cloned from placental DNA is also not active in the
NIH-3T3 focus assay. Therefore, the difference be-
tween the transforming and normal genes lies at the
nucleotide level. We are beginning to perform
systematic recombination experiments between the
normal and transforming versions of this gene to
determine the nucleotide alterations that result in
functionally altered biological activity. To facilitate
this, we are in the process of isolating cDNA clones
of the N-ras transcript. Preliminary results from
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other labs have begun to indicate that this gene is Publications
implicated in a very wide range of tumors.
Other Assays for Transforming Genes
0. Fasano, M. Wig ler
It is a significant and curious result that all the
transforming genes detectable by us with the
NIH-3T3 focus assay are members of the ras gene
family. On the one hand, this implies that the altera-
tion by mutation of ras genes may be an important
step in the development of many kinds of human
cancer. On the other hand, it may point to a bias in
the assay system that readily scores altered ras genes
but is insensitive to many other tumor genes. For
this reason, we have begun to develop another
assay system, still utilizing NIH-3T3 cells as recip-
ients for DNA-mediated transfer, but scoring for the
transformation event by injecting cells exposed to
DNA directly into nude mice. These experiments
are being performed in collaboration with Jorgen
Fogh of Sloan Kettering Cancer Research Institute,
Rye, New York. Preliminary results indicate that this
method will be sensitive to genes previously
undetectable by the focus assay system.
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HORMONAL CONTROL OF GENE EXPRESSION
D.T. Kurtz, D. Danna, L. McCullough, W. Addison, I. Maclnnes
For the past several years, we have been studying
the hormonal modulation of the synthesis of a rat
liver protein called oz, globulin. a, represents
1-2% of protein synthesis in the livers of adult male
rats. It is induced in vivo by androgens, glucocor-
ticoids, thyroid hormone, and growth hormone, and
is strongly repressed by estrogens.
02, Globulin Gene Structure
Southern blot and kinetic hybridization analysis
with a cloned ce2u cDNA have indicated that this
protein is encoded by a multigene family, with
18-20 copies per haploid genome. Twelve genes
have been isolated from a library of the rat genome
cloned in X phage. The a, structural genes are
3.5 kb in length and contain six introns. The
homology between the different 02, genes extends
beyond the 5' and 3' ends of the structural gene to
encompass a length of 10-12 kb. For the most part,
the different genes show extensive homology in ex-
on, intron, and flanking regions. Two of the clones,
however, show a complete divergence of sequence
in the 3' portion of the structural gene. This region
corresponds to the 3' untranslated region of oe2u
mRNA. If small segments of DNA from these variant
3' ends are cloned and used as a probe versus
mRNA from rat tissues, no hybridization can be
detected, suggesting that these genes are not
transcribed in vivo. The divergence at the 3' end of
these genes is the most obvious difference between
these variants and the normal genes. Other more
subtle sequence differences exist, which will be
described below.
Globulin Induction by Glucocorticoids
As we reported previously, the cloned 02 globulin
genes, when transfected into mouse L cells, retain
their ability to respond to glucocorticoids. Initial ex-
periments were done using the entire X clone con-
taining the gene. We have subcloned 02u gene
fragments containing progressively less flanking se-
quence and have found that a cloned XbaBam
fragment containing 235 bases of 5' flanking se-
quence and approximately 400 bases of 3' informa-
tion continues to respond to glucocorticoids when
transfected into L cells. The regulatory elements ap-
parently lie quite close to, or in the gene, in agree-
ment with the findings in other laboratories for
other inducible genes.
To determine if the ability of the CY, gene to re-
spond to glucocorticoids lies in the 5' flanking
region, a fragment from the promoter region of the
globulin gene was ligated to the structural gene
for herpes thymidine kinase (TK), using a mutant tk
gene (obtained from D. Zipser) which had had a
Xho linker inserted between amino acids 9 and 10
of the protein-coding sequence. The a2u-tk hybrid
construct should result in a chimeric protein con-
taining the first three amino acids from oe2u, three
amino acids from the linker, and the remainder
from tk. The «24-tk hybrids were used to transfect
Ltk cells to the tk' phenotype. tk' clones were
isolated and tk activity and tk mRNA were
measured with and without dexamethasone. It was
found that both TK enzyme activity and total tk
mRNA were induced slightly (2-4-fold) by dexa-
methasone treatment. This is significantly less than
the induction seen when the intact ce, gene is used.
When the tk mRNA produced by these cells was
analyzed on Northern blots, two tk mRNA species
were detected-one of approximately 1250 bases,
the size expected for tk mRNA produced from the
cx2u promoter, and another short ( 800 base)
transcript. This short mRNA, apparently produced
from a promoterlike sequence inside the normal tk
protein-coding region, has been found by other in-
vestigators.
The 1250-base tk message produced from the oe,u
promoter is inducible by dexamethasone, whereas the
short transcript is unaffected. The 5'
flanking region of the 02, gene apparently contains
sequences that are at least in part responsible for
glucocorticoid inducibility. Sequence analysis of
the 5' flanking region of 02, shows no obvious ho-
mology with other glucocorticoid-inducible genes
that have been sequenced.
A clue to the DNA sequences that may be involved
in glucocorticoid regulation is provided by the
transcriptional behavior of the variant «24 genes
mentioned above. When these genes are trans-
fected into L cells, they are transcribed at relatively
high levels even with no hormone added. The level
of ce2u mRNA produced by these variant genes is
similar to the induced level seen for the inducible
genes and is unaffected by glucocorticoid. This con-
stitutive high phenomenon seems to be dependent
on the 5' end of the variant genes: An a2, tk hybrid
gene was constructed using the 5' promoter frag-
ment from X clone 211, one of the variant genes.
This hybrid construct, when transfected into cells,
results in constitutive high expression of tk mRNA,
in the absence of hormones, in contrast to the
results using the inducible promoter. (These studies
were done in tk- Rat 2 cells, which do not transcribe
tk mRNA from the internal promoter mentioned
above. All tk mRNA in these cells derives from the
02,, promoter.) The 5' flanking sequence of X clone
211, the constitutive promoter, is identical to the se-
quence of the inducible promoter from 230 until
88. From this point, there is a sequence of 11
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bases in the inducible promoter ( - 88 to - 77) that
is absent from the constitutive promoter, where it is
replaced by a sequence of five bases. At - 76, the
two sequences pick up again and are identical
through the cap site into the mRNA coding region,
with the exception of four bases at -49 to -46,
which are altered.
This suggests the possibility that sequences be-
tween approximately - 90 and - 75 may be impor-
tant in the hormonal response of the 02 gene. Fur-
thermore, the fact that the uninducible genes are
transcribed at a constitutive high level, rather than
simply uninducible and off, is consistent with a
model in which steroid inducibility is the result of
removal of a repression, i.e., the DNA sequences
that modulate inducibility keep the gene off in the
absence of hormones. One need not necessarily
postulate a repressor protein that interacts with the
DNA. The sequence itself may keep the chromatin
in a transcriptionally inactive configuration until
acted upon by the hormone-receptor complex. It
may be of note that the sequences from - 88 to
- 77 that are missing in the constitutive variant are
part of a 9-bp direct repeat TGAGAAGA which
recurs 23 bases downstream. A 10-base direct
repeat occurs in approximately the same position in
the promoter region of MMTV, another well-charac-
terized dexamethasone-responsive gene. Site-
specific mutagenesis in the 5' promoter region will
ultimately delineate which sequences are responsi-
ble for hormonal induction, and hopefully will pro-
vide information as to the nature of the induction.
Induction of a, by Other Hormones
Glucocorticoid hormones are only one of many in-
ducers of ce2u globulin in vivo. Androgens, thyroid
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hormones, growth hormone, and insulin all in-
crease 02. levels in rat liver, and estrogens strongly
repress a, synthesis. However, L cells, and most
tissue culture cell lines used for gene-transfer ex-
periments, lack receptors for these other hormones.
Several cell lines have been described with ap-
propriate receptors (MCF-7 cells have estrogen
receptors, CHO cells have androgen receptors, and
10T1/2 cells have thyroid hormone receptors). A
dominant-acting vector for gene-transfer experi-
ments in tissue culture cells has been developed.
The vector consists of the prokaryotic neomycin-
resistance gene from Tn5, linked to the SV40 T an-
tigen promoter, and followed by the SV40 small t
splice region, and the large T poly(A) addition site.
This vector has proven to be very successful in
transforming several tissue culture cell lines (in-
cluding those mentioned above) to resistance to the
neomycin analog G418. Various ci2u genes have
been inserted into these cell lines, and the effects of
estrogen, thyroxine, and androgens are currently
being assessed.
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Immunological Screening of cDNA
Expression Libraries
Relatively straightforward methods have been
established for the construction of essentially com-
plete cDNA or genomic DNA libraries from many
sources. Although such libraries usually contain
many thousands of members, the major difficulty is
the identification of clones of particular interest.
Final identifications are usually made by sequenc-
ing the cDNA insert, by using the cDNA to select a
specific mRNA for in vitro translation, or both. Such
assays are not ordinarily suited to screening large
libraries for individual clones, and steps are usually
taken to enrich for the clones of interest. The most
commonly used procedures rely on cDNA hybridi-
zation probes made from an mRNA preparation that
contains high levels of the sequence of interest.
Variations of this general approach include physical
fractionation of the mRNA by sedimentation, gel
electrophoresis, or immunoprecipitation of poly-
somes. Alternatively, differential hybridization can
be used if two mRNA preparations are available that
differ principally in their content of the mRNA of in-
terest. These approaches are generally limited to the
identification of genes that are expressed at moder-
ate to high levels.
At least two new techniques have been devel-
oped that permit the identification of clones for
genes that are expressed at low levels. If part or all
of the amino acid sequence of a protein is known, it
is possible to synthesize specific oligonucleotides
for use either as hybridization probes themselves or
as primers for the enzymatic synthesis of specific
cDNA probes. This procedure is limited by the
degeneracy of the genetic code. Other techniques
require that the cDNA preparation, ideally made
from total poly(A)* mRNA, be cloned into plasmids
that promote expression of the cDNA in Escherichia
coll. The resultant "expression libraries" are then
screened for appropriate translation products using
either a functional or an immunological assay.
These protocols bypass the need for enrichment of
the mRNA and provide promising approaches for
the cloning of genes expressed at low levels.
We have developed procedures for constructing
cDNA expression libraries from total poly(A)* mRNA,
and the immunological screening of such libraries
with specific antibodies to identify the gene prod-
ucts. These techniques improve upon previously
described immunological screening methods in that
the expression library is made directly from unfrac-
tionated poly(A)+ mRNA and that the antibody-
antigen complexes are detected on the same nitro-
cellulose filters used to grow the colonies. A cDNA
expression library of about 100,000 total members
has been constructed using chick smooth muscle
poly(A)+ RNA as a template. After screening with
anti-tropomyosin antibodies, we isolated about a
dozen independent bacterial clones that express
proteins antigenically related to tropomyosin. DNA
sequence analysis demonstrated that these cDNAs
encode tropomyosin. One of the clones contains
the entire coding region of tropomyosin and ex-
presses this protein in E.coli.
The same library has been screened for a-actinin;
colonies have been identified that (1) react specif-
ically with two independent actinin antisera and (2)
produce a novel protein that can be immunoprecip-
itated with actinin antisera. Since the a-actinin pro-
tein has not yet been sequenced, DNA sequence
data is not helpful in the identification of the clones;
selection of mRNA and translation into protein will
be necessary.
Construction of a cDNA Expression Library
Kurtz and Nicodemus have described a method for
cDNA cloning in which two different oligonucleo-
tide linkers, EcoRI and Sall, are simultaneously
ligated to the blunt-ended cDNA. After the linkers
are digested with appropriate restriction enzymes,
the cDNA can be ligated to an EcoRI-Sall -cut
plasmid vector which, if the insert is physically
removed, cannot ligate to itself. This highly efficient
method permits the use of an excess of vector and
yields libraries in which greater than 95% of the
bacterial clones contain cDNA inserts. However,
with the simultaneous ligation of both linkers, one
expects that at least 50% of the cDNA molecules
will have the same linker at each end and therefore
cannot be cloned in a double-cut vector. In practice,
we find that the Sall linkers ligate more rapidly than
the EcoRl linkers so that greater than 50% of the
cDNAs have homogeneous ends. John Fiddes and
Doug Hanahan (Structure and Expression of Eukary-
otic Genes Section) have modified the procedure to
overcome this problem. One set of linkers is ligated
to the end of cDNA corresponding to the 3' end of
the poly(A)+ RNA before cleavage of the hairpin
loop with 51 nuclease (see Fig. 1). Following the S1
reaction, the second set of linkers is ligated to the
end of the cDNA that previously was protected by
the hairpin loop. This greatly increases the percen-
tage of cDNA molecules with different linkers at
each end.
If the linkers are chosen appropriately, the cDNA
can then be ligated to a plasmid expression vector
that contains both a transcriptional and a transla-
tional start site. The sequential addition of linkers
permits the insertion of the cDNA in a defined
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Figure 1
Construction of a cDNA expression library. At the top of the panel is shown the poly(A)* RNA, which is copied into
single-stranded cDNA by reverse transcriptase, employing an oligo(dT) primer. The template RNA is degraded with base,
and the second strand synthesized, generating a double-stranded DNA hairpin. The open end of the hairpin is filled in
with the Klenow fragment of E. coli DNA polymerase I and ligated to Sall linkers (S). The hairpin loop is destroyed with
SI, and the ends of the resulting double-stranded cDNA are again filled in with the Klenow fragment of E. coli DNA
polymerase I and ligated to EcoRl linkers (R). After digestion with EcoRl and Sall, the double-stranded cDNA has a Sall
site at the end that corresponds to the 3' end of the template RNA and an EcoRl site at the end that corresponds to the
5' end of the template RNA. This cDNA is ligated to the larger Sall-EcoRl fragment of pUC8. In such constructions, the
transcript made in E. coil has the same polarity as the template mRNA.
orientation (Fig. 1). Under these conditions, approx- of the protein the template mRNA normally
imately one bacterial clone in three should have a translates.
cDNA insert capable of expressing at least a portion This protocol has one drawback. Some cDNAs
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will contain restriction sites that are the same as
those in the linkers. This will give either an
unclonable DNA insert or an insert that is always
cloned in the same, possibly incorrect, translational
frame. The pUC8/pUC9 plasmid expression vector
system has been used in an attempt to overcome
this problem. Both of these vectors have a poly-
linker with multiple cloning sites inserted in the
aminoterminal region of the E. coli lacZ gene but
differ in the orientation of the polylinker. It is
therefore possible to take half of a cDNA prepara-
tion and add linkers in one temporal order and
clone in the appropriate orientation in pUC8, then
take the other half of the same cDNA preparation,
Figure 2
Immunological screening of a cDNA expression library.
The transformed E. coli are plated on detergent-free
nitrocellulose sheets on ampicillin plates. After the col-
onies grow up, replicas of the original filter are made and
the clones grown up either on selective media for im-
munological and cDNA screening or grown up on
glycerol plates for long-term storage at - 70°. For the im-
munological screening, one of the replica filters is
suspended in chloroform vapor to lyse the cells; then the
filter is treated with a mixture of BSA, DNase, and
lysozyme. The filter is then incubated with a specific an-
tiserum, in our case rabbit anti-tropomyosin serum, then
washed and incubated with an 1251-labeled second anti-
body (goat anti-rabbit IgG). After washing, the appropriate
clones are identified by autoradiography.
add the same set of linkers in the opposite order,
and clone in the correct orientation in pUC9. This
will overcome most of the problems caused by in-
ternal restriction sites in the cDNA. We can also
block cleavage of the cDNA with the appropriate
methylases or use two nonoverlapping sites of
linkers.
Figure 2 shows, in schematic form, the steps in
antibody screening. The transformed E.coli are
plated on detergent-free nitrocellulose sheets laid
onto ampicillin plates. After the colonies reach 1-2
mm in diameter, replicas are made and the clones
regrown either on selective media for immunologi-
cal and cDNA screening or on glycerol plates for
Transform E.coli with Recombinant Plasmids
1 (Plate Bacteria on
Nitrocellulose filter)
select on amp plates
Replica plate - store one copy at
-70°C
lyse with Chloroform
BSA absorbtion/DNAse/Lysozyme
Incubate with primary
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long-term storage at 70°C. For the immunological
screening, one of the replica filters is suspended in
chloroform vapor to lyse the cells, then the filter is
treated with a mixture of bovine serum albumin,
DNase, and lysozyme. The filter is then incubated
with a specific antiserum (we'used rabbit anti-tropo-
myosin serum to isolate the tropomyosin clones),
then washed and incubated with an 1251-labeled
second antibody (goat anti-rabbit IgG). After wash-
ing, the appropriate clones are identified by auto-
radiography.
One potential 'problem is the synthesis of a pro-
tein product lethal to E. coli. Fortunately, all that is
required in the immunological screening procedure
is that an antigenic fragment be produced. In the
tropomyosin screening experiments, we successful-
ly detected a recombinant making a protein that is
less than 50% of the full-sized tropomyosin protein
(containing only 133 of the 284 tropomyosin amino
acids). It seems likely that in many cases where a
complete or nearly complete protein would be
lethal to E. coli, an antigenically active fragment
would not. For example, Mary Jane Gething and her
collaborators demonstrated that synthesis of a com-
plete copy of influenza hemagglutinin is apparently
lethal to E. coli. However, if the DNA sequences
coding for the aminoterminal hydrophobic signal
sequence are deleted, and the hemagglutinin DNA
is inserted in the correct translational reading frame
into a plasmid expression vector, these E. coil syn-
thesize a protein antigenically related to flu hemag-
glutinin. Mary Jane Gething supplied us with such
clones, and we have used our immunological
screening technique to detect specifically the E. coli
clones making the hemagglutinin-related protein.
This argues for the generality of our protocol in two
ways. Because the flu hemagglutinin is unrelated to
tropomyosin, it is likely that the protocol will work
with many different genes. In addition, we are able
to detect clones that synthesize nonlethal proteins
antigenically related to flu hemagglutinin. Even if
there are problems with lethal synthesis of proteins
in some cases, this problem can be overcome using
inducible expression vectors. The pUC8/pUC9 vec-
tors contain the lacZ operator/promoter region; ex-
pression of inserts introduced into these plasmids is
inducible in an E. coli I' strain.
We do not have a precise assessment of the sen-
sitivity of the protocol. Clearly, the bacterial clones
we have successfully detected make large amounts
of the novel protein. It is likely, however, that the
antisera will be the most variable (and crucial)
reagent. From tests with purified proteins spotted
onto nitrocellulose, the sensitivity depends critically
on the quality of the antisera used. Polyclonal sera
have been used in the tropomyosin a-actinin, and
flu hemagglutinin experiments. A single mono-
clonal antibody might specifically detect a site near
the amino terminus of the protein, which would
mean only a small fraction of the appropriate cDNA
clones would make an antigen that a particular
monoclonal antibody would detect. However a
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mixture of several monoclonal antibodies recogniz-
ing antigenic determinants throughout the length of
the protein could be substituted for polyclonal sera.
Avian Retrovirus Vectors
We have been modifying cloned copies of retroviral
DNA with two specific goals: (1) to try and take ad-
vantage of the unique properties of retrovirus in the
construction of vectors and (2) to learn more about
the way retroviruses work. Of the known viruses
that infect higher eukaryotes, only retroviruses act
as vectors in nature. Retroviruses are nonlytic and
when not carrying an oncogene have little or no ef-
fect on the growth or behavior of cells in culture.
The viral genome associates stably with the host
cell; as a requisite part of the virus life cycle, one or
a few copies of the viral genome are integrated into
host DNA. The infection is self-limiting; the produc-
tion of viral proteins by the infected cell blocks viral
receptors on the cell surface-infected cells are
resistant to reinfection. Replication-competent
retroviruses are relatively small. The prototype
viruses are about 7.5 kb long, making the cloning
and manipulation of the viral genomes reasonably
straightforward. The efficiency of infection is high;
an infection of cultured cells can be initiated by
transfecting cloned viral DNA into susceptible cells,
and in a week or two essentially every cell in the
culture will be infected. On rare occasions, retro-
viruses acquire cellular oncogenes and cause them
to be expressed at moderate to high levels. In most
cases, the acquisition of the oncogene occurs con-
comitantly with the loss of one or more viral genes.
There is one exception: Rous sarcoma virus (RSV)
has aquired an oncogene, src, without losing any
viral information.
RSV is therefore a natural helper-independent
retrovirus vector, and it serves as the basis for our
vector constructions. RSV was chosen because we
could, by suitable manipulations, remove the src
gene and replace it with any sequence we chose.
The resulting constructions would be helper in-
dependent; there would be no requirement for
selectable markers, and growth of the virus would
be sufficient to ensure the propagation of any se-
quence inserted into the vector.
To exploit the virus as a vector successfully, it is
necessary to understand the relationship between
viral sequence and function. Over the past 2 years,
we have made a variety of defined deletion mutants
by manipulation of a cloned copy of the RSV
genome (see Fig. 3). The RSV genome contains no
site for the restriction enzyme Cal, and the end
points of the deletions were all created by ligation
to synthetic Clal linkers. In all cases, the exact end
points of the deletions have been determined by
DNA sequencing. In addition to facilitating the con-
struction of a series of defined deletion mutants, the
Oat site can be used as the point of insertion of a
variety of foreign DNAs.
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Figure 3
Helper-independent avian retrovirus vector constructions. At the top of the drawing is a scale in kilobases. Below this
scale are drawings of an avian leukosis virus (ALV) and Rous sarcoma virus (RSV). The four genes (gag, poi, env, and src) are
labeled on the drawings. Important regions and sites are also given: U3, R, and U, in the LTRs; the primer binding site (PBS);
the splice donor (SD) just inside gag; the two splice acceptors (SA) for env and src messages; the direct repeat (DR) present
once in ALV and twice in RSV; the sequences of unknown origin near src (E.T.); and the polypurine trace adjacent to the LTR
(PPT). The Sstl site just past the left-hand LTR and two of the four EcoRI sites, those flanking src, are also marked. The region
between the EcoRl sites is shown on an expanded scale under the drawing of RSV. The numbers denote the distance from the
EcoRI site in env. The position of a series of defined deletion mutants, generated by the addition of Clal linkers is given below.
Two src-containing fragments flanked by synthetic Clal linkers; L-v-src (which lacks the splice acceptor) and 482-v-src (which
contains the SA), have also been generated. Similarly, a small fragment (SA) has been made with an Xhol linker at 1089. This
fragment has been used to generate double-deletion mutants. At the bottom of the figure is a schematic representation of the
relationship of the LTRs and adjacent regions of an ALV virus and the endogenous virus RAV-0. Two fragments containing the
RAV-0 LTR were created that extend from the natural Sst site just past the LTR (these constructions are done with the circular
form of viral DNA) to a synthetic Cal linker lying just past the DR or just past the PPT. These fragments were used, together
with the 779 and the 882 deletions, to replace the ALV-RSV LTR region with a RAV-0 LTR.
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Functions of the Noncoding Regions
between enu and the Long Terminal Repeat
of RSV
The noncoding sequences adjacent to the src
coding region are derived from at least three
sources: (1) the avian leukosis virus (ALV) that ac-
quired src, (2) the region of the host (probably
chicken) genome that contains c-src, and (3) one
segment (E.T.) of unknown origin. Figure 3 shows
the arrangement of these segments in the RSV strain
that we use, the Schmidt-Ruppin A (SRA) strain. The
same sequences are present, although in a different
arrangement, in the Prague C strain. Our analysis
has demonstrated that at least two of the noncoding
segments between env and the long terminal repeat
(LTR) are required for viral replication, and that a
third segment, unnecessary for replication, is re-
quired for expression of src, and presumably for
other inserts as well.
Obviously only those sequences present in the
parental ALV virus are needed for replication (see
Fig. 3). There are two functionally separate seg-
ments we can identify: (1) the polypurine tract (PPT)
that lies immediately adjacent to the LTR and (2) the
direct repeat (DR) present in two copies flanking src
in RSV and present only once in ALVs (see Fig. 3).
The PPT is absolutely required for replication; viral
genomes lacking this segment do not replicate and
cannot be rescued by a helper virus (Sorge and
Hughes, I.. Virol. 43: 482 [1982a]). It is likely that
these mutants cannot properly initiate plus-strand
DNA synthesis; this would explain the cis-dominant
phenotype of the mutants. The boundary is both
sharp and absolute. Mutants deleted from position
884 or 1089 to position 2900 replicate normally; if
the deletion is extended to position 2918, replica-
tion is completely abolished.
At least one copy of the DR is required as well.
Virus variants that contain the PPT but no DR (dele-
tions extending from 779 to 2900) do not replicate,
even though the PPT is present. Such variants are
not viable; even though RNA is synthesized and
spliced, RNA from these variants does not appear in
virions, even in the presence of a helper. Although
the two direct repeats differ slightly in sequence,
both functional deletion variants containing either
the upstream copy (884-2900 and 1090-2900) or
the downstream copy (779-2667 and 779-2795)
replicate normally.
Although the noncoding sequences near src that
are not of viral origin are not involved in replica-
tion, at least one plays a crucial role in src expres-
sion. src mRNA is created from a full-length
transcript by splicing. Sequences just beyond the
gag ATG are joined to sequences just upstream of
the src coding region (see Fig. 3). Deletion of se-
quences just upstream of src (884-1077) allows
normal viral replication; src expression is abolished.
It is unlikely that the manipulations alone have a
deleterious effect; a similar construction (1090-
1077) that causes a small duplication expresses src
normally. What function, if any, do the mysterious
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E.T. sequences have? We are currently testing a
series of new deletions (779-989 and 882-989) in
hopes of answering this question.
We also hope to be able to answer another in-
teresting question. All the known RSV messages are
apparently derived from a single full-length precur-
sor. The subgenomic messages are derived from this
precursor by splicing; however, even the subge-
nomic env and src messages contain the AUG at
which gag translation initates, and the splice donor
site lies just past the sixth gag codon. Both env and
gag-pol messages appear to initiate translation at the
gag AUG (see Fig. 3). By contrast, the src translation
begins with a src-encoded AUG about 80 by past
the splice acceptor (SA) site in src. How is this possi-
ble? It is likely that the termination codon, TAG,
located 4 codons past the src SA, plays a key role in
allowing translation from the src AUG. We have
subcloned the splice acceptor on a 100-bp frag-
ment, and will soon modify the TAG termination
codon by in vitro mutagenesis. This experiment will
not only answer an important question in viral func-
tion; it may also permit us to express gene fragments
cloned into vectors deleted for src using the gag
AUG as the point of translation initiation.
Introduction of Foreign DNA into Retrovirus
Vectors
One of our major goals is to use retroviruses to con-
trol the expression of a variety of genes, especially
those of the cytoskeleton. To this end, we have in-
troduced several new genes into the src deletion
mutants described in the previous section.
The first major problem we encountered was
stability. This is hardly surprising since the parent
virus, RSV, is itself unstable. The major source of in-
stability appears to be the DR sequences that flank
src. At high frequency, there is recombination be-
tween these repeats; the recombination event
eliminates the src sequences and gives rise to an
ALV virus (see Fig. 3). Our initial constructions,
which had inserts introduced into the 884-2667 or
into the 1089-2667 deletions were, like RSV,
unstable. To enhance stability, either the upstream
or the downstream direct repeats could be elimi-
nated. However the position of the SA (at 1057)
makes elimination of the downstream direct repeat
easier. Constructions with inserts into the 1089-
2900 deletion are much more stable; however a small
repeat (11 bp) is retained. For this reason, we have
subcloned the SA site (989-1089) and are now con-
structing double-deletion mutants (779-989 plus
1089-2795, see Fig. 3) that retain the SA but com-
pletely eliminate the upstream DR. Other construc-
tions of this type (884-989) are being used to probe
for the possibility that the E.T. sequences play a role in
src expression. We would like to eliminate all un-
necessary sequences because the total size of the virus
is strongly constrained. Constructions much larger
than 10 kb do not grow, and if growth is forced,
deleted derivatives are obtained.
There are several potential uses of retrovirus vec-
tors. One is as a tool for controlling the expression
of genes; genes can be introduced into a retrovirus
in such a fashion that their expression is dependent
on the retroviral promoter. Another potential use
would take advantage of the unique ability of a
retrovirus, through its alternation of life cycles be-
tween DNA and RNA, to remove precisely the in-
tervening sequenes from genomic DNA, creating
cDNA in vivo.
The most direct test of expression with the helper-
independent retrovirus vectors has been the ability
of constructions carrying the E. coli neomycin resis-
tance gene to make chicken cells resistant to the
drug G418. A construction was made in which the
neo gene was inserted, in the proper orientation, in-
to the deletion mutant 1089-2900. Chicken cells
were infected under nonselective conditions and
the virus allowed to spread through the culture. The
cells were completely resistant to G418 challenge;
uninfected cells were completely susceptible. We
have also modified the src gene itself as a test insert
(see Fig. 3). Tests for expression of these two inserts,
src and neo, are trivial; vector constructions can be
tested rapidly and easily. Once appropriate vector
constructions are made, we will attempt to insert
and express cytoskeletal genes.
The second set of experiments involves making a
vector for the efficient conversion of genomic
clones to cDNA clones both for use in the helper-
independent retrovirus vector and for expression in
E. coli. It would be helpful if the retrovirus were also
a shuttle vector and carried plasmid sequences that
would render the vector capable of growth in both
E. coli and chicken cells. Our initial attempts with
such vectors-vectors carrying a small plasmid in-
serted into the 889-2667 deletion-were suc-
cessful; that is, virus was rescued into E. coli, albeit
at very low frequency (D. Hanahan and S. Hughes,
unpubl.). However, such constructions are quite
unstable in chicken cells. Furthermore, since RSV is
strongly size constrained, there is no room for addi-
tional sequences in these constructions. We are
therefore attempting to build helper-dependent vec-
tors, basing the selection for the defective vector
virus on transformation by src. To leave as much
room as possible, we are trying to determine how
much of the 5' region of the viral genome must be
retained to have the virus replicate in the presence
of a helper.
In Vivo Vectors and Activation of
Endogeneous Oncogenes
RAV-0 is an endogeneous virus of chickens. By
several criteria, including sequence (Hughes,
Virol. 43: 191 [198211, it is closely related to the
ALV viruses. However, RAV-0 causes no apparent
disease; by contrast, the related ALV viruses cause
lymphoid leukosis. Two simple and several more
complex explanations are possible. The ALV viruses
activate the endogenous oncogene c-myc when
they integrate nearby; either RAV-0 does not in-
tegrate next to c-myc or, alternatively, if it does in-
tegrate next to c-myc, it does not activate c-myc.
Logic dictates that some difference in the RAV-0 and
ALV viral genomes makes ALV oncogenic and
RAV-0 not. If the ALV and RAV-0 genomes are com-
pared, the major differences in sequence reside in
the U3 region of the LTR. It appears as if the RAV-0
U3 was derived from the ALV U3 by a series of
small deletions (or, alternatively, as if the ALV U3
was derived from the RAV-0 U3 by a series of small
insertions). Since the U3 region is intimately involved
in integration and transcription, these changes
could explain the differences in oncogenicity be-
tween RAV-0 and ALV. To demonstrate the involve-
ment of the LTR region, we have substituted the LTR
of some of the src deletion mutants (which cause
lymphoid leukosis) with the RAV-0 LTR.
A series of such recombinants have been made
based on the 779 and 889 deletions. Such deletions
were linked to RAV-0 fragments that do and do not
contain the direct repeat region from RAV-0 (see
Fig. 3). These recombinant viruses, which do not
contain any coding region from RAV-0, are being
tested for oncogenicity in vivo by Lyman Crit-
tenden. If, as we expect, the ALV viruses that con-
tain the RAV-0 LTR are not oncogenic in vivo, they
will serve as the prototype in vivo vectors. It is
possible that such vectors could be used to in-
troduce sequences into the germ line as well as into
somatic tissue.
The Organization of the Chicken 0-Actin
Gene
There is a single 0-actin gene in chickens; this gene
encodes a major cytoskeletal protein in nonmuscle
cells. We have isolated two genomic clones that en-
code this entire gene by a direct screen of a chicken
genomic library (Hughes et al., Cold Spring Harbor
Symp. Quant. Biol. 46: 507 [19821). Both of these
clones, originally isolated as bacteriophage X
recombinants, have been subcloned into pBR322;
both appear to contain a complete copy of chicken
0-actin and adjacent sequences. The coding region
of chicken (3-actin is interrupted by four intervening
sequences. A precise map of this region is given in
Figure 4. This entire region has been sequenced,
and the 3' untranslated region as well. A com-
parison of the sequence of the genomic clone, with
the 3' untranslated region of two (3-actin cDNA
clones derived by D. Cleveland locates the poly(A)
addition site. There is a very slight heterogenicity in
poly(A) addition; one of the two cDNA clones has
two additional base pairs before the poly(A) stretch.
The start of transcription has been determined by
primer extension on (3-actin mRNA, and lies about
1000 by upstream of the AUG. Electron microscopy
(Hughes et al., Cold Spring Harbor Symp. Quant.
Biol. 46: 507 [19821) does not reveal additional in-
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Figure 4
Organization of the chicken 8-actin gene. The drawing depicts the single genomic copy of chicken IS- actin. Exons are shown
as boxes, introns as thin lines; the coding region is cross-hatched. Base pair coordinates are given from the AUG codon used
to initiate translation. There is a 3' untranslated region of about 600 bp. The site of Dolv(A) addition is heterogeneous; two sites(3221, 3223) 2 by apart are used. Transcription begins about 1 kb upstream of the AUG. The region that includes sites at
which translation is initiated has been sequenced; part of the first intervening sequence hasnot (marked ND).
tervening sequences. However a comparison of the
sequences in the corresponding regions upstream of
the AUG in the genomic clone and in a full-length
0-actin cDNA clone (provided by D. Cleveland)
suggests that there is a fifth intervening sequence in
the 5' untranslated region. Hybridization of the 5'
untranslated region of the cDNA clone to the
genomic clones places the start of transcription
within 1.2 kb of the AUG. The transcriptional start
site has been located about 1000 by upstream of the
0-actin AUG; there is a fifth intervening sequence of
about 900 by in the 5' untranslated region of the
chicken /3-actin gene. This large intervening se-
quence will permit the easy separation of the
coding region and the promoter for /3- actin, making
it relatively easy to manipulate both the gene and its
promoter.
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STRUCTURE AND EXPRESSION OF EUKARYOTIC GENES
J.C. Fiddes, W.R. Boorstein, M. DeLuca, D. Hanahan, W. Huse, K.D. Talmadge, and N.C. Vamvakopoulos
Glycoprotein Hormone Genes
I.C. Fiddes, W.R. Boorstein, M. DeLuca, W. Huse,
K.D. Talmadge, and N.C. Vamvakopoulos
The four glycoprotein hormones-chorionic
gonadotropin (CG), luteinizing hormone (LH),
follicle-stimulating hormone (FSH), and thyroid
stimulating hormone (TSH)-play a major role in
regulating reproduction (LH, FSH, and CG) and
thyroid function (TSH). Three of the hormones, LH,
FSH, and TSH, are synthesized in the anterior
pituitary whereas the fourth, CG, is made in the
placenta. In the female, a surge of pituitary LH
stimulates the ovary to produce the steroids
necessary for ovulation. During pregnancy, CG
functions in a very similar way to LH in that it
stimulates the corpus luteum of the ovary to pro-
duce the steroids necessary for the maintenance of
pregnancy. This functional similarity between CG
and LH is reflected in their close structural
resemblance.
All four glycoprotein hormones are dimeric, con-
sisting of dissimilar a and (3 subunits that are
associated noncovalently. The a subunit is common
to all four hormones whereas the 0 subunits are
unique and give biological specificity to the hor-
mone. The 0 subunits show sequence homologies
to each other, indicating that they form a multigene
family. The highest homology (82%) is observed
between the f3 subunits of CG and LH. All other
subunits, when compared in pairs, have amino acid
sequence homologies ranging from about 25% to
40%.
Previously, we have isolated and characterized
cDNA clones for both the a and 13 subunits of CG.
The a subunit was then used as a probe to isolate
the a-subunit genes from a bacteriophage X library.
Comparison of the structure of the cloned a-subunit
gene with the hybridizing fragments detected in
total human DNA showed that there is a single copy
of the a-subunit gene. This is expressed in the
pituitary to make the a subunit for LH, FSH, and
TSH and in the placenta to make the a subunit for
CG.
More recently, we have been examining the struc-
ture of the 0-subunit genes for two of the hormones,
CG and LH. The 0CG cDNA was used to isolate
genomic recombinants from two independent
human chromosomal libraries, one in bacterio-
phage Charon 4A and one in bacteriophage Is
Charon 28. We purified a total of 16 hybridizing
phage and determined restriction enzyme maps.
We thus identified three different groups of overlap-
ping recombinants, as shown in Figure 1. Eight
separate regions that hybridize to the 0CG cDNA
probe were identified in these groups of phage and
are shown in Figure 1. Detailed restriction enzyme
mapping and DNA sequence analysis showed that
seven of the genes, labeled 1-3 and 5-8 on Figure
1, are 0CG genes or pseudogenes, whereas one of
the genes, labeled 4 on Figure 1, codes for 0LH.
The genes show an unusual structural arrange-
ment. Four of the genes, 01 and 02 and 05 and 06,
are found in inverted pairs with the 3' ends
separated by about 2.2 kb. In contrast to these, 03
and 04 and 07 and 138 form tandem gene pairs.
To determine whether these seven 0CG genes
and the single 0LH gene represent all the CG and
LH genes present in the human genome, we analyzed
several different digests of human placental DNA by
filter hybridization, using both f3CG and 0LH
fragments as probes. Fragments corresponding to all
eight genes were identified in this way and no addi-
tional fragments were detected. Thus, it appears that
the human genome has a total of seven genes, or
pseudogenes, coding for the (3 subunit of CG and a
single gene coding for the 0 subunit of LH.
The significance of the complex organization of
the 0-subunit gene is not obvious. Examination of
the distribution of restriction enzyme sites around
the genes reveals extensive regions of repeats. For
example, the positions of the Kpnl, Xbal, and Xhol
sites preceding 03 and (38 are identical (Fig. 1). The
Kpnl site is almost 5 kb upstream from the proposed
transcriptional start. The inverted and tandem pairs
presumably arose from a complicated series of
duplications and inversions encompassing an area
considerably larger than the coding regions
themselves. It is interesting to note that OLH, which
appears to be coded for by a single gene, is a much
older gene in evolutionary terms than 0CG, which
is coded for by a multigene family. Presumably 0CG
evolved from 0LH prior to the gene duplication and
rearrangement.
Although it is not known to which chromosome the
(3 subunit of CG maps, we have some evidence for
the linkage of all the f3CG hybridizing fragments. A
single hybridizing band of 50-60 kb is observed in
filter hybridizations of human DNA digested with
either EcoRl or Sall. However, despite this sug-
gestive evidence that the genes are all linked, exten-
sive screening of two distinct libraries failed to pro-
duce an overlapping series of sequences linking the
seven 0CG genes and the one (3LH gene.
DNA sequencing and restriction enzyme map-
ping reveal that all of the genes have the same basic
structure. There are two introns that separate codon
16 of the signal peptide from codon 15, and
codon 41 of the mature protein from codon 42. The
two introns, A and B, are 350 and 230 nucleo-
tides long, respectively. We have almost established
the complete nucleotide sequence of two of the
(3CG genes, 5 and 6, and the single (3LH gene, 4.
The two 0CG genes are very similar, with an overall
nucleotide sequence homology of greater than
95°/0. Most of the differences are in the introns and
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Figure 1
Restriction enzyme maps of the three groups of genomic isolates (A, B, Cl. The positions of the eight genes (1-8) are in-
dicated by arrows that point in the proposed direction of transcription. Restriction enzyme analysis and DNA sequencing
has shown that genes 1-3 and 5-8 code for BCC whereas gene 4 codes for OW. Each gene spans 1.45 kb from the cap
site to the poly(A) site.
in the 350-nucleotide-long 5' untranslated region.
The 0LH gene is also very closely related to the (3CG
genes. The nucleotide sequence homology is about
95% whereas the amino acid sequence homology is
about 80%. Very few silent third-position changes
are observed.
Detailed comparison of the restriction enzyme
maps of all eight genes shows that they are very
similar, although no two genes are identical. We
have used the slight differences between the genes
to study their expression. One of the genes, 03, is
identified by a single silent third-position change
that generates a new restriction enzyme site.
Analysis of placental cDNA clones with this restric-
tion enzyme showed that two out of 15 cDNAs con-
tained the new site, showing that (33 was expressed.
Another difference, this time between genes 5
and 6, was detected by sequencing. In this case, the
single nucleotide change alters the coding potential
of the gene. Gene 05 has a codon for Asp at position
126, whereas in gene (36 the corresponding codon
is for Ala. The sequence containing Asp cor-
responds to the published amino acid sequence and
to the previously determined cDNA sequence.
Analysis of all seven (3CG genes shows that genes 1,
3, and 5 appear to have Asp at this position whereas
genes 2, 6, 7, and 8 have Ala. None of the cDNA
clones that we have analyzed has Ala. This
evidence suggests that the actively expressed (3CG
genes are numbers 1, 3, and 5.
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We have also made constructions of genes (3CG
2, 3, and 5-8 to examine their transient expression
in COS cells (the 5' end of (3CG 1 has not been
cloned). RNA was isolated from the transfected cells
and analyzed with S1 nuclease to establish correct
initiation of the (3CG genes directed by their own
promoters. In these experiments, we have detected
correct initiation of genes 3 and 5 but can detect no
initiation from genes 2, 6, 7, and 8. The (3LH gene
(4) has not been studied in this way. The transient
expression results are therefore consistent with the
analysis of the cDNA clones and suggest that not all
of the (3CG genes are expressible despite their
strong structural similarity.
We are now attempting to use oligonucleotide
probes to isolate the 0-subunit genes for both TSH
and FSH to establish whether they are linked to the
(3 subunits of CG and LH and to see if they are cod-
ed for by single or multiple genes.
Isolation of cDNA and Genomic Clones for
the Hypothalamic Releasing Factor. gnimi
I.C. Fiddes, W.R. Boorstein, and M. DeLuca
The release, and probably the synthesis, of the
pituitary glycoprotein hormones LH and FSH is con-
trolled by the hypothalamic peptide, gonadotropin-
releasing hormone (gnRH). The sequence of this
10-amino-acid-long peptide has been established
previously. In collaboration with James Roberts and
Marion Evinger (Columbia University) and Alex
Markham (ICI, England), we have been trying to use
oligonucleotide probes synthesized to correspond
to the amino acid sequence to isolate the gene
coding for gnRH. We are interested in isolating this
gene to establish whether gnRH, in common with
other small polypeptide hormones, is made initially
in a larger precursor form, and to provide a probe
for studying its synthesis in the brain.
Two approaches have been taken in our attempt
to isolate sequences coding for gnRH. In one, we
have made cDNA libraries from both rat hypothala-
mic and human placental mRNA and screened
them using oligonucleotide hybridization probes.
This has not resulted in the identification of any
recombinants that positively hybridize to the
oligonucleotides, possibly because of the very low
abundance of gnRH mRNA. In the second ap-
proach, we have used the oligonucleotide probes to
screen directly both rat and human genomic
libraries in bacteriophage X vectors. This approach
avoids the need to make very large cDNA libraries.
Approximately 50 positively hybridizing bacteri-
ophage X recombinants have been isolated from the
two libraries by this approach. We are now in the
process of subcloning these phage Is recombinants
into M13 vectors to identify by DNA sequencing
which, if any, of them contain sequences coding for
gnRH.
cDNA Cloning Methods
I.C. Fiddes and D. Hanahan
We have developed a directional cDNA cloning
method that is very efficient and is well suited to the
construction of cDNA expression libraries. This pro-
cedure is a modification of the double-linker
method of Kurtz and Nicodemus (Gene 13: 145
[1981]). Instead of ligating cDNA to a single set of
oligonucleotide linkers, as had been done previous-
ly, they used a mixture of two different sets of
linkers. Double-stranded cDNA, following diges-
tion of the hairpin loop with S1 nuclease, was
ligated to a mixture of Ecol and Sall linkers, and the
resulting products were ligated to a Sall -EcoRl vec-
tor prepared from pBR322 DNA. This considerably
increased the efficiency of cDNA cloning because
the problems of self-ligation of the vector were
largely eliminated.
In theory, this approach should result in 50% of
the cDNAs with nonhomologous ends and the
other 50% of the cDNAs with homologous ends
that therefore cannot be cloned into a double-cut
vector. In practice, we find that considerably less
than 50% of the cDNA molecules have hetero-
geneous ends, due to appreciable differences in the
rates of ligation of the EcoRl and Sall linkers. To
overcome this problem, we have modified the pro-
cedure to ensure that the cDNA molecules all have
mixed linker ends. Double-stranded cDNA is syn-
thesized by standard methods, and the hairpin loop
at the end corresponding to the 5' end of the mRNA
is left intact. One set of oligonucleotide linkers is
then ligated to this cDNA. These linkers will ligate
only to the end of the cDNA corresponding to the
poly(A) tail because the hairpin loop will block liga-
tion to the other end. The hairpin loop is then cleaved
with nuclease S1 and a second set of linkers is
ligated to the cDNA. The cDNA is then digested
with the restriction enzymes corresponding to both
sets of linkers, which results in cDNA molecules
with mixed linker ends of defined orientation.
These molecules can then be cloned with very high
efficiency into double-cut plasmid vectors.
One advantage of adding the linkers sequentially
is that the orientation of the cDNA within the vector
is known. As well as being very useful in the
analysis of the cDNA clones, this advantage also
permits the method to be used for the construction
of expression libraries that can be screened im-
munologically. In collaboration with D. Helfman,
J. Feramisco, P. Thomas, and S. Hughes, we have
used the sequential linker method to make cDNA
libraries from chicken smooth muscle in the expres-
sion vectors pUC8 and pUC9. These have been
screened with antibodies against tropomyosin, and
several tropomyosin cDNA clones have been
isolated and characterized.
Isolation of cDNA Clones for the Sodium
Channel
IC. Fiddes and W. Huse
The sodium channel is a transmembrane protein
essential for nerve and muscle excitation. This chan-
nel has been isolated from the electric organ of the
eel, Electrophorus electrocus, and partially charac-
terized. The protein consists of a large polypeptide
of molecular weight <250 kD that probably forms
the sodium-selective pore, and possibly smaller
subunits. Using polyadenylated mRNA isolated
from the electric organ, we have made cDNA ex-
pression libraries in the vectors pUC8 and pUC9.
These have been screened immunologically with
antibodies, provided by William Agnew, directed
against the sodium channel large polypeptide. Ten
recombinants that reacted positively with the an-
tibodies have been identified and purified. We are
now in the process of trying to establish that these
recombinants contain sequences that code for the
sodium channel. As no amino acid sequence infor-
mation is known for the sodium channel, this iden-
tification is being made by mRNA selection and by
characterization of the protein products made by
the recombinants in Escherichia coli.
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MOLECULAR GENETICS OF THE MOUSE
L.M. Silver, L. Cisek, I. Danska, H. Fox, M. Harper, C. Jackson, M. Krangel, D. Lukralle, C. Parra,
N. Sarvetnick, J. Uman, P. Weinstein
Our laboratory combines classical and molecular
approaches to obtain an understanding of the
organization and expression of the mouse genome.
Most of our efforts are directed toward a small
region of the mouse genome known as the t com-
plex. The t complex is located along the proximal
half of chromosome 17 and includes the entire ma-
jor histocompatibility complex (MHC or H-2).
Variant forms of the t complex are known as t
haplotypes and exhibit a series of effects on em-
bryogenesis, spermatogenesis, and meiotic recom-
bination along the t complex region. Partial t
haplotypes obtained as the products of rare recom-
binant events carry a subset of the genetic factors
responsible for the various t haplotype effects. This
indicates the presence within complete t haplotypes
of multiple and interacting mutant genes. Most of
the studies described below represent our effort to
identify and characterize the DNA sequences,
genes, and gene products that mediate the t
haplotype effects.
Complex Proteins Expressed during
Spermatogenesis
L. Silver, L. Cisek, J. Uman, J. Carrels, J. Danska
tin collaboration with Norman Hecht, Tufts
University]
We have used a system of high-resolution two-
dimensional gel electrophoresis (see Quest 2-D Gel
Laboratory Section) to identify and characterize
testicular cell proteins specified by t haplotypes. So
far, a total of nine independent t complex proteins
(TCPs) have been identified. Mutant forms of eight
of these proteins are expressed in common by all
complete t haplotypes studied. Alternate wild-type
forms of six of these proteins have been identified,
and evidence from cell-free translation experiments
suggests that all of these proteins are encoded
directly by genes within the t complex. Partial t
haplotypes have been used to map the genes speci-
fying each TCP to a subregion of the t complex, and
correlations have been made between particular
Tcp genes and the t haplotype genes involved in
sperm differentiation. A quantitative analysis was
performed on TCP expression during particular
stages of spermatogenesis. The expression of three
of the TCP proteins was of particular interest. Both
p63/6.9 (TCP-1) and TCP-3 peak in expression dur-
ing the round spermatid stage of haploid germ cell
differentiation. The Tcp-2 gene only begins to ex-
press in round spermatids and is highly active dur-
ing the last stages of spermiogenesis. Genetic data
suggest that all three of these genes could be involved
in t haplotype effects on sperm differentiation.
r Complex Proteins Expressed during
Embryogenesis
M. Krangel, 1. Carrels
Embryos homozygous for complete t haplotypes die
at specific stages during development and display
distinct morphologic abnormalities. As a first step
toward an understanding of the effects of t haplo-
types on embryonic development, we are embark-
ing on a project to identify and characterize t
haplotype-encoded proteins that are expressed dur-
ing embryogenesis. Strain-129 embryos and 129
embryos congenic for different t haplotypes will be
metabolically labeled with [35S]methionine and
analyzed by high-resolution two-dimensional gel
electrophoresis. By analyzing embryos at different
stages of pre- and early postimplantation develop-
ment, we should be able to follow the expression of
a large number of proteins through early develop-
ment, and identify polymorphic proteins that are en-
coded by t haplotypes. Once this set of proteins is
defined, a variety of criteria, including genetic map-
ping, time course of expression, adult tissue distri-
bution, and patterns of expression in embryos carry-
ing different t haplotypes, will be used to identify
proteins most likely to be mediating the effects of t
haplotypes on embryonic development. Detailed
characterization will likely require the identification
of cell types that express these products in quan-
tities sufficient for biochemical analysis. If such
sources can be obtained, we should be in a position
to begin to ask questions as to the roles of these pro-
teins in embryonic development.
Cloning Sequences Coding for TCP Proteins
N. Sarvetnick, C. Muckeman, G.P. Thomas
The TCP proteins described above are specified by
the t complex region of chromosome 17. We are
identifying clones that encode two of these proteins.
Toward this end, we have constructed a testis cDNA
library of 20,000 members using the double-linker
method developed at Cold Spring Harbor Labo-
ratory. This library has been subjected to several dif-
ferent screens to help in choosing clones that are
possible TCP-1 candidates. Total poly(AP RNA was
size-fractionated on two successive sucrose gra-
dients and translated, and the fraction most en-
riched in TCP-1 mRNA was chosen. Two "differen-
tial"screens were used; one is with similarly
fractionated ThP/* liver RNA. Liver contains approx-
imately 5% of the TCP-1 in the testis; ThP is a variant
form of chromosome 17 with a deletion covering
TCP-1, and should maximize the differential. The
second differential screen is a slightly smaller-size
fraction of message than the testis fraction chosen to
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be enriched for TCP-1. As estimated from two-di-
mensional gels, this fraction contains very little
TCP-1 message but is enriched for several other pro-
teins in common with the enriched fraction. Follow-
ing screening, about 70 clones fit the criteria of
strong hybridization to the testis fraction and weak
hybridization to liver and the smaller testis fraction.
These clones are being subjected to further analysis.
After eliminating a group of cross-hybridizing
clones, the members were subjected to a different
level of analysis. Each clone was used to probe a
blot of restriction enzyme-digested genomic DNA
to identify restriction fragment-length polymor-
phisms. Any polymorphisms that correlate with the
presence of t chromatin will be mapped by using
numerous partial t haplotypes available in our col-
ony. All clones will need to be subjected to hybrid
selection for definitive identification. Analysis on
Northern blots has satisfactorily double-checked the
differential expression between testes and liver of
chosen clones. From in vivo labeling experiments,
the TCP-2 protein has been shown to become pro-
minent in the two-dimensional gel pattern only in
the final stage of spermatogenesis. In fact, this pro-
tein is made in vast quantities at this stage, ex-
ceeding levels of actin and tubulin. By exploiting
this knowledge, we can create a probe from RNA of
this late fraction of spermatogenesis and screen the
library. After eliminating actin and tubulin, the only
other prominent hybridization should be from
TCP-2 clones. Once the clones specifying these pro-
teins have been obtained, we can isolate genomic
clones from a 129 and a t homozygous library.
These genomic clones will enable us to compare
and map genes and/or gene clusters within the t
complex. We will also define the pathway and ex-
tent of expression of Tcp-1 and Tcp-2 during sper-
matogenesis. Finally, we can define whether or not
each gene is identical to a t factor involved in
transmission ratio distortion.
Molecular Dissection of r Complex DNA
H. Fox [in collaboration with G. Martin, University
of California, San Francisco, and A. Frishauf and
H. Lehrach, European Molecular Biology
Laboratory, Heidelberg]
We would like to isolate the DNA sequences
responsible for the varied properties of the t com-
plex. These will include both coding sequences, in
the case of genes involved in such processes as
segregation distortion, sterility, and lethality, and
noncoding sequences responsible for recombina-
tion suppression. To accomplish this goal, we plan
to obtain molecular markers dispersed throughout
the t complex. By classical mapping of a gene be-
tween two markers, it could be isolated through
chromosome-walking techniques. In parallel, by
comparing the ordering of these markers within the
t chromosome and wild-type chromosome 17, as
well as comparing detailed restriction maps and se-
quences of genomic t and wild-type clones obtained
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with these probes, the general organization of t
complex DNA may be discerned.
We have constructed a genomic library from a
homozygous tw5 embryonic stem cell line. Two ap-
proaches were used to isolate t complex-specific
clones from this library. The first of these was to use
an H-2 cDNA probe, provided by Lee Hood
(California Institute of Technology), to isolate the
tw5 H-2 genes. Since the H-2 region is an integral
component of the t complex, all of the clones ob-
tained will be from the t complex. By isolation of
unique subclones from these genomic clones, we
can obtain molecular markers for a 3-cM region of
the t complex. These markers will be especially
useful for the isolation of the lethal genes, since
many of these map near the H-2 complex. Twenty-
four unique H-2 clones have been isolated so far.
One of the clones, Xtw5P3, contains a 10-kb EcoRl
fragment, identical to the genomic restriction frag-
ment found on Southern blots to be specific for the
tw5 haplotype. We isolated a subclone 8 kb down-
stream from the gene, which appeared to hybridize
exclusively to C'5 haplotype genomic DNA on
Southern blots. It was then found that the same
hybridization was obtained with mice of the t1 b3
and thth7 haplotypes, members of the t' ub' lethal
group, which is distinct from the t's lethal group.
Other members of the t'ub' complementation group
did not show this hybridization. Examination of the
EcoRl genomic H-2 restriction pattern of these mice
showed the t'u" and t' "" pattern to be a hybrid be-
tween those of tw5 and Club', containing the
t"'5- specific 10-kb band, while having other bands
present in thth1 and not in tw5. The 0'1'3 and th"57
haplotypes most likely arose by recombination
events within the H-2 region of feral female mice
doubly heterozygous for C"5 and ti"". Work is in
progress on the analysis of the other H-2 clones.
We are using a novel, second method to isolate
DNA distributed throughout the t complex. Jon-Erik
Edstrom (EMBL, Heidelberg) has used a microma-
nipulator to dissect out the proximal half of
chromosome 17, corresponding to the t region.
DNA was purified in a nanoliter droplet, a complete
EcoRl digestion was performed, and the fragments
were cloned into a X vector. Repetitive clones were
screened out and the remaining clones were
subcloned into pUC8. To prove their localization to
the t complex, we looked for polymorphisms on
genomic blots between congenic inbred mice con-
taining t haplotypes, which are thus identical at all
DNA sequences except those mapping to t. Clones
with polymorphic restriction fragments could then
be further localized within the t region by using par-
tial t haplotypes. We have so far obtained seven t-
specific probes this way, three of which have been
mapped using the partial t haplotypes. Clone Tu66e
identifies two t-specific bands, one of which maps
to the proximal region and one of which maps to
the middle area; clone Tu122s identifies a single t-
specific band which maps to the middle area; and
clone Tu108 identifies three polymorphic bands, all
of which map to the distal region. Many more
clones will be examined, and a more detailed
analysis will be made using other partial t haplo-
types. Large genomic clones are also being isolated,
using these smaller clones as probes.
Oa Is a Novel, Variant Form of Mouse
Chromosome 17 with a Deletion in a Partial t
Haplotype
L. Silver, D. Lukralle, J. Carrels
Moutier discovered, in a mouse from a noninbred
Swiss/Orleans laboratory stock, a spontaneous
dominant mutation that mapped to the T locus and
was named T°''. Genetic analyses indicated that
rri was not a simple mutation at one locus, but
rather a deletion over a 3-cM region of chromosome
17 that included both T and quaking (qk). Further
experiments have demonstrated that rri is associ-
ated with recessive genetic properties affecting
sperm function, characteristic of the proximal
region of complete t haplotypes. These results were
interpreted as evidence for the location of proximal
t haplotype sperm factors within the region deleted
by r`i.
To investigate the possibility that the rri deletion
is associated with a region of mutant t chromatin, a
high-resolution, two-dimensional gel analysis was
performed on [35S]methionine- labeled protein from
animals heterozygous for the T°4 mutation. The
results of this experiment demonstrate that all five of
the proximally located t haplotype-specific proteins
are expressed by animals carrying rn/. This result
clearly demonstrates the association of the Vri
mutation with an extended segment of t haplotype
DNA. At least three separable factors (one proximal,
one central, and one distal) interact to distort male
transmission ratio. Only a complete t haplotype can
be transmitted consistently at a very high ratio-loss
of either the proximal end or the distal end causes a
loss of the high transmission. To determine whether
the Ttc''' haplotype carries a proximal t haplotype
distortion factor, we set up a series of crosses to ob-
tain two parallel genotypes in which Tt°4 was pre-
sent in trans to a partial, distal t haplotype. Tt°H,
t"7, and ttub2 each carry only a subset of the eight
variant Tcp genes associated with all complete t
haplotypes. However, a genotype with Tt°4 in com-
bination with either thu or ttub2 reconstitutes the
complete set of eight variant Tcp genes. If the three
t haplotype distortion factors can interact in trans
and if the Tt °" haplotype carries the proximal factor
Tcd-1, then TeDdIth" and TtOrlitlub2 males should ex-
hibit severe transmission ratio distortion. The results
from this experiment dramatically demonstrate that
the TOri haplotype can function in trans to promote
a high transmission frequency for each of the par-
tial, distal t haplotypes studied. The cumulative
transmission ratio obtained for the 169 offspring
born to seven males was 95%. As neither TOri nor
the distal t haplotypes are transmitted at a high fre-
quency when isolated in separate genotypes, it
seems likely that the synergistic effect reported here
for trans heterozygotes is a consequence of a
positive interaction among gene products from TO"
and a distal t haplotype. This implies that it is the t
chromatin associated with the Tt°r1 haplotype and
not the deletion that promotes the high transmission
frequency.
Polymorphism of Ribosomal DNA Patterns
within an Inbred Strain
M. Harper, L. Chow
The 18S and 28S ribosomal genes of the mouse are
present in tandem repeats of approximately 40 kb,
each containing three EcoRl sites. One of these
EcoRl fragments contains the origin of the 45S
transcript, most of the 18S gene, and a region of
nontranscribed spacer DNA. The size of this EcoRl
fragment varies in a strain-specific manner. Par-
ticular fragments are characteristic of different in-
bred strains of mice. Using a probe to the 18S gene,
we have also found a polymorphism within the
highly inbred strain 129/SvJ. In some 129 /SvJ mice,
the probe hybridizes to a single RI fragment of 13
kb, in others it hybridizes to the 13-kb fragment and
an additional 16-kb fragment.
We are investigating this unusual phenomenon in
two ways. We are studying the genetics of the
system to understand the inheritance of the two
types of patterns in the 129/SA strain. The second
approach is to compare the structure of the two RI
fragments at the molecular level. The 13-kb and
16-kb RI fragments have been cloned into Charon
4A, and these fragments and their internal Sall
fragments have been subcloned into pBR322. The
region that is transcribed into the 45S transcript is
conserved between the two forms, whereas the
nontranscribed region diverges. 5' to the site of
origin of the 45S transcript is a Sall fragment that
contains multiple Pvull sites. The size of this frag-
ment varies between the two forms and is probably
analogous to the "variable" region in the BALB/c
strain described by Arnheim (SUNY, Stony Brook).
5' to this SallSall! fragment is an EcoRl Sall frag-
ment that also contains variable regions. From map-
ping studies and electron microscopy studies per-
formed by Louise Chow, it appears that this region
also contains a number of direct as well as indirect
repeats. Despite the potentially destabilizing fea-
tures of this genomic region, it remains very stable
in the mouse genome, showing that there are con-
straints on homologous recombination in vivo.
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CELL CYCLE-MODULATED GENE EXPRESSION
D. Zipser, I. Lewis, L. Rodgers, D. Matkovich
We have recently succeeded in isolating the
thymidine kinase (tk) gene from the A-29 line of
Chinese hamster cells, and in doing so, have ac-
complished the first major technical objective in our
intended study of the genetic determinants that
govern the S-phase-specific cell cycle expression of
mammalian tk genes. This clonal isolation from a
recombinant phage library was facilitated in large
measure by the technique of tRNA suppressor
rescue developed here at Cold Spring Harbor
Laboratory by Kenji Shimizu and Mike Wig ler. The
hamster tk gene is contained with 13.3 kb of
genomic DNA in a XL47 recombinant phage
designated X34S4 (Fig. 1). Based on the following
lines of preliminary evidence, we believe the
hamster tk gene may extend over 8.5 kb. (1) We
have isolated a recombinant phage designated X52
which contained the genomic DNA in the 2.6-kb,
4.2-kb, and 5.5-kb EcoRl fragments. This X52 was,
however, biologically inactive in transformation
assay on mouse Ltk- cells. The hamster tk gene in
X34S4 may, therefore, contain DNA sequences
within the 1.8-kb and 3.2-kb EcoRI fragments. (2)
The digestion of X3454 with Sall and Smal abolishes
X34S4 tk transformation activity, and, therefore, se-
quences within the 2.6-kb and 4.2-kb EcoRl frag-
ments must be part of the hamster tk gene. (3) The
X3454 clone has no detectable nucleotide sequence
homology to the cloned herpes simplex virus I tk
gene, but it does share limited homology with the
previously cloned chicken tk gene. Using high-
stringency Southern blot as a criterion, the 3.2-kb
EcoRl and 4.2-kb EcoRl fragments of X34S4 react
with a nick-translated chicken tk gene probe. This
data suggests that the hamster tk gene in X34S4 ex-
tends from the Smal site within the 4.2-kb EcoRl in-
to the 3.2-kb EcoRl fragment, a distance of approx-
imately 8.5 kb.
Based on our preliminary experiments, we be-
lieve the hamster tk mRNA is a 1350-nucleotide
polyadenylated RNA. We detect this RNA in North-
ern blots probed with the 3.2-kb and 4.2-kb EcoRl
fragment but not with the 2.6-kb and 1.8-kb EcoRl
fragments of X34S4. Since both the 3.2-kb and
4.2-kb EcoRl fragments show homology with the
chicken tk gene, we expect that the 1350-nucleo-
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tide RNA these probes detect is in fact the hamster
tk mRNA. Using the 3.2-kb EcoRl fragment of X3454
as a nick-translated probe, we have analyzed the
concentration of the 1350-nucleotide RNA in poly(A)*
RNA preparations obtained from A-29 under
various growth conditions. This 1350-nucleotide
mRNA is readily detected in RNA prepared from
asynchronous midlog cultures of A-29 cells, but is
virtually undetectable in RNA prepared from
Go-phase populations of A-29 cells, synchronized
by serum starvation methods. This result is compati-
ble with a body of indirect experimental evidence
that suggests that the cell-cycle-dependent S-phase-
specific expression of hamster tk activity is
regulated most proximally by the S-phase appear-
ance of hamster tk mRNA.
We are presently defining the extent to which the
expression of the hamster tk gene in X3454 is cell-
cycle dependent when transfected into a variety of
mammalian tk- host cells. Our preliminary evidence
suggests that the expression of the cloned hamster
tk gene in mouse Ltk- cells shows a moderate
degree of S-phase specificity. We are analyzing the
pattern of tk gene expression in BHK tk- ts13, rat tk-,
and CHO tk- cells transfected with X3454 as well.
The ultimate objective of this work is, of course,
to define the mechanisms operating to restrict the
appearance of the hamster tk mRNA to the S phase
of the eukaryotic cell cycle. Because the hamster tk
mRNA is represented among the least abundant
class of cytoplasmic poly(A)* RNAs, we are prevented
from directly assaying cell-cycle phase-specific rates
of tk gene transcription, modes of RNA processing,
and tk mRNA stability from which we might discern
the physiological processes governing hamster tk
regulation. As an alternative approach to this prob-
lem, we intend to construct chimeric hamster tk
genes, combining specific fragments of the hamster
tk gene with fragments of the herpes tk gene, which
is expressed constitutively through all phases of the
cell cycle in mouse cells transformed with the gene.
These gene constructions will be transfected into
appropriate tk- host cells, and tk' transformants will
then be analyzed for their cell-cycle pattern of tk ac-
tivity. These constructs will be designed to assay 5'
and 3' flanking sequence, hamster tk coding, and
x3454
Eco RI
11 1
Hind III Sol I
4 2KB
Figure 1
XL47 recombinant phage X3454 containing hamster tk gene.
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intron sequences for genetic determinants that regu-
late S-phase-specific tk gene expression. When such
determinants are identified in chimeric tk genes, we
intend to analyze their mutagenesis techniques, and
when indicated, analyze their orientation and posi-
tioning requirements within the chimeric genes as
well. This knowledge of the nature and position of
the genetic determinants of the cell cycle regulation
within the tk gene may permit us to propose with
confidence the physiological processes governed
by these determinants.
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Cell Biology
The Cell Biology Group has had for the past several years a keen interest in the organization of the
cytoplasm and in cell motility and the underlying molecular mechanisms governing these processes. In the
last year or two, this work has led us into two related areas of research: the cell biology of transformation
and of the heat-shock or stress response. It is becoming increasingly clear that a full understanding of these
biological phenomena will require the analysis of the functions of several key protein components of these
systems.
With a variety of biochemical and cellular experimental techniques now available, such as immunology,
two-dimensional gel electrophoresis, microinjection of tissue culture cells, protein chemistry, and DNA
cloning, we have been probing the roles of the cytoskeletal, transforming, and heat-shock proteins as in-
dicated below.
The makeup of the group has changed over the past year, most notably with the departure of our dear col-
league, Guenter Albrecht-Buehler. He has assumed the role of Professor of Cell Biology at Northwestern
University School of Medicine in Chicago. The loss of Guenter will be felt for years to come. Kent Matlack,
who is a graduate student from Berkeley, has joined us to work on the biochemistry of the cytoskeleton, and
Tohru Kamata, a postdoctoral fellow from Tokyo, has begun working on the biochemistry of the human on-
cogene product, p21. Robert Franza joined our group to study transformation by two-dimensional gel elec-
trophoresis after serving as a Resident at Dartmouth Medical School. Additions to our technical staff were
Georgia Binns, Cecilia Fraser, Gladys Blose, Patricia Smith, and Joseph Suhan.
CELL BIOCHEMISTRY
J. Feramisco, J. Lin, G. Binns, A. Ca lasso, B. Daniels, C. Fraser, N. Haffner, D. Helfman, T. Kamata,
K. Matlack, F. Matsumura, S. Matsumura, M. Szadkowski, W.I. Welch
The Mammalian Stress Response
W.I. Welch, G. Binns, I. Feramisco
Mammalian cells incubated under adverse condi-
tions undergo what has been termed the stress
response. As was described in last year's report,
such a response is most notably characterized by
changes at the protein synthetic level. Briefly, in the
stressed cell, the rate of synthesis of a small number
of proteins (the stress proteins) is increased along
with a concomitant decrease in the production of
most other cellular polypeptides. Although their
synthesis is increased during the stress response,
almost all of the stress proteins (except for one or
two) appear to be expressed at lower levels in cells
grown under "normal" tissue culture conditions.
The stress response, in general, appears to be a
defensive one in nature since a brief induction of
the stress proteins appears to confer a degree of pro-
tection to the cell upon subsequent stress situations.
Whereas it is clear which proteins are induced
following the onset of the stress response, their
function in both the normal and stressed cell and
the manner by which they afford the cell protection
are not known and constitute the focus of our
research.
To gain a better understanding of the stress
response and the role the stress proteins serve, we
have been examining the response in mammalian
cells both at the cellular and protein levels. With
regard to changes in the cell, we have found that
cells grown under stress appear to: (1) show a more
flattened and spread morphology; (2) have an in-
creased number of intracellular actin bundles; and
(3) display a rearrangement in their intermediate
filament network, with the filaments redistributing
from their normal splayed array throughout the
cytoplasm into a tight cap near the nucleus (Thomas
et al., Cold Spring Harbor Symp. Quant. Biol. 46:
985 [1982]). At the protein level, mammalian cells
grown under stress and labeled with [35S]methio-
nine synthesize at high levels proteins with ap-
parent molecular masses of 72, 73, 80, 90, 100, and
110 kD. In addition, we recently have found, as
have others, a smaller mammalian stress protein
with an apparent molecular mass of approximately
28, kD that contains little or no methionine resi-
dues. The increases in the amounts of the stress pro-
teins in the stressed cell appear to result from
changes at both the transcriptional and translational
levels. Specifically, mRNAs coding for the stress
proteins appear elevated and these messages are
preferentially translated while transcription and
translation of other cellular mRNAs appear reduced.
The mechanisms by which such controls are ex-
erted in the stressed cell are not understood and
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constitute one aspect of our research (see also
Thomas, Protein Synthesis Section).
Examination of the stress proteins induced in a
variety of different mammalian cell types by two-
dimensional gel electrophoresis indicates that the
molecular mass and isoelectric charge of the in-
dividual stress proteins are well conserved amongst
different species. The only major differences
amongst the various cell types are the number and
multiple charge variants of the 72-kD stress protein.
For example, in gerbil fibroma and Chinese hamster
ovary cells, only one to two isoelectric variants of
72 kD are found, while in BHK cells approximately
four and in HeLa cells as many as seven to eight
72-kD charge variants are observed. Interestingly,
we have found that all of the HeLa 72-kD (and
73-kD) isoforms appear related, as determined by
one-dimensional peptide mapping. In addition, an-
tibodies raised against the HeLa 72-kD stress pro-
tein also cross-react with the 72-kD isoforms from
other mammalian cell types as well as with the
avian 70-kD heat-shock protein. Hence, although
there appear to be differences between the number
of 72-kD isoforms induced in each cell type, the
protein in general appears to be well conserved
across evolutionary lines.
In addition to heat-shock treatment, exposure of
cells to a variety of biological agents gives rise to the
stress response (Thomas et al., Cold Spring Harbor
Symp. Quant. Biol. 46: 985 [1982]). Such agents in-
clude amino acid analogs, certain drugs, transition
series metals, and inhibitors of oxidative phosphory-
lation to name a few. Although it is clear that all of
these diverse treatments in some way adversely af-
fect cellular metabolism, no common cellular target
appears obvious. Furthermore, it is now apparent
that induction of all six stress proteins is not a coor-
dinate event, since certain treatment of cells results
in the enhanced synthesis of only a subset of the
stress proteins. For example, we have found that
two of the stress proteins, the 80-kD and 100-kD
species, are also induced in cells grown in the
absence of glucose (i.e., the "glucose-regulated pro-
teins"). Similarly, the same two proteins also are in-
duced in cells treated with calcium ionophores
(Welch et al., I. Biol. Chem. [1983, in press]).
Whereas the synthesis of the 72-kD and 73-kD
stress proteins is unaffected, these same two
treatments also result in the decreased production
of the 90-kD stress protein. Thus, it appears that the
rates of synthesis of the 80-, 90-, and 100-kD pro-
teins are all affected to different extents by calcium
ionophores, glucose deprivation, and by stress. The
question then arises as to whether there is any con-
nection between these various effectors. While we
are continuing to investigate this question, it is
worth noting that others have reported a possible
relationship between intracellular calcium concen-
trations and the activation of glucose transport. It
will be interesting to determine whether the onset of
stress in the cell also affects glucose uptake and/or
metabolism.
One approach to dissect the biological role of the
stress response and the function of the stress pro-
teins is to learn more about the nature of the pro-
teins themselves and to determine their location in
the cell. We have found through metabolic labeling
studies (Welch et al., J. Biol. Chem. [1983, in press])
that the 100-kD stress protein is a glycoprotein and
that the 80-kD and 90-kD stress proteins are both
phosphoproteins, with there being as many as six to
eight phosphorylated variants of 90-kD. In addition,
the 100-kD protein was found to incorporate
phosphate in some but not all cell types examined.
Our cell fractionation studies have shown that the
90-kD protein is located almost exclusively in the
cytoplasm, whereas the 80-kD and 100-kD stress
proteins appear associated with intracellular mem-
A
Figure 1
Immunofluorescent localization of the 72 kD heat-shock protein in stressed human cells. Antibodies specific to the 72 kD
protein indicate that this induced, heat-shock protein is localized primarily in the nucleoli, sites of ribosome assembly,
and RNPs. (Top) Immunofluorescence; (bottom) phase contrast.
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branes. The 72-kD and 73-kD proteins, related pro-
teins as described earlier, fractionate equally be-
tween the nucleus and the cytoplasm following
heat-shock treatment of cells. As was described in
last year's report, we have successfully purified the
72-kD and 73-kD proteins as well as the 90-kD pro-
tein. A number of physical properties of the purified
proteins were determined, including their Stokes'
radii, 520, value, isoelectric point, and native
molecular weight (Welch and Feramisco, I. Biol.
Chem. 257: 14949 [1982]). More recently, we have
succeeded in purifying both the 80-kD and 100-kD
proteins from Triton-extracted, stressed He La cells
(W.J. Welch and J. Feramisco, in prep.).
Using the purified proteins as antigens, we have
prepared and characterized polyclonal antibodies
against the 72-kD, 80-kD, 90-kD, and 100-kD stress
proteins (Welch et al., in Heat shock: From bacteria
to man, p. 257, Cold Spring Harbor Laboratory
[1982]). In addition, Jim Lin has prepared a
monoclonal antibody against the 100-kD stress pro-
tein. Production of more monoclonal antibodies
against all of the stress proteins currently is in pro-
gress. The specificity of all our antibodies has been
confirmed by immunoprecipitation and analysis of
the immunoprecipitates by two-dimensional gel
electrophoresis as well as by preabsorption of each
individual antibody with the purified antigen. In-
direct immunofluorescence studies using our 80-kD
antibody showed vesicularlike staining of the an-
tigen, a result consistent with our cell fractionation
data showing 80-kD to be present within in-
tracellular membranes. A similar analysis using the
90-kD serum revealed the antigen to be present
with discrete particles throughout the cytoplasm.
The identity of these particles is presently under ex-
aminaton. Staining with both the monoclonal and
polyclonal antibodies against the 100-kD protein
showed the antigen to be present primarily in or on
the Golgi apparatus and less prominently within the
nucleus and on the plasma membrane. Upon heat-
shock treatment, the number of cells displaying
nuclear staining increased while the Golgi staining
became less prominent (Lin et al., in Heat shock:
From bacteria to man, p. 267, Cold Spring Harbor
Laboratory [1982]). Finally, the location in the cell
of the 72-kD stress protein has generated much ex-
citement. While little or no staining is observed in
cells grown at 37°C, heat-shock-treated cells
display intense nuclear fluorescence. Such nuclear
staining appears to be specific for the nucleoli.
Following reversal of the heat-shock treatment, the
nucleolar staining disappears (W.J. Welch and J.
Feramisco, in prep.). Since the nucleolus is at least
in part associated with ribonucleoprotein (RNP) for-
mation, we are examining the possibility that the
72-kD stress protein is in fact part of a RNP com-
plex. Preliminary studies show this to be the case.
Associations of Vinculin In Vivo
K. Matlack, J. Feramisco
Physical contact between cells within a tissue and
between a cell in culture and its substrate occurs
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largely at small areas comprising only a small frac-
tion of the cell's surface (Izzard and Lochner, J. Cell
Sci. 21: 129 [1976]). These specialized areas,
known as adhesion plaques, are also the sites at
which microfilaments terminate on the inner sur-
face of the cell membrane (Heath and Dunn, ). Cell
Sci. 29: 197 [1978]). Vinculin, a protein first
isolated from chicken smooth muscle, localizes to
these sites in cultured cells, as well as colocalizing
with fibronectin on the upper surface of the cell
(Geiger, Cell 18: 193 [1979]; Feramisco and Bur-
ridge, J. Biol. Chem. 255: 1194 [1980]; Burridge
and Feramisco, Cell 19: 587 [1980]). Vinculin from
at least one nonmuscle source is a calcium-
dependent actin-binding protein that binds to actin
filaments at their ends (Burridge and Feramisco,
Cold Spring Harbor Symp. Quant. Biol. 46: 507
[1982]). Its localization within cells to the sites at
which microfilaments terminate, then, raises the
possibility that vinculin may be involved not only in
stabilizing the ends of microfilament bundles but in
establishing their positions as well. Vinculin's col-
ocalization with fibronectin in cultured cells also
suggests that it may be involved in interactions be-
tween the cell's cytoskeleton and the extracellular
matrix.
Little is known, however, about the structures in
which vinculin is found. Vinculin is likely to be only
one of a number of proteins involved in an adhesion
plaque, and the way in which the adhesion plaque
functions in the cytoskeleton will require knowl-
edge of the interactions among these proteins and
their interactions with actin. We are trying to iden-
tify components involved in adhesion plaques or in
the interaction of the cytoskeleton with the ex-
tracellular matrix by identifying proteins that are
associated with vinculin. Presently, we are trying to
use immunoprecipitation with antisera against
chicken gizzard vinculin to recover complexes in-
cluding vinculin that are formed when living
chicken embryo fibroblasts are exposed to a variety
of cross-linking agents. We hope to purify com-
ponents that we find associated with vinculin, to
localize them using immunological methods both
in cells with relatively stable cytoskeletons and in
cells in which the cytoskeleton is being assembled,
and to study in vitro the interactions between these
proteins and vinculin.
Molecular Cloning of Cytoskeleton Protein:
Immunological Screening of Expression
Libraries
D. Helfman, J. Feramisco, J. Fiddes, P. Thomas,
S. Hughes
(For more information, see Genes for the Major
Structural Proteins: Organization and Control of
Expression Section.)
Relatively straightforward methods have been
established for the construction of essentially com-
plete cDNA or genomic DNA libraries from many
sources. Such libraries usually contain many thou-
sands of members; the major difficulty is the iden-
tification of clones of particular interest. Final iden-
tifications are usually made by sequence analysis of
the DNA insert, by using the DNA to select a
specific mRNA for in vitro translation, or both. Such
assays are not usually suited to screening large
libraries for individual clones, and steps are usually
taken to enrich for the clones of interest. The most
commonly used procedures rely on cDNA
hybridization probes made from a mRNA prepara-
tion that contains high levels of the sequence of in-
terest. Variations of this general approach include
the physical fractionation of the mRNA by sedimen-
tation, gel electrophoresis, or immunoprecipitation
of polysomes. Alternatively, differential hybridiza-
tion can be used if two mRNA preparations are
available that differ principally in their content of
the mRNA of interest. These approaches are gener-
ally limited to the identification of genes that are ex-
pressed at moderate to high levels.
At least two techniques have been developed that
permit the identification of clones for genes that are
expressed at low levels. If part or all of the amino
acid sequence of a protein is known, it is possible to
synthesize specific oligonucleotides for use either
as hybridization probes themselves or as primers for
the enzymatic synthesis of cDNA probes. This pro-
cedure is limited by the degeneracy of the genetic
code. Other techniques require that the cDNA
preparation, ideally made from total poly(A)*
mRNA, be cloned into plasmids that promote ex-
pression of the cDNA in Escherichia coll. The resul-
tant expression libraries then are screened for ap-
propriate translation products by using either a func-
tional or an immunological assay. These protocols
bypass the need for enrichment of the mRNA and
provide promising approaches for the cloning of
genes expressed at low levels.
A cDNA library of -9,000 members has been
prepared from chicken smooth muscle mRNA by
using the plasmid expression vector pUC8. Addi-
tion of Sall and EcoRl linkers at different stages dur-
ing the preparation of the cDNA resulted in a
population of molecules, most of which had EcoRl
linkers at the end of the cDNA that corresponded to
the 5' end of the template mRNA and Sall linkers at
the end that corresponded to the 3' end of the
mRNA. The cDNA molecules then were inserted in-
to a EcoRl -Sall -cut plasmid vector, pUC8, that con-
tains the transcriptional and translational start se-
quences from the lacZ gene upstream of the EcoRl
site. The sequential addition of the linkers to the
cDNA ensured that most of the cDNAs were in-
serted into pUC8 in the proper orientation for ex-
pression. The colonies were replica-plated onto
nitrocellulose filters and lysed in situ with chloro-
form vapor. The library was screened for colonies
producing products immunologically related to
chicken tropomyosin by incubating the filters first
with a rabbit antitropomyosin antibody and second
with a 7251-labeled goat anti-rabbit IgG. Two col-
onies were detected that reacted specifically with
the antisera. Plasmids from both clones have been
partially subjected to sequence analysis; both
plasmids contain cDNAs that encode tropomyosin.
These protocols are potentially useful for the iden-
tification of cDNA clones for genes expressed at
low levels from large cDNA expression libraries.
Microinjection of Monoclonal Antibodies
against Tubulin into Living Fibroblasts
S. Blose, I. Feramisco
(For more information, see Biology of the
Cytoskeleton Section.)
Four monoclonal antibodies have been generated
against either a- or (3-tubulin subunits and one that
has activity against both subunits. Cells were
microinjected with these antibodies and the effects
on cytoplasmic microtubules and 10-nm filaments
were assessed. Two monoclonals, DM1A and
DM3B3, an anti-a- and anti-O-tubulin, respectively,
caused the 10-nm filaments to collapse into tight
juxtanuclear caps; the other monoclonal antibodies
had no effect. The filament capping was observed to
be complete at 1.5-2 hours after injection. During
the first 30 minutes after injection, a few cyto-
plasmic microtubules near the cell periphery could
be observed. By 1.5 hours, when most of the 10-nm
filaments were capped, the complete cytoplasmic
array of microtubules was observed. Cells injected
in prophase were able to assemble a mitotic spin-
dle. These results suggest that though a direct in-
teraction of antibodies with either a- or 0-tubulin
subunits, 10-nm filaments were dissociated from an
interaction with microtubules.
Monoclonal Antibodies Directed against the
Human Oncogene Protein, p21
T. Kamata, Y. Suarde, G. Binns, C. Fraser,
M. Wigler, I. Feramisco
Recently, there have been important leads into the
control of the transformation process through the
identification of human genes that are capable of
converting normal cells into transformed cells (see
Mammalian Cell Genetics Section). In general,
these newly described oncogenes show homology
to previously described genes of Harvey or Kirsten
sarcoma viruses. The genes encode a protein of
-21 kD that is thought to be able to alter the nor-
mal growth phenotype to that of a transformed
phenotype. To unravel the molecular mechanisms
of the transformation process in terms of the cell, it
will be of utmost importance to characterize p21
biochemically. We have begun a program aimed at
the understanding of the transformation process
some of which will be described here.
To have specific monoclonal antibodies to p21,
four synthetic peptides were made, coupled to KLH,
and injected into mice (and rabbits). The four pep-
tides correspond to: (1) the aminoterminal region
where a single amino acid substitution is thought to
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alter the "normal" version of p21 to the "transfor-
mation" version, (2) the middle of the protein
where a site common to all p21s is present, and (3)
the carboxyterminal region where divergence oc-
curs between the various p21s. We have produced
10 stable hybridomas secreting antibodies to the
peptide from the region in (2) above and are in the
process of getting similar antibodies specific to the
other two regions.
Multiple Forms of Tropomyosin Associated
with Microfilaments from a Variety of Cell
Types
F. Matsumura, S. Yamashiro-Matsumura, J. Lin
It is known that skeletal muscle tropomyosin, in
association with troponin complex, regulates ac-
tomyosin interaction in a calcium-dependent man-
ner. Because no troponin complex was found in
smooth muscle or nonmuscle cells, the biological
functions of tropomyosin in these cells are not yet
determined. Using the microfilament isolation
method that we have developed (Matsumura et al.,
J. Biol. Chem. [1983, in press]), we have found
multiple forms of tropomyosin associated with our
microfilament preparation from a variety of cell
types, including chicken embryo fibroblasts and
myoblasts, rat REF-52 cells, rat L6 myoblasts, "nor-
mal" rat kidney (NRK) cells, mouse NIH-3T3 cells,
mouse myeloma (SP-2) cells, mouse neuroblastoma
cells, gerbil fibroma (CCL-146) cells, baby hamster
kidney (BHK-21) cells, and human fibroblast (KD)
cells. Five forms of tropomyosin with apparent
molecular weights of 40K, 36.5K, 35K, 32.4K, and
32K and six forms of tropomyosin with apparent
molecular weights of 46K, 44K, 38K, 36.5K, 32.8K,
and 32.6K can be identified from rat cell lines and
chicken embryo fibroblasts, respectively, by two-
dimensional gel analysis. These protein spots are:
(1) immunoprecipitable with rabbit polyclonal an-
tibody against smooth muscle tropomyosin from
total cell extracts; (2) lacking tryptophan and pro-
line; (3) heat stable; and (4) able to bind to skeletal
muscle F actin. Expression of these multiple forms
of tropomyosin was found to be different between
normal REF-52 and its viral transformed cells (see
details in next section). Because microfilaments in
transformed cells appear to be less ordered, it is in-
teresting to know whether different forms of
tropomyosin may be responsible for this. It may fur-
ther suggest different functions in the stabilizing
and/or bundling of microfilaments for these
tropomyosin isoforms in nonmuscle cells. Purifica-
tion and characterization of individual forms of
tropomyosin are currently in progress.
Use of Monoclonal Antibodies to Isolate and
Characterize Tropomyosin-enriched and a-
Actinin-enriched Microfilaments from
Chicken Embryo Fibroblasts
J. Lin, F. Matsumura, S. Yamashiro-Matsumura
We have used monoclonal antibodies against tropo-
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myosin and against cx-actinin to isolate two classes
of microfilaments, i.e., tropomyosin-enriched and
a-actinin-enriched microfilaments, respectively,
from cultured chicken embryo fibroblasts. As
described in last year's report, the microfilament
isolation method consists of three simple steps, i.e.,
Triton/glycerol extraction to stabilize microfila-
ments, homogenization in Mg"-ATP to disperse mi-
crofilaments, and immunoprecipitation of microfila-
ments by either anti-tropomyosin or anti-a-actinin
monoclonal antibody in a native condition. Electron
microscopic studies of the isolated tropomyosin-
enriched microfilaments showed periodic localiza-
tion of tropomyosin along the microfilaments with a
35-nm repeat (Fig. 2A). On the contrary, the isolated
a-actinin-enriched microfilaments showed no ob-
vious periodicity. About 10-30 individual a-actinin-
enriched microfilaments with average lengths vary-
ing from 1 to 5µm were associated at certain parts of
microfilaments by anti-a-actinin monoclonal an-
tibodies (Fig. 2, B and C). This area may represent
the a-actinin-enriched region along microfilaments.
These two classes of microfilaments also differ in
their protein composition. Molar ratios c` major
identifiable proteins in the isolated microfilaments
are a-actinin (dimer):actin (monomer):tropomyosi n
(dimer)-trace (<0.031:8.06:1.00 for tropomyosin-en-
riched microfilaments and 1.00:17.61:0.43 for a-
actinin-enriched microfilaments. Both the isolated
microfilaments retained their abilities to activate
myosin ATPase activity.
Differential Expression of Tropomyosin
Forms in the Microfilaments Isolated from
"Normal" and Transformed Rat Cultured
Cells
F. Matsumura, J. Lin, S. Yamashiro-Matsumura
Microfilaments were isolated from "normal" and si-
mian virus 40 (SV40)- or adenovirus type 5 (Ad5)-
transformed REF-52 cells by a newly developed
method (Matsumura et al., J. Biol. Chem. [1983, in
press]). Electron microscopy shows that micro-
filaments isolated from transformed cells are much
shorter in length than those from "normal" cells. By
one- and two-dimensional gel analysis of such
isolated microfilaments, we have found changes in
the pattern of the five identifiable species of tropo-
myosin (M, 40,000, 36,500, 35,000, 32,400, and
32,000) upon transformation (Fig.3). A decrease in
the level of one or both of major tropomyosins (Mr
40,000, 36,500) of normal cells and an increase of
one or both of minor tropomyosins (M, 35,000,
32,000) are common to both types of viral transfor-
mants. REF-52 cells transformed by a defective
SV40 (c11884) incapable of expressing the viral small
t protein do not show these changes, suggesting the
involvement of this protein in the altered pattern of
tropomyosin gene expression. The degree of altera-
tion in the patterns of tropomyosin correlates well
with the degree of morphological transformation.
Furthermore, the changes in tropomyosin patterns
Figure 2
Tropomyosin-enriched (A) and alpha-actinin-enriched (8, C) microfilaments isolated from chicken embryo fibroblasts by
anti-tropomyosin and anti-a-actinin monoclonal antibodies, respectively.
are to be specific to the morphological changes in-
duced by transformation, because "rounding-up"
after trypsin or cytochalasin B treatment does not
cause these changes in tropomyosin patterns.
Similar changes in tropomyosin patterns are also
observed both in total cell lysates and in cell-free
translation products directed with total mRNA.
These results would suggest that at least five mRNAs
are present for these multiple forms of tropomyosin
and that the changes in tropomyosin patterns are
regulated at the level of RNA rather than by post-
translational modification.
The differential expression of different forms of
tropomyosin appears to be a general phenomenon.
In addition to DNA viral transformation described
above, we have found similar changes in tropomyo-
sin patterns in various types of transformants, in-
cluding RNA virus-transformed rat kidney cells,
chemically transformed BALB/c mouse 3T3 cells,
and NIH -3T3 cells transformed by tumor cell DNA.
Tropomyosin is one of the major components of
microfilaments of cultured cells. In fibroblasts,
tropomyosin appears to be localized in stress fibers
or actin cables but to be absent in the movable por-
tions of cells, such as ruffling membranes. This
observation, coupled with the ability of this protein
to stabilize actin filaments, suggests that tropo-
myosin may regulate the organization of micro-
filaments into bundles as stress fibers. Therefore, the
altered patterns of tropomyosin expression may be
one of the causes for morphological transformation.
To explore this hypothesis, purification and charac-
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Figure 3
Two-dimensional gel analysis of the microfilament frac-
tions from "normal" and transformed cells (pH 5-7 am-
pholytes for the first dimension, 12.5% polyacrylamide for
the second dimension). After electrophoresis, gels were
processed for fluorography. Only those parts of the two-
dimensional gels containing tropomyosin and actin are
shown here. (A) Microfilaments from normal cells, REF-52;
(8) microfilaments from SV40-transformed cells, REF-
WT4A; (C) microfilaments from adenovirus-transformed
cells, Ad5D.tA. Numbers indicate multiple forms of
tropomyosin (TM-1 to TM-5). Note the decrease in the
level of both TM-1 and TM-2 and the increase of both
TM-3 and TM-5 in the microfilaments from SV40 transfor-
mants (B). TM-1 is entirely missing and TM-3 is greatly in-
creased in the microfilaments from adenoviral transfor-
mants (C). A protein found in the microfilaments from
adenovirus-transformed cells (a in C) is heat stable but
does not appear to be a tropomyosin.
terization of each form of tropomyosin are currently
in progress.
A New Actin-binding 83K Protein Found in
L6 Myoblasts
S. Yamashiro-Matsumura, F. Matsumura, J. Lin
Our new method for microfilament isolation has
allowed us to detect a new actin-binding protein
with a molecular weight of 83,000 in the micro-
filaments of L6 myoblasts. This protein is missing in
the microfilaments isolated from myotubes, sug-
gesting a role of this protein in the formation of thin
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filaments during myogenesis. We have found that
the 83K protein, like tropomyosin, is a heat-stable
protein. Using this property, we have purified the
protein from REF-4A cells because the same protein
is also present in this cell line. Purified protein
shows binding to skeletal muscle F actin and is
focused around pl 7-8 as four spots. Furthermore,
83K protein appears not to have villinlike or gelsol-
inlike activities, i.e., severing of F actin, although its
M, is similar to these proteins. None of the
previously reported actin-binding proteins, except
tropomyosin, is known to be heat-stable. Therefore,
we believe that 83K protein is a new actin-binding
protein. Immunofluorescent localization with poly-
clonal rabbit antiserum raised against this 83K pro-
tein has revealed that the protein is localized in
stress fibers of myoblasts but disappears after fusion
into myotubes. This is consistent with the finding
that the 83K protein is missing in the microfilaments
of myotubes. Further characterization of 83K pro-
tein as well as detailed intracellular localization dur-
ing myogenesis is currently in progress.
Production of Monoclonal Antibodies to 83K
and Multiple Forms of Tropomyosin
J. Lin, S. Yamashiro-Matsumura, F. Matsumura
As described in previous sections, we have found a
new microfilament-associated protein (83K), which
may play some roles in myogenesis, and a multiple
form of tropomyosin, which may have different
functions in stabilizing and/or bundling of microfila-
ments. We have begun to prepare monoclonal an-
tibodies to these proteins by immunizing mice with
gel-purified 83K and with individual forms of
tropomyosin. These antibodies will be used in con-
junction with microinjection techniques and immu-
nofluorescence and immunoelectron microscopy to
probe the in vivo function and intracellular localiza-
tion of these proteins.
In a preliminary fusion experiment with microfila-
ment fractions from L6 myoblasts as antigens to im-
munize mice, we have isolated two interesting
hybridoma clones, NHY3 and NHY6. Clone NHY3
secreted antibody that gave the immunofluor-
escence staining pattern on L6 myoblasts similar to
that obtained by rabbit antiserum against purified
83K protein. The other clone, NHY6, producing an-
tibody gave the a-actininlike staining pattern. Ex-
periments identifying the specific antigens recognized
by these antibodies are currently in progress.
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BIOLOGY OF THE CYTOSKELETON
S. Blose, G. Blose, A. Bushnell, C.-Y. Cai, D. Meltzer, P. Renna, J. Suhan
10-nm Filaments Induced to Collapse in
Cells Microinjected with
Monoclonal Antibodies against Tubulin
S. Blose, D. Meltzer, I. Feramisco
Numerous studies have proposed that the spatial ar-
ray of 10-nm filaments in a cell is dependent on in-
teractions with an intact cytoplasmic network of
microtubules. To probe this possible interaction in
vivo, CCL 146 cells were microinjected with several
monoclonal anti-tubulins: DM1A and DM3A1 were
mouse monoclonal IgGi anti-cx-tubulins; DM1B
and DM3B3 were mouse monoclonal IgG, anti-0-
tubulins; and mouse monoclonal (IgM) DM3B2 was
an anti-a/13-tubulin (Fig. 1). After microinjection,
cells were fixed and stained for double-label im-
munofluorescence at various times to assess any
changes in distribution of the 10-nm filaments or
microtubules. Within 2-3 hours after injection of
DM1A or DM3B3, all of the 10-nm filaments were
collapsed into tight aggregates (Fig. 2). If these an-
tibodies were first preabsorbed with assembled
microtubules and then injected, the filament collaps-
ing was abolished, while preabsorption with CCL
146 vimentin had no effect on collapsing. Microin-
jection of DM1B, DM3B2, or DM3A1 had no effect.
In the microinjected cells, tubulin staining was
observed to be diffuse in the first 30-60 minutes
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after injection, followed by a period in which some
microtubules were then observed (Fig. 3). At 1.5-3
hours after injection, when the 10-nm filaments
were maximally collapsed, the complete normal
cytoplasmic array of microtubules was observed
(Fig. 3). Several cells injected in the early prophase
also appeared to assemble a normal mitotic spindle
surrounded by a 10-nm filament cage (Fig. 4). This
suggests that the injected antibodies did not inhibit
microtubule assembly into a spindle. Although the
mechanism of 10-nm filament collapse in response
to microinjected anti-tubulin is not yet understood,
it is likely that interference with cytoplasmic micro-
tubules (through a- and/or (3-tubulin) may be
responsible. The interference may be through: (1) a
transient depolymerization of the microtubules
and/or (2) the coating of the microtubule surface
with antibody that sterically blocks micro-
tubule-10-nm filament interactions.
Molecular Basis of the Monoclonal Antibody
(LCK-16) Cross-reaction with Tropomyosin
and 10-nm Filament Proteins: vimentin and
Desmin
S. Blose, F. Matsumura, I. Lin fin collaboration
with K. Weber and N. Geisler, Max Planck In-
stitute for Biophysical Chemistry, Goettingen,
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Figure 1
Western blot analysis of the monoclonal anti-tubulin binding to a total cell lysate of the CCL-146 cells. Lane A, M, stan-
dards x 10-3; 57 and 54, correspond to a- and ft-tubulin, respectively. Lane B, the total cell lysate. Both of these lanes
were 12%-5D5 gels stained with Coomassie blue. Lanes C and D, blots of A and B, respectively, stained with amido
black. Monoclonal antibody blots of these lanes (s, M, standards corresponding to lane A; and c, cell lysate correspon-
ding to lane B) revealed that DM1A and DM3A1 stained oi-tubulin; DM1 B and DM3B3 stained 0-tubulin; DM3B2 stain-
ed predominantly or-tubulin. The last two lanes (DM1A + DM1B) show that the mixing of DM1A and DM1B stained
both tubulin subunits.
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Figure 2
Fluorescent micrographs of cells microinjected with DM3B3, monoclonal anti-B-tubulin, and stained to observe the
vimentin filament distribution at 30 min (A and B), 1.5 hr (C and D), and 3 hr (E and F) after injection. Each pair, A-B,C-D,
and E-F, represents the same cell stained for the distribution of DM3B3 with TMRITC goat anti-mouse (A,C,E) and for the
distribution of the vimentin filaments with FITC-labeled #240 anti-vimentin (B,D,F). At each time point, the injected
DM3B3 (A,C,E) was found to be diffusely distributed in the cytoplasm. Within the first 30 min after injection, the vimen-
tin filaments (B) appeared to have the same distribution as an uninjected cell. By 1.5 hr after injection (D), the vimentin
filaments had collapsed next to the nucleus. At 3 hr after injection (F), the vimentin filaments had completely moved into
a tight cap next to the nucleus.
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Figure 3
Fluorescence micrographs of cells microinjected with DM3B3 (monoclonal anti-O-tubulin) and stained to observe the
microtubule distribution at 30 min (A,B), 1.5 hr (C,D), and 3 hr (E,F) after injection. Each pair, A-B, C-D, and E-F,
represents the same cell stained for the distribution of DM3B3 with TMRITC-labeled goat anti-mouse (A,C,E) and for the
distribution of microtubules probed with FITC-labeled guinea pig anti-tubulin (GP1T4)(B,D,F). At each time point, the in-
jected DM3B3 (A,C,E) was found diffusely distributed in the cytoplasm. Within the first 30 min after injection, the
microtubules (B) were hard to visualize with GP1T4,except in the cell periphery. At 1.5 hr postinjection (D),
microtubules were observed in their normal radial array, and, by 3 hr postinjection, the microtubules maintained their
normal cytoplasmic distribution (F) at a time when the vimentin filaments were maximally collapsed into a cap (see
Fig.2F).
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0Figure 4
Fluorescence micrographs of two metaphase cells 30 min after microinjection with DM3B3. Each pair, A-B and C-D,
represents the same cell stained for the distribution of DM3B3 with TMRITC goat anti-mouse (A,C) and for vimentin
filaments with FITC-labeled #240 anti -vimentin (B,D). DM3B3 was visualized on the metaphase spindle microtubules
(A,C); the antibody did not block assembly of the spindle to this stage. The distribution of vimentin filaments formed a
cage around the spindle and was not affected by the injected anti-tubulin.
West Germany, and I. Heuser, Department of
Physiology and Biophysics, Washington Universi-
ty, St. Louis, Missouri]
We have recently described a mouse monoclonal
antibody, LCK-16 (IgM), that cross-reacts with two
unrelated cytoskeletal proteins-tropomyosin and
vimentin (Blose et al., Cold Spring Harbor Symp.
Quant. Biol. 46: 455 [1982]). LCK-16 decorates
10-nm filaments in a periodic fashion with a repeat
of decoration at 31 -38 nm (Fig. 5A). In collabora-
tion with Dr. John Heuser, we have confirmed that
the antibody decoration of the 10-nm filament ap-
pears to be helical as determined by stereo-electron
micrographs of deep-etched, processed specimens
decorated with antibody. The LCK-16 also dec-
orates tropomyosin-containing microfilaments with
a 33-nm repeat (Fig. 5B). The antibody causes the
microfilaments to aggregate into large macromolec-
ular structures and has been used to isolate native
microfilaments from a variety of cell types (Mat-
sumura et al., Biol. Chem. [1983, in press]). In our
attempt to determine where LCK-16 binds to the
tropomyosin molecule, paracrystals of skeletal mus-
cle tropomyosin were generated (Matsumura and
Lin, I. Mol. Biol. 157: 163 [1982]) and then dec-
orated with LCK-16. Electron micrographs made of
these negatively stained specimens revealed that (1)
the antibody bound with a 38.3 ± 1.8-nm peri-
odicity and (2) that the antibody bound over the
aminoterminal overlap region of the paracrystal
(Fig. 5C). This region represents approximately one-
third of the N-terminal end of tropomyosin. Future
studies will focus on the location that LCK-16 binds
to within the aminoterminal region.
In collaboration with Dr. K. Weber and N.
Geisler, we are also determining where LCK-16
binds to desmin molecule (a 10-nm-filament pro-
tein). Desmin was fragmented by enzyme proteo-
lysis and chemical cleavage according to published
schemes (Geisler et al., Cell 30: 277 [1982]; Geisler
et al., Nature 296: 448 [1982]). The various
fragments were then probed by solid-phase radioim-
munoassay using LCK-16. Our preliminary results
indicate that LCK-16 binds desmin in the region
spanning from the aminoterminus to the sole tryp-
tophan. Work in progress seeks to determine with
greater resolution the site to which LCK-16 binds.
From these studies, we hope to determine if the
tropomyosin and desmin molecules have common
functional and/or structural domains.
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Figure 5
Electron micrographs of negatively stained (uranyl acetate) specimens decorated with a mouse monoclonal LCK-16 (IgM)
that cross-reacts with tropomyosin and 10-nm filaments (desmin and vimentin). (A) 10-nm Filament decorated with
LCK-16. The antibody bound in a helical fashion (arrowheads) with a repeat period of approximately 38 nm. (8)
Tropomyosin-containing microfilaments isolated from tissue culture cells. LCK-16 caused the lateral aggregation of the
filaments and decorated (arrowheads) them with 33-nm period repeat. (C) Skeletal muscle tropomyosin
Mr-paracrystal decorated with LCK-16. The antibody (.) bound in the amino-overlap region of the molecule; this do-
main represents a region spanning from the amino terminus one-third into the molecule.
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QUEST-2D GEL LABORATORY
J.I. Garrels, R. Franza, 1. Emanuele, L. Cascio, P. Smith
Our goal for several years has been the establish-
ment of protein data bases derived from quantitative
analysis of two-dimensional gels. We have previ-
ously established techniques and equipment for
routine production of standardized two-dimen-
sional gels, and we have been developing a soft-
ware package for complete two-dimensional gel
analysis. In previous reports, we have described our
data management system, our programs for spot
detection and integration, and our programs for pat-
tern matching. During the past year, we have greatly
enhanced the matching programs, we have devel-
oped programs to create and manage our standard
patterns (representing spots seen on many gels), we
have developed programs to reduce data from
multiple films and multiple gels into a single data
base file for each sample, and we have developed
numerous programs for analysis of data after entry
into the data base.
The QUEST Software System
The QUEST software package is large. It contains
over 150 separate programs and about 5 million
characters of Fortran code and documentation. The
programs are all written in a consistent style and use
similar naming conventions and data structures
throughout. The system is highly integrated in the
sense that programs share many subroutines for ac-
cess of the data-base files and programs com-
municate with one another by sending packets of
data through common memory. The QUEST system
has proven easy to use, especially since all user inter-
action takes place at formatted screens. A thorough
description of the QUEST system from the point of
view of the user is now in press (Garrels et al., in
Two-dimensional gel electrophoresis of proteins:
Methods and applications, Academic Press, New
York [1983]).
The QUEST system is large because it supports all
aspects of quantitative two-dimensional gel elec-
trophoresis including the experimental protocols,
the record-keeping for the gel laboratory, the film
scanning and data reduction, and the analysis of
data contained in the data-base files. In this report,
we will describe more fully the programs for data
reduction and data analysis. The process of data
reduction is summarized in Figure 1. A typical sam-
ple might be run on several different types of two-
dimensional gel (say three different pH ranges) and
each gel is usually exposed to film several times (say
three times). The task of the data reduction system is
to quantitate and combine all of this data into a
single data file that best represents the intensity of
each protein in the original sample.
The data reduction begins by scanning the film
(SCAN) and the calibration film (CALSCAN). A series
of programs then detects and integrates the spots
resulting in a FILMSPOTS file (FSP). The FSP file is
next matched to an appropriate STANDARD file
(STD), which represents all spots previously seen on
this type of gel. The matching procedure produces a
file called MATCHLIST (MTL). Next the data from
each FSP file derived from the same gel is combined,
using the MATCHLIST information, into a GEL-
SPOTS file (GSP). This file contains the best quan-
titation of each spot on the gel, considering all
available film exposures. Finally, the data from all
three gels is combined into a single file called
SMPSPOTS (SSP). In the latter process, the com-
puter must know where each protein of the sample
appears on each of the separate types of gels. This
information is provided to the system by matching
the standard patterns to one another.
The final SMPSPOTS files are important com-
ponents of the protein data base. However, the data
base must be flexible. What happens if yet another
gel is run, if longer exposures later become avail-
able, or if details of the initial match are found to be
incorrect? Additions and corrections to the data will
frequently occur and our data-base structure must
allow the data to be constantly updated and im-
proved. For this reason, we consider the FILM-
SPOTS and MATCHLIST files to be more permanent
than the SMPSPOTS file. With these files available,
we can always redisplay and reedit the match of any
film to its standard. An automatic series of programs
will generate a new SMPSPOTS file from the mod-
ified MATCHLIST and FILMSPOTS files. If addi-
tional films representing the given sample have
been analyzed and matched in the meantime, their
data will also be utilized in the generation of the up-
dated SMPSPOTS file. The system presently allows
the combining of data from as many as 10 gels per
sample with up to five exposures of each gel to film.
By this strategy, each protein is quantitated from the
gel or gels where it best resolved using the level of
exposure to film that best represents its intensity
without saturation.
For analysis of reduced (SMPSPOTS) data, we aim
to make the data as visible to the user as possible.
From any image displayed on the color TV screen, a
user can indicate any spot of interest. A simple com-
mand brings up the standard spot number, the name
of the spot (if known), and the intensity of the pro-
tein in any preselected set of samples. If desired, the
intensity of the spot throughout a series of samples
will be plotted in the corner of the screen. To read
other information that might have been previously
entered about the spot, the user can bring up forms
on the terminal screen containing entries relating to
transformation, posttranslational modification, mu-
tations, cell-type specificity, subcellular localiza-
tion, etc.
To ask which proteins are increased or decreased
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SAMPLE
GEL(5-7) GEL(6-B)
PROCESS FLM FLM FLM FLM FLM FLM
SCAN
CALSCN
LNANAL
CHNBLD
CHANAL
FSSORT
FSNBRS
SYNIMG
FSP FSP FSP FSP FSP FSP
(gT9) (0)
GEUBRM
FLM FLM FLM
FSP FSP FSP
MATCH MTL MTL MTL MTL MTL MTL MTL MTL MTL
MERGE GIPJ L.GIPJ
RECONCILE
. SSP <
Figure 1
Flow chart for processing of two-dimensional gel data. A radiolabeled sample (top) is prepared for two-dimensional gel
electrophoresis and the proteins are resolved on several types of gels (for example, three different pH ranges). Each gel is
exposed to film for several different lengths of time (three times shown here) to detect both the very intense and the very
faint proteins. The task of the data reduction programs is to quantitate and combine the data from these nine films into a
single file (the SMPSPOTS or SSP file) in which the best quantitative determination for each protein is recorded. The pro-
grams following the SCAN and CALSCAN automatically detect and integrate the spots, creating a FILMSPOTS file (FSP)
for each film. The FILMSPOTS files are matched to STANDARD files (STD) to create MATCHLIST (MTL) files. Following
the matching process, which is partly manual and partly automatic, the final two stages of data reduction proceed
automatically. The MERGE process combines data from all films representing the same gel (yielding a GELSPOTS or GSP
file), and the RECONCILE process examines the data from each gel to determine the best overall value for each spot. If
a spot is detected without overlap on several gels, its intensity from each gel will be averaged. If a spot is overlapped, or
badly shaped on one gel, that data will be ignored and only data from gels that properly resolved the spot will be used.
At the end of the data-reduction process, all available information about the original sample has been reduced to a single
SMPSPOTS (SSP) file.
under the conditions of an experiment, the user can
specify his criteria on the MAKESETS form. The
members of a spot set can be selected by degree of
quantitative change between specified samples, by
range of intensity, by range of coordinates, and by
spot quality (excluding overlapped or poorly
shaped spots if desired). Using any displayed image,
the members of any set can be indicated by a
change in color. The computer can be asked to
combine spot sets to give, for example, proteins that
both increase in transformed cells and that respond
to a growth factor. Many spot sets can be selected
and stored permanently.
An overall measure of difference between any
two samples can be obtained by the COMPARE
form which can be used to plot either a scatter plot
(a log-log plot in which each protein is plotted as its
intensity in the first sample versus its intensity in the
second sample), or as a histogram of protein intensi-
ty ratios. These programs report satistically the
standard deviation of the distribution of intensity
ratios, which is a measure of the overall difference.
Until the QUEST system was complete, including
these data reduction and data analysis programs,
data could not be entered into the permanent data
base and little information could be extracted from
the system. Now data are flowing into the system at
a steady rate and our data on normal and trans-
formed cells are being analyzed. Further improvement
to the throughput of the system will require a faster
computer supporting two or more graphics work
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stations, allowing several users to enter and analyze
data simultaneously.
Studies of Human Disease
During 1981 we concluded our electrophoresis
work on human fibroblasts from individuals with
cystic fibrosis (CF). In the final round of ex-
periments, we prepared 75 samples from 21 cell
lines representing both normal and CF genotypes.
Each of these samples has been run on two-
dimensional gels optimized for different pH and
molecular-weight ranges. A total of 484 gels and
nearly 1000 film exposures have been completed as
part of these experiments.
The complete computer analysis of this much
data is still beyond the capacity of our computer
system, but we have done a computer-assisted
analysis of approximately 1100 proteins from 13
cell lines. The computer was used to generate a
large map of the human patterns and to number
each of the proteins. The films were compared
visually for major differences and the observed dif-
ferences were recorded by spot number in com-
puter files. The computer was then used to deter-
mine whether any of the observed differences cor-
related with the presence of the genes for cystic
fibrosis. Among the 13 cell lines (4 normals, 2
heterozygotes, and 7 CF homozygotes), 20 proteins
were found to be missing or greatly reduced in one
or more cell lines. These appear to be natural
polymorphisms in the population; none of the
observed differences correlated with the presence
of the cystic fibrosis genes.
Our data on human fibroblasts from the cystic
fibrosis study and the Huntington's disease study
(see Annual Report 1981) constitute an important
resource that we intend to analyze more fully to
form a human fibroblast data base. This is now be-
ing done gradually, but since our computing
resources are still limited, the task will require some
months. We hope within the next 12-18 months to
upgrade to a system with much more speed and
storage capacity, and we expect the upgraded
system to support two or more graphic work stations
so that matching and analysis can be done by
several users at once.
Studies of Transformed Cells
Our main application of the quantitative two-
dimensional gel technology is The thorough
characterization of a single cell line and its trans-
formed derivatives. Our criteria for choosing a line
are that it be stable in culture, that its origin and
history are known, that it can be grown in defined
media, and that it can be transformed by various
agents including 5V40 and adenovirus. The line
chosen is the REF52 rat embryo. line recently
described by W. Topp and M. Hightower (see An-
nual Report 1981). A defined medium for REF52
cells has been reported by Topp and Hightower, in
collaboration with D. McClure of the University of
California, San Diego. These workers have isolated
a series of SV40 transformants of REF52, and some
of these transformed lines have been further
selected for growth in soft agar and for tumori-
genesis in nude mice. The nutritional requirements
and growth characteristics of each transformed line
are already known. Other derivatives of REF52, in-
cluding adenovirus and Kirsten murine sarcoma
virus transformants, are being characterized by
Topp and colleagues. With this series of cell lines
and the helpful cooperation of Bill Topp, we have
begun an extensive series of studies to determine
how protein changes are related to growth control
and transformation.
Since his arrival to the laboratory, Robert Franza
has cultured all of the normal and transformed
REF52 lines and prepared the samples that we con-
sider necessary to establish the core of our REF52
data base. Each line has been labeled with
E"Simethionine at a variety of densities and growth
rates. The normal REF52 line has been subcloned to
measure its clonal heterogeneity, and the stability of
the parent line has been determined by labelings
done over a period of months in continuous culture.
The labeling protocols have included short pulses,
long steady-state labelings, and pulse-chase ex-
periments. In addition to normal [35S]methionine
labeling, many lines have also been labeled with
[33P]phosphate and with rHimannose.
Each line has been grown in both regular (serum-
containing) medium and in defined medium. Single
components have been selectively deleted from the
defined medium to reveal the response to EGF,
vasopression, HDL, insulin, and hydrocortisone.
Other growth factors, such as IGF2, and other
treatments, such as tumor promoters, tunicamycin,
calcium ionophores, and heat shock, have been
tested for their effects on normal REF52 and some of
its transformants.
For each of these samples, gels of several pH and
acrylamide concentrations have been run and both
long and short exposures of the gels to film have
been prepared. A large number of reproducible,
high-quality films are now being quantitatively pro-
cessed by the system. Experiments with labeling
times, defined versus regular medium, and some
heat-shock experiments have already been partially
analyzed for both normal and SV40-transformed
cells. As this baseline data on normal and trans-
formed REF52 cells is entered into our computer,
we can define sets of proteins that are altered in rate
of synthesis, turnover, or phosphorylation with each
alteration of the medium or at each stage of transfor-
mation. For any protein of particular interest, we
can ask the computer to create a table and a graph
immediately that will report the amount of the pro-
tein in each sample of any experiment that has been
analyzed. This core of data will be informative in
terms of overall relatedness of responses and in
terms of defining proteins of particular interest.
Moreover, it will serve as background information
against which to compare the results of our next line
of experimentation.
We have begun, in collaboration with Jim
Feramisco, a series of experiments based on micro-
injection of cloned genes into the nucleus of REF52
cells. Initial experiments have shown successful
transformation of REF52 cells by microinjection of
the SV40 A gene contained on the pSV7 plasmid
kindly provided by Dr. T. Shenk of the State Univer-
sity of New York, Stony Brook. Approximately 30
cells growing on a small square of glass were in-
jected with the plasmid. After the injected cells had
proliferated to approximately 300 cells, they were
labeled with ["S]methionine and run on a two-
dimensional gel. Figure 2 shows the gel obtained. It
is clearly possible to detect thousands of proteins
from the small numbers of cell involved in
microinjection experiments. This demonstration
opens the way for the study of early events that oc-
cur in cells after injection of a transforming gene, a
mutated gene, or a purified protein or antibody. It is
possible to label cultures in which every cell is
known to be injected and in which the exact cell
numbers and doubling times are known by direct
observation. Using the knowledge of protein
changes in REF52 cells that is becoming available in
our data base, we can use the microinjection techni-
ques to dissect further the responses by direct
manipulation of gene expression and functional
protein content.
Collaborative Experiments
We have continued fruitful collaborative ex-
periments with several groups at Cold Spring Har-
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Figure 2
Proteins from REF52 cells transformed by microinjection. Normal REF52 cells on a glass chip were microinjected with a
plasmid containing the SV40 early region. DNA was placed directly into the nucleus by pressure injection from a
micropipette. Nine days later, the chip covered with about 300 morphologically transformed, rapidly dividing cells was
labeled with 250 pCi of e'S]methionine for 12 hr and the proteins were resolved by two-dimensional gel elec-
trophoresis. The pattern Shown represents the broad-range pH gradient resolving most proteins from pH 4 to 8. About 4.5
million dpm were applied to this gel and it was exposed to film for only 19 hr. This result demonstrates that we can now
study transformation in REF52 cells at many time points beginning immediately after microinjection of transforming
DNA. The experiment was done in collaboration with Jim Feramisco using the pSV7 plasmid kindly provided by Dr. T.
Shenk.
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bor Laboratory. The heat-shock work has continued
in conjunction with Bill Welch, Jim Feramisco, and
Paul Thomas. The major heat-shock proteins of
He La and rat cells have been detected and quan-
titated on our system, and their modifications by
phosphate and carbohydrate have been examined.
(See Cell Biochemistry Section for details.)
We have continued to collaborate with Lee Silver
to examine the protein differences in mice carrying
various t-locus haplotypes. A set of nine t-locus-
specific proteins has been identified, and these have
been further mapped into specific regions of the t
locus on chromosome 17. (See Molecular Genetics
of the Mouse Section and the references below for
more details.)
In collaboration with Michele Franceour and
Mike Mathews, we have analyzed proteins im-
munoprecipitated by antisera from patients with
lupus erythematosis. Most of these recognize pro-
teins of ribonucleoprotein complexes and the same
proteins have been identified in whole-cell protein
patterns for He La cells. A recent antisera has been
shown to recognize a different nuclear protein
which is more predominant in dividing than in
quiescent cells, and this protein is especially high in
SV40 or adenovirus-transformed cells. This protein
will be further characterized in collaboration with
Mike Mathews.
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Neurobiology
Year-round neurobiology has been growing by leaps and bounds, and in the last year, the two neurobiology
groups have easily doubled in size. Although much of the emphasis remains focused on the leech, an ex-
quisite model system introduced to modern neuroscience by John Nicholls, work is also being carried out
on the far more comlex mammalian brain. The attraction of leech neurobiology continues to be the
possibility of a multifaceted approach combining antibody technology with electrophysiology, bio-
chemistry, histology, and developmental studies. Interestingly, what is still missing is precisely what Cold
Spring Harbor Laboratory is famous for-no one has yet peeked at leech DNA. The Neurobiology summer
teaching program was updated again with the introduction of new courses emphasizing the latest
technologies in the field.
LEECH NEUROBIOLOGY
B. Zipser, T. Flanagan, M. Flaster, C. Schley
In the past few years, monoclonal antibodies against
single types of neurons or small sets of neurons
have taught us a great deal about the molecular
neuroanatomy of the adult leech nervous system.
While new antibodies are still being generated, we
are using our existing antibodies to analyze in detail
the temporal and spatial pattern of antigen expres-
sion during neuronal development, the biochemical
nature of the neural antigens, and the physiological
function of neurons carrying these specific antigens.
We are also happy to have succeeded in dissemi-
nating monoclonal antibody technology among our
colleagues in the leech field. Other laboratories
such as that of Bill Kristan (University of California,
San Diego) and Gunter Stent (University of Califor-
nia, Berkeley) are tooling up to generate their own
leech monoclonals, thus promising to make leech
monoclonal antibodies a vibrant field.
Characterization of a Previously Unknown
Type of Leech Neuron
T. Flanagan
While many of the monoclonal antibodies
generated over the course of the last few years stain
neurons that repeat from ganglion to ganglion-
such as the N cells responding to noxious stimu-
lation-some antibodies were made that label
single types or small sets of neurons found only in
one or two specialized ganglia. An example is
Lan3-11, a monoclonal antibody that stains a pair of
cell bodies only present in the second ganglion of
the head and in the second ganglion of the midbody
chain. To explore the specialized function of such a
neuron previously largely ignored in leech neuro-
biology, the Lan3-11-labeled neurons were charac-
terized with respect to their detailed morphological
and electrophysiological signatures.
The pair of Lan3-11-labeled cells in segmental
ganglion 2 have been identified through a double-
labeling experiment combining intracellular Lucifer
Yellow injection with antibody staining (Fig. 1).
These neurons are readily identified in the live
ganglia. Their large cell bodies are easily distin-
guished from neighboring pressure cells and Leydig
cells because of their characteristic action potential,
a 35-mV spike. Unlike the Leydig cells, the pair of
Lan3-11-labeled cells is not electronically coupled
to each other.
After intracellular recordings were taken, the
Lan3-11 somata were filled with a fluorescent dye
(Fig. 1b). Lan3-11 cells project into adjacent anteri-
or and posterior ganglia, but do not project directly
into segmental sensory fields through the ganglionic
roots and they display only sparse neurite arboriza-
tions within their ganglion of origin. This may sug-
gest that these cells have specialized to coordinate
events anterior and posterior to the second segmen-
tal ganglion, rather than processing information
primarily obtained within the second segmental
ganglion. The first segmental ganglion contains
neurons that process signals descending from
cephalic photoreceptors (E. Peterson, pers. comm.).
In subsequent studies, we plan to examine the
Lan3-11 cells' response to photoreceptor stimu-
lation, as Lan3-11 cells may be second-order photo-
sensory interneurons.
We have not found any somata homologous to
the Lan3-11 cells in other segmental ganglia. The
results already available from this study indicate the
utility of antigenic markers in locating unique cell
types within neuronal systems, and further studies
are intended to indicate the functional significance
of such rare cells. In this application, the antigen
serves as a marker, and while we have a genuine in-
terest in the identity of this antigen (i.e., the Lan3 -1 1
antigen may be a neuropeptide), the characteriza-
tion of cells does not depend upon the characteriza-
tion of antigens.
Characterization of Broadly Distributed
Neuronal Antigens
M. Flaster, C. Schley, T. Flanagan, B. Zipser
In addition to neuron-specific monoclonal an-
tibodies whose staining pattern includes a single
neuron pair or only a handful of neurons in each
segmental ganglion, we have generated mono-
clonal antibodies that stain large sets of neurons.
One such antibody, Laz2-1, stains about 40 neurons
in each segmental ganglion (Fig. 2A). This relatively
large, but nevertheless restricted set of antigen-
bearing cells, includes a diversity of cell types. To
understand the significance of this staining pattern,
a multifaceted investigation has been initiated. In-
tracellular recording and dye injection of cells in the
Laz2-1 staining pattern has shown that some, but
not all of the primary mechanosensory cells, are
members of this set. Other identified neurons in-
clude the annulus erector motor neurons and the
anterior pagoda cells (of yet unspecified function).
Morphologically, all members of this set studied to
date project peripherially via the roots of the
ganglion in which they are situated. As additional
members of the antigen ically related set are iden-
tified, we hope to discern a relationship among the
cells that may include either a common function or
a common pattern of connections.
In addition to the physiological investigations, we
have begun a developmental study using Laz2-1
with our collaborators, R. Stewart and E.R. Macagno
at Columbia University. The Laz2-1 antigen appears
in a few neurons quite early in embryogenesis, but
does not appear in some cells until well after all
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Figure 1
(A) Rhodarnine-labeled Lan3-11 cells. (B) Lucifer Yellow-filled Lan3-11 cell in the same preparation as above. (C) Elec-
trical recording of the Lan3-11 cell prior to Lucifer Yellow-injection.
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Figure 2
Immunoblot and histological data on Lan3-2 and Laz2-369. (A) On a 10% SDS-acrylamide gel, high-molecular-weight markers were run on lane 1 and extracted central nervous system
proteins on lanes 2, 3, and 4. Proteins were transferred from the gel to nitrocellulose. The strip of nitrocellulose carrying lanes 1 and 2 was stained with amido black to visualize molecular-
weight markers and leech central nervous system proteins. Lanes 3 and 4 were separately stained with monoclonal antibodies Lan3-2 and Laz2-369, respectively. Both monoclonal an-
tibodies stain major broad bands centered at 130K. Lan3-2, in addition, stains two minor bands at 103K and 95K. (8) Lan3-2 brilliantly labels the two pairs of nociceptive cell bodies
in a 4% paraformaldehyde-fixed leech ganglion in the presence of Triton X-100. Lan3-2-stained axons are visible in the fiber tracts above and below the ganglion. Lan3-2 (not shown
here) will stain surface antigens in live ganglia. (C) Laz2-369 stains the pair of lateral nociceptive cell bodies in a live ganglion, suggesting that its antigen is localized on surface membrane.
cells in a typical midbody segmental ganglion are
presumed to be postmitotic. Cellular developmental
events concomitant with the appearance of the
Laz2-1 antigen in identified cells may be ex-
perimentally accessible.
Neuron-specific Monoclonal Antibodies
Cross-react with Other Select Tissues
N. Hogg, M. Flaster, B. Zipser
Three monoclonal antibodies, originally studied
because of their neuron-specific staining in the
leech central nervous system, have been charac-
terized further, both immunocytochemically and
biochemically (with Western blot staining) in the
central nervous system and peripheral tissues. The
three antibodies react both with neurons and select
epithelial tissue in the central nervous system, gut,
and penis. Antibody Lan3-8, reacts with neurons in
the nerve cord and gut and with epithelial cells in
the penis; it binds to a 65K molecule in all three
tissues. Lan3-2 and Laz2-369 are considered as a
related pair of antibodies; the former stains all (four)
and the latter generally only half (two) of the
neurons in a standard midbody ganglion respond-
ing to nociceptive stimulation (see Fig. 3). In the gut,
both antibodies label patches of epithelial cells and
Laz2-369 stains a previously unknown type of gut
neuron. Whereas a given antibody stains different
bands in gut and central nervous system im-
munoblots, comparing the bands of both antibodies
for the same tissue extract makes it apparent that
there are similarities in the molecular species that
both antibodies recognize.
For each monoclonal antibody, the histologically
identified tissue antigens need to be correlated with
proteins identified on Western blots. Of particular
interest are the broad 130K bands of central nervous
system extract to which Lan3-2 and Laz2-369 bind
(see Fig. 2A). The question is raised whether the
molecular species in these bands represents a family
of proteins that serve a specific nociceptive cell
function.
Figure 3
Histological data on Laz2-1. (A) Laz2-1 stains about 45 cell bodies in a leech ganglion. Laz2-1 labels axons in the fiber
tracts below and right and left of the ganglion.
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Gel Band Fusion
B. Zipser, M. Flaster, C. Schley
One of the major goals of our research is to detect
neuron-specific molecules (proteins) using mono-
clonal antibody technology and then to further
characterize them biochemically. A powerful first
step in the biochemical characterization of leech
nervous system antigens is their identification on
nitrocellulose replicas of SDS-gels (immunoblots);
however, the antigen(s) that binds a monoclonal an-
tibody on immunoblots is not necessarily the same
as the antigen(s) localized by the same monoclonal
antibody in fixed tissue. We tested the strength of
the correlation between histological and immuno-
blot data by generating monoclonal antibodies
against SDS-denatured protein in a particular im-
munoblot band and successfully obtained new
monoclonal antibodies with histological and
biochemical binding properties similar to those of
the original neuron-specific monoclonal antibodies.
Two previously described monoclonal antibod-
ies-Lan3-2, which stains both pairs of N cells in a
typical leech segmental ganglion, and Laz2-369,
which characteristically stains only the lateral N-cell
pair-both elicit bands on SDS-gel immunoblots, in-
cluding bands centered at 130 kD. We excised the
130-kD region from SDS-polyacrylamide gels and
used it as immunogen in two spleen cell fusions.
Hybridomas were screened histologically on whole
mounts of leech ganglia in one fusion and were
screened on immunoblots in a second fusion. Of
the 350 clones screened histologically, 16% were
positive. Of these, 60% were positive on immuno-
blots, with two monoclonal antibodies resembling
Lan3-2 and one resembling Laz2-369. Of the 148
clones screened initially on immunoblots, 30%
were positive of which three monoclonal antibodies
resembled Lan3-2 while three others resembled
Laz2-369.
The Lan3-2-like monoclonal antibodies share the
original Lan3-2 properties: They stain all four N
cells in a typical midbody segmental ganglion, they
stain an array of axon bundles in the ventral
quadrants of cryostat cross sections of the inter-
ganglionic connectives, and they elicit immunoblot
bands at 130, 103, and 95 kD as does the original
monoclonal antibody, Lan3-2. The Laz2-369-like
monoclonal antibodies characteristically stain the
lateral N-cell pair, stain an array of axon bundles in
the ventral quadrants of cross sections of the in-
terganglionic connectives, and elicit an im-
munoblot band centered at 130 kD, as well as ap-
parently high-molecular-weight material just below
the stacking gel/running gel boundary, as does
Laz2-369. We did not succeed in obtaining mono-
clonal antibodies that separated any of the proper-
ties of the original N-cell monoclonal antibodies.
Entirely novel monoclonal antibodies, as judged by
their immunoblot staining patterns, were also
isolated. They are conveniently grouped into two
classes: monoclonal antibodies yielding multiple
bands, some of which include the three Lan3-2
bands as well as several different bands of both
higher and lower molecular weight, and mono-
clonal antibodies yielding single bands of varying
width and mean molecular weight in the 130-kD
region. Both of these classes are currently being
analyzed in more detail.
Gel band fusions are an interesting experimental
strategy from several points of view. They can dem-
onstrate that determinants present in extracted pro-
tein and in fixed tissue are equivalent. Additionally,
the frequency of histologically positive monoclonal
antibodies whose binding is SDS-resistant is
enhanced (roughly twofold in our experience), a
useful property when one wishes to move from
histological to biochemical analyses of neuronal an-
tigens. Finally, should a family of CNS proteins of
similar molecular weight exist, they would be
demonstrable using this approach.
The Expression of Antigens by Embryonic
Neurons and Glia in Segmental Ganglia of
the Leech Haemopis marmorata
B. Zipser [in collaboration with E. Macagno and R.
Stewart, Columbia University]
Monoclonal antibodies raised against adult leech
nervous systems were screened on embryos of the
leech Haemopis marmorata to determine when in
development specific antigens are first expressed
and the order in which they are expressed by dif-
ferent cells or tissues. Three of the monoclonal an-
tibodies produced by Zipser and McKay (Nature
289: 549 [1981]) were screened: Lan3-1, Lan3-5,
and Lan3-6. Each monoclonal antibody shows a dif-
ferent pattern of labeling in the adult leech nerve
cord (Zipser, J. Neuroscience 2: 1453 [1982]). The
embryonic stages studied were from 5 days after egg
deposition to 30 days (hatching). The pattern of
labeling was assayed in whole mounts using HRP-
conjugated second antibodies. The principal results
are: (1) Antigens recognized by Lan3-5 are first ex-
pressed by the glia of the roots of the anterior
segmental ganglia at 6-7 days, several days later by
the interganglionic connective glia, and near the
end of embryonic development by ganglionic
neurons. An anterior-to-posterior temporal gradient
is observed in the expression of these antigens. In
addition, Lan3-5 also labels the protonephridia and
nephridia from early development onwards. (2) An-
tigens recognized by Lan3-6 are first expressed by a
pair of neurons in each segmental ganglion and
later in development by additional neurons. By the
time of hatching, however, only about half of the
neurons that label in the adult have done so, imply-
ing that some neurons express these antigens
postembryonically. Labeling with Lan3-6 is first
seen in neuronal somata, and only later in neuronal
processes. (3) Antigens recognized by Lan3-1 and
expressed by segmentally specific neurons in
ganglia 5 and 6 are not detectable during em-
bryonic development but are detected in early
postembryonic stages. Thus, these three mono-
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clonal antibodies provide an approach to the study
of different aspects of the development of the leech
nervous system, specifically the relation between
glial and neuronal differentiation and the genesis of
segmentally specific phenotypes.
A New Monoclonal Antibody Specifically
Stains the Pressure Cells of the Leech
C.M. Loer, C. Schley
The success of Zipser and colleagues in producing
monoclonal antibodies to the leech nervous system
has brought other neurobiologists to Cold Spring
Harbor to learn the techniques of hybridoma pro-
duction and culture. Curtis Loer, a graduate student
from Bill Kristan's lab at the University of California,
San Diego, came to the Zipser lab to produce
monoclonal antibodies to be used in studying the
development of the nervous system of the glosso-
phoniid leech, Haementeria. Under the expert
guidance of Carol Schley and Birgit Zipser, 201
hybridoma clones were produced and screened for
the production of antibodies to the Haementeria
nervous system. Of 52 positive clones (an unusually
high rate of positive clones), some 30 were chosen
to be saved and studied. Antibodies from the clones
bound to a large variety of components of the leech
nervous system: to all or almost all neurons (5), ax-
on hillocks (6), muscle, glial, and connective tissue
(12), unidentified fibers (6), varicosities (4), small
subsets of neurons (8), and others (11). Some of the
antibodies gave staining patterns similar or identical
to antibodies produced in the past to Haemopis ner-
vous tissue, while others revealed patterns never
before seen. One particularly impressive antibody
specifically stains two pairs of well-characterized
sensory neurons found in each ganglion, the
pressure (P) cells (Fig. 4). This antibody is unusual in
that not only is it quite specific for these cells, but it
marks the neurites of the P cells as well as their cell
bodies. This particular antibody should prove very
useful in studying the development of these sensory
neurons.
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ANATOMICAL STUDIES WITH MONOCLONAL ANTIBODIES
S. Hockfield, E. Waldvogel, L. Kleina, S. Hendry
Much of neurobiology over the last hundred years
has involved the description of different neuron
types. Anatomical, physiological, and pharmaco-
logical approaches have all been used to categorize
neurons in an attempt to understand how the ner-
vous system is organized. Until the advent of
hybridoma technology, there was no means to look
for molecules that correlated with or determined
these characteristics. Our studies using monoclonal
antibodies examine the molecular diversity of
neurons in the central nervous system of vertebrates
and invertebrates to determine relationships among
neuron subclasses at the molecular level.
Antibodies to the Leech Nervous System
In the last year, we have further developed tech-
niques for immuno-electron microscopy, allowing
us to visualize antibody binding sites while preserv-
ing ultrastructural quality. This has allowed us to
pursue our analysis of the subcellular organelles
that carry specific antigens. The relative simplicity
of the leech central nervous system is seen in the
repeating organization of approximately 400
neurons in each segmental ganglion. The positions,
shapes of these neurons have been
shown to be consistent by anatomical, physio-
logical, and immunological techniques. In the
leech, however, interactions between neurons do
not occur on cell bodies but on fine processes of
these cells (axons). The organization of axons in the
leech is apparently more complex than that of cell
bodies, as 5000 axons run in a bundle (called the
connective) between each pair of ganglia. We have
found that the antibodies first described to
recognize subsets of neuron cell bodies in the leech
by Zipser and McKay in 1981 also recognize
subsets of axons (Hockfield and McKay 1983). Us-
ing this information, we have shown that antibody-
identified axons occupy consistent positions in the
connective. Although the general features of axon
position and symmetry between the two halves of
the connective are quite closely conserved, the fine
details are not. For example, the number of axons in
a particular fascicle may vary as may the position of
the fascicle within an arc of approximately 30°. The
determination of axon position must be a regulated
event. In many cases where small subsets of axons
are antibody positive, these axons travel together in
bundles (fascicles) and are not distributed through-
out the connective, even when the cell bodies
recognized by that antibody are dispersed in the
ganglia. This suggests that the presence of the an-
tigen recognized by a particular antibody may be
related to axon position. Many hypotheses for deter-
mination of axonal trajectory have postulated the
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presence of surface markers to serve as recognition
cues. We have shown that in at least two cases
when antibody-positive axons travel together in
fascicles, the antibody recognizes an antigen pre-
sent on the surface of the axons. This observation
strengthened the possibility that these antigens
might be involved in axon position finding. One re-
quirement for such a molecule is that, if it does pro-
vide cues for the determination of specific routes, it
be present from the earliest stage of axon
outgrowth. We have shown, using immuno-
electron microscopy, that during embryogenesis the
antigens are indeed present from the earliest stages
of axon outgrowth. Importantly, even in young em-
bryos, the antibody-positive axons travel together in
bundles and the antigen is located on the surface of
these axons. Other details of the organization of
specific identified axons are described in the
Molecular Studies of the Nervous System Section.
What does the demonstrably great degree of an-
tigenic diversity among leech neurons reflect in the
functioning nervous system? Does this diversity
reflect variations in a single characteristic among
neurons, or are there many characteristics that vary
teidifferentiate neurons from one another? Our elec-
tron microscopic studies of the organelles that carry
the antigens recognized by monoclonal antibodies
address these questions. It was possible that all the
variability might be reflected in a single characteris-
tic, such as different surface antigens as described
above. We have found, however, that antibody-bind-
ing sites, while consistent among all elements rec-
ognized by each antibody, vary considerably be-
tween antibodies. For example, in contrast to the
results described above, antibody Lan3-8 rec-
ognizes an internal antigen. Lan3-8 binds to an an-
tigen present in all neuron cell bodies of the leech
central nervous system but in only a subset of ax-
ons. At the ultrastructural level, using electron mi-
croscope-innmunocytochemistry, this antibody ap-
pears to bind to cytoskeletal elements of axons. In
1-am-thick plastic sections of leech ganglia,
Lan3-8-stained cell bodies have an uneven distribu-
tion of antigen similar to a neurofilamentous net-
work. The molecular weight of the Lan3-8-antigen
(65,000 daltons) approximates that of one of the
core neurofilament proteins. However, immuno-
blots run concurrently with Lan3-8 and an antibody
that recognizes intermediate filament proteins
shows a slight difference in molecular weight be-
tween the Lan3-8 antigen and a major band iden-
tified with the anti-neurofilament antibody.
Lan3-8-positive axons are located towards the
perimeter of each of the large lateral connectives
and in the medial connective. Unlike axons stained
with antibodies that recognize surface antigens,
Lan3-8-positive axons are not grouped together into
Figure 1
Transverse sections (50 Arn thick) of the cervical spinal cord illustrate the staining patterns achieved with four different
monoclonal antibodies (A). An antibody that did not bind to spinal cord sections left both the gray (GM) and white matter
(WM) unstained. SG, substantia gelatinosa; VH, ventral horn. (B Cat-101 bound to axons in the white matter (WM) and
gray matter (GM). In the ventral horn, antibody-labeled axons outline the unstained, negative images of cell bodies. The
small rectangular area is shown at high magnification (inset) with unstained cell bodies (asterisks) outlined by stained
processes. (C) Cat-201 bound to axons in the white (WM) and (GM) matter and to cell bodies. Prominently stained cell
bodies are found in the ventral horn motor neuron pools. The inset shows antibody-staining localized to the cytoplasm
of labeled cell bodies (arrowheads). (D) Cat -301 bound to neuron cell bodies and proximal dendrites in many areas of the
spinal cord gray matteer (GM) but not to axons. The substantia gelatinosa (SG) contains no antibody-labeled cell bodies.
The large ventral horn neurons (asterisks) shown enlarged in the inset demonstrated that Cat-301 binds to the surface of
neurons. Magnification, 6 x; insets, 25.6 x.
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fascicles and often travel among a number of un-
stained axons. Although it is tempting to correlate
surface antigens with axons that form fascicles and
internal antigens with axons dispersed in the con-
nective, results with another antibody, Lan3-6, in-
dicate that there is no simple correlation between
the subcellular location of an antigen and axon
fasciculation. Lan3-6 recognizes an internal antigen
in axons that form a small number of axon fascicles.
Further studies will be necessary to show what
kinds of antigens actually participate in the deter-
mination of axon position. That different antibodies
have different subcellular binding sites shows that
there is more than a single characteristic that can
vary to differentiate one neuron from another.
Antibodies to the Vertebrate Central
Nervous System
Perhaps the most exciting result of the past year was
the generation of antibodies that recognize subsets
of neurons in the vertebrate central nervous system
(McKay and Hockfield 1982). This showed that the
hybridoma technique so successful in the leech
could also be applied to the analysis of the verte-
brate brain. The initial panel of approximately 50
antibodies (generated against the adult vertebrate
spinal cord) included antibodies specific for cell
bodies, for axons only, and for axons and cell
bodies. Each antibody has a characteristic staining
pattern in every area of the central nervous system
we have examined. In the spinal cord (Fig. 1), for
example, antibody Cat-201 binds to axons and to
neuron cell bodies in the ventral horn whereas
Cat-301 binds to cell bodies in both the ventral and
dorsal horns. Each antibody binds to a different
functional group of neurons, as ventral horn
neurons are involved in generating movements and
dorsal horn neurons are involved in processing sen-
sory input from the skin.
Antibody Cat-301 Is Present on the Surface
of Specific Neuronal Subsets
Cat-301 is an intriguing antibody in two respects.
First, at the light microscopic level, it appears to
bind to an antigen on the surface of neurons; and
second, it binds to an unusual subset of neurons in
several areas of the central nervous system.
Using electron microscopic immunocytochem-
istry, we have now shown that Cat-301 binds to an
antigen on the external surface of neurons (Fig. 2).
Binding sites are irregularly distributed over the sur-
face of a neuron, dense on the membrane between
synapses, and sparse or absent at the synaptic cleft.
The antigen appears to extend around presynaptic
profiles, similar to the distribution of extracellular
matrix and basal lamina described at a peripheral
synapse, the neuromuscular junction. At the neuro-
muscular junction, the extracellular matrix has been
shown to be an important element of synaptic struc-
ture and can actually determine the location of the
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synapse on the muscle. Using standard electron mi-
croscopic techniques, extracellular matrix is absent
from synapses in the central nervous system. In fact,
neither surface molecules nor components of extra-
cellular space have been described in the vertebrate
central nervous system. Studies currently in pro-
gress will show if the Cat-301 antigen is a compo-
nent of synaptic extracellular matrix in the central
nervous system as the extracellular matrix at the
neuromuscular junction is in the peripheral nervous
system.
In the spinal cord, Cat-301 recognizes many kinds
of neurons with the notable exception of the in-
terneurons (local circuit neurons) in the substantia
gelatinosa. In other areas of the central nervous
system, more limited classes of neurons bind
Cat-301. In the cerebellar cortex, only one cell type,
the Lugaro cell, is recognized by Cat-301. This cell
has not been integrated into descriptions of
cerebellar circuitry because it was only rarely seen.
Cat-301 may prove useful in identifying Lugaro
cells so that they could be further studied.
Three areas of the brain involved in visual percep-
tion contain Cat-301-positive neurons. In the visual
cortex, patches of Cat-301-positive neurons alter-
nate with patches of Cat-301-negative neurons. The
periodicity of these patches matches the dimensions
of the ocular dominance columns described by
Hubel and Weisel. The superior colliculus also
receives visual input, and here, too, subsets of
neurons are recognized by Cat-301. In the
thalamus, the lateral geniculate nucleus receives
visual input and layers of the lateral geniculate con-
taining antibody-labeled cells are separated from
layers containing unlabeled cells (Fig. 3). Further
studies will show whether Cat-301-positive neurons
in the lateral geniculate, superior colliculus, and
visual cortex are physiologically related.
The thalamus is a major relay station in all sensory
processes. Cat-301 also differentiates among cell
types throughout the thalamus. In addition to the
lateral geniculate nucleus, several, but not all,
thalamic nuclei contain Cat-301-positive neurons.
The distribution of antibody-identified neurons
within a given nucleus reveals features of the
nuclear organization, which, in some cases, was not
apparent using previously described techniques.
For example, in the ventro-basal nucleus, involved
in skin and joint perceptions, patches of labeled
neurons interdigitate with patches of unlabeled
neurons. These patches may correspond to areas
receiving a particular class of input. An intriguing
possibility raised by these observations is that
neurons serving similar functions for different
modalities may be antigenically related. The
neurons along a pathway for a single modality (vi-
sion, skin sense [somatosensory], or smell, for ex-
ample) are physiologically related, that is, they have
similar responses to particular stimuli. For each
modality, the basic organization of relay stations is
similar. In the visual system and in the somatosen-
sory system, similar kinds of neurons are recognized
Figure 2
Light (A) and electron (B-D) micrographs of a layer-IV neuron from a 1% glutaraldehyde, 1% paraformaldehyde-fixed cat spinal cord. IA) Cat-301 staining is visible around the cell body and
proximal dendrites of a layer-IV neuron whose nucleus (NI) contains the nucleolus in this section (520x1. (8) In a low-power electron micrograph of another sectionof the cell shown in A,
Cat-301 staining along the surface of the cell body and a proximal dendrite appears interrupted by other profiles. Areas on boxes are shown enlarged in(C) and D (2800 x (Cl Area in the upper
box in A shows two axo-somatic synapses. Antibody staining (white asterisks) is present in the extracellular space along the surfaces of both the pre- and postsynaptic profiles but is excluded
from the synapse (S) (23,000 x ). (D) Area in the lower box in A also shows antibody staining (white asterisks) around pre- and postsynapticelements but excluded from synapses (s). A short
stretch of rough endoplasmic recticulum (rER) in the postsynaptic cell stains with Cat-301 (23,000x).
Figure 3
Antibody Cat-301 recognizes subsets of neurons in the lateral geniculate nucleus (LGN) of the thalamus in the cat (A)
and monkey (8). (A) In the cat LGN, many neurons in the interlaminar zones (arrowheads) are heavily stained by Cat-301.
Fewer neurons are stained in the intervening layers. (B) In the monkey LGN, many Cat-301-positive neurons are found in
the magnocellular layers (arrowheads) while the parvicellular layers (p) are relatively free of labeled neurons. In both
the cat and monkey, particular classes of physiologically identified neurons are found in layers that contain
Cat-301-labeled cells.
by Cat-301 at each relay station. Using Cat-301 to
analyze these structures may reveal similarities of
organization conserved through sensory systems.
Studies on the Embryonic Vertebrate
Nervous System
Many theories of neuronal development have
postulated the presence of specific markers that
guide neurons to make appropriate connections. As
Cat-301 recognizes a surface antigen that might be
involved in the formation or maintenance of
specific connections, we have studied the devel-
opmental time course of the appearance of the
Cat-301 antigen. In the spinal cord, the motor
neurons in the ventral horn are generated before
birth. During the first two postnatal weeks, the
development of the adult pattern of synapses on
motor neurons is completed. Very few motor
neurons have Cat-301 surface staining at birth. The
number of Cat-301 surface-labeled neurons in-
creases during the first postnatal weeks, but even at
3 weeks, the adult pattern is not yet seen. This is
consistent with the possibility that Cat-301 may be a
component of synaptic extracellular material, as at
the neuromuscular junction many extracellular
components are seen only after synaptogenesis is
complete. While the function of such molecules is
not yet known in detail, the extracellular matrix has
been shown to play an important role in maintain-
ing the organization of receptors in the postsynaptic
membrane.
To explore further molecules that might function
in cell-cell interactions during development, we
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have now generated a panel of antibodies against
early embryonic spinal cord. We have screened
over 2000 cell lines and have obtained many an-
tibodies that recognize neural elements in the em-
bryonic spinal cord. These antibodies distinguish
among cell types present early in development.
Some antigens are transiently expressed whereas
others are expressed in the developing and adult
nervous system. Together with the antibodies raised
against the adult nervous system, we can now trace
the development of specific neuronal types.
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MOLECULAR STUDIES OF THE NERVOUS SYSTEM
R. McKay, S. Hockfield, J. Johansen, L. Kleina, J. Monnier, 0. Sundin, K. Fredrickson
Our interest in using molecular techniques to study
the nervous system continues. In the past year we
have made progress in a number of areas. The most
important changes are that we now devote a great
deal of our time to studying the vertebrate nervous
system and our studies on the leech have focused
around a particular question, the organization of the
leech connective.
The Leech Connective
R. McKay, S. Hockfield, J. Johansen, L. Kleina
The leech ganglion contains 400 neuronal cell
bodies and these ganglia form a chain along the
length of the animal. Many cell bodies send pro-
cesses up and down this chain so that ganglia are
hooked together by about 5000 axons that run in a
structure called the connective. Although our
monoclonal antibodies were initially screened for
their ability to bind to specific cell bodies, it soon
became clear that they also recognized subsets of
axons in the connective. When we asked how these
specific axons were arranged, we were surprised by
the fact that the connective was stereotypically and
symmetrically organized. Our surprise was derived
from the fact that the leech connective had been
studied ultrastructurally and this simplifying feature
of its organization not understood. The reason for
this is that the organization in the connective is not
geometrically precise, but the results we obtain
when we use antibodies to detect specific axons
suggest that order exists.
Naturally, we wanted to confirm these interpreta-
tions with a different technique. Fortunately, in the
leech, we can readily fill identified single cells with
a tracer, horseradish peroxidase. This enzyme fills
the processes of the cell and allows us to locate
them in the connective at the electron microscopic
level. The question we asked was, Do the processes
of physiologically identified cells occupy stereo-
typed positions in the connective? We chose to
study the processes of the mechanosensory cells
first because we have several antibodies that bind to
specific subsets of neurons that include these cells.
The axons of the mechanosensory cells always run
in an arc of about 30° of the lateral connectives;
often the axons of physiologically similar cells run
together. (Fig. 1, left, shows the positions of the
seven main mechanosensory axons and Fig. 1,
right, shows an electron micrograph of three filled
touch cell axons.) We next filled other types of
cells-the serotonergic Retzius cells and the Leydig
cells; their axons also run in the same quadrant of
the connective as the process of the mechanosen-
sory cells. We hope to map the connective in this
way and we are already studying the arrangement of
these axons in the nerve bundles that run from the
ganglion to the periphery.
The filling of identified cells confirms our im-
munohistochemical observation that some axons
occupy stereotyped positions in the leech connec-
tive. The immunohistochemical evidence also sug-
gests other important features of the organization of
the connective. First, axons appear to be arranged in
bundles or fascicles. Some features of this fascicula-
tion are obviously conserved in a bilaterally sym-
metrical way in both halves of the connective. More
importantly, we have shown that axons which run
together in fascicles can share surface antigenic
markers recognized by a monoclonal antibody, for
example Lan3-2 (Hockfield and McKay 1983). This
evidence suggests that markers of this kind might
promote specific fasciculation. We know from
studies on other organisms that axons choose
specific growth routes in early development, so we
have looked at the time of appearance of this sur-
face antigen. We reported in the 1981 Annual
Report that the antigens bound by Lan3-2 are on the
surface of axons early in the development of the
nervous system. This kind of data is intriguing and
suggests that specific molecules, in addition to
marking specific axons in the adult, may also play a
direct role in regulating axon organization.
To pursue the biochemistry of this type of surface
antigen further, we have followed two routes. We
have continued to generate similar monoclonal an-
tibodies using our initial shotgun approach and we
have followed a much more directed strategy, par-
tially purifying small amounts of these surface an-
tigens using immunopurification techniques. The
shotgun approach has generated several interesting
antibodies, including antibodies that bind to the sur-
face of specific subsets of axons as well as subsets of
cell bodies. The more directed approach of purify-
ing particular antigens has the advantage that it does
not continue to depend on the low chance of ob-
taining particular antibodies using the whole leech
cord as antigen. In last year's annual report, we
presented evidence that we could identify antigens
in specific hand-dissected cell types on im-
munoblots. We had shown, then, that the antibody,
Lan3-2, which recognizes an antigen on the surface
of some axons, binds to several high-molecular-
weight bands on immunoblots of different species
of leech. These antigens all bind to ConA beads,
suggesting they are glycoproteins. We chose the
leech species, which gave the simplest pattern on
immunoblots, and we have used single-step im-
munopurification procedures to purify these glyco-
proteins partially. Using the ultrasensitive silver
staining procedures, we have been able to see
stained protein bands at the molecular weights ex-
pected for the Lan3-2 antigens from Lan3-2 im-
munoblots. These bands are not immunoprecipi-
tated when another control monoclonal antibody is
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Figure 1
Electron micrograph showing the horseradish peroxidase-labeled processes of mechanosensory cells. The diagram
shows the location of these axons in a stereotyped zone of the connective.
used in the purification. The very small amounts of
antigen that we obtain from a single leech nerve
cord (<100 ng) restrict the practical use we can
make of this purification, but there are new pro-
cedures for generating monoclonal antibodies by in
vitro immunization against nanogram quantities of
antigen, and protein-sequencing techniques have
been developed so only small amounts of pure pro-
tein are required. We are now using in vitro im-
munization to generate large numbers of antibodies
against neuronal glycoproteins. We hope to use
these techniques to obtain a thorough molecular
description of those antigens that mark groups of ax-
ons. We may then be able to ask whether all axons
carry specific surface antigens early in embryonic
development and to ask what role these molecules
play in axon organization during embryonic devel-
opment.
The Development of Molecular Diversity in
the Vertebrate Nervous System
R. McKay, S. Hockfield, I. Monnier
The application of hybridoma technology to the
analysis of the adult vertebrate nervous system has
yielded many antibodies that distinguish discrete
neuronal types in different areas of the central ner-
vous system (see Anatomical Studies with Mono-
clonal Antibodies Section). More recently, we have
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used hybridoma technology to probe the cellular
organization of early stages in the development of
the vertebrate central nervous system. We already
knew that this approach worked on the adult brain.
So our next step towards the developmental events
we are interested in studying was simply to explore
the difficulties and rewards of applying this techni-
que to the analysis of central neural development.
The nervous system is derived from a plate of ec-
todermal cells (a columnar epithelium) that rolls up
in development to form a tube of approximately
10' cells, which proliferate and differentiate to
generate the 101' cells and possibly hundreds of
cell types of the adult vertebrate brain. We chose
El 5 rat embryo because at this age the nervous
system still contains both the rapidly proliferating
epithelial cells and the recently differentiated
neurons that have just begun to send out processes
and receive sensory input. So this stage of develop-
ment seemed suitable to study the cellular differen-
tiation of the neural plate and the initial events in
axon outgrowth and synaptic recognition between
neurons using monoclonal antibodies. Although we
are still in the early stages of this project, we do
have antibodies that bear on both of these
questions.
The antibody Rat6-7G12 binds to an antigen
which is expressed in a subset of radial cells in the
columnar epithelium. These cells have the mor-
phological characteristics of the neuroblast cells first
described by the Golgi technique and called radial
glial cells by Cajal. Immunoblots show the antigen
to be a doublet of bands of approximately 180,000
daltons. Both biochemical and histochemical assays
show the antigen to be absent in the adult rat brain.
At the electron microscopic level, the antibody
recognizes an internal antigen in a subset of the El 5
radial cells-some of these cells contain mitotic
figures, so we know they are dividing. The only
other cells in the embryo that express a related an-
tigen are located in the region of the developing
somites. We hope to use antibodies of this kind to
identify the stage in embryonic development when
the molecular diversity of neurons first becomes ex-
pressed. Embryological transplantation experiments
in the developing chick central nervous system and
more recent experiments making chimeras with
mouse cerebellar mutants suggest that some neuron
types may be determined at the neural plate stage.
Clearly, antigenic differences between cells at this
early stage are consistent with this possibility.
The antibody Rat6-2F2 and a number of other
monoclonal antibodies bind to antigens present in
the processes of neurons. Immunoblots show that
2F2 binds to the same three bands in the developing
and adult central nervous system. Using this an-
tibody, we have been able to follow the growth of
single axons from the developing motor neurons of
the spinal cord. These studies show that the first ax-
ons grow out from several sites on the periphery of
the spinal cord and congregate at one point, which
we assume to be the site of the future nerve plexus,
before radiating towards their peripheral targets.
This observation suggests that the site of congrega-
tion (the future nerve plexus) is attractive to the first
growing axons that find their way to this point by
different routes. Although this approach is simple,
students of axon pathfinding in invertebrate systems
have used similar, simple immunological probes
with great success.
Identification of Genes and Gene Products
Active in Early Development of the Rat
Nervous System
0. Sundin, R. McKay
Monoclonal antibodies have already given us an ex-
citing glimpse into the molecular architecture of the
nervous system and in the process have raised new
questions concerning the relation of this molecular
architecture to neural function. However, the
molecular analysis of neural systems using
hybridoma technology as our only tool would be an
arduous task. Fortunately, recombinant DNA tech-
nology may provide new and powerful methods for
cloning genes expressed in the nervous system and
we hope these methods will simplify our task. For
example, once a gene has been cloned, nucleic acid
hybridization can be used to isolate additional
related genes; nucleic acid sequencing is then a
rapid way of establishing the evolutionary relation-
ships amongst a family of genes and the gene can be
expressed in bacterial or higher cells to give com-
plementary message RNA and protein. The next
question is how to identify a gene of interest?
A common strategy for identifying interesting
genes is to take antibodies against the gene product
and use these to identify and purify the mRNA or a
cDNA clone expressing this protein in bacteria. We
are developing cDNA expression systems that may
allow us to use this approach to genes, and we also
hope these systems will allow us to generate an-
tibodies from cloned cDNAs. The scheme we are
devising is, in spirit, the reverse of traditional
methods. The idea is first to choose a cDNA clone
complementary to a message RNA specifically pres-
ent in embryonic rat nervous tissue; we then want to
obtain protein complementary to this gene, raise an-
tibodies against the protein, and then localize the
native gene product to cell types within the devel-
oping nervous system.
We have built upon two existing bacterial
plasmids to implement this idea. Both of these
plasmids were designed to express proteins under
the control of the lac promoter. One of these
plasmids, MR100, which we obtained from Mike
Rosbash (Brandeis University), was specifically
designed to look for open reading frames in DNA
fragments. The plasmid is designed so that bacterial
colonies containing plasmid with inserted and ex-
pressed cDNA have the lacZ' phenotype. With in-
sert sizes of over 300 bp, one selects strongly for
biologically relevant polypeptides. To use this
plasmid as an acceptor of cDNA fragments, it was
necessary to increase the efficiency of insertion
greatly and to allow strictly only single inserts. To
achieve this, a new method was devised in which a
BamHl restriction site was introduced into the vec-
tor. To prevent self-ligation and multiple inserts of
the vector, we filled the two inner nucleotides of the
four-base-pair staggered ends of the BamHI site and
of the Xhol linkers on the double-stranded cDNA.
The modified Xhol end can still efficiently ligate to
the modified BamHI end through the two-base-pair
overlap. Barn-Barn and Xho-Xho self-ligation is
blocked by the partial fills so vector and cDNA can-
not ligate to themselves but only to each other. In
our experience, this method of cloning cDNAs is
extremely efficient and we have isolated large
numbers of lacZ* clones; some of these clones ex-
press stable fusion proteins. We are currently assess-
ing the stability of the hybrid proteins and raising
monoclonal antibodies against these fusion pro-
teins, and we plan to examine the native gene pro-
duct in the embryonic rat nervous system by im-
munohistochemistry and protein blotting.
One drawback of a 0-galactosidase vector is that
the bacterial portion of the fusion protein is at least
six times the size of that derived from the cDNA. It
would be less complicated to raise insert-specific
monoclonals if the "carrier" portion of the protein
were smaller in size and not as immunogenic. We
have obtained from David Helfman a pUC8-derived
plasmid that expresses an unusually stable 17K C-
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Figure 2
Western blot showing that several bacterial colonies trans-
formed with a plasmid derived from pUC9 express a
31-kD protein that binds monoclonal antibodies against
the amino terminus of SV40 large T antigen.
Tropomyosin
(13000, 17 Kd)
terminal fragment of chick tropomyosin under con-
trol of the lac promoter. When fused to a 14K N-
terminal fragment of SV40 T antigen, which by
itself appears highly unstable in E.coli, one obtains a
31K fusion protein with considerable stability (Fig.
2). To develop this plasmid to meet our needs, an
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out-of-phase tropomyosin-coding region is being
constructed. cDNA will then be cloned into the
BamHI site located between SV40 T antigen and
chicken tropomyosin-coding regions. Stable fusion
proteins will then be identified by replica-filter
screening bacterial colonies with antibody against
tropomyosin. Using an affinity column of mono-
clonal antibodies that bind to T antigen, we hope to
purify the fusion protein quickly prior to its use as
an antigen.
Our optimism in this enterprise is based on the
assumption that genes which are selectively ex-
pressed at certain stages of development in specific
neuronal types are common rather than rare. Initial-
ly, we are only studying a small number of hybrid
proteins but we are hopeful that with new methods
for generating antibodies against very small
amounts of protein, it will be possible to obtain very
rapidly sets of antibodies for many different fusion
proteins. These antibodies will then be used to find
genes expressed in subsets of neurons. The
biochemical analysis of these antigens will then be
vastly simplified by having the gene precloned.
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The double helix is deceptively simple. When first found in 1953, it appeared so beautifully clear that for a
brief period it seemed that by mere visual inspection we must learn all its mysteries. Now almost 30 years
later, DNA structure is no longer a child's game, and those who play with it must be both experienced and
of the courage to seek elegance among the almost overwhelming perturbations of its basic double-helical
configuration. Not only can DNA be overcoiled or undercoiled, all under strict enzymatic control, it can
turn to the left as well as to the right. Since these complexities are not laboratory artifacts but, in fact, pro-
vide the molecular underpinnings for the successful functioning of our genetic material, further progress in
more firmly establishing the various forms of DNA is likely to be essential for the future of much biological
research.
The moment thus was propitious for a high-level meeting in which all aspects of DNA could be presented
and analyzed. So, for the topic of our 47th annual Symposium, we chose "The Structures of DNA." From
the start we realized that the number of speakers was likely to be very large, and so we sought the advice of
many experts as to whom to invite. In particular, I wish to acknowledge the invaluable counsel given by
Charles Cantor, Pierre Chambon, Don Crothers, Richard Dickerson, Gary Felsenfeld, Aaron Klug, Alex
Rich, and Jim Wang. The formal program contained 114 speakers with many additional, last-minute infor-
mal presentations made during the course of the various sessions. Given the inherent complexity of the
topics, this was indeed a very demanding Symposium. But because of the consistently high quality of the
presentations, this Symposium was also felt by virtually all of the 244 participants to rank among the most
stimulating of the scientific meetings that they had ever attended.
The most necessary financial help that let us assemble such a massive program was again provided by the
National Institutes of Health, the National Science Foundation, and the Department of Energy.
Opening Remarks: A. RICH, Dept. of Biology, Massachusetts Institute of Technology, Cambridge,
Massachusetts
SESSION 1 The Handedness of DNA. I.
Chairperson: S. ARNOTT, Purdue University, West Lafayette, Indiana
S. IKUTA,1 A. DUGAICZYK,2 T. HUANG,t R.B. WALLACE,' and K. ITAKURA,' 'Dept. of Molecular Genetics, City
of Hope Research Institute, Duarte, California; 2Dept. of Cell Biology, Baylor College of Medicine,
Texas Medical Center, Houston: Synthetic oligodeoxyribonucleotides as indispensable chemicals in
modern biological laboratories.
R.E. DICKERSON,' H.R. DREw,2 B.N. CONNER,' and M.L. KOPKA,1 'Molecular Biology Institute, University of
California, Los Angeles; 2MRC Laboratory of Molecular Biology, Cambridge University, England: The
anatomy of A, B,- and Z DNA.
M.A. VISWAMITRA, ICMR Centre of Genetics and Cell Biology, Indian Institute of Science, Bangalore, India:
Structural diversity in DNA-From monomer structures to oligonucleotides.
A. H.-J. WANG,' S. FUJI1,1 J.H. VAN BOOM,2 and A. RICH,' 'Dept. of Biology, Massachusetts Institute of
Technology, Cambridge; 2Gorlaeus Laboratories, Leiden State University, The Netherlands: The
molecular structure of a modified A-DNA octamer, a methylated Z-DNA, and a DNA-RNA hybrid.
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SESSION 2 The Handedness of DNA.
Chairperson: C. CANTOR, Columbia University, New York, New York
V. SASISEKHAREN, Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India: The history of
left-handed DNA.
S. ARNOTT, R. CHANDRASEKARAN, I.H. HALL, L.C. PUIGJANER, and J.K. WALKER, Dept. of Biological Sciences,
Purdue University, West Lafayette, Indiana: DNA secondary structures-Helices, wrinkles, and
junctions.
S. ZIMMERMAN and B. PHEIFFER, NIADDK, National Institutes of Health, Bethesda, Maryland: DNA confor-
mations and transitions-X-ray diffraction studies of solvated fibers.
R.D. WELLS, t,2 P.A. HART,' M. KILPATRICK,L2 J. KLYSIK,',2 J.E. LARSON, 1,2 J.J. MIGLIETTA,' C.K. SINGLETON, 1'2
S.M. STIRDIVANT,1 R.M. WARTELL,3 and W. ZACHARIAS, t,2 'Dept. of Biochemistry, University of Wiscon-
sin, Madison; 2Dept. of Biochemistry, University of Alabama, Birmingham; ;Schools of Physics and
Biology, Georgia Institute of Technology, Atlanta: Left-handed DNA in restriction fragments and recom-
binant plasmids.
T.M. JOVIN,1 J.H. VAN DE SANDE,2 and D. ZARLING,3 'Max Planck Institute for Biophysical Chemistry, Got-
tingen, Federal Republic of Germany; 2Dept. of Medical Biochemistry, University of Calgary, Canada;
3Institute of Genetics, University of Cologne, Federal Republic of Germany: Formation, identification,
and properties of left-handed DNAs.
M. LENG, E. SAGE, and B. MALFOY, Centre de Biophysique Moleculaire, CNRS, Orleans, France: Interactions
between double-stranded nucleic acids and antibodies to Z DNA.
A. NORDHEIM,1 L.J. PEcK,2 E.M. LAFER,3 B.D. STOLLAR,3 J.C. WANG,2 and A. RICH,' Dept. of Biology,
Massachusetts Institute of Technology, Cambridge; 2Dept. of Biochemistry and Molecular Biology, Har-
vard University, Cambridge, Massachusetts; 3Dept. of Biochemistry and Pharmacology, Tufts University
School of Medicine, Boston, Massachusetts: Antibody reactivity with left-handed Z DNA in supercoiled
plasmids.
M.L. PARDUE,' A. NORDHEIM,1 E.M. LAFER,2 B.D. STOLLAR,2 and A. RICH,' 'Dept. of Biology, Massachusetts
Institute of Technology, Cambridge; 2Dept. of Biochemistry and Pharmacology, Tufts University School
of Medicine, Boston, Massachusetts: Z-DNA and the polytene chromosome.
SESSION 3 Conformational Analysis. 1.
Chairperson: P. DOTY, Harvard University, Cambridge, Massachusetts
M.J. GAIT, H.W.D. MATTHES, M. SINGH, B. SPROAT, and R.C. TITMAS, MRC Laboratory of Molecular Biology,
Cambridge, England: A continuous flow phosphotriester method for solid phase synthesis of oligodeoxy-
ribonucleotides.
J.H. VAN BOOM,' G.A. VAN DER MAUL,' H. WESTERINK,1 C.A.G. VAN BOECKEL,1 J.R. MELLEMA,1 C. ALTONA,1
C.W. HILBERS,2 and C.A.G. HAASNOOT,2 'Dept. of Organic Chemistry, State University of Leiden; 2Dept.
of Biophysics, University of Nijmegen, The Netherlands: Synthesis and conformational analysis of DNA
fragments.
M.H. CARUTHERS, P. DEHASETH, E. FISHER, R. GOLDMAN, M. INSLEY, and W. MANDECKI, Dept. of Chemistry,
University of Colorado, Boulder: Chemical synthesis and biological studies on mutated gene control
regions.
D.J. PATEL,' S. KOZLOWSKI,' S. IKUTA,2 A. NORDHEIM,3 M. WEISS,4 and K. ITAKURA,2 'Bell Laboratories, Murray
Hill, New Jersey; 2City of Hope National Medical Center, Duarte, California; 3Dept. of Biology,
Massachusetts Institute of Technology, Cambridge; 4Dept. of Biochemistry, Harvard University, Cam-
bridge, Massachusetts: DNA conformation, dynamics, and interactions in solution.
D.M. CROTHERS, N. DATTAGUPTA, and M. FRIED, Depts. of Chemistry and Molecular Biophysics and
Biochemistry, Yale University, New Haven, Connecticut: Transmission of long-range effects in DNA.
M. YANAGIDA,t Y. HIRAOKA,1 and I. KATSURA,2 'Dept. of Biophysics, Kyoto University; 2Dept. of Biophysics
and Biochemistry, University of Tokyo, Japan: Dynamic behaviors of DNA molecules in solution
studied by fluorescence microscopy.
V. IVANOV, L. MINCHENKOVA, E. MINYAT, and A. SCHYOLKINA, Institute of Molecular Biology, USSR Academy
of Sciences, Moscow: Cooperative transitions in DNA with no separation of strands.
D. SCHWARTZ, W. SAFFRAN, J. WELSH, R. HAAS, M. GOLDENBERG, R. MURPHY, and C.R. CANTOR, Dept. of
Human Genetics and Development, Columbia University, New York, New York: New techniques for
the study of large DNAs.
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SESSION 4 Conformational Analysis. II.
Chairperson: D. CROTHERS, Yale University, New Haven, Connecticut
C. BENHAM, Dept. of Mathematics, University of Kentucky, Lexington: Statistical mechanical analysis of
competing conformational transitions in superhelical DNA.
W.K. OLSON, Dept. of Chemistry, Rutgers University, New Brunswick, New Jersey: Theoretical probes of
DNA conformation.
K. BECHERER, A. COUREY, D. HOROWITZ, L.J. PECK, Y.-C. TSE, and J.C. WANG, Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge, Massachusetts: DNA supercoiling and its effects on
DNA structure and function.
D.M.J. LILLEY, Medical Sciences Institute, University of Dundee, Scotland: Dynamic, sequence-dependent
DNA structure as exemplified by hairpin extrusion from inverted repeats in negatively supercoiled DNA.
E.N. TRIFONOV, Polymer Dept., Weizmann Institute of Science, Rehovot, Israel: Sequence-dependent varia-
tions of B-DNA structure and protein- DNA recognition.
A. KLUG, L.C. LUTTER, D. RHODES, P.J.G. BUTLER, and G.P. LOMONOSSOFF, MRC Laboratory of Molecular
Biology, Cambridge, England: Use of nucleases to probe the structure of DNA on and off the
nucleosome.
SESSION 5 Chemically Modified DNA
Chairperson: J. HEARST, University of California, Berkeley, California
H.M. SOBELL, S.C. JAIN, T.D. SAKORE, and K.K. BHANDARY, Dept. of Radiation Biology and Biophysics,
University of Rochester School of Medicine and Dentistry, New York: Structural concepts to understand
simple vs. complex intercalators.
F. TAKUSAGAWA and H.M. BERMAN, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia,
Pennsylvania: Some new aspects of actinomycin D-Nucleic acid binding.
J.M. ESSIGMANN, R.C. CROY, G.H. BUCHI, and G.N. WOGAN, Dept. of Nutrition and Food Science,
Massachusetts Institute of Technology, Cambridge: Interactions of aflatoxin B, and alkylating agents
with DNA-Structural and functional studies.
R.M. SANTELLA, D. GRUNBERGER, and I.B. WEINSTEIN, Division of Environmental Sciences and Institute of
Cancer Research, Columbia University, New York, New York: Carcinogens can induce alternate confor-
mations in nucleic acid structure.
P.B. DERVAN and M.W. VAN DYKE, Division of Chemistry and Chemical Engineering, California Institute of
Technology, Pasadena: Map of antibiotic binding sites on heterogeneous DNA-Footprinting with
MPEFe(II).
S.J. LIPPARD, Dept. of Chemistry, Columbia University, New York, New York: Platinum complexes and
DNA-Intercalation, Z-DNA, and sequence-specific structures produced by the antitumor drug cis-DDP.
S.-H. KIM, Dept. of Chemistry, University of California, Berkeley: 3-D structure of a psoralen-thymine
monoadduct formed in photoreaction with DNA and its implications.
R. Axel, J. Steitz, L. Hood S. Weissman, B. McClintock
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G.V. GURSKY, A.A. ZASEDATELEV, A.L. ZHUZE, A.A. KHORLIN, S.L. GROKHOVSKY, S.A. STRELTSOV, S.M. NIKITIN,
M.V. MIKHAILOV, A.N. SUROVAYA, V.O. RECHINSKY, R.S. BEABEALASCHVILLY, A.S. KRYLOV, and B.P. GoT-
TIKH, Institute of Molecular Biology, USSR Academy of Sciences, Moscow: Synthetic sequence-specific
ligands-Design, DNA binding properties, and biological activity.
SESSION 6 DNA-Protein Interactions
Chairperson: B. ALBERTS, University of California, San Francisco, California
B.W. MATTHEWS,' D.H. OHLENDORF,t W.F. ANDERSON,' R.G. FISHER,' and Y. TAKEDA,3 tInStltute of
Molecular Biology, University of Oregon, Eugene; 'MRC Group on Protein Structure and Function,
University of Alberta, Edmonton, Canada; 3Chemistry Dept., University of Maryland, Baltimore County:
cro repressor and its interaction with DNA.
T.A. STEITZ, S. ABDEL-MEGUID, P. BRICK, A. GOLDMAN, D. MCKAY, D. OLLIS, I. WEBER, and P. WEBER, Dept. of
Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut: Crystallographic
studies of proteins that recognize specific DNA structures-CAP, DNA polymerase I, SSB, and resolvase.
M. LEWIS, J. WANG, A. JEFFREY, and C. PABO, Dept. of Biochemistry, Harvard University, Cambridge,
Massachusetts: Structure of the operator-binding domain of the X repressor and models for operator
recognition.
H. NELSON, M. HECHT, and R.T. SAUER, Dept. of Biology, Massachusetts Institute of Technology, Cambridge:
Genetic and biochemical studies of X repressor-operator interactions.
J.E. HEARST and H.B. GAMPER, Dept. of Chemistry, University of California, Berkeley: DNA winding and un-
winding by transcriptional complexes.
M.T. RECORD, JR.,' P. MELANCON,' S.L. SHANER,1 R.R. BURGESS,' K.S. LEE,' S.J. MAZUR,' M. MOSSING,1 and
J.-H. ROE,' 'Dept. of Chemistry and 2McArdle Laboratory for Cancer Research, University of Wisconsin,
Madison: Ion effects on the interactions of E. coli RNA polymerase and DNA.
W.R. MCCLURE, D.K. HAWLEY, B.C. HOOPES, and M.E. MULLIGAN, Dept. of Biological Sciences, Carnegie-
Mellon University, Pittsburg, Pennsylvania: DNA determinants of promoter selectivity in E. coli.
R.S. JACK and W.J. GEHRING, Biozentrum, University of Basel, Switzerland: Sequence-specific DNA binding
proteins in eukaryotes.
SESSION 7 DNA within Nucleosomes
Chairperson: P. CHAMBON, Faculte de Medicine, Strasbourg, France
T.J. RICHMOND, J.T. FINCH, and A. KtuG, MRC Laboratory of Molecular Biology, Cambridge, England: X-ray
diffraction from crystals of the nucleosome core particle.
A. MIRZABEKOV, V. KARPOV, S. BAVYKIN, O. PREOBRAZHENSKAYA, and A. BELYAVSKY, Institute of Molecular
Biology, USSR Academy of Sciences, Moscow: Nucleosome structure and the alignment of nucleo-
somes in chromatin.
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A. VARSHAVSKY, L. LEVINGER, 0. SUNDIN, J. BARSOUM, E. OZKAYNAK, D. FINLEY, P. SWERDLOW, and K.C. Wu,
Dept. of Biology, Massachusetts Institute of Technology, Cambridge: Cellular and SV40 chromatin-
Replication, segregation, ubiquitination, AT-DNA-binding proteins, and functionally significant
nucleosome arrangements.
A. LARSEN and H. WEINTRAUB, Dept. of Genetics, Fred Hutchinson Cancer Research Center, Seattle,
Washington: An altered DNA conformation detected by S1 nuclease occurs at specific regions in active
chick globin chromatin.
S.C.R. ELGIN, I.L. CARTWRIGHT, M.A. KEEN, and K. LOWENHAUPT, Dept. of Biology, Washington University,
St. Louis, Missouri: Chromatin structure and DNA sequence organization.
G. GARGIULO, G. GLIKIN, B. JESSEE, and A. WORCEL, Dept. of Biology, University of Rochester, New York:
DNA and chromatin structure of the 5000-bp histone gene unit of D. melanogaster.
G. FELSENFELD, J. NICKOL, J. MCGHEE, and M. BEHE, NIADDK, National Institutes of Health, Bethesda,
Maryland: Chromatin structure and DNA methylation.
P. LABHART,' P. NESS,' E. BANZ,2 R. PARISH,2 and T. KOLLER,' 'Institut fUr Zellbiologie, ETH-Honggerberg;
'Institut fur Pflanzenbiologie, Universitat Zurich, Switzerland: A model for the structure of the active
nucleolar chromatin.
SESSION 8 The Organization of Genes along DNA
Chairperson: W. GILBERT, The Biological Laboratories, Harvard University, Cambridge, Massachusetts
J.J. DUNN and F.W. STUDIER, Dept. of Biology, Brookhaven National Laboratory, Upton, New York:
Organization and expression of bacteriophage T7 DNA.
D.L. DANIELS,' F. SANGER,2 and A.R. COULSON,2 'Dept. of Genetics, University of Wisconsin, Madison;
2MRC Laboratory of Molecular Biology, Cambridge, England: Features of bacteriophage X-The latest
analysis of the complete nucleotide sequence.
R.J. ROBERTS, B.D. JIANG, P.A. BULLOCK, R.E. GELINAS, T.R. GINGERAS, M.M. KELLY, K.E. O'NEILL, B.L. PARSONS,
D. SCIAKY, and C.E. YEN, Cold Spring Harbor Laboratory, New York: The information content of the
adenovirus-2 genome.
V. TATE, H. BOEDTKER, and P. DOTY, Dept. of Biochemistry and Molecular Biology, Harvard University,
Cambridge, Massachusetts: The procollagen genes-Further sequence studies and interspecies
comparisons.
L. HOOD, K. EAKLE, D. FISHER, J. FRELINGER, R. GOODENOW, M. MCMILLAN, A. ORN, M. PECHT, B. SHER, M.
STEINMETZ, Y. STROYNOWSKI, H. SUN, and A. WINOTO, Division of Biology, California Institute of
Technology, Pasadena: Genes of the major histocompatibility complex.
P.A. BIRO,' J. PAN,' V.B. REDDY,2 S.M. WEISSMAN,' P. JAGADEESWARAN,1 M. COHEN-SOLAL,3 and B.G.
FORGET,4 'Dept. of Human Genetics, Yale University Medical School, New Haven, Connecticut;
'Integrated Genetics, Framingham, Massachusetts; 3INSERM, Hopital Henri Mondor, Creteil, France;
4Dept. of Internal Medicine, Yale University Medical School, New Haven, Connecticut: Sequences of
human globin and MHC gene complexes.
T. IKEMURA and H. OZEKI, Dept. of Biophysics, Kyoto University, Japan: Codon usage and 'RNA contents-
Organism-specific codon choice patterns in reference to the isoacceptor contents.
J.C.W. SHEPHERD, Biozentrum, University of Basel, Switzerland: From primeval message to present-day
gene.
SESSION 9 Methylated DNA
Chairperson: G. FELSENFELD, National Institutes of Health, Bethesda, Maryland
A.P. BIRD, A. LA VOLPE, M. TAGGART, and D. MACLEOD, MRC Mammalian Genome Unit, Edinburgh,
Scotland: Methylation and expression of rRNA genes in X. laevis and X. borealis.
W. DOERFLER, L. VARDIMON, I. KRUCZEK, D. EICK, and I. KUHLMANN, Institute of Genetics, University of Col-
ogne, Federal Republic of Germany: DNA methylation and gene activity-In vitro studies, promoter
methylation, and shifts in DNA methylation.
H. CEDAR, A. RAZIN, Y. GRUENBAUM, R. STEIN, and T. NAVEH-MANY, Dept. of Cellular Biochemistry, Hebrew
University Medical School, Jerusalem, Israel: The effect of DNA methylation on gene expression.
D. FANNER, C.L. STEWART, H. STUHLMANN, K. HARBERS, and R. JAENISCH, Heinrich-Pette-lnstitut far Ex-
perimentelle Virologie and Immunologie, Universitat Hamburg, Federal Republic of Germany: De novo
methylation, expression, and infectivity of retroviral genomes introduced into early mouse embryo cells.
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B.R. MIGEON and S.F. WOLF, Johns Hopkins University Medical School, Baltimore, Maryland: Implications
for X chromosome regulation from studies of human X DNA.
L.J. SHAPIRO and T. MOHANDAS, Division of Medical Genetics, Harbor-UCLA Medical Center, UCLA School
of Medicine, Torrence, California: DNA methylation and the control of gene expression of the human X
chromosome.
R. KAHMANN, Max-Planck-Institut fur Biochemie, Munich, Federal Republic of Germany: Methylation
regulates the expression of a DNA-modification function encoded by bacteriophage Mu.
S. HATTMAN,1 M. GORADIA,2 C. MONAGHAN,' and A.I. BUKHARI,2 'Dept. of Biology, University of Rochester:
2Cold Spring Harbor Laboratory, New York: Regulation of the DNA-modification function mom of
bacteriophage Mu.
SESSION 10 Replicating DNA
Chairperson: J. CAIRNS, Harvard School of Public Health, Boston, Massachusetts
B.M. ALBERTS, J. BARRY, P. BEDINGER, T. FORMOSA, C.V. JONGENEEL, and K.N. KREUZER, Dept. of Biochemistry
and Biophysics, University of California, San Francisco: Studies of DNA replication in the T4
bacteriophage in vitro system.
C.W. FULLER, B.B. BEAUCHAMP, M.J. ENGLER, R.L. LECHNER, S.W. MATSON, S. TABOR, J.H. WHITE, and C.C.
RICHARDSON, Dept. of Biological Chemistry, Harvard Medical School, Boston, Massachusetts:
Mechanisms for the initiation of bacteriophage T7 DNA replication.
K. MATSUBARA and T. TSURIMORO, Laboratory of Molecular Genetics, Osaka University Medical School,
Japan: Replication of bacteriophage X DNA.
M. STAYTON, L. BERTSCH, S. BISWAS, P. BURGERS, N. DIXON, J. FLYNN, R. FULLER, J. KAGUNI, J. KOBORI, M.
KODAIRA, R. Low, and A. KORNBERG, Dept. of Biochemistry, Stanford University Medical School, Califor-
nia: Enzymatic recognition of DNA replication origins.
D.R. BROWN, D. REINBERG, T. SCHMIDT-GLENEWINKEL, and J. HURWITZ, Dept. of Developmental Biology and
Cancer, Albert Einstein College of Medicine, Bronx, New York: Specific DNA structures required for in-
itiation and termination of .75X A-protein-directed rolling circle DNA replication.
B. Moss, B.M. BAROUDY, and S. VENKATESAN, NIAID, National Institutes of Health, Bethesda, Maryland:
Flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into the uninterrupted
polynucleotide chain.
J. LICHY, T. ENOMOTO, J. FIELD, R. GUGGENHEIMER, J.-E. IKEDA, K. NAGATA, M. HORWITZ, and J. HURWITZ,
Depts. of Developmental Biology and Cancer and Cell Biology, Albert Einstein College of Medicine,
Bronx, New York: Identification of factors involved in adenoviral DNA replication in vitro.
B.W. STILLMAN and F. TAMANOI, Cold Spring Harbor Laboratory, New York: Initiation of adenovirus DNA
replication-Structure of the origin and enzymes involved.
C. ASTELL,1 M. CHOW,' M. MERCHLINSKY,2 J. LEARY,' and D. WARD, Dept. of Biochemistry, University of
British Columbia, Vancouver, Canada; 2Dept. of Human Genetics, Yale University, New Haven, Con-
necticut: Structure and replication of minute virus of mice DNA-Evidence for a type I topoisomerase ac-
tivity in maturing the genome termini.
P. Doty, A. Mug
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A. Rich, G. Georgiev J. Huberman, G. Eichhorn,
K. Matsubara
SESSION 11 Recombining and Mutating DNA
Chairperson: F. STAHL, Institute of Molecular Biology, University of Oregon, Eugene, Oregon
M.M. Cox, D.A. Souris, and I.R. LEHMAN, Dept. of Biochemistry, Stanford University Medical School,
California: Role of single-stranded DNA binding protein in recA-protein-promoted DNA strand
exchange.
A. STASIAK, E. DICAPUA, and T. KOLLER, Institut fur Zellbiologie, ETH- Honggerberg, Zurich, Switzerland:
The unwinding of duplex DNA in complexes with recA protein.
A. Wu, R. KAHN, C. DASGUPTA, and C. RADDING, Depts. of Human Genetics and Molecular Biophysics and
Biochemistry, Yale University, New Haven, Connecticut: Nonpolar synapsis vs. polar strand exchange
in homologous pairing promoted by recA protein.
L.R. BELL and B. BYERS, Dept. of Genetics, University of Washington, Seattle: Homologous association of
chromosomal DNA during yeast meiosis.
SESSION 12 Supercoiled DNA
Chairperson: J. WANG, Harvard University, Cambridge, Massachusetts
M. GELLERT,t R. MENZEL,' K. MIZUUCHI,t M.H. O'DEA,t and D. FRIEDMAN,2 tNIADDK, National Institutes of
Health, Bethesda, Maryland; 2Dept. of Microbiology, University of Michigan, Ann Arbor: Control of
DNA supercoiling in E. coli.
M. KRASNOW, F. DEAN, R. OTTER, M. PASTORCIC, M.M. MATZUK, and N. COZZARELLI, Dept. of Biochemistry,
University of Chicago, Illinois: Catenation, recombination, and the mechanism of type-1
topoisomerases.
A.N. LUCHNIK,' V.V. BAKAEV,2 and V.M. GLASER,3 1 Institute of Developmental Biology; 2lnstitute of
Molecular Biology, USSR Academy of Science, Moscow; 3Moscow State University, USSR: DNA
supercoiling-Changes during cellular differentiation and transcription.
P. MARGOLIN, K.M. OVERBYE, and S. BASU, Public Health Research Institute of the City of New York, Inc.,
New York: Loss of topoisomerase-I activity in S. typhimurium causes alterations in many cellular
functions.
J.W. ACKERSON and J.D. GRALLA, Molecular Biology Institute, University of California, Los Angeles: Effects
of mutation of /ac promoter function-Comparison of in vivo and in vitro results.
A.M. ALBERTINI, M.P. CALOS, M. HOFER, and J.H. MILLER, Dept. de Biologie Moleculaire, Universite de
Geneva, Switzerland: Spontaneous deletion mutations in E. coli.
L.S. RIPLEY and B.W. GLICKMAN, Laboratory of Genetics, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina: The unique self-complementarity of palindromic se-
quences provide DNA structural intermediates for mutation.
SESSION 13 Transcribing DNA
Chairperson: J. HURWITZ, Albert Einstein College of Medicine, Bronx, New York
L. OLSON, J. DE VILLIERS, J. BANERJI, and W. SCHAFFNER, Institut (Dr Molekularbiologie II der Universitat
Zurich, Switzerland: Studies on the transcriptional "enhancer" effect.
S. CEREGHINI, P. HERBOMEL, J. JOUANNEAU, S. SARAGOSTI, M. KATINKA, B. BOURACHOT, B. DE CROMBRUGGE, and
M. YANIV, Dept. of Molecular Biology, Institut Pasteur, Paris, France: Structure and function of the pro-
moter enhancer region of polyoma and SV40.
P. CHAMBON, Laboratoire de Genetique Moleculaire des Eucaryotes du CNRS, and Unite 184 de Biologie
Moleculaire et de Genie Genetique de I INSERM, Medical School, Strasbourg, France: Promoter se-
quences of eukaryotic genes coding for proteins.
B. DAVISON, J.-M. EGLY, E. MULVIHILL, and P. CHAMBON, Laboratoire de Genetique Moleculaire des
Eucaryotes and Unite 184 de Biologie Moleculaire et de Genie Genetiquedel'INSERM, Medical School,
Strasbourg, France: Formation of stable preinitiation complexes between eukaryotic class-B (II) transcrip-
tion factors and promoter sequences.
S.L. MCKNIGHT, Developmental Biology Program, Fred Hutchinson Cancer Research Center, Seattle,
Washington: Mapping transcriptional control signals of the thymidine kinase gene.
R.H. REEDER' and B. SOLLNER-WEBB,2 'Fred Hutchinson Cancer Center, Seattle, Washington; 2Johns
Hopkins University, Baltimore, Maryland: Mapping the X. laevis ribosomal gene promoter by use of
deletion mutants.
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S.G. CLARKSON,' R.A. HIPSKIND,1 and B.D. HALL,2 1Dept. of Microbiology, University of Geneva Medical
School, Switzerland; 2Dept. of Genetics, University of Washington, Seattle: DNA conformation and
transcription initiation of eukaryotic tRNA genes.
M. WORMINGTON and D.D. BROWN, Dept. of Embryology, Carnegie Institution of Washington, Baltimore,
Maryland: Developmental regulation of Xenopus 5S RNA genes.
J. STEITZ, S. MOUNT, M. HINTERBERGER, I. PETTERSSON, E. LERNER, J. RINKE, E. GOTTLIEB, and S. WOLIN, Dept. of
Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut: Small ribonucleo-
proteins from eukaryotes-Structures and roles in RNA biogenesis.
SESSION 14 Repetitive DNA Sequences
Chairperson: S.M. WEISSMAN, Yale University School of Medicine, New Haven, Connecticut
G.P. GEORGIEV, Institute of Molecular Biology, USSR Academy of Sciences, Moscow: On the structure and
possible functions of middle repetitive sequences in the eukaryotic genome.
W. JELINEK and S. HAYNES, Dept. of Biochemistry, New York University Medical Center, New York: The
mammalian Alu family of dispersed repeats.
G.M. Fox) J.F. HESS,' C.-K.J. SHEN,2 and C.W. SCHMID,' Dept. of Chemistry and 2Dept. of Genetics,
University of California, Davis: Base sequence studies of Alu family members in the a-globin gene
cluster.
L. BERNSTEIN, S. VAN ARSDELL, R. DENISON, S. MOUNT, K. MOWRY, and A. WEINER, Dept. of Molecular
Biophysics and Biochemistry, Yale Medical School, New Haven, Connecticut: Genes and pseudogenes
for human snRNA species U1, U2, and U3-Evidence that cellular RNA molecules are reverse-
transcribed and integrated into new chromosomal sites in germ-line DNA.
J. BROACH, M. JAYARAM, Y-Y. Li, and J. FELDMAN, Dept. of Microbiology, State University of New York, Stony
Brook: Analysis of yeast replication origins.
K. BLOOM, M. FITZGERALD-HAYES, and J. CARBON, Dept. of Biological Sciences, University of California, San-
ta Barbara: Structural analysis and sequence organization of yeast centromeres.
E. BLACKBURN, M. BUDARF, P. CHALLONER, M. CHERRY, E. HOWARD, A. KATZEN, W.C. PAN, and T. RYAN, Dept.
of Molecular Biology, University of California, Berkeley: DNA termini in ciliate macronuclei.
J.W. Szos-rAK, Sidney Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts: Structural
requirements for telomere function in yeast.
SESSION 15 The Regulation of Eukaryotic DNA Expression
Chairperson: J. STEITZ, Yale University, New Haven, Connecticut
P. DIERKS, B. WIERINGA, A. VAN 00YEN, M. COCHRAN, J. REISER, F. MEYER, T. KUHNE, C. DOBKIN, and C.
WEISSMANN, Institut fur Molekularbiologie I, Universitat Zurich, Switzerland: Analysis of the transcrip-
tion of the rabbit13-globin gene and splicing of the transcripts by reversed genetics.
R. AXEL, Institute of Cancer Research, Columbia University College of Physicians and Surgeons, New York,
New York: The regulated expression of human genes in mouse cells.
J. Cairns
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J. Van Boom, G. Gursky T. Schopf, M.L. Pardue
R.A. FLAVELL, Laboratory of Gene Structure and Expression, National Institute for Medical Research, Lon-
don, England, and Biogen, Inc., Cambridge, Massachusetts: Expression of globin and H-2 genes.
K.R. YAMAMOTO, V.L. CHANDLER, G.L. FIRESTONE, B. MALER, and F. PAYVAR, Dept. of Biochemistry and
Biophysics, University of California, San Francisco: Analyzing biological activity of cloned mammary
tumor virus DNA fragments that bind purified glucocorticoid receptor protein in vitro.
D.T. KURTZ, D.K. BISHOP, M.M. MANOS, and L. McCuLLoucH, Cold Spring Harbor Laboratory, New York:
Hormonal control of cau globulin synthesis.
A.W. SENEAR and R.D. PALMITER, Dept. of Biochemistry, University of Washington, Seattle: 5'regulatory
sites of the mouse metallothionein-I gene are packaged in a special chromatin structure.
J. ABRAHAM, K. NASMYTH, J. FELDMAN, J. HICKS, J. STRATHERN, A. KLAR, and J. BROACH, Cold Spring Harbor
Laboratory, New York: Regulation of mating-type genes in yeast-A novel negative control mechanism
requiring sequences both 5"and 3"to the regulated region.
Summary: A. KLUG, MRC Laboratory of Molelcular Biology, Cambridge, England
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SUMMER MEETINGS
Induction of Heat Shock Proteins
May 5-May 9
Arranged by Milton J. Schlesinger, Washington University, St. Louis, Alfred Tissieres, University of
Geneva, Michael Ashburner, University of Cambridge
128 participants
This was the first meeting to focus exclusively on heat-shock-induced changes in gene expression. The in-
itial observation that a mild heat shock could dramatically alter an organism's gene activity was reported for
Drosophilia embryos in 1964, but it was not until 1978 that heat-induced changes in protein synthesis pat-
terns were reported for several other organisms. It was the realization that heat-shock effects on gene ex-
pression occurred universally that prompted a call for a meeting that could bring together the diverse
groups of scientists engaged in studies of heat shock. The areas of research ranged from cloning of heat-
shock genes to studies of thermotolerance in heat- and alcohol-stressed tissue culture cells.
The important conclusions reaffirmed the universality of this kind of stress. Several of the major heat-
shock genes and proteins were shown to be strongly conserved in sequence and structure from bacteria to
man, and a region of the gene controlling expression of the major Drosophilia heat-shock gene was
reported to function effectively in mammalian cells and regulate non-heat-shock genes. It was also shown
that a major function of heat-shock proteins was to protect cells from thermal damage, but the biochemical
mechanisms for thermotolerance remain unknown. The 54 papers presented at the meeting were published
by Cold Spring Harbor Laboratory in November 1982 in Heat Shock: From Bacteria to Man.
This meeting was supported by grants from External Research Development, Monsanto Company;
Research Division, Monsanto Agricultural Products Company; National Science Foundation; National In-
stitutes of Health; National Institutes of General Medical Sciences; and Fogarty International Center.
SESSION 1 Introduction and Overview
M. ASHBURNER, Cambridge University, Cambridge, England
M. Ashburner, H.R.B. Pelham
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F. Ritossa, M.J. Schlesinger
SESSION 2 Gene Organization
Chairperson: M. MESELSON, Harvard University, Cambridge, Massachusetts
E. CRAIG, T. INGOLIA, M. SLATER, and L. MANNSEAU, Dept. of Physiological Chemistry, University of Wiscon-
sin, Madison: Drosophila and yeast multigene families related to the major Drosophila heat-shock in-
ducible gene.
I. TOROK,' P.J. MASON,2 F. KARCH,2 I. Kiss,' and A. UDVARDY,1 'Institute of Biochemistry, Hungarian
Academy of Sciences, Szeged; 2Dept. of Molecular Biology, University of Geneva, Switzerland: DNA
sequence analysis of the hsp 70 heat-shock genes in D. melanogaster.
C.G. CoRcEs,1 A. PELLICER,2 R. AXEL,3 and M. MESELSON,3 'Dept. of Biochemistry and Molecular Biology,
Harvard University, Cambridge, Massachusetts; 2Dept. of Pathology, New York University Medical
Center, New York; 3College of Physicians and Surgeons, Columbia University, New York, New York:
Localization of sequences responsible for heat shock-induced transcription.
M.-E. MIRAuLT, Dept. of Molecular Biology, University of Geneva, Switzerland: The mechanism of heat-
shock induction studied by transfection of monkey cells with SV40-derived vectors carrying D.
melanogaster hsp 70 genes.
H.R.B. PELHAM, MRC Laboratory of Molecular Biology, Cambridge, England: Functional analysis of a heat-
shock promoter.
J. La, N. COSTLOW, J. DE BANZIE, D. KNIPPLE, and D. O'CONNOR, Dept. of Molecular and Cell Biology, Cor-
nell University, Ithaca, New York: Structure and expression of Drosophila heat-shock genes cloned in
yeast.
D.B. FINKELSTEIN and S. STRAUSBERG, Dept. of Biochemistry, University of Texas Health Science Center,
Dallas: Expression of a cloned yeast heat-shock gene.
SESSION 3 Chromatin Structure
Chairperson: S. ELGIN, Washington University, St. Louis, Missouri
M.A. KEENED and S.C.R. ELGIN,2 'Dept. of Biochemistry and Molecular Biology, Harvard University, Cam-
bridge, Massachusetts; 2Dept. of Biology, Washington University, St. Louis, Missouri: Perturbations of
chromatin structure associated with gene expression.
C. Wu, NCI, National Institutes of Health, Bethesda, Maryland: An exposed chromatin structure at the 5'
end of Drosophila heat-shock genes.
A. LEVY and M. NOLL, Dept. of Cell Biology, Biozentrum, University of Basel, Switzerland: Chromatin struc-
ture of hsp 70 genes of Drosophila.
L. LEVINGER and A. VARSHAVSKY, Dept. of Biology, Massachusetts Institute of Technology, Cambridge: Selec-
tive arrangement of variant nucleosomes within the genome and the heat-shock response of
D. melanogaster.
J.C. EISSENBERG and J.C. LUCCHESI, Dept. of Zoology, University of North Carolina, Chapel Hill: Chromatin
structure and dosage compensated heat-shock genes in D. pseudoobscura.
R.S. JACK and W.J. GEHRING, Biozentrum, University of Basel, Switzerland: A DNA binding protein from
Drosophila shows specificity for sequences close to heat-shock genes.
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J.R. PELLON,' R.F. GOMEZ,2 and A.J. SINSKEY,1 1Dept. of Nutrition and Food Science, Massachusetts Institute
of Technology, Cambridge; 2Genentech, Inc., San Francisco, California: Association of proteins syn-
thesized during heat shock to the E. coli nucleoid.
M.A. GOROVSKY, C.V. GLOVER, S.D. GUTTMAN, K.J. VAVRA, S. HOROWITZ, and D.S. PEDERSON, Dept. of
Biology, University of Rochester, New York: Stress-induced changes in nuclear proteins of
Tetrahymena.
K. SIROTKIN, Dept. of Microbiology, University of Tennessee, Knoxville: Detection in embryos of the
developmentally regulated transcript in the center of the cluster of small heat-shock genes using end-
labeled DNA and nuclease S1.
SESSION 4 Regulation
Chairperson: A. TISSIERES, University of Geneva, Geneva, Switzerland
T. YAMAMORI, T. OSAWA, T. TORE, K. 1-ro, and T. YURA, Institute for Virus Research, Kyoto University, Japan:
E. coli gene (hin) controls transcription of heat-shock operons and cell growth at high temperature.
F.C. NEIDHARDT, R.A. VAN BOGELEN, and E.T. LAU, Dept. of Microbiology and Immunology, University of
Michigan, Ann Arbor: The high temperature regulon of E. coli.
A.A. TRAVERS, MCR Laboratory of Molecular Biology, Cambridge, England: DNA sequences necessary for
the shutoff of E. coli tyrT transcription at high temperature.
J.J. BONNER, Dept. of Biology, Indiana University, Bloomington: Feedback regulation of the Drosophila
heat-shock response.
R. MORIMOTO, J. SCHAFFER, and M. MESELSON, Harvard Biochemical Laboratories, Cambridge,
Massachusetts: In vitro transcription of Drosophila actin and heat-shock genes in He La cell-free extracts.
J. MOHLER and M.L. PARDUE, Dept. of Biology, Massachusetts Institute of Technology, Cambridge: Genetic
analysis of the region containing the 93 D heat-shock locus.
J.F. BURKE and D. IsH-HoRowicz, Imperial Cancer Research Fund, London, England: Cloning and expres-
sion of a mutant, truncated Drosophila hsp 70 gene.
SESSION 5 Regulation
Chairperson: S. LINDQUIST, University of Chicago, Chicago, Illinois
B.J. DiDomENico, G.E. BUGAISKY, and S. LINDQUIST, Dept. of Biology, University of Chicago, Illinois: Feed-
back regulation in the heat-shock response.
D.G. BALLINGER and M.L. PARDUE, Dept. of Biology, Massachusetts Institute of Technology, Cambridge: The
subcellular compartmentalization of messenger RNAs in heat-shocked Drosophila cells.
C. KROGER and B.J. BENECKE, Dept. of Biochemistry, Ruhr-Universitat, Bochum Federal Republic of Ger-
many: Translation and turnover of Drosophila heat-shock and non-heat-shock mRNA.
M. BIENZ and J.B. GURDON, MRC Laboratory of Molecular Biology, Cambridge, England: The heat-shock
response in Xenopus oocytes is controlled at the translational level.
C.V. GLOVER, Dept. of Biochemistry, Stanford University School of Medicine, California: Rapid
dephosphorylation of ribosomal protein following heat shock of Drosophila tissue culture cells.
V. ERNST, E. ZUKOFSKY BAUM, and P. REDDY, Dept. of Biochemistry, Brandeis University, Waltham,
Massachusetts: Heat-shock, elF-2 phosphorylation, and control of translation in rabbit reticulocytes,
reticulocyte lysates and He La cells.
E. HICKEY and L. WEBER, Dept. of Biology, University of South Florida, Tampa: Preferential translation of
heat-shock mRNAs in He La cells.
SESSION 6 Proteins
Chairperson: M. SCHLESINGER, Washington University, St. Louis, Missouri
M.J. SCHLESINGER, P.M. KELLEY, and C. MALFER, Dept. of Microbiology and Immunology, Washington
University Medical School, St. Louis, Missouri: Properties of three chicken heat-shock proteins and their
antibodies.
W.I. WELCH and J.R. FERAMISCO, Cold Spring Harbor Laboratory, New York: Purification of three mam-
malian stress proteins.
J.M. WILHELM, P. SPEAR, and C. SAX, Dept. of Microbiology, University of Rochester, New York: Heat-shock
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proteins in the protozoan Tetrahymena-Induction by protein synthesis inhibition and possible role in
carbohydrate metabolism.
R.H. BURDON, Dept. of Biochemistry, University of Glasgow, Scotland: Human hsp gene expression and
the modulation of plasma membrane Na +K+ ATPase activity.
H. BIESSMANN,1 F.G. FALKNER,2 H. SAUMWEBER,3 and M.F. WALTER,4 1 Dept. of Genetics, University of Califor-
nia, Davis; 2Dept. of Physiological Chemistry, University of Munich, Federal Republic of Germany;
3Dept. of Biochemistry, University of California, San Francisco; 4Dept. of Zoology, University of
California, Davis: Disruption of the vimentin cytoskeleton may play a role in heat-shock response.
W. YONEMOTO, L.A. LIPSICH, and J.S. BRUGGE, Dept. of Microbiology, State University of New York, Stony
Brook: An analysis of the interaction of the RSV transforming protein, pp605c, with a major heat-shock
protein.
J.J.-C. LIN, W.J. WELCH, J.I. GARRELS, and J.R. FERAMISCO, Cold Spring Harbor Laboratory, New York: The
mammalian 100K heat-shock protein is a Golgi-associated protein.
M.M. SANDERS, Dept. of Pharmacology, UMDNJ-Rutgers Medical School, Piscataway, New Jersey: Heat-
shock histone H2b becomes associated with chromatin and the nuclear matrix in heat shock.
SESSION 7 Inducers
Chairperson: F. RITOSSA, Institute of Genetics, Ban, Italy
L.E. HIGHTOWER1 and F.P. WHITE,2 'Microbiology Section, University of Connecticut, Storrs; 2Faculty of
Medicine, Memorial University of Newfoundland, St. John's, Canada: Preferential synthesis of rat heat
shock and glucose-regulated proteins in stressed cardiovascular cells.
F.P. WHITE and R.W. CURRIE, Faculty of Medicine, Memorial University of Newfoundland, Canada: The in-
duction of a 71 kD protein in various rat organs as a function of postnatal development.
I.R. BROWN and J.W. COSGROVE, Dept. of Zoology, University of Toronto, Canada: Physiologically relevant
increases in body temperature induce the synthesis of a heat-shock protein in mammalian brain and
other organs.
P.M. KELLEY and M. FREELING, Dept. of Genetics, University of California, Berkley: Comparison of maize
anaerobic and heat-shock proteins.
C.H. BUZIN and N. BOURNIAS-VARDIABASIS, Division of Cytogenetics and Cytology, City of Hope Medical
Center, Duarte, California: The induction of a subset of heat-shock proteins by drugs that inhibit differen-
tiation in Drosophila embryonic cell cultures.
G.P. THOMAS, J.I. GARRELS, and M.B. MATHEWS, Cold Spring Harbor Laboratory, New York: Differential in-
duction of HeLa and CEF stress proteins by alternate inducers.
J.R. NEVINS, Rockefeller University, New York: Induction of synthesis of the HeLa cell 70kD heat-shock
protein by the adenovirus El A gene product. -
SESSION 8 Physiological Response
Chairperson: H. MITCHELL, California Institute of Technology, Pasadena, California
H.K. MITCHELL and N.S. PETERSEN, Dept. of Biology, California Institute of Technology, Pasadena: Heat-
shock induction of abnormal morphogenesis in Drosophila.
N.S. PETERSEN and H.K. MITCHELL, Dept. of Biology, California Institute of Technology, Pasadena: Effects of
heat shock on mRNA synthesis, stability, and translation in differentiating Drosophila wings.
W.F. Loomis and S.A. WHEELER, Dept. of Biology, University of California San Diego, La Jolla: The
physiological role of heat-shock proteins in Dictyostelium.
G.C. L1,1 D.C. SHRIEVE,1 and Z. WERB,2 1Dept. of Radiation Oncology; 2Dept. of Anatomy, University of
California, San Francisco: Correlation between synthesis of heat-shock proteins and development of
thermotolerance in Chinese hamster fibroblasts.
J.R. SuBiEcK and J.J. SCIANDRA, Dept. of Radiation Biology, Roswell Park Memorial Institute, Buffalo, New
York: Heat-shock proteins and thermotolerance.
R.R. KLEVECZ,t G.A. KING,' and C.H. BuziN,2 'Division of Biology, City of Hope Research Institute; 2Dept.
of Cytogenetics and Cytology, City of Hope National Medical Center, Duarte, California: Cell-cycle
phase response and the induction of thermotolerance and heat-shock proteins.
J.L. KEY, C.Y. LIN, E. CEGLARZ, Y.M. CHEN, and F. SCHOFFL, Dept. of Botany, University of Georgia, Athens:
Physiological aspects of the heat-shock response in soybean.
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M. ALTSCHULER and J.P. MASCARENHAS, Dept. of Biological Sciences, State University of New York, Albany:
The synthesis of heat-shock and normal proteins at high temperatures in plants.
Posters
G. ALIPERTI and M.J. SCHLESINGER, Dept. of Microbiology and Immunology, Washington University Medical
School, St. Louis, Missouri: Recovery of normal chicken embryo fibroblast mRNAs after heat shock is in-
hibited by actinomycin D and cyclohexamide.
B.G. ATKINSON,' M. SOMERVILLE,' and D.B. WALDEN,' 'Dept. of Zoology and 'Dept. of Plant Sciences,
University of Western Ontario, London, Canada: The effect of heat shock and other stresses on the gene
expression of differentiating myogenic cells.
E. BERGER,' R. IRELAND,' K. SIROTKIN,2 M.A. YUND,3 and D. OSTERBUR,3 'Dept. of Biology, Dartmouth Col-
lege, Hanover, New Hampshire; 'Dept. of Microbiology, University of Tennessee, Knoxville; 3Dept. of
Genetics, University of California, Berkeley: The regulation of small hsp gene activity is under dual
control.
N. BOURNIAS-VARDIABASIS and C.H. BUZIN, Division of Cytogenetics and Cytology, City of Hope Medical
Center, Duarte, California: Mild heat pretreatment protects Drosophila embryonic cells from inhibition
of differentiation caused by hyperthermia.
T. BRADY and M. SORLEY, Dept. of Biological Sciences, Texas Tech University, Lubbock: Chromosomal
binding of pyridoxine (vitamin B6) at the tyrosine aminotransferase (TAT) gene site during heat shock
and pyridoxine-induced gene activation.
P.A. BROMLEY and R. VOELLMY, Dept. of Molecular Biology, University of Geneva, Switzerland: The effect
of a reversible heat shock on the expression of RSV and vesicular stomatitis virus in infected cells.
P.A. BROMLEY and R. VOELLMY, Dept. of Molecular Biology, University of Geneva, Switzerland: Massive
heat-shock polypeptide synthesis in late chicken embryos-A convenient system for the study of protein
synthesis in highly differentiated organisms.
R. CAIZZI, C. CAGGESE, and F. RITOSSA, Institute of Genetics, Bari, Italy: Modifications of the 70K heat shock
protein in Drosophila.
R. CAMATO, L. NICOLE, and R.M. TANGUAY, Dept. of Medicine, Universite Laval, Ste. Foy, Canada: Histone
gene expression and histone modifications during heat shock in Drosophila cells.
A. DANGLI,t C. GROND,2 R. KABISCH,1 and E.K.F. BAu-rz,1 1Molekulare Genetik, Universitat Heidelberg,
Federal Republic of Germany; 'Dept. of Genetics, University of Nijmegen, The Netherlands: Heat-
shock puff 93 D in D. melanogaster-Ultrastructural and immunocytochemical aspects of organization
and homology to other species.
K. DYBVIG, G. ALIPERTI, C.D. CLARK, D. LITEANU, and M.J. SCHLESINGER, Dept. of Microbiology and Im-
munology, Washington University Medical School, St. Louis, Missouri: Cloning of the gene coding for
the 24,000 D heat-shock protein (HSP24) from chicken embryo fibroblasts.
G. GRAZIOSI, F. MICALI, A. Di MARCOTULLIO, A. SAVOINI, F. DE CRISTINI, and R. MARZARI, Institut° di Zoologia
e Anatomia Comparata, Universita di Trieste, Italy: Heat shock of the Drosophila egg-Mortality,
cellular multiplication, DNA replication, and hsp synthesis.
J.J. HEIKKILA, L. GEDAMU, K. IATROU, and G.A. SCHULTZ, University Biochemistry Group, University of
Calgary, Canada: Expression of a set of fish genes following heat or metal ion exposure.
H. IIDA and I. YAHARA, Tokyo Metropolitan Institute of Medical Science, Japan: Durable synthesis of heat-
shock proteins in yeast cells and chicken embryonic cells during entering the resting state.
E.W. KHANDJIAN and H. TORLEZ, Dept. of Molecular Biology, University of Geneva, Switzerland: Mam-
malian "heat-shock" proteins are also induced by viral infection.
J.K.C. KNOWLES and K. HEMMINKI, Dept. of Medical Chemistry and Dept. of Genetics, University of
Helsinki, Finland: Induction of heat-shock puffs in D. hydei salivary gland cells by microinjection of a
chromatin fraction.
S. Kurcrz, L. PETKO, and S. LINDQUIST, Dept. of Biology, University of Chicago, Illinois: Heat-induced genes
of S. cerevisiae.
K.W. LANKS, Dept. of Pathology, State University of New York, Downstate Medical Center, Brooklyn: Heat
shock induces synthesis of the 85K glucose-regulated protein.
W. LEVINSON, G. Li, H. OPPERMAN, D. JOHNSTON, and J. JACKSON, Dept. of Microbiology, University of
California, San Francisco: Chemical induction of heat-shock proteins.
D.L. LOWE, W.D. FULFORD, M.D. PERRY, and L.A. MORAN, Dept. of Biochemistry, University of Toronto,
Ontario, Canada: Heat shock in mouse cells.
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R.E.J. MITCHEL and D.P. MORRISON, Dept. of Radiation Biology, Atomic Energy of Canada Limited, Chalk
River, Ontario: Heat-shock induction of radiation resistance and recombinational repair ability in
S. cerevisiae.
R. MORIMOTO and M. MESELSON, Harvard Biochemical Laboratories, Cambridge, Massachusetts: The hyper-
thermal protective role of the mammalian 68K stress-induced protein.
T.S. NOWAK, JR., W.D. LUST, and J.V. PASSONNEAU, NINCDS, National Institutes of Health, Bethesda,
Maryland: Metabolic correlates of amphetamine-induced hyperthermia in mouse brain.
F.P.A.M.N. PETERS, C.J. GROND, P.A. SONDERMEIJER, and N.H. LUBSEN, Dept. of Genetics, University of Ni-
jmegen, The Netherlands: Chromosomal arrangement of heat-shock locus 2-488 of Drosophila hydei.
I. PLESSET, J.J. Fos, and C.S. MCLAUGHLIN, Dept. of Biological Chemistry, University of California, Irvine:
Heat shock in S. cerevisiae-Quantitation of transcriptional and translational effects.
0. PONGS, W. KOERWER, and A. POETING, Lehrstuhl fur Biochemie, Ruhr-Universifat Bochum, Federal
Republic of Germany: Two small heat-shock proteins are ecdysterone inducible proteins in salivary
glands of D. melanogaster larvae.
C.M. PRESTON and E. NOTARIANNI, Institute of Virology, Glasgow, Scotland: HSV immediate-early polypep-
tides induce heat-shock proteins.
I. RUBIN and H. SWIFT, Dept. of Pathology, University of Chicago, Illinois: Effect of growth conditions and
treatment patterns on the heat-shock response of chick embryo cells.
F. SCHOFFL and J.L. KEY, Dept. of Botany, University of Georgia, Athens: Soybean heat shock-Molecular
studies on mRNAs for a group of heat-shock proteins.
V.F. SEMESHIN, I.E. VLASSOVA, E.M. BARICHEVA, E.S. BELYAEVA, and I.F. ZHIMVLEV, Group of Drosophila
Cytogenetics, USSR Academy of Sciences, Novosibirsk: Development of heat shock puffs in D.
melanogaster.
J.C. SILVER and D. PEKKALA, Dept. of Microbiology, University of Toronto, Canada: Effect of heat shock on
synthesis and phosphorylation of nuclear and cytoplasmic proteins in the fungus Achlya.
R.M. SINIBALDI and P.W. MORRIS, Dept. of Biological Chemistry, University of Illinois Medical Center,
Chicago: D. melanogaster Kc cell heat-shock proteins and the nucleoskeleton.
T.P. SNUTCH and D.L. BAILLIE, Dept. of Biological Sciences, Simon Fraser University, Burnaby, Canada:
Heat-shock induction in C. elegans.
R.M. TANGUAY and M. VINCENT, Dept. of Medicine, University Laval, Ste. Foy, Canada: Intracellular
distribution and modification of cellular and heat-shock proteins during heat shock in Drosophila.
G.P. THOMAS, Cold Spring Harbor Laboratory, New York: Isolation and preliminary characterization of
recombinant phage containing the gene for the human 90K stress protein.
G.P. THOMAS and M.B. MATHEWS, Cold Spring Harbor Laboratory: Alterations in gene expression of HeLa
cells exposed to amino acid analogs.
J. VELAZQUEZ and S.L. LINDQUIST, Dept. of Biology, University of Chicago, Illinois: Studies with monoclonal
antibodies against hsp 70.
R. VOELLMY,1 P. BROMLEY,2 and H.P. KOCHER,3 t Dept. of Biochemistry, University of Miami School of
Medicine, Florida; 'Battelle, Geneva Research Center, Switzerland; 3Dept. of Medical Biochemistry,
University of Geneva Medical Center, Switzerland: Structural similarities between heat-shock proteins
from different eukaryotes.
R. VOELLMY1 and D. RUNGGER,2 'Dept. of Biochemistry, University of Miami School of Medicine, Florida;
2Dept. of Animal Biology, University of Geneva, Switzerland: Heat-induced transcription of Drosophila
heat-shock genes in Xenopus oocytes.
S.C. WADSWORTH, Cell Biology Group, Worcester Foundation for Experimental Biology, Shrewsbury,
Massachusetts: A family of related proteins is encoded by the major Drosophila heat-shock gene family.
D.B. WALDEN,' B.G. ATKINSON,2 C.L. BASZCZYNSKI,1 J. BOOTHE,' and M.W. KLINCK,1 1 Dept. of Plant
Sciences; 'Dept. of Zoology, University of Western Ontario, London, Canada: Temperature shift
response in Zea mays.
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In Vitro Mutagenesis
May 12-May 16
Arranged by Robert Schleif, Brandeis University, David Shortie, State University of New York, Stony
Brook, R. Bruce Wallace, City of Hope Research Institute
198 participants
In 1981 progress in genetic engineering had reached the stage at which the ability to generate closely
related variants of cloned DNA fragments was rate-limiting to the research of many investigators. Conse-
quently, a meeting on the subject of in vitro mutagenesis was organized to bring together scientists active in
the area as well as those interested in the subject.
During the meeting many methods were described for the production of variant DNA molecules by in
vitro manipulations. They ranged from direct chemical synthesis of desired variants to clever schemes for
specifically modifying bases in a small stretch of a cloned DNA segment. The approaches were applied to
a broad range of biological systems and resulted in a meeting unusual in the breadth of its scope. Perhaps
the main lesson of the meeting was that no unique best method for variant generation yet exists. Chemical
synthesis is valuable when the exact sequence of the desired variant is known, but otherwise, approaches
that produce many different types of alteration within small regions are favored.
The subject was of both theoretical and practical interests and a healthy mix of academic and industrial
scientists attended. Reflecting this interest, the meeting was supported by the National Science Foundation
as well as Pfizer, Inc.; New England Biolabs, Inc.; Applied Molecular Genetics; Cetus Corporation; Merck
and Company; Abbott Laboratories, Diagnostics Division; Lilly Research Laboratories; Schleicher and
Schuell, Inc.; and New England Nuclear.
SESSION 1 Chemical Synthesis. I.
Chairperson: M. SMITH, University of British Columbia, Vancouver, Canada
M. SMITH, Dept. of Biochemistry, Faculty of Medicine, University of British Columbia, Vancouver, Canada:
In vitro construction of mutants using oligodeoxyribonucleotides.
L.W. COHEN,' K. ITAKURA,' A.D. RIGGS,' G. DALBADIE-MCFARLAND,2 and J.H. RICHARDS,2 'City of Hope Na-
tional Medical Center, Duarte, California; 2California Institute of Technology, Pasadena: Oligonucleo-
tide-directed mutagenesis as a general and powerful method for studies of protein function.
A.E. GAUTIER,' A.D. CHARLES,' M.D. EDGE,2 and J.R. KNOWLES,' Dept. of Chemistry, Harvard University,
Cambridge, Massachusetts; 21CI Pharmaceutical Division, Cheshire, England: Targeted point mutation
that creates a unique EcoRI site within the signal codons of the 13-lactamase gene without altering en-
zyme secretion or processing.
M. SATO and K. ITAKURA, Dept. of Molecular Genetics, City of Hope Research Institute, Duarte, California:
Simple solid phase method for the synthesis of oligodeoxyribonucleotides.
M. Smith
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D. Shortie, M. Manos C. Tibbetts
R.B. WALLACE,' M. SCHOLD,1 B. CONNER,2 and K. ITAKURA,t 'Dept. of Molecular Genetics; 2Dept. of
Cytogenetics; City of Hope Research Institute, Duarte, California: The use of synthetic DNA for the in-
troduction and identification of site-specific mutations.
J. ESSIGMANN,1 C. GREEN,' E. LOECHLER,2 and K. FOWLER,' Depts. of Nutrition and Food Science; 2Dept. of
Biology; 3Dept. of Chemistry; Massachusetts Institute of Technology, Cambridge: Synthesis of
oligonucleotides containing carcinogen-modified bases and their insertion into viral and plasmid
genomes.
M.J. GAIT, H. MATTHES, M. SINGH, and R.C. TITMAS, MRC Laboratory of Molecular Biology, Cambridge,
England: Total synthesis of short duplex DNA.
SESSION 2 Deletions/Insertions/Fusions. I.
Chairperson: T. SHENK, State University of New York, Stony Brook, New York
D. BOGENHAGEN, Dept. of Pharmacological Sciences, State University of New York, Stony Brook: Control
of transcription of Xenopus 5S RNA genes.
D. GRASS, D. LEWIS, Y.T. Yu, and J. MANLEY, Dept. of Biological Sciences, Columbia University, New York,
New York: Construction of specific deletion mutants to analyze gene expression in DNA tumor viruses.
P. HEARING and T. SHENK, Dept. of Microbiology, State University of New York, Stony Brook: Mutational
analysis of the adenovirus type 5 El A transcriptional control region.
M. JASIN and P. SCHIMMEL, Dept. of Biology, Massachusetts Institute of Technology, Cambridge: Functional
domains in a protein determined by progressive deletions from one end of the gene coding region.
E. Cox and D. HORNER, Dept. of Biology, Princeton University, New Jersey: A structural and functional
analysis of an E. coli mutator, mutD.
G.M. SANTANGELO, J. TORNOW. and C.N. COLE, Dept. of Human Genetics, Yale Medical School, New
Haven, Connecticut: The role of 3"-end signals in gene expression.
F.A. LAsKi,1A. FIRE, R. BELAGAJE,2 U. RAJBHANDARY,1 and P.A. SHARP,' 'Dept. of Biology, Massachusetts In-
stitute of Technology, Cambridge, 2Lilly Research Laboratories, Indianapolis, Indiana: Mutagenesis of a
tRNA gene to an amber suppressor.
SESSION 3 Site-directed Mutagenesis. 1.
Chairperson: D. BOTSTEIN, Massachusetts Institute of Technology, Cambridge, Massachusetts
W.R. FOLK and J. HOFSTETTER,2 1 Dept. of Biological Chemistry, University of Michigan, Ann Arbor;
2lnstitut fur Molekularbiologie II, Universitat Zurich, Switzerland: Nucleotides within the X. laevis tRNA
melt gene required for transcription by RNA polymerase Ill.
L.A. LOEB, R.M. SCHAAPER, and T.A. KUNKEL, Joseph Gottstein Memorial Cancer Research Laboratory,
University of Washington, Seattle: Infidelity of DNA synthesis as a basis of mutagenesis.
D. SHORTLE,1 P. GRISAFI,1 S.J. BENKOVIC,2 and D. BOTSTEIN,1 1 Dept. of Biology, Massachusetts Institute of
Technology, Cambridge; 2Dept. of Chemistry, Pennsylvania State University, University Park: Gap
misrepair mutagenesis with a-thiophosphate nucleotides.
E. LORENSEN and J.W. CHASE, Dept. of Molecular Biology, Albert Einstein College of Medicine, Bronx, New
York: Bisulfite-induced mutations of E. coli single-strand DNA binding protein.
C.-T. CHU, D.M. COEN, S.K. WELLER, and P.A. SCHAFFER, Sidney Farber Cancer Institute, Boston,
Massachusetts: In vitro mutagenesis of herpes simplex virus DNA and DNA fragments-Introduction of
mutations into selected regions of the viral genome.
W.-C. LEUNG, Dept. of Pathology, McMaster University, Hamilton, Canada: In vitro mutants of a herpes
simplex virus regulatory protein ICP4.
K.W.C. PEDEN and D. NATHANS, Dept. of Molecular Biology and Genetics, John Hopkins University School
of Medicine, Baltimore, Maryland: Local mutagenesis within deletion loops of DNA heteroduplexes.
SESSION 4 Allele Replacement-Applications. I.
Chairperson: A. BERK, University of California, Los Angeles, California
V.R. RACANIELLO and D. BALTIMORE, Center for Cancer Research, Massachusetts Institute of Technology,
Cambridge: Studies on poliovirus using an infectious viral cDNA clone.
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C.-J. LAI and M.M. SVEDA, NIAID, National Institutes of Health, Bethesda, Maryland: Requirements for sur-
face expression of the hemagglutinin and the neuraminidase of influenza A virus.
A.J. BERK,' C. MONTELL,' T. OSBORNE,1 D. ROSSER,' E. TYAU,1 D. ARVIDSON,' E. FISHER,' and M. CARUTHERS,'
'Molecular Biology Institute, University of California, Los Angeles; 2Dept. of Chemistry, University of
Colorado, Boulder: Mutagenesis of the adenovirus transforming region.
F. AUSUBEL, W. BUIKEMA, C. EARL, S. GIBBONS, S. LONG, G. RUVKUN, and R. ZUCKERMAN, Dept. of Cellular and
Developmental Biology, Harvard University, Cambridge, Massachusetts: Genetic analysis of symbiotic
nitrogen fixation genes.
M. GRUNSTEIN,' D. KOLODRUBETZ,2 M. RYKOWSKI,2 and J. CHoE,21Molecular Biology Institute; 'University of
California, Los Angeles: A genetic test for the association of histone H2A and H2B subtypes in yeast.
D. SHORTLE and D. BOTSTEIN, Dept. of Biology, Massachusetts Institute of Technology, Cambridge: Directed
mutagenesis of the yeast actin locus-Integrative transformation with actin gene sequences modified in
vitro.
R.J. ROTHSTEIN,' T.L. ORR-WEAVER,' and J.W. SZOSTAK,2 1 Dept. of Microbiology, New Jersey Medical
School, Newark; 2Dept. of Biological Chemistry, Sidney Farber Cancer Institute, Harvard Medical
School, Boston, Massachusetts: Directed integration into the yeast genome.
SESSION 5 Poster Session
S.A. BENNER, K.P. NAMBIAR, J. STACKHOUSE, J. ELDREDGE, and D. STAUFFER, Dept. of Chemistry, Harvard
University, Cambridge, Massachusetts: Structure-function relationships in catalytic proteins-
Ribonuclease.
J.D. BOEKE, M. RUSSEL, and P. MODEL, Rockefeller University, New York: Bisulfite mutagenesis of a signal
peptide coding region by deletion heteroduplexing using the single-stranded DNA bacteriophage f1.
W. BUIKEMA, C. EARL, R. ZUCKERMAN, S. GIBBONS, and F. AUSUBEL, Dept. of Cellular and Developmental
Biology, Harvard University, Cambridge, Massachusetts: Cloning and mapping of symbiotic nitrogen
fixation genes.
S. BUSBY, M. HERBERT, A. KOLB, and H. Buc, Institut Pasteur, Paris, France: Comparison of the binding sites
for the cAMP receptor protein at the galactose and lactose promoters.
M.H. CARUTHERS, P. DE HASETH, R. GOLDMAN, and W. MANDECKI, Dept. of Chemistry, University of Col-
orado, Boulder: Chemical synthesis and biological studies on mutated promoters.
L. DoosoN,1 R. FOOTE,' S. MITRA,2 and W. MASKER,' t University of Tennessee School of Biomedical
Sciences, Oak Ridge; 'Biology Division, Oak Ridge National Laboratory, Tennessee: In vitro site-
specific mutagenesis of bacteriophage T7 DNA with 06-methylguanine.
R.C. HAYES and J.E. LECLERC, Dept. of Biochemistry, University of Rochester School of Medicine and Den-
tistry, New York: A simple method using single-stranded DNA binding protein to preferentially transfect
replicated DNA molecules.
R. SALGANIK, G. DYMSHITZ, and L. FRUMGARTZ, Institute of Cytology and Genetics, Siberian Division of the
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USSR, Academy of Sciences, Novosibirsk: Identification of DNA restricts by complementary polynucle-
otides carrying fluorescent groupings.
M. SATO,' H. TOYODA,1 Y. KAJUMURA,1 S. KAPLAN,' J. SHIVELY,2 R.B. WALLACE,' and K. ITAKURA,1 'Dept. of
Molecular Genetics, 2Division of Immunology, City of Hope Research Institute, Duarte, California: A
screening method using synthetic oligonucleotides as hydridization probes.
N. STOW, M. ANDERSON, J. ENGLER, P. ROSSMAN, and M. ROSSINI, Cold Spring Harbor Laboratory, New York:
Construction and characterization of deletion mutants in early region 1 of adenovirus 2.
R.C. THOMPSON' and M. YARUS,2 tDept. of Chemistry, Temple University, Philadelphia, Pennsylvania;
2Dept. of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder: In vitro
mutagenesis of an anticodon-Replacement of U33, the "Universal U."
C. TIBBETTS, L. KOSTURKO, and C. ROBINSON, Dept. of Microbiology, University of Connecticut School of
Medicine, Farmington: Evolutionary variants of adenovirus type 3 which delimit the DNA sequence re-
quired for left-end polar encapsidation of the viral genome.
J.C. WAY, M.A. DAVIS, D.E. ROBERTS, and N. KLECKNER, Dept. of Biochemistry and Molecular Biology, Har-
vard University, Cambridge, Massachusetts: New tools for transposon mutagenesis in bacteria.
M.J. ZOLLER and M. SMITH, Dept. of Biochemistry, University of British Columbia, Vancouver, Canada: Site-
specific mutagenesis of cloned genes.
SESSION 6 Chemical Synthesis. II.
Chairperson: R.B. WALLACE, City of Hope Research Institute, Duarte, California
J. Rossi,' G. LARSON,' Y. MARUMOT0,1 X. SOBERON,2 and K. ITAKURA,t 'Dept. of Molecular Genetics, City of
Hope Research Institute, Duarte, California; 2lnstituto de Investigaciones Biomedias, Cuidad Univer-
sitario, Mexico: Synthetic oligodeoxyribonucleotide directed site-specific mutagenesis of prokaryotic
and eukarotic regulatory regions.
S.A. NARANG,1 R. BROUSSEAU,1 and R. Wu,2 1Division of Biological Sciences, National Research Council,
Ottawa, Canada; 2Section of Biochemistry, Molecular and Cell Biology, Cornell University, Ithaca,
New York: Detection of a clone containing a single base-pair mutation in synthetic human proinsulin
gene.
H. HSIUNG,t S. INOUYE,' J. WEST) B. STURM,' and M. INOUYE,' 'Lilly Research Laboratories, Indianapolis, In-
diana; 2State University of New York, Stony Brook: Improvements on phosphotriester synthesis of
deoxyribooligonucleotides-Applications to synthesis of oligonucleotide fragments for site-specific
mutagenesis of E. coli prolipoprotein gene.
M. INOUYE,' S. INOUYE,' M. INUKAI,t G. VLASUK,1 J. COLEMAN,' K. ITAKURA,2 and H. HSUING,3 'Dept. of
Biochemistry, State University of New York, Stony Brook: 2Division of Biology, City of Hope Research
Institute, Duarte, California; 'Lilly Research Laboratories, Indianapolis, Indiana: Use of site-specific
mutagenesis for the study of protein secretion and membrane protein assembly.
C.A. BRENNAN and R.I. Gumport, Dept. of Biochemistry and School of Basic Medical Science, University of
Illinois, Urbana: The synthesis of oligodeoxyribonucleotides using T4 RNA ligase.
W.M. BARNES and M. BEVAN, Dept. of Biological Chemistry, Washington University Medical School, St.
Louis, Missouri: Kilo-sequencing-A nonrandom strategy for sequencing large amounts of DNA.
G.G. CARMICHAEL,' B. SCHAFFHAUSEN,2 D. DORSKY,2 D. OLIVER,3 and T.L. BENJAMIN,' 'Dept. of Microbiology,
University of Connecticut Health Center, Farmington; 2Dept. of Pathology; 3Dept. of Microbiology;
Harvard Medical School, Boston, Massachusetts: Studying polyoma virus gene expression and function
by site-directed mutagenesis using synthetic oligonucleotides.
G.F. TEMPLE,' A.M. Dozy,' K.L. RoY,2 and Y.W. KAN,1,3 1 University of California, San Francisco;
2University of Alberta, Edmunton, Canada; 3Howard Hughes Medical Institute, University of California,
San Francisco: Construction of human suppressor tRNA gene-Its potential for gene therapy in (3-
thalassemia.
SESSION 7 Deletions/Insertions/Fusions. II.
Chairperson: F. HURON, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
J. MESSING,' J. VIEIRA,1 and R. GARDNER,2 1 Dept. of Biochemistry, University of Minnesota, St. Paul;
2Calgene, Inc., Davis, California: Codon insertion mutagenesis to study functional domains of 0-
lactamase.
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C. TIBBETTS, S. SHARNICK, and C. GREEN, Dept. of Microbiology, University of Connecticut School of
Medicine, Farmington: Opportunistic diversions-Mutagenesis and gene transfer with closed circular
DNA.
R. HOESS, K. ABREMSKI, and N. STERNBERG, NCI-Frederick Cancer Research Facility, Frederick, Maryland;
Deletion analysis of lox, the recombining site in P1 site-specific recombination.
B. WASYLYK, C. WASYLYK, A. DIERICH, P. AUGEREAU, and P. CHAmBoN, Laboritoire de Genetique Moleculaire
des Eucaryotes, CNRS, and Genie Genetique, INSERM, Strasbourg, France: The role of both upstream
sequences and the "TATA" box from SV40 and conalbumin genes on transcription and gene
expression.
P.F. LAMBERT and R.D. WELLS, Dept. of Biochemistry, University of Wisconsin, Madison: Targeted
mutagenesis at nonunique restriction enzyme sites-Alteration of the bacteriophage G4 ori(-).
D.R. BROWN, T. SCHMIDT-GLENEWINKEL, D. REINBERG, and J. HURWITZ, Dept. of Developmental Biology and
Cancer, Albert Einstein College of Medicine, Bronx, New York: Nucleotide sequences required for in-
itiation of icosahedral phage DNA replication.
M. ROSE and D. BOTSTEIN, Dept. of Biology, Massachusetts Institute of Technology, Cambridge: Analysis of
yeast gene expression by use of lacZ gene fusion.
J.D. BOEKE, Rockefeller University, New York, New York: Deletion and fusion analysis of bacteriophage fl
gene III protein, an integral membrane protein.
K. HORIUCHI, G.P. DOTTO, and K.S. JAKES, Rockefeller University, New York, New York: Deletion mutants
near the origin of DNA replication of bacteriophage fl.
SESSION 8 Site-directed Mutagenesis. II.
Chairperson: L.A. LOEB, University of Washington, Seattle, Washington
T.A. VOLKER,t J. GAFNER,t M.K.S. SHOWE,2 A.U. KUHN,' and T.A. BICKLE,1 'Dept. of Microbiology, Biozen-
trum, University of Basel, Switzerland: 2Waksman Institute of Microbiology, Rutgers University,
Piscataway, New Jersey: Site-directed mutagenesis leads to the discovery of a new, essential T4 head
gene.
S. BUSBY, Institut Pasteur, Paris, France: Transcription initiation in the galactose operon-Dissection of a
complex regulatory region using local mutagenesis.
P. GIZA, D. SCHMIT, and B. MURR, Dept. of Chemistry, John Hopkins University, Baltimore, Maryland:
Mutagenesis of gapped plasmids derived from purified single-stranded restriction fragments.
M.D. TOPAL, D. TOORCHEN, and R. REID, Depts. of Pathology and Biochemistry, University of North
Carolina Medical School, Chapel Hill: Transversion mutations-Induction by purine deoxynucleoside
triphosphates in the syn conformation.
W.A. SAFFRAN, M. GOLDENBERG, C.L. SMITH, and C.R. CANTOR, Dept. of Human Genetics and Development,
Columbia University, New York: Formation and repair of site-specific psoralen crosslinks in plasmid
pBR322.
R.A. ZAKOUR and L.A. LOEB, Gottstein Memorial Cancer Research Laboratory, University of Washington,
Seattle: Infidelity of DNA synthesis as a basis for site-specific mutagenesis.
R. KOSTRIKEN and F. HEFFRON, Cold Spring Harbor Laboratory, New York: Site-directed linker mutagenesis.
J.L. ELIASON and M. PTASHNE, Dept. of Biochemistry and Molecular Biology, Harvard University, Cam-
bridge, Massachusetts: Mutagenesis of the right operator of bacteriophage lambda by nucleotide
misincorporation.
R. CORTESE, C. TRABONI, G. CILIBERTO, and G. CESARENI, European Molecular Biology Laboratories,
Heidelberg, Federal Republic of Germany: A general method to select for mutations in a cloned DNA
segment without a phenotype in E. coli.
SESSION 9 Allele Replacement-Applications. II.
Chairperson: F. AUSUBEL, Harvard University, Cambridge, Massachusetts
S.M. ANDERSON and E.M. SCOLNICK, NCI, National Institutes of Health, Bethesda, Maryland: Construction
of a murine transforming virus containing the src gene of Rous sarcoma virus.
N. MUZYCZKA and D. RAWLINS, Dept. of Immunology and Medical Microbiology, University of Florida,
Gainesville: Construction and characterization of a nonsense mutant in the early region of SV40.
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B. HOWARD and M. GOTTESMAN, NCI, National Institutes of Health, Bethesda, Maryland: XSV2, a plasmid
cloning vector that can be stably integrated in E. coli.
T.A. VOLKER,' S. liDA,2 and T.A. BICKLE,2 'Dept. of Microbiology, Biozentrum, Basel, Switzerland; 2Dept. of
Microbiology, University of Basel, Switzerland: A single gene code for resistance to both chloram-
phenicol and fusidic acid.
G. CHINNADURAI,t K. FUJINAGA,2 T. SHimizu,2 and K. YOSHIDA,2 'Institute for Molecular Virology, St. Louis
University Medical Center, Missouri; 2Cancer Research Institute, Sapporo Medical College, Japan: In-
sertion of a human repeated DNA that resembles transposable elements into an adenovirus type 7
genome.
E.R. KANTROWITZ, R.S. SILVER, and H.W. REED, Dept. of Chemistry, Boston College, Chestnut Hill,
Massachusetts: Isolation of a series of E. coil aspartate transcarbamylase mutants with single amino acid
substitutions.
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RNA Processing
May 19May 23
Arranged by John J. Dunn, Brookhaven National Laboratory, Michael Mathews, Cold Spring Harbor
Laboratory, Joan A. Steitz, Yale University
236 participants
Genetic information flows from DNA to protein via RNA. In recent years it has become increasingly clear
that the role of RNA is far from passive. RNA molecules are synthesized as colinear copies of their genes,
but in many (if not most) instances these primary transcripts are substantially modified before ac-
complishing the functions for which they are designed. These events, collectively termed RNA processing,
are much more than merely cosmetic. They are observed in all organisms so far examined and, in different
cases, are responsible for the conversion of an inactive primary transcript to a functioning product, for
drastically changing its function, or for enhancing its stability. The modifications include alteration of in-
dividual nucleotides, the addition or removal of sequences from one or both ends, and, most surprisingly,
the deletion of a segment from an RNA chain and the rejoining of the flanking regions (splicing).
The field is a dynamic one and interest in it has increased dramatically since the discovery in 1977 that
splicing is involved in the production of most mRNAs of higher cells, and mRNA metabolism figured large-
ly in the meeting. There is much that remains to be learned here, but the shape of things to come was
reflected in the reports of the impressive progress that has been made in defining the detailed maturation of
rRNA and tRNA. Also of particular interest were sessions on the nature of the ribonucleoprotein complexes
and one on a class of small RNA molecules whose functions and properties have recently attracted con-
siderable attention. Providing a backdrop to the meeting as a whole was an enlightening discussion, led by
Uhlenbeck, of the nature of interactions between RNA sequences on the one hand and other RNA se-
quences or proteins on the other.
From a meeting of such broad scope it is difficult to select the high points. The splicing mechanism pro-
pounded by Filipowicz was brought into sharp focus by work on tRNA splicing in Abelson's lab. The role
of a small RNA in tRNA maturation was demonstrated clearly by Altman and Shimura, and the elegant work
presented by Shenk and Walter revealed the function of small RNAs in protein synthesis and secretion. The
idea, offered by Steitz, that small RNAs are involved in mRNA splicing was widely debated but remained
only an attractive hypothesis. Perhaps most striking of all was Chech's report that the splicing of an rRNA
precursor occurs spontaneously and without enzyme mediation.
This meeting was supported by grants from the National Science Foundation, National Institutes of
Health, National Institute of General Medical Sciences, and Fogarty International Center.
Introduction: I.E. DARNELL, Molecular Cell Biology Dept., Rockefeller University, New York, New York:
RNA processing-Accidental discovery to present-day logic.
SESSION 1 Large RNP Particles
Chairperson: R. KORNBERG, Stanford University Medical School, Stanford, California
R. KABISCH,' A. DANGLI,1 K. GRONT,2 and E.K.F. BAUTZ," Institute of Molecular Genetics, University of
M. Matthews, J. Steitz, J. Dunn
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A. Beyer, J. Darnell, E.F.K. Bautz, W. LeStourgeon
Heidelberg, Federal Republic of Germany; 'Laboratory of Genetics, University of Nijmegen, The
Netherlands: Existence of at least two types of nuclear RNP particles in Drosophila.
A. BEYER, Dept. of Biology, University of Virginia, Charlottesville: Ultrastructural analysis of the RNP struc-
ture of nascent adenoviral RNA.
M. JACOB, R. GATTONI, P. KEOHAVONG, and J. STEVENIN, Laboratoire de Genetique Moleculaire des
Eucaryotes, CNRS, Unite 184 de Biologie Moleculaire et de Genie Genetique, INSERM, Strasbourg,
France: Localization of cellular and adenoviral RNA sequences in the two classes of units of hnRNP.
W. J. VAN VENROOIJ and C.A.G. VAN EEKELEN, Dept. of Biochemistry, University of Nijmegen, The
Netherlands: In vivo cross-linking of proteins to RNA by ultraviolet irradiation of intact cells.
T.E. MARTIN, G.P. LESER, and J.M. PULLMAN, Dept. of Biology, University of Chicago, Illinois: Biochemical
and immunological studies of nuclear RNP complexes.
L. LOTHSTEIN,t J.C. WOOLEY,2 S.Y. CHUNG,2 and W.M. LESTOURGEON,' 'Dept. of Molecular Biology, Vander-
bilt University, Nashville, Tennessee; 'Dept. of Biochemical Sciences, Princeton University, New
Jersey: The subunit structure and arrangement of protein and RNA in 40S hnRNP particles.
R. KORNBERG, A.D. LEVINE, R. SPERLING, and J.L. WELIKY, Dept. of Structural Biology, Stanford University
Medical School, California: A unitary structure for hnRNP.
SESSION 2 Small RNAs
Chairperson: J.E. DAHLBERG, University of Wisconsin, Madison, Wisconsin
A. KROL,' C. BRANLANT,1 E. LAZAR,2 H. GALLINARO,2 and M. JACOB,' Institut de Biologie Moleculaire et
Cellulaire; 2Laboratoire de Genetique Moleculaire des Eucaryotes, CNRS, Strasbourg, France: The nu-
cleotide sequences of chicken, rat, and man snRNAs.
C. BRANLANT,' A. KROL,1 E. LAZAR,2 H. GALLINARO,2 and M. JACOB,' 'Institut de Biologie Moleculaire et
Cellulaire; 2Laboratoire de Genetique Moleculaire des Eucaryotes, CNRS, Strasbourg, France: The
snRNA sequences which are good candidates to interact with nuclear proteins or with pre-mRNA.
R. REDDY, D. HENNING, P. EPSTEIN, D. SPECTOR, L. ROTHBLUM, S. CHIRALA, and H. BUSCH, Dept. of Phar-
macology, Baylor College of Medicine, Houston, Texas: Nucleotide sequences of snRNAs, Alu snRNA,
and 8S RNA.
D. TOLLERVEY, D. MALONEY, J.A. WISE, H. SWERDLOW, and C. GUTHRIE, Dept. of Biochemistry and
Biophysics, University of California, San Francisco: Identification of putative snRNAs in yeast.
C. WEINBERGER, R. SCHNEIDER, B. THIMMAPPAYA, and T. SHENK, Dept. of Microbiology, State University of
New York, Stony Brook: What is the function of adenoviral VA RNAs?
E. LUND, J.E. DAHLBERG, R.R. BURGESS, and J.T. MURPHY, University of Wisconsin, Madison: Expression and
possible processing of human U1 snRNA.
Y. OHSHIMA, N. NAGASU, T. TANI, Y. ITOH, N. KOGA, and N. OKADA, Institute of Biological Sciences, Univer-
sity of Tsukuba, Japan: Structure and expression of mammalian snRNA genes.
T. MANSER and R.F. GESTELAND, Howard Hughes Medical Institute, University of Utah, Salt Lake City: Study
of human Ul RNA genes and pseudogenes-Implications regarding the transcription and processing of
the RNA and its role in the creation of Ul pseudogenes.
L. BERNSTEIN, S. VAN ARSDELL, R. DENISON, S. MOUNT, K. MOWRY, and A. WEINER, Dept. of Molecular
Biophysics and Biochemistry, Yale Medical School, New Haven, Connecticut: Genes and pseudogenes
for human snRNA species Ul, U2, and U3-Evidence that cellular RNA molecules are reverse-
transcribed and integrated into new chromosomal sites in germ line DNA.
POSTER SESSION
P.F. AGRIS,1 C.W. GEHRKE,' C. SMITH,' P. THURIAUX,2 W. HEYER,2 and J. KOHu,2 1 University of Missouri, Col-
umbia; 'Institute of General Microbiology, University of Bern, Switzerland: Two mutants of RNA
processing-Identification, analyses, and effect of modification-deficient suppressor tRNA mutations.
A. ALONSO,' M. GREZ,1 G. SCHERER,2 and W. SCHMID,2 'Institute of Experimental Pathology; 'Institute for
Tumor Biology, German Cancer Research Center, Heidelberg, Federal Republic of Germany: The
presence of transcripts from a Alu-related DNA sequence in rat hnRNA and mRNA.
A. BALMAIN, R. KRUMLAUF, K. VASS, and G.D. BIRNIE, Beatson Institute for Cancer Research, Glasgow,
Scotland: The use of a cloned mouse 7S RNA sequence to study the structure, expression, and genomic
organization of 7S RNA in eukaryotic cells.
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F.A. BAUTZ, B. HUGLE, and E. JOCKERS, Institute of Molecular Genetics, University of Heidelberg, Federal
Republic of Germany: Monoclonal antibodies directed against RNP proteins.
B. BHAT and D. APIRION, Dept. of Microbiology, Washington University, St. Louis, Missouri: A genetic ap-
proach to study RNA processing in RNP particles.
S.G. BONITZ,' G. HOMISON,' F.G. NOBREGA,2 B. THALENFELD,' and A. TZAGOLOFF,1 1Dept. of Biological
Sciences, Columbia University, New York, New York; 2lnstituto de Quimica-Bioquimic, CadadeUniversidade, San Paolo, Brazil: Processing of apocytochrome-b precursor RNA in yeast.
S. BONITZ, J. HILL, and B. THALENFELD, Dept. of Biological Sciences, Columbia University, New York, New
York: 5"and 3 'processing of yeast mitochondria! gene products.
D. BOURGAIZE,' C. FARRELL,' J. MILLER,' L.M. Hsu,2 K.H. LANGLEY,3 and M.J. FOURNIER,' 1 Dept. of
Biochemistry, University of Massachusetts, Amherst; 2Dept. of Chemistry, Mount Holyoke College,
South Hadley, Massachusetts; 3Dept. of Physics, University of Massachusetts, Amherst: Physical proper-ties of the E. colt 4.5S RNA-First results suggest a near-perfect hairpin helix.
C. BRANLANT,1 A. KROL,' J.P. EBEL,' K. EDWARDS,2 H. KOSSEL,2 G. VELDMAN,3J. KLOOTWIJK,3 V. DE REGT,3 and
R. PLANTA,3 1 Institut de Biologie Moleculaire et Cellulaire, Strasbourg, France; 2Institut fur Biologie III,
Freiburg, Federal Republic of Germany; 3Biochemisch Laboratorium, Amsterdam, The Netherlands:
The secondary structure of the large rRNA -Implication for rRNA processing.
A. CARRASCO, I. MATTAJ, and E. DE ROBERTIS, Biozentrum, University of Basel, Switzerland: RNA transport in
microinjected frog oocytes.
C.L. CASTIGLIA, G.A. BELTZ, J.J. PLUNKETT, and S.J. FLINT, Dept. of Biochemical Sciences, Princeton Universi-
ty, New Jersey: Effects of adenoviral infection on synthesis and maturation of cellular RNA.
S.Y. CHUNG, R. CONE, L. ZUKERBERG, and J.C. WOOLEY, Dept. ofBiochemical Sciences, Princeton Universi-
ty, New Jersey: snRNP complexes of D. melanogaster.
J.-L. DARLIX and P.-F. SPAHR, Dept. of Molecular Biology, Universityof Geneva, Switzerland: The binding
sites of viral protein P19 onto RSV RNA and possible controls ofviral functions.
N. DELIHAS,1 J. ANDERSEN,' J. VOURNAKIS,2 and W.C. CuR-riss,2 'Dept. of Microbiology, State University of
New York, Stony Brook; 2Dept. of Biology, Syracuse University, New York: Generalized structures for
prokaryotic, eukaryotic, and organelle 5S rRNAs and phylogenetic relationships.
D.T. DUBIN and C.-C. HSUCHEN, Dept. of Microbiology, UMDNJ-Rutgers Medical School, Piscataway,
New Jersey: Terminal sequences of animal cell mitochondrial rRNA.
M.J. FOURNIER,' H. KLEE,' C. FARRELL,' and L.M. Hsu,2 1 Dept. of Biochemistry, University of Massachusetts,
Amherst; 2Dept. of Chemistry, Mount Holyoke College, South Hadley, Massachusetts: Structure of an E.
coil operon containing genes for histidine-, leucine- and proline-tRNAs.
I. GABALDON DE KOCH, H.E. WILK, and K.P. SCHAFb2, Ruhr-Universitat Bochum, Lehrstuhl Biochemie,
Federal Republic of Germany: 40S hnRNP particles in resting and concanavalin A-stimulated lympho
cytes and their association with snRNP particles.
J.R. GREENBERG, Cell Biology Group, Worcester Foundation for Experimental Biology, Shrewsbury,
Massachusetts: A protein associated with mRNA in intact cells is involved in initiation of protein
synthesis.
W. GRUISSEM,' B.M. GREENBERG,2 R.B. HALLICK,2 and D.M. PRESCOTT,' 1 Dept. of Molecular, Cellular, and
Developmental Biology and 2Dept. of Chemistry, University of Colorado, Boulder: Processing of
polycistronic tRNA transcripts from E. coil and Euglena chloroplast tRNA gene clusters in a HeLa cell-free system.
M. GUREVITZ, N. WATSON, and D. APIRION, Dept. of Microbiology, Washington University, St. Louis,Missouri: RNase F, a putative RNA processing endoribonuclease from E. colt that generates 5' hydroxyl
and 3' phosphate at the cleavage site.
J.A. HARDIN, Yale University, New Haven, Connecticut: Systemic lupus erythematosus and the "autoim-
mune" diseases-Clinical, pathophysiologic, and immunologic considerations.
P.C. HEINRICH,' G. KRUPP,2 B. WALCKHOFF,2 B. KUHN,' W. NORTHEMANN,' K. SCHNEIDER,' and H.J. GROSS,2
1Biochemisches Institut, Freiburg; 2Institut fur Biochemie, Wurzburg, Federal Republic of Germany: A
new type of small cytoplasmic RNA from rat liver RNP particles
-Isolation and structure.
M. HINTERBERGER, I. PETTERSSON, and J. STEITZ, Dept. of Molecular Biophysics and Biochemistry, YaleUniversity, New Haven, Connecticut: Fractionation ofsRNP particles and identification of anti-Sm and
anti-(U1)RNP antigens.
L.M. Hsu,' D.A. McKAY,2 and M.H. FOURNIER,2 'Dept. of Chemistry, Mount Holyoke College, South
Hadley, Massachusetts; 2Dept. of Biochemistry, University of Massachusetts, Amherst: Cloning and se-quence analysis of the gene for the 4.5S RNA of E. colt.
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L. IRELAND, J. SZYSZKO, and M.O. KRAUSE, Dept. of Biology, University of New Brunswick, Fredericton,
Canada: Differential patterns in the biosynthesis and turnover of snRNAs in Drosophila lc cells and in
SV40(TsA)-transformed mouse cells.
A. JACOBSON and M. FAVREAU, Dept. of Molecular Genetics and Microbiology, University of Massachusetts
Medical Center, Worcester: Possible involvement of poly(A) in protein synthesis.
S. JAIN, M. GUREVITZ, and D. APIRION, Dept. of Microbiology, Washington University, St. Louis, Missouri: A
small stable RNA with a role in RNA processing.
S. JINKS-ROBERTSON, D.M. BEDWELL, and M. NOMURA, Institute for Enzyme Research, University of Wiscon-
sin, Madison: Regulation of a operon protein synthesis in E. coli.
SESSION 3 Small RNP Particles
Chairperson: H. BUSCH, Baylor College of Medicine, Houston, Texas
J. STEITZ, S. MOUNT, M. HINTERBERGER, I. PETTERSSON, J. RINKE, E. GOTTLIEB, S. WOLIN, M. LERNER, M. ROSA, C.
HASHIMOTO, J. HENDRICK, and C. BERG, Dept. of Molecular Biophysics and Biochemistry, Yale Universi-
ty, New Haven, Connecticut: Studies of small RNPs from mammalian cells.
R. ZELLER, T. NYFFENEGGER, and E.M. DE ROBERT'S, Biozentrum, University of Basel, Switzerland: snRNPs in
frog oocytes.
D.J. FORBES, T.B. KORNBERG, and M.W. KIRSCHNER, Dept. of Biochemistry and Biophysics, University of
California, San Francisco: snRNA in the early Xenopus embryo.
P.F. AGRIS,t Y. KIKUCHI,' H.J. GROSS,' M. TAKANO,1 and G.C. SHARP,' University of Missouri, Columbia;
2University of Wurzburg, Federal Republic of Germany: Biochemical definition of an autoimmune an-
tigenic determinant of a small RNP particle.
S.O. HOCH, P.B. BILLINGS, and P.J. WHITE, Dept. of Cellular Biology, Research Institute of Scripps Clinic, La
Jolla, California: Characterization of RNP complexes recognized by autoimmune sera.
C.S. KINLAW, S.D. SWARTZ, and S.M. BERGET, Dept. of Biochemistry, Rice University, Houston, Texas: Ul
snRNP versus U2 snRNP polypeptides.
J. SRI-WIDADA, C. ASSENS, J.P. LIAUTARD, C. BRUNEL, and P. JEANTEUR, Laboratoire de Biologie Moleculaire et
Laboratoire de Biochimie, Montpellier, France: Fine structure and antigenicity of snRNPs.
J.H. SMITH and G.L. ELICEIRI, St. Louis University School of Medicine, Missouri: Anti-N2,N2,7-trimethyl-
guanosine antibodies as probes for snRNAs and RNPs.
E.D. WIEBEN, S. MADORE, and T. PEDERSON, Cell Biology Group, Worcester Foundation for Experimental
Biology, Shrewsbury, Massachusetts: In vitro assembly of snRNP.
A.M. FRANCOEUR and M.B. MATHEWS, Cold Spring Harbor Laboratory, New York: The lupus antigen, La,
binds the termini of VA RNA and is not required for transcription.
R.H. GROSS and M.S. CETRON, Dept. of Biological Sciences, Dartmouth College, Hanover, New Hamp-
shire: Behavior of liposome-introduced snRNAs in Drosophila cells.
P. THOMPSON, Dept. of Zoology, University of Georgia, Athens: Localization of snRNPs with the Ui splic-
ing function on intact Drosophila chromosomes.
SESSION 4 RNA:RNA and RNA:Protein Interactions
Chairperson: O.C. UHLENBECK, University of Illinois, Urbana, Illinois
I. TINOCO, JR., Laboratory of Chemical Biodynamics, University of California, Berkeley: Can ther-
modynamics be used to predict correct secondary structures in RNA?
H. SWERDLOW and C. GUTHRIE, Dept. of Biochemistry and Biophysics, University of California, San Fran-
cisco: Probing the conformation of spliced tRNA precursors.
H.F. NOLLER,t R.R. GUTELL,1 J. KOP,t and C.R. WOESE,' tThimann Laboratories, University of California,
Santa Cruz; 2Dept. of Genetics and Development, University of Illinois, Urbana: Secondary structures
of rRNAs-Implications for assembly, structure, and function.
P. WOLLENZIEN,1 C. CANTOR,' D. GRANT,' and A. LAMBOWITZ,2 'Dept. of Human Genetics and Develop-
ment, Columbia University College of Physicians and Surgeons, New York, New York; 2Dept. of
Biochemistry, St. Louis University Medical School, Missouri: Structure of the unspliced 35S pre-rRNA in
N. crassa mitochondria detected by psoralen cross-linking.
B.K. KLEIN, T.C. KING, and D. SCHLESSINGER, Division of Biology and Biomedical Sciences, Washington
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University School of Medicine, St. Louis, Missouri: Electron microscopy of secondary structure in E. coli
rRNA and ribosomes.
F.R. KRAMER and D.R. MILLS, Institute of Cancer Research, Columbia University College of Physicians and
Surgeons, New York, New York: Secondary structure formation during RNA synthesis.
F.M. RICHARDS, Dept. of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connec-
ticut: Ribonuclease and catalysis-An early example of a detailed structure for a protein-nucleotide
complex.
P.J. ROMANIUK, J. CAREY, and O.C. UHLENBECK, Dept. of Biochemistry, University of Illinois, Urbana: Single
nucleotide substitution alters the R17 coat-proteinRNA interaction.
POSTER SESSION
A. JOACHIMIAK, V. KLINGHOFER, E.J. ACKERMAN, and P.B. SIGLER, Dept. of Biophysics and Theoretical Biology,
University of Chicago, Illinois: Nucleotides involved in the photo-induced covalent joining of E. coli
tRNATYr2 with E. coil TyrtRNA synthetase.
P.F. JOHNSON and J. ABELSON, Dept. of Chemistry, University of California San Diego, La Jolla: A role for the
intervening sequence in the biosynthesis of yeast tyrosine tRNA.
R. JOVE and J.L. MANLEY, Dept. of Biological Sciences, Columbia University, New York: mRNA processing
at the 5 'end-Methylation of the cap structure as required for protective transcription initiation.
J.M. KEITH, M. CASTLE, D. GALER, and L. WESTREICH, New York University, New York: mRNA biosynthesis-
Initiation of transcription and post-transcriptional modification.
A.K. KINNIBURGH,11 L.E. MAQUAT,1 T. SCHEDL,1 E.A. RACHMILEWITZ,2 and J. Ross,' 1McArdle Laboratory for
Cancer Research, University of Wisconsin, Madison; 2Dept. of Hematology, Hadassah University Hos-
pital, Jerusalem, Israel: Unstable 0-globin mRNA in mRNA-deficient (3° thalassemia.
R. LAST and J.L. WOOLFORD, Dept. of Biological Sciences, Carnegie-Mellon University, Pittsburgh, Penn-
sylvania: Cloning and characterization of genes implicated in processing of ribosomal protein mRNAs in
S. cerevisiae.
C. LAWRENCE, Dept. of Cell Biology, Baylor College of Medicine, Houston, Texas: Effect of adenovirus-2 in-
fection on nuclear matrix.
R. MACKAY, Dept. of Biochemistry, Dalhousie University, Halifax, Canada: Hypothesis concerning the role
in 5S rRNA function of helices containing looped-out nucleotide residues.
E.C. MARIMAN and W.J. VAN VENROOIL Dept. of Biochemistry, University of Nijmegen, The Netherlands:
Adenoviral hnRNA is associated with the host nuclear matrix during processing.
E.S. MAXWELL and T.E. MARTIN, Dept. of Biology, University of Chicago, Illinois: Complementarity of se-
quences in low-molecular-weight RNAs to regions of mRNAs and rRNAs.
P. McGRAw and A. TZAGOLOFF, Dept. of Biological Sciences, Columbia University, New York, New York:
A nuclear gene product required for processing the apocytochrome-b transcript.
A. MICZAK and D. APIRION, Dept. of Microbiology, Washington University, St. Louis, Missouri: A new gene
that affects endonucleolytic RNA processing in E. coll.
K.S. MILLER1'2 and A.G. SAPONARA,1 1Los Alamos National Laboratory, New Mexico; 2Lindsley F. Kimball
Research Institute of the New York Blood Center, New York: Small RNA containing RNPs from
cytoplasmic and nuclear extracts of CHO cells.
G. MORRIS, D. BROWN, C. CARD, and W.F. MARZLUFF, Dept. of Chemistry, Florida State University,
Tallahassee: Organization and expression of sea urchin snRNAs.
C.M. NEBIOLO and G.H. DIXON, Dept. of Medical Biochemistry, University of Calgary, Canada:
Characterization and subcellular localization of low-molecular-weight RNAs in developing trout testis.
L.K. PAPE,' S.G. BONITZ,2 C.L. DIECKMANN,1 J.E. HILL,' G. HOMISON,1 P. McGRAw," B.E. THALENFELD,3 and A.
TZAGOLOFF,1 'Dept. of Biological Sciences, Columbia University, New York, New York; 2Genentech,
South San Francisco, California; 3Enzo Biochem, Inc. New York, New York: Processing of S. cerevisiae
mitochondria) mRNAs.
B. PRAGAI, M. GUREVITZ, and D. APIRION, Dept. of Microbiology, Washington University, St. Louis,
Missouri: Processing of RNA from the T4 tRNA cluster by host enzymes.
M. ROY, B. SINGH, A. RAY, B. RAY, and D. APIRION, Dept. of Microbiology, Washington University Medical
School, St. Louis, Missouri: Processing of rRNA by ribonuclease E.
0. SAMARINA, 0. BORISOVA, and A. KRICHEVSKAYA, Institute of Molecular Biology, Academy of Sciences of
the USSR, Moscow: Physical properties of nuclear hnRNP particles-Evidence in favor of surface
localization of RNA.
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0. SAMARINA, I. LEKACH, and A. RYSKOV, Institute of Molecular Biology, Academy of Sciences of the USSR,
Moscow: The sequences B1 and B2 in hnRNA, cytoplasmicpoly(AU and polysomal poly(A)-containing
RNAs.
K. SCHERRER, Institut de Recherche Biologie Moleculaire, Paris, France: Globin pre-mRNA processing in
normal and AEV-transformed avian erythroblasts.
J.C. SCHMIT,1 T.J. SEB0,1 and P.J. RUSSELL,' t Dept. of Chemistry and Biochemistry, Southern Illinois Univer-
sity, Carbondale; 'Reed College, Portland, Oregon: rRNA processing in N. crassa.
B. SETYON0,1 J. VAN STEEG,2 C. VAN DER MAST,' M. KASPERAITIS,2 M. SALIMANS,2 and H.O. VooKmA,21Institute
of Biology, University of Stuttgart, Federal Republic of Germany; 2Molecular Cell Biology Dept., State
University of Utrecht, The Netherlands: RNA-protein interaction-Ultraviolet crosslinking in vitro of
eukaryotic initiation factors (elFs) to mRNA and rRNA.
A. SOLARI and M.P. DEUTSCHER, Dept. of Biochemistry, University of Connecticut Health Center, Farm-
ington: Subcellular localization of the tRNA processing enzyme, tRNA nucleotidyltransferase, in
Xenopus oocytes and in somatic cells.
M.J.R. STARK,' R.L. GOURSE,1 D.L. THURLOW,2 R.J. GREGORY,' R.A. ZIMMERMANN,2 and A.E. DAHLBERG,'
'Section of Physiological Chemistry, Brown University, Providence, Rhode Island; 2Dept. of Bio-
chemistry, University of Massachusetts, Amherst: Site-specific mutations in E. coli 16S rRNA that perturb
the binding of ribosomal proteins.
J. STEVENIN, P. KEOHAVONG, R. GATTONI, and M. JAcoB, Laboratoire de Genetique Moleculaire des
Eucaryotes, CNRS, Unite 184 de Biologie Moleculaire et de Genie Genetique, INSERM, Strasbourg,
France: A specific test of ligation for the analysis of in vivo and in vitro splicing of pre-mRNA.
1.0. THOMAS, RAZIUDDIN, and W. SZER, Dept. of Biochemistry, New York University School of Medicine,
New York: The hnRNPs from brine shrimp, beef, and wheat both unwind and condense single-stranded
nucleic acids.
N.S.B. THOMAS, P.D. BUTCHER, and H.R.V. ARNSTEIN, Dept. of Biochemistry, King's College, London,
England: The importance of eukaryotic mRNA-RNP interaction in protein synthesis. I. Discovery of a
role for a rabbit reticulocyte polysomal mRNP in the formation of the 40S-mRNA preinitiation complex.
P. THOMAS and R. REEDER, Fred Hutchinson Cancer Research Center, Seattle, Washington: Nucleolar an-
tibodies from patients with scleroderma recognize a novel small RNP complex.
J.F. THOMPSON and J.E. HEARST, Dept. of Chemistry, University of California, Berkeley: Function and struc-
ture of E. coli 16S rRNA probed by psoralen photochemistry.
P. THOMPSON, Dept. of Zoology, University of Georgia, Athens: The immunofluorescent labeling of the
Drosophila 5S rRNA locus and an associated nucleolus with lupus serum against La snRNPs.
A. VINCENT and K. SCHERRER, Institut de Recherche Biologie Moleculaire, Paris, France: Biological activity
and structure of mRNP complexes.
G. WESTIN, H.-I. MONSTEIN, J. ZABIELSKI, K. HAMMERSTROM, L. PHILIPSON, and U. PETTERSSON, Biomedical
Center, Uppsala University, Sweden: Genes and pseudogenes for human snRNAs.
H.E. WILK, G. ANGELI, and K.P. SCHAFER, Abteilung Chemie, Ruhr-Universitat Bochum, Federal Republic of
Germany: In vitro reconstitution of RNP particles containing 30S hnRNP proteins and exogenous RNAS.
J.A. WISE and C. GUTHRIE, Dept. of Biochemistry and Biophysics, University of California, San Francisco: Ef-
fects of rnal and rna2 mutations on small RNAs in yeast.
S.B. ZAIN,' R. CHANDA,1 N. STow,2 and C.M. I. AHMED,' 'Microbiology and Cancer Center, University of
Rochester Medical Center, New York; 2lnstitute of Virology, Glasgow, Scotland: mRNA processing
from early gene block III of adenovirus 2.
M. ZASLOFF,' M. ROSENBERG,' D. HAMER,' and T. SANTOS,' "NIADDK and 2NCI, National Institutes of
Health, Bethesda, Maryland: Transcription and precursor processing of normal and mutant human in-
itiator methionine tRNA genes.
G. ZIEVE, Center for Cancer Research, Massachusetts Institute of Technology, Cambridge: Progressive
association of snRNA species C and D with the cytoplasmic and nuclear skeleton.
SESSION 5 tRNA Processing
Chairperson: C. GUTHRIE, University of California, San Francisco, California
L. COOLEY, B. APPEL, and D. Son, Dept. of Molecular Biophysics and Biochemistry, Yale University, New
Haven, Connecticut: The 5' terminus of mature histidine tRNA species is formed by posttranscriptional
nucleotide addition.
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M. BAER,' H. DONIS-KELLER,2 P. FURDON,1 C. GUERRIER-TAKADA,1 R. REED,' and S. ALTMAN,' 'Dept. of
Biology, Yale University, New Haven, Connecticut; 2Biogen, Cambridge, Massachusetts: Structure and
function of RNase P from E. coll.
P.Y. SHIMURA, N. KIMURA, F. NAGAWA, N. NAKAJIMA, H. SAKAMOTO, and J. OZEKI, Dept. of Biophysics, Kyoto
University, Japan: Structure and function of the RNA component of ribonuclease P.
N.C. MARTIN, D.L. MILLER, T.A. VIDA, and N.A. DOBRIAN, Division of Molecular Biology, University of Texas
Health Science Center, Dallas: Is an RNase P required for mitochondrial tRNA biosynthesis?
A.K. HOPPER,' N.C. MARTIN,' N.S. ATKINSON,' and A. FURUKAWA,' 'Hershey Medical Center, Pennsylvania;
2University of Texas Health Science Center, Dallas: Mutations of yeast affecting tRNA synthesis.
C.L. PEEBLES,' P. GEGENHEIMER,2 and J.ABELsoN,2 'Dept. of Biological Sciences, University of Pittsburgh,
Pennsylvania; 2Dept. of Chemistry and Agouron Institute, University of California, San Diego, La Jolla:
Enzymatic mechanism of pre-tRNA splicing-Cleavage by the purified splicing RNase of yeast produces
phosphatase-resistant "3"" termini.
P. GEGENHEIMER, C.L. PEEBLES, C. GREER, R.C. SCHWARTZ, and J.N. ABELSON, Dept. of Chemistry, University of
California, San Diego, La Jolla: Formation of a novel phosphodiester bond by tRNA-splicing ligases from
yeast and wheat germ.
D.S. COLBY and C. GUTHRIE, Dept. of Biochemistry, University of California, San Francisco: In vivo process-
ing pathway of wild-type and mutant yeast tRNATYr.
M.P. DEUTSCHER, G. ADAM!, P. ROY, and R. ZANIEWSKI, Dept. of Biochemistry, University of Connecticut
Health Center, Farmington: E. coli exoribonucleases and their roles in tRNA processing.
T. BARKAY,' A. GOLDFARB,2 and V. DANIEL,' 'Dept. of Biochemistry, Weizmann Institute of Science,
Rehovot, Israel; 2College of Physicians and Surgeons, Columbia University, New York: An E. coil en-
doribonuclease responsible for primary cleavage of tRNA precursors.
F.J. SCHMIDT, K. LEE, H. MOTAMEDI, and L. NICHOLS, Dept. of Biochemistry, University of Missouri, Colum-
bia: Cloning and characterization of an RNA component of E. coif RNase P.
SESSION 6 rRNA Processing
Chairperson: N.R. PACE, University of Colorado Medical School, Denver, Colorado
D.A. STAHL,' B. PACE,' and N.R. PACE,1.2 National Jewish Hospital and Research Center, Denver, Col-
orado; 2University of Colorado Health Sciences Center, Denver: The RNP substrate for an rRNA-
processing endonuclease.
L.H. BOWMAN, G.I. GOLDBERG, W.E. GOLDMAN, and D. SCHLESSINGER, Division of Biology and Biomedical
Sciences, Washington University School of Medicine, St. Louis, Missouri: Processing of pre-rRNA in
cultured mouse cells.
R.J. CROUCH, P. EARL, S. KANAYA, and R. FELDMANN, National Institutes of Health, Bethesda, Maryland: Pro-
cessing of chick rRNA-Conversion of 32S RNA to 5.8S rRNA and 285 rRNA.
M.F. TRENDELENBURG,' W.W. FRANKE,' and M.L. BIRNSTIEL,2 'Institute of Cell and Tumor Biology, German
Cancer Research Center, Heidelberg, Federal Republic of Germany; 2lnstitute of Molecular Biology II,
University of Zurich, Switzerland: Ultrastructure of initiation and termination sites of Xenopus rDNA
transcription and of filament associations of pre-RNP particles.
T. Martin
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D. Schlessinger, A. Tissieres Y. Shimura
R.J. PLANTA, J. KLOOTWIJK, and G.M. VELDMAN, Biochemisch Laboratorium, Vrije Universiteit, Amsterdam,
The Netherlands: Processing of yeast rRNA precursor.
K. KRUGER, P. GRABOWSKI, A. ZAUG, S. BREHM, and T.R. CECH, Dept. of Chemistry, University of Colorado,
Boulder: Autoexcision and autocyclization of the intervening sequence of the Tetrahymena rRNA
precursor.
H. KOSSEL, K. EDWARDS, W. KOCH, P. LANGRIDGE, Z. SCHWARZ, G. STRITTMATTER, and G. ZENKE, Institute fur
Biologie III, Universitat Freiburg, Federal Republic of Germany: The rRNA operon and its flanking tRNA
genes from Zea mays chloroplasts.
A. LAMBOWITZ," H. BERTRAND,' P. BRIDGE,' R. COLLINS,' G. GARRIGA,1 and D. GRANT,' 'Dept. of Biochem-
istry, St. Louis University Medical School, Missouri; 2Dept. of Biology, University of Regina, Canada:
RNA splicing in Neurospora mitochondria.
A.E. DAHLBERG, M.J.R. STARK, and R.L. COURSE, Section of Physiological Chemistry, Brown University, Pro-
vidence, Rhode Island: Effects of site-directed mutations on processing of 16S and 23S rRNA.
S. JAIN and D. APIRION, Dept. of Microbiology, Washington University Medical School, St. Louis, Missiouri:
A "processome"-A processor nightmare or pipedream.
SESSION 7 mRNA Splicing
Chairperson: J. FLINT, Princeton University, Princeton, New Jersey
C.L. DIECKMANN and A. TZAGOLOFF, Dept. of Biological Sciences, Columbia University, New York, New
York: DNA sequence of a nuclear gene involved in the processing of the mitochondria! apocytochrome
b gene.
P.Q. ANZIAN0,1 M.L. HALDI,1 M.R. LAMB,2 H.R. MAHLER,2 and P.S. PERLMAN,' 'Dept. of Genetics, Ohio State
University, Columbus; 2Dept. of Chemistry, Indiana University, Bloomington: cis-acting point muta-
tions that block RNA splicing in yeast mitochondria.
P.S. PERLMAN,' H.R. MAHLER,2 P.Q. ANZIAN0,1 M.R. LAMB,2 D.K. HANSON,2 and M.A. NICHOLAS,' 'Dept. of
Genetics, Ohio State University, Columbus; 2Dept. of Chemistry, Indiana University, Bloomington:
trans-acting point mutations that block RNA splicing in yeast mitochondria.
B. WIERINGA, F. MEYER, J. REISER, T. KOHNE, and C. WEISSMANN, Institut fur Molekularbiologie I, Universitat
Zurich, Switzerland: Splicing of transcripts from rabbit 0-globin genes modified in vitro.
C. BENYAJATI, NCI, Frederick Cancer Research Facility, Maryland: Deletions splitting the GT- and AG-
mRNA splice sites cause an adh-mRNA-negative phenotype in Drosophila.
D. GAti.wrtz, W. NELLEN, and C. LANGFORD, Institut fur Physiologische Chemie I, Universitat Marburg,
Federal Republic of Germany: Requirements for mRNA splicing and splicing selectivity in yeast.
H. Esumi,1 Y. TAKAHASHI,' R. MAKINO,t S. SATO,' S. NAGASE,2 and T. SUGIMURA,1 'National Cancer Center
Research Institute; 'Sasaki Institute, Tokyo, Japan: An intron mutation at a splicing junction blocks albu-
min mRNA splicing in analbuminemic rats.
M. ROSBASH, N. ABOVICH, T. LIN, J. RODRIGUEZ, and J. TEEM, Rosenstiel Research Center, Brandeis Universi-
ty, Waltham, Massachusetts: Effect of the temperature-sensitive mutation rna2 on splicing.
V.E. AVVEDIMENTO1 and B. DE CROMBRUGGHE,2 1C.E.O.S. CNR Instituto di Patologia Generale, Naples, Ita-
ly; 2NCI, National Institutes of Health, Bethesda, Maryland: Splicing pathway in a segment of the chick
collagen gene.
R. ZIELINSKI, S. KAMIJO, and P. LIZARD!, Rockefeller University, New York, New York: Multiple sites for splic-
ing in the intervening sequence of fibroin mRNA.
T. CREFELD, N. HERNANDEZ, K. SASS, A. SERGEANT, D. SOLNICK, B. WEINGARTNER, and W. KELLER, Institute of
Cell and Tumor Biology, German Cancer Research Center, Heidelberg, Federal Republic of Germany:
Transcription and processing of mRNAs in vitro.
R. KOLE and S.M. WEISSMAN, Dept. of Human Genetics, Yale University School of Medicine, New Haven,
Connecticut: Accurate splicing of human 13-globin mRNA in vitro.
SESSION 8 mRNA Processing
Chairperson: H.D. ROBERTSON, Rockefeller University, New York, New York
J.J. DUNN, A.H. ROSENBERG, and F.W. STUDIER, Dept. of Biology, Brookhaven National Laboratory, Upton,
New York: RNase-III cleavage sites in bacteriophage T7 RNA.
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Y. FURUICHI, R. SMITH, M. YAMAKAWA, and A.J. SHATKIN, Roche Institute of Molecular Biology, Nutley, New
Jersey: Biosynthesis of G(5')pppp(5')G and G(5')pppp(5')A and effects on in vitro transcription by
double- stranded RNA viruses.
R.M. KRUG, I. ULMANEN, J. BRAAM, and B. BRONI, Molecular Biology and Genetics Unit, Memorial Sloan-
Kettering Cancer Center, New York: Influenza viral mRNA synthesis-The role of individual viral pro-
teins in cap recognition, transcription initiation, and elongation.
T.W. NILSEN) P.A. MARONEY,1 C. BAGLIONI,t and H. ROBERTSON,' 1Dept. of Biological Sciences, State
University of New York, Albany; 'Rockefeller University, New York, New York: Is the 2; 5"oligo(A)-
activated endonuclease involved in mRNA processing?
J.C. ALWINE, University of Pennsylvania, Philadelphia: Evidence that the SV40-associated small RNA is syn-
thesized by specific cleavage from large viral transcripts.
W. FILIPowicz,1,2 M. KONARSKA,1 H.J. GROSS,' and A.J. SHATKIN,2 'Institute of Biochemistry and Biophysics,
Polish Academy of Sciences, Warsaw; 2Roche Institute of Molecular Biology, Nutley, New Jersey;
3lnstitut ftir Biochemie, WUrzburg, Federal Republic of Germany: RNA ligase activities in extracts of
plant and animal cells.
C. GREER, P. GEGENHEIMER, R.C. SCHWARTZ, C.L. PEEBLES, and J.N. ABELSON, Dept. of Chemistry, University of
California, San Diego, La Jolla: Mechanism of ligation during tRNA splicing.
A.D. BRANCH and H.D. ROBERTSON, Rockefeller University, New York, New York: RNA processing of plant
viroid RNA as a model system for eukaryotic RNA splicing.
I. WINICOV and J.D. BUTTON, Dept. of Biochemistry, University of Nevada, Reno: Nuclear ligation of 50H
polynucleotide kinase products in endogenous RNA.
168
RNA Tumor Viruses
May 26-May 30
Arranged by Erwin Fleissner, Memorial Sloan-Kettering Cancer Center, Hidesaburo Hanafusa, Rockefeller
University
436 participants
This was the seventh meeting devoted to discussion of progress in RNA tumor virus research. The meeting's
continuing popularity is reflected by the increase in attendance and number of presentations.
Many speakers talked of efforts to construct vectors derived from retrovirus sequences and incorporation
of various eukaryotic genes in the retrovirus genome. Sequence determination of v-onc genes has been ex-
tended to many strains of virus, and from these analyses have emerged unexpected similarities among
several oncogenes, particularly those encoding protein kinases, suggesting the existence of a family of
genes. The relationship between cellular and viral oncogenes was also discussed. Identification of cellular
oncogenes and their activation by promoter insertion reported at last year's meeting suggested the involve-
ment of oncogene activation in human cancer. Several reports this year described the elevated expression
of cellular oncogenes in human tumor tissues. One exciting discovery related to this topic was the iden-
tification of human cellular transforming genes detected by transfection to 3T3 cells as cellular ras" and
rasK genes. This was the first demonstration that the oncogenes originally identified in the viral genome are
involved in human cancer. Human adult T-cell leukemia virus was the retrovirus isolated recently from
human leukemic patients. In addition to further biological characterization, a molecular clone of this
leukemia virus was reported and some unique features of the genome of the first human retrovirus were
described.
This meeting was supported in part by the Cancer Center Grant to Cold Spring Harbor Laboratory from
the National Cancer Institute, National Institutes of Health.
SESSION 1 Reconstructed Viral Genomes
Chairperson: J.M. COFFIN, Tufts University School of Medicine, Boston, Massachusetts
A. PERKINS, P. KIRSCHMEIER, S. GATTONI-CELLI, and I.B. WEINSTEIN, Dept. of Human Genetics and Develop-
ment and Cancer Center, Columbia University, New York, New York: Development of a new transfec-
tion vector containing LTR sequences.
E. GILBOA, J. PARK, S. HWANG, and M. KOLBE, Dept. of Biochemical Sciences, Princeton University, New
Jersey: Transduction and expression of nonselectable genes using retrovirus-derived vectors.
M. KRIEGLER, C.F. PEREZ, and M. BOTCHAN, Dept. of Molecular Biology, University of California, Berkeley:
Construction and analysis of Ha-MSV/SV40 hybrid retrovirus proviruses-Biological activities and struc-
tural analysis.
B. MERMER, M. MALAMY, and J.M. COFFIN, Dept. of Molecular Biology and Microbiology, Tufts University
Vannevar Bush Lecture Hall on left, Blackford Hall on right. Tents on rear lawn provided outdoor dining area.
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School of Medicine, Boston, Massachusetts: RSV DNA as a bacterial gene-Synthesis and processing of
gag-related proteins.
I.S.Y. CHEN, S. WATANABE, K. SHIMOTOHNO, and H.M. TEMIN, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: Mapping the regions of reticuloendotheliosis viruses necessary for
encapsidation of virus and expression of eukaryotic genes.
R. MANN, R. MULLIGAN, and D. BALTIMORE, Center for Cancer Research, Massachusetts Institute of
Technology, Cambridge: A Mo-MLV mutant that cannot package its own RNA.
J.J. KOPCHICK and D.W. STACEY, Roche Institute of Molecular Biology, Nutley, New Jersey: Localization and
biological analyses of genetic lesions in cloned retroviral DNA.
M.L. MCGEADY, R. ASCIONE, G.F. VANDE WOUDE, NCI, National Institutes of Health, Bethesda, Maryland:
The effect of methylation on the transforming ability of MoSV.
S.M. ANDERSON and E.M. SCOLNICK, NCI, National Institutes of Health, Bethesda, Maryland: Construction
of a murine transforming virus containing the src gene of RSV.
L.-H. WANG and C. GRANDORI, Rockefeller University, New York, New York: Replicative function and site
of integration affect transcription and processing of ASV mRNAs.
J. SORGE and S.H. HUGHES, Cold Spring Harbor Laboratory, New York: The splicing of intervening se-
quences introduced into an infectious retrovirus vector.
E. HUNTER,' G. DAVIS,' M. HARDWICK,' G. DAVIS,' M.J. GETHING,2 and J. SAMBROOK,2 'Dept. of
Microbiology, University of Alabama, Birmingham; 2Cold Spring Harbor Laboratory, New York: Expres-
sion of the RSV env gene products from an SV40-RSV hybrid vector.
SESSION 2 Oncogenes
Chairperson: I.M. VERMA, The Salk Institute, San Diego, California
J.Y.J. WANG, S. GOFF, C. QUEEN, and D. BALTIMORE, Center for Cancer Research, Massachusetts Institute of
Technology, Cambridge: Structure and function of the Abelson virus transforming gene and its normal
cellular homolog.
T. TAKEYA and H. HANAFUSA, Rockefeller University, New York, New York: Comparison of DNA sequences
of the src genes of two strains of ASV and the cellular homolog.
R.C. PARKER, R. SWANSTROM, H.E. VARMUS, and J.M. BISHOP, Dept. of Microbiology and Immunology,
University of California, San Francisco: Cellular gene capture by retroviruses-Evidence for involvement
of DNA recombination.
M. YOSHIDA,' N. KITAMURA,' K. TOYOSHIMA,2, Y. HIRAYAMA,1 and A. KITAMURA,1 'Cancer Institute, Kami-
Ikebukuro, Toshima-ku, Tokyo; 2lnstitute for Medical Sciences, University of Tokyo, Japan: Nucleotide
sequence of ASV Y73-Similarity of its transforming gene product to that of RSV.
M. SHIBUYA and H. HANAFUSA, Rockefeller University, New York, New York: Similarities exist between
transforming genes of RSV and FSV in nucleotide and amino acid sequences.
C. VAN BEVEREN, F. VAN STRAATEN, T. CURRAN, and I.M. VERMA, Tumor Virology Laboratory, Salk Institute,
San Diego, California: A novel oncogene (fos) of an osteosarcoma virus-Complete molecular analysis.
K.H. KLEMPNAUER," T.J. GONDA,2 and J.M. BISHOP,' 'Dept. of Microbiology and Immunology, University of
California, San Francisco; 2Ludwig Institute for Cancer Research, Victoria, Australia: Nucleotide se-
quence of the oncogene of AMV and its cellular homolog.
E.P. REDDY, K. REYNOLDS, D.K. WATSON, J. LAUTENBERGER, and T. PAPAS, NCI, National Institutes of Health,
Bethesda, Maryland: Nucleotide sequence analysis of the AMV (MC29).
Y. Li, C. MAGARIAN and E. STAVNEZER, Graduate School of Medical Sciences, Sloan-Kettering Institute, New
York, New York: The SKVs have a unique transforming gene.
P. BESMER,1 H.W. SNYDER, JR.,' J.E. MURPHY,' M.C. SINGHAL,' W.D. HARDY JR.,' and A. PARODI,2 1MeMOrial
Sloan-Kettering Cancer Center, New York, New York: 2Ecole Nationale Veterinaire, Maisons, Alfort,
France: P1-FeSV-Biological and biochemical characterization.
S. JOSEPHS, R. DALLA-FAVERA, E.P. GELMANN, R.C. GALLO, and F. WONG-STAAL, NCI, National Institutes of
Health, Bethesda, Maryland: Nucleotide sequence of the transforming gene (v-sis) of SSV and com-
parison with 5' human c-sis sequences.
S.G. DEVARE, P.E. REDDY, K.C. ROBBINS, P.R. ANDERSON, S.R. TRONICK, and S.A. AARONSON, NCI, National
Institutes of Health, Bethesda, Maryland: Nucleotide sequence of the transforming gene of SSV.
N.R. RICE,' R.R. HIEBSCH,1 R.M. STEPHENS,' H.R. BOSE,2 and R.V. GILDEN,1 NCI- Frederick Cancer Research
Facility, Frederick, Maryland; 2Dept. of Microbiology, University of Texas, Austin: Sequence analysis of
the rel gene of reticuloendotheliosis virus.
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SESSION 3 Poster Session: Provirus Structure and Function
J.M. ONG and K.F. WATSON, Dept. of Chemistry, University of Montana, Missoula: A ribonucleoprotein
complex from AMV efficient in reverse transcription.
C.A. OMER and A.J. FARAS, Dept. of Microbiology, University of Minnesota Medical School, Minneapolis:
Mechanism of release of the tRNAtrP primer molecule from viral DNA during reverse transcription-
Site-specific endonucleolytic RNase H.
J. SUMMERS, J. TAYLOR, and W. MASON, Institute for Cancer Research, Philadelphia, Pennsylvania: Replica-
tion of a "DNA" virus via reverse transcription-Studies on a hepatitis B virus of ducks.
E. KESHET, G. ROTMAN, and A. ITN, Dept. of Virology, Hadassah Medical School, Hebrew University,
Jerusalem, Israel: Unusual genomic arrangements of murine "retroviruslike" (VL30) sequences.
S.V.S. KASHMIRI, R. MEHDI, B. ALTLAND, and J.F. FERRER, University of Pennsylvania, Kennett Square: Detec-
tion and characterization of two species of covalently closed circular proviral DNA molecules of BLVO.
T.S. HOROWIT and P.R. SHANK, Division of Biology and Medicine, Brown University, Providence, Rhode
Island: Instability of RSV proviral DNA in quail cells.
M. HILL,' J. HILLOVA,t R. MARIAGE-SAMSON,2 and J. BELEHRADEK,2 'Institut de Cancerologie et d' Immunogen-
etique, CNRS, Villejuif; 2lnstitut Gustave-Roussey, Villejuif, France: Provirus amplification in RSV-
transformed Chinese hamster cells and its segregation in Chinese hamster-mouse cell hybrids.
V. PARSONS,' M. GOLOMB,t T. MISRA,2 P. HIPPENMEYER,2 and D. GRANDGENETT,2 Division of Biological
Sciences, University of Missouri, Columbia; 2St. Louis University, Missouri: Binding selectivity of the
avian retrovirus pp32 protein to cloned retroviral DNA.
E. CANAANI,1 E. SHTIVELMAN,t and P. ARTHUR,2 tWeizmann Institute, Rehovot, Israel; 2Hazelton
Laboratories, Vienna, Virginia: Mo-MSV DNA in clonally derived nonproduce transformants-1) High
frequency generation of mutants defective in virion RNA packaging. 2) Presence of subpopulations of
cells with different viral integration patterns.
M.S. KAHN and D.W. STACEY, Roche Institute of Molecular Biology, Nutley, New Jersey: Characterization
of an unusually large src region in an RSV clone.
P. Luciw," M. CAPECCHI,2 J.M. BISHOP,' and H. VARMUS,1 'University of California, San Francisco;
2University of Utah, Salt Lake City: Enhancement of tk transformation by retroviral LTR sequences.
D. SCHOLL,' R. MALAVARCA,1 S. ASTRIN,2 and A.M. SKALKA,t 'Roche Institute of Molecular Biology, Nutley,
New Jersey; 2lnstitute for Cancer Research, Fox Chase, Pennsylvania: Comparison of the nucleotide se-
quences of LTRs and adjacent regions of integrated endogenous virus 2 (ev 2) and unintegrated RAV-0.
J. SORGE and S.H. HUGHES, Cold Spring Harbor Laboratory, New York: The polypurine tract adjacent to the
U3 region of the RSV genome provides a cis-acting function.
D.W. STACEY, M. KAHN, B. CULLEN, and J. KOPCHICK, Roche Institute of Molecular Biology, Nutley, New
Jersey: Interrelationship of viral and exogenous DNA signals in microinjected chimeric clones.
G. PETERS and C. DICKSON, Imperial Cancer Research Fund, London, England: Conservation of coding
potential in the LTRs of exogenous and endogenous MMTV.
E.P. REDDY, K.C. ROBBINS, S.R. TRONICK, and S.A. AARONSON, NCI, National Institutes of Health, Bethesda,
Maryland: Nucleotide sequence analysis of retroviral deletion mutants-Localization of sequences re-
quired for efficient transforming retrovirus rescue.
E.C. WOODLAND and P.R. SHANK, Division of Biology and Medicine, Brown University, Providence, Rhode
Island: Analysis of two spontaneous deletion mutants of RSV missing 2/3 of the viral genome.
A. HONIGMAN and A. PANET, Depts. of Microbiological Chemistry and Virology, Hebrew University-
Hadassah Medical School, Jerusalem, Israel: A transcription termination signal in the LTR of Mo-MLV.
E. TISCHER and A.P. CZERNILOFSKY, Austrian Academy of Sciences, Salzburg, Austria: Generation of partially
deleted src-specific DNA via M13 miniphages.
C.Y. 00,1 L.R. BooNE,2,3 F.E. MEYER,2 and W.K. YANG,2 'School of Biomedical Sciences, University of Ten-
nessee, Oak Ridge; 2Biology Division, Oak Ridge National Laboratory, Tennessee; 3National Institute of
Environmental Health Sciences, Research Triangle Park, North Carolina: Sequence characterization of a
cloned proviral DNA endogenous of BALB/c mouse.
T. PUGATSCH and D.W. STACEY, Roche Institute of Molecular Biology, Nutley, New Jersey: Biological pro-
perties associated with virus replication, packaging, or transcription localized in three defined regions of
avian retrovirus clones.
G.M. STOLTZFUS and T.A. FIGHT, Dept. of Microbiology, University of Iowa, Iowa City: Stability of ASV
RNAs-Comparison of genome size and subgenomic mRNAs.
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N. SARKAR,1 P. ETKIND,' E. LASFARGUES,2 and E. WHITTINGTON,' tMemorial Sloan-Kettering Cancer Center,
New York, New York, 2lnstitute for Medical Research, Camden, New Jersey; Towards an understanding
of the pathogenesis of spontaneous mammary tumors in BALB/c mice-Cell culture and MMTV proviral
DNA analysis.
A.J.J. VAN 00YEN,1 A. ARNBERG,2 R. MICHALIDES,' N. KENNEDY,3 B. GRODNER,3 and N.E. HYNES,3 'The
Netherlands Cancer institute, Amsterdam; 2Biochemical Laboratory, University of Groningen, The
Netherlands; 3Kernforschungszentrum Karslruhe, Institute of Genetics, Federal Republic of Germany:
Structure and function of the LTRs of MMTV.
M. KESSEL, M. OSTROWSKI, G. HAGER, G. KHOURY, and P. GRUSS, NCI, National Institutes of Health,
Bethesda, Maryland: Hormone induction mediated by MMTV LTR sequences analyzed in a transient
assay.
D. OWEN and H. DIGGELMANN, Swiss Institute for Experimental Cancer Research, Laussane, Switzerland:
MMTV DNA clones transfected into nonmurine cells exhibit glucocorticoid-dependent expression.
J.J. MERMOD,' S. BOURGEOIS,' and M. CREPIN,2 'Salk Institute, San Diego, California; 2Dept. of Molecular
Biology, Institute Pasteur, Paris, France: MMTV mRNA synthesis and methylation of proviral DNA in
dexamethasone-sensitive, -supersensitive, and -resistant mouse thymoma cell lines.
S.M.S. REDMOND and C. DICKSON, Imperial Cancer Research Fund, London, England: Nucleotide sequence
analysis of the env region of MMTV.
J.W. GAUTSCH and M.C. WILSON, Research Institute of Scripps Clinic, La Jolla, California: Restriction of Mo-
MLV growth in teratocarcinoma-Involvement of DNA methylation.
0. NIWA, Y. YOKOTA, and H. ISHIDA, Dept. of Experimental Radiology, Kyoto University, Japan: Mo-MLV
genome in mouse teratocarcinoma cells is methylated but can be activated by 5-AzaCyd only after dif-
ferentiation of the cells.
C. HAMMOND,' J.M. BISHOP,' and G.R. MARTIN? 'Dept. of Microbiology and Immunology, and 2Dept. of
Anatomy, University of California, San Francisco: Mo-MLV viral expression in undifferentiated and dif-
ferentiated teratocarcinoma cells.
L. D'AURIOL,t W.K. YANG,2 F. SAAL,1 F. CAVALIERI,1 J. PERIES,' and R. EmANoit-RAvicoviTcH," Unite 107 IN-
SERM, Hospital Saint Louis, Paris, France; 20.R.N.L. Biology Division, Oak Ridge, Tennessee: DNA in-
tegration in undifferentiated teratocarcinoma cell lines restrictive to type-C retrovirus replication.
H. STUHLMANN, C. STEWART, D. JAHNER and R. JAENISCH, Heinrich-Pette-Institut fur Experimentelle Virologie
and Immunologie, Universitat Hamburg, Federal Republic of Germany: De novo methylation, infectivi-
ty, and expression of retroviral genomes introduced into embryonal carcinoma cells.
J. LEIS,' G. DUYK,1 M. LONGIARU,2 and A. SKALKA,2 'Case Western Reserve University Medical School,
Cleveland, Ohio, 2Roche Institute of Molecular Biology, Nutley, New Jersey: Mechanism of action of
the DNA endonuclease associated with the 00 and the «0 forms of ASV reverse transcriptase.
T.M. SHINNICK, R.A. LERNER, and J.G. SUTCLIFFE, Dept. of Immunopathology, Research Institute of Scripps
Clinic, La Jolla, California: Mo-MLV pol gene encodes three polypeptides.
W.P. TSAI, T.D. COPELAND, and S. OROSZLAN, Biological Carcinogenesis Program, NCI-Frederick Cancer
Research Facility, Frederick, Maryland: Avian reticuloendotheliosis virus (REV) gag and env gene
products-Organization, structural and immunological relatedness to mammalian type-C and type-D
viruses.
R.V. SRINIVAS and R.W. COMPANS, Dept. of Microbiology, University of Alabama, Birmingham: Glycosyla-
tion and intracellular transport of SFFV glycoproteins.
R.B. PEPINSKY and V.M. VOLT, Section of Biochemistry, Cornell University, Ithaca, New York: Low-
molecular-weight proteins of ASV and ALV.
H.L. NIMAN, J.W. GAUTSCH, and J.H. ELDER, Dept. of Immunopathology, Scripps Clinic and Research Foun-
dation, La Jolla, California: Neutralizing properties of monoclonal antibodies directed against Rauscher
gp70.
R. NASD, C. EDBAUER, and Y.-H. Wu, M.D. Anderson Hospital and Tumor Institute, University of Texas
System Cancer Center, Houston: Retrovirus assembly and the antiretroviral effects of interferon and
temperature-sensitive mutations.
M.S. MCGRATH,' L. CHEN,' J.M. BISHOP,2 M.D. COOPER,3 G. GASIC,4 W. HAYWARD,5 and I.L. WEISSMAN,'
'Stanford University, California; 2University of California, San Francisco; 3University of Alabama, Birm-
ingham; 4Rockefeller University, New York, New York; 'Sloan-Kettering Cancer Center, New York,
New York; Avian bursa! lymphoma cell-surface IgM recognizes ALV.
D. MATHIEU-MAHUL,' J.M. HEARD,2 S. FICHELSON,2 M. MAucHAuFEE,and C.J. LARSON,' tLaboratoire Phar-
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macologie Experimentale, Hopital Saint Louis, and 2Laboratoire Virologie et Immunologie de:
Tumeurs, Hopital Cochin, Paris, Frange: gp66-a particular specific env gene expression common tc
MLV-infected myelomonocytes and mastocytes.
T.H. LEE, J. MCCARTY, and M. ESSEX, Dept. of Microbiology, Harvard School of Public Health, Boston
Massachusetts: Expression of FeLV proteins at the surface of virus-producer lymphoma cells.
N.C. KAN and T.S. PAPAS, NCI, National Institutes of Health, Bethesda, Maryland: The predicted carboxy
termini of reverse transciptase are different in AMV and MAV.
H. SCHETTERS,1 R. HEHLMANN,1 and V. ERFLE,2 tMedizinische Poliklinik, Universitat Munchen, Munich, anc
2Gesellshaft fur Strahlen and Umwelforschung, Neuherberg, Federal Republic of Germany: Detection
of group and interspecies reactivities of mammalian type-C-virus p30 proteins by the ELISA method.
R. FRIEDRICH, W. KOCH, and G. HUNSMANN, Institute of Tumor Immunology, University of Freiburg, Federal
Republic of Germany: Nucleotide sequence of the env gene of Fr-MLV.
T.A. FICHT and C.M. STOLTZFUS, Dept. of Microbiology, University of Iowa, Iowa City: Translation products
and efficiencies of hybrid-selected avian retrovirus polysomal RNAs.
T.C. COPELAND, M.A. MORGAN, and S. OROSZLAN, NCI-Frederick Cancer Research Facility, Frederick,
Maryland: BLV and FeLV nucleic acid binding proteins-Primary structure and immunological
characterization.
J.E. CLEMENTS and L. BHADURI, Johns Hopkins University, Baltimore, Maryland: Presence ofa 15,000-dalton
protein in the envelope of visna virus and the role of this protein in the antibody response in persistently
infected sheep.
J.G. LEVIN,1 B.F. HUGHES,' J.S. GRAETER,1 A. REIN,3 E. RANDS,4 and A.B. MUKHERJEE,2 'Laboratory of
Molecular Genetics; 2NICHHD, National Institutes of Health; 3Biological Carcinogenesis Program,
Frederick Cancer Research Center, Frederick, Maryland; 4NCI, National Institutes of Health, Bethesda,
Maryland: Chromosome-mediated transfer of MLV and MSV genes.
A. PANET, G. ARAD, I. GLOGER, and H. FALK, Dept. of Virology, Hebrew University-Hadassah Medical
School, Jerusalem, Israel: Inhibition of Mo-MLV production by interferon.
SESSION 4 Poster Session: Structure of Cellular and Viral Oncogenes
H.W. SNYDER, JR., P. BESMER, E.E. ZUCKERMAN, M.C. SINGHAL, L. LEDERMAN, and W.D. HARDY, JR., Memorial
Sloan-Kettering Cancer Center, New York, New York: Translation products of three new isolates of
FeSV.
W.D. HARDY, JR., E.E. ZUCKERMAN, R. MARKOVICH, P. BESMER, and H.W. SNYDER, JR., Memorial Sloan-
Kettering Cancer Center, New York, New York: Isolation of two new FeSVs, one of which contains a
new cat one sequence.
U.R. RAPP,' F.H. REYNOLDS, JR.,' and J.R. STEPHENSON,' 'National Cancer Institute and 2Frederick Cancer
Research Facility, Frederick, Maryland: Isolation of a new mammalian type-C transforming virus.
Y. YUASA, J.H. PIERCE, A. SRINIVASAN, S.G. DEVARE, E.P. REDDY, and S.A. AARONSON, NCI, National Institutes
of Health, Bethesda, Maryland: Ab-MLV mutants constructed from molecularly cloned DNA-Deletion
mutants of Bglll fragments in the transforming gene.
N. SAGATA, H. AMANUMA, T. MATSUGI, and Y. IKAWA, Dept. of Viral Oncology, Cancer Institute, Tokyo,
Japan: Specific sequences and biological activities of molecularly cloned genomes of FrLV complex (K-I
strain).
P.N. TSICHLIS,' L. DONNEHOWER,' G. HAGER,' N. ZELLER,' R. MALAVARCA,2 S. ASTRIN,3 and A.M. SKALKA,2
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Health, Bethesda, Maryland: Cloning and characterization of different classes of human genomic se-
quences homologous to the baboon endogenous virus.
E. GELMANN, F. WONG-STAAL, R. KITTMAN, A. BURNEY, and R.C. GALLO, NCI, National Institutes of Health,
Bethesda, Maryland: Human T-cell leukemia virus (HTLV) has a high degree of homology to a specific
sequence of the BLV and has regions homologous to other retroviruses.
N. YAMAMOTO, M. OKADA, Y. KOYANAGI, T. CHOSA, Y. TANAKA, and Y. HINUMA, Institute for Virus Research,
Kyoto University, Japan: Transformation of human leukocytes by cocultivation with an adult T-cell
leukemia virus (ATLV)-producer cell line.
V.S. KALYANARAMAN,1 M.G. SARNGADHARAN,t M. ROBERT-GUROFF,2 Y. Iro, 3 Y. NAKAO,4 and R.C. GALLO,2
'Litton Bionetics, Inc., Kensington, Maryland; 2NCI, National Institutes of Health, Bethesda, Maryland;
'Kyoto University, 4Kobe University, Japan: Natural antibodies to human leukemia lymphoma virus
(HTLV) in Japanese sera.
L. THIRY, J. COGNIAUX-LECLERC, S. SPRECHER-GOLDBERGER, and R. OLISLAGER, Institut Pasteur du Bragant,
Brussels, Belgium: Monoclonal antibodies against specific cell receptors for baboon endogenous virus.
J. SuNI,1'2 L. PARTANEN,1 T. WAHLSTROM,3 P. LEHTOVIRTA,3 and A. VAHERI," Dept. of Virology, University of
Helsinki; 2Dept. of Virology, Aurora Hospital, Helsinki; 3Dept. of Obstetrics and Gynecology, Helsinki
University Central Hospital, Finland: p28 and precursor polypeptides of human endogenous retrovirus
in placental syncytiotrophoblastic cells.
R.B. NASO and S.A. FUQUA, M.D. Anderson Hospital and Tumor Institute, University of Texas System
Cancer Center, Houston: On the origin of SSAV.
J. JORE, R. DUBBES, and P. BENTVELZEN, Radiobiological Institute TNO, Rijswijk, The Netherlands: Sequences
related to SSAV in normal cellular DNA of several mammals.
E. HEFTI, A. HARDEN, and S. PANEM, Kovler Viral Oncology Laboratories, University of Chicago, Illinois:
Genomic DNA rearrangements in patients with leukemia.
G. CARLON!, A. LE PATEZOUR, M.L. MICHEL, C. BRECHOT, A. FRITSCH, P. TIOLLAIS, and S. WAIN-HOBSON, IN-
SERM, Institut Pasteur, Paris, France: Cellular transformation of cloned and uncloned sequences of
hepatocellular carcinoma DNA.
M.J. KOURY,t I.B. PRAGNELL,1 J. LANG,' J. NEIL, and N.M. WILKIE,t tBeatson In- stitute for Cancer Research,
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Glasgow; 2lnstitute of Virology, Glasgow, Scotland: Induction of granulocyte-macrophage colony
stimulation factor (GM-CSF) by murine retroviruses.
SESSION 8 Poster Session: Biology of Endogenous Viruses, Control of Viral Gene Expression
M. MARX,' R. MARIAGE-SAMSON, J. HILLOVA,' M. HILL,' and A. SARGEANT,2 'Institute of Cancerology and Im-
munogenetics, CNRS, Villejuif; 2Oncologie Moleculaire and INSERM, Institut Pasteur, Lille, France:
Host- cell-induced restriction of the src gene during RSV replication on transformed and mutagenized
quail cell lines.
M. KOTLER and H. MOSKOWITZ, Dept. of Molecular Virology, Hebrew University-Hadassah Medical School,
Jerusalem, Israel: Factors involved in the expression of ASV proviruses in productive and non- produc-
tive cells.
D.L. EWERT and M.S. HALPERN, Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania: En-
dogenous retrovirus antigen expression by B cells.
R. To, W. SCHUBACH, and P. NEIMAN, Fred Hutchinson Cancer Research Center, Seattle, Washington: On-
cogenicity of ALV 3"regions.
J.H. MORGAN and R.E. SMITH, Dept. of Microbiology and Immunology, Duke University Medical Center,
Durham, North Carolina: Construction and characterization of recombinants between RAV-0 and
MAV-2(0).
H.L. ROBINSON,' P.N. TsicHu5,2 and J.M. COFFIN,3 'Worcester Foundation for Experimental Biology,
Shrewsbury, Massachusetts; 2NCI, National Institutes of Health, Bethesda, Maryland; 3Tufts University
Medical School, Boston, Massachusetts: ALV5 target for specific forms of non- acute disease.
P. SCHATZ and P.R. SHANK, Division of Biology and Medicine, Brown University, Providence, Rhode Island:
Construction of in vitro recombinants between molecular clones of two ALV5 with distinct disease
tropisms.
C.L. Ow, J.K. CARTER, and R.E. SMITH, Dept. of Microbiology and Immunology, Duke University Medical
Center, Durham, North Carolina: Hyperlipidemia induced by an avian retrovius.
A.S. KHAN and M.A. MARTIN, NIAID, National Institutes of Health, Bethesda, Maryland: Characterization of
env and LTR segments of endogenous MLV proviruses.
F.S. PEDERSEN, H.D. ANDERSEN, M. ETZERODT, J. FRYDENBERG, P. JORGENSEN, N.O. KJELDGAARD, and H. SKIODT,
Dept. of Molecular Biology, University of Aarhus, Denmark: Analysis of MLV-specific mRNA5 in cell
lines derived from lymphomas of AKR mice.
J. LENZ,' R. CROWTHER,' S. KLIMENK0,2 A. SHELDON,' E. ELFASSI,1 and W. HASELTINE,' 'Sidney Farber Cancer
Institute, Harvard Medical School, Boston, Massachusetts; 2D.l. Ivanosky Institute, Moscow, USSR:
Leukemogenic determinants of the SL3-3 virus.
R. VILLEMUR, E. RASSART, and P. JOLICOEUR, Institut de Recherches Cliniques de Montreal, Universite de
Montreal, Canada: Restriction analysis and sequencing of the leukemogenic Gross Passage A MLV clon-
ed DNA reveals significant changes at the 3"end of the genome and on a short portion of its LTR.
D.L. BUCHHAGEN and J.D. MORRISSEY, Dept. of Microbiology and Immunology, State University of New
York, Downstate Medical Center, Brooklyn: Molecularly-cloned Gross proviral DNA contains se-
quences homologous to xenotropic AKR virus.
J.H. WOLFE, E.P. BLANKENHORN, and K.J. BLANK, University Of Pennsylvania Medical School, Philadelphia:
Virus protein processing in H-2-congenic Gross-virus-induced tumor cell lines.
K.E. FRY, R.A. GRYMES, H.S. KAPLAN, and J.P. KIM, Cancer Biology Research Laboratory, Stanford University
Medical School, California: Interrelations between the viruses inhabiting the C57BUKa mouse.
E. RASSART, P. SANKAR, and P. JOLICOEUR, Institut de Recherches Cliniques de Montreal, Universite de Mon-
treal, Canada: Molecular studies of the ecotropic MLV recovered from primary x-ray-induced thymoma
in C57BU6 mice.
M. ZIJLSTRA,1 R.E.Y. DE GOEDE,' H.J. SCHOENMAKERS,1 A.H. SCHINKEL,' W.G. HESSELINK,' J.L. PORTIS,2 and
C.J.M. MELIEF,' 1 Laboratory of Experimental and Clinical Research, University of Amsterdam, The
Netherlands; 2NIAID, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana:
Isolation and characterization of different host-range classes of MLV from virus-induced C57BL
lymphomas.
M. MOWAT and A. BERNSTEIN, Ontario Cancer Institute, Toronto, Canada: Association of the Fv-2 locus with
an endogenous ecotropic provirus in C57BU6J.S mice.
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A. REIN, Biological Carcinogenesis Program, NCI-Frederick Cancer Research Facility, Maryland: A distinct
receptor for MCFs on mouse cells.
A. HABARA, E.P. REDDY, C. DUNN, and S.A. AARONSON, NCI, National Institutes of Health, Bethesda,
Maryland: Construction of recombinants between Rauscher MLV and Mo-MLV.
T. SHIBUYA and T.W. MAK, Ontario Cancer Institute, Toronto, Canada: Erythroleukemia induction by Friend
leukemia virus-A host gene in the control of early anemia and polycythemia induction and the rate of
proliferation of late (post-CFU-E) erythroid precursor cells.
D. BARBIERI-WEILL and F. GAY, CNRS, Villejuif, France: Genesis of a SFFV -Possible role of Fr-MCF viruses.
A.M. SCHULTZ, L.E. HENDERSON, A. REIN, G.W. SMYTHERS, and S. OROSZLAN, NCI-Frederick Cancer Research
Facility, Maryland: Structural characterization of Rauscher-MCF virus proteins.
L. EVANS, B. CHESEBRO, and M. CLOYD, NIAID, National Institutes of Health, Rocky Mountain Laboratories,
Hamilton, Montana: Comparison of MCF viruses derived from Fr-MLV or Mo-MLVs.
L. WOLFF and S. RUSCETTI, NCI, National Institutes of Health, Bethesda, Maryland: Mapping of endogenous-
ly acquired portion of Fr-MCF gp70 to its N terminus and a structural comparison of MCF gp70 with
SFFV gp52.
W. BRITT and B. CHESEBRO, NIAID, National Institutes of Health, Rocky Mountain Laboratories, Hamilton,
Montana: Cells from the late stages of FV leukemia express a non-ecotropic MLV gp70 closely related to
a gp70 expressed on fetal hematopoietic cells.
N.M. TEICH and J. ROWE, Imperial Cancer Research Fund, London, England: Studies of BSB, a murine
erythroleukemia virus complex distinct from Friend virus.
T.W. MAK and T. SHIBUYA, Ontario Cancer Institute, Toronto, Canada: Host control of the types of leukemia
(erythroid granulocytic and T-lymphoid) induced by helper-independent MLVs and isolation of
erythroid and myeloid cell lines.
J.M. HEARD,' F. WENDLING? R. BERGER,3 S. FICHELSON,1 and S. GISSELBRECHT,1 1Laboratoire Immunologie et
Virologies de Tumeurs, INSERM, Paris; 'Unite de Recherches de Physiologie Cellulaire, INSERM, Or-
say; 3Laboratoire de Cytogenetique, Hopital Saint-Louis, Paris, France: Establishment of in vitro
myelomonocytic permanent cell lines from in vivo virus-induced chloroleukemias in mice.
E. PILLEMER,1 D. KOOISTRA,1 0. WITTE,' and I. WEISSMAN,t 'Stanford University, California; 'Molecular
Biology Institute, University of California, Los Angeles: Identification of MuLV-related nonvirion an-
tigens on the surface of murine T- and B-cell lymphomas.
D.E. LEVY,' R.A. LERNER,2 and M.C. WILSON,' 'Division of Biology, California Institute of Technology,
Pasadena; 'Dept. of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California:
Control of endogenous retrovirus mRNA expression by a separate regulatory gene.
S. RASHEED and M. LAI, Depts. of Pathology and Microbiology, University of Southern California, Los
Angeles: Genomic analysis of a thymoma- inducing amphotropic virus.
S. MOHAN and B.K. PAL, Dept. of Biological Sciences, California State Polytechnic University, Pomona:
Wild mouse retrovirus-induced paralysis-Role of virus infection, replication, and gene expression in
CNS.
J. Coffin, P. Tsichlis Lecture Hall
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B.R. BROOKS,' P. BOWMAN,2 and G. GOLDSTEIN, 'Dept. of Neurology, Johns Hopkins University Medical
Center, Baltimore, Maryland; 'Dept. of Neurology, University of Michigan Medical School, Ann Arbor:
Murine neutrotropic retrovirus infection is not restricted in purified CNS capillary endothelial cells in
vitro.
K.B. ANDERSEN and B.A. NEXO, Fibiger Laboratory, Copenhagen, Denmark: The pathway of entry of
retrovirus into mouse fibroblasts.
J. MCCUBREY, P. GREEN, J. HOROWITZ, C. SINAIKO, and R. RISSER, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: DNA transfection studies of endogenous ecotropic MLV.
M.-A. AUGER-BuENDIA, J. DEVAUX, and A. TAVITIAN, INSERM, Faculte de Medecine, Paris, France: Mo-MSV
of large genomic size produced by a transformed rat-cell line.
C. DE GIULI MORGHEN, A. RADAELLI, M. RIGHI, and E. LIBOI, CNR Center for Cytopharmacology, Milano,
Italy: Ultrastructural and biochemical analysis of defectiveness of L929 cell retrovirus.
G.L.C. SHEN-ONG and M.D. COLE, Dept. of Biochemistry, St. Louis University Medical School, Missouri:
Differing populations of intracisternal A-particle genes in myeloma tumors and mouse subspecies.
D.K. HAAPALA,1 K.J. DUNN,' and J.H. GILBERT,2 'NCI, Frederick Cancer Research Center, Frederick,
Maryland; 'Michigan State University, East Lansing: Studies of the nature and control of RD-114-like
viruses in cat cells.
J.H. GILBERT,' J. DUNN,2 and D.K. HAAPALA,2 'Dept. of Microbiology and Public Health, Michigan State
University, East Lansing; 'NCI, Frederick Cancer Research Center, Maryland: Differential expression of
RD-114 virus genetic information by cells producing FeLV.
M.A. MINK, A. HABERMAN, and L.F. VELICER, Dept. of Microbiology and Public Health, Michigan State
University, East Lansing: A putative envelope glycoprotein gene recombinant between FeLV and RD-
114-Immunoprecipitation analysis and comparison of tryptic and chymotryptic peptide maps.
C. BRUCK,' D. PORTETELLE,1 A. BURNY,1 and J. ZAVADA,2 'Dept. of Molecular Biology, University of Brussels,
Belgium; 'Institute of Virology, Slovak Academy of Sciences, Bratislava, Czechoslovakia: Molecular
dissection of BLV envelope glycoprotein gp51 by monoclonal antibodies.
S. MOLINEAUX and J.E. CLEMENTS, Johns Hopkins University, Baltimore, Maryland: Characterization of visna
virus mRNAs using cloned viral DNAs.
M.S. REITZ, JR., E.P. GELMANN, C.D. TRAINOR, and F. WONG-STAAL, NCI, National Institutes of Health,
Bethesda, Maryland: Construction and analysis of molecular clones of oncogenic (SEATO) and non- on-
cogenic (Brain) strains of gibbon ape leukemia virus.
S. BROOME, The Biological Laboratories, Harvard University, Cambridge, Massachusetts: A retroviral pro-
moter located in the 3' end of the env gene.
G.L. FIRESTONE, F. PAYVAR, and K.R. YAMAMOTO, Dept. of Biochemistry and Biophysics, University of
California, San Francisco: Glucocorticoid- dependent processing and compartmentalization of MMTV
proteins in infected HTC cells.
SESSION 9 Transforming Proteins
Chairperson: C.J. SHERR, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
R. PRYWES and D. BALTIMORE, Center for Cancer Research, Massachusetts Institute of Technology, Cam-
bridge: Site-directed mutagenesis of the Ab-MLV genome and its expression in SV40 vectors.
D. BRYANT,' V. WILKERSON,' I. BRUGGE,2 and J.T. PARSONS,' 'Dept. of Microbiology, University of Virginia
Medical School, Charlottesville; 'State University of New York, Stony Brook: Site-directed mutagenesis
in the src gene of RSV.
J. BRUGGE and D. DARROW, Dept. of Microbiology, State University of New York, Stony Brook: Analysis of
the turnover and distribution of the protein complex consisting of pp6O5rc and two cellular
phosphoproteins.
S. COURTNEIDGE1 and J.M. BisHoP,2 'National Institute for Medical Research, Mill Hill, London, England;
'Dept. of Microbiology and Immunology, University of California Medical Center, San Francisco: The
subcellular location of the transforming protein of RSV and its effect on phenotype.
E.A. GARBER, J.G. KRUEGER, H. HANAFUSA, and A.R. GOLDBERG, Rockefeller University, New York, New
York: Phosphorylation of pp6Ostc in membrane vesicles from RSV-transformed cells.
R.A. FELDMAN, E. WANG, and H. HANAFUSA, Rockefeller University, New York, New York: Subcellular
localization of the transforming protein of FuSV.
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P. Moss, T. GILMORE, and G.S. MARTIN, Dept. of Zoology, University of California, Berkeley: Membrane
association of the transforming protein of FuSV.
B. ADKINS,' R. MORGAN,2 and K. BEEMON,2 lInStitUt fiir Virusforshung, Im Neuenheimer Feld, Heidelberg,
Federal Republic of Germany; 2Dept. of Biology, Johns Hopkins University, Baltimore, Maryland: Two
structurally and functionally distinct forms of the PRCII ASV transforming protein.
J. PAPKOFF, I.M. VERMA, and T. HUNTER, Salk Institute, San Diego, California: Detection of a transforming
gene product in Mo-MSV-transformed cells.
M.L. PRIVALSKY,1 A.D. LEVINSON,' J.P. MCGRATH,2 and J.M. Bis HoP,1 'University of California, San Fran-
cisco; 2Genentech, Inc., South San Francisco, California: Identification of the protein product of the
AEV erb-B domain.
B. VENNSTROM,1 L. FRYKBERG,1 H. BEUG,2 S. PALMIERI,2 and M. HAYMAN,3 'Dept. of Microbiology, University
of Uppsala, Sweden; 2Deutsche Krebsforschungszentrum, Heidelberg, Federal Republic of Germany;
3lmperial Cancer Research Fund, London, England: Analysis of the transforming capacity of mutants of
AEV generated by site-directed mutagenesis in vitro.
K.C. ROBBINS, S.G. DEVARE, E.P. REDDY, and S.A. AARONSON, NCI, National Institutes of Health, Bethesda,
Maryland: Detection of the transforming gene product of SSV-Preliminary analysis of its functional
properties.
M.O. WEEKS, C.M. WEI, and E.M. SCOLNICK, NCI, National Institutes of Health, Bethesda, Maryland:
Molecular and biological characterization of Ha-MSVtk, a retrovirus containing the p21 ras gene and the
tk gene.
P. KAPLAN, J. ZACK, and B. OZANNE, Dept. of Microbiology, University of Texas Health Science Center,
Dallas: Transforming growth factor production and use by Ki-MSV transformed cells.
SESSION 10 Leukemogenesis
Chairperson: P.V.O. O'DONNEL, Memorial Sloan-Kettering Cancer Center, New York, New York
L. DESGROSEILLERS and P. JOLICOEUR, Institut de Recherches Cliniques de Montreal, Universite de Montreal,
Canada: Construction and characterization of in vitro recombinants of N- and 8-tropic endogenous
BALB/c MLV DNA-Gene mapping of Fv-I tropism determinant and thymotropism.
R. SoEiRo,' J. CHINSKY,t and J. KOPCHICK,2 'Albert Einstein College of Medicine, Bronx, New York; 2Roche
Institute of Molecular Biology, Nutley, New Jersey: Fv-I host restriction of Fr-MLV-Studies of non- in-
tegrated DNA.
C.A. HOLLAND,' J.W. HARTLEY,2 W.P. ROWE,' and N. HOPKINS,' 'Massachusetts Institute of Technology,
Cambridge; 2National Institutes of Health, Bethesda, Maryland: Genetic analysis of leukemogenicity
and tissue tropism by construction of in vitro recombinants between molecular clones of AKV and MCF
247 viruses.
C.Y. THOMAS and M. COFFIN, Tufts University Medical School, Boston, Massachusetts: Independent origin
of the non-AkV p1 5E gene/U3 region and gp70 gene sequences in recombinant viruses of AKR/J mice.
N.G. FAMULARI, C.F. KOEHNE, and P.V. O'DONNELL, Memorial Sloan- Kettering Cancer Center, New York,
New York: Leukemogenesis by Gross Passage of A-MLV-Expression of viruses with recombinant env
genes in transformed cells.
R.A. BOSSELMAN,1 F. VAN STRAATEN,2 C. VAN BEVEREN,2 M. VOGT,' and I.M. VERMA,2 'Applied Molecular
Genetics, Inc., Newbury Park; 2Salk Institute, San Diego, California: Analysis of the env gene of a
molecularly cloned and biologically active Moloney mink cell focus-forming (MCF) proviral DNA.
R. REPASKE, R.P. ONEILL, C.E. BUCKLER, and M.A. MARTIN, NIAID, National Institutes of Health, Bethesda,
Maryland: Nucloetide sequence of the env-specific region of NFS-Th-1 xenotropic proviral DNA.
J. DUDLEY and R. RISSER, McArdle Laboratory for Cancer Research, Univer- sity of Wisconsin, Madison:
Alterations in genomic DNA of murine T cell lymphomas-Detection of novel restriction enzyme
fragments containing endogenous MMTV proviruses.
J. KAMINCHIK, W.D. HANKINS, and E.M. SCOLNICK NCI, National Institutes of Health, Bethesda, Maryland:
Molecular cloning of biologically active proviral DNA of the anemia-inducing strain of SFFV.
A. OLIFF1 and S. RuscErn,2 'Memorial Sloan-Kettering Cancer Center, New York; 2NCI, National Institutes
of Health, Bethesda, Maryland: Localization of the pathogenic functions of Fr-MLV and Friend mink
cells focus-inducing virus (Fr-MCF) to the env gene by in vitro construction of recombinant viruses.
D. KABAT, C. MACHIDA, M. RUTA, and R. BESTWICK, Dept. of Biochemistry, Oregon Health Sciences Univer-
sity Medical School, Portland: Glycoprotein structural gene mutants of SFFV are nonleukemogenic.
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K. RADKE, H. BEUG, and T. GRAF, Institute for Virology, German Cancer Research Center, Heidelberg,
Federal Republic of Germany: Transformation of both erythroid and myeloid cells by E26, an avian
erythroleukemia virus which contains the myb gene.
G. WANECK and N. ROSENBERG, Cancer Research Center, Tufts University Medical School, Boston,
Massachusetts: Erythroid target cells for Abelson virus and Harvey virus.
SESSION 11 Activation of Host Genes
Chairperson: G.F. VANDE WOUDE, National Cancer Institute, National Institutes of Health, Bethesda,
Maryland
B.E. NEEL,' C.-K. SHIN,' G.P. GASIC,1 and W.S. HAYWARD,2 t Rockefeller University, New York, New York;
2Sloan-Kettering Institute for Cancer Research, New York, New York: Localization of potential initiation
sites for RNA polymerase II in the c-myc gene.
D. WESTAWAY,1 G.S. PAYNE,' C. MOSCOVICI,' J.M. BISHOP,' and H.E. VARMUS,1 'Dept. of Microbiology and
Immunology, University of California, San Francisco; 2Tumor Virology, Veteran's Administration
Hospital, Gainesville, Florida: Induction of lymphoid and renal tumors by Rous and myeloblastosis-
associated viruses.
G. GOUBIN,1 P.A. NEIMAN,2 and G.M. COOPER,' 'Sidney Farber Cancer Institute, Harvard Medical School,
Boston, Massachusetts; 2Fred Hutchinson Cancer Research Center, Seattle, Washington: Molecular
cloning and characterization of a cellular transforming gene of chicken B-cell lymphoma.
A.D. ZELENETZ and G.M. COPPER, Sidney Farber Cancer Institute, Harvard Medical School, Boston,
Massachusetts: LTR-mediated activation of endogenous transforming genes of NIH/3T3 mouse cells.
Y. -K. FUNG,t L. CRITTENDEN,2 and HA KUNG,' 1Dept. of Biochemistry, Michigan State University, East Lan-
sing; 2United States Dept. of Agriculture, Sciences, and Education Administration, Regional Poultry
Research Laboratory, East Lansing, Michigan: Involvement of c-erb in avian leukemogenesis.
J.K. CARTER,' S.J. PROCTOR,' and R.E. SMITH,' 'Dept. of Microbiology and Immunology, Duke University
Medical Center, Durham; 2Experimental Pathology Laboratories, Inc., Raleigh, North Carolina: Induc-
tion of sarcomas by an ALV.
M.C. SIMON,' R.E. SMITH,2 and W.S. HAYWARD,3 1 Rockefeller University, New York, New York; 2Duke
University Medical Center, Durham, North Carolina; 3Sloan-Kettering Institute for Cancer Research,
New York, New York: Pheasant viruses may induce lung tumors by activating a cellular gene.
R. NuSSE1 and H.E. VARmus,2 t Dept. of Virology, Antoni van Leeuwen- hoekhuis, Amsterdam, The
Netherlands; 2Dept. of Microbiology, University of California, San Francisco: Acquired proviruses of
the MMTV are integrated in a common domain of tumor DNA.
P.R. ETKIND and N.H. SARKAR, Memorial Sloan-Kettering Cancer Center, New York, New York: New pro-
viral integration and differential hypomethylation of the endogenous MMTV proviral DNA sequences in
tissues of the C3Hf mouse.
F. YOSHIMURA and K. LEVINE, Fred Hutchinson Cancer Research Center, Seattle, Washington: Characteriza-
tion of MLV proviral DNA and RNA from AKR thymic lymphomas.
P.N. TSICHLIS, L. Hu, and P.G. STRAUSS, NCI, National Institutes of Health, Bethesda, Maryland: Mo-MLV-
induced rat thymomas.
M. BOCCARA, M. SOUYRI, C. MAGARIAN, E. STAVNEZER and E. FLEISSNER, Memorial Sloan-Kettering Cancer
Center, New York, New York: A novel species of MLV env-related RNA in radiation leukemias from
BALB/c mice.
E. ATHAN, M. GOODENOW, F. LILLY, and D. DINA, Dept. of Genetics, Albert Einstein College of Medicine,
Bronx, New York: Expression of virus- related sequences in carcinogen-induced lymphomas.
SESSION 12 Viruses, Oncogenes, and Human Tumors
Chairperson: J.M. BISHOP, University of California, San Francisco, California
P. STEELE, R. REPASKE, T. BRYAN, A. RABSON, R. O'NEILL, and M. MARTIN, NIAID, National Institutes of Health,
Bethesda, Maryland: Human DNA contains endogenous type-C retrovirus sequences.
C. O'CONNELL, M. COHEN, and T. BONNER, NCI-Frederick Cancer Research Facility, Frederick, Maryland:
Characterization of a cloned retrovirus- like genome from human DNA.
R. CALLAHAN, W. DROHAN, S. TRONICK, and J. SCHLOM, Laboratory of Cellular and Molecular Biology, NCI,
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National Institutes of Health, Bethesda, Maryland: Identification and molecular cloning of novel MMTV-
related- DNA sequences in mouse and human cellular DNA.
M. ROBERT-GUROFF,' V.S. KALYANARAMAN,t M.G. SARNGADHARAN,1 W.A. BLATTNER,' D. CATOVSKY,2 F.
MERINO,3 and R.C. GALLO,' 'NCI, National Institutes of Health, Bethesda, Maryland; 2Royal
Postgraduate Medical School, London, England; 3lnstituto Venezolano de Investigaciones Cientificas,
Caracas, Venezuela: Serologic studies show HTLV is associated with aggressive T-cell malignancies in
various geographic locations.
M. POPOVIC,' P.S. SARIN,' V.S. KALYANARAMAN,2 M. ROBERT-GUROFF,' M.G. SARNGADHARAN,2 J. MINOWADA,3
T. AoKI,4 D. MANN,' W. BLATTNER,' S. BRODER,' D. GOLDE,5 and R.C. GALLO,' 1 NCI, National Institutes
of Health, Bethesda, Maryland; 2Litton Bionetics, Inc., Kensington, Maryland; 3Roswell Park Memorial
Institute, Buffalo, New York; 4Shimrakuen Hospital, Niigata, Japan; 5University of California, Los
Angeles: New HTLV isolates from geographically different parts of the world and their infectivity of
human T cells.
M. YOSHIDA, M. SEIKI, and S. HATTORI, Cancer Institute, Kami- Ikebukuro, Toshima-ku, Tokyo, Japan: Human
retrovirus ATLV-Characterization of the viral genome and association with ATL.
F. WONG-STAAL, V. MANZARI, E.P. GELMANN, E. WESTIN, G. FRANCHINI, S. JOSEPHS, R. DALLA-FAVERA, and R.C.
GALLO, NCI, National Institutes of Health, Bethesda, Maryland: Integration and expression of HTLV in
infected cells and molecular cloning of the 5:proximal viral sequences.
L.F. PARADA, C. TABIN, C. SHIH, and R.A. WEINBERG, Center for Cancer Research and Dept. of Biology,
Massachusetts Institute of Technology, Cambridge: Homology between the EJ human bladder car-
cinoma oncogene and the HaSV oncogene, ras.
C.J. DER, T.G. KRONTIRIS, and G.M. COOPER, Sidney Farber Cancer Institute, Dept. of Pathology, Harvard
Medical School, Boston, Massachusetts: Transforming genes of human bladder and lung carcinoma cell
lines are homologous to the ras genes of HaSV and KiSV.
M. BARBACID, E. SANTOS, and S. PULCIANI, NCI, National Institutes of Health, Bethesda, Maryland: A transfor-
ming gene involved in human bladder carcinomas.
E.H. CHANG,' M.A. GONDA,2 R.W. ELLIS,t M.E. FURTH,' E.M. SCOLNICK,1 and D.R. Lowy,' 1NCI, National In-
stitutes of Health, Bethesda; 2NCI, Frederick Cancer Research Facility, Frederick, Maryland:
Characterization of four members of the p21 gene family isolated form normal human genomic DNA
and demonstration of their oncogenic potential.
M.A. LANE, A.C. SAINTEN, and G.M. COOPER, Sidney Farber Cancer Institute, Harvard Medical School,
Boston, Massachusetts: Isolation of a molecular clone containing the human mammary tumor transform-
ing sequence.
U.G. ROVIGATTI, R. DIEHL, and S.M. A5TRIN, Institute for Cancer Research, Fox Chase Cancer Center,
Philadelphia, Pennsylvania: Oncogene expression in human tumors.
E.H. WESTIN,' F. WONG-STAAL,' E.P. GELMANN,1 G. FRANCHINI,1 S.K. ARYA,1 R. DALLA-FAVERA,1 T.S. PAPAS,'
J.A. LAUTENBERGER,1 A. EVA,' P. REDDY,' S.R. TRONICK,' M.A. BALUDA,2 S.A. AARONSON,' and R.C.
GALLO,' 1 NCI, National Institutes of Health, Bethesda, Maryland; 2Dept. of Pathology, University of
California Medical School, Los Angeles: Human hematopoietic cells express cellular homologs of
retroviral one genes.
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SV40, Polyoma, and Adenoviruses
August 18-August 22
Arranged by Terri Grodzicker, Cold Spring Harbor Laboratory, Michael Botchan, University of California,
Berkeley
378 participants
The annual meeting on the molecular biology of SV40, polyoma, and adenoviruses is now held in alternate
years at the Cold Spring Harbor Laboratory. That over 350 scientists attended the 1982 meeting, attests to
the active interest in the study of the molecular biology and transforming properties of small DNA tumor
viruses. Areas of active research that were discussed include: development of in vitro systems for DNA
replication and transcription; purification of viral and cellular proteins active in in vitro systems;
characterization of sequences that enhance gene expression; viral regulatory proteins and RNAs involved in
the control of transcription and translation; the role of different viral T antigens in transformation; and the
purification and properties of transforming proteins. It was clear that the use of recombinant DNA
technology, prokaryotic and viral expression vectors, and sets of monoclonal antibodies and peptides to be
used as antigens have become routine and valuable tools in this area of research.
This meeting was supported in part by the Cancer Center Grant to Cold Spring Harbor Laboratory from
the National Cancer Institute, National Institutes of Health.
SESSION 1 SV40, Polyoma, and Adenoviruses: Replication and Recombination
Chairperson: D. NATHANS, John Hopkins University School of Medicine, Baltimore, Maryland
J.M. OSTROVE,1 P. ROSENFELD,' J. WILLIAMS,' and T.J. KELLY, JR.) 'Dept. of Molecular Biology and Genetics,
Johns Hopkins University Medical School, Baltimore, Maryland; 'Dept. of Biological Sciences, Mellon
Institute, Pittsburgh, Pennsylvania: In vitro complementation as an assay for the purification of
adenovirus replication proteins.
B.FRIEFELD, M. KREVOLIN, J. LICHY, R. KORN, J. HURWITZ, and M. HORWITZ, Albert Einstein College of
Medicine, Bronx, New York: Studies on adenovirus H5ts107 and H5ts149 DNA synthesis defective
mutants in vitro.
F.TAMANOI, M.B. MATHEWS, and B.W. STILLMAN, Cold Spring Harbor Laboratory, New York: Enzymes and
DNA sequence required for initiation of adenovirus DNA replication.
R.T.HAY, E.A. HENDRICKSON, and M.L. DEPAMPHILIS, Dept. of Biological Chemistry, Harvard Medical
School, Boston, Massachusetts: Comparison of initiation events at the origin of SV40 DNA replication
with Okazaki fragments.
G. MAGNUSSON, H. LUTHMAN, and M. oSTERLUND, Dept. of Biochemistry, Karolinska Institute, Stockholm,
Sweden: Altered rate of DNA replication in cis-active mutants of polyoma virus.
L. DANDOLO, J. AGHION, and D. BLANGY, Institut de Recherches Scientifiques sur In Cancer, Villijuif, France:
Replication of polyoma virus DNA in embryonal carcinoma cells.
P. Bourgaux, Y. Aloni
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P. Sharp, T. Grodzicker M. Botchan
E. WINOCOUR and D. DORSETT, Dept. of Virology, Weizmann Institute of Science, Rehovot, Israel: SV40
recombination in monkey cells.
M. RUBEN,' S. BACCHETTI,1 and F.L. GRAHAM,1,2 1 Dept. of Pathology; 2Dept of Biology, McMaster Universi-
ty, Hamilton, Canada: Evidence for head to tail joining of human Ad5 DNA molecules.
R. GAHLMANN, S. STABEL, R. DEURING, U. WINTERHOFF, and W. DOERFLER, Institute of Genetics, University of
Cologne, Federal Republic of Germany: Integration sites of adenovirus DNA in transformed and tumor
cells.
D. HUBERDEAU, B.S. SYLLA, D. BOURGAUX-RAMOISY, and P. BOURGAUX, Dept. de Microbiologie, Universite
de Sherbrooke, Canada: Excision of polyoma DNA in transformed mouse cells.
SESSION 2 5V40 and Polyoma: Transcription
Chairperson: R. TBAN, University of California, Berkeley, California
E. RULEY and M. FRIED, Imperial Cancer Research Fund Laboratories, London, England: Duplicated regions
of polyoma which enhance gene expression.
B. FARMERIE, S. TRIEZENBERG, and W. FOLK, Dept. of Biological Chemistry, University of Michigan, Ann Ar-
bor: Isolation of polyoma mutants with altered expression of the early region.
B. BYRNE, J. YAMAGUCHI, D. BERGSMA, and K. SUBRAMANIAN, Dept. of Microbiology and Immunology,
University of Illinois Medical Center, Chicago: The SV40 promoter regions-a) location of the early pro-
moter within the 21-bp repeat; and b) the 72-bp repeat exhibits a pronounced host range in its enhance-
ment effect.
M. BOTCHAN, P. ROBBINS, M. LUSKY, L. BERG, and H. WEINER, Dept. of Molecular Biology, University of
California, Berkeley: Characterization of the SV40 enhancer/activator sequence and other related
experiments.
J. DE VILLIERS,' C. TYNDALL,2 L. OLSON,' R. KAMEN,3 and W. SCHAFFNER,t 1111SLitUL fur Molekularbiologie II der
Universitat Zurich, Switzerland; 2Biochemistry Division, MRC, London; 'Imperial Cancer Research
Fund, London, England: A functional analysis of polyoma virus-SV40 hybrid recombinants.
S. LORD, J. SAFFER, M. LERMAN, and M. SINGER, NCI, National Institutes of Health, Bethesda, Maryland: Func-
tional characterization of a monkey DNA segment homologous to the SV40 regulatory region.
J. BRADY, M. RADONOVICH, M. VODKIN, V. NATARAJAN, M. THOREN, G. DAS, and N.P. SALZMAN, NIAID, Na-
tional Institutes of Health, Bethesda, Maryland: Site specific mutations which enhance or suppress
transcription of the SV40 major late RNA.
J.C. ALWINE, Dept. of Microbiology, University of Pennsylvania, Philadelphia: SV40 late transcriptional
control.
Y. ALONI, N. HAY, H. SKOLNIK-DAVID, R. PRUZAN, and P. PFEIFFER, Dept. of Genetics, Weizmann Institute of
Science, Rehovot, Israel: Attenuation in the control of SV40 gene expression.
A. BARKAN, S. SEDMAN, and J.E. MERTZ, MCARDLE Laboratory for Cancer Research, University of Wisconsin,
Madison: Effect of alternative leader region sequences on the relative rates of translation of genes encod-
ed by the SV40 late mRNAs.
M. GRAESSMANN and A. GRAESSMANN, Institut fur Molekularbiologie and Biochemie der Freien Universitat
Berlin, Federal Republic of Germany: SV40 cRNA is processed into functional mRNA in microinjected
cells.
SESSION 3 Poster Session: Adenoviruses
P. ALESTROM, G. AKUSJARVI, M. PETTERSSON, and U. PETTERSSON, Dept. of Medical Genetics, University of
Uppsala, Sweden: The DNA sequence of the region encoding the terminal protein and the hypothetical
N-gene of Ad2.
K.P. ANDERSON and D.F KLESSIG, Dept. of Cellular, Viral, and Molecular Biology, University of Utah, Salt
Lake City: Ad2 fiber message isolated from abortively infected monkey cells is translatable in vitro.
G. ANTOINE, T. DORPER, R. SCHILLING, and E.-L. WINNACKER, Dept of Biochemistry, University of Munich,
Federal Republic of Germany: Defective expression of mouse adenovirus strain Fl in human cells.
F.A.M. ASSELBERGS, M.B. MATHEWS, and J.E. SMART, Cold Spring Harbor Laboratory, New York: Functional
domains and complexity of the adenovirus early region 2A proteins.
A. BABICH and J.R. NEVINS, Rockefeller University, New York, New York: Control of mRNA stability by the
Ad-5 72K DNA binding protein and evidence for its presence in mRNP.
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K.L. BERKNER and P.A. SHARP, Dept. of Biology, Massachusetts Institute of Technology, Cambridge:
Adenovirus as a mammalian cloning vector.
P.E. BRANTON,' S.-P. YEE,1 and D.T. ROWE,2 'Dept. of Pathology; 2Dept of Biology, McMaster University,
Hamilton, Canada: Identification of El polypeptides of Ad5 using a serum directed against the predicted
carboxy termini.
K.-C. CHOW, R.E. ENNS, K.G. AHERN, C.Z. MATHEWS, and G.D. PEARSON, Dept. of Biochemistry and
Biophysics, Oregon State University, Corvallis: Mapping the adenovirus origin.
B.M.M. DEKKER and J. VAN ORMONDT, Dept. of Medical Biochemistry, State University of Leiden, The
Netherlands: Structure and organization of the Ad5 genome between map positions 17 and 31.5 (frag-
ment Hind-C).
G.J. Duicou and S.G. ZIMMER, Dept. of Pathology, University of Kentucky Medical Center, Lexington:
Recombination of superinfecting Ad5 DNA with the integrated Ad2 DNA sequences of a rat cell
genome.
F. EGGERDING and W. PIERCE, Dept. of Pathology, University of California, Los Angeles: Construction of a
cloned library of restriction enzyme fragments from the Ad2 genome utilizing bacteriophage M13.
H. E5CHE, 1 B. SIEGMANN,1 and E. BAUSE,2 'Institute of Genetics, University of Cologne; 2Dept. of
Biochemistry, University of Cologne, Federal Republic of Germany: Antibodies to chemically synthe-
sized peptides localized on the amino-and carboxy-terminal regions of Ad12 tumor antigens.
L. FELDMAN and J. NEVINS, Rockefeller University, New York, New York: Antisera to adenovirus E1A
proteins.
T.R. GINGERAS, D. SCIAKY, R.E. GELINAS, B.-D. JIANG, C.E. YEN, M.M. KELLY, P.A BULLOCK, B.L. PARSONS, K.E.
O'NEILL, and R.J. ROBERTS, Cold Spring Harbor Laboratory, New York: Sequences from the Ad2 genome.
C.R. GORING and W.C. RUSSELL, National Institute for Medical Research, London, England: Characteristics
of adenovirus replication in vitro.
R.A. GUILFOYLE, W. OSHEROFF, and M. ROSSINI, Cold Spring Harbor Laboratory, New York: Analysis of the
regulatory interaction between early regions 1A and 2A.
D.N. HALBERT and T.E. SHENK, Dept. of Microbiology, State University of New York, Stony Brook: Analysis
of deletion and insertion mutations within early region 4 of Ad5.
P. HEARING and T. SHENK, Dept. of Microbiology, State University of New York, Stony Brook: Mutational
analysis of Ad5 E1A transcriptional control region.
D.R. HURWITZ and G. CHINNADURAI, Institute for Molecular Virology, St. Louis University Medical Center,
Missouri: Expression of Ad2 early gene region El A lacking the intervening sequences for the 13S mRNA.
M.J. IMPERIALE and J.R. NEVINS, Rockefeller University, New York, New York: Definition of transcriptional
control sequences of early adenovirus genes.
I. KRUCZEK and W. DOERFLER, Institute of Genetics, University of Cologne, Federal Republic of Germany:
Unmethylated DNA sequences in the promoter/leader and 5:regions of integrated adenovirus genes cor-
relate with gene expression.
H.J. LAANEN, B. ZELLE, J.S. SUSSENBACH, and T.H. ROZIJN, Laboratory for Physiological Chemistry, University
of Utrecht, The Netherlands: Integration of adenovirus sequences in human cells.
F.A. LASKI,' A. FIRE,' R. BELAGAJE,2 U. RAJBHANDARY.1 and P.A. SHARP,' 'Dept. of Biology, Massachusetts In-
stitute of Technology, Cambridge; 'Lilly Research Laboratories, Indianapolis, Indiana: Mutagenesis of a
tRNA gene to an amber suppressor.
J.B. LEWIS' and C.W. ANDERSON,2 'Molecular Biology Program, Fred Hutchinson Cancer Research Center,
Seattle, Washington; 2Dept. of Biology, Brookhaven National Laboratory, Upton, New York: The Ad2
"i-leader" encodes a 13.6K protein.
P. MALETTE, S.-P. YEE, and P.E. BRANTON, Dept. of Pathology, McMaster University, Hamilton, Canada:
Phosphorylation of the 58K El B antigen of Ad5.
V. MAUTNER, MRC Institute of Virology, Glasgow, Scotland: Recombination in adenovirus-Construction
and analysis of interserotypic recombinants with crossing-over sites in a defined region of the genome.
E.A. OOSTEROM-DRAGON and C.W. ANDERSON, Dept of Biology, Brookhaven National Laboratory, Upton,
New York: Polypeptide structure and encoding location of the Ad2 late, non-structural, phosphopro-
tein-33K.
T.F. OSBORNE, D. ROSSER, and A.J. BERK, Molecular Biology Institute, University of California, Los Angeles:
Upstream adenovirus DNA sequence required for E1A transcription in vivo.
J. OVERHAUSER and N.C. JONES, Dept. of Biological Sciences, Purdue University, West Lafayette, Indiana:
Splicing mutants in the transformation region of Ad5.
J. PUNTER,' E. LESCHINSKI,1 and E.-L. WINNACKER,2 'Dept. of Biochemistry, Hoechst A. G., Pharma Research,
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Frankfurt; 'Dept. of Biochemistry, University of Munich, Federal Republic of Germany: Monoclonal an-
tibodies against proteins from adenovirus type infected rat cells.
R.L. RADNA,1 L.A. FELDMAN,2 and H.L. OZER,' 'Dept. of Biological Sciences, Hunter College, City Universi-
ty of New York, New York; 'Dept. of Microbiology, College of Medicine and Dentistry, Newark, New
Jersey: Restriction of Ad2 replication in CHO.
W.D. RICHARDSON' and H. WESTPHAL,2 1Biochemistry Division, National Institute for Medical Research,
London, England; 'Laboratory of Molecular Genetics, NICHD, National Institutes of Health, Bethesda,
Maryland: Regulatory interactions among adenovirus early genes and adeno-associated virus.
A.W.M. RIJNDERS and J.S. SUSSENBACH, Laboratory for Physiological Chemistry, State University of Utrecht,
The Netherlands: Immunological analysis of Ad5 terminal protein.
J.A. RosE and J.E. JANIK, NIAID, National Institutes of Health, Bethesda, Maryland: Adenovirus-associated
virus polypeptide synthesis requires the adenovirus DNA-binding protein and VAI RNA.
M.L. SOPORI,t J.M. SHELL,' G.J. Duioou,2 and S.G. ZimmER,2 'Dept. of Medical Microbiology Immunology;
'Dept. of Pathology, University of Kentucky Medical Center, Lexington: Susceptibility of Ad2
transformed rat cell lines to natural killer cells-Lack of correlation between natural cytotoxicity and
tumorigenesis.
D.J. SPECTOR and M.J. TEVETHIA, Dept. of Microbiology, College of Medicine, Pennsylvania State University,
Hershey: Transformation of mouse embryo fibroblasts by DNA from adenovirus transformed human cell
line 293.
C. SVENSSON, U. PETTERSSON, and G. AxusJARvi, Dept. of Microbiology, University of Uppsala, Sweden: Ex-
perimental evidence that RNA splicing proceeds over intermediate stages.
H.E. TAKIFF and S.E. STRAUS, NIAID, National Institutes of Health, Bethesda, Maryland: Enteric adenovirus
(EAd) DNAs-Cloning, mapping, and homology studies.
M. TOTH and J. WEBER, Dept. de Microbiologie, Faculte de medecine, Centre Hospitalier Universitaire,
Sherbrooke, Canada: Nuclease sensitivity of Ad2 chromatin.
M. TREMBLAY, C.V. DERV, and J. WEBER, Dept. de Microbiologie, Centre Hospitalier Universitaire de Sher-
brooke, Canada: In vitro cleavage specificity of the Ad2 protease.
B.G.M. VAN BERGEN, P.A. DER LEIJ, W. VAN DRIEL, and P.C. VAN DER VLIET, Laboratory for Physiological
Chemistry, University of Utrecht, The Netherlands: Replication of adenovirus DNA and various
plasmids in vitro using nuclear extract of Ad5, H5ts125 and H5ts36.
M.P. VAN BREE and J.A. ENGLER, Cold Spring Harbor Laboratory, New York: Comparable regulatory signals
encoded in DNAs from different classes of adenoviruses are usually conserved.
P. VAN DEN ELSEN, A. HOUWELING, and A. VAN DER EB, Dept. of Medical Biochemistry, State University of
Leiden, The Netherlands: Studies on the role of region E1b of Ad5 in cell transformation.
L. VARDIMON, D. RENZ, and W. DOERFLER, Institute of Genetics, University of Cologne, Federal Republic of
Germany: Methylation of specific DNA sequences inhibits expression of a viral gene.
M.E. VAYDA, K. LEONG, and S.J. FLINT, Dept. of Biochemical Sciences, Princeton University, New Jersey:
The structure and transcription in vitro of nucleoprotein cores isolated from adenovirions.
A. VIRTANEN, P. ALESTROM, N. BALGOBIN, J. CHATTOPADHYAYA, and U. PETTERSSON, Depts. of Medical
Genetics and Microbiology, University of Uppsala, Sweden: Analysis of adenovirus 51termini by reverse
transcription.
R.J. VOSATKA, A.R. SHAW, and E.B. ZIFF, Dept. of Biochemistry, New York University Medical Center, New
York: Ad2 chromatin and transcriptional control.
K. YOSHIDA and K. FUJINAGA, Dept of Molecular Biology, Cancer Research Institute, Sapporo Medical Col-
lege, Japan: Structure and expression of integrated viral DNA in a rat cell line transformed by the left-
most 7.8% fragment of Ad7 DNA.
SESSION 4 Adenoviruses: Transcription
Chairperson: D. KLESSIG, University of Utah Medical Center, Salt Lake City, Utah
P. SASSONE-CORSI, J. CORDEN, R.HEN, R. ELKAIM, T. LEFF, C. KEDINGER, and P. CHAMBON, Laboratoire de Gen-
etique Moleculaire des Eucaryotes du CNRS Unite 184 de Biologie Moleculaire et de Genie Genetique
de INSERM, Faculte de Medecine, Strasbourg, France: Sequence elements controlling the transcription
of adenovirus protein coding genes.
M. SAMUELS, A. FIRE, and P.A. SHARP, Dept. of Biology, Massachusetts Institute of Technology, Cambridge:
Protein fractions required for transcription of adenovirus genes in vitro.
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T. BURGESS, T. CREFELD, N. HERNANDEZ, K. SASS, D. SOLNICK, B. WEINGARTNER, and W. KELLER, Institute Of Cell
and Tumor Biology, German Cancer Research Center, Heidelberg, Federal Republic of Germany:
Transcription and processing of mRNAs in vitro.
C. AHMED, R. CHANDA, R. WATKINS, and S. ZAIN, Microbiology and Cancer Center, University of Rochester
Medical Center, New York: Transcription and RNA processing of mRNA in vivo and in vitro from early
gene block III of Ad2.
C. MONTELL,1 E. FISHER,2 M. CARUTHERS,2 and A. BERK,' Molecular Biology Institute, University of Califor-
nia, Los Angeles; 2Dept. of Chemistry, University of Colorado, Boulder: Site specific mutagenesis into
adenovirus mRNA processing signals.
J.S. LOGAN, P.D. SOLOWAY, and T. SHENK, Dept. of Microbiology, State University of New York, Stony
Brook: Sequences involved in the control of the production and translation of late mRNA in adenovirus
infected cells.
G. AKusJAKvi and C. SVENSSON, Dept. of Microbiology, University of Uppsala, Sweden: Cloning of the com-
plex arrangement of 5 '-leaders attached to the fiber mRNA of Ad2.
G.A. FREYER, Y. KA-roH, and R.J. ROBERTS, Cold Spring Harbor Laboratory, New York: Characterization of the
mature transcripts from region E4 of Ad2.
M.G. KATZE, H. PERSSON, and L. PHILIPSON, Dept. of Microbiology, University of Uppsala, Sweden: A left-
ward reading transcript from the transforming region of adenovirus DNA encoding a low molecular
weight polypeptide.
A.M. FRANCOEUR and M.B. MATHEWS, Cold Spring Harbor Laboratory, New York: Formation of ribonucleo-
protein particle containing adenovirus VA RNAs and the lupus antigen, La.
J. MANLEY, D. GRASS, Y.-T. Yu, and D. LEWIS, Dept. of Biological Sciences, Columbia University, New York,
New York: Properties of some adenovirus-5V40 hybrids created in vitro.
SESSION 5 Adenoviruses: Regulation of Gene Expression
Chairperson: T. SHENK, State University of New York, Medical School, Stony Brook, New York
M.J. IMPERIALE, L.T. FELDMAN, H.-T. KAO, and J.R. NEVINS, Rockefeller University, New York, New York:
Mechanism of induction of early adenovirus transcription by the El A protein.
D.L. WEEKS and N.C. JONES, Dept. of Biological Sciences, Purdue University, West Lafayette, Indiana: The
effect of the Ela gene product on early viral promotors.
J.L. B05, A.-G. JOCHEMSEN, H. TEN WOLDE, H. VAN ORMONDT, and A.J. VAN DER EB, Dept. of Medical
Biochemistry, State University of Leiden, The Netherlands: Expression of an Ad12 El B-hsv tk fusion
gene is controlled by adenovirus region El a.
C. WEINBERGER, R. SCHNEIDER, B. THIMMAPPAYA, and T. SHENK, Dept. of Microbiology, State University of
New York, Stony Brook: Adenovirus VAI RNA is required for efficient translation of viral late mRNAs.
R.A. BHAT and B. THIMMAPPAYA, Dept. of Microbiology and Immunology, Northwestern University Medical
School, Chicago, Illinois: Construction and in vivo analysis of deletion and substitution mutations of VA
RNA genes of Ad5.
C. THUMMEL,1 R. TJIAN,1 S.-L. Hu,2 and T. GRODZICKER,2 Dept. Of Biochemistry, University of California,
Berkeley; 'Cold Spring Harbor Laboratory, New York: Regulatory sequences required for efficient ex-
pression of SV40 T antigen from the adenovirus late promoter.
B.D. KARGER," Y.-S. Ho,' C.L. CASSTIGLIA,2 S.J. FLINT,2 and J. WILLIAMS,' 'Dept. of Biological Sciences,
Carnegie-Mellon University, Pittsburgh, Pennsylvania; 2Dept. of Biochemical Sciences, Princeton
University, New Jersey: An adenoviral E1B gene product is involved in control of the early-late switch in
lytic infection of HeLa cells.
G. KETNER, Dept. of Biology, Johns Hopkins University, Baltimore, Maryland: An adenovirus mutant defec-
tive in the accumulation of translatable late mRNA.
S. RICE, R. BOONE, and D.F. KLESSIG, Dept. of Cellular, Viral, and Molecular Biology, University of Utah, Salt
Lake City: Genetic and biochemical characterization of the adenovirus 72Kd DNA-binding protein.
L.FELDMAN, A. BABICH, and J. DARNELL, Rockefeller University, New York, New York: Effects of adenovirus
infection on host cell RNA metabolism.
SESSION 6A Poster Session: Papovaviruses. I.
A. BARKAN and J.E. MERTZ, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison:
Mutations in the SV40 VP-1 gene can partially compensate for deletions in the late leader region.
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S. BEECHER, V. BLASQUEZ, and M. BINA, Dept. of Chemistry, Purdue University, West Lafayette, Indiana: A
topoisomerase activity copurifies with SV40 virions.
A. BEN-ZE'EV, R. ABULAFIA, and Y. ALONI, Dept. of Genetics, Weizmann Institute of Science, Rehovot, Israel:
5V40 virions and viral RNA metabolism are associated with cellular substructures.
S.S. CHEN, and M.T. Hsu, 2 'Shanghai Second Medical College, China; 2Dept. of Molecular Cell Biology,
Rockefeller University, New York, New York: Enrichment of SV40 active chromatin by differential
precipitation with Mg+2.
L.T. CHOW and T.R. BROKER, Cold Spring Harbor Laboratory, New York: Transcription of human papilloma
virus-1 from the SV40 early and late promotors in hybrid shuttle vectors transfected into COS-1 cells.
C. CREMISI, Institut de Recherches Scientifiques sur le Cancer, Villejuif, France: Undifferentiated murine
teratocarcinoma cells (EC cells) treated by 5-azacytidine become sensitive to polyoma virus and SV40.
H.J. EDENBERG, Dept. of Biochemistry, Indiana University Medical School, Indianapolis: Ultraviolet light in-
hibits SV40 DNA replication.
M.S. FEATHERSTONE, M.A. NAUJOKAS, B.J. POMERANTZ, C.R. MUELLER, and J.A. HASSELL, Dept of Microbiology
and immunology, McGill University, Montreal, Canada: Construction of a plasmid vehicle suitable for
the molecular cloning and characterization of mammalian promoters.
M.M. FLUCK, Dept. of Microbiology, Michigan State University, East Lansing: Recombination between
unintegrated viral genomes-A potentially essential step in transformation by polyoma virus.
A. FRADIN, T. MICHAELI, R. JOVE, D. GRASS, C. PRIVES, and J. MANLEY, Dept. of Biological Sciences, Columbia
University, New York, New York: The Influence of DNA structure on 5V40 gene expression in Xenopus
Laevis oocytes.
T. GURNEY, D. SORENSON, E. GURNEY, and N. WILLS, Dept. of Biology, University of Utah, Salt Lake City: A
new method for rapid isolation of rare SV40 RNA species.
G.Z. HERTZ, L.A. TRIMBLE, A. BARKAN, M. SOMASEKHAR, and J.E. MERTZ, McArdle Laboratory for Cancer
Research, University of Wisconsin, Madison: Sequences involved in the promotion and initiation of late
strand transcription.
M. HOROWITZ, R.J. KAUFMAN, and P.A. SHARP, Dept. of Biology, Massachusetts Institute of Technology,
Cambridge: Expression of the mouse dihydrofolate reductase cDNA cloned in the early region of SV40.
E.B. JAKOBOVITS, R. ABULAFIA, and Y. ALONI, Dept. of Genetics, Weizmann Institute of Science, Rehovot,
Israel: Temperature sensitive B mutants of SV40 de-assemble intracellular encapsidation particles at
elevated temperature.
S.R. JASKUNAS, S.R. KING, and S.L. MARVO, Dept. of Chemistry, Indiana University, Bloomington: The role
of DNA gyrase in catalyzing illegitimate recombinations.
M. LANGE and E. MAY, Institut de Recherches Scientifiques sur le Cancer, Villejuif, France: Study of DNA
sequences required for transcription of SV40 late genes.
S.G. LAZAROWITZ and S. LEE, Dept of Molecular Biology and Genetics, Johns Hopkins University Medical
School, Baltimore, Maryland: Mutations in the control region of SV40 that affect late gene expression.
D. LYCAN and K.J. DANNA, Dept. of Molecular, Cellular, and Developmental Biology, University of Col-
orado, Boulder: Characterization of the 5' termini of purified nascent SV40 late transcripts.
G. MAGNUSSON and S.V. NILSSON, Dept. of Biochemistry, Karolinska Institute, Stockholm, Sweden:
Polyoma splice point mutants produce a restricted set of T-antigens.
H. MANOR, N. BARAN, and A. NEER, Dept. of Biology, Technion-Israel Institute of Technology, Haifa:
"Onion skin" replication of chromosome-associated polyoma virus DNA and flanking sequences in
polyoma-transformed rat cells-Identification of a cellular termination site for replication.
B. MILAVETZ, and T. HOPKINS, Cancer Research Laboratory, University of Western Ontario, Canada: Iden-
tification of an early SV40 encapsidation intermediate.
C.R. MUELLER, A.-M. MES, B.J. POMERANTZ, M.A. NAUJOKAS, M. FEATHERSTONE, and J.L. HASSELL, Dept. of
Microbiology and Immunology, McGill University, Montreal, Canada: The structure of the polyoma
virus early promoter-Sequences required for expression and T-antigen binding.
W.J. MULLER, M.A. NAUJOKAS, C.S. MUELLER, A.-M. MES, M. FEATHERSTONE, and J.A. HASSELL, Dept. of
Microbiology and Immunology, McGill University, Quebec, Canada: Cis-acting sequences required for
the replication of polyoma virus DNA.
S.-C. NG, S. BEECHER, and M. BINA, Dept. of Chemistry, Purdue University, West Lafayatte, Indiana:
Chromatin structure of the SV40 assembly defective mutant, tsBC216.
F. O'NEILL, 1,2E. MARYON, land T. MILLER, 2 'Dept. of Cellular, Viral, and Molecular Biology, University of
Utah; 'Veterans Administration Medical Center, Salt Lake City, Utah: Production of latent infections in
green monkey cells with SV40 containing a bipartite genome.
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A. PATER, M. PATER, L.S. CHANG, and G. DI MAYORCA, Dept. of Microbiology, University of Medicine and
Dentistry of New Jersey, Newark: The genome of RF consists of two complementary defective
molecules.
B.J. POMERANTZ, W.J. MULLER, A.-M. MES, M.A. NAUJOKAS, and J.A. HASSELL, Dept. of Microbiology and Im-
munology, McGill University, Montreal, Canada: Homologous recombination between cotransfected
polyoma virus-plasmid genomes.
M. RABIN, O.C. UHLENBECK, D.M. STEFFENSEN,2 and W.F. MANGEL,' 'Dept. of Biochemistry; 2Dept. of
Genetics and Development, University of Illinois, Urbana: Chromosomal sites of integration of SV40
DNA sequences mapped in in situ hybridization are identical in two independently transformed hybrid
cell lines.
K. RUDOLPH and K. MANN, Dept. of Biology, University of Alaska, Anchorage: Effect of salt on the associa-
tion of SV40 T antigen with SV40 nucleoprotein complexes.
P. SHAW, and W. KELLER, Institute of Cell and Tumor Biology, German Cancer Research Center,
Heidelberg, Federal Republic of Germany: Chimaeric mRNAs in SV40-transformed cells.
C.C. SIMONSEN, H.M. SHEPARD, A.D. LEVINSON, and D.V. GOEDDEL, Dept. of Molecular Biology, Genentech,
Inc., South San Francisco, California: Synthesis of human immune interferon in cultured monkey cells
using SV40-pBR322 hybrid plasmids.
J.R. STRINGER and Y. GLUZMAN, Cold Spring Harbor Laboratory, New York: Exision of SV40 from a
specialized Ad-SV40 hybrid virus.
K.N. SUBRAMANIAN, Dept. of Microbiology and Immunology, University of Illinois Medical Center,
Chicago: Effect of in vitro methylation at CpG sites on gene expression in a papovavirus genome func-
tioning autonomously in a vertebrate host.
G. SWIMMER and T. SHENK, Dept. of Microbiology, State University of New York, Stony Brook: Mutational
events which restore poly A addition sites to SV40 variants whose late transcription unit lacks the wild-
type signal.
A. VARSHAYSKY,1 E. OZKAYNAK,1 and 0. SUNDIN.2 'Dept. of Biology, Massachusetts Institute of Technology,
Cambridge; 2Cold Spring Harbor Laboratory, New York: Multiply intertwined catenated SV40 dimers as
segregation intermediates-Formation, processing, and chromatin structure.
M.A. WAGAR, B.M. SAHAI, L.R. DAVIS, D. KOWALSKI, and J.A. HUBERMAN, Dept. of Cell and Tumor Biology,
Roswell Park Memorial Institute, Buffalo, New York: Association of exonuclease and topoisomerase II
activities with SV40 chromosomes.
M. ZANNIS-HADJOPOULOS, A.B. CHEPELINSKY, and R.G. MARTIN, NIADDK, National Institutes of Health,
Bethesda, Maryland: Mapping of the 3 '-ends of SV40 nascent strands.
SESSION 6B Poster Session: Papovaviruses. II.
S. BENCHIMOL and L. CRAWFORD, Imperial Cancer Research Fund Laboratories, London, England: A novel
radioimmunoassay to measure p53 levels in SV40-transformed and other rodent cells.
G. BLANCK,1 A. LEVITT,' S. CHEN,' R. POLLACK,' and S. WEISSMAN,' 'Dept. of Biological Sciences, Columbia
University, New York, New York; 2Yale University Medical School, New Haven, Connecticut: Integra-
tion and loss of defective viral DNA in SV40 mouse transformants.
K. BLASHKA, A. PATER, M. PATER, and G. DI MAYORCA, Dept. of Microbiology, University of Medicine and
Dentistry of New Jersey, Newark: Cloning of BKV DNA sequences from a carcinoma of kidney and a
carcinoid tumor.
C. BURGER, A. DORN, D. BRAUER, R. KNIPPERS, and E. FANNING, Faculty for Biology, University of Konstanz,
Federal Republic of Germany: DNA binding properties of subclasses of large T antigen from SV40-infec-
ted and -transformed cells.
B. CARROLL,' E.G. GURNEY,' and J.A. MELER0,1 'Dept. of Pathology, New York University Medical School,
New York; 2Dept. of Biology, University of Utah, Salt Lake City: Studies of the time-dependent matura-
tion of the SV40 large T Agp53 complex using monoclonal antibodies.
A.E. CAMPBELL and S.S. TEVETHIA, Dept. of Microbiology, Pennsylvania State University College of
Medicine, Hershey: Evidence for multiple antigenic sites of the SV40 TSTA using cytotoxic T lympho-
cyte clones.
K. CHANDRASEKARAN,1 D.T. SIMMONS,2 and P.T. MORA,' 1 NCI, National Institutes of Health, Bethesda,
Maryland; 2School of Life and Health Sciences, University of Delaware, Newark: Selection of SV40 T
antigen negative "mutants" and the cellular p53; also embryogenesis, embryonal carcinoma cell dif-
ferentiation and the cellular p53.
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S. CHEN and R. POLLACK, Dept. of Biological Sciences, Columbia University, New York, New York: Linkage
of expression of host 54K protein and susceptibility to SV40 transformation in inbred strains of mice.
R. CLARK,' K. PEDEN,2 J.M. PIPAS,3 D. NATHANS,2 and R. TJIAN,1 'Dept. of Biochemistry, University of Califor-
nia, Berkeley; 'Dept. of Molecular Biology and Genetics, Johns Hopkins Medical School, Baltimore,
Maryland; 3Dept. of Biological Sciences, University of Pittsburgh, Pennsylvania: Biochemical analysis
of mutant SV40 T antigens.
P. CLERTANT and F. CUZIN, Centre de Biochimie du CNRS, Universite de Nice, France: Characterization of
the nucleotide binding site evidenced by covalent affinity labeling with oxidized-ATP on the large-T pro-
teins of polyoma and SV40 viruses.
L. COVEY, A. SCHELLER, and C. PRIVES, Dept. of Biological Sciences, Columbia University, New York, New
York: The different forms and functions of SV40 large T antigen.
J. FEUNTEUN, F. PECCEU, and B. GRIMA, Institut de Recherches Scientifique sur le Cancer, Villejuif, France:
Analysis of immortalization by SV40.
L. FISCHER FANTUZZI1 and C. VEsco,' 'Centro Studi Acidi Nucleici del CNR; 'Istituto di Biologia Cellulare
del CNR, Roma, Italy: Cold-sensitive growth of SV40 in semipermissive variants of CV1 cells.
R.E. GILES, F. BOYCE, and W.W. BROCKMAN, Dept. of Microbiology and Immunology, University of
Michigan Medical School, Ann Arbor: Evaluation of the mutagenic effects of SV40 in mouse, hamster,
human and mouse X human hybrid cells.
J. GOUDSMIT, J. TER SCHEGGET, A. VAN STRIEN, and J. VAN DER NOORDAA, Laboratorium voor de Gezondheid-
sleer, University of Amsterdam, The Netherlands: Primary BKV infections associated with acute
respiratory disease and characterization of a BKV isolate (Dik) from a child with tonsillitis.
D. GRASS, S. CHEN, G. BLANCK, N. NICHOLSON, A. SCHELLER, C. PRIVES, R. POLLACK, and J. MANLEY, Dept. of
Biological Sciences, Columbia University, New York, New York: Lytic and transforming properties of a
novel origin-minus SV40 mutant.
A. GRAESSMANN and M. GRAESSMANN, Institut fur Molekularbiologie and Biochemie der Freien Universitaet
Berlin, Federal Republic of Germany: Transformation capacity of early SV40 DNA fragments.
Y. ITO,t E. APPELLA,2 K. SEGAWA," and Y. HAMAGISHI,1 1NIAID; 'NCI, National Institutes of Health, Bethesda,
Maryland: Antiserum against a synthetic polypeptide representing a part of the unique region of
polyoma virus middle T antigen which inhibits middle T antigen phosphorylating activity.
D. KALDERON, B. OOSTRA, and A.E. SMITH, Biochemistry Division, National Institute for Medical Research,
London, England: Site-specific mutagenesis to produce deletion and point mutants in a putative DNA
domain of SV40 large-T.
D.P. LANE and J. GANNON, Dept. of Biochemistry, Imperial College of Science and Technology, London,
England: Radioimmunometric assay of human p53-Application to the quantitation, characterization,
and purification of human p53 proteins.
E.O. MAJOR,' 2 and T. KOKIOHN,2 1NINCDS, National Institutes of Health, Bethesda, Maryland; 'Dept. of
Microbiology, Loyola University Medical School, Maywood, Illinois: Expression of human papova-
viruses in experimental cell substrates.
L.H. MALKAS,1 E. BARIL,2 and H.L. OzER,t 'Hunter College, City University of New York, New York;
'Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts: Induction of enzymes of
nucleotide metabolism by SV40 in quiescent mouse cells temperature sensitive for DNA synthesis.
N. MILLER, W. WALLEN, and W. LONDON, NIAID, National Institutes of Health, Bethesda, Maryland: Brain
tumors produced in owl monkeys by JC virus contain integrated JCV DNA.
M. MONTENARH and R. HENNING, Dept. of Biochemistry, University of Ulm, Federal Republic of Germany:
SV40 large T antigen is oligomerized in vivo via divalent cations.
M. OREN' and A.J. LEVINE,2 'Dept. of Chemical Immunology, Weizmann Institute of Science, Rehovot,
Israel; 'Dept. of Microbiology, State University of New York, Stony Brook: Molecular cloning of cDNA
specific for the murine p53 cellular tumor antigen.
N.C. REICH, R. THOMAS, and A.J. LEVINE, Dept. of Microbiology, State University of New York, Stony Brook:
The regulation of a cellular protein, P53, in nontransformed and transformed cells.
K. RUNDELL, Dept. of Microbiology and Immunology, Northwestern University, Chicago, Illinois: Effects of
MGBG and some mitochondria! ionophores on SV40 small t-antigen functions.
A.H. SAMAD,1 W.N. SCHMIDT,2 L.S. HNILICA,2 J.E. HARPER,' A.S. BLUM,t R.S. MANN,' Si. KENNETT,' and R.B.
CARROLL,' 'Dept. of Pathology, New York University Medical School, New York; 'Dept. of
Biochemistry, Vanderbilt University Medical School, Nashville, Tennessee: SV40 T antigen, the host
p53, Novikoff hepatoma p39, p49, and p56 antigens, and cytokeratins cross-react with purified lamins
(Mr 60K, 67K, and 70K, nuclear matrix proteins).
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B. SCHAFFHAUSEN,' G. CARMICHAEL,' T. ROBERTS,' H. DORAI,t and T. BENJAMIN,' 'Dept. of Pathology, Har-
vard Medical School, Boston, Massachusetts; 'Dept. of Microbiology, University of Connecticut, Farm-
ington; 3Sidney Farber Cancer Institute, Boston, Massachusetts: Studies on polyoma virus middle T
antigen.
K.H. SCHEIDTMANN, B. ECHLE, and G. WALTER, Institut fur Immunbiologie, Freiburg, Federal Republic of Ger-
many: Mapping of phosphorylation sites of SV40 large T antigen.
M.K. SCHMITT and K. MANN, Dept. of Biology, University of Alaska, Anchorage: Modification of SV40 T an-
tigen by glycosylation.
K. SEGAWA,1 D. COSMAN,2 T. KANDA,1 G. KHOURY,' and K.K. TAKEMOT0,1 1NIAID; 2NCI, National Institutes
of Health, Bethesda, Maryland: Identification of B-Iymphotropic papovavirus-coded proteins.
R. SEIF, Laboratoire d'Enzymologie du CRNS, Gif-sur-Yvette, France: Rat cells transformed by SV40 give
rise to tumor cells that contain no viral proteins and often no detectable viral DNA.
A.E. SMITH, M. GALLEGO, E. PAUCHA, R. HARVEY, N. LINDSAY, R. FAULKES, and P. GILLETT, Biochemistry Divi-
sion, National Institute for Medical Research, London, England: Conventional and monoclonal an-
tibodies against peptides from SV40 large-T and small-t and polyoma virus middle-T.
E. SOEDA, Y. MAKI, Y. NAKANO, and H. TASHIRO, National Institute of Genetics, Misima, Japan: Transforma-
tion with the DNA fragments encompassing the polyoma virus promoter.
M. STAL'FENBIEL and W. DEPPERT, University of UM, Federal Republic of Germany: Nuclear subclasses of
SV40 T-antigen.
D. STEDMAN and R. HAND, McGill Cancer Centre, Montreal, Canada: Enzymatic activities of the multiple
forms of D2 T antigen.
V. STEINBERG and L. NORKIN, Dept. of Microbiology, University of Massachusetts, Amherst: State of the viral
genomes in Rhesus monkey kidney, human neuroblastoma, and human glioblastoma cell lines per-
sistently infected with SV40 or BKV.
J. TER SCHEGGET, C.J.A. SOL, E. WOUTERS, and J. VAN DER NOORDAA, Laboratorium voor de Gezondheidsleer,
University of Amsterdam, The Netherlands: Comparison of the genomes of two BKV variants BKV (JL)
and BKV (Dik) with prototype BKV.
J. WALSH,' J. OELTGEN,1 S. ZIMMER,' and M. PERDUE,' Dept. of Neurosurgery, Lexington VA Hospital,
University of Kentucky; 2Dept. of Pathology and 3Dept. of Medical Microbiology and Immunology,
University of Kentucky, Lexington: Determinants of histological type and degree of invasiveness in ex-
perimentally produced primary intracranial tumors.
G. WALTER, M. HARDUNG, and K.-H. SCHEIDTMANN, Institute for Immunebiology, University of Freiburg,
Federal Republic of Germany: Relationship between DNA-binding, age, oligomerization, and
phosphorylation state of SV40 large T antigen.
SESSION 7 SV40, Polyoma, and Adenovirus: Transformation
Chairperson: P. RIGBY, Imperial College, London, England
C. GELINAS, C. ASSELIN, and M. BASTIN, Dept. of Microbiology, University of Sherbrooke, Canada: Mutant of
polyoma virus with normal transforming ability but impaired tumorigenic potential.
H. Ozer, B. Stillman, P. Sharp, E. Winocour
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M. Horowitz, A. Levine
D. DORSKY and T. BENJAMIN, Dept. of Pathology, Harvard Medical School, Boston, Massachusetts: Host cell
alterations induced by polyoma small t-antigen.
M. RASSOULZADEGAN,1 A. COWIE,2 A. CARR,2 Z. NAGHASHFAR,1 N. GLAICHENHAUS,1 R. TREISMAN,2 J. FAVA-
LOR0,2 R. KAMEN,2 and F. CUZIN,1 'Centre de Biochimie du CNRS, Universite de Nice, France;
'Transcription Laboratory, Imperial Cancer Research Fund Laboratories, London, England: Separate and
complementary roles for polyoma virus early proteins in the alteration of cell growth requirements
leading to transformation.
L.-S. CHANG, M.M. PATER, and G. DI MAYORCA, Dept. of Microbiology, University of Medicine and Dentistry
of New Jersey, Newark: SV40 small t can enhance large T to transform BHK cells to anchorage
independence.
0. SUNDIN and Y. GLUZMAN, Cold Spring Harbor Laboratory, New York: Stable transformation of monkey
cells by genes expressing temperature sensitive SV40 T antigen.
K.-H. CHOI,' S. TEVETHIA,2 and S. SHIN,' 'Dept. of Genetics, Albert Einstein College of Medicine, Bronx,
New York; 'Dept. of Microbiology, Pennsylvania University College of Medicine: Tumor rejection of
SV40- transformed human cells by nude mice.
E.H. BROWN, F. LABELLA, and C. BASILICO, Dept. of Pathology, New York University School of Medicine,
New York: Induction of amplification of the DHFR gene in polyoma transformed rat cells.
M.R.D. SCOTT,' P.M. BRICKELL,1 D.S. LATCHMAN,1 D. MURPHY,' K.-H. WESTPHAL,' K. WICLISON,2 and P.W.J.
RIGBY,' 'Dept. of Biochemistry, Imperial College of Science and Technology; 'Chester Beatty Research
Institute, London, England: The activation of cellular genes in SV40-transformed cells.
T. SCHUTZBANK, R. ROBINSON, and A.J. LEVINE, Dept. of Microbiology, State University of New York, Stony
Brook: Cells transformed by a wide variety of agents express higher abundance levels of some cellular
RNA species.
R. BERNARDS, M.J. VAESSEN, P.I. SCHRIER, and A.J. VAN DER EB, Dept. of Medical Biochemistry, State Universi-
ty of Leiden, The Netherlands: Localization of the oncogenic potential of human adenoviruses.
P.J. BYRD, J.L. WHITTAKER, K.W. BROWN, and P.H. GALLIMORE, Dept. of Cancer Studies, University of Birm-
ingham Medical School, England: Transformation of human cells by cloned Ad12 El.
SESSION 8 SV40 and Polyoma: T Antigens. I.
Chairperson: M. FRIED, Imperial Cancer Research Fund Laboratories, London, England
R. TJIAN, D. Rio, and M. LEARNED, Dept. of Biochemistry, University of California, Berkeley: Regulation of
viral and host transcription by 5V40 T antigen.
R.F. MARGOLSKEE, R.A.F. DIXON, and D. NATHANS, Dept. of Molecular Biology and Genetics, Johns Hopkins
University, Baltimore, Maryland: The binding of SV40 T antigen to DNA of viral regulatory mutants.
A. DELuciA, B. LEWTON, K. RYDER, V. WILSON, and P. TEGTMEYER, Dept. of Microbiology, State University of
New York, Stony Brook: The arrangement of SV40 A protein bound to the SV40 origin of replication.
D.G. TENEN,1 R.G. MARTIN,' L.L. HAINES,' and T.S. TAYLOR,' tSidney Farber Cancer Institute, Harvard
Medical School, Boston, Massacusetts; 'National Institutes of Health, Bethesda, Maryland: Origin
specific DNA binding activity of SV40 T antigen (T) from lytically infected cells and comparison of its
behavior with D2T antigen.
A. COWIE,' S. DILWORTH,' F. CHAUDRY,2 R. KAMEN,' S. LUPTON,' C. TYNDALL,2 G. VELDMAN,' and Z. ZHU,'
'Imperial Cancer Research Fund; 'National Institute for Medical Research, London, England: Two in-
dependent binding sites for the large-T protein in polyoma virus DNA.
A. SCHELLER and C. PRIVES, Dept. of Biological Sciences, Columbia University, New York, New York:
Polyoma and SV40 T antigens bind to two discrete sites at both viral origins.
P. GAUDRAY, L. TREJO-AVILA, C. GALUP, and F. CUZIN, Centre de Biochimie du CNRS, Universite de Nice,
France: A high affinity binding site for polyoma virus large-T protein in the mouse genome.
J. PIPAS,1 K. PEDEN,' K. SOPRANO,3 N. GALANTI,3 G. JONAK,3 R. BASERGA,3 and D. NATHANS,2 1 Dept. of
Biological Sciences, University of Pittsburgh, Pennsylvania; 'Dept. of Molecular Biology and Genetics,
Johns Hopkins University Medical School, Baltimore, Maryland; 3Dept. of Pathology, Temple Universi-
ty Medical School, Philadelphia, Pennsylvania: Characterization of mutants with deletions in the gene
for SV40 T antigen.
J. TORNOW and C.N. COLE, Dept. of Human Genetics, Yale University, New Haven, Connecticut: In-
tracistronic complementation in the A gene of SV40.
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H. TURLER and C. SALOMON, Dept. of Molecular Biology, University of Geneva, Switzerland: Role of small
and middle T-antigens in lytic and abortive infections by polyoma virus.
D. TEMPLETON' and W. ECKHART,' 'University of California, San Diego; 'Salk Institute, La Jolla, California:
Cold-sensitive non-transforming mutants of polyoma virus.
SESSION 9 SV40, Polyoma, and Adenoviruses: T Antigens. II.
Chairperson: C. PRIVES, Columbia University, New York, New York
K. SEGAWA and Y. I-ro, NIAID, National Institutes of Health, Bethesda, Maryland: Differential subcellular
localization of in vivo phosphorylated and non-phosphorylated middle T antigen of polyoma virus and
its relationship to middle T antigen phosphorylating activity in vitro.
B. ELY and A.E. SMITH, Biochemistry Division, National Institute for Medical Research, London, England:
Temperature-sensitive mutants in the polyoma virus middle-T associated protein kinase.
G. WALTER,' M.A. HUTCHINSON,' T. HUNTER,' and W. ECKHART,' tInstitut filir Immunbiologie der Albert-
Ludwigs Universitat, Freiburg, Federal Republic of Germany; 'Salk Institute, San Diego, California:
Purification of the polyoma virus middle size t antigen by immune affinity chromatography.
S.M. DILWORTH,' M. GINSBURG,' B.E. GRIFFIN,' H.A. HANSON,' and G. BJURSELL,3 'Imperial Cancer Research
Fund, London, England; 2Dept. of Histology; 3Dept. of Medical Biochemistry, University of Gothen-
berg, Sweden: Investigation of the properties of polyoma T-antigens by monoclonal antibodies.
K. LEPPARD and L.V. CRAWFORD, Imperial Cancer Research Fund Laboratories, London, England: A new
series of monoclonal antibodies specific for primate p53.
I. BIKEL, T. ROBERTS, R. GREEN, M.L. BLADON, and D. LIVINGSTON, Sidney Farber Cancer Institute, Harvard
Medical School, Boston, Massachusetts: Extensive purification of biologically active SV40 small t an-
tigen from an overproducing clone of E. coli
R. SE[F, Laboratoire d'Enzymologie du CNRS, Gif-sur-Yvette, France: SV40 large T releases a C-terminal
peptide, binds to protease inhibitors and is similar to Rec A protein of E. coli.
D.T. ROWE and F.L. GRAHAM, Depts. of Biology and Pathology, McMaster University, Hamilton, Canada:
Kinetics of synthesis of early viral proteins in KB cells infected with WT and HR mutants of human Ad5.
TSUKAMOT0,2 F. PONTICELLI,2 and A. BERK,' 1 Dept. of Medicine, School of
Medicine; 'Molecular Biology Institute, University of California, Los Angeles: Enhanced expression and
analysis of phosphorylation of adenovirus El A proteins.
P. SARNOW,1 C.W. ANDERSON,' N.C. REICH,' and A.J. LEVINE,' 1 Dept. of Microbiology, State University of
New York, Stony Brook; 2Dept. of Biology, Brookhaven National Laboratory, Upton, New York; Iden-
tification and characterization of two adenovirus type 5 early region 4 polypeptides.
SESSION 10 SV40 and Polyoma: Chromatin Replication, Organization and Virion Assembly
Chairperson: M. DEPAMPHILIS, Harvard Medical School, Boston, Massachusetts
W. WALDECK, Institute for Virus Research, German Cancer Research Center, Heidelberg, Federal Republic
of Germany: SV40 chromatin associated topoisomerase recombines DNA in a homologous reaction.
K. MANN, Dept. of Biology, University of Alaska, Anchorage: Association of topoisomerase activity with
SV40 nucleoprotein complexes.
M.E. CUSICK, M.L. DEPAMPHILIS, and P.M. WASSARMAN, Dept. of Biological Chemistry, Harvard Medical
School, Boston, Massachusetts: Segregation and maturation of nucleosomes on replicating SV40
chromosomes
G.W. ROBINSON,' S.K. KONDOLEON,2 and L.M. HALLICK,2 Dept. of Biochemistry; 2Dept. of Microbiology
and Immunology, Oregon Health Sciences University, Portland: Psoralen photoaddition to
SV40-Virion "nucleosomes" differ from intracellular nucleosomes.
S.A. NEDOSPASOV,1 A.N. SHAKHOV,1 S.V. RASIN,t S.A. CHUVPILL0,2 V.G. KOROBK0,2 and G.P. GEORGIEV,1
'Institute of Molecular Biology; 1Shemyakin Institute of Bioorganic Chemistry, Moscow, USSR: Specific
structure of SV40 minichromosomes.
E.B. JAKOBOVITS, S. BRATOSIN, and Y. ALONI, Dept. of Genetics, Weizmann Institute of Science, Rehovot,
Israel: Formation of a nucleosome-free region in SV40 minichromosomes is dependent upon a restricted
segment of DNA.
R.D. GERARD,' M. WOODWORTH-GUTAI,2 and W.A. SCOTT,' Dept. of Biochemistry, University of Miami
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Medical School, Florida; 2Dept. of Cell and Tumor Biology, Roswell Park Memorial Institute, Buffalo,
New York: Deletion mutants which affect the nuclease-sensitive site in SV40 chromatin.
W. LIN, M. SHYAMALA, and H. KASAMATSU, Dept. of Biology, University of California, Los Angeles: Biosyn-
thesis of SV40 structural polypeptides. I. Amount of viral polypeptides synthesized and the identification
of complexes of VP1, VP2, and VP3.
V. BLASQUEZ, S. BEECHER, and M. BINA, Dept. of Chemistry, Perdue University, West Lafayette, Indiana:
SV40 morphogenesis-An analysis of assembly defective tsB and tsC mutants.
R. GARCEA,1'2 and T. BENJAMIN,2 'Sidney Farber Cancer Institute; 2Harvard Medical School, Boston,
Massachusetts: Intermediate steps in polyoma virion assembly are controlled by the host-range transfor-
ming gene products.
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Bacteriophage
August 24-August 29
Arranged by Ahmad Bukhari, Cold Spring Harbor Laboratory
139 participants
The bacteriophage meeting has been a tradition at Cold Spring Harbor since 1950. The meeting has been
the focal point for discussions on the regulatory mechanisms in bacteriophages lambda and P22 and on the
replication of various bacteriophages, particularly T4. Integrative recombination has also been featured pro-
minently at the meeting, and in the last few years the integration of transposable genetic elements has been
a major part of this discussion. Phage morphogenesis is another important topic that is discussed regularly
at the meeting.
Work on bacterial control mechanisms has increasingly been a topic of discussion at the phage meeting.
For example, at this year's meeting the Gross and Godson groups presented their work on the organization
of genes encoding rpsU (the ribosomal protein S21 that seems to interact with the Shine-Dalgarno se-
quence), dnaG (the protein that primes Okazaki fragments), and rpoD (the sigma factor required for initia-
tion of transcription). The three "initiation" genes apparently constitute one operon, and their regulation is
connected with the cell cycle.
Many bacterial control mechanisms are now being studied in great detail. In view of this expanding domain
of prokaryotic molecular biology, it was decided at the phage meeting this year that the future meetings will
formally include work on bacterial systems. The name of the meeting in 1983 will be Phage and Bacterial
Regulatory Mechanisms.
This year's meeting was supported in part by a grant from the National Cancer Institute, National In-
stitutes of Health.
SESSION 1 DNA Modification and Metabolism
S. HATTMAN, Dept. of Biology, University of Rochester, New York: DNA- methylase-dependent transcrip-
tion of the phage Mu mom gene.
M. GORADIA and A.I. BUKHARI, Cold Spring Harbor Laboratory, New York: How is the mom gene expres-
sion controlled?
W.P. FITZMAURICE, R.C. BENJAMIN, P.C. HUANG, and J.J. ScoccA, Dept. of Biochemistry, Johns Hopkins
University School of Hygiene and Public Health, Baltimore, Maryland: Phage DNA sequences that in-
teract with the DNA receptor of competent Haemophilus influenzae.
K. CARLSON1'2 and J. WIBERG,' 'Dept. of Radiation Biology and Biophysics, University of Rochester School
of Medicine and Dentistry, New York; 2lnstitute of Pharmaceutical Microbiology, University of Uppsala
Biomedical Center, Sweden: In vivo degradation of cytosine-containing bacteriophage T4 DNA to
genetically distinct, discrete-size fragments.
J.R. ALLEN, J.W. BOOTH, D.A. GOLDMAN, G.W. LASSER, R.G. SARGENT, and C.K. MATHEWS, Dept. of
Biochemistry and Biophysics, Oregon State University, Corvallis: Regulation of the branched pyrimidine
phosphate pathway in the dNTP-synthesizing multienzyme complex of T4.
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SESSION 2 Morphogenesis
C. ESCARMIS, R.P. MELLADO, and M. SALAS, Centro de Biologia Molecular, Universidad Autonoma, Madrid,
Spain: Sequencing and cloning of the gene coding for the protein covalently bound to the 5 'ends of the
DNA of bacteriophage 4929.
H. DREXLER, Dept. of Microbiology and Immunology, Bowman Gray School of Medicine, Wake Forest
University, Winston-Salem, North Carolina: A phage T1 preferred packaging site is located between
genes P and Q in phage X.
J. KOCHAN and H. MURIALDO, Dept. of Medical Genetics, University of Toronto, Canada: Bacteriophage X
preconnector-An intermediate in X prohead assembly.
E. WYCKOFF and S. CASJENS, Dept. of Cellular, Viral and Molecular Biology, University of Utah Medical
Center, Salt Lake City: Phage P22 scaffolding protein is autoregulatory.
R.-Z. JIANG, J. GEISSELSODER, C. DIANA, J. SEDIVY, and R. GOLDSTEIN, Dept. of Microbiology and Molecular
Genetics, Harvard Medical School, Boston, Massachusetts: In vitro construction of new P4 sid-type
mutants based on analysis of the reiterated genome of P4 sidl.
P.B. BERGET and M. CHIDAMBARAM, University of Texas Medical School, and Graduate School of
Biomedical Sciences, Houston: Alignment of the genetic and physical maps of the phage P22 tail protein
gene.
C. ROESSNER, D. STRUCK, and G. IHLER, Dept. of Medical Biochemistry, Texas A & M University, College Sta-
tion: Binding of bacteriophage X to liposomes containing X receptor protein.
K.D. YOUNG,' E.C. ALTMAN,2 J.M. GARRETT,' and R. YOUNG,' 'Dept. of Medical Biochemistry, Texas A & M
University College of Medicine, College Station; 2Division of Biology, California Institute of
Technology, Pasadena: Lysis gene function of X and OX174.
SESSION 3 DNA Replication. I.
T. FORMOSA, R.L. BURKE, and B.M. ALBERTS, Dept. of Biochemistry and Biophysics, University of California,
San Francisco: Affinity chromatography on columns containing immobilized T4 DNA replication
proteins.
B. KEMPER, F. JENSCH, H.-J. FRITZ, and M.V. DEPKA, Institut fUr Genetik der Universitat zu lcoln, Federal
Republic of Germany: Cleavage of hairpins by T4-induced endonuclease VII.
G. MOSIG and M. LEVIN, Dept. of Molecular Biology, Vanderbilt University, Nashville, Tennessee: Phage
T4 topoisomerase mutations differentially influence expression of late T4 genes in a is gyrB host.
K. HORIUCHI, G.P. Dorro, and K.S. JAKES, Rockefeller University, New York, New York: Initiation and ter-
mination signals at the origin of DNA replication of bacteriophage fl.
K. HORIUCHI, Rockefeller University, New York, New York: Evolution of bacteriophage fl during the mass
transfer.
J. LUPSKI, B. SMILEY, and G.N. GODSON, Dept. of Biochemistry, New York University Medical Center, New
York: Is antitermination involved in initiating DNA replication?-The cloning, transposon (Tn5) map-
ping, and nucleotide sequence of the dnaG chromosomal region of E. coli K-12.
SESSION 4 DNA Replication. II.
G. DEHO, D. GHISOTTI, S. ZANGROSSI, M.G. BORRELLO, P. ALANO, and G. SIRONI, Institute of Genetics, Univer-
sity of Milano, Italy: Satellite phage P4 in the plasmid state-Induction and maintenance.
R. LAGOS and R. GOLDSTEIN, Dept. of Microbiology and Molecular Genetics, Harvard Medical School,
Boston, Massachusetts: Characterization of the plasmid state of satellite phage P4.
A. ABELES, S. AUSTIN, D. CHATTORAJ, and M. YARMOLINSKY, NCI, Frederick Cancer Research Facility,
Frederick, Maryland: Plasmid replication and incompatibility functions of the phage P1.
V.N. KRYLOV, E.N. EREMENKO, and M.A. BYCHKOVA, All-Union Research Institute for Genetics and Selection
of Industrial Microorganisms, Moscow, USSR: R plasmids' interference with Mu-like phage D3112
growth in Pseudomonas aeruginosa PAO1.
N.P. HIGGINS,' D. MONCECCH1,1 P. MANLAPAZ-RAMOS,2 and B.M. OLIVERA,2 'Dept. of Biochemistry, Univer-
sity of Wyoming, Laramie; 2Dept. of Biology, University of Utah, Salt Lake City: Mu DNA replication in
vitro.
M. PATO,t C. REICH,1 B. WAGGONER,' and A. TOUSSAINT,2 'National Jewish Hospital and Research Center,
Denver, Colorado; 2Free University of Brussels, Belgium: Replication of bacteriophage Mu DNA.
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A. RE5IB0I5, M. COLET, and A. ToussAiNT, Genetic Laboratory, Free University of Brussels, Belgium: Replica-
tion intermediates of mini -Mu 26.
SESSION 5 Poster Session
B.A. CASTILHO,1 P. OLFSON,2 and M.J. CASADABAN," 'Committee on Genetics, 2Dept. of Microbiology, and
'Dept. of Biophysics and Theoretical Biology, University of Chicago, Illinois: Mini-Mulac fusion
elements-Novel constructions and uses.
R. CALENDAR and G.E. CHRISTIE, Dept. of Molecular Biology, University of California, Berkeley:
Bacteriophage P2 late gene expression requires the E. col/ RNA polymerase sigma factor.
N. HANNETT, M. COSTANZO, J. JOLLY, G. LEE, and J. PERO, The Biological Laboratories, Harvard University,
Cambridge, Massachusetts: Bacteriophage SPO1 late gene promoters are different from early and mid-
dle gene promoters.
I. TESSMAN, J.S. FASSLER, and D.C. BENNETT, Dept. of Biological Sciences, Purdue University, West Lafayette,
Indiana: Mapping of the rep gene of E. coli between rho and INC.
J. HOSODA and H. MOISE, Lawrence Berkeley Laboratory, University of California, Berkeley: The role of T4
gene-32 protein terminal domains on protein-protein interactions, as examined by affinity
chromatography.
M.A. JABBAR and L. SNYDER, Dept. of Microbiology and Public Health, Michigan State University, East Lans-
ing: Studies on the host locus responsible for the restriction of polynucleotide kinase and RNA ligase
mutants of T4.
T. ELLIOT, G. KASSAVETIS, and E.P. GEIDUSCHEK, Dept. of Biology, University of California, San Diego, La
Jolla: A newly detected class of T4 late transcripts-Are mutually interacting transcription events impor-
tant for late RNA synthesis?
S.L. SCHLAGMAN and S.M. HATTMAN, University of Rochester, New York: Cloning and expression of the
phage T4 DNA adenine methylase gene (dam+).
M. TROJANOWSKA, C. ALFORD, M. DAWSON, and J. KARAM, Dept. of Biochemistry, Medical University of
South Carolina, Charleston: Structure and function of the T4 regA gene and its protein product.
K.-C. LUK and W. SZYBALSKI, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison:
Cloning and characterization of the transcription termination sites in the major leftward operon of
bacteriophage X.
I. RASCHED, P. BROSS, K. BUSSMANN, and B. PELZER, Fakultat ffir Biologie, Universitht Konstanz, Federal
Republic of Germany: Identification of a 60 kd protein associated with purified bacteriophage fd,
necessary for infection, but apparently not coded in its DNA.
K.-C. LUK and W. SZYBALSKI, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison:
Cloning and characterization of the leftward promoter /Du in the b2 region of bacteriophage K DNA.
A.B. CHEPELINSKY, T. VOGEL, D. COURT, and M. ROSENBERG, NCI, National Institutes of Health, Bethesda,
Maryland: Characterization of a bacterial promoter signal carried on the SV40 genome.
SESSION 6 Transposition
A.H. PUSPURS and J.N. REEVE, Dept. of Microbiology, Ohio State University, Columbus: Infecting Mu DNA
forms circles.
R.H. HARSHEY, R. McKAY, and A.I. BUKHARI, Cold Spring Harbor Laboratory, New York: DNA intermediates
in transposition of phage Mu.
R.M. HARSHEY, Cold Spring Harbor Laboratory, New York: Protein-mediated switch in the transposition
products of Mu DNA-Cointegrates vs. simple insertions.
M. MIZUUCHI and K. MIZUUCHI, NIADDKD, National Institutes of Health, Bethesda, Maryland: Effect of
distance between the ends of bacteriophage Mu on the transposition reaction.
V.N. KRYLOV, T.G. PLOTNIKOVA, and A.S. YANENKO, All-Union Research Institute for Genetics and Selection
of Industrial Microorganisms, Moscow, USSR: Transposition of D3112 phage specific for Pseudomonas
aeruginosa PAO1 in E. coli cells.
E.A. RALEIGH and N. KLECKNER, Dept. of Biochemistry and Molecular Biology, Harvard University, Cam-
bridge, Massachusetts: Multiple- linked Tn 10- promoted rearrangements occur at high frequency.
R.W. SIMONS and N. KLECKNER, Dept. of Biochemistry and Molecular Biology, Harvard University, Cam-
bridge, Massachusetts: Translation of the ISIO transposase gene is regulated by a trans-acting IS10-
specified RNA.
J. WAY and N. KLECKNER, Dept. of Biochemistry and Molecular Biology, Harvard University, Cambridge,
Massachusetts: Tn10 mutants that fail to transpose.
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SESSION 7 Recombination and Repair
M. BETTER," C. LU,1 R.C. WILLIAMS,' and H. ECHOLS,1 'Dept. of Molecular Biology, University of Califor-
nia, Berkeley; 2Dept. of Biochemistry, Brandeis University, Waltham, Massachusetts: Site-specific DNA
condensation and synapsis mediated by the int protein of bacteriophage X.
A.M. SEGALL,' M. GELLERT,2 D.L. CARVER,' and D.I. FRIEDMAN,' 1 Dept. of Microbiology and Immunology,
University of Michigan, Ann Arbor; 2NIAMDD, National Institutes of Health, Bethesda, Maryland:
Synergistic effect of himA and gyrB mutations.
T.A.G. SMITH and J.B. HAYS, Dept. of Chemistry, University of Maryland Baltimore County, Catonsville: Ex-
cision repair of pyrimidine dimers stimulates recombination of nonreplicating phage X DNA.
D. LEE and P. SADOWSKI, Dept. of Medical Genetics, University of Toronto, Canada: Genetic recombination
of phage T7 DNA studied by a simple in vitro assay.
J. DUL and H. DREXLER, Dept. of Microbiology and Immunology, Bowman Gray School of Medicine, Wake
Forest Univerity, Winston-Salem, North Carolina: The effect of transcription on recombination-
Transduction' of markers stimulated and repressed in transcription.
B.E. WINDLE and J.B. HAYS, Dept. of Chemistry, University of Maryland Baltimore County, Catonsville: A
P1 prophage function that stimulates certain recA-dependent recombination events.
N.E. MELECHEN and G. Go, Dept. of Microbiology, St. Louis University Medical School, Missouri: Dissec-
tion of the SOS responses.
E.M. PHIZICKY and J.W. ROBERTS, Dept. of Biochemistry, Cornell University, Ithaca, New York: The interac-
tion of recA protein with NTP and ssDNA.
D. BURBEE and J.W. ROBERTS, Dept. of Biochemistry, Cornell University, Ithaca, New York: Cleavage of
lexA repressor by recA430 protein.
A.R. POTEETE and A.C. FENTON, Dept. of Molecular Genetics and Microbiology, University of Massachusetts
Medical School, Worcester: Structure and activities of the P22 erf protein.
SESSION 8 Gene Expression. I.
K. FIEN, J. PLACE, S. KIELTY, M. MAHONEY, and D.L. WULFF, Dept. of Biological Sciences, State University of
New York, Albany: N protein is required for efficient translation of the X cll gene.
E.R. OLSON,' E.L. FLAMM,2 and D.I. FRIEDMAN,' 'Dept. of Microbiology and Immunology, University of
Michigan Medical School, Ann Arbor; 2NICHHD, National Institutes of Health, Bethesda, Maryland:
Analysis of nutR, a region required for the action of the X pN antitranscription termination function.
G. SOMASEKHAR, J.S. SALSTROM, D. DRAHOS, and W. SZYBALSKI, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: Sequencing of phage X nutL mutations, gene-N deletions, and
modified N products.
D. DRAHOS and W. SZYBALSKI, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison:
Importance of sequences flanking the 17-bp nutL core in the Is N-mediated antitermination of
transcription.
A.T. SCHAUER, D.L. CARVER, E.J. MASHNI, B. SHELL, and D.I. FRIEDMAN, Dept. of Microbiology and Im-
munology, University of Michigan Medical School, Ann Arbor: What's new with nus.
W. Szybalski, A. Hershey H. Murialdo, H. Drexler
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L. PERITZ and J. GREENBLATT, Dept. of Medical Genetics and Banting and Best Dept. of Medical Research,
University of Toronto, Canada: The nusA protein of E. coli is required for transcription termination in
vivo.
R. HABER) S. ADHYA,1 S. GARGES,1 D. FRIEDMAN,2 and L. BARON,3 'NCI, National Institutes of Health,
Bethesda, Maryland; 2Dept. of Microbiology, University of Michigan, Ann Arbor; 'Walter Reed Army
Institute of Research, Washington, DC: Structural and functional analysis of the nusA gene of E. coli.
J. GREENBLATT,' J. LI) and D. FRIEDMAN,2 t Banting and Best Dept. of Medical Research, University of Toron-
to, Canada; 2Dept. of Microbiology, University of Michigan, Ann Arbor: Regulation by the nusB gene of
E. coli gene expression in vitro.
D. WARD, A. DELONG, and M. GOTTESMAN, NCI, National Institutes of Health, Bethesda, Maryland: The role
of nusB in the specificity of action of the X N gene product.
SESSION 9 Gene Expression. II.
E.J. GRAYHACK and J.W. ROBERTS, Dept. of Biochemistry, Cornell University, Ithaca, New York: Antitermina-
tion of X 6S RNA transcription by Is Q protein in vitro.
L.F. LAU, J.W. ROBERTS, and R. Wu, Dept. of Biochemistry, Cell and Molecular Biology, Cornell University,
Ithaca, New York: Transcription termination at X tRl.
G.N. GUSSIN, K. MATZ, and M. SCHMANDT, Zoology Dept., University of Iowa, Iowa City: rex redux-Two X
rex genes.
M.A. How, D. KNIGHT, and H. ECHOLS, Dept. of Molecular Biology, University of California, Berkeley: Post
transcriptional control of cll function-The role of cIII, HfIA, HimA, and HimD.
A. HOCHSCHILD, N. IRwitsi, and M. PTASHNE, Dept. of Biochemistry and Molecular Biology, Harvard Univer-
sity, Cambridge, Massachusetts: The characterization of positive control mutations in the X cl gene and
in the P22 c2 gene.
P. YOUDERIAN,1 M.M. SUSSKIND,1 D. HAWLEY,2 and W. McCLuRE,2 'Dept. of Molecular Genetics and
Microbiology, University of Massachusetts Medical School, Worcester; 2Dept. of Biological Sciences,
Carnegie-Mellon University, Pittsburgh, Pennsylvania: Dual repressor control of P22 ant gene
expression.
D.K. HAWLEY,' W.R. MCCLURE,' P. YOUDERIAN,2 and M.M. SUSSKIND,2 'Dept. of Biological Sciences,
Carnegie-Mellon University, Pittsburgh, Pennsylvania; 2Dept. of Molecular Genetics and Microbiology,
University of Massachusetts Medical School, Worcester: DNA sequence determinants of promoter
strength.
W. RICE, R. GREEN, and L. SNYDER, Dept. of Microbiology and Public Health, Michigan State University, East
Lansing: Studies on the shutoff of X late transcription by the T4 unf/alc function.
SESSION 10 Gene Expression. III.
E. LJUNGQUIST and K. KOCKUM, Dept. of Microbial Genetics, Karolinska Institutet, Stockholm, Sweden: The
DNA sequence of the phage P2 repressor gene, the early operator, and the coxll gene.
K. Mizuuchi, B. Kemper
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G. Mosig, N. Godson
A. SPADAR0,1 E. LJUNGQUIST,2 and R. GOLDSTEIN,' 'Dept. of Microbiology and Molecular Genetics, Harvard
Medical School, Boston, Massachusetts; 2Dept. of Microbial Genetics, Karolinska Institutet, Stockholm,
Sweden: Sequencing analyses of the regulatory region of phage P4.
G.E. CHRISTIE and R. CALENDAR, Dept. of Molecular Biology, University of California, Berkeley: Identifica-
tion of P2 late gene promoters by sequence analysis and S1 mapping.
H. PRIESS,1 D. KAMP,' R. KAHMANN,1 B. BRAUER,' and H. DELIUS,2 'Max Planck Institute of Biochemistry,
Martinsreid; 2EMBO Laboratory, Heidelberg, Federal Republic of Germany: Nucleotide sequence of
the immunity and the early region of phage Mu.
C.F. MARRS and M.M. HOWE, Dept. of Bacteriology, University of Wisconsin, Madison: Kinetics and regula-
tion of transcription of bacteriophage Mu.
S.F. STODDARD and M.M. HOWE, Dept. of Bacteriology, University of Wisconsin, Madison: Cloning and
mapping of bacteriophage Mu DNA fragments with promoter activity.
M. COSTANZO and J. PERO, The Biological Laboratories, Harvard University, Cambridge, Massachusetts:
Cloning the regulatory genes of bacteriophage SPO1.
H. AIBA, Radioisotope Laboratory, Kyoto University, Japan: Autogenous regulation of the E. coli crp gene-
Transcriptional repression by CRP- cAMP.
A. GOLDFARBL2 and T. BARKAY,3 Dept. of Microbiology, Columbia University, New York, New York:
2Max Planck Institute of Biochemistry, Martinsreid, Federal Republic of Germany; 3Dept. of
Biochemistry, Weizmann Institute, Rehovot, Israel: Processing of phage T4 transcripts with RNase III.
M.L. ROMANTSCHUK and U.R. MULLER, Dept. of Microbiology, East Carolina University, School of
Medicine, Greenville, North Carolina: Loss of a hairpin structure in the J-F intercistronic region of
bacteriophage OM 74 causes overexpression of downstream genes.
SESSION 11 Gene Mapping and Cloning
A.D. GROSSMAN, W. WALTER, R. BURGESS, and C. GROSS, Dept. of Bacteriology, University of Wisconsin,
Madison: Mutations in the Ion gene of E. coli K12 phenotypically supress mutations in the sigma subunit
of RNA polymerase.
J. Hu and C. GROSS, Dept. of Bacteriology, University of Wisconsin, Madison: Fine-structure mapping of is
mutations in rpoD, the structural gene for the sigma subunit of E. coli RNA polymerase.
A.R. SHATZMAN, C. DEBOUCK, and M. ROSENBERG, NCI, National Institutes of Health, Bethesda, Maryland: A
plasmid cloning vector using X regulatory sequences for inducible overproduction of proteins in E. coli.
J. TEIFEL, Institut fur Genetik and Mikrobiologie der Universitat Munchen, Federal Republic of Germany:
Bacteriophage-Mu-mediated transduction of multicopy plasmids.
C. WAGHORNE, Dept. of Medical Genetics, University of Toronto, Canada: Analysis of the cloned E. coli
mat locus.
R. Christiansen, T. Broker, J. Wiberg A. Bukhari, A. Toussaint
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Herpesviruses
August 31-September 5
Arranged by George Miller, Yale University School of Medicine, Mark Stinski, University of Iowa College
of Medicine
387 participants
This meeting, which covered most aspects of basic research on herpesviruses, was an effort to integrate fin-
dings on the biology of these complex viruses with molecular biology. Among the more striking findings
presented were the identification of sequences involved in the initiation of herpes simplex DNA synthesis
and in packaging and the identification of sequences responsible for inversion of the genome of herpes
simplex. The construction and assay of tRNAs which would suppress mutations in the herpes simplex
thymidine kinase gene was reported, and preliminary data on the complete nucleotide sequence of EB viral
DNA were presented. The location of a gene in the EB viral genome responsible for synthesis or induction
of the EB nuclear antigen was described. Two groups reported that lymphocyte transformation by EBV call-
ed forth the expression of a novel B-cell surface antigen that could be recognized by a monoclonal
antibody.
The meeting was supported in part by a small grant from the National Science Foundation and by con-
tributions from Abbott Laboratories; American Cyanamid Company-Lederle Laboratories; Beckman In-
struments, Inc.; Boehringer Mannheim Biochemicals; Bristol-Myers Co.; Burroughs Wellcome Co.; Cetus
Corp.; CIBA-Geigy Corp.; Genetics Systems Corp.; Hoffmann-LaRoche, Inc.; Merck Sharp and Dohme
Research Laboratories; National Science Foundation; New England Biolabs, Inc.; New England Nuclear
Corp.; Ortho Pharmaceutical Corporation; Schering Coroporation; Searle Laboratories; Showa University
Research Institute for Biomedicine in Florida; Upjohn Co.; and Viratek, Inc. These funds were used as par-
tial stipends to assist graduate students and postdoctoral fellows in covering expenses for the meeting.
SESSION 1 Latency and Persistent Infection
Chairperson: J. STEVENS, University of California, Los Angeles, California
A. ADAMS, M. BYWATER, and E. GUSSANDER, Wallenberg Laboratory, University of Uppsala, Sweden: New
intracellular forms of latent EBV DNA in leukemic lymphocytes.
A.K. SAEMUNDSEN, C. PERLMAN, and G. KLEIN, Dept. of Tumor Biology, Karolinska Institutet, Stockholm,
Sweden: Methylation in EBV DNA.
H. COLLANDRE, D. GUETARD, and L. MONTAGNIER, Unite d'Oncologie Virale, Institut Pasteur, Paris, France:
Methylation state of EBV DNA in Daudi cells.
R. WEIGEL and G. MILLER, Yale University Medical School, New Haven, Connecticut: Major EBV-specific
cytoplasmic transcripts in a Burkitt lymphoma line during latency and after induction of viral replicative
cycle by phorbol esters.
V. VAN SANTEN and E. KIEFF, Kovler Viral Oncology Laboratories, University of Chicago, Illinois: Detailed
mapping of EBV-specific transcripts in a nonproductively infected, EBV-transformed cell line.
D. Galloway
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P. Schaffer, I. Subak-Sharpe
B. L. WIGDAHL,' A.C. SCHECK,1 E. DE CLERCQ,2 and F. RAPP,' 'Pennsylvania State University College of
Medicine, Hershey; 2Katholieke Universiteit Leuven, Belgium: Analysis of latent HSV-1 genome in
human cells.
D. L. ROCK and N. W. FRASER, Wistar Institute, Philadelphia, Pennsylvania: Detection of the HSV-1 genome
in the central nervous system of persistently infected mice.
R. TENSER and J. JONES, Dept. of Microbiology, Pennsylvania State University College of Medicine, Her-
shey: Acute and latent trigeminal ganglion infection by thymidine kinase mutants of HSV-2.
M. COOK and J. STEVENS, Dept. of Microbiology and Immunology, University of California Medical School,
Los Angeles: A basis for differing susceptibilities of mouse strains to HSV.
S. AL-SAADi, G. CLEMENTS, and J. H. SUBAK-SHARPE, Institute of Virology, Glasgow, Scotland: HSV-2 wt and
is mutants can be recovered from the footpad and dorsal root ganglia of latently infected mice.
SESSION 2 Genome Structure, Replication and Recombination
Chairperson: G. S. HAYWARD, Johns Hopkins University, Baltimore, Maryland
Y. BECKER, Y. SHTRAM, and Y. ASHER, Dept. of Molecular Virology, Faculty of Medicine, Hebrew University,
Jerusalem, Israel: Cloning and properties of HSV-1 genes present in the Bglll fragment of HSV-1 DNA
that carries one of the origins of replication of the viral genome.
N. D. STOW and E. C. MCMONAGLE, Institute of Virology, Glasgow, Scotland: Localization of sequences in-
volved in the initiation of HSV-1 DNA synthesis and in the packaging of replicated viral DNA.
E. MOCARSKI and B. ROIZMAN, Kovler Viral Oncology Laboratories, University of Chicago, Illinois: HSV
genome inversion is mediated by viral gene products and the viral a sequence.
S. K. AMUNDSEN and D. S. PARRIS, Dept. of Medical Microbiology and Immunology and Comprehensive
Cancer Center, Ohio State University, Columbus: Early recombination during HSV productive
replication.
R. L. LAFEMINA and G. S. HAYWARD, Johns Hopkins University Medical School, Baltimore, Maryland:
Replicative forms of the human cytomegalovirus genome are found in permissive but not in non-
permissive cells.
J. TAMASHIR0,1 D. FILPULA,2 T. FRIEDMANN,' and D. SPECTOR,' 1 Dept. of Biology; 'Pediatrics, University
of California San Diego, La Jolla: Characterization of the heterogeneous joint region of human
cytomegalovirus (strain AD169).
B. E. HENRY, N. J. RAAB-TRAUB, and J. S. PAGANO, Cancer Research Center, University of North Carolina,
Chapel Hill: Determination of the number and location of autonomous replicating sequences present in
the genome of EBV.
M. HELLER,' V. VAN SANTEN,t M. HUMMEL,' E. KIEFF,' and A. HENDERSON,' 1University of Chicago, Il-
linois; 'Columbia University, New York, New York: A simple sequence repeat array in EBV DNA has
homology to cell DNA and is transcribed.
M.-S. CHO, G. W. BORNKAMM, and H. ZUR HAUSEN, Institut fUr Virologie, Zentrum fUr Hygiene University of
Freiburg, Federal Republic of Germany: Inter- and intramolecular recombination in EBV DNA.
I. HAY, T. A. CASEY, W. T. RUYECHAN, and S. E. STRAUS, Depts. of Microbiology and Biochemistry, NIAID,
National Institutes of Health, Bethesda, Maryland: Insertion and deletion events are the basis for some
stable strain differences in VZV DNAs.
K. PEDEN, P. MOUNTS, K.-T. RANG, E. GAVIS, and G. S. HAYWARD, Johns Hopkins Medical School, Baltimore,
Maryland: Further studies on cell-virus homology sequences in HSV, EBV and CMV.
WORKSHOP 1 Herpesvirus Nuclear Proteins
Chairperson: R. J. COURTNEY, University of Tennessee, Knoxville, Tennessee
V. BIBOR-HARDY and R. SIMARD, Institut du Cancer de Montreal, Canada: Modifications of the nuclear
matrix during HSV infection.
B. J. DILLE and R. J. COURTNEY, Dept. of Microbiology, University of Tennessee, Knoxville: Synthesis of
HSV-1 polypeptides and subsequent association with the nuclear fraction.
C. K. LEE, M. P. QUINLAN, and D. M. KNIPE, Dept. of Microbiology and Molecular Genetics, Harvard
Medical School, Boston, Massachusetts: HSV mutations that alter the nuclear localization or DNA-
binding function of an early viral protein.
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C. M. PRESTON, M. E. M. CAMPBELL, and E. L. NOTARIANNI, Institute of Virology, Glasgow, Scotland: Studies
on the function and modification of the HSV-1 immediate early polypeptide Vmw 175.
S. FABER and K. WiLcox, Dept. of Microbiology, Medical College of Wisconsin, Milwaukee: Synthesis and
properties of an immediate early HSV polypeptide produced by tsLB2.
E. L. NOTARIANNI and C. M. PRESTON, Institute of Virology, Glasgow, Scotland: HSV immediate early
polypeptides induce cellular heat-shock proteins.
P. F. PIGNATTI,1 F. SAMMARTANO,1 G. RAPPAZZ0,1 C. PARISI,' M. TOGNON,2 R. MANSERVIGI,2 and E.
CAssm,2 'Dept. of Animal Biology, University of Catania; 'Institute of Microbiology, University of Fer-
rara, Italy: Proteins bound to HSV DNA during infection, and their possible role in the expression of the
viral genetic program.
E.-C. MAR and E.-S. HUANG, Cancer Research Center, University of North Carolina, Chapel Hill: A novel
human cytomegalovirus-specific 150K phosphorylated DNA binding protein in purified virion and
virus-infected cell.
J. LUKA,1 H. JORNVALL,2 and G. KLEIN,' 'Dept. of Tumor Biology; 'Dept. of Chemistry, Karolinska In-
stitutet, Stockholm, Sweden: The 48 K component of the EBV determined nuclear antigen (EBNA) and
higher molecular weight forms of the antigen are structurally related.
J.-C. LIN, M. C. SMITH, and J. S. PAGANO, Cancer Research Center, University of North Carolina, Chapel
Hill: Selective stimulation of synthesis of chromosomal proteins associated with activation of latent EBV
genomes by a tumor promoter.
C. C. SMITH and L. AURELIAN, Johns Hopkins University Medical School, Baltimore, Maryland: Further
characterization of the transformation associated protein ICP-10.
WORKSHOP 2 VZV
Chairperson: S. E. STRAUS, National Institutes of Health, Bethesda, Maryland
C. GROSE, D. P. EDWARDS, W. E. FRIEDRICHS, K. A. WEIGLE, and W. L. MCGUIRE, Depts. of Pediatrics,
Microbiology and Medicine, University of Texas Health and Science Center, San Antonio: Glycopro-
teins specified by VZV.
E. KINNEY-THOMAS, K. SHRIVER, L. GOLDSTEIN, T. CROY, and K. BEACH, Genetic Systems Corporation, Seattle,
Washington: Monoclonal antibodies specific for varicella zoster-infected cell proteins.
C. M. EDSON,' B. HOSLER,2 D. WATERS,' and D. A. THORLEY-LAWSON,' tDepts. of Pathology and
Geographic Medicine, Tufts University Medical School; 'Dept. of Public Health, Boston, Massa-
chusetts: Functional and biochemical analysis VZV proteins with monoclonal antibodies.
Z. WROBLEWSKA1 and D. H. GILDEN,1-2 'Multiple Sclerosis Research Center, Wistar Institute; 'Dept. of
Neurology, University of Pennsylvania Medical School, Philadelphia: Monoclonal antibodies against
VZV.
S. E. STRAUS,' J. HAY,2 H. A. SmiTH,1 J. OWENS,' and P. BRUNNELL,3 1 National Institutes of Health;
'Uniformed Services University of the Health Sciences, Bethesda, Maryland; 3University of Texas, San
Antonio: Molecular epidemiologic studies of VZV infections.
M. SEIDLIN,1 H. E. TAKIFF,1 S. E. STRAUS,' T. CASEY,' and J. HAY,' 'National Institutes of Health;
'Uniformed Services University of the Health Sciences, Bethesda, Maryland: Dot-blot hybridization
assay for rapid diagnosis of VZV infection.
A. BUCHAN,' A. FULLER,1 C. R. ROBERTS,' J. HAY,2 M. BARTOSKI,2 and G. S. HAYWARD,' tDept. of
Medical Microbiology, University of Birmingham Medical School, England; 'Dept. of Microbiology,
Uniformed Services University of Health Services, Bethesda, Maryland; 3Dept. of Pharmacology, Johns
Hopkins University, Baltimore, Maryland: The immunological cross reactions between HSV and VZV.
WORKSHOP 3 DNA of Lymphotropic Viruses
Chairperson: A. ADAMS, University of Uppsala, Uppsala, Sweden
R. BAER, A. BANKIER, B. BARRELL, M. BIGGIN, P. DEININGER, P. FARRELL, T. GIBSON, G. HUDSON, S. SATCHWELL,
and C. SEGUIN, MRC Laboratory of Molecular Biology, Cambridge, England: Nucleotide sequences of
EBV DNA.
J. SKARE, J. FARLEY, and J. STROMINGER, Sidney Farber Cancer Institute, Boston, Massachusetts: Small tandem
repeats in EBV DNA.
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T. DAMBAUGH, W. KING, and E. KIEFF, University of Chicago, Illinois: The P3HR-1 deletion includes one
member of a pair of related tandem direct repeats in EBV DNA.
M. D. JONES, J. R. ARRAND, T. SHEEDY, L. KARRAN, A. HARRIS, and B. E. GRIFFIN, Imperial Cancer Research
Fund Laboratories, London, England: Analysis of the large interval repeat unit of EBV and adjacent DNA
sequences.
S. YANO, T. AYA, K. TAKADA, and T. OSATO, Dept. of Virology, Cancer Institute, Hokkaido University
Medical School, Sapporo, Japan: Identification of incomplete B95-8 EBV-Evidence indicating its
transforming ability.
M. ANVRET and A. KARLSSON , Dept. of Medical Biochemistry, University of GOteborg, Sweden: Detection
and characterization of a new EcoRl EBV DNA fragment in Raji cellular DNA.
R. DESROSIERS, A. BAKKER, R. BURGHOFF, and L. FALK, Harvard Medical School, New England Regional
Research Center, Southborough, Massachusetts: The nononcogenic variant of Herpesvirus saimiri strain
11.
A. BANKIER,1 R. BAER,' B. G. BARRELL,1 F. COLBERE-GARAPIN,2 W. DIETRICH,3 E. KNUST,3 and B. FLECKEN-
STEIN,3 'Laboratory of Molecular Biology, MRC, Cambridge, England; 'Institut Pasteur, Paris, France;
3lnstitut fUr Klinische Virologie, University of Erlangen-NUrnberg, Federal Republic of Germany:
Nucleotide sequence of Herpesvirus saimiri H-DNA.
W. BODEMER and E. KNUST, Institut fUr Klinische Virologie, University of Erlangen-NUrnberg, ..ederal
Republic of Germany: Herpesvirus saimiri and Herpesvirus ateles transcription in lytically infected and
transformed cells.
S. SCHIRM,1 C. KASCHKA-DIERICH,1 R. C. DESROSIERS,2 D. ABLASHI,3 H. RABIN,3 and B. FLECKENSTEIN,'
'Institut fUr Klinische Virologie, University of Erlangen-NUrnberg, Federal Republic of Germany; 'New
England Primate Research Center, Harvard Medical School, Southborough, Massachusetts; 3NCI, Na-
tional Institutes of Health, Bethesda, Maryland: Deletions in the circular, nonintegrated viral DNA of
herpesvirus saimiri-transformed lymphoid cell lines.
SESSION 3 Transformation of Cell Growth
Chairperson: M. NONOYAMA, Showa University Research Institute for Biomedicine, Clearwater, Florida
J. A. NELSON,' J. K. MCDOUGALL,' D. A. GALLOWAY,' R. GELINAS,1 L. GOLDSTEIN,' A. GRASSMANN,2 H.
SCHMULLA,3 T. SARRE,3 G. JAHN,3 and B. FLECKENSTEIN,3 'Fred Hutchinson Cancer Research Center,
Seattle, Washington; 'Institut fur Physiologische Chemie der Freien Universitat Berlin; 3lnstitut fUr
Klinische Virologie, University of Erlangen-NUrnberg, Federal Republic of Germany: Analysis of the
transforming sequences of human cytomegalovirus strain AD169.
D. A. GALLOWAY, S. P. WEINHEIMER, M. A. SWAIN, J. B. LEWIS, K. SHRIVER, and J. K. MCDOUGALL, Fred Hut-
chinson Cancer Research Center, Seattle, Washington: An unusual mechanism of transformation by a
fragment of HSV-2 DNA.
R. J. JARIWALLA,1 L. AURELIAN,1,2 and P. O. P. Ts'o,' 'Dept. of Biophysics and 'Dept. of Comparative
Medicine, Johns Hopkins University, Baltimore, Maryland: Neoplastic transformation by various
fragments of HSV-2 DNA.
B. A. BLAZAR, L. SUTTON, and M. STROME, Brigham and Women's Hospital, Harvard Medical School,
Boston, Massachusetts: Autostimulatory growth factor production by B lymphocyte lines from tumors
and EBV transformed cells-A mechanism for perpetual growth.
J. W. SIXBEY and J. S. PAGANO, Cancer Research Center, University of North Carolina, Chapel Hill: EBV
transformation of human lymphocytes in the presence of the viral DNA polymerase inhibitor acyclovir.
B. E. GRIFFIN, Imperial Cancer Research Fund, London, England: Mediation of epithelial cell transformation
by cloned fragments of EBV DNA.
R. H. NEUBAUER, R. L. BROWN, and H. RABIN, NCI, Frederick Cancer Research Facility, Frederick,
Maryland: Herpesvirus saimiri-induced lymphoma-Tumor phenotype defined by monoclonal an-
tibodies and T cell growth factor responses.
M. RABSON and G. MILLER, Dept. of Epidemiology and Public Health, Yale University, New Haven, Con-
necticut: Nonimmortalizing P3J-HR-1 EBV-A deletion mutant of its transforming partent, Jijoye.
J. STOERKER and R. GLASER, College of Medicine and Comprehensive Cancer Center, Ohio State University,
Columbus: Rescue of transforming EBV from IUdr induced D98/HR-1 epithelial hybrid cells after
transfection with cloned subgenomic fragments of B95-8 virus.
I. M. SHAPIRO and D. J. VOLSKY, Dept. of Pathology and Laboratory Medicine, University of Nebraska
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Medical Center, Omaha: Infection of normal human nasopharyngeal epithelial cells by EBV following
EBV receptor transplantation.
SESSION 4 Proteins and Clycoproteins
Chairperson: G. H. COHEN, University of Pennsylvania, Philadelphia, Pennsylvania
P. J. GODOWSKI and D. M. KNIPE, Dept. of Microbiology and Molecular Genetics, Harvard Medical School,
Boston, Massachusetts: Role of the HSV DNA binding protein in regulation of HSV gene expression.
S. S. LEINBACH, Dept. of Microbiology, University of South Alabama, College of Medicine, Mobile: Studies
on DNP complexes containing a HSV-1 protein of molecular weight 133,000.
L. COHEN,' R. IMHOF,t B. ROBERTS,2 and J. STROMINGER,' 'Sidney Farber Cancer Institute; 2Dept. of
Biological Chemistry, Harvard Medical School, Boston, Massachusetts: Identification and genomic map-
ping of EBV DNA binding proteins.
T. COMPTON and R. J. COURTNEY, Dept. of Microbiology, University of Tennessee, Knoxville: Virus-specific
glycoproteins associated with the nuclear fraction of HSV-infected cells.
L. PEREIRA,' D. DONDER0,1 and B. ROIZMAN,2 'California Dept. of Public Health, Berkeley; 2Kovler Viral
Oncology Laboratories, University of Chicago, Illinois: HSV glycoprotein gA/B-Evidence that the in-
fected Vero cell products co-map and arise by proteolysis.
A. M. ARVIN,' C. M. KOROPCHAK,t A. S. YEAGER,t and L. PEREIRA,2 'Stanford University Medical School,
California; 2California Dept. of Health Services, Berkeley: The detection of type specific antibody to
HSV-1 by radioimmunoassay using HSV-1 glycoprotein C purified with monoclonal antibody.
J. T. MATTHEWS,' G. H. COHEN,' and R. J. EISENBERG,2 'Center for Oral Health Research, School of Den-
tal Medicine and 2School of Veterinary Medicine, University of Pennsylvania, Philadelphia: In vitro
translation and processing of glycoprotein gD of HSV-1 and HSV-2.
H. HAMPL and T. B. PoRA-r, Dept. of Microbiology, Vanderbilt University Medical School, Nashville, Ten-
nessee: Arrangement of the glycoproteins in the envelope of pseudorabies virus.
J. ZAIA, B. CLARK, R. EBERLE, and Y.-P. TING, Divisions of Pediatrics and Immunology, City of Hope Medical
Center, Duarte, California: Isolation and characterization of a 64,000 dalton polypeptide of human
cytomegalovirus (CMV) using high performance liquid chromatography (HPLC).
T. J. STINCHCOMBE and W. G. CLOUGH, Dept. of Molecular Biology, University of Southern California, Los
Angeles: EBV-producing cell lines contain a unique pyrimidine deoxynucleoside kinase activity.
D. C. JOHNSON AND P. G. SPEAR, Dept. of Microbiology, University of Chicago, Illinois: Maturation of
HSV-1 glycoproteins.
J. L. M.0 GEELEN, W. R. Boom, C. BUURMAN, and J. VAN DER NOORDAA, Laboratorium voor de Gezon-
dheidsleer, Universiteit van Amsterdam, The Netherlands: Protein kinase activity associated with an
immediate-early CMV-induced protein.
SESSION 5 Poster Session
R. H. COSTA, L. M. HALL, K. G. DRAPER, and E. K. WAGNER, Dept. of Molecular Biology and Biochemistry,
University of California, Irvine: High resolution mapping of HSV-1 transcripts encoded by the left third
of the UL region.
D. YAGER, E. HARRIS, and S. BACHENHEIMER, Dept. of Bacteriology and Immunology, University of North
Carolina, Chapel Hill: Physical mapping of transcripts in the 0.0 to 0.3 region of the HSV-1 genome.
V. C. BOND and S. PERSON, Molecular and Cell Biology Program, Pennsylvania State University, University
Park: Fine-structure mapping of loci that affect cell fusion in HSV-1 (KOS).
A. EPSTEIN and B. JACQUEMONT, Unite de Virologie Fondamentale et Appliquee, INSERM, CNRS, Lyon,
France: Expression of different HSV variants in nonpermissive rat XC cells-Localization of implicated
virus functions.
H. J. FIELD, Dept. of Pathology, University of Cambridge, England: The role of latent TK-defective viruses in
the emergence of clinical resistance 'to acyclovir.
B. SVENNERHOLM, S. OLOFSSON, R. LUNDEN, A. VAHLNE, and E. LYCKE, Dept. of Virology, University of
GOteborg, Sweden: Adsorption and penetration of HSV enveloped particles modified by tunicamycin
and 2-deoxy-o-glucose.
Y. SAITO and R. W. PRICE, Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer
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Center, New York, New York: Prospects for in vivo diagnosis of HSV encephalitis using radiolabeled
antivirals-Autoradiographic studies using an animal model.
A. LARSSON, M. BERG, C-E. HAGBERG, N-G. JOHANSSON, and B. OBERG, Astra L'Aemedel AB, Research and
Development Laboratories, Dept. of Antiviral Chemotherapy, SOdert.ilje, Sweden: A 36434-A new
nucleoside analog with selective antiherpes activity.
E. THIRY, P.-P. PASTORET, H. VINDEVOGEL, A. SCHWERS, B. BROCHIER, and P. LEROY, Faculty of Veterinary
Medicine, University of Liege, Bruxelles, Belgium: In vitro and in vivo effect of acyclovir on infectious
bovine rhinotracheitis virus, pseudorabies virus, and pigeon herpesvirus.
N. SCHEK, G. SHERMAN, E. HARRIS, and S. BACHENHEIMER, Dept. of Bacteriology and Immunology, University
of North Carolina, Chapel Hill: Effects of amino acid analogs on the regulation of HSV gene expression.
D. M. MEREDITH, Research Division, G. D. Searle and Co., High Wyncombe, England: Phosphorylation
and subsequent incorporation of E-5-(2-bromoviny1)2'-deoxyuridine (BVDU) into DNA in cells infected
with HSV-1 and 2.
M. D. TROUSDALE, A. B. NESBURN, and D. E. WILLEY, Estelle Doheny Eye Foundation, Los Angeles, Califor-
nia: Effect of intensive ACV therapy during stimulation to induce reactivation of latent HSV in rabbits.
S. HARADA, R. ANDERSON, T. BECHTOLD, and D. PURTILO, Dept. of Pathology and Laboratory Medicine,
University of Nebraska Medical Center, Omaha: Comparison of EBV-specific antibody, memory T cells
in regression assays, and natural killer-cell activity in X-linked lymphoproliferative syndrome.
B. VOLSKY and D. J. VOLSKY, Dept of Pathology and Laboratory Medicine, University of Nebraska Medical
Center, Omaha: Anti-EBV immune response in mice inoculated with autologous EBV-infected
lymphocytes.
C. KUSZYNSKI and D. J. VOLSKY, Dept. of Pathology and Laboratory Medicine, University of Nebraska
Medical Center, Omaha: Cytofluorographic studies on the distribution and relationship between EBV
receptors and complement c3 receptors.
J. JONCAS, F. GHIBU, L. ROBILLARD, S. MONTPLAISIR, and M. BLAGDEN, Pediatric Research Center, University
of Montreal, Ste-Justine Hospital, Canada: EBV target cell defect and other immunological defects in
ataxia telangiectasia (AT).
R. W. ANDERSON, B. R. GREENBERG, S. J. KNOX, T. BECHTOLD, C. KUSZYNSKI, S. HARADA, D. T. PURTILLO, and
D. J. VOLSKY, Dept. of Pathology and Laboratory Medicine, University of Nebraska Medical Center,
Omaha: Lymphocyte abnormalities in preleukemia include lack of EBV receptors.
D. CASAREALE, T. SAIRENJI, W. JONES, and R. E. HUMPHREYS, University of Massachusetts Medical School,
Worcester: p105-An EBV-induced, phosphonoacetic acid-insensitive, glycoprotein target of the anti-
EBV immune response.
G. AHRONHEIM,1 F. AUGER,' L. ROBILLARD,1 F. GHIBU,1 J. JONCAS,1 J. DEMERS,' and N. TRAUB,3
'Research Institute and 'Dept. of Hematology, HoPital Ste-Justine, University of Montreal, Canada;
3Cancer Research Center, University of North Carolina, Chapel Hill: Aplastic anemia and primary EBV
infection.
T. OOKA, D. DECAUSSIN, F. ANGEL, A. CHEVALLIER, E. MANET, and J. DAILLIE, Laboratoire d'Immunovirologie,
Faculte de Medecine Alexis Carrel, Lyon, France: Immunological characterization of EBV-associated
early antigens induced by TPA in combination with N-butyrate.
G. BAUER, Institut fur Virologie, Zentrum fiir Hygiene, University of Freiburg, Federal Republic of Ger-
many: Quantitative analysis of the cooperative effect between inducers of EBV antigen synthesis.
E. FOWLER,' L. M. HUTT-FLETCHER,' and R. J. FEIGHNY,1 tCancer Research Center, University of North
Carolina, Chapel Hill; 'Dept. of Experimental and Comparative Pathology, University of Florida,
Gainesville: Nonionic density gradient purification of EBV.
M. J. REDDEHASE, G. M. KEIL, and U. H. KOSZINOWSKI, Federal Research Institute for Animal Virus Diseases,
Tiibingen, Federal Republic of Germany: Estimation of frequency, specificity, and state of activation of
cytolytic T-lymphocyte precursors generated in vivo during MCMV infection.
J. G. NEDRUD,1 R. Wu,2 S. L. JOHNSON,' and J. S. PAGANO,' 1Cancer Research Center, University of
North Carolina, Chapel Hill; 'Laboratory of Pulmonary Function and Toxicology, Research Triangle
Park, North Carolina: MCMV infection of isolated tracheal epithelial cells-Differences and similarities
to infection of tracheal organ cultures.
J. F. BASKER, S. C. STANAT, and E.-S. HUANG, Cancer Research Center, University of North Carolina, Chapel
Hill: Interaction of MCMV with the reproductive system.
M. J. REDDEHASE, R. L. LORENZ, M. REDDEHASE, and U. H. KOSZINOWSKI, Federal Research Institute for
Animal Virus Diseases, Tiibingen, Federal Republic of Germany: Poisson distribution analysis of the in
vivo expressed cytolytic T-lymphocyte repertoire during MCMV infection.
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J. R. MARKS, J. A. MERCER, and D. H. SPECTOR, Dept. of Biology, University of California San Diego, La Jolla:
Molecular cloning and restriction mapping of the MCMV genome.
P. C. PATEL, J.-L. Liu, E.-C. MAR, and E.-S. HUANG, Cancer Research Center, University of North Carolina
Medical School, Chapel Hill: Monoclonal antibodies against the 54K and 94K proteins of human
cytomegalovirus.
S. CHOU and T. C. MERIGAN, Stanford University Medical School, California: Preliminary observations on
the effect of human leukocyte interferon on viral excretion in CMV retinitis.
A. S. TYMS, Dept. of Medical Microbiology, St. Mary's Hospital Medical School, London, England: Strain
characterization of fresh isolates of HCMV.
U. HEEG,t G. HILLER,' V. HARLE-GRUPP,1 and D. FALKE,1 'Division of Experimental Virology, Institute for
Medicine Microbiology, Mainz; 2Max-Planck-Institute of Biophysical Chemistry, GOttingen, Federal
Republic of Germany: The cytoskeleton of HSV-infected cells.
S. L. VARMUZA and J. R. SMILEY, Dept. of Pathology, McMaster University, Hamilton, Canada: In-
tramolecular sequence heterozygosity within the inverted repeats flanking the S segment of HSV DNA.
S. K. WELLER, B. A. PANCAKE, W. SACKS, D. COEN, and P. A. SCHAFFER, Sidney Farber Cancer Institute, Har-
vard Medical School, Boston, Massachusetts: Genetic analysis of HSV-1, strain KOS-An update.
C. H. SCHRODER and B. HENNES-STEGMANN, Institute of Virus Research, German Cancer Research Center,
Heidelberg, Federal Republic of Germany: Intra- and intertypic interference by HSV DNA in transfection
assays.
C. P. GRAY and H. C. KAERNER, Institute of Virus Research, German Cancer Research Center, Heidelberg,
Federal Republic of Germany: Sequence arrangement of defective HSV-1 DNA-About 500 by of the
"c"-sequence are multiply amplified in the repeat unit of a class II defective HSV-ANG DNA.
S. JEANSSON and E. NILHEDEN, Institute of Medical Microbiology, University of GOteborg, Sweden: Typing of
HSV strains with monoclonal antibodies.
P.-P. PASTORET, B. BROCHIER, E. THIRY, and G. DERBOVEN, Dept. of Virology, University of Liege, Bruxelles,
Belgium: Evolution of specific and nonspecific blastogenesis following experimental infection of cattle
with Bovid herpesvirus 1.
H.-J. RZIHA, H.-J. THIEL, F. WEILAND, N. LUKACS, and G. WITTMAN, Federal Research Institute for Animal
Virus Diseases, TUbingen, Federal Republic of Germany: Pseudorabiesvirus DNA in continuous cell
lines derived from tissues of latent-infected pigs.
V. MISRA and L. A. BABIUK, Western College of Veterinary Medicine, University of Saskatchewan, Canada:
Characterization of a herpesvirus induced 'early' glycoprotein.
J. JANIK,1 J. A. ROSE,' R. M. L. BULLER,' and J. HAY,1,2 1NIAID; USUHS, National Institutes of Health,
Bethesda, Maryland: An HSV function(s) exerts translational control over AAV mRNA.
N. H. PARK,',2 and D. PAVAN-LANGSTON2,3 'Dept. of Oral Biology, 2Eye Research Institute of Retina
Foundation, and 3Dept. of Ophthalmology, Harvard Medical School, Boston, Massachusetts:
Therapeutic efficacy of E-5-(2-bromovinyI)-2'-deoxyuridine on herpes simplex and virus encephalitis in
mice.
S. MODROw, H. SCHMIDT, and H. WOLF, Max von Pettenkofer Institute, Munich, Federal Republic of Ger-
many: Characterization of proteins induced by Herpesvirus saimiri.
L. L. WILLIAMS and G. R. PENN, Dept. of Pediatrics, Ohio State University, Columbus: CMV-specific sup-
pressor cells identified in Charcot-Marie-tooth disease peripheral blood.
WORKSHOP 4 Herpesvirus Pathogenesis
Chairperson: R. TENSOR, Pennsylvania State University, Hershey, Pennsylvania
G. DARAI and J. SCHOLZ, Institut fUr Medizinische Virologie, University of Heidelberg, Federal Republic of
Germany: Generation of intertypic recombinants of HSV in vivo for the study of viral latency and
tropism.
Y. BECKER,t Y. SHTRAM,1 Y. ASHER,1 E. TABOR,' Y. GORDON,' T. BEN-HUR,' J. HADAR,' and D. GILDEN,3
'Dept. of Molecular Virology; 2Dept. of Opthalmology, Hebrew University-Hadassah Medical Center,
Jerusalem, Israel; 3Wistar Institute, University of Pennsylvania Medical School, Philadelphia: Role of
HSV-1 tk gene in viral neurovirulence in weanling and adult mice.
Z.-Y. FANG, R. TENSER, and F. RAPP, Dept. of Microbiology, Pennsylvania State University, Hershey: HSV
replication in regenerating liver cells.
J. M. HILL, Y. SHIMOMURA, G. L. COLBORN, and L. P. GANGAROSA, Medical College of Georgia, Augusta: In-
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duced reactivation of HSV-1-Infectious virus in neural tissue homogenates from latently infected
rabbits.
L. PULLIAM, R. D. Dix, and J. R. BARINGER, Veterans Administration Medical Center, University of California,
San Francisco: Use of aggregating brain cultures to study the replication of HSV-1 and HSV-2 within cen-
tral nervous system tissue.
R. BRAUN, H. TEUTE, M. DAWSON, K. MUNK, and H. KIRCHNER, Institute for Virus Research, German Cancer
Research Center, Heidelberg, Federal Republic of Germany: Replication of HSV in human
lymphocytes-Identification of the target cell of virus replication.
A. L. EPSTEIN,' J. BERTOGLIO,2 and B. JACQUEMONT,' 'Unite de Virologie Fondamentale et Appliquee (IN-
SERM U 51) CNRS; 2Unite de Recherches d'Immunologie et de Cancerologie Experimentale (INSERM
U 218), Centre Leon Berard, Lyon, France: Differential replication of HSV-1 in human lymphoid cell
lines representing various steps of differentiation.
R. D. Dix and J. R. BARINGER, Veterans Administration Medical Center, University of California, San Fran-
cisco: Passive transfer studies using monoclonal antibodies to glycoprotein gA/gB of HSV-1 or 2.
G. R. B. SKINNER,' A. BUCHAN,' C. WOODMAN,' C. E. HARTLEY,' A. FULLER,' J. MELLING,2 J. WIBLIN,' and
G. WILKINS,2 'Dept. of Medical Microbiology, University of Birmingham Medical School; 2Centre for
Applied Microbiological Research, Salisbury, England: Prevention of herpes genitalis in subjects at risk
by immunization with antigenoid vaccine Ac NFU,(S-) MRC.
J. RECTOR, R. LAUSCH, and J. OAKES, Dept. of Microbiology, University of South Alabama Medical College,
Mobile: Neutralizing and nonneutralizing monoclonal antibodies specific for HSV-1 glycoproteins
mediate protection against acute herpetic encephalitis.
J. F. SHERIDAN,' T. IWASAKA,2 E. CHAIKOF,1 and L. AURELIAN,'" 'Dept. of Comparative Medicine; 2Dept.
of Biophysics, Johns Hopkins University Medical School, Baltimore, Maryland: HSV-specific supressor
cells in exogenous reinfection.
R. J. ZIEGLER' and R. S. Pozos,2 'Dept. of Medical Microbiology; 2Dept. of Physiology, University of
Minnesota Medical School, Duluth: Protective effects of various immune mechanisms on rat sensory
neurons infected by HSV-1.
WORKSHOP 5 Viral Enzymes
Chairperson: W. SUMMERS, Yale University, New Haven, Connecticut
R. M. FLUGEL1 and G. DARAI,2 lInstitute of Virus Research, German Cancer Research Center; 2lnstitute of
Medical Virology, University of Heidelberg, Federal Republic of Germany: Specific phosphorylation of
viral proteins by the protein kinase activity associated with the tree shrew herpesvirus.
R. M. FLUGEL1 and G. DARAI,2 'Institute of Virus Research, German Cancer Research Center; 2lnstitute of
Medical Virology, University of Heidelberg, Federal Republic of Germany: Thymidine kinase induced
by Tupaia herpesvirus.
J. S. GRONOWITZ and C. KALLANDER, Dept. of Medical Virology, Biomedical Center, University of Uppsala,
Sweden: dTk isozyme expression as the result of herpes virus infection.
L. M. HUTT-FLETCHER,' R. J. FEIGHNY,2 E. FOWLER,' and J. S. PAGANO,2 Dept. of Comparative and Ex-
perimental Pathology, University of Florida, Gainesville; 2Cancer Research Center, University of North
Carolina, Chapel Hill: Phosphorylation of extracts from EBV receptor positive cells by an EBV-associated
protein kinase.
K. LEARY, B. GARRETT, and B. FRANCKE, Dept. of Human Genetics, Yale University, New Haven, Connec-
ticut: Growth of HSV on hydroxyurea-resistant cells.
E. A. COHEN, J. PERRET, and Y. LANGELIER, Institut du Cancer, Montreal, Canada: Ribonucleotide reductase
induced by HSV.
D. HUSZAR and S. BACCHETTI, Dept. of Pathology, McMaster University, Hamilton, Canada: HSV-induced
ribonucleotide reductase-Development of antibodies specific for the enzyme.
J. D. HALL,' D. M. COEN,2 and P. A. SCHAFFER,2 'Dept. of Cellular and Developmental Biology, Universi-
ty of Arizona, Tucson; 2Sidney Farber Cancer Institute, Harvard Medical School, Boston, Massachu-
setts: An apparent antimutator phenotype in HSV maps in the DNA polymerase locus.
C. KNOPF' and P. A. SCHAFFER,2 'Institute of Virus Research, German Cancer Research Center,
Heidelberg, Federal Republic of Germany; 2Sidney Farber Cancer Institute, Harvard Medical School,
Boston, Massachusetts: HSV DNA polymerase associated 3' exonuclease provides an editing function.
F. WOHLRAB and B. FRANCKE, Dept. of Human Genetics, Yale University, New Haven, Connecticut: Ther-
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molability of the deoxypyrimidine triphosphatase induced by a is mutant in complementation group
2-4.
WORKSHOP 6 Cytomegaloviruses
Chairperson: D. SPECTOR, University of California, San Diego, California
S. MCDONOUGH and D. SPECTOR, Dept. of Biology, University of California San Diego, La Jolla: Transcrip-
tion of HCMV strain AD169 during the permissive infection.
S. STAPRANS and D. H. SPECTOR, University of California San Diego, La Jolla: Transcription from a region of
the HCMV genome which contains sequences related to the avian retrovirus oncogene myc.
K.-T. JEANG and G. S. HAYWARD, Dept. of Pharmacology, Johns Hopkins University Medical School,
Baltimore, Maryland: Regulation of CMV(Colburn) 1E94 gene expression after infection of permissive
and nonpermissive cells.
A. IRMIERE and W. GIBSON, Dept. of Pharmacology and Experimental Therapeutics, Johns Hopkins Univer-
sity Medical School, Baltimore, Maryland: Characterization of a novel virionlike particle from CMV-
infected cell medium.
J. EPSTEIN, W. TURNER, and G. QUINNAN, Food and Drug Administration, Bethesda, Maryland: Im-
munogenic and surface glycoproteins of HCMV, strain AD169, identified by 1-D and 2-D
polyacrylamide gel electrophoresis (PAGE).
M. G. DAVIS and E.-S. HUANG, Cancer Research Center, University of North Carolina, Chapel Hill:
Distribution of repetitive sequences at the L-S repeats and L-S junction of HCMV DNA.
K. M. SCHEGG and S. C. ST. JEOR, Dept. of Microbiology, University of Nevada Medical School, Reno:
Replicative intermediates of HCMV DNA.
D. H. SPECTOR, J. P. VACQUIER, S. STAPRANS, and S. MCDONOUGH, University of California San Diego, La
Jolla: HCMV strain AD69 contains sequences related to the avian retrovirus onogene myc.
R. RUGER and B. FLECKENSTEIN, Institut fur Klinische Virologie, University of Erlangen-NUrnberg, Federal
Republic of Germany: Repetitive cellular DNA in the HCMV genome.
L. EINHORN, H. GADLER, and B. WAHREN, Dept. of Virology, National Bacteriological Laboratory,
Stockholm, Sweden: Adsorption of purified HCMV and induction of early antigens in different cells.
J. M. MIDDELDORP, L. DE LEIJ, and T. H. THE, Dept. of Clinical Immunology, University Hospital Groningen,
The Netherlands: Monoclonal antibodies against HCMV-specific membrane antigens (CMV-MA).
SESSION 6 Transcription
Chairperson: C. M. PRESTON, Institute of Virology, Glasgow, Scotland
M. G. CORDINGLEY, M. E. M. CAMPBELL, and C. M. PRESTON, Institute of Virology, Glasgow, Scotland:
Analysis of HSV-1 immediate early promoter sequences.
J. B. CLEMENTS, J. L. WHITTON, J. MCLAUCHLAN, and F. J. RIXON, Institute of Virology, University of Glasgow,
Scotland: Signals involved in transcriptional regulation of HSV immediate-early and early genes.
K. G. DRAPER, R. J. FRINK, R, H. COSTA, and E. K. WAGNER, Dept. of Molecular Biology and Biochemistry,
University of California, Irvine: Comparative analysis of putative class-specific HSV-1 promoters.
R. J. FRINK and E. K. WAGNER, Dept. of Molecular Biology and Biochemistry, University of California, Ir-
vine: Detailed analysis of a family of HSV-1 mRNAs apparently related by splicing.
T. BECK, K. ENGSTROM, and R. MILLETTE, Dept. of Immunology and Microbiology, Wayne State University
School of Medicine, Detroit, Michigan: Transcription of HSV-1 genes in vitro by RNA polymerase II
prepared from infected and uninfected HEp-2 cells.
J. Buz,' T. HILL,' M. PEAKE,2 J. SADLER,' and L. PIZER,2 'Dept. of Biochemistry, Biophysics, and Genetics
and 2Dept. of Microbiology and Immunology, University of Colorado Health Sciences Center, Denver:
Transcripts from the short unique region of HSV-1.
M .F. STINSKI,1 D. R. THOMSEN,' and L. C. GOLDSTEIN,2 'Dept. of Microbiology, University of Iowa, Iowa
City; 2Fred Hutchinson Cancer Research Center, Seattle, Washington: Organization and expression of
the immediate early genes of HCMV.
R. M. STENBERG and M. F. STINSKI, Dept. of Microbiology, University of Iowa, Iowa City: Structural analysis
of the major immediate early mRNA in HCMV infected cells.
K.-T. JEANG and G. S. HAYWARD, Dept. of Pharmacology, Johns Hopkins University Medical School,
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Baltimore, Maryland: Characterization of the CMV(Colburn) 1E94 gene and expression of the 1E94 pro-
tein in transfected L-cells.
K.-T. JEANG and S. D. HAYWARD, Johns Hopkins University Medical School, Baltimore, Maryland: The Notl
repeats in the EBV DNA molecule form part of an abundant transcript synthesized in the B95-8 cell line
but are deleted from the genome of HR-1.
SESSION 7 Gene Structure and Function
Chairperson: W. SUMMERS, Yale University, New Haven, Connecticut
S. MACKEM and R. ROIZMAN, Kovler Viral Oncology Laboratories, University ofChicago, Illinois: Functional
and structural characterization of the promoter-regulatory regions ofa genes of HSV-1.
G. S. READ,' J. R. SMILEY,' and W. C. SUMMERS,"
'Yale University Medical School, New Haven, Connec-
ticut; 2McMaster University Medical Center, Hamilton, Canada: Analysis of the DNA sequences re-
quired for in vitro transcription of the tk gene of HSV.
J. R. SMILEY and M. HALPERN, Dept. of Pathology, McMaster University, Hamilton, Canada: Upstream DNA
sequences required for positive control of HSV tk expression.
L. HAARR,1 C. M. PRESTON,' and H. S. MARSDEN,' 1 Dept. of Biochemistry, University of Bergen, Nor-
way; 2MRC Institute of Virology, Glasgow, Scotland: Translation of tk mRNA is initiated at three
separate AUG codons.
W. C. SUMMERS, W. P. SUMMERS,' F. A. LAsm,2 U. L. RAJBHANDARY,2 P. A. SHARP,' and R. BELAGAJE,3
'Yale University Medical School, New Haven, Connecticut; 'Massachusetts Institute of Technology,
Cambridge; 'Lilly Research Laboratories, Indianapolis, Indiana: Suppression in mammalian cells of
HSV tk nonsense mutations by translational suppressors contructed in vitro.
F. JENKINS, M. K. HowErr, and F. RAPP, Dept. of Microbiology, Pennsylvania State University Medical Col-
lege, Hershey: Detection by RNA blot hybridization of RNA sequences homologous to the 8g111-N frag-
ment of HSV-2 DNA.
L. E. HOLLAND, R. M. SANDRI-GOLDIN, M. LEVINE, and J. C. GLORIOSO, University of Michigan, Ann Arbor:
Correlation of transcription and complementation group mapping fora region of the HSV-1 genome.
M. HUMMEL and E. KIEFF, University of Chicago, Illinois: Mapping of polypeptides encoded by EBV in pro-ductive infection.
W. P. SUMMERS,1 E. A. GROGAN,' D. SHEDD,' M. ROBERT,3 C.-R. Liu,' and G. MiLLER,2,3
'Dept. of
Therapeutic Radiology; 2Dept. of Epidemiology and Public Health; 3Dept. of Pediatrics, Yale Universi-
ty School of Medicine, New Haven, Connecticut: Stable expression in mouse cells of nuclear neoan-
tigen following transfer of a 3.4 megadalton cloned fragment of EBV DNA.
WORKSHOP 7 HSV Glycoproteins
Chairperson: L. PEREIRA, University of California, Berkeley, California
K. KOUSOULAS, D. DONDERO, P. BOEHME, and L. PEREIRA, California Dept. of Public Health, Berkeley: HSV
glycoprotein gA/B-Purification and studies on two antigenic domains.
P. R. KINCHINGTON and. I. W. HALLIBURTON, Dept. of Microbiology, University of Leeds, England:
Biochemical and antigenic comparisons of glycoprotein B of HSV-1 and
-2.
D. J. BZIK, B. A. Fox, N. DeLucA, and S. PERSON, Molecular and Cell Biology Program, Pennsylvania State
University, University Park: Nucleotide sequence of a region of HSV-1 (KOS) DNA encoding
phenotypes associated with glycoprotein B.
J. W. PALFREYMAN,1 L. HAARR,' A. CROSS," R. G. HOPE,1 and H. S. MARSDEN,' 1MRC Institute of
Virology, Glasgow, Scotland; 2Dept. of Biochemistry, University of Bergen, Norway: Processing of
glycoproteins induced by HSV-1 and identification of a new and major glycosylated species.
B. NORRILD,1 I. VIRTANEN,2 B. PEDERSEN,' and L. PEREIRA,'
'Institute of Medical Microbiology, University
of Copenhagen, Denmark; 2Dept. of Pathology, University of Helsinki, Finland; 3Dept. of Health Ser-
vices, University of California, Berkeley: Processing of the HSV-1 glycoproteins in infected cells.
V. MISRA and L. A. BABIUK, Western College of Veterinary Medicine, University of Saskatchewan, Canada:
Bromovinyl deoxyuridine (BVdU) inhibits the glycosylation of herpesvirus glycoproteins.
R. KUMARASAMY and H. A. BLOUGH, Scheie Eye Institute, University of Pennsylvania, Philadelphia:
Oligosaccharides of envelope glycoprotein gC of HSV-1.
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S. OLOFSSON, S. JEANSSON, and E. LYCKE, Dept. of Virology, University of GOteborg, Sweden: The
heterogeneity of 0-linked carbohydrates associated with the HSV-1 glycoprotein gC.
R. MANSERVIGI,1 M. TOGNON,1 A. ROTOLA, 1 P. F. PIGNATTI,2 and E. CASSAI,1 "Institute of Microbiology,
University of Ferrara; 2Dept. of Animal Biology, Catania, Italy: Characterization of a syn mutant of
HSV-1 (HFEM) defective in gA/gB dimer and gC accumulation.
R. A. RESPESS, B. A. PANCAKE, and P. A. SCHAFFER, Sidney Farber Cancer Institute and Harvard Medical
School, Boston, Massachusetts: Lentil lectin-binding characteristics and immunologic specificity of
HSV-1(KOS)- and HSV-2(186)-specified glycoproteins.
I. HIRSCH, A. SUCHANKOVA, and V. VONKA, Dept. of Experimental Virology, Institute of Sera and Vaccines,
Prague, Czechoslavakia: A novel assay of type-specific antibodies in HSV.
M. ZWEIG, S. D. SHOWALTER, C. J. HEILMAN, JR., S. V. BLADEN, and B. HAMPAR, NCI, Frederick Cancer
Research Facility, Frederick, Maryland: A monoclonal antibody against an HSV-2 75K MW glycoprotein
that also reacts with HSV-1 glycoprotein gC.
WORKSHOP 8 Genome Structure and Cloning
Chairperson: D. J. O'CALLAGHAN, University of Mississippi, Jackson, Mississippi
A. J. DAVISON' and N. M. WILKIE,2 'Institute of Virology; 2Beatson Institute for Cancer Research,
Glasgow, Scotland: Localization of homologous regions in the genomes of five members of the
al phaherpesvi rinae.
M. WATHEN,t W. T. RUYECHAN,' T. CASEY," S. E. STRAUS,' D. J. O'CALLAGHAN,2 and J. HAY,' "NIAID,
National Institutes of Health, Bethesda, Maryland; 2Dept. of Microbiology, University of Mississippi
Medical School, Jackson: Sequence relationships between VZV DNA and the DNAs of other human and
nonhuman herpesviruses.
J. C. Ruiz, J. B. DODGSON, and R. K. MAES, Dept. of Microbiology and Public Health, Michigan State
University, East Lansing: Cloning and characterization of pseudorabies virus DNA sequences.
A. GIELKENS,1 J. VAN OIRSCHOT,1 and A. BERNS,2 'Dept. of Virology, Central Veterinary Institute,
Lelystad; 2Laboratory of Biochemistry, University of Nijmegen, The Netherlands: Aujeszky's disease
variation of viral genomes and differentiation of field isolates and modified live virus
vaccines.
D. SULLIVAN,' S. ATHERTON,' W. RUYECHAN,2 S. DAUENHAUER,1 and D. O'CALLAGHAN,' "Dept. of
Microbiology, University of Mississippi Medical Center, Jackson; 2USUHS, National Institutes of
Health, Bethesda, Maryland: Physical structure and properties of the equine herpesvirus type 3(EHV-3)
genome.
H.-G. KOCH,' H. DELIUS,2 and G. DARAI,1 'Institut fur Medizinische Virologie, University of Heidelberg;
2European Molecular Biology Laboratory, Heidelberg; Federal Republic of Germany: Molecular clon-
ing and characterization of Tupaia herpesvirus DNA.
H. ROUHANDEH, R. COHRS, and A. VAFAI, Dept. of Microbiology, Southern Illinois University, Carbondale:
Molecular biology of herpesvirus sylvilagus.
S. ST. JEOR," B. SEAL,1 and R. TAYLOR,2 'School of Medicine; 2School of Veterinary Medicine, University
of Nevada, Reno: Characterization of infectious bovine rhinotracheitis virus isolates.
J. SKARE,1 N. SULLIVAN,2 and I. B. SKARE,2 'Sidney Farber Cancer Institute, Boston; 2Dept. of Biological
Sciences, University of Lowell, Massachusetts: Cloning of bovine herpesvirus-1 DNA and localization of
sequences in defective genomes.
S. T. PORTEOUS,' J. SKARE,2 and I. B. SKARE,1 'Dept. of Biological Sciences, University of Lowell; 2Sidney
Farber Cancer Institute, Boston, Massachusetts: Analysis of defective interfering particles of bovine
herpesvirus -1.
K. FUKUCHI, M. SUTO, A. TANAKA, and M. NONOYAMA, Dept. of Virology, Showa University Research In-
stitute for Biomedicine, Clearwater, Florida: Marek's disease virus DNA and expression of the viral
genome.
WORKSHOP 9 EBV Cellular Biology and Immunology
Chairperson: D. THORLEY-LAWSON, Tufts University, Boston, Massachusetts
R. GLASER,' A. BOYD,2 J. STOERKER,1 and B. HAMPAR,2 'Ohio State University, College of Medicine, Col-
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umbus; 'Frederick Cancer Research Facility, Frederick, Maryland: Microinjection of EBV DNA and
cloned fragments into EBV-genome negative epithelial tumor cells and EBV-genome positive epithelial
hybrid cells.
R. J. FEIGHNY,t L. M. HUTT-FLETCHER,2 E. FOWLER,' and J. S. PAGANO,' 1Cancer Research Center, Univer-
sity of North Carolina, Chapel Hill; 'Dept. of Comparative and Experimental Pathology, University of
Florida, Gainesville: Structural polypeptides of Epstein-Barr virions.
H. RABIN,' B. C. STRNAD,1 R. F. HOPKINS, III,1 M. NONOYAMA,2 A. TANAKA,2 and R. H. NEUBAUER,'
'NCI, Frederick Cancer Research Facility, Frederick, Maryland; 2Showa University Research Institute
for Biomedicine, St. Petersburg, Florida: Studies on EBV in cell lines established from P3HR-1 virus
superinfected Raji cells.
A. J. MORGAN, J. R. NORTH, and M. A. EPSTEIN, Dept. of Pathology, University of Bristol Medical School,
England: Purification, properties, and immunogenicity of the gp340 component of EBV membrane an-
tigen (MA).
G. BAUER and H. ZUR HAUSEN, Institut kir Virologie, Zentrum fiir Hygiene, University of Freiburg, Federal
Republic of Germany: Induction of EBV antigens by a serum factor.
A. TANAKA, D. CASAREALE, S. SHIN, M. SMITH, and M. NONOYAMA, Dept. of Virology, Showa University
Research Institute, Clearwater, Florida: Early events during blastogenic transformation of B- lymphocytes
with EBV.
D. CASAREALE,1 R. E. HUMPHREYS,2 and M. NONOYAMA,1 1Showa University Research Institute for
Biomedicine, Clearwater, Florida; 'University of Massachusetts Medical School, Worcester: Effect of
lytic infection by EBV on HLA-DR synthesis.
R. SZIGETI,1 G. KLEIN,' G. MASUCCI,1 K. BENDTZEN,2 B. EHLIN-HENRIKSEN,1 and A. K. SAEMUNDSEN,1
'Dept. of Tumor Biology, Karolinska Institutet, Stockholm, Sweden; 'Laboratory of Clinical Im-
munology, Rigshospital, Copenhagen, Denmark: Studies of EBNA-induced leukocyte migration
inhibition.
D. J. VOLSKY, Dept. of Pathology and Laboratory Medicine, University of Nebraska Medical Center,
Omaha: New EBV-producer line established from EBV receptor-negative human lymphocytes.
R. KHELIFA and J. MENEZES, Pediatric Research Center, University of Montreal, Ste-Justine Hospital, Canada:
A new approach for infecting EBV receptor-negative cells with EBV.
C. DESGRANGES,1 J. M. SEIGNEURIN,2 and J. PAIRE,1 'Laboratory of Epidemiology and Immunovirology of
Tumors, Faculty of Medicine, Alexis Carrel, Lyon; 'Virology Laboratory, Grenoble, France: Production
of human monoclonal antiviral antibodies by "EBV-immortalized" lymphoblastoid lines.
B. A. BLAZAR,1 L. SUTTON,' M. STROME,' D. ARBIT,2 and R. SCHOOLEY,2 'Brigham and Women's
Hospital; 'Massachusetts General Hospital, Harvard Medical School, Boston: Interferon dependent
and independent natural killing of human lymphoid lines following induction of Epstein-Barr viral cycle
by P3HR-1 superinfection.
L. STERNAs,t J. LUKA,1 B. KALLIN,1 A. ROSEN,' W. HENLE,2 G. HENLE,2 and G. KLEIN,' Dept. of Tumor
Virology, Karolinska Institutet, Stockholm, Sweden; 'Joseph Stokes, Jr. Research Institute, Philadelphia,
Pennsylvania: Enzyme linked immunosorbent assay (ELISA) for the detection of EBV-induced antigens.
B. KALLIN,1 J. LUKA,1 A. K. SAEMUNDSEN,1 L. STERNAS,1 H. JORNVALL,2 and G. KLEIN,' 1 Dept. of Tumor
Biology; 'Dept. of Medical Chemistry, Karolinska Institutet, Stockholm, Sweden: Isolation of EBV-
binding polypeptides and characterization of associated enzymatic activities.
G. H. Pi,' C. DESGRANGES,2 G. BORNKAMM,3 Y. ZENG,1 and G. DE-T4,2 'Institute of Virology, Chinese
Academy of Science, Peking; 'Faculty of Medicine, Alexis Carrel, Lyon, France; 'Institut fur Virologie,
Zentrum fUr Hygiene, Freiburg, Federal Republic of Germany: Pre-NCP conditions-IgANAC an-
tibodies do not relate to increase presence of EBV/DNA in NP mucosa.
G. J. BAYLISS and H. WOLF, Max von Pettenkofer Institute, Munich, Federal Republic of Germany:
Multiplicity dependence of EBV expression in P3HR1 superinfected Raji cells and infected BJA cells.
M. LOSTROM, Genetic Systems Corp., Seattle, Washington: Cell-driven viral transformation-An efficient
method to prepare human monoclonal antibody secreting cell lines.
WORKSHOP 10 Herpesvirus Transformation
Chairperson: D. GALLOWAY, Fred Hutchinson Cancer Research Center, Seattle, Washington
M. PARK, H. C. KITCHENER, R. P. EGLIN, J. B. CLEMENTS, and J. C. M. MACNAB, Institute of Virology, Glasgow,
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Scotland: Analysis of HSV DNA in oncogenically transformed rodent cells and cervical carcinoma
tissue.
Y. EIZURU,' R. HYMAN,' J. KREIDER,2 and F. RAPP,' tDept. of Microbiology and 2Dept. of Pathology,
Pennsylvania State University College of Medicine, Hershey: Map positions of HSV RNA in an
HSV-1-transformed hamster cell line.
F. M. VAN DEN BERG,' A. J. VAN (DOYEN,' and J. M. M. WALBOOMERS,1 'Section for Experimental On-
cology, University of Amsterdam; 2Dutch Cancer Institute, Section for Virology, Amsterdam, The
Netherlands: Structural and biological analysis of molecularly cloned HSV-2 DNA fragments covering
the entire virus genome.
M. SUFI,' C. CHAUVIN,2 M. FILION,' G. SHORE,3 and E. FROST,' 'Institut du Cancer de Montreal, Centre
Hospitalier Notre-Dame, Canada; 2Centre d'Etude et de Recherches sur les Macromolecules Organis-
ees, Grenoble, France; 3Dept. of Biochemistry, McGill University, Montreal, Canada: Localization of
35K polypeptide in HSV-2 infected cells with the 8g/11 "N" fragment.
J. K. McDouGALL,1 H. K. TAMIMI,2 P. SMITH,' E. TOLENTINO,' and D. A. GALLOWAY,' 'Fred Hutchinson
Cancer Research Center; 2Dept. of Obstetrics and Gynecology, University of Washington, Seattle: HSV
DNA in genital neoplasia.
J. R. SCHLEHOFER and H. ZUR HAUSEN, Institut kir Virologie, University of Freiburg, Federal Republic of Ger-
many: Host cell genome mutations induced by infection with inactivated HSV-1.
M. MIZELL,' M. A. DIBERARDINO,2 P. W. SIMONEAUX, D. G. FRIESENDORF,1 and N. J. HOFFNER," 'Laboratory
of Tumor Cell Biology, Tulane University, New Orleans, Louisiana; 2Dept. of Physiology and
Biochemistry, Medical College of Pennsylvania, Philadelphia: Sequential transformation in frog em-
bryos using the Lucke' tumor herpesvirus-Frog larvae from cloned tumor nuclei.
J. STACZEK and D. J. O'CALLAGHAN, University of Mississippi Medical Center, Jackson: Detection of ECMV
DNA and antigens in transformed and tumor cell lines.
SESSION 8 Immunology
Chairperson: B. SUGDEN, University of Wisconsin, Madison, Wisconsin
A. A. NASH, Dept. of Pathology, University of Cambridge, England: Lyt phenotype of effector and sup-
pressor T cells involved in delayed type hypersensitivity and immunity to HSV.
S. R. JENNINGS, P. L. RICE, R. W. ANDERSON, and S. S. TEVETHIA, Pennsylvania State University College of
Medicine, Hershey: Reduction of class I major histocompatability antigens (H-2) on mouse cells infected
with HSV and its consequences on H-2 restricted lysis by cytotoxic T lymphocytes.
B. PEDERSEN, H. J. KREBS, and B. NORRILD, Institute of Medical Microbiology, University of Copenhagen,
Denmark: The effect of Monensin on target and effector cells participating in antibody-dependent cell-
mediated immunecytolysis of HSV-1 infected cells.
G. A. BISHOP,' S. A. SCHWARTZ,2 and J. C. GLORIOSO,3 'Graduate Program in Cellular and Molecular
Biology; 2Depts. of Epidemiology and Pediatrics; and 3Unit for Laboratory Animal Medicine, Universi-
I. McDougall
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Coffee break
ty of Michigan, Ann Arbor: Characterization of human natural killer cell activity against target cells in-
fected with HSV.
Y. GORDON,' B. JOHNSON,' P. SIMON,' J. ARMSTRONG,3 and S. BROWN,1 'Dept. of Opthalmology,
'Dept. of Pathology, and 'Dept. of Microbiology, Graduate School of Public Health, University of Pitt-
sburgh, Pennsylvania: The effect of immunosupression on HSV-1 TK CNS avirulence.
A. B. RICKINSON, I. HART, M. ROWE, and M. A. EPSTEIN, Dept. of Pathology, University of Bristol Medical
School, England: T cell control of EBV infection-Studies with cyclosporin A.
S. F. SLOVIN,1 R. SCHOOLEY,' and D. A. THORLEY-LAWSON,' 'Dept. of Pathology, Tufts University Medical
School; 'Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts:
Cloned cytotoxic T-cell lines against EBV LYDMA-complexity of the response and HLA restriction.
B. SUGDEN and S. ME-rzENBERG, McArdle Laboratory, University of Wisconsin, Madison: An analysis of EBV-
cell surface (EBVCS) determinants.
D. THORLEY-LAWSON,' R. SCHOOLEY,' and L. NADLER,' 'Dept. of Pathology and Medicine, Tufts Universi-
ty Medical School; 'Division of Infectious Diseases, Massachusetts General Hospital; 3Sidney Farber
Cancer Institute, Harvard Medical School, Boston, Massachusetts: EBV superinduces a new human B
cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts.
W. FREDERICK,' H. MASUR,2 A. ROOK,' K. MITTAL,1 J. MANISCHEWITZ,1 L. JACKSON,' S. STRAUS,' and G.
QUINNAN, JR.,' 1FDA and 2NIAID, National Institutes of Health, Bethesda, Maryland: Immune func-
tions during CMV infection in immunodeficient male homosexuals.
SESSION 9 Gene Transfer and Expression
Chairperson: M. LEVINE, University of Michigan, Ann Arbor, Michigan
S. L. BACHENHEIMER and S. J. SILVERSTEIN, Dept. of Microbiology, Columbia University College of Physicians
and Surgeons, New York, New York: Transfer and expression of HSV immediate-early genes to mam-
malian cells.
J. C. LANG' and N. M. WILKIE,' tlnstitute of Virology; 2Beatson Institute for Cancer Research, Glasgow,
Scotland: The use of hybrid tk genes as an assay for eukaryote promoters and enhancer sequences.
Y. BECKER, Y. SHTRAM, Y. ASHER, and E. TABOR, Faculty of Medicine, Hebrew University, Jerusalem, Israel:
Role of bacterial, viral, and cellular promoters in the expression of HSV-1 tk gene in bacterial and mam-
malian host cells.
J. R. ARRAND and E. HARLOW, Imperial Cancer Research Fund Laboratories, London, England: Expression in
E. coli of fusion proteins containing herpesvirus specified peptides.
A. M. COLBERG- POLEY,t C. MARCUS-SEKURA,1 M. WEST,' B. CARTER,' and L. W. ENQUIST,2 1NIADDK, Na-
tional Institutes of Health, Bethesda, Maryland; 'Molecular Genetics, Inc., Minnetonka, Minnesota: Ex-
pression of the HSV-1 gD gene in Xenopus oocytes.
R. J. WATSON, J. H. WEIS, and L. W. ENQuIST, Molecular Genetics, Inc., Minnetonka, Minnesota: Genome
localization, DNA sequence and expression in E. coli of the HSV-1 glycoprotein D gene.
R. R. SPAETE, L. P. DEISS, and N. FRENKEL, Dept. of Biology, University of Chicago, Illinois: Construction of
eukaryotic cloning vectors containing cis replication functions of HSV.
D. COEN,' M. MANOS,2,4 R. MULLIGAN,3 L. MCREYNOLDS,4 and P. A. SCHAFFER,' 'Sidney Farber Cancer
Institute, Harvard Medical School, Boston, Massachusetts; 'Cold Spring Harbor Laboratory, New York;
'Cancer Research Center, Massachusetts Institute of Technology, Cambridge; 4Dept. of Biochemistry,
University of Arizona, Tuscon: Introduction of an intron and other DNA modifications into HSV using a
cloned mutant tk gene.
L. RYMO, Dept. of Clinical Chemistry, University of Gothenburg, Sahlgran's Hospital, Sweden: Transforma-
tion of lymphoid cells with vectors that contain the gene for the E. coli enzyme xanthine-guanine
phosphoribosyltransferase and defined segments of the EBV genome.
G. R. REYES, E. R. GAVIS, D. CIUFO, P. PITHA, and G. S. HAYWARD, Johns Hopkins Medical School, Baltimore
Maryland: Studies of HSV gene regulation using a hybrid tk-interferon gene and microinjection into
Xenopus oocytes.
R. M. SANDRI-GOLDIN, A. L. GOLDIN, L. E. HOLLAND, M. LEVINE, and J. C. GLORIOSO, University of Michigan,
Ann Arbor: Expression of nonselected HSV-1 sequences in cell lines transformed by protoplast fusion
gene transfer.
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SESSION 10 Antivirals
Chairperson: C. SHIPMAN, Yale University, New Haven, Connecticut
M. J. Oro and W. H. PRUSOFF, Yale University Medical School, New Haven, Connecticut: Production of
interfering particles during infection of Vero cells by HSV-1 in the presence of AldUrd (5-10D0-5'-
AMINO-2 ',5 '-dideoxyuridine) or IdUrd (5-10D0-2 '-deoxyuridine).
D. M. COEN, D. P. ASCHMAN, P. T. GELEP, S. K. WELLER, and P. A. SCHAFFER, Sidney Farber Cancer Institute,
Harvard Medical School, Boston, Massachusetts: Cloning and fine structural mapping of mutations in or
near the HSV DNA polymerase locus which confer altered sensitivity to antiviral drugs, temperature and
aphidicolin.
C. CRUMPACKER,1 H. S. ALLAUDEEN,2 and L. E. SCHNIPPER,' 'Dept. of Medicine, Beth Israel Hospital,
Boston, Massachusetts; 2Dept. of Pharmacology, Yale School of Medicine, New Haven, Connecticut:
Physical mapping of mutations conferring resistance of purified herpes DNA polymerase to nucleoside
tri phosphate analogues.
L. SCHNIPPER,' C. CRUMPACKER,1 H. S. ALLAUDEEN,2 and D. KUFE,1 'Harvard Medical School, Boston,
Massachusetts; 2Yale School of Medicine, New Haven, Connecticut: Mechanism of resistance to
arabinofuranosyl derivatives in a mutant herpesvirus.
A. K. DATTA and J. S. PAGANO, Cancer Research Center, University of North Carolina, Chapel Hill:
Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl) guanine] in vitro in activated Burkitt somatic
cell.
P. C. PATEL, E.-C. MAR, Y.-C. CHENG, and E.-S. HUANG, Cancer Research Center, University of North
Carolina, Chapel Hill: Antiviral activities of deoxyuridine and deoxycytidine analogues on HCMV.
B. ERIKSSON AND B. OBERG, Astra Lakemedel AB, Dept. of Antiviral Chemotherapy, SOder6lje, Sweden:
Different susceptibilities of herpesvirus DNA polymerases to pyrophosphate analogs.
C. SHIPMAN, JR., S. H. SMITH, S. R. TURK, C. M. REINKE, and J. C. DRACH, University of Michigan, Ann Arbor:
2-acetylpyridine thiosemicarbazones-A new class of compounds active against HSV-1 and 2.
W. GIBSON, R. VANBREEMEN, A. FIELDS, and R. LAFEMINA, Dept. of Pharmacology and Experimental
Therapeutics, Johns Hopkins Medical School, Baltimore, Maryland: Alpha-difluoromethylornithine in-
hibits CMV replication.
H. GAOLER, Dept. of Virology, National Bacteriology Laboratory, Stockholm, Sweden: Use of nucleic acid
hybridization for studies on the efficacy of antiviral compounds.
SESSION 11 Genetics (Gene Location)
Chairperson: P. A. SCHAFFER, Harvard University Medical School, Boston, Massachusetts
N. DELucA, D. J. BZIK, V. C. BOND, W. SNIPES, and S. PERSON, Molecular and Cell Biology Program, Penn-
sylvania State University, University Park: Genetic domains of the HSV-1 (KOS) genome affecting virus
entry, cell fusion and the production of gB.
W.-C LEUNG, Dept. of Medicine, University of Alberta, Canada: In vitro mutagenesis of a HSV regulatory
protein ICP4.
S. K. WELLER,' R. A. F. DIXON,' K. J. LEE,' D. J. SABOURIN,' and P. A. SCHAFFER,' 'Sidney Farber Cancer
Institute, Harvard Medical School, Boston, Massachusetts; 2Johns Hopkins University Medical School,
Baltimore, Maryland: Genetic analysis of is mutants which define the gene for the major HSV DNA-
binding protein.
B. A. PANCAKE, D. P. ASCHMAN, and P. A. SCHAFFER, Sidney Farber Cancer Institute, Harvard Medical
School, Boston, Massachusetts: Genetic and phenotypic analysis of HSV-1 is mutants resistant to im-
mune cytolysis-Identification of four new HSV-1 complementation groups.
S. PERSON, N. DELucA, V. C. BOND, D. J. BZIK, and W. SNIPES, Molecular and Cell Biology Program, Penn-
sylvania State University, University Park: Regions of the HSV-1 (KOS) genome affecting cell fusion and
the production of gB and gC.
S. D. MARLIN,' T. C. HOLLAND,2 M. LEVINE,2 and J. GLORIOS0,3 'Graduate Program in Cellular and
Molecular Biology, 2Dept. of Human Genetics, and 3Unit for Laboratory Animal Medicine, University
of Michigan, Ann Arbor: Antigenic variants of HSV-1 selected with glycoprotein specific monoclonal
antibodies.
V. G. PRESTON, B. MATZ, and F. J. RIXON, Institute of Virology, Glasgow, Scotland: Identification and
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characterization of an HSV-1 gene which is required for packaging virus DNA into empty
nucleocapsids.
B. M. Du-nA, MRC Virology Unit, Institute of Virology, Glasgow, Scotland: The genetic control of the
ribonucleotide reductase activity induced by HSV-1 and HSV-2.
B. FRANCKE and B. GARRETT, Dept. of Human Genetics, Yale University, New Haven, Connecticut: In vitro
complementation of is DNA mutants of HSV-1.
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10th Cold Spring Harbor Conference on Cell Proliferation
Teratocarcinoma Stem Cells
September 8September 12
Arranged by Lee Silver, Cold Spring Harbor Laboratory, Gail Martin, University of California, San Fran-
cisco, Sidney Strickland, The Rockefeller University
131 participants
This meeting represented the first time in seven years that an open international forum had been devoted
entirely to the teratocarcinoma system. The last such meeting was held at the Roche Institute of Molecular
Biology in Nutley, New Jersey, and much progress in this field has been made since that time. We were
pleased to have in attendance representatives of almost every laboratory in the world in which teratocar-
cinoma stem cell biology is being studied. This field has its roots in classical embryology and has long been
of interest to those concerned with the problem of tumorigenesis. The program of this meeting, however,
reveals the extend to which embryonal/embryonic stem cells have become experimental material for in-
vestigators with a diversity of primary scientific interests Embryology, tumorigenesis, virology, car-
bohydrate chemistry, DNA methylation, and eukaryotic vectors were among the topics discussed. It was
gratifying to find that there was a free flow of ideas, catalyzed by the beautiful weather and relaxed at-
mosphere, among scientists using techniques as diverse as descriptive morphology and molecular cloning
of DNA. The proceedings of this meeting will be published in 1983 as volume 10 in Cold Spring Harbor
Conferences on Cell Proliferation: Teratocarcinoma Stem Cells.
This meeting was supported in part by the Cancer Center Grant to Cold Spring Harbor Laboratory from
the National Cancer Institute, National Institutes of Health.
SESSION 1 Introduction
S. GLUECKSOHN-WAELSCH, Dept. of Genetics, Albert Einstein College of Medicine, Bronx, New York:
Genetic control of differentiation.
G. B. PIERCE and R. WELLS, Dept. of Pathology, University of Colorado Health Sciences Center, Denver:
Malignancy and differentiation-The role of trophectoderm in control of colony formation.
L. C. STEVENS, Jackson Laboratory, Bar Harbor, Maine: Origin and development of testicular, ovarian, and
embryo-derived teratomas.
SESSION 2 In Vitro Differentiation
Chairperson: G. MARTIN, University of California, San Francisco, California
R. KEMLER, Friedrich-Miescher-Laboratorium, Max-Planck-Gesellschaft, Tiibingen, Federal Republic of Ger-
many: Differentiation induction of embryonal carcinoma cells-Cell type analysis with monoclonal
antibodies.
H. Fox, M. Krangel, G. Martin, L. Silver, N. Sarvetnick
220
J. Rossant, V. Papaioannou, H. Axelrod, C. Webb, R.
Kemler, I. Damjanov
R. G. OSHIMA,' J. M. TABOR,2 W. H. HOWE,' and E. ADAMSON,' tLa Jolla Cancer Research Foundation,
California; 2Bristol-Myers Company, Syracuse, New York: Identification of extra-embryonic endoder-
mal cytoskeletal proteins and mRNAs in retinoic acid-treated embryonal carcinoma cells and blastocyst
stage embryos.
D. TALMAGE and S. STRICKLAND, Rockefeller University, New York, New York: Disappearance of an HMG-
like protein following retinoic acid treatment of F9 cells.
E. D. ADAMSON and A. GROVER, La Jolla Cancer Research Foundation, California: The production and
maintenance of a functioning epithelial layer from embryonal carcinoma cells.
A. RIZZINO, Laboratory of Viral Carcinogenesis, NCI, Frederick, Maryland: Differentiation of three multipo-
tent embryonal carcinoma cell lines into a single cell type-The use of defined media and the role of
fibronectin and laminin.
M. DARMON1 and G. SERRERO,2 'Institut Pasteur, Paris, France; 2Dept. of Biology, University of Califor-
nia, San Diego, La Jolla: Isolation of two different fibroblastic cell types from the embryonal carcinoma
cell line 1003-Study of tumorigenic properties, surface antigens, and differentiation responses to
5-azacytidine and dexamethasone.
M. W. MCBURNEY,1 E. M. V. JONES-VILLENEUVE,2 and M. K. S. EDWARDS,2 Depts. of 'Medicine and
2Biology, University of Ottawa, Ontario, Canada: Controlled differentiation of an embryonal carcinoma
cell line.
W. B. ANDERSON and A. S. KRAFT, NCI, National Institutes of Health, Bethesda, Maryland: Effect of retinoic
acid and phorbol ester treatment of embryonal carcinoma cells on calcium, phospholipid-dependent
protein kinase activity.
M.J. SHERMAN, M.L. PATERNOSTER, M.A. EGLITIS, and P.A. MCCuP, Roche Institute of Molecular Biology,
Nutley, New Jersey: Studies on the mechanism by which chemical inducers promote differentiation of
embryonal carcinoma cells.
SESSION 3 Poster Session
S. AIZAWA," L. A. LOEB,2 and G. M. MARTIN,' 1 Division of Genetic Pathology; 2Joseph Gottstein
Memorial Cancer Research Laboratory, Dept. of Pathology, University of Washington, Seattle; 3Dept.
of Biochemistry, Tokyo Metropolitan Institute of Gerontology, Japan: Isolation and preliminary
characterization of mouse teratocarcinoma cells resistant to aphidicolin and arabinofuranosyl cytosine.
S.-Y. WANG1'2 and L. J. GuDAs,1,2 'Sidney Farber Cancer Institute; 2Dept. of Pharmacology, Harvard
Medical School, Boston, Massachusetts: Selection of F9 stem cell mutants with altered responses to
retinoic acid.
S. KARTHA and J. S. FELIX, Developmental Genetics Laboratory, Dept. of Pediatrics, Johns Hopkins Universi-
ty School of Medicine, Baltimore, Maryland: Cell surface interactions of H6 teratocarcinoma cells.
G. D. PATERNO and M. M. MCBURNEY, Depts. of Biology and Medicine, University of Ottawa, Ontario,
Canada: X chromosome inactivation in embryonal carcinoma cells.
E. GOOTWINE and C. G. WEBB, Dept. of Hormone Research, Weizmann Institute of Science, Rehovot,
Israel: Embryo-derived teratomas in Wistar rats-Characterization of transplantable tumors and cell
lines.
A. GIALLONGO, K. B. TAN, C. GREEN, and C. M. CROCE, Wistar Institute, Philadelphia, Pennsylvania:
Monoclonal antibodies to chromosomal proteins and teratocarcinoma stem cell surface antigens.
J. F. HARRIS,1'2 J. CHIN,' N. KARTNER,1 and M. A. S. JEWETT,2 Depts. of 'Medical Biophysics and
2Surgery, University of Toronto, Ontario, Canada: Characterization of two monoclonal antibodies
against mouse embryonal carcinoma cells.
B. FENDERSON, A. HAHNEL, and E. M. EDDY, Dept. of Biological Structure, University of Washington, Seattle:
Patterns of cell surface carbohydrate expressions in early mouse embryos detected with monoclonal
antibodies.
F. FUJIMURA, La Jolla Cancer Research Foundation, California: Polyoma mutant DNA replication in F9 em-
bryonal carcinoma cells.
K. SEKIKAWA, Dept. of Molecular Biology, Cancer Institute, Sapporo Medical College, Japan: cis-acting
regulatory mutation for early and late gene expression of polyoma virus on nullipotential embryonal car-
cinoma cells.
J. CAMPIONE-PICCARDO and M. W. MCBURNEY, Dept. of Medicine, University of Ottawa, Canada: Ex-
perimental and theoretical kinetics of the response of embryonal cells to retinoic acid.
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W. DEWOLF and P. CARROLL, Divisions of Immunogenetics, Sidney. Farber Cancer Institute and Cellular
Genetics, Charles A. Dana Research Institute, Boston, Massachusetts: An immunological profile
characterizing human teratocarcinoma cell differentiation.
T. DUCIBELLA,1 J. AALBERG,1 D. ANDERSON,2 and W. C. DEWOLF,2 'Dept. of Anatomy, Tufts University
School of Medicine; 2Division of Immunogenetics, Sidney Farber Cancer Institute, Boston,
Massachusetts: Human teratocarcinoma embryoid bodies are characterized by cell surface polarization,
tight junctions, and eccentric inner cells.
P. NARAYAN,1 C. MILLETTE,2 and W. DEWOLF,1 'Dept. of Cellular Genetics, Beth Israel Hospital; 2Dept.
of Anatomy and Laboratory of Human Reproduction and Reproductive Biology, Harvard Medical
School, Boston, Massachusetts: Biochemical characterization of the stage specific proteins in normal
human germ cells and human teratocarcinoma.
C. L. STEWART, D. JAHNER, H. STUHLMANN, and R. JAENISCH, Heinrich-Pette-Institut fUr Experimentelle
Virologie and Immunologie, Universitat Hamburg, Federal Republic of Germany: De novo methylation,
expression, and infectivity of retroviral genomes introduced into early mouse embryonic cells.
C. M. ISACKE and J. K. HEATH, CRC Developmental Tumour Group, Dept. of Zoology, University of Oxford,
England: Secretion of growth regulatory molecules by PC13 embryonal carcinoma cells.
SESSION 4 Cell Surface Molecules
Chairperson: F. JACOB, Institut Pasteur, Paris, France
L. B. GRABEL, M. S. SINGER, S. D. ROSEN, and G. R. MARTIN, Dept. of Anatomy, University of California, San
Francisco: The role of carbohydrates in the intercellular adhesion and differentiation of teratocarcinoma
stem cells.
M. TAKEICHI,1 C. YOSHIDA-NOR0,1 S. OGOU,1 Y. SHIRAYOSHI,1 and J. WARTIOVAARA,2 Dept. of Bio-
physics, Kyoto University, Japan; 2Dept. of Electron Microscopy, University of Helsinki, Finland: A
teratocarcinoma cell-cell adhesion molecule and its roles in embryonic cellular interactions.
T. MURAMATSU, Dept. of Biochemistry, Kagoshima University School of Medicine, Japan: The high-
molecular-weight carbohydrates found in teratocarcinoma stem cells and early embryos.
B. D. SHUR, Dept. of Anatomy, University of Connecticut Health Center, Farmington: The role of cell sur-
face galactosyltransferase in embryonal carcinoma cell adhesion.
C. HOWE, B. DIETZSCHOLD, and D. SOLTER, Wistar Institute, Philadelphia, Pennsylvania: Laminin as a marker
for differentiation in teratocarcinoma cell system.
K. WILLISON,1 A. SUZUKI? R. KAROL,3 S. KUNDU,3 and D. MARCUS,' 'Institute of Cancer Research,
Chester Beatty Research Institute, London, England; 2Tokyo Metropolitan Institute of Medical Science,
Japan; 'Baylor College of Medicine, Houston, Texas: Neutral glycolipid antigens of mouse teratocar-
cinoma and early embryos.
L. J. GUDAS,1'2 J. P. SINGH," and C. STILES,1'3 'Sidney Farber Cancer Institute; Depts. of 2Pharmacology
and 3Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts: Growth
response and binding of PDGF to mouse teratocarcinoma cells.
S. C. CHUA and M. F. MAYLIE-PFENNINGER, Dept. of Anatomy and Cell Biology, Columbia University, New
York, New York: A 105-kD cell surface component is critical for mouse preimplantation development.
SESSION 5 DNA Viruses
Chairperson: A. LEVINE, State University of New York, Stony Brook, New York
M. VASSEUR and C. MARLE, Unite de Genetique Cellulaire du College de France et de ['Institut Pasteur,
Paris: Properties of F9 cells chronically infected with polyoma EC virus.
E. LINNEY, S. DONERLY, B. OLINGER, M. BENDER, and F. FUJIMURA, La Jolla Cancer Research Foundation,
Cancer Research Center, California: Expression of genes transferred into teratocarcinoma cells.
P. HERBOMEL, B. DE CROMBRUGGHE, and M. YANIV, Institut Pasteur, Paris, France: Recombinant vectors to
study controlling elements of polyoma virus expression in EC cells.
K. TANAKA,' K. CHOWDHURY,2 K. S. S. CHANG,' M. ISRAEL,2 and Y. 110,2 'NCI; 2NIAID, National In-
stitutes of Health, Bethesda, Maryland: Differentiation-stage-dependent polarity of the growth of
polyoma virus mutants capable of growing in embryonal carcinoma and trophoblast cells.
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F. KELLY,' C. BABINET,1 and K. WILLISON,2 'Institut Pasteur, Paris France; 2lnstitute of Cancer Research,
London, England: Studies on interactions between EC cells andearly mouse embryo cells with SV40.
M. TAKETO, J. J. KOPCHICK, P. A. McCuE, D. STACEY, and M. I. SHERMAN, Dept. of Cell Biology, Roche In-
stitute of Molecular Biology, Nutley, New Jersey: Studies on SV40 T antigen expression in wild-type and
differentiation-defective murine embryonal carcinoma cell lines.
J. M. LEHMAN, K. TREVOR, M. ROSENBERG, and K. HELD, Dept. of Pathology, University of Colorado School
of Medicine, Denver: Teratocarcinoma-A model for virus-cell interactions.
SESSION 6 Retroviruses
Chairperson: R. JAENISCH, Heinrich-Pette Institut Universi6t Hamburg, Federal Republic of Germany
K. HUEBNER,' A. LINNENBACH,2 P. GHOSH,2 H. ROMANCZUK,1 A. AR-RusHol," N. TSUCHIDA,3 andC.CRocE,1 1Wistar Institute, Philadelphia, Pennsylvania; 2Dept. of Internal Medicine, Yale UniversitySchool of Medicine, New Haven, Connecticut; 3Yakult Central Institute for Microbiological Research,
Tokyo, Japan: Regulation of expression of oncogenic viral genomes in DNA-transformed F9 cells.J. W. GAUTSCH and M. C. WILSON, Research Institute of Scripps Clinic, La Jolla, California: Restriction of M-
MuLV growth in teratocarcinoma-Involvement of factors other than DNA methylation.
C. HAMMOND,' J. M. BISHOP,' and G. R. MARTIN,2 Depts. of 'Microbiology and Immunology and
2Anatomy, University of California, San Francisco: Moloney murine leukemia viral expression in undif-ferentiated and differentiated teratocarcinoma cells.
R. JAENISCH, K. HARBERS, D. JAHNER, J. LoHLER, C. STEWART,
and H. STUHLMANN, Heinrich-Pette-Institut fiir Ex-
perimentelle Virologie and Immunologie, Universitat Hamburg, Federal Republic of Germany: Expres-
sion of retroviral genomes introduced into early mouse embryos.
SESSION 7 Differentiation Studies with Cloned DNA Probes
Chairperson: S. STRICKLAND, The Rockefeller University. New York, New York
K. R. MAROTTI, D. A. TALMAGE, and S. STRICKLAND, Rockefeller University, New York, New York: Specific
induction of gene expression during differentiation.
B. HOGAN, M. KURKINEN, A. COOPER, and D. BARLOW, Imperial Cancer Research Fund, Mill Hill
Laboratories, London, England: Gene expression during endoderm differentiation.
P. BRULET, Unite de Genetique Cellulaire du College de France et de l'Institut Pasteur, Paris: Molecular
probes to study the first differentiation in the mouse embryo.
M. H. BUC-CARON,1 J. GAILLARD,' M. DARMON,1 D. PAULIN,' C. SELLEM,2 and J. SALA TREPAT,2
1Genetique Cellulaire, Institut Pasteur, Paris; 2Laboratoire d'Enzymologie du CNRS, France: Analysis of
AFP and albumine gene expression in teratocarcinoma cells.
D. MORELLA, G. GACHELIN, and P. KOURILSKY, Unite de Biologie Moleculairedu Gene, CNRS and INSERM,
Institut Pasteur, Paris, France: The expression of H-2 and I32 microglobulin genes is controlled at thelevel of transcription.
P. N. GOODFELLOW,' P. W. ANDREWS,2 M. V. WILES," M. QUINTERO,' and F. BENHAM,' 'Imperial CancerResearch Fund, London, England; 2Wistar Institute, Philadelphia, Pennsylvania: Developmental
genetics of MHC expression using human-mouse hybrid cell lines.
R. MULLER,' D. J. SLAMON,2 E. ADAMSON,3 J. M. TREMBLAY,' M. J. CLINE,2 and I. M. VERMA,1 'Tumor
Virology Laboratory, Salk Institute, San Diego; 2Dept. of Medicine, University of California, Los
Angeles; 3La Jolla Cancer Research Foundation, California: Expression of cellular oncogenes during
pre- and postnatal development of the mouse and in embryonal carcinoma cell lines.
J. F. NICOLAS and P. BERG, Dept. of Biochemistry, Stanford University Medical Center, California: Expres-
sion of genes introduced into embryonal carcinoma cells (EC) by cotransformation.
J. JAMI, D. BUCCHINI, C. LASSERRE, R. LOVELL-BADGE, J. THILLET, F.KUNST, and R. PICTET, Institut de Recherche
en Biologie Moleculaire, Paris, France: Stable transformation of embryonal carcinoma cells with thedominant marker Eco.gpt does not impair their developmental potentialities.
SESSION 8 Genetics
Chairperson: L. SILVER, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
I. DAMJANOV,1 0. BAGASRA,1 and D. SOLTER,2
'Dept. of Pathology, Hahnemann University; 2Wistar In-
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stitute, University of Pennsylvania, Philadelphia: Genetic and epigenetic factors regulate the malignancy
of embryo-derived teratomas.
S. OSTRAND-ROSENBERG, A. L. COHN, J. W. SANDOZ, M. L. SCHWARTZMAN, and C. MCCARTHY, Dept. of
Biological Sciences, University of Maryland, Catonsville: Host regulation of major histocompatibility
complex (MHC) antigens on 402AX teratocarcinoma cells during tumor rejection.
L. L. JOHNSON, A. SHEDLOVSKY, L. CLIPSON, and W. F. DOVE, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: The genetics of allograft rejection of teratocarcinoma cell lines.
J. FOREJT, Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Czechoslovakia: Expression
of T-t and H-2 genes in teratocarcinoma cells.
T. BOON, A. VAN PEL, and F. VESSIERE, Ludwig Institute for Cancer Research, Brussels, Belgium: Tumor cell
variants with increased immunogenicity obtained by mutagen treatment.
M. J. ROSENSTRAUS, Dept. of Biological Sciences and. Bureau of Biological Research, Rutgers, State Universi-
ty, New Brunswick, New Jersey: Isolation and characterization of mutant embryonal carcinoma cells
lacking stage specific embryonic antigen 1.
L. NAGARAJAN, A. M. JETTEN, and W. B. ANDERSON, NCI, National Institutes of Health, Bethesda, Maryland:
Characterization of a new endodermal cell line (DIF 5) derived from retinoic acid-treated F9 teratocar-
cinoma cells.
SESSION 9 Human Teratocarcinoma Workshop
Chairperson: P. W. ANDREWS, The Wistar Institute, Philadelphia, Pennsylvania
P. W. ANDREWS,' P. N. GOODFELLOW,' and D. L. BRONSON,' tWistar Institute, Philadelphia, Penn-
sylvania; 2lmperial Cancer Research Fund, London, England; 'University of Minnesota, Minneapolis:
Cell surface characteristics and other markers of differentiation of human teratocarcinomas in culture.
Y. FRADET,' A. HOUGHTON,' G. BOSL,t D. BRONSON,' W. WHITMORE, JR.,' and L. J. OLD,' tMemorial
Sloan-Kettering Cancer Center, New York, New York; 2University of Minnesota, Minneapolis: Cell sur-
face antigens of human teratocarcinoma cell lines analyzed by monoclonal antibodies.
BRONSON,' P. W. ANDREWS,' R. L. VESSELLA,t and E. E. FRALEY,' lUniVerSity of Minnesota Medical
School, Minneapolis; 2Wistar Institute, Philadelphia, Pennsylvania: In vitro differentiation of human
embryonal carcinoma cells.
N. J. VOGELZANG,' D. L. BRONSON,' D. SAviNo,2 and E. E. FRALEY,' tUniversity of Chicago, Illinois;
2University of Minnesota, Minneapolis: An in vivo and in vitro model of human embryonal and yolk
sac carcinoma.
P. CARROLL,t W. DEWOLF,2 and G. SCHWARTING,3 'Tufts University, Boston; 2Beth Israel Hospital,
Boston; 3Eunice Kennedy Shriver Center, Waltham, Massachusetts: Glycosphingolipids of human
teratocarcinoma.
R. Jaenisch
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F. Jacob, B. Pierce S. Strickland
SESSION 10 Embryos and Embryonic Stem Cell Lines
Chairperson: V. E. PAPAIOANNOU, Tufts University, Boston, Massachusetts
J. ROSSANT1 and M. W. MCBURNEY,2 'Dept. of Biological Sciences, Brock University, St. Catharines;
2Dept. of Medicine, University of Ottawa, Ontario, Canada: Euploid teratocarcinoma cell lines differ in
their ability to differentiate normally after blastocyst injection.
G. R. MARTIN and L. F. LOCK, Dept. of Anatomy, University of California, San Francisco: Pluripotent cell
lines derived from early mouse embryos.
M. J. EVANS, A. BRADLEY, E. J. ROBERTSON, and M. H. KAUFMAN. Depts. of Genetics and Anatomy, University
of Cambridge, England: Isolation, properties, and karyotypes of pluripotential (EK) cells from normal and
parthenogenetic mouse embryos.
H. R. AXELROD' and D. BENNETT,2 tWistar Institute, Philadelphia, Pennsylvania; 2Sloan-Kettering In-
stitute for Cancer Research, New York, New York: A simplified method for obtaining embryonic stem
cell lines from blastocysts.
T. MAGNUSON,' G. R. MARTIN,' L. M. SILVER,3 and C. J. EPSTEIN,' Depts. of 'Pediatrics and 2Anatomy,
University of California, San Francisco; 3Cold Spring Harbor Laboratory, New York: Studies of the
viability of tw5/tw, embryonic cells in vitro and in vivo.
H.S. Fox", A. FRISCHAUT,2 H. LEHRACH,2 G.P. MARTIN' and L.M. SILVER,3 UniVerSity of California, San
Francisco; 2EMBL, Heidelberg, Germany; 3Cold Spring Harbor Laboratory, New York: t haplotype
specific genomic clones derived from a homozygous t' embryonic stem cell line.
R. L. BRINSTER,1 and R. D. PALMITER,2 'Laboratory of Reproductive Physiology, School of Veterinary
Medicine, University of Pennsylvania, Philadelphia; 2Howard Hughes Medical Institute Laboratory,
Dept. of Biochemistry, University of Washington, Seattle: Introduction of new genes into mice.
Summary: F. JACOB, Institut Pasteur, Paris, France
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Papilloma Viruses
September 14-September 18
Arranged by Thomas R. Broker, Cold Spring Harbor Laboratory, Peter M. Howley, National Cancer
Institute
117 participants
A spin-off from the DNA Tumor Virus Meeting, this meeting was a new "specialty" conference at Cold
Spring Harbor Laboratory. That such a meeting would be desirable became evident as interest in and
research on these wart viruses, their interaction with epithelial cells, and their clinical and veterinary
manifestations increased dramatically over the past few years. The meeting attracted over three times as
many participants as any previous conference on the subject.
Until recently, few basic researchers studied the papilloma viruses (PVs) because they could not be pro-
pagated in cell culture. However, most of the 16 known types of human papilloma viruses (HPVs), the five
bovine types, Shope (cottontail rabbit) papilloma virus, and the deer, European elk, and chaffinch
papilloma viruses have now been cloned in bacterial plasmid vectors. This has permitted the preparation of
homogeneous quantities of material for detailed molecular characterization, development of hybridization
probes for clinical diagnosis, and use of papilloma virus genomes themselves as cloning vectors for the ex-
pression of bacterial, viral, and eukaryotic genes in eukaryotic cells.
The most notable clinical development reported was the increasing incidence (now 10%) of HPV type 6
in venereal disease and its correlation with cervical dysplasias and carcinomas. Several other HPV types
have also been clearly implicated in carcinogenesis of human epithelia, the analogs of cancers caused by
certain animal papilloma viruses. The DNA sequences of HPV-1, HPV-6, bovine PV-1, and Shope
papilloma virus were presented. Their genetic organizations are extremely similar, and the disposition of all
significant open translation frames along only one of the DNA strands clearly distinguishes the papilloma
viruses from SV40 and polyoma viruses, with which they were originally classified as "papovaviruses."
Some RNA transcripts of BPV-1, HPV-1, and Shope papilloma virus have been mapped and correlated with
encoded functions. Various host systems were described, but a fully permissive system for lytic infection
has yet to be found. The unique qualities as well as some of the problems of papilloma virus-based
episomal cloning vectors were illustrated. An informal open discussion considered suggestions for
nomenclature, taxonomy, and sharing of cloned prototype strains.
The success of this meeting has been marked by the decision of the European Molecular Biology
Organization to sponsor a similar conference in Sweden in July 1983 and by the probability of holding such
a meeting again at Cold Spring Harbor Laboratory in alternate years.
Through the generosity of the National Cancer Institute, Fogarty International Center, National Science
Foundation, Council for Tobacco Research-USA, Abbott Laboratories, Applied Molecular Genetics,
Biogen, CIBA-Geigy, Cetus Corporation, Genentech, and Lilly Research Laboratories we were able to fund
many of the participants.
Papilloma Viruses Meeting
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SESSION 1 Human Disease. I. Genital Papillomas
Chairperson: L. G. Koss, Montefiore Medical Center, Bronx, New York
L. G. Koss, Dept. of Pathology, Montefiore Medical Center, Bronx, New York: Papilloma virus infections
and cancer of the female genital tract and anus.
R. J. KURMAN, A. B. JENSON, and W. D. LANCASTER, Georgetown University School of Medicine,
Washington, DC: Immunocytochemical localization of papilloma virus antigens in cervical dysplasia
and carcinoma in situ.
R. REID, Sinai Hospital and Wayne State University Medical School, Detroit, Michigan: Can HPV infection
trigger cervical carcinogenesis?
K. SYRJANEN,1 M. VAYRYNEN,2 0. CASTREN,2 R. MANTYJARVI,3 S. PYRHONEN,4 S. SYRJANEN,1 and M.
YLISKOSKI,2 Depts. of 'Pathology, 2Gynecology, and 3Clinical Microbiology, University of Kuopio;
4Dept. of Virology, University of Helsinki, Finland: HPV-antigens in the dysplastic lesions of the uterine
cervix.
B. WINKLER,' C. CRUM,' R. RICHART,' T. FUIII,2 A. FERENCZY,3 M. BooN,4 L. BRAUN,' W. LANCASTER,6 and
Y. Fu,7 'Dept. of Obstetrics and Gynecological Pathology, Columbia University, New York, New
York; 2Dept. of Obstetrics and Gynecology, Hiroshima University, Japan; 3Dept. of Pathology, Jewish
General Hospital, Montreal, Quebec, Canada; 4Leids Cytologisch Laboratorium, Holland; 'Dept. of
Pathobiology, Johns Hopkins School of Medicine, Baltimore, Maryland; 'Dept. of Pathology,
Georgetown University, Washington, DC; 7Institute of Pathology, Case Western Reserve University,
Cleveland, Ohio: Koilocytic lesions of the cervix-The relationship of mitotic abnormalities to the
presence of papilloma virus antigens and nuclear DNA content.
T. OKAGAKI,1'2 B. A. CLARK,' L. B. TWIGGS,' K. ZACHOW,3 R. Os-rizow,3 S. WATTS,3 and A. FARAS,3 Depts.
of 'Obstetrics and Gynecology, 2Laboratory Medicine and Pathology, and 3Microbiology, University
of Minnesota Medical School, Minneapolis: HPV DNA and ultrastructurally identifiable viruslike par-
ticles in cervico-vaginal intraepithelial and invasive squamous cell neoplasia.
L. GISSMANN, H. IKENBERG, and H. ZUR HAUSEN, Institut fur Virologie, Freiburg, Federal Republic of Ger-
many: HPV infections of the genital tract and the larynx.
L. G. Koss, Dept. of Pathology, Montefiore Medical Center, Bronx, New York: Human polyoma virus
infection.
SESSION 2 DNA Sequences and Genetic Organization
Chairperson: M. YANIV, Institut Pasteur, Paris, France
Y. YABE, Dept. of Virology, Cancer Institute, Okayama University Medical School, Japan: Bridge connec-
tion and subunits of capsomeres in HPV.
0. DANOS, and M. YANIV, Unite des Virus oncogenes, Dept. de Biologie Moleculaire, Institut Pasteur, Paris,
France: DNA sequence and genetic organization of papilloma viruses.
E. CHEN,' P. HOWLEY,' A. LEVINSON,' and P. SEEBURG,1 Dept. of Molecular Biology, Genentech, Incor-
porated, South San Francisco, California; 2NCI, National Institutes of Health, Bethesda, Maryland: The
primary structure and genetic organization of BPV-1 genome.
U. PETTERSSON, Dept. of Medical Genetics, Biomedical Center, Uppsala, Sweden: DNA sequence of
BPV-1.
E. SCHWARZ, M. DUERST, 0. LATTERMANN, C. WOELFLE, E. WOLFSPERGER, R. ZECH, and H. ZUR HAUSEN, Institut
fur Virologie, Universi6t Freiburg, Federal Republic of Germany: DNA sequence and genome organiza-
tion of human genital papilloma virus HPV6b.
I. Gilt', 0. DANOS, and M. YANIV, Unite des Virus Oncogenes, Dept. de Biologie Moleculaire, Institut
Pasteur, Paris, France: DNA sequence studies on the Shope CRPV.
Y. NAKABAYASHI, S. K. CHATTOPADHYAY, and D. R. Lowy, NCI, National Institutes of Health, Bethesda,
Maryland: The sequences required for morphologic transformation by BPV DNA are discontinuous.
N. SARVER, Y.-C. YANG, J.C. BYRNE, and P. M. HowLEY, NCI, National Institutes of Health, Bethesda,
Maryland: Analysis of BPV-1 genetic elements required for transformation and extrachromosomal
plasmid replication.
G. SAUER, F. RosL, and W. WALDECK, Institute for Virus Research, German Cancer Research Center,
Heidelberg, Federal Republic of Germany: Isolation of BPV chromatin and identification of a DNase
sensitive region.
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SESSION 3 Poster Session
H. AHOLA,1 A. OSTERHAUS,2 A. STENLUND,1 J. MORENO-LOPEZ,3 and U. PETTERSSON,1 1Dept. of Medical
Genetics, Biomedical Center, Uppsala; 2Rijksinstituut voor de Volksgenzondheid, Bilhoven, The
Netherlands; 3National Veterinary Institute, Biomedical Center, Uppsala, Sweden: Characterization of
the avian (Fringilla Coelebs) papillomavirus DNA (FPV).
C. BLANCHET-BARDON,1 M. A. LUTZNER,1,2 A. PUISSANT,' and G. ORTH,2 1 CliniqUe Dermatologique, HOpital
Saint-Louis; 2Unite INSERM 190, Institut Pasteur, Paris, France: Interferon treatment of skin cancers of
patients with epidermocysplasia verruciformis.
M. H. BUNNEY, Dept. of Dermatology, Royal Infirmary, Edinburgh, Scotland: Some clinical pictures il-
lustrating the influence of host defects on HPV infections.
M. S. CAMPO and D. A. SPANDIDOS, Beatson Institute for Cancer Research, Glasgow, Scotland: In vitro
transformation of mouse fibroblasts by molecularly cloned BPV genomes.
0. CROISSANT, N. BONNEAUD, and G. ORTH, Unite INSERM 190, Institut Pasteur, Paris, France: Detection of
the vegetative viral DNA replication in papillomavirus-induced tumors by in situ molecular
hybridization.
0. CROISSANT,' S. JABLONSKA,2 G. PEHAU-ARNAUDET, and G. ORTH,1 'Unite INSERM 190, Institut Pasteur,
Paris, France; 2Dept. of Dermatology, Warsaw School of Medicine, Poland: Heteroduplex mapping of
conserved nucleotidic sequences between animal and human papillomaviruses.
M. FAVRE,1 S. JABLONSKA,2 0. CROISSANT,' S. OBALEK,2 and G. ORTH,1 1 Unite INSERM 190, Institut Pasteur,
Paris, France; 2Dept. of Dermatology, Warsaw School of Medicine, Poland: Genetic heterogeneity of
human papillomaviruses from skin warts-Analysis by restriction endonucleases and molecular
hybridization.
G. JAUREGUIBERRY, M. FAVRE, F. BREITBURD, and G. ORTH, Unite INSERM 190, Institut Pasteur, Paris, France:
Bovine papillomavirus genome in hamster sarcoma cells in vivo and in vitro-Variation in the level of
expression.
D. KREMSDORF,1 S. JABLONSKA,2 M. FAVRE,1 and G. ORTH,1 1 Unite INSERM 190, Institut Pasteur, Paris,
France; 2Dept. of Dermatology, Warsaw School of Medicine, Poland: Molecular cloning and
biochemical characterization of the genomes of eight human papillomaviruses associated with epider-
modysplasia verruciformis.
W. D. LANCASTER,' R. J. KURMAN,1 L. E. SANZ,1 S. PERRY,2 and A. B. JENSON,' 'Georgetown University
Medical Center; 2DC General Hospital, Washington, DC: Detection of HPV DNA sequences and
evidence for molecular heterogeneity in premalignant lesions of the uterine cervix.
M. H. MOAR1 and W. F. H. JARRETT,2 'Dept. of Zoology, University of Edinburgh; 2Dept. of Veterinary
Pathology, University of Glasgow, Scotland: Tumor induction and cell transformation by BPV-4.
D. M. MORGAN,' W. MEINKE,2 and V. DEFEND'," t Dept. of Pathology, New York University Medical Center,
New York; 2Dept. of Molecular and Medical Microbiology, University of Arizona College of Medicine,
Tucson: Susceptibility of the rabbit to BPV-1 tumor induction, and transfection of cells with cloned HPV
DNA fragments.
C. MORIN, M. CASAS-CORDERO, A. MEISELS, and M. RABREAU, Dept. of Pathology, Saint-Sacrement Hospital
and Laval University, Quebec, Canada: HPV infection and associated premalignant lesions of the
uterine cervix.
P. SCHNEIDER,' W. TOPP,2 A. ABRAMSON,' B. KRUMHOLTZ,1 S. WEINBERG,' D. CASPER,' R. STRAUSS,' E.
BODIAN,1 and B. STEINBERG,' Long Island Jewish Medical Center, New Hyde Park, New York; 2Cold
Spring Harbor Laboratory, New York: Molecular heterogeneity of human genital wart (condylomata
acuminata) papilloma viruses.
A. STENLUND,1 H. AHOLA,2 J. MORENO-LOPEZ,2 and U. PETTERSSON,1 1Dept. of Medical Genetics; 2National
Veterinary Institute, Biomedical Center, Uppsala, Sweden: Structure of viral transcripts in BPV-
tranformed mouse cells.
S. L. WAITS, R. S. OSTROW, W. C. PHELPS, and A. J. FARAS, Dept. of Microbiology, University of Minnesota,
Minneapolis: CRPV DNA in warts and carcinomas of cottontail and domestic rabbits.
SESSION 4 Transformation
Chairperson: G. ORTH, Institut Pasteur, Paris, France
B. BINETRUY,1 G. MENEGUZZI,1 R. BREATHNACH,2 and F. CUZIN,1 'Centre de Biochimie du CNRS, Universite
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de Nice; 2Laboratoire de Genetique Moleculaire des Eucaryotes du CNRS, Strasbourg, France:
BPV-1-pBR322 recombinant DNA molecules maintained in a plasmidial state both in rodentfibroblast
and in bacterial cells.
G. M. GRAHAM,' L. E. BABISS,1 J. BRYNE,2 P. M. HOWLEY,2 and P. B. FISHER,' 'Institute for Cancer Research,
Columbia University College of Physicians and Surgeons, New York, New York; 2NCI, National In-
stitutes of Health, Bethesda, Maryland: Transformation of Fischer rat embryo (CREF) cellsby BPV and
plasmid cloned BPV DNA.
I. DVORETZKY,1 S. K. CHATTOPADHYAY," W. D. LANCASTER,2 and D. R. LOWY,' 'NCI, National Institutes of
Health, Bethesda, Maryland; 'Dept. of Pathology, Georgetown University Medical Center, Washington,
DC: The in vitro biological activity of DFV differs from that of BPV.
S. L. WATTS, W. C. PHELPS, R. S. OSTROW, and A. J. FARAS, Dept. of Microbiology, University of Minnesota,
Minneapolis: Human and rabbit papilloma viruses transform C127 and NIH 3T3 cells in culture.
L. TUREK," J. BYRNE," D. LOWY,' I. DVORETZKY,1 R. FRIEDMAN,2 and P. HOWLEY,' "NCI, National Institutes of
Health; 'Uniformed Services University of the Health Sciences, Bethesda, Maryland: Interferon induces
morphologic reversion with elimination of extrachromosomal viral genomes in BPV-transformed cells.
M. HENLEY and W. MEINKE, Dept. of Molecular and Medical Microbiology, University of Arizona, Tucson:
Effects of retinoic acid on BPV transformed mouse cells.
G. GROSS,' A. GASSENMAIER,2 M. LAMMEL,3 and H. PFISTER,3 'Dept. of Dermatology; 'Institute of Virology,
Freiburg; 'Institute of Clinical Virology, Erlangen, Federal Republic of Germany: In vivo and in vitroef-
fect of Ro 10-9359 on papilloma virus DNA persistence.
SESSION 5 RNA Transcription
Chairperson: T. R. BROKER, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
L. BERG, M. LUSKY, H. WEIHER, and M. BOTCHAN, University of California, Berkeley: Regulatory signals in
BPV.
M. S. CAMPO, D. A. SPANDIDOS, and N. WILKIE, Beatson Institute for Cancer Research, Glasgow, Scotland:
Transcription-promoter in BPV-1 genome.
C. HEILMAN, L. ENGEL, and P. HOWLEY, NCI, National Institutes of Health, Bethesda, Maryland: Analysis of
the virus-specific transcripts in BPV-1 infected bovine fibropapillomas.
R. F. LAPORTA, S. REILLY, and L. B. TAICHMAN, School of Dental Medicine, State University of New York,
Stony Brook: Transcription of HPV-1 in cultures of human keratinocytes.
L. T. CHOW, D. CAMPANELLI, R. GALLI and T. R. BROKER, Cold Spring Harbor Laboratory, New York:
Transcription of HPV-1 DNA from hybrid shuttle vectors transfected into COS-1 cells.
M. NASSERI and F. 0. WETTSTEIN, University of California School of Medicine, Los Angeles: Colinear and
spliced viral transcripts are present in nonvirus producing benign and malignant neoplasms induced by
the Shope (rabbit) papilloma virus.
E. GEORGES, 0. CROISSANT, N. BONNEAUD, and G. ORTH, Unite INSERM 190, Institut Pasteur, Paris, France:
Transcription of the genome of the CRPV in domestic rabbit papillomas and in the transplantable VX2
carcinoma.
S. MITRANI-ROSENBAUM,1 L.MAROTEAUX,2 Y. Mom( ,2 M. REVEL,2 and P.M. HOWLEY' 'NCI, National Institutes
of Health, NIH, Bethesda, Maryland, 'Dept. of Virology, Weizmann Institute for Science, Rehovot,
Israel; Inducible expression of the human beta-interferon gene linked to a BPV DNA vector and main-
tained extrachromosomally in mouse cells.
SESSION 6 Epidermal Cells
Chairperson: H. GREEN, Harvard Medical School, Boston Massachusetts
H. GREEN, Dept. of Physiology and Biophysics, Harvard Medical School, Boston, Massachusetts: Epidermal
cell differentiation in tissue culture.
S. BANKS-SCHLEGEL,' and P. HOWLEY,2 'Laboratory of Human Carcinogenesis; 'Laboratory of Pathology,
NCI, National Institutes of Health, Bethesda, Maryland: Differentiation of human epidermal cells
transformed by SV40.
Y. CHARDONNET, C. JAILLARD, and P. ELBAZE, INSERM and ERA CNRS, Pavillon R, Ripka' E. Herriot, Lyon,
France: Cultures of keratinocytes derived from cutaneous warts.
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L. B. TAICHMAN, S. REILLY, and R. F. LAPORTA, School of Dental Medicine, State University of New York,
Stony Brook: Replication of HPV-1 in cultured human keratinocytes.
T. S. BURNETT and P. H. GALLIMORE, Dept. of Cancer Studies, University of Birmingham, England: HPV-1
transcription in rat fibroblast and human keratinocyte cell lines.
F. BREITBURD,1 0. CROISSANT,' S. JABLONSKA,2 and G. ORTH,1 'Unite INSERM 190, Institut Pasteur, Paris,
France; 2Dept. of Dermatology, Warsaw School of Medicine, Poland: Two low molecular weight
cytoplasmic polypeptides induced in infected cells of human skin warts caused by HPV-1.
SESSION 7 Human Disease. II. Laryngeal, Genital, and Epidermal Papillomas
Chairperson: S. JABLONSKA, Warsaw School of Medicine, Warsaw, Poland
S. SYRJANEN,' K. SYRJANEN,2 M. LAMBERG,t and S. PYRHONEN,3 'Institute of Dentistry, University of Kuopio;
2Dept. of Pathology, University of Kuopio; 'Dept. of Virology, University of Helsinki, Finland: HPV in-
volvement in the squamous cell lesions of the oral cavity.
A. ABRAMSON and B. STEINBERG, Dept. of Otolaryngology, Long Island Jewish-Hillside Medical Center, New
Hyde Park, New York: Clinical aspects of laryngeal papilloma.
B. STEINBERG,' A. ABRAMSON,' and W. ToPP,2 'Long Island Jewish Medical Center, New Hyde Park; 2Cold
Spring Harbor Laboratory, New York: HPV presence in laryngeal papilloma.
P. MOUNTS,' L. METCALFE,' K. V. SHAH,' J. D. WOODRUFF,2 A. FERENCZY,3 R. REiD,4 and H. KASHIMA,2 'Johns
Hopkins University; 2Johns Hopkins Hospital, Baltimore, Maryland; 'Jewish General Hospital, Mon-
treal, Canada; 4Sinai Hospital, Detroit, Michigan: Papilloma virus etiology of genital tract lesions and
laryngeal papillomas.
A. B. JENSON,' R. J. KURMAN,' E. E. LACK,2 and W. D. LANCASTER,' 'Georgetown University Medical Center,
Washington, DC; 2Children's Hospital Medical Center, Boston, Massachusetts: Papilloma virus etiology
of proliferative squamous epithelial lesions of the skin and oral, tracheo-laryngeal and anogenital
mucosa.
S. JABLONSKA,' 0. CROISSANT,2 S. OBALEK,t M. FAVRE,2 D. KREMSDORF,2 and G. ORTH,2 'Dept. of Der-
matology, Warsaw School of Medicine, Poland; 2Unite INSERM 190, Institut Pasteur, Paris, France:
Morphology of HPV-induced lesions and immunologic response as related to the virus type.
G. ORTH,' S. JABLONSKA,2 S. OBALEK,2 L. A. RUEDA,3 C. BLANCHET- BARDON,t M. LUTZNER,1 M. FAVRE,1 D.
KREMSDORF,1 N. JIBARD,t and 0. CROISSANT,' 'Unite INSERM 190, Institut Pasteur, Paris, France; 2Dept.
of Dermatology, Warsaw School of Medicine, Poland; 'Bogota, Columbia; Role of the virus in the
pathogenesis of epidermodysplasia verruciformis.
H. PFISTER,' A. GASSENMAIER,2 and P. G. FUCHS,' 'Institut (Lir Klinische Virologie, Erlangen; 2lnstitut (Ur
Virologie, Freiburg, Federal Republic of Germany: Characterization of HPV from warts and carcinoma
of an epidermodysplasia verruciformis patient.
M. A. LUTZNER, M. F. DUCASSE, V. DUTRONQUAY, and G. ORTH, Unite INSERM 190, Institut Pasteur, Paris,
France: HPV-5 genome found in in situ cancers of an immunosuppressed renal transplant recipient.
K. ZACHOW,' R. OSTROW,' T. OKAGAKI,1 L. TWIGGS,' B. CLARK,' M. NIIMURA,2 M. BENDER,' F. PASS,' and A.
FARAS,' 'University of Minnesota Medical School, Minneapolis; 2Jikei University School of Medicine,
Tokyo, Japan; 'Molecular Genetics, Inc., Minnetonka, Minnesota: Presence of HPV DNA in human
benign and malignant epithelial tumors.
M. GREEN,' K. BRACKMANN,t P. LOEWENSTEIN,' M. CARTAS,' H. THORNTON,' J. SYMINGTON,' and M. EISINGER,2
'Institute for Molecular Virology, St. Louis University Medical Center, Missouri; 2Memorial Sloan-
Kettering Institute for Cancer Research, New York, New York: HPV genomes-DNA homology,
presence in malignant human tissues, and introduction into mammalian cells.
H. PFISTER, Institut fiir Klinische Virologie, Erlangen, Federal Republic of Germany: Isolation and
characterization of HPV-13 from certain ethnic tribes.
R. REID, Sinai Hospital and Wayne State University Medical School, Detroit, Michigan: Coloscopic movie
of laser cauterization of an HPV-induced cervical lesion.
SESSION 8 Animal Papilloma Viruses and Carcinogenesis
Chairperson: Y. ITO, Kyoto University, Kyoto, Japan
C. OLSON, Dept. of Veterinary Science, University of Wisconsin, Madison: Introductory review of animal
papilloma viruses.
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K. SUGAWARA,1 K. FUJINAGA,2 and Y. ITO,' 'Dept. of Microbiology, Faculty of Medicine, Kyoto University;
2Cancer Research Institute, Sapporo Medical College, Japan: "Masking" revisted-Persistence of SPV
genome in Shope papilloma-carcinoma complex.
F. 0. WETTSTEIN1 and M. NASSERI2 1Dept. of Microbiology and Immunology and 2Molecular Biology In-
stitute, University of California Medical School, Los Angeles: The unique state of CRPV DNA in malig-
nant rabbit tumors and tumor derived cell lines.
E. AMTMANN,1 K. WAYHS,2 M. VOLM,2 and G. SAUER,' 'Institute for Virus Research; 2lnstitute for Pathology,
German Cancer Research Center, Heidelberg, Federal Republic of Germany: Tissue specificity of a la-
tent papilloma virus in Mastomys natalensis.
S. SCHERNECK,' J. FEUNTEUN,2 F. VOGEL,' and E. GESSLER,1 'Central Institute of Molecular Biology, Academy
of Sciences of the German Democratic Republic, Berlin; 2lnstitut de Recherches Scientifiques sur le
Cancer, Villejuif, France: Sequence homology between polyoma virus, SV40, and a papilloma produc-
ing virus from a Syrian hamster-Evidence for highly conserved sequences.
J. MORENO-LOPEZ,' A. STENLUND,2 H. AHOLA,1 and U. PETTERSSON,2 Depts. of 'Virology, Faculty of
Veterinary Medicine and 2Medical Genetics, Biomedical Center, Uppsala, Sweden: The European elk
papilloma virus (EEPV)-Characterization of the genome, induction of tumors in animals, and transfor-
mation in vitro.
D. E. GROFF and W. D. LANCASTER, Georgetown University Medical Center, Washington, DC: Two sub-
types of DFV show specific regions of rapid nucleotide divergence.
P. SPRADBROW, Dept. of Veterinary Pathology and Public Health, University of Queensland, Brisbane,
Australia: Papilloma viruses, papillomas, and ocular and cutaneous carcinomas in ruminant animals.
G. H. THEILEN,' E. B. WHEELDON,2 N. EAST,' B. R. MADEWELL,1 and W. D. LANCASTER,3 UniVerSity of Califor-
nia School of Veterinary Medicine, Davis; 2Smith Kline & French Laboratories, Philadelphia, Penn-
sylvania; 'Georgetown University, Washington, DC: Goat papillomatosis.
SESSION 9 Vectors
Chairperson: P. Howley, National Cancer Institute, Bethesda, Maryland
D. DIMAIO, R. TREISMAN, and T. MANIATIS, Dept. of Biochemistry and Molecular Biology, Harvard Universi-
ty, Cambridge, Massachusetts: Properties of BPV/human globin gene recombinant plasmids that effi-
ciently transform mouse cells.
N. SARVER, J. C. BYRNE, and P. M. HOWLEY, NCI, National Institutes of Health, Bethesda, Maryland: Transfor-
mation and replication in mouse cells of a BPV/pML2 plasmid vector that can be rescued in bacteria.
C. STRATOWA, Y. WANG, M. SCHAFER-RIDDER, and P. H. HOFSCHNEIDER, Max-Planck-Institut fUr Biochemie,
Martinsried, Federal Republic of Germany: Transfer of a nonselectable gene, hepatitis-B-surface-antigen,
into NIH 3T3 fibroblasts using BPV DNA as a vector.
A. STENLUND,1 D. LAMY,3 J. MORENO-LOPEZ,2 E. SOBZACK,3 H. AHOLA,2 P. TIOLLAIS,3 and U. PETTERSSON,1
Depts. of 'Medical Genetics and 2Virology, Faculty of Veterinary Medicine, National Veterinary In-
stitute, Biomedical Center, Uppsala, Sweden; 'Institut Pasteur, Paris, France: The use of BPV-1 genome
as a vector for cloning and expression of the hepatitis B surface antigen.
K. ZINN, P. MELLON, and T. MANIATIS, Dept. of Biochemistry and Molecular Biology, Harvard University,
Cambridge, Massachusetts: Regulated expression of an extrachromosomal human 0-interferon gene in
mouse cells.
J. JOUANNEAU, I. GIRT, and M. YANIV, Unite des Virus Oncogenes, Dept. de Biologie Moleculaire, Institut
Pasteur, Paris, France: Cell transformation by hybrid plasmids containing BPV DNA and Eco gpt gene.
M.-F. LAW, B. H. HOWLEY, Y.-C. YANG, and P. M. HOWLEY, NCI, National Institutes of Health, Bethesda,
Maryland: The use of dominant selective markers in the BPV-1 vector system.
G.N. PAVLAKIS and D.H. HAMER, NCI, National Institutes of Health, Bethesda, Maryland: Regulated expres-
sion of cloned genes in bovine papilloma virus vectors.
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Pox- Iridovirus
September 20-September 23
Arranged by John A. Holoczak, Rutgers Medical School, Piscataway, New Jersey, Riccardo Wittek, Univer-
sity of Lausanne, Switzerland
69 participants
A poxvirus-iridovirus workshop is held approximately every second year. This was the fourth such
workshop at Cold Spring Harbor Laboratory, and, so far, these workshops have been the only gatherings to
focus specifically on these viruses. They therefore represent a unique opportunity for people working in this
field to meet one another and to discuss ongoing research. Although the number of participants was small,
they represented a significant fraction of the people working on these viruses and they had the opportunity
to engage in the informal exchange of ideas which may be more difficult at larger meetings.
More than fifty abstracts were submitted for presentation and these were organized into sessions covering
all aspects of current poxvirus and iridovirus research, including such topics as DNA structure, replication,
protein synthesis, genetics, transcription, and gene mapping. One entire session was devoted to the vac-
cinia virus thymidine kinase gene which has been analyzed in detail by several groups. The presentations
on the use of vaccinia virus as a eukaryotic cloning vector attracted much attention. Large pieces of foreign
DNA have successfully been inserted into the vaccinia virus genome by in vivo recombination. Moreover,
these foreign genes can be expressed during vaccinia virus infection. These recombinant viruses should
provide a powerful tool for exploring the genetic regulation of vaccinia virus and may finally allow the
development of vaccinia virus vectors for the production of live vaccines. The future will have to show
whether our optimism is justified.
SESSION 1
Chairperson: J.A. HOLOCZAK, Rutgers Medical School, Piscataway, New Jersey
G.D. WALLACE, National Institues of Health, Bethesda, Maryland: Research on ectromelia at NIH.
J. BENAVENTE and M. ESTEBAN, Downstate Medical Center, Brooklyn, New York: Mechanism of inhibition of
vaccinia virus protein synthesis by interferon.
A. RICE, T. HUNT, and I.M. KERR, Imperial Cancer Research Fund Laboratories, London, England: Transla-
tional control in interferon-treated vaccinia virus-infected cells.
E. PAEZ and M. ESTEBAN, Downstate Medical Center, Brooklyn, New York: Vaccinia virus can overcome the
antiviral action of interferons in some cells.
M.G. SANTORO, J. BEVEVENTE, E. PAEZ, B. JAFE, and M. ESTEBAN, Downstate Medical Center, Brooklyn, New
York: Inhibition of vaccinia virus protein synthesis by prostaglandins of the A series.
SESSION 2
Chairpersons: R.W. MOYER, Vanderbilt University, Nashville, Tennessee and A. GRANOFF, St. Judes
Children's Research Hospital, Memphis, Tennessee
S. Dales, E. Paoletti
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R. Wittek, D. Pickup, A. Mahr
R.M. FLUGEL and G. DARAI, Institut Virusforschung, Heidelberg, Federal Republic of Germany: Identifica-
tion of viral proteins and enzymatic activities of purified fish lymphocystic disease virus.
C. MONNIER, S. BARRAY, F. PETIT, and G. DEVAUCHILL, CNRS, Mont-St. Aignan, France: Chi lo-iridescent virus
replication Structural and non structural proteins in infected cells.
S. DALES and M.B.A. OLSTONE, University of Western Ontario, Ontario, Canada: Interrelationship at the cell
surface between the vaccinia virus-induced hemagglutinin (HA) and the major histocompatibility
complex.
V. RUSZALA and J.A. HOLOWCZAK, Rutgers Medical School, Piscataway, New Jersey: Membrane modifica-
tions in vaccinia virus infected cells.
R. GOORHA and K.G. MURTI, St. Judes Children's Research Hospital, Memphis, Tennessee: Role of DNA
methylation in frog virus 3 (FV3) replication.
E.M. BERKOWITZ' and B.G.T. POGO,2,1New York, New York; 2Mt. Sinai School of Medicine, New York,
New York: Comparative studies with two stains of Shope fibroma virus.
R. GOORHA, St. Judes Children's Research Hospital, Memphis, Tennessee: A temperature-sensitive (TS) mu-
tant of frog virus 3 (FV3) is defective in second-stage DNA replication.
B.G.T. P000, Mt. Sinai School of Medicine, New York, New York: Mechanism of DNA replication of a
temperature sensitive mutant of vaccinia virus.
T. CALANDRA and J.A. HOLOWCZAK, Rutgers Medical School, Piscataway, New Jersey: Vaccinia virus DNA
replication in infected He La cells.
SESSION 3
Chairpersons: M.J. ENSINGER, Wistar Institute, Philadelphia, Pennsylvania, and R. DRILLEN, St. Mary's
Hospital Medical School, London, England
M.J. ENSINGER and M. ROVINSKY, Wistar Institute, Philadelphia, Pennsylvania: Genetic and physical map-
ping of temperature-sensitive mutations of vaccinia virus WR.
V.G. CHINCHAR, and A. GRANOFF, St. Jude Children's Hospital, Memphis, Tennessee: Isolation and
characterization of frog virus 3 (FV3) temperature-sensitive mutants.
R. CONDIT, A. MOTYCZKA, and G. SPIZZ, State University of New York, Buffalo: Temperature sensitive
mutants of vaccinia virus.
R.W. MOYER and G. DALON BROWN, Vanderbilt University, Nashville, Tennessee: In vitro translational
analyses of two early RPUHR mutants of rabbit poxvirus.
P. SRIDHAR and R. CONDIT, State University of New York, Buffalo: Isolation and characterization of a PAA-
resistant ts-mutant of vaccinia virus.
B. Moss and E. JONES, National Institutes of Health, Bethesda, Maryland: Genetic evidence for vaccinia
virus encoded DNA polymerase. Isolation of phosphonoacetate-resistant enzyme from the cytoplasm of
cells infected with mutant virus.
E. KATZ, Hebrew University-Hadassah Medical, Jerusalem, Israel: Differences in restriction DNA fragment
profiles between IBT resistant and dependent mutants of vaccinia virus and the wild type strain.
P. RACZYNSKI and R. CONDIT, State University of New York, Buffalo: Inhibition of vaccinia virus replication
by 2 '-0-methyladenosine-isolation of a drug resistant mutant.
R. DRILLEN' and K.R. DUMBELL,1 St. Mary's Hospital Medical School, London, England; 2 St. Mary's
Hospital Medical School, Berkhampstead, England: Physical mapping of a cowpox host-range gene(s)
and a vaccinia virus TS-mutation.
M. MACKETT1, C.K. SAM and K.R. DUMBELL2, 'National Institutes of Health, Bethesda, Maryland, 2St. Mary's
Hospital Medical School, Berkhampstead, England: Analysis of orthopoxvirus interspecies
recombinants.
SESSION 4
Chairpersons: E. PAOLETTI, New York State Dept. of Health, Albany, New York and J. Esposito, CID
Division of Viral Diseases, Atlanta, Georgia
M.L. SALAS, J.M. ALMENDRAL, A. TALAVERA, and E. VINUELS, Universidad Autonoma, Madrid, Spain: RNAs
synthesized in vitro and in vivo by African swine fever virus-hybridization to DNA restriction fragments
and cell-free translation.
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F. GOLIN and J. KATZ, Hebrew University Hadassah Medical, Jerusalem, Israel: Transcription of an early
region of the vaccinia genome characterized by overlapping RNAs.
A. MAHR and B. ROBERTS, Department of Biology, Harvard Medical School, Boston, Massachusetts: Map-
ping of early and late mRNAs to a 7.6 Kb DNA fragment.
J. MORGAN and B. ROBERTS, Harvard Medical School, Boston Massachusetts: RNA transcript organization
within an early gene cluster.
S. VENKATESON, M. HAFFEY, B.M. BAROUDY, and B. Moss, National Institutes of Health, Bethesda, Maryland:
Nucleotide sequences of five vaccinia virus early genes.
J. MORGAN, A. MAHR, P. TRAKTMAN, and B. ROBERTS, Depts. of Biology and Chemistry, Harvard Medical
School, Boston Massachusetts: Mapping of the DNA binding proteins of vaccinia virus.
R. WITTEK,1 G. BAiszAR,2 J. WEIR,2 and B. Moss,2 'Institute of Animal Biology, Lausanne, Switzerland; 2 Na-
tional Institutes of Health, Bethesda, Maryland: Transcriptional mapping of the Hindlll J fragment of vac-
cinia virus.
P. TRAKTMAN and B. ROBERTS, Harvard Medical School, Boston, Massachusetts: The role of DNA replication
in the early-late switch of vaccinia virus.
M. ESTEBAN, C. BONI, and A. PELLICER, Downstate Medical Center, Brooklyn, New York: Phenotypic
changes of cells transformed with vaccinia virus.
SESSION 5
Chairpersons: K.R. DUMBELL, St. Mary's Hospital Medical School, Berkhampstead England and B.
Moss, National Institutes of Health, Bethesda, Maryland.
J. ESPOSITO, CID Division of Viral Diseases, Atlanta, Georgia: A comparison of orthopoxvirus DNA maps.
A.A. DOLLERY,' D. KINCHINGTON,2 P.J. GREENAWAY,3, and K.R. DUMBELL,3 PHLS Centre APP Micro,
Salisbury, England; St. Mary's Hospital Medical School, Salisbury, England;3 St. Mary's Hospital
Medical School, Berkhampstead, England: Comparison of variola and monkeypox genomes by restric-
tion endonuclease analysis.
A. TALAVERA, J.M. ALMENDRAL, V. LEY, R. BLASCO, J.M. SOGO, and E. VINUELA, Universidad Autonoma,
Madrid, Spain: Structure of the African swine fever virus genome.
R.D. WESLEY, Plum Island Animal Disease Center, Greenport, New York: African swine fever virus DNA-
differentiation of field isolates by restriction endonuclease analyses.
G. DARAI, H. DELIUS, and R.M. FLUGEL, Institute Virusforschung, Heidelberg, Germany: Analysis of the
genome of fish lymphocystis disease virus.
D.J. PICKUP, H.O. STONE, D. BASTIA, and W.K. JOKLIK, Duke University Medical Center, Durham, North
Carolina: The arrangement of repeated and unique sequences at the termini of cowpox virus DNA.
D. KINCHINGTON,1 A.A. DROLLERY,' P.G. GREENAWAY,2 and K.R. DUMBELL,2 1St. Mary's Hospital Medical
School, Salisbury, England; 2St. Mary's Hospital Medical School, Berkhampstead, England: Electron
microscopy of recombinant plasmid DNA containing fragments of variola or of monkeypox DNA.
Mx.
D. Moyer, D. Hruby, S. Holoczak
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A. Granoff, F. Fenner
B.M. BAROUDY and B. Moss, National Institutes of Health, Bethesda, Maryland: Structure and replication of
vaccinia virus telomeres.
R. GOORHA and G. KITCHINGMAN, St. Judes Children's Research Hospital, Memphis, Tennessee: A high
degree of frog virus 3 (FV3) DNA methylation inhibits its cloning.
M. MACKETT, G.L. SMITH, and B. Moss, National Institutes of Health, Bethesda, Maryland: Vaccinia virus-A
selectable eukaryotic cloning and expression vector.
SESSION 6
Chairperson: R. WITTEK, Institute Animal Biology, Lausanne, Switzerland
D. PANICALI and E. PAourri, New York State Dept. of Health, Albany, New York: Poxviruses as eukaryotic
cloning vectors.
A.M. DELANGE, B. FUTCHER, A.R. MORGAN, and G. MCFADDEN, University of Alberta, Canada: Replication of
cloned vaccinia virus DNA terminal restriction fragments containing the hairpin turnaround sequence in
a yeast plasmid vector.
D.E. HRUBY1 and L.A. BALL,2 2University of Texas, Austin; 2University of Wisconsin, Madison: Fine struc-
ture analysis of the vaccinia virus thymidine kinase gene.
A. VASSEL, F. BEN HAMIDA, F. KUNST, R. PICTET, and G. BEAUD, Institute I.R.B.M. -J. Monod, Paris, France:
Mapping of a mutation site in the thymidine kinase gene of vaccinia virus by marker rescue with
restricted fragments of a cloned DNA.
JEFFY W. WEIR, G. BAJSZAR, and B. Moss, National Institutes of Health: Identification and nucleotide se-
quence of the thymidine kinase gene of wild-type vaccinia virus and nonsense mutants.
D.J. ALBRIGHT', L.A. BALL,' and D.E. HRUBY,2 'University of Wisconsin, Madison; 2University of Texas,
Austin: Transcription of the vaccinia virus thymidine kinase gene during infection.
D.R. HRUBY,1 D.B. MILLER,2 and L.A. BALL,2 'University of Texas, Austin; 2University of Wisconsin,
Madison: Synthesis of vaccinia virus thymidine kinase in microinjected Xenopus oocytes.
235
BANBURY CENTER
1982 ACTIVITIES
1982 represented the fifth year of Banbury Center
programs. During the course of the year, the Center
was the site of nine conferences as well as a full
program of high-level summer courses. Four new
books in the ongoing Banbury Report series were
also published during the year, bringing the total in
that series to thirteen.
The range of Banbury meetings held in 1982
reflected the widening sphere of social impact of
biological sciences. Two of these emanated from
rapidly developing areas of recombinant DNA ap-
plications, while a third addressed new insights,
gained at least partly through recombinant DNA
methods, into the molecular processes of car-
cinogenesis. Two other conferences looked at car-
cinogenesis from more immediate aspects-one
through an assessment of one particular prevalent
class of agents, the nitrosamines; the other by
assembling a range of newly developed approaches
for directly assessing the effects of genotoxic
chemical exposure. The remaining 1982 confer-
ences included a novel combination of clinicians
and basic researchers in an exploration of biological
aspects of Alzheimer's disease, a probing of one
rapidly developing area of molecular genetic ap-
plications to industrial processes, and two retro-
spective meetings placing some current thrusts of
molecular biology within historical perspectives.
The first meeting of the year was on a topic
which, barely ten months later, would become the
subject of newspaper editorials and congressional
hearings. This conference, Gene Therapy: Fact and
Fiction, was held early in February and was orga-
nized by W. French Anderson from the National
Heart, Lung and Blood Institute, Paul Berg of Stan-
ford University, and Theodore Friedmann from the
University of California at San Diego. Supported by
a grant from the Kaiser Family Foundation, the
three-day meeting explored current capabilities,
likely future developments, and the needs which
might best be addressed through the at least
theoretically possible direct alteration or re-
placement of aberrant disease-causing genes. This
meeting transcript is currently being excerpted and
edited for inclusion in a broadly accessible descrip-
tion of the nature and current state of this field.
The two Banbury spring conferences explored, re-
spectively, two different aspects in assessing human
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carcinogenesis. The first of these, organized by
Peter Magee of the Fels Research Institute, was a
comprehensive assessment of the role of nitro-
samines in the genesis of human cancers. Over one
hundred nitrosamine compounds are currently
known to be carcinogenic, several of these proving
to be so in a wide range of animal species. These
compounds may be found in the environment, or
may be formed metabolically from precursors once
inside the body. This Banbury conference spe-
cifically addressed human aspects of such meta-
bolic transformations, detection of these com-
pounds and their metabolites, and their biological
effects. Nitrosamines and Human Cancer was
published as Banbury Report 12 in December 1982.
Also published in December was Banbury Report
13, emanating from the other spring conference,
which was held during the third week of April. This
conference, Indicators of Genotoxic Exposure, was
organized by Bryn Bridges of the University of
Sussex in England, Byron Butterworth from the
Chemical Industry Institute of Toxicology, and I.
Bernard Weinstein from Columbia University. The
meeting brought together the multiplicity of emerg-
ing procedures for directly assessing the effects of
genotoxic agents in the very individuals placed at
risk through such exposure. Approaches of this sort
will play important roles in quantitating the effects
of such exposure and in the further development of
rational bases in the regulation of such agents.
In the summer of 1982 three events were added
to the regular program of summer courses. Two of
these were an unusual departure for Banbury and
were very special meetings. The first was held in
honor of the memory of Luigi Gorini and, appro-
priately enough, was a high-level scientific con-
ference on gene expression in prokaryotic organ-
isms with nearly all participants tracing the origin of
their research to some aspect of Gorini's seminal
work in this area. The second conference was on
the use of the simple fungus Phycomyces as a
model organism in which to begin to understand
the molecular mechanisms involved in the trans-
duction of sensory input into behavioral responses.
These participants were the disciples of Max Del-
bruck. After playing a major role in the forties and
fifties in establishing bacterial viruses as simple
model organisms with which to probe the molecu-
lar basis of heredity, DelbrUck turned to the ques-
tion of the mechanisms by which cells or organisms
respond to their environment. His choice simple
organism for probing this area was Phycomyces,
whose rather rudimentary cellular organization
belied a prodigious capacity for responding to an ar-
ray of environmental stimuli. Again, the tracing of
these scientific lines of investigation to an in-
dividual whose intellect and personality had such
an impact upon both the origins of the field and cur-
rent workers in it gave great insight both into the
development of science and into the nature of this
extraordinary individual. The Delbrbck and Gorini
meetings' proceedings will both be appearing as
books from the Cold Spring Harbor publications of-
fice. The last meeting of the summer was a two-day
intensive exploration of genetic manipulations in
the cultivation and application of anaerobic bac-
teria. While noted as interesting pathogens, many of
the anaerobes are also important potential sources
of organic chemical intermediates and solvents. Or-
ganized by Ahmad Bukhari of Cold Spring Harbor
Laboratory and Leonard E. Mortenson from Exxon
Research and Engineering Company, this meeting
proved to be an incisive and in-depth survey of this
bacterial group and their possible industrial applica-
tions in production of acetone, butanol, methane,
and volatile fatty acids.
The final three conferences of the year returned to
more traditional Banbury topics, although in them-
selves encompassing a range almost as broad as the
entire range of prior Banbury conferences. The first
of these examined the application of recombinant
DNA procedures to human disease. Organized by
C. Thomas Caskey of the Baylor College of
Medicine and Raymond L. White from the Howard
Hughes Medical Institute, this meeting was, in a
sense, an outgrowth of the earlier 1982 conference
on gene therapy. The emphasis in this later meeting,
however, was on the extremely rapid development
of methods for the actual molecular identification
and localization of disease-causing aberrant genes
within the human genome. Given the extraordinary
pace of development, this is probably the last time
that a meeting of this small size and spontaneity of
interaction could possibly even begin to encompass
the essential features of this field. Recombinant
DNA Applications to Human Disease will be ap-
pearing as Banbury Report 14 in the spring of 1983.
This meeting was followed within three weeks by
the second major conference of October, Biological
Aspects of Alzheimer's Disease. The organizer for
this meeting, Robert Katzman of Albert Einstein Col-
lege of Medicine, brought together a heterogeneous
mix of clinicians and basic researchers for a multi-
disciplinary approach to looking at the biology of
this devastating affliction. The interaction of
neuropathologists, psychiatrists, epidemiologists,
virologists, and molecular geneticists in considering
this major public health concern, responsible for at
least half of all cases of dementia in the aged, led to
both novel formulations and discussions arising
from this stimulus of participatory "hybrid vigor."
The proceedings of this conference will also be ap-
pearing in the spring of 1983 as Banbury Report 15.
The final 1982 meeting was a special workshop
for congressional staff made possible through a
grant from the Sloan Foundation. Judiciously held
after the November elections, this conference
recapped one of the most exciting and rapidly
developing areas of cancer research-the nature of
oncogenes and their implications for determining
the mechanisms of human carcinogenesis. Congres-
sional staff members seemed especially gratified at
the opportunity to partake of the excitement of
science so directly while both they and the scien-
tists addressing them were appreciative of the op-
portunity of interacting outside of the almost
automatically adversary setting of formal congres-
sional hearings.
February 1, 1983 Michael Shodell
Director, Banbury Center
Banbury staff: Lynda Moran, Beatrice To liver, Michael Shodell
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Robertson House
1982 SUPPORT
Along with the donation of his estate, Charles S.
Robertson also established a fund for the mainte-
nance of the grounds and of Robertson House. Sup-
port for the activities of the Banbury Center,
however, are dependent upon government and
foundation grants and private and corporate con-
tributions. In 1982, core support for operation of the
Center in general came from the generous dona-
tions of the following twelve companies: The
Bristol-Myers Fund, The Chevron Fund, Conoco,
Inc., The Dow Chemical Company, E. I. du Pont de
Nemours & Company, Exxon Corporation, Getty
Oil Company, Grace Foundation Inc., Hoffman La
Roche Inc., International Business Machines Cor-
poration, Eli Lilly and Company, New York Life
Foundation, and Rockwell International Corpora-
tion Trust. While support for specific meetings came
partially from National Institutes of Health grants
and from the National Science Foundation, these
programs would have been impossible without ma-
jor additional funding. The Kaiser Family Founda-
tion was instrumental in enabling the holding of the
Gene Therapy meeting, while an ongoing grant
from the Sloan Foundation has supported sci-
ence writers and congressional workshops. The
Alzheimer's meeting and preparation of its publica-
tion was largely supported by the National Institute
on Aging, the National Insitute of Neurological and
Communicative Disorders and Stroke, and the
Fogarty International Center, in conjunction with
the Retirement Research Foundation (International
Symposium on Aging and Cancer). The March of
Dimes Birth Defects Foundation and The Burroughs
Wellcome Fund joined with the National Cancer In-
stitute, the Fogarty International Center, and the Na-
tional Institute of General Medical Sciences in sup-
port of the conference on Recombinant DNA Ap-
plications to Human Disease, while the American
Petroleum Institute largely supported the meeting
on Genotoxic Indicators. Additional sources of fun-
ding for the holding of particular meetings were
generously donated by the following: Bayer
AG/Cutter/Miles, Biogen, S.A., Bristol-Myers Com-
pany, Cetus Corporation, E. I. du Pont de Nemours
& Company, Merck Sharp & Dohme Research
Laboratories, Schering-Plough, Searle Research and
Development, SmithKline, Society for Microbi-
ology, The Squibb Institute for Medical Research,
Stauffer Chemical Company, and The Upjohn
Company.
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1982 PROGRAMS AND PARTICIPANTS
Prospects for Gene Therapy: Fact and Fiction
February 5-February 7
Opening Session
Chairperson: W.F. Anderson, National Heart, Lung and Blood Institute, Bethesda, Maryland
V.A. McKusick, Johns Hopkins University, Baltimore, Maryland: Review of genetic components of human
disease.
Y.W. Kan, University of California, San Francisco: New approaches to diagnosis.
Session 1 Therapy
Chairperson: T. Friedmann, University of California, San Diego
W.L. Nyhan, University of California, San Diego: Current methods of therapy.
W.F. Anderson, National Heart, Lung and Blood Institute, Bethesda, Maryland: New approaches to
therapy.
Session 2 Introduction of Genes into Cells and Complex Organisms
Chairperson: P. Berg, Stanford University, California
T. Maniatis, Harvard University, Cambridge, Massachusetts: Characterization and isolation of genes.
R. Axel, College of Physicians and Surgeons, Columbia University, New York, New York: Genes into cells.
F. Costantini, University of Oxford, England: Genes into complex organisms.
Session 3 Animal Models and Target Organs
Chairperson: U. Pettersson, University of Uppsala, Sweden
R.J. Desnick, Mount Sinai Medical Center, New York, New York: Animal models for human disease.
M.J. Cline, UCLA School of Medicine, Los Angeles, California: Potential human target organs.
Session 4 Approaches to Human Disease
Chairperson: L. Siminovitch, Hospital for Sick Children, Toronto, Canada
B.G. Forget, Yale University, New Haven, Connecticut: Hematological disease.
W.S. Sly, Stanford University, California: Lysosomal and other storage diseases.
M.S. Brown, University of Texas, Dallas: LDL receptor deficiency hypercholesterolemia.
P. Berg B. Forget J. Tooze W. McKusick
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The Possible Role of Nitrosamines in Human Cancer
April 4April 7
Session 1 Evidence Suggesting That Human Beings are Susceptible to
Carcinogenesis by N-nitroso
Compounds
Chairperson: S. Goldfarb, University of Wisconsin, Madison
In vitro studies
G.E. Milo, Ohio State University, Columbus: In vitro transformation in cultured human diploid fibroblast
cells.
I. Parsa, SUNY Downstate Medical Center, Brooklyn, New York: Transplantation of dimethylnitrosamine-
transformed cultured tumor cells.
In vivo studies
R.D. Kimbrough, Centers for Disease Control, Atlanta, Georgia: Pathological changes in human beings
acutely poisoned by dimethylnitrosamine.
W.E. Fleig, University of Ulm, Federal Republic of Germany: Pathological changes in a human subject
chronically exposed to dimethylnitrosamine.
Session 2 Comparative Metabolism and Alkylation Reactions
Chairperson: A.E. Pegg, Pennsylvania State University, Hershey
P.F. Swann, Middlesex Hospital Medical School, London, England: Metabolism of N-nitroso compounds
and alkylation of cellular macromolecules including DNA-An overview.
C.J. Michejda, Frederick Cancer Research Facility, Maryland: Metabolic formation of N2 from N-nitroso
compounds in vitro and in vivo.
M.C. Archer, University of Toronto, Canada: Metabolism of unsymmetrical nitrosamines.
S. Hecht, American Health Foundation, Valhalla, New York: Metabolism and activation of tobacco-
associated nitrosamines in human and animal tissues.
C.C. Harris, National Cancer Institute, Bethesda, Maryland: Metabolism of N-nitrosamines by cultured
human tissues and cells.
R. Montesano, International Agency for Research on Cancer, Lyon, France: Metabolism of nitrosamines by
human liver slices in vitro.
R.C. Shank, California College of Medicine, Irvine: Liver nucleic acids after homicidal poisoning by di-
methylnitrosamine.
R. Montesano' and A.E. Pegg', 'International Agency for Research on Cancer, Lyon, France; 'Pennsylvania
State University, Hershey: Overview of repair by microbial and mammalian enzyme systems of DNA le-
sions induced by N-nitroso compounds, and recent studies with human enzymes.
Session 3 Analytical Methods for Nitrosamines in Biological Media
Chairperson: D.H. Fine, New England Institute for Life Sciences, Waltham, Massachusetts
D.H. Fine, New England Institute for Life Sciences, Waltham, Massachusetts: Analytical methods for nitro-
samines-Overview.
G.W. Harrington, Temple University, Philadelphia, Pennsylvania: Electrochemical detection of N-nitroso
compounds with high performance liquid chromatography (HPLC).
W. Garland and A.H. Conney, Hoffman-La Roche Inc., Nutley, New Jersey: Mass spectrometry in the
analysis of nitrosamines in biological media.
Session 4 Exposure of Human Beings to Nitrosamines
Chairperson: J.H. Weisburger, American Health Foundation, Valhalla, New York
Exogenous sources of nitrosamines
D.H. Fine, New England Institute for Life Sciences, Waltham, Massachusetts: Nitrosamines in the general
environment and food.
D. Hoffmann, American Health Foundation, Valhalla, New York: Nitrosamines in tobacco carcinogenesis.
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Endogenous Formation
S. Mirvish, University of Nebraska, Omaha: Nitrosation reactions in vitro and in vivo.
B.C. Challis, Imperial College of Science and Technology, London, England: A kinetic model for the gastric
synthesis of N-nitroso compounds.
W. Lijinsky, Frederick Cancer Research Facility, Maryland: Carcinogenesis by simultaneous exposure to
nitrites and amines.
D.H. Fine, New England Institute for Life Sciences, Waltham, Massachusetts: Presence of nitrosamines in
human beings.
M.L. Simenhoff, Jefferson Medical College, Philadelphia, Pennsylvania: Presence of nitrosamines in the
blood and gastrointestinal fluids of normal and diseased human subjects.
H. Bartsch, International Agency for Research on Cancer, Lyon, France: Endogenous nitrosation in human
beings-Pro line I.
S.R. Tannenbaum, Massachusetts Institute of Technology, Cambridge: Endogenous nitrosation in human
beings-Proline II.
P.I. Reed' and C. Walters', Wexham Park Hospital, 'Berkshire, 'Horsham, West Sussex, England: Possible
effects of cimetidine on intragastric nitrosation in human beings.
J.B. Elder, University of Manchester, England: Possible role of cimetidine and its nitrosation products in
human stomach cancer.
D.E. Jensen and C.T. Gombar, Temple University, Philadelphia, Pennsylvania: Chemistry, phar-
macokinetics and biological actions of nitrosocimetidine-DNA methylation.
W. Lijinsky, Frederick Cancer Research Facility, Maryland: Carcinogenesis studies with nitrosocimetidine I.
R. Preussmann, Deutsches Krebsforschungszentrum, Heidelberg, Federal Republic of Germany: Car-
cinogenesis studies with nitrosocimetidine II.
Session 5 Nitrites and Amines
Chairperson: N.P. Sen, Health and Welfare Canada, Ottawa
P.E. Hartman, Johns Hopkins University, Baltimore, Maryland: Metabolism of nitrite-Overview.
S.R. Tannenbaum, Massachusetts Institute of Technology, Cambridge: Endogenous formation of nitrite.
C. Walters, Horsham, West Sussex, England: Endogenous amines-Amines in human gastric juice.
Session 6 Human Epidemiology
Chairperson: P. Correa, Louisiana State University, New Orleans
R.M. Hicks, Middlesex Hospital Medical School, London, England: Nitrosamines as possible etiological
agents in bilharzial bladder cancer.
L.Y.-Y. Fong, University of Hong Kong: Possible relationship of nitrosamines in the diet to causation of
cancer in Hong Kong.
C.S. Yang, New Jersey Medical School, Newark: Nitrosamines and other etiological factors in esophageal
cancer in Northern China.
S.R. Tannenbaum, Massachusetts Institute of Technology, Cambridge: Stomach cancer.
J. Weisburger P. Magee R. Peto
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Session 7 Dose-Response Relationships in Nitrosamine Carcinogenesis
Chairperson: R. Preussmann, Deutsches Krebsforschungszentrum, Heidelberg, Federal Republic of
Germany
L.M. Anderson, Sloan-Kettering Institute for Cancer Research, Rye, New York: Dimethylnitrosamine
metabolism and tumorigenesis during early life in the mouse.
W. Lijinsky, Frederick Cancer Research Facility, Maryland: Comparative carcinogenesis of some nitro-
samines in rats and hamsters.
R. Peto, University of Oxford, England: Carcinogenesis study with dimethylnitrosamine and diethylnitro-
samine in 4080 inbred rats-Experimental design and general nature of the dose-response relationship.
P. Grasso, BP Group Occupational Health Centre, Sunbury-on-Thames, Middlesex, England: Pathology of
tumors observed in study with 4080 inbred rats.
Indicators of Genotoxic Exposure in Man and Animals
April 18April 21
Session 1 Clinical Perspectives
Chairperson: B.A. Bridges, University of Sussex, England
I.B. Weinstein, College of Physicians and Surgeons, Columbia University, New York, New York: Molecular
epidemiology-Combined laboratory and epidemiologic approaches to genetic toxicology.
E.B. Hook, Birth Defects Institute, New York State Department of Health, Albany: The value and limitations
of clinical observations in assessing chemically induced genetic damage.
Session 2 Detection of Mutagens in Body Fluids
Chairperson: N.L. Petrakis, University of California, San Francisco
Urine
E. Eisenstadt, Harvard School of Public Health, Boston, Massachusetts: Urine as a monitor of mutagenic ex-
posure of smokers.
Feces
R.D. Combes, Portsmouth Polytechnic, England: Rat, human and other animal samples.
Breast Fluid
N.L. Petrakis, University of California, San Francisco: Mutagens in nipple aspirates of breast fluid.
Session 3 DNA Damage and Repair
Chairperson: B.E. Butterworth, Chemical Industry Institute of Toxicology, Research Triangle Park, North
Carolina
Unscheduled DNA synthesis
J.C. Mirsalis, SRI International, Menlo Park, California: Rat hepatocytes.
B.E. Butterworth, Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina:
Chemically induced DNA repair in rodent and animal cells.
M.J. Skinner, Mobil Oil Corporation, Princeton, New Jersey: Unscheduled DNA synthesis in rat
lymphocytes.
C. Furihata, University of Tokyo, Japan: Unscheduled DNA synthesis in rat stomach-Short-term assay of
potential stomach carcinogens.
Alkaline elution
S. Parodi, University of Genoa, Italy: Alkaline elution in vivo-Quantitative predictivity of carcinogenicity
as compared with other, shorter-term tests.
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Alkylated macromolecules
C.J. Calleman, University of Stockholm, Sweden: Alkylated hemoglobin.
P.B. Farmer, MRC Toxicology Unit, Carshalton, England: Significance of the occurrence of S-methyl cys-
teine in normal, untreated animals.
M.A. Pereira, United States Environmental Protection Agency, Cincinnati, Ohio: The use of alkylated
hemoglobin as a dose monitor for chemical carcinogens and mutagens.
Session 4 DNA Adducts
Chairperson: I.B. Weinstein, College of Physicians and Surgeons, Columbia University, New York,
New York.
W.K. Lutz, University of Zurich, Switzerland: DNA adducts as quantitative indicators of carcinogenic
exposure.
Animal models
J.A. Swenberg, Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina: Cell
specific effects-Application of new fluorometric techniques to detect adducts.
G.N. Wogan, Massachusetts Institute of Technology, Cambridge: AflatoxinDNA adducts and their detec-
tion in urine.
G. Theall, College of Physicians and Surgeons, Columbia University: Quantitative relationships between
adduct formation and biological effects.
Human studies
D.C. Herron, Atlantic Richfield Company, Los Angeles, California: DNA adductsfollowing a human DMN
poisoning.
W.A. Haseltine, Sidney Farber Cancer Institute, Boston, Massachusetts: Studies using defined DNA se-
quences and postlabeling techniques.
Monoclonal antibodies to carcinogen-DNA adducts
M.F. Rajewsky, University of Essen, Federal Republic of Germany: High-affinity monoclonal antibodies
specific for DNA components structurally modified by alkylating agents.
Session 5 Cytogenetics and Sister-Chromatid Exchange (SCE)
Chairperson: H.J. Evans, MRC Clinical and Population Cytogenetics Unit, Edinburgh, Scotland
Sister chromatid exchange in animal models
A. Kligerman, Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina: In vivo
and in vitro rat lymphocytes.
J.W. Allen, United States Environmental Protection Agency, Research Triangle Park, North Carolina:
Species and organ specificity of sister-chromatid exchange in the mouse.
S. Parodi, A. Wyrobek
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Human studies
A.V. Carrano, Lawrence Livermore National Laboratory, Livermore, California: Measurement of sister-
chromatid exchange induction in human populations as an indicator of exposure.
W.H. McKenzie, North Carolina State University, Raleigh: Controlled human exposure studies.
N.J. Evans, MRC Clinical and Population Cytogenetics Unit, Edinburgh, Scotland: Industrially exposed
populations.
M. Sorsa, Institute of Occupational Health, Helsinki, Finland: Sister chromatid exchange induction among
nurses handling cytostatic drugs.
L.M. Henderson, University of Sussex, England: Measuring prenatal genotoxic effects in mice and men.
Micronucleus test
J.A. Heddle, Ludwig Institute for Cancer Research, Toronto, Canada: Application in human and animal
systems.
Session 6 Mutagenesis
Chairperson: R.J. Albertini, University of Vermont, Burlington
Animal models
L.B. Russell, Oak Ridge National Laboratory, Tennessee: The Russell spot test.
Human studies
R.J. Albertini, University of Vermont, Burlington: Human lymphocytes.
G. Zetterberg, University of Uppsala, Sweden: Use of the cell sorter to concentrate mutants.
G.H. Strauss, University of Sussex, England: Development of a lymphocyte cloning assay.
H.D. Garcia, Philip Morris U.S.A., Richmond, Virginia: Development of a rat assay.
T.R. Skopek, Yale University, New Haven, Connecticut: Induced versus spontaneous mutations in human
lymphocytes.
W.G. Thilly, Masssachusetts Institute of Technology, Cambridge: Use of mutational spectra to diagnose the
causes of somatic mutation in man.
Altered gene products
H. Mohrenweiser, University of Michigan, Ann Arbor: Biochemical approaches to monitoring human
populations for germinal mutation rates.
Session 7 Germ Cell Effects
Chairperson: A.J. Wyrobek, Lawrence Livermore National Laboratory, Livermore, California
Animal models
G. Sega, Oak Ridge National Laboratory, Tennessee: DNA repair in spermatocytes.
H.V. Mailing, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina:
Detecting sperm mutants.
R.J. Preston, Oak Ridge National Laboratory, Tennessee: Chromosome aberrations in decondensed sperm
DNA.
Human studies
A.J. Wyrobek, Lawrence Livermore National Laboratory, Livermore, California: Sperm morphology (man
and animals) and the fluorescent Y marker.
H.J. Evans, MRC Clinical and Population Cytogenetics Unit, Edinburgh, Scotland: Sperm morphology in
smokers.
B.A. Bridges, University of Sussex, England: Summation-Future directions.
Prokaryotic Gene Expression-Symposium
In Memory of Luigi Gorini
June 27-July 1
D. Fraenkel, Harvard Medical School, Boston, Massachusetts: Remembrance of Luigi Gorini.
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Session 1 Ribosome Function
Chairperson: R.A. Zimmermann, University of Massachusetts, Amherst
Biosynthesis
M. Nomura, University of Wisconsin, Madison: Regulation of the synthesis of ribosomes and ribosomal
components in E. coli.
J.D. Friesen, University of Toronto, Canada: Mutations affecting gene expression in the rplJ operon.
Structure and genes
K. Isom Max-Planck-Institut, Berlin, Federal Republic of Germany: Genetics of the E. coli ribosomal
protein-Some new aspects.
I.G. Wool, University of Chicago, Illinois: Alpha sarcin action and the structure and function of eukaryotic
ribosomes.
J. Warner, Albert Einstein College of Medicine, Bronx, New York: Ribosomal protein genes of S. cerevisiae
and their regulation.
Session 2 Translational Fidelity I
Chairperson: J. Davies, Biogen, S.A., Geneva, Switzerland
J.A. Gallant, University of Washington, Seattle: The ribosome's frame of mind.
C.G. Kurland, University of Uppsala, Sweden: Proofreading on ribosomes?
D. Elseviers, New York Medical College, Valhalla, New York: E. colt mutants with reduced misreading
levels.
E.J. Murgola, University of Texas, Houston: tRNA, suppression, and the code.
Session 3 Regulation of Gene Expression: Transcription and Translation
Chairperson: W.K. Maas, New York University Medical Center, New York, New York
C. Yanofsky, Stanford University, California: Attenuation control of tryptophan operon expression.
B. Weisblum, University of Wisconsin, Madison: Translational control of resistance to MLS antibiotics.
M. Rosenberg, National Cancer Institute, Bethesda, Maryland: Regulation of gene expression by transcrip-
tion termination and RNA processing.
K. Campbell, University of Colorado, Boulder: RegA-T4's amazing translational repressor.
H.E. Umbarger, Purdue University, West Lafayette, Indiana: The multivalent repression of isoleucine and
valine biosynthesis in E. coll.
T. Eckhardt, Smith, Kline and French Laboratories, Philadelphia, Pennsylvania: The E. coli argenine
repressor gene (argR).
S. Adhya, National Cancer Institute, Bethesda, Maryland: Ribosomal proteins control transcription
termination.
Prokaryotic Gene Meeting
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Session 4 Translational Fidelity II
Chairperson: J.A. Gallant, University of Washington, Seattle
J. Parker, Southern Illinois University, Carbondale: Nonrandom codon misreading.
M.'Yarus, University of Colorado, Boulder: Interaction of suppressor tRNA with the strA ribosome.
L. Bossi and J.R. Roth, University of Utah, Salt Lake City: Role of a tRNA modified base (anticodon loop 4,)
in code translation and gene regulation.
R.C. Thompson, Temple University, Philadelphia, Pennsylvania: The reciprocal relationship between
fidelity and speed in protein biosynthesis.
Session 5 Protein Secretion I
Chairperson: A. Torriani-Gorini, Massachusetts Institute of Technology, Cambridge
S.A. Benson, Frederick Cancer Research Center, Maryland: Genetic analysis of protein export.
L. Randall, Washington State University, Pullman: Processing of exported proteins in E. coli.
J. Beckwith, Harvard Medical School, Boston, Massachusetts: Gehetics of the secretory apparatus of E. coli.
M. Schwartz, Institut Pasteur, Paris, France
J.O. Lampen, Rutgers University, Piscataway, New Jersey: Lipoprotein intermediates in secretion by Gram-
positive bacteria.
Session 6 Protein Secretion II
Chairperson: P. Margolin, The Public Health Research Institute of the City of New York, Inc., New York.
B.D. Davis, Harvard Medical School, Boston, Massachusetts: Some aspects of protein secretion in bacteria.
W. Wickner, UCLA School of Medicine, Los Angeles, California: Stud* of membrane assembly in E. coli.
G. Blobel, Rockefeller University, New York, New York: Mechanism of protein translocation across and in-
tegration into membranes.
Phycomyces
August 2-August 8
Session 1 Physiology I
Chairperson: E.D. Lipson, Syracuse University, New York
E.D. Lipson, Syracuse University, New York: Sensory transduction in Phycomyces.
D.S. Dennison, Dartmouth College, Hanover, New Hampshire: Phototropic perplexities.
P. Meyer, California Institute of Technology, Pasadena: Phycomyces' avoidance in a wind-free environ-
ment.
J.-F. Lafay and J. Matricon, University of Paris, France: Interferences between two simultaneous stimuli (bar-
rier/wind; barrier/light).
Session 2 The Photoreceptor
Chairperson: D.E. Presti, University of Oregon, Eugene
D.E. Presti, University of Oregon, Eugene: The photoreceptor in Phycomyces photobiology considered in
the light of flavin and carotene.
M. Jayaram, State University of New York, Stony Brook: Light-induced carotene synthesis in Phycomyces.
W. Shropshire, Jr., Smithsonian Radiation Biology Laboratory, Rockville, Maryland: Action spectra for light-
induced carotenoid synthesis.
E. Schafer and G. Loser, University of Freiburg, Federal Republic of Germany: Photogeotropism of
Phycomyces.
P.A. Galland, Syracuse University, New York: Action spectra of photogeotropic equilibrium in Phycomyces
wild type and three behavioral mutants.
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Session 3 Genetics
Chairperson: A.P. Es lava, University of Salamanca, Spain
M.I. Alvarez and A.P. Es lava, University of Salamanca, Spain: Mutants of Phycomyces with abnormal
phototropism isolated with ICR-170.
M.I.G. Roncero and E. Cerda-Olmedo,`University of Seville, Spain: Mutagenesis.
I. Lopez-Diaz and E.D. Lipson, Syracuse University, New York: Genetics of hypertropic mutants.
M. Orejas Suarez and A.P. Es lava, University of Salamanca, Spain: Mutagenesis with EMS in Phycomyces.
F, Rivero and E. Cerda-Olmedo, University of Seville, Spain: Spontaneously germinating mutants.
Session 4 Biochemistry I
Chairperson: R.J. Cohen, University of Florida, Gainesville
J. Ruiz-Herrera, University of Guanajuato, Mexico: Chitin biosynthesis in Mucorales with emphasis on
Phycomyces.
J. Soler, D. De Arriaga, and F. Busto, University of Leon, Spain: Regulation of carbohydrate metabolism of
Phycomyces blakesleeanus by lactic dehydrogenase.
G. Sandmann, University of Constance, Federal Republic of Germany: Inhibitory effect of continuous il-
lumination on intermediary metabolism in Phycomyces.
A. Flores-Carreon, M.A. Avalos, and J. Ruiz-Herrera, University of Guanajuato, Mexico: Gluceronosyl
transferase activity in cell free extracts of Phycomyces blakesleeanus.
J.A. Pollock, D.T. Sullivan, and E.D. Lipson, Syracuse University, New York: Characterization of plasma
membrane flavoproteins from stage-1-sporangiophores of Phycomyces wild type and class-1 mutants by
two-dimensional gel electrophoresis.
Session 5 Physiology
Chairperson: D.S. Dennison, Dartmouth College, Hanover, New Hampshire
K.W. Foster, Mount Sinai School of Medicine, New York, New York: The signal processing of light in
Phycomyces.
R.C. Poe and E.D. Lipson, Syracuse University, New York: White-noise analysis of Phycomyces
photomutants as a probe of the internal dynamics of the light growth response.
P.A. Gal land and E.D. Lipson, Syracuse University, New York: Wavelength dependence of phototropic
dark adaptation in Phycomyces.
S.M. Block, J. Segall, and H. Berg, California Institute of Technology, Pasadena: Excitation and adaptation in
bacterial chemotaxis.
Session 6 Special Lecture
E.-P. Fischer, University of Konstanz, Federal Republic of Germany: Max Delbruck-A physicist who
looked at biology.
Session 7 Genetics and Sexual Development
Chairperson: R.P. Sutter, West Virginia University, Morgantown
M.I. Pelaez and A.P. Eslava, University of Salamanca, Spain: Recombination studies in Phycomyces.
R.P. Sutter, West Virginia University, Morgantown: Why do cultures of each mating type emit unique sex
pheromones-Precursors of TAs (trisporic acids)?
W. Gauger, University of Nebraska, Lirtcoln: Mating-type heterokaryons and isogenicity in Phycomyces.
T. Suarez, A.P. Eslava, and A. Jimenez,,University of Salamanca, Spain: Toward the isolation of a plasmid
with a Phycomyces replication origin.
Session 8 Biochemistry/Genetics
Chairperson: E. Cerda-Olmedo, University of Seville, Spain
P.M. Bramley, Royal Holloway College, Egham, Surrey, England: Carotene biosynthesis in cell extracts of
Phycomyces.
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F. Parra, A. De La Concha, and F.J. Murillo, University of Murcia, Spain: Regulation of carotenogenesis in
Phycomyces.
J.-L. Revuelta Doval' and A.P. [slava', 'University of Leon; 'University of Salamanca, Spain: A new type of
mutant disturbed in the photoindication of carotenoids in Phycomyces.
D. De Arriaga, J. Soler, F. Teixido, and E.G. Gallarraga, University of Leon, Spain: Pyridine-dependent
dehydrogenases in Phycomyces blakesleeanus-Effects of light and vitamin A.
J.R. Medina, University of Seville, Spain: Genetics and regulation of alcohol-dehydrogenase in
Phycomyces.
Session 9 Cytology and Development
Chairperson: T. Ootaki, Yamagata University, Japan
S.K. Malhotra and J.P. Tewari, University of Alberta, Canada: Phycomyces blakesleeanus-Plasma mem-
brane as a model for studies on the structure and function.
A.J. Van Laerel, B. Furch,' and J. Van Assche, 'Catholic University of Louvain, Belgium; 'University of
Kiel, Federal Republic of Germany: Dormancy and germination of Phycomyces sporangiophores.
B. Furch, University of Kiel, Federal Republic of Germany: On the cell wall of sporangiophores of
Phycomyces blakesleeanus in relation to heat-induced germination.
K. Koga and T. Ootaki, Yamagata University, Japan: Growth and behavior of piloboloid mutants in
Phycomyces.
F. Gutierrez-Corona and E. Cerda-Olmedo, University of Seville, Spain: Microphorogenesis and carotene
biosynthesis.
Session 10 Biochemistry II
Chairperson: P.V. Burke, University of California, Santa Cruz
R.J. Cohen, University of Florida, Gainesville: Cyclic nucleotide and polyamine metabolism.
L.S. Leutwiler and M. Brandt, California Institute of Technology, Pasadena: The absence of light-induced
changes in cAMP concentration in the sporangiophore of Phycomyces.
M.V. Reddy, University of Florida, Gainesville: cAMP phosphodiesterase in Phycomyces blakesleeanus-A
genetic and biochemical analysis.
W. Hilgenberg and F. Hoffman, J.W. Goethe-Universitat, Frankfurt, Federal Republic of Germany: In-
doleacetic acid (IAA) in Phycomyces blakesleeanus.
Session 11 Physiology III
Chairperson: W. Shropshire, Jr., Smithsonian Radiation Biology Laboratory, Rockville, Maryland
K. Bergman, Northeastern University, Boston, Massachusetts: Controlled-release polymers-A new tool for
the study of chemosensory systems.
R.I. Gamow, University of Colorado, Boulder: Fine structure analysis of the growing zone.
P.V. Burke, University of California, Santa Cruz: Geotropism in the hypertropic mutant C5.
Session 12 Directions of Future Research
Chairpersons: P.V. Burke, University of California, Santa Cruz, and E.D. Lipson, Syracuse University,
New York.
E. Cerda-Olmedo' and E.D. Lipson', 'University of Seville, Spain; 'Syracuse University, New York: Status
report on the Phycomyces monograph.
Panel led by session chairpersons: Directions of future research.
248
Anaerobic Genetics
August 16August 17
Session 1
Chairperson: L.E. Mortenson, Exxon Research and Engineering Company, Linden, New Jersey
Clostridium
J.L. Johnson, Virginia Polytechnic Institute and State University, Blacksburg: General taxonomy.
C. acetobutylicum-pasteurianum
G. Gottschalk, University of Gottingen, Federal Republic of Germany: A continuous process for the pro-
duction of butanol and acetone.
J.-S. Chen, Virginia Polytechnic Institute and State University, Blacksburg: (1) Acetone-butanol fermentation
by C. beijerinckii (C. butylicum) in cultures maintained at neutral pH. (2) Study of nitrogenase genes and
nitrogen-fixation in C. pasteurianum.
J.G. Morris, University College of Wales, Aberystwyth: The physiology of solvent production in continuous
flow cultures of C. acetobutylicum.
D.R. Woods, University of Cape Town, South Africa: Molecular genetic studies on C. acetobutylicum.
M. Hermann, Institut Francais du Petro le, Rueil-Malmaison, France: Isolation of butanol resistant mutants of
C. acetobutylicum.
Session 2
Chairperson: J.G. Morris, University College Wales, Aberystwyth, United Kingdom
C. thermocellum
E.A. Johnson and A.L. Demain, Massachusetts Institute of Technology, Cambridge: Anaerobic nature of C.
thermocellum cellulase.
R.F. Gomez, Genentech, Inc., South San Francisco, California: An insertion seqence from C. thermocellum.
Other clostridia
L.G. Ljungdahl, University of Georgia, Athens: Aspects of electron transfer processes in acetogenic bacteria.
M.L. Britz, Masssachusetts Institute of Technology, Cambridge: Production of larger varied (C. to Ca)
volatile fatty acids by anaerobes.
J.N. Grindley, Biogen Inc., Cambridge, Masssachusetts: Attempts to create a transformation system and
cloning vector for C. thermosaccharolyticum.
M. Sebald, Institut Pasteur, Paris, France: Present status of genetics in clostridia-Emphasis on pathogens.
Other systems
A. Matin, Stanford University, California: Physiology of bacterial acidophilism.
B.L. Marrs, St. Louis University, Missouri: Development of genetic systems for photosynthetic bacteria.
Participants at Anaerobic Genetics Meeting
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Session 3
Chairperson: G. Gottschalk, University of Gottingen, Federal Republic of Germany
Methanogens
M.J. Wolin, New York State Department of Health, Albany: Overview of methanogens-Methane-produc-
ing bacteria of the human gut.
S. Yamazaki, National Institutes of Health, Bethesda, Maryland: Properties of selenium-containing
hydrogenase from Methanococcus vannielii.
G. Bertani and L. Baresi, Jet Propulsion Laboratory, Pasadena, California: Some mutants of Methanococcus
voltae.
W.B. Whitman, University of Georgia, Athens: Physiology of Methanococcus voltae.
J. Konisky, University of Illinois at Urbana-Champaign: Expression of Methanococcus voltae genes in E.
co/i.
P. Hamilton, Ohio State University, Columbus: Cloning and expression of methanogen DNA.
Other systems
C.E. Nord, National Bacteriology Laboratory, Stockholm, Sweden: 0-lactamases in anaerobic bacteria.
Session 4
Chairperson: M. Sebald, Institut Pasteur, Paris, France
Bacteroides
F. Tally, Tufts University, Boston, Massachusetts: Introduction.
F. Tally and M. Malamy, Tufts University, Boston, Massachusetts: Drug-resistance transfer in Bacteroides
fragilis.
J.L. Johnson, Virginia Polytechnic Institute and State University, Blacksburg: Plasmid distribution in
Bacteroides.
F.L. Macrina, Virginia Commonwealth University, Richmond: Plasmid- and nonplasmid-mediated gene
transmission in Bacteroides.
C.J. Smith, Bethesda Research Laboratories, Gaithersburg, Maryland: Transferable Clindamycin resistance
in B. ovatus.
D.G. Guiney, University of California, San Diego: Cloning and expression in E. coli of a tetracycline-
resistance gene from B. fragilis.
D.R. Woods, University of Cape Town, South Africa: UV repair systems in B. fragilis.
Session 5 Summary and Discussion
Chairperson: A.I. Bukhari, Cold Spring Harbor Laboratory, New York
J.E. Brenchley, Genex Corporation, Gaithersburg, Maryland
J.G. Morris, University College of Wales, Aberystwyth
L.E. Mortenson, Exxon Research and Engineering Company, Linden, New Jersey
J. Konisky, University of Illinois at Urbana-Champaign
B.L. Marrs, St. Louis University, Missouri
Comments
E.B. Priestley, Exxon Research and Engineering Company, Linden, New Jersey
O.H. Smith, United States Department of Energy, Washington, D.C.
Recombinant DNA Applications to Human Disease
October 3October 6
Session 1 Globin Genes, HLA, and Immunoglobins
Chairperson: S.M. Weissman, Yale University, New Haven, Connecticut
B.G. Forget, Yale University, New Haven, Connecticut: Normal human globin gene structure and muta-
tions causing different thalassemia syndromes.
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S. Orkin, The Children's Hospital Medical Center, Boston, Massachusetts: A review off3-thalassemias-The
spectrum of gene mutations.
H.H. Kazazian, Jr., Johns Hopkins Hospital, Baltimore, Maryland: DNA polymorphisms in the 0-globin
gene cluster: Use in discovery and in prenatal diagnosis.
S.M. Weissman, Yale University, New Haven, Connecticut: Molecular studies of the genes of the human
major histocompatibility complex.
T.A. Waldmann, National Cancer Institute, Bethesda, Maryland: The arrangement of immunoglobulin
genes in human lymphoid leukemias.
D. Pious, University of Washington, Seattle: Analysis of the HLA region using somatic cell mutants.
D.E. Housman, Massachusetts Institute of Technology, Cambridge: Discussion.
Session 2 Specific Disease Entities
Chairperson: C.T. Caskey, Baylor College of Medicine, Houston, Texas
C.T. Caskey, Baylor College of Medicine, Houston, Texas: Mutation at the hprt locus in rodent and man.
T. Friedmann, University of California, San Diego: Characterization of an expressible human HPRT cDNA.
A.L. Beaudet, Baylor College of Medicine, Houston, Texas: Altered mRNA for argininosuccinate synthetase
in citrullinemia.
S.L.C. Woo, Baylor College of Medicine, Houston, Texas: co-antitrypsin deficience and pulmonary
emphysema-Identification of recessive homozygotes by direct analysis of the mutation site in the
chromosomal gene.
D. Pious, University of Washington, Seattle: Discussion.
Session 3 Oncogenes and Heritable Cancers
Chairperson: D. Botstein, Massachusetts Institute of Technology, Cambridge
F. Dautry, Massachusetts Institute of Technology, Cambridge: Mechanism of activation of an oncogene
from a human bladder carcinoma.
M. Wig ler, Cold Spring Harbor Laboratory, New York: Human transforming genes.
W.F. Benedict, Children's Hospital of Los Angeles: Human retinoblastoma-A prototype of a suppressor
class of human cancer genes.
L.C. Strong, University of Texas Cancer Center, Houston: Genetic heterogeneity and retinoblastoma.
S.M. Weissman, Yale University, New Haven, Connecticut: Discussion.
Session 4 Chromosome Alteration and Mapping
Chairperson: P.L. Pearson, Sylvius Laboratories, Leiden, The Netherlands
M.E. Harper, The Agouron Institute, La Jolla, California: Chromosome mapping of single copy sequences
by in situ hybridization.
T.B. Shows, Roswell Park Memorial Institute, Buffalo, New York: Chromosome mapping of cloned genes
and DNA polymorphisms associated with disease.
S. Brenner, K.E. Davies, M. Shodell M. Siniscalco, U. Francke, D. Botstein
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U. Francke, Yale University, New Haven, Connecticut: Mapping of DNA sequences to chromosome
regions in somatic cell hybrids.
S.A. Latt, Children's Hospital Medical Center, Boston, Massachusetts: Construction, analysis, and utiliza-
tion of recombinant phage libraries enriched for the human X chromosome by florescence activated flow
sorting.
T.T. Puck, Eleanor Roosevelt Institute for Cancer Research, Inc., Denver, Colorado: Human gene mapping,
exposure, and expression.
D. Patterson, Eleanor Roosevelt Institute for Cancer Research, Inc., Denver, Colorado: Somatic cell genetics
and molecular analysis of Down's syndrome.
P.L. Pearson, Sylvius Laboratories, Leiden, The Netherlands: Discussion.
Session 5 Specific Linkage Associations
Chairperson: R.L. White, University of Utah, Salt Lake City
R.L. White, University of Utah, Salt Lake City: Approaches to linkage analysis in the human.
M. Skolnick, LDS Hospital, Salt Lake City, Utah: The variation in expected LOD score by degree of
polymorphism and recombination.
J.F. Gusella, Massachusetts General Hospital, Boston: The use of restriction fragment length polymorphisms
to map the Huntington's disease gene.
D.C. Page, Massachusetts Institute of Technology, Cambridge: Homologous single-copy sequences on the
human X and Y chromosomes.
H. Erlich, Cetus Corporation, Berkeley, California: Discussion.
R. Williamson, St. Mary's Hospital Medical School, London, England: The study of the basic defects in
cystic fibrosis.
K.E. Davies, St. Mary's Hospital Medical School, London, England: An X chromosome probe linked to
Duchennes muscular dystrophy.
M. Siniscalco, Memorial Sloan-Kettering Cancer Center, New York, New York: Molecular mapping of the
human genome-A crossroad between basic and applied research.
R.L. Nussbaum, Baylor College of Medicine, Houston, Texas: Molecular analysis of the hprt locus.
B.G. Forget, Yale University, New Haven, Connecticut: Discussion.
Session 6 Growth Hormone and Therapies
Chairperson: S. Brenner, Cambridge University, England
J.D. Baxter, University of California, San Francisco: Expression of growth hormone-related genes.
J.A. Phillips, Johns Hopkins Hospital, Baltimore, Maryland: The growth hormone gene in human disease.
G.I. Bell, University of California, San Francisco: The polymorphic locus adjacent to the human insulin
gene and its association with diabetes mellitus-A population study.
H. Erlich, Cetus Corporation, Berkeley, California: Restriction fragment length polymorphism analysis of
HLA-typed families using cloned HLA probes.
H.I. Miller, Food and Drug Administration, Rockville, Maryland: The role of the Food and Drug Administra-
tion in the regulation of the products of recombinant DNA technology-Update 1983.
D. Botstein, Massachusetts Institute of Technology, Cambridge: Growth hormone therapies.
S. Brenner, Cambridge University, England: Discussion.
Biological Aspects of Alzheimer's Disease
October 24October 27
Session 1 The Alzheimer's Patient-The Human Dimension
R. Katzman, Albert Einstein College of Medicine, Bronx, New York.
Panel Discussion-G.D. Cohen, National Institute of Mental Health, Rockville, Maryland; J.P. Blass, The
Burke Rehabilitation Center, White Plains, New York: D.A. Drachman, University of Massachusetts,
Worcester; M.F. Folstein, Johns Hopkins Hospital, Baltimore, Maryland.
Session 2 Cell and Tissue Changes in Alzheimer's Disease
Chairperson: R. Katzman, Albert Einstein College of Medicine, Bronx, New York
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T.L. Kemper, Boston City Hospital, Massachusetts: Organization of the neuropathology of the amygdala in
Alzheimer's disease.
P.C. Burger, Duke University, Raleigh, North Carolina: Limbic system in Alzheimer's disease.
M.J. Ball, University of Western Ontario, Canada: Hippocampal morphometry in Alzheimer's dementia-
Implications for neurochemical hypotheses.
G.D. Cohen, National Institute of Mental Health, Rockville, Maryland: Discussion.
D.L. Price, Johns Hopkins University, Baltimore, Maryland: Basal forebrain cholinergic neurons and
neuritic plaques in primate brain.
M. Mesulam, Beth Israel Hospital, Boston, Massachusetts: Cortical projections from the nucleus basalis in
primates.
R.D. Terry, Albert Einstein College of Medicine, Bronx, New York: Cortical morphometry in Alzheimer's
disease.
R. Katzman, Albert Einstein College of Medicine, Bronx, New York: Discussion.
Session 3 Fibrous Proteins
Chairperson: R.J. Lasek, Case Western Reserve University, Cleveland, Ohio
W.W. Schlaepfer, University of Pennsylvania, Philadelphia: Some observations on the structural and
chemical nature of neurofilaments.
L. Autilio-Gambetti, Case Western Reserve University, Cleveland, Ohio: Paired helical filaments-
Relatedness to neurofilaments shown by silver staining and reactivity with monoclonal antibodies.
D.J. Selkoe, McLean Hospital, Belmont, Massachusetts: Protein chemistry of paired helical filaments.
G.G. Glenner, University of California, San Diego: Alzheimer's disease-Multiple cerebral amyloidosis.
H.M. Wisniewski, New York State Institute for Basic Research in Mental Retardation, Staten Island:
Pathogenesis of neuritic and amyloid plaques.
S. Yen, Albert Einstein College of Medicine, Bronx, New York: Discussion.
Session 4 Genetics and Biochemistry of Alzheimer's and Related Disorders
Chairperson: X.O. Breakefield, Yale University, New Haven, Connecticut
C.J. Epstein, University of California, San Francisco: Down's syndrome and Alzheimer's disease-
Implications and approaches.
L.L. Heston, University of Minnesota, Minneapolis: Dementia of the Alzheimer's type-Perspectives from
studies of families.
C.A. Marotta, McLean Hospital, Belmont, Massachusetts: In vitro protein synthesis by messenger RNA from
the Alzheimer's disease brain.
D.E. Housman, Massachusetts Institute of Technology, Cambridge: Molecular genetic approaches.
X.O. Breakefield, Yale University, New Haven, Connecticut: Discussion.
Session 5 Neurotransmitter Changes in Alzheimer's Disease
Chairperson: P. Davies, Albert Einstein College of Medicine, Bronx, New York
R.T. Bartus, Leder le Laboratories, Pearl River, New York: Evidence for a cholinergic deficiency using animal
models of aging-Implications for studying and treating Alzheimer's disease.
D.M. Bowen, Institute of Neurology, London, England: Neurotransmitters and metabolism in Alzheimer's
disease.
J.T. Coyle, Johns Hopkins University, Baltimore, Maryland: Synaptic neurochemistry of the basal forebrain
cholinergic projections.
I. Hanin, University of Pittsburgh, Pennsylvania: Chemically induced cholinotoxicity in vivo-Studies
utilizing ethylcholine aziridinium ion (AF64A).
P. Davies, Albert Einstein College of Medicine, Bronx, New York: Neurotransmitters and neuropeptides in
Alzheimer's disease.
R.H. Perry, Newcastle General Hospital, England: Discussion.
Session 6
Chairperson: C.W. Cotman, University of California, Irvine
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Trophic factors
R. Katzman, Albert Einstein College of Medicine, Bronx, New York: In vivo cholino-trophic activity.
C.W. Cotman, University of California, Irvine: Increase in neurotrophic factor following brain injury.
S.H. Appel, Baylor College of Medicine, Houston, Texas: Neurotrophic effects of hippocampal extracts on
medial septal nucleus.
Metabolism
J.P. Blass, The Burke Rehabilitation Center, White Plains, New York: Fibroblast phosphofructokinase in
Alzheimer's disease and Down's syndrome.
D.F. Benson, University of California, Los Angeles: Alterations in glucose metabolism in Alzheimer's
disease.
F.S.J. Frackowiak, Hammersmith Hospital, London, England: 015 metabolism.
C.W. Cotman, University of California, Irvine: Discussion.
Session 7 Behavioral Correlates
Chairperson: C.W. Cotman, University of California, Irvine
M.F. Folstein, The Johns Hopkins Hospital, Baltimore, Maryland: Differential cognitive changes in the
hereditary form of Alzheimer's disease.
R.H. Perry, Newcastle General Hospital, England: Relation of cholinergic loss to dementia.
D.A. Drachman, University of Massachusetts, Worcester: Aging and dementia-Insights from the study of
anticholinergic drugs.
R. Katzman, Albert Einstein College of Medicine, Bronx, New York: Discussion.
Session 8 Viral and Environmental Agents
Chairperson: R.G. Rohwer, National Institute of Neurological and Communicative Disorders and
Stroke, Bethesda, Maryland
S.B. Prusiner, University of California, San Francisco: On the molecular biology of prions.
A.G. Dickinson, ARC and MRC Neuropathogenesis Unit, Edinburgh, Scotland: The relevance of scrapie as
an experimental model for Alzheimer's disease.
R.G. Rohwer, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda,
Maryland: Discussion.
E.E. Manuelidis, Yale University, New Haven, Connecticut: Novel biological properties of Creutzfeldt-
Jakob brains in vitro.
L. Manuelidis, Yale University, New Haven, Connecticut: Fractionation and infectivity studies in
Creutzfeldt-Jakob disease.
D.C. Gajdusek, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda,
Maryland: Environmental factors responsible for ALS, P-D, and other neurological syndromes in high in-
cidence foci.
D.P. Perl, University of Vermont, Burlington: Aluminum in Alzheimer's disease.
R. Katzman, H. Wisniewski
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L. Manuelidis, M. Folstein, G. Glenner
R.G. Rohwer, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda,
Maryland: Discussion.
Session 9 Therapeutic Interventions
Chairperson: R.I. Wurtman, Massachusetts Institute of Technology, Cambridge
K.L. Davis, Veterans Administration Medical Center, Bronx, New York: Pharmacological and biological
studies of Alzheimer's disease.
J.H. Growdon, Massachusetts General Hospital, Boston, Precursor therapies.
L.J. Thal, Albert Einstein College of Medicine, Bronx, New York: Oral physostigmine and lecithin improve
memory in Alzheimer's disease.
R.J. Wurtman, Massachusetts Institute of Technology, Cambridge: Discussion.
Congressional Workshop:
Carcinogenesis-From the Environment to the Gene
November 19-November 21
Session 1
J. Cairns, Harvard School of Public Health, Boston, Massachusetts: Epidemiology and molecular biology-
More than just good friends?
Session 2
A.J. Levine, State University of New York at Stony Brook: What we now know about the organization of the
human genome.
J. Sambrook, Cold Spring Harbor Laboratory, New York: How we know what we now know about the
organization of the human genome.
Session 3
R.A. Weinberg, Massachusetts Institute of Technology, Cambridge: Finding oncogenes by "transfection."
R.L. Erikson, University of Colorado, Denver: Retroviruses and oncogenes.
D.E. Housman, Massachusetts Institute of Technology, Cambridge: Probing the human genome.
Session 4
R.C. Gallo, National Cancer Institute, Bethesda, Maryland: Viruses and human cancer.
R. Wilson, Harvard University, Cambridge, Massachusetts: New parameters for the health-risk equation?
J.M. Bishop, University of California, San Francisco: Summary.
R. Gallo A. Levine, J. Tuchman-Mathews M. Bishop
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Postgraduate
Training Program
SUMMER 1982
The Postgraduate Training Program at Cold Spring Harbor Laboratory is aimed at meeting the special need
for training in interdisciplinary subjects which are either so new or so specialized that they are not ade-
quately treated by universities. Our aim is to provide intensive study in the most recent developments and
techniques in these subjects and to prepare students to enter directly into research in a particular area. To
ensure up-to-date coverage of current research work, we bring together a workshop staff from many
laboratories around the world and supplement this staff with a series of seminar speakers.
Principles of Developmental Neurobiology, June 12-June 25
INSTRUCTORS
Purves, D., M.D., Washington University School of Medicine, St. Louis, Missouri
Patterson, P.N., Ph.D., Harvard Medical School, Cambridge, Massachusetts
The aim of this intensive two-week course was to expose a group of 18 students to the classical literature of
neural development, with special emphasis on recent advances and controversies in this rapidly growing
field. The selection of students was based primarily on recommendations and potential rather than
background; thus this year's group included 11 postdoctoral fellows, 5 graduate students, and 2 fulltime
faculty members from the United States and Europe involved in widely different research programs. The
common denominator was an interest in pursuing research related to neural development.
The usual format was a detailed review of particular subjects given by invited lecturers in a three-hour
morning session. The speaker then chose several important papers, generally ones not discussed in the
morning, for the students to read during the afternoon. In the late afternoon the speaker (and instructors)
met with groups of 6 students to discuss the reading and prepareone of the students in each group to pre-
sent the papers at an evening meeting of the whole class. The evening then consisted of several student
presentations of aspects of the morning's subject not covered by the invited lecturer, as well as a general
discussion of the issues raised during the day. Most evenings ended with one or two student research
seminars in which an individual's work in progress was uescribed for discussion and criticism by fellow
students, instructors and the guest lecturers. In general, we attempted to have such presentations on an
evening when the day's guest lecturer had a special interest in the student's field. An occasional variant of
this format was to end the evening with a research seminar by an additional invited speaker whose material
was deemed of special interest, but not broad enough to devote an entire day to.
PARTICIPANTS
Bernhardt, Robert, M.S., Friedrich Meischer Institut, Basel, Switzerland
Blanks, Janet, Ph.D., University of Southern California, Los Angeles
Caudy, Michael, B.S., University of California, Berkeley
Diaz-Arrastia, Ramon, B.A., Baylor College of Medicine, Houston, Texas
Forehand, Cynthia, Ph.D., Washington University School of Medicine, St. Louis, Missouri
Johnson, Jim, B.S., Bowman Gray School of Medicine, Winston-Salem, North Carolina
Kalcheim, Chaya, M.Sc., Weizmann Institute of Science, Rehovot, Israel
Kinnamon, Sue, Ph.D., University of Colorado Medical Center, Denver
Korsching, Sigrun, M.S., Max-Planck Institute for Psychiatry, Munich, Federal Republic of Germany
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Maeder, Jacques, M.Sc., Friedrich Miescher Institut, Basel, Switzerland
Pearson, John, M.D., New York University Medical Center, New York
Price, Jack, B.A., University College of London, England
Rosenheimer, Julie, B.A., University of Wisconsin, Madison
Stbrmer, Claudia, Ph.D., University of Michigan, Ann Arbor
Scherer, Steve, B.S., University of Michigan, Ann Arbor
Tomaselli, Kevin, B.S., University of California, San Francisco
Weber, Art, B.A., University of Wisconsin, Madison
Wolinsky, Eve, B.S., Harvard Medical School, Boston, Massachusetts
SEMINARS
Cowan, W.M., Salk Institute. An overview of neural development.
Rakic, P., Yale University Medical School. Cell proliferation.
. Neuronal migration.
Lawrence, P.A., MCR Laboratory of Molecular Biology. Pattern formation: Insect cuticle.
. Compartments, segments, and postitional information.
Spitzer, N.C., University of California, San Diego. Development of the grasshopper nervous system: Mor-
phology, chemosensitivity, and electrical properties.
Horvitz, R., Massachusetts Institute of Technology. Development of C. elegans: 1) Cell diversity, 2) Cell
death, 3) Egg-laying.
Spitzer, N.C., University of California, San Diego. Development of Rohan-Beard cells.
Patterson, P.H., Harvard Medical School. Influence of environment on phenotype in vivo and in vitro.
Landmesser, L.T., Yale University. Axon guidance in vertebrates.
Landis, S., Harvard University Medical School. The growth cone.
Bentley, D., University of California, Berkeley. Insect pioneer axons.
Aguayo, A.J., McGill University. Axon regeneration; interactions of nerve and glia.
Purves, D., Washington University School of Medicine, St. Louis. Neuronal death.
Patterson, P.H., Harvard Medical School. Nerve growth factor.
Hall, Z.W., University of California School of Medicine, San Francisco. Synapse formation.
Patterson, P.H., Harvard Medical School. Trophic effects in sensory systems.
Purves, D., Washington University School of Medicine. Specificity in the peripheral nervous system.
Easter, S., University of Michigan. Specificity in the retinotectal system.
Gottlieb, D.I., Washington University School of Medicine. Molecular basis of cell recognition I.
Sanes, J., Washington University School of Medicine. Molecular basis of cell recognition II.
Raff, M., Yale University School of Medicine. Molecular basis of cell recognition III.
Purves, D., Washington University School of Medicine. Synaptic rearrangement; synaptic maintenance.
Stent, G.S., University of California, Berkeley. Development of the leech.
Stryker, M.P., University of California Medical School, San Francisco. Development of the visual system I.
. Development of the visual system II.
Drager, U., Harvard Medical School. Mutations in visual development.
Nottebohm, F., Rockefeller University. Development of birdsong.
Hildebrand, J.G., Columbia University. Development of insect behavior.
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Nervous System of the Leech, June 22-July 1
INSTRUCTORS
Nicholls, John, M.D., Ph.D., Stanford University, California
Parnas, Itzhak, Ph.D., Hebrew University, Jerusalem, Israel
Muller, Ken, Ph.D., Carnegie Institution of Washington, Baltimore, Maryland
Zipser, Birgit, Ph.D., Cold Spring Harbor Laboratory, New York
The aim of this workshop was to provide students with an intensive lab and seminar course that would
enable them to pursue independent work on the leech. To this end, we hoped to provide the students with
techniques for recording from leech cells, now considered straightforward and relatively easy, that took
much time and effort to be refined. With this knowledge, they might avoid many of the trivial technical dif-
ficulties that bedevil anyone starting on the nervous system of the leech or other animals.
The initial work was devoted mainly to recognizing the individual cells, learning how to record from
them with intracellular and extracellular electrodes, getting familiar with the equipment, and performing
dissections. The students then progressed to more difficult experiments, such as recording synaptic poten-
tials while changing the fluid, bathing the preparation, or injecting individual cells with marker substances
to study their geometry.
PARTICIPANTS
Drapeau, Pierre, Ph.D., University of Maryland, College Park
Flaster, Murray S., B.S., Cold Spring Harbor Laboratory, New York
Hoppe, Pamela E., B.A., Princeton University, New Jersey
Johansen, Jorgen, M.S., Cold Spring Harbor Laboratory, New York
Mc Glade, Ellen, M.S., University of Maryland, College Park
Mehaffey, Leathem, Ph.D., Vassar College, Poughkeepsie, New York
Metzmer, Henri, M.S., Hebrew University, Jerusalem, Israel
Soileau, Carmen L., M.S., University of Texas, Austin
Ways, Nancy R., B.A., Stanford University, California
Wordeman, Linda G., B.A., University of California, Berkeley
SEMINARS
Kristen, W., University of California, San Diego. The swimming leech.
. Circuitry that generates leech swimming.
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Stent, G., University of California, Berkeley. Embryonic development.
Friesen, W.O., University of Virginia, Charlottesville. Wave detectors.
Hockfield, S. and R. McKay, Cold Spring Harbor Laboratory. Monoclonal antibodies to identified
neurons.
Payton, B., Memorial University. Giant leech in Newfoundland.
Salzberg, B., University of Pennsylvania Dental School. Optical recording.
Molecular Biology of Plants, June 12-July 2
INSTRUCTORS
Bedbrook, John R., Ph.D., CSIRO, Canberra, Australia
Ausubel, Frederick, Ph.D., Harvard University, Cambridge, Massachusetts
ASSISTANTS
Waldren, John, CSIRO, Canberra, Australia
Schoene, Vinni, Harvard University, Cambridge, Massachusetts
Brown, Susan E, Harvard University, Cambridge, Massachusetts
Dunn, Barbara, B.S., Harvard University, Cambridge, Massachusetts
Buikema, Bill, Harvard University, Cambridge, Massachusetts
The three week Plant Molecular Biology Course consisted of a series of lectures by the staff and by
distinguished invited speakers and a series of laboratory exercises designed to acquaint the students with
the fundamentals of current plant molecular biology research. The course assumed that most students come
with a good background in molecular genetic techniques but with a poor understanding of general botany,
plant physiology, plant sexual reproduction, and plant development. Therefore, the course began with lec-
tures to acquaint the students with some of the fundamental differences between plants and animals. The
introductory topics were tied together by considering plants from a developmental point of view.
Laboratory experiments involving whole plant anatomy, embryo and meristem culture, and somatic cell
tissue culture complemented the introductory lectures.
The introductory section was followed by a series of detailed lectures covering topics which were
relatively unique to plants including photosynthesis, seed formation and germination, and regeneration of
intact plants from somatic cultures. Among the topics covered were classical transmission genetics in-
cluding transposable genetic elements, cytogenetics, plant viruses, plant-bacterial interactions, and the
molecular biology of the plant organelle and nuclear genomes. The laboratory projects paralleled the lec-
tures and included experiments on (1) the mechanism of a-amylase induction in germinating seeds; (2) the
manipulation of plant tissue cultures; (3) the generation of plant mutants; (4) the isolation, characterization
and manipulation of plant DNAs and RNAs; and (5) cytogenetics.
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PARTICIPANTS
Barta, Andrea, Ph.D., University of Vienna, Austria
Bonitz, Susan G., Ph.D., Genentech, San Francisco, California
Daniell, Ellen, Ph.D., University of California, Berkeley
Digan, Mary Ellen, Ph.D., National Institutes of Health, Bethesda, Maryland
Grabau, Elizabeth A., Ph.D., University of Utah, Salt Lake City
Hernalsteens, Jean-Pierre, Ph.D., Vrije Universiteit Brussel, Belgium
Higuchi, Russell G., Ph.D., University of California, Berkeley
Huang, Wai Mun, Ph.D., University of Utah, Salt Lake City
Ladin, Beth, Ph.D., Washington University, St. Louis, Missouri
Leutwiler, Leslie S., Ph.D., California Institute of Technology, Pasadena
Lu, Deru, National Institutes of Health, Bethesda, Maryland
Machida, YasunOri, Ph.D., State University of New York, Stony Brook
Muskavitch, Karen, M.T., Ph.D., Harvard University, Cambridge, Massachusetts
Nixon, B. Tracy, M.S., Harvard Medical School, Boston, Massachusetts
Riazuddin, Sheikh, Johns Hopkins University, Baltimore, Maryland
Robinson, Steven J., Ph.D., University of Chicago, Illinois
Tabor, Paul S., Ph.D., Naval Research Laboratory, Bethesda, Maryland
SEMINARS
Schmidt, G., University of Georgia. Chloroplast assembly.
Steinback, K., Michigan State University. Structure of the chloroplast membrane.
Bogorad, L., Harvard University. Molecular biology of the chloroplast.
Goldberg, B., University of California, Los Angeles. Seed storage protein genes.
Varner, J., Washington University. Structure of the plant cell wall.
Miles, D., University of Missouri. Genetics of photosynthesis.
Ho, D., University of Illinois, Urbana. Molecular biology of alpha amylase.
Burr, B. and F., Brookhaven National Laboratory. Controlling elements in maize.
Shepard, J., Kansas State University. Plant tissue culture and agriculture.
Animal Cell Culture, June 19-July 2
INSTRUCTORS
Barnes, David, Ph.D., University of California, San Diego
Mather, Jennie, Ph.D., The Population Council, Rockefeller University, New York, New York
ASSISTANTS
Byers, Alicia, B.S., The Population Council, Rockefeller University, New York, New York
Kaczorowski, Flo, B.S., The Population Council, Rockefeller University, New York, New York
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The course was designed to introduce investigators familiar with conventional culture methodology to the
special techniques and approaches of hormone-supplemented serum-free cell culture. Techniques for the
handling of cells for serum-free culture and details of the preparation of media etc. were discussed. The
handling, storage and methods of purification of various growth factors, hormones, and attachment factors
were discussed. A large number of the currently available hormones, attachment factors, growth factors
media, and growth surfaces were made available for participants to use in devising the supplements re-
quired for the growth of their own cell lines or those provided for use in the course. Exercises and
demonstrations taught primary culture techniques for the isolation and culture of neuroblasts, thyroid,
kidney, liver, and testicular cells. Clonal cell lines available were derived from a variety of tissues and
species and were of both normal and transformed phenotype.
Seminars were designed to acquaint the participants with various approaches to the study of hormone ac-
tion in cells and to stimulate thinking on approaches to studies of differentiation, cell function, and hor-
mone action which can only be performed in a serum-free culture system.
The course was designed with maximum flexibility so as to allow participants to concentrate on areas of
maximum interest to them with advice and discussion with the instructors, speakers and other course
participants.
PARTICIPANTS
Angadi, Channabasappa, Ph.D., Nassau County Medical Center, East Meadow, New York
Anzano, Mario A., Ph.D., National Cancer Institute, Bethesda, Maryland
Brodie, Ann E., Ph.D., Oregon State University, Corvallis
Glaser, Janet, Ph.D., University of Illinois, Chicago
Kudo, Yoshihisa, Ph.D., Mitsubishi-Kasei Institute, Tokyo, Japan
Pannier-Poulain, Claude, M.D., Paris-South University, France
Pinset, Christian, M.D., Pasteur Institute, Paris, France
Van deWalle, Philippe, Universite Libre de Bruxelles, Belgium
SEMINARS
McKeehan, W., W. Alton Jones Cell Science Center. Nutrition in cell culture.
Strickland, S., Rockefeller University. Differentiation of embryonal carcinoma cells in vitro.
Pawelek, J., Yale University. Effects of insulin on melanoma cell cultures.
Phillips, D., The Population Council. Use of morphological techniques for the study of hormone action
in vitro.
Reid, L., Albert Einstein College of Medicine. Biomatrix in cell culture.
Taub, M., State University of New York Buffalo. Kidney cell culture in serum-free medium.
Coon, H., National Cancer Institute. Growth and function of thyroid and neuroblast cells in vitro.
Sato, G., University of California, San Diego. The endocrine system/hormone effect in vitro.
Solomon, Y., Weizmann Institute. Adenylate cyclase.
Breitman, T.R., National Cancer Institute. Terminal differentiation of HL-60 and leukemic cells by
retinoic acid.
Glass, J., Beth Israel Hospital. Transferrin.
Kaplan, J., University of Utah Medical School. Control of a=m and transferrin receptors in culture.
Werb, Z. University of California, San Francisco. Collagenase and elastace secretion by cultured cells.
Single-Channel Recording, July 5-July 23
INSTRUCTORS
Corey, David P., Ph.D., Yale University, New Haven, Connecticut
Dionne, Vincent E., Ph.D., University of California, San Diego
Ohmori, Harunori, M.D., Ph.D., University of California, Los Angeles
Pallotta, Barry, Ph.D., University of Miami, Florida
Patlak, Joseph, Ph.D., University of Vermont, Burlington
Stevens, Charles F., M.D., Ph.D., Yale University, New Haven, Connecticut
Yellen, Gary, B.A., Yale University, New Haven, Connecticut
ASSISTANT
Stevens, Meg, Harvard University, Boston, Massachusetts
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The Single-Channel Recording Course brought together ten students whose backgrounds ranged from
graduate student to department chairman, with seven instructors currently using the patch-clamp technique
in their own research. The goals were two: Students, through intensive lab work and lectures, became profi-
cient at the new patch-clamp technique, which is presently revolutionizing electrophysiology. Instructors,
by comparing methods used in different laboratories, reached consensus on some aspects of the technique,
and laid the groundwork for further development.
Lectures, by instructors and by invited lecturers, covered both the detailed methods for recording currents
through single membrane channels and from whole cells, and the theoretical basis for analyzing and
understanding the records. Laboratory work, at five electro-physiological setups, enabled students to learn
and practice the various permutations of the patch-clamp technique, to become proficient at recognizing
and specifically activating different membrane channel species, and to carry out short research projects on
the tissues used in their own laboratories. Research projects included such diverse studies as development
of Na* and Ca" currents in embryonic frog neurons, Cl- transport in red blood cells, an inwardly rectifying
K' channel in adult frog muscle, Na* channels in dissociated mammalian cardiac muscle, and the observa-
tion of a large (500 pS), hitherto unreported channel in a skeletal muscle cell line.
PARTICIPANTS
Cook, Daniel L., Ph.D., Seattle VA Medical Center, Washington
Coronado, Roberto B., Ph.D., Harvard Medical School, Cambridge, Massachusetts
Datyner, Nicholas, Ph.D., State University of New York, Stony Brook
Freschi, Joseph E., M.D., National Naval Medical Center, Bethesda, Maryland
Gray, Richard A., B.S., Baylor College of Medicine, Houston, Texas
Gruol, Donna L., Ph.D., Salk Institute, San Diego, California
Gunn, Robert B., M.D., Emory University, Atlanta, Georgia
O'Dowd, Diane, B.S., University of California, San Diego
Stanfield, Peter R., Ph.D., University of Leicester, England
Willard, Alan, L., Ph.D., Harvard Medical School, Boston, Massachusetts
SEMINARS
Aldrich, R.W., Yale University. Stochastic Processes.
Breakfield, X.O., Yale University. Tissue preparation: Primary cultures and cell lines.
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Advanced Neuroanatomical Methods, July 5-July 25
INSTRUCTORS
Jones, Edward G., Ph.D., Washington University Medical School, St. Louis, Missouri
Hand, Peter J., Ph.D., University of Pennsylvania, Philadelphia
Pickel, Virginia M., Ph.D., Cornell Medical College, New York, New York
Wise, Steven P., Ph.D., National Institutes of Mental Health, Bethesda, Maryland
Swanson, Larry W., Ph.D., Salk Institute, San Diego, California
ASSISTANTS
McClure, Bertha, Washington University, St. Louis, Missouri
Hendry, Stewart, B.A., Washington University, St. Louis, Missouri
The course for 1982 was conducted along new lines with students individually or in pairs carrying out a
morphological investigation of selected areas of the central nervous system. The fundamental
neuroanatomical techniques were not neglected but incorporated within the framework of advanced
technology. Students were intensively supported by a relatively large group of teachers and assistants who,
with the visiting faculty, also provided lectures on selected topics in current research.
Methods covered included autoradiography of axoplasmic transport, transmitter uptake and receptor
localization, anterograde and retrograde labeling with horseradish peroxidase and fluorescent dyes, light
and electron microscopic immunocytochemistry using a number of different polyclonal and monoclonal
antibodies, the 2-deoxy-D-glucose method and localization of oxidative enzymes. Where feasible, methods
for physiological localization were employed and the material carried to both light and electron
microscopic levels.
PARTICIPANTS
Bielajew, Catherine H., M.A., Concordia University, Montreal, Canada
Blakely, Randy D., B.A., Emory University, Atlanta, Georgia
Fairbanks, Mary E., Dartmouth College, Hanover, New Hampshire
Gibson, Candace J., Ph.D., Massachusetts Institute of Technology, Cambridge
Gizzi, Martin S., M.A., New York University, New York
Kilduff, Thomas S., Ph.D., Stanford University, California
Lang, William J., B.S., University of Oxford, England
Priestley, John V., B.A., University of Oxford, England
Schuz, Almut, Ph.D., Max-Planck Institut, Berlin, Federal Republic of Germany
Wysocki, Charles J., Ph.D., Monell Chemical Senses Center, Philadelphia, Pennsylvania
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SEMINARS
Hendrickson, A.E., University of Washington. Study of the visual system by autoradiographic techniques.
Priestley, J.V., Oxford University. lmmunocytochemical techniques as applied to the study of spinal cord
organization.
Raviola, E., Harvard University. Freeze fracture and related techniques in the study of the retina.
Peters, A., Boston University. The golgi-EM technique in the study of the cerebral cortex.
MacKay, R.W., Cold Spring Harbor Laboratory. Neuroimmunology and hybridoma technology.
Kitai, S.P., Michigan State University. Intracellular injection studies of the basal ganglia.
Advanced Bacterial Genetics, July 5-July 25
INSTRUCTORS
Silhavy, Thomas J., Ph.D., NCI, Frederick Cancer Research Facility, Frederick, Maryland
Berman, Michael L., Ph.D., NCI, Frederick Cancer Research Facility, Frederick, Maryland
Enquist, Lynn W., Ph.D., Molecular Genetics, Inc., Minnetonka, Minnesota
ASSISTANTS
Bear, Susan, Ph.D., National Institutes of Health, Bethesda, Maryland
Benson, Spencer, Ph.D., NCI, Frederick Cancer Research Facility, Frederick, Maryland
Taylor, Ronald, B.S., NCI, Frederick Cancer Research Facility, Frederick, Maryland
The Advanced Bacterial Genetics course was designed to teach students how to isolate and characterize
defined mutations in any gene in Escherichia coli, even if the mutation alters a gene whose product is essen-
tial for cellular viability. Such defined mutations include Tn10 insertions, nonsense mutations and dele-
tions. Experimental protocols for performing the various types of mutagenesis on chromosomal genes,
genes on transducing phages, and genes on multi-copy plasmids were presented. The course emphasized
the use of gene fusions to effect genetic analysis. Accordingly, students were taught how to construct gene
fusions in vivo and in vitro, isolate specialized X transducing phage and clone the gene fusion onto a multi-
copy plasmid vector. In addition, bacteriophage X vectors were also employed to construct transducing
phage that carry any gene. Clones of interest were identified using several different genetic and biochemi-
cal techniques.
The model system employed for demonstrating these techniques is the omp regulon of E. coli. The
regulon contains two regulatory genes and two structural genes. The latter specify the major outer mem-
brane porin proteins of the bacterium. As in many cases, the phenotypes conferred by mutations in this
regulon are difficult to score. To permit genetic analysis, gene fusions of the porin structural genes to the
lactose operon are employed. Such fusions confer readily identifiable phenotypes which facilitate mutant
isolation and characterization. Using bacteriophage X vectors, envZ. transducing phage were constructed
and identified by lytic and lysogenic complementation. Students isolated mutations using a number of
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mutagenic protocols that abolished expression of one of the porin regulatory genes, envZ. By using ap-
propriate diploid strains, students were able to characterize these mutations despite the fact that in wild-
type strains they appear to affect viability. In addition, gene libraries of several other Gram-negative bacteria
were constructed using the same vectors. Both the libraries and genomic DNAs were screened for the
presence of DNA homologous to envZ by either plaque hydridization or Southern blot analysis.
PARTICIPANTS
Arps, Peggy J., Ph.D., Johns Hopkins University, Baltimore, Maryland
Clarke, Robert C., B.S., Ontario Veterinarian College, Canada
DeVeaux, Linda C., B.S., University of Virginia, Charlottesville
Franco, Robert J., M.S., University of Rochester, New York
Freundlieb, Sabine, B.S., University of Konstanz, Federal Republic of Germany
Garcia, Alphonse, M.A., Pasteur Institute, Paris, France
Kaplan, Heidi Beth, B.A., Cornell University, Ithaca, New York
Kellman, Susan I., B.S., Public Health Research Institute, New York, New York
Meier, Joseph T., B.A., University of California, San Diego
Nazos, Penelope M., M.S., University of Michigan, Ann Arbor
Ohman, Dennis, E., Ph.D., University of California, Berkeley
Progulske, Ann, Ph.D., University of Massachusetts, Amherst
Ryan, James Patrick, B.S., University of North Carolina, Chapel Hill
Sen, Jyoti, M.S., Columbia University, New York, New York
Trun, Nancy J., B.S., Ohio State University, Columbus
Whoriskey, Susan K., B.S., Harvard Medical School, Boston, Massachusetts
SEMINARS
Kleckner, N., Harvard University. Mechanism and regulation Tn 10 transposition.
Beckwith, J., Harvard Medical School. The lac operon is terrific.
Gottesman, S., National Institutes of Health. Coping with emergencies.
Shapiro, J., University of Chicago. Two types of translocatable elements.
Court, D., National Institutes of Health. The tail of lambda int regulation.
Roth, J., University of Utah. Behavior of three transposable elements in Salmonella.
Botstein, D., Massachusetts Institute of Technology. New approaches for the study of old genetic
problems.
Molecular Cloning of Eukaryotic Genes, July 5-July 25
INSTRUCTORS
Fritsch, Edward F., Ph.D., Genetics Institute, Boston, Massachusetts
Engel, Doug, Ph.D., Northwestern University, Chicago, Illinois
Dodgson, Jerry, Ph.D., Michigan State University, East Lansing
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ASSISTANTS
Fischer, David, Ph.D., Northwestern University, Chicago, Illinois
Grandy, David, B.A., Michigan State University, East Lansing
Friderici, Karen, B.S., Michigan State University, East Lansing
The course was designed to give "hands on" experience in the isolation and analysis of eukaryotic genes.
Experiments performed during the course included double-strand cDNA synthesis: poly(dG):poly(dC) tail-
ing; DNA fragment isolation from gels; P labeling of nucleic acids in vitro; preparation and isolation of Is
arms and preparation of eukaryotic DNA inserts for X cloning; preparation of in vitro packaging extracts; for-
mation of eukaryotic X libraries; screening of the eukaryotic DNA libraries in X phage by plaque hybridiza-
tion screening and by recombinational screening; formation of libraries in cosmid vectors; specific methods
of subcloning fragments of eukaryotic DNA in plasmid vectors; screening of plasmids for insert fragments
by size and by filter colony hybridization screening; and Northern and chromosomal Southern blotting
analysis, Laboratory demonstrations, prepared by outside experts, detailed the identification of recom-
binants by RNA filter selection and subsequent in vitro translation. Topics covered include the transient
replication and expression of genes in SV40 subclones of chromosomal genes transfected into simian cells
and the expression of isolated genes introduced into cultured cells by microinjection. Through the seminar
series, students were also introduced to a wide variety of topics in which recombinant DNA studies have
proven to be indispensable in the analysis of the organization and expression of genes in a wide variety of
organisms and eukaryotic viruses.
PARTICIPANTS
Bewley, Glen C., Ph.D., North Carolina State University, Greensboro
Chang, Long-Sheng, B.S., University of Medicine and Dentistry, Newark, New Jersey
Dean, Jurrien, M.D., National Institutes of Health, Bethesda, Maryland
Greene, Warner C., M.D., National Institutes of Health, Bethesda, Maryland
Kalthoff, Klaus 0., Ph.D., University of Texas, Austin
Lindqvist, Bjorn, Ph.D., University of Tromso, Norway
Miller, Louis H., M.D., National Institutes of Health, Bethesda, Maryland
O'Farrell, Minnie K., Ph.D., University of Essex, Colchester, England
Rao, Anjana, Ph.D., Sidney Farber Cancer Institute, Boston, Massachusetts
Redmond, Shelagh, M.S., B.A., Imperial Cancer Research Fund, London, England
Searls, David, B., Ph.D., Wistar Institute, Philadelphia, Pennsylvania
Sher, Franklin A., Ph.D., National Institutes of Health, Bethesda, Maryland
Strauss, William L., Ph.D., National Institutes of Health, Bethesda, Maryland
Valerio, D., B.A., Sylvius Laboratories, The Netherlands
White, Judith M., Ph.D., Yale Medical School, New Haven, Connecticut
Worton, Ronald G., Ph.D., Hospital for Sick Children, Toronto, Canada
SEMINARS
Seed, B., Harvard University. Screening bacteriophage libraries by recombination in E. coli.
Dodgson, J., Michigan State University. Chicken histone genes.
Sambrook, J., Cold Spring Harbor Laboratory. Expression of a cloned influenza.
Gething, M.J., Cold Spring Harbor Laboratory. Hemmagglutinin gene in prokaryotic and eukaryotic cells.
Korman, A., Harvard University. Application of immunopurification of polysomes to gene cloning.
Wigler, M., Cold Spring Harbor Laboratory. Human transforming genes.
Irwin, N., Harvard University. Expression of eukaryotic genes in E. coli.
Shortie, D., State University of New York, Stony Brook. Site-directed mutagenesis.
Levings, C., North Carolina State University. Plasmid-like DNA in the corn mitochondrial genome.
Baltimore, D., Massachusetts Institute of Technology. Immunoglobulin genes and gene cloning.
Shenk, T., State University of New York, Stony Brook. Genetic manipulation of the adenovirus genome.
McKnight, S., Fred Hutchinson Cancer Research Center. Transcriptional control signals of a constitutive-
ly expressed eukaryotic protein-coding gene.
Capecchi, M., University of Utah. Patterns of integration of DNA microinjected into cultured mammalian
cells.
Goodman, H., Harvard Medical School. Structure, evolution, and expression of mammalian polypeptide
genes.
Spradling, A., Carnegie Institution. P. elements as transformation vectors in Drosophila.
Bender, W., Harvard Medical School. Transposable elements in the Bithorax locus of Drosophila.
Engel, D., Northwestern University. Avian red cell gene expression.
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The Synapse: Cellular and Molecular Neurobiology, July 12-August 1
INSTRUCTORS
Rahamimoff, Rami, M.D., Hebrew University, Hadassah Medical School, Jerusalem, Israel
McMahan, U. Jack, Ph.D., Stanford University School of Medicine, California
PART-TIME INSTRUCTORS
Stevens, Charles F., M.D., Ph.D., Yale University School of Medicine, New Haven, Connecticut
Yoshikami, Doju, Ph.D., University of Utah, Salt Lake City
This intensive lecture course was intended for graduate students and research workers interested in an inter-
disciplinary understanding of cellular and molecular biology of the synapse. The topics covered included
synaptic excitation and inhibition; structure of presynaptic and postsynaptic elements; release, synthesis,
storage, and inactivation of neurotransmitters; noise analysis of transmitter action; synthesis properties and
distribution of receptor molecules; synaptic immunology; electrical synapses and gap junctions; slow
synaptic potentials; principles of neuronal development, denervation, and reinnervation; synaptic phar-
macology; role of peptides in neuronal function; principles of sensory transduction; synaptic transmission
at the retina; and pathophysiology of synapses. The course consisted of lectures, seminars, reading of
papers, small group discussions, presentations by the course participants, and workshops on morphological
techniques, analysis of synaptic activity, noise analysis, principles of the usage of digital computers in data
collection and analysis, and quantal analysis.
PARTICIPANTS
Ashe, John H., Ph.D., University of California, Riverside
Blaxter, Timothy J., B.S., St. Andrews University, Winnipeg, Canada
Carman, George John, B.A., California Institute of Technology, Pasadena
Carroll, Paul T., Ph.D., Texas Tech University, Lubbock
Constantini, Schlomo, B.S., Hadassah Medical School, Jerusalem, Israel
Coopersmith, Robert, M., University of California, Irvine
Covault, Jon, M., Ph.D., University of Iowa, Iowa City
Craft, Cheryl M., B.S., University of Texas, Corpus Christi
Hoshi, Toshinori, B.A., Yale University, New Haven, Connecticut
Kudo, Yoshihisa, Ph.D., Mitsubishi-Kasei Institute, Tokyo, Japan
Leonard, Reid J., B.S., Purdue University, West Lafayette, Indiana
Lisak, Joan W., B.S., New York University Medical College, New York
Murakami, Fujio, Ph.D., National Institute for Sciences, Tokyo, Japan
Nitkin, Ralph M., Ph.D., Stanford Medical School, California
Owen, David G., Ph.D., National Institutes of Health, Bethesda, Maryland
Radvanyi, Francois, Institut Pasteur, Paris, France
Smith, Kirk E., B.S., University of Florida, Gainesville
Ueno, Ryuji, M.D., Kyoto University, Japan
Ways, Nancy R., B.A., Stanford University, California
SEMINARS
McMahan, U.J., Stanford University School of Medicine. Structure of the nervous system: The
neuromuscular junction; structure of central synapses.
Rahamimoff, R., Hebrew University, Hadassah Medical School. Principles of signaling in the nervous
system; Transport across membranes: Forces and Fluxes; Determinants of the membrane
potential; Resting potential: Passive and active mechanisms; Generation of the action potential;
Cable properties of nerve and the conduction of the action potential; Ionic basis of the action
potential: 1) the currents, 2) the conductances and the Hodgkin-Huxley model.
Yoshikami, Doju, University of Utah. The excitatory post-synaptic response.
-. Ionic basis of the excitatory post-synaptic response.
-. Visualization of synaptic activity of neurons by autoradiography.
McMahan, U.J., Stanford University. Localization of acetylcholine receptors at the neuromuscular
junction.
-. Localization of acetylcholinesterase at the neuromuscular junction.
Yoshikami, D., University of Utah. Ionic basis of synaptic inhibition.
Goodenough, D., Harvard Medical School. Cell biology of gap junctions.
. Structure of gap junctions.
Bennett, M., Albert Einstein College of Medicine. Coupling between cells.
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. The role of Fl+ ions and calcium in coupling and uncoupling of cells.
McKay, R., Cold Spring Harbor Laboratory. Principles of neuro-immunology.
Hockfield, S., Cold Spring Harbor Laboratory. Immunology of the cat spinal cord.
McMahan, U.J., Stanford University School of Medicine. Vesicle hypothesis.
Rahamimoff, R., Hebrew University, Hadassah Medical School. Quantal transmitter release.
. Frequency modulation of transmitter release.
-. The role of calcium ions in transmitter release.
. Slow regulation of transmitter release.
. The role of the sodium calcium exchanger in transmitter release at the neuromuscular junction.
Yoshikami, D., University of Utah. Fate of acetylcholine released from the nerve.
. Number of acetylcholine molecules in a quantum.
Stevens, C., Yale University School of Medicine. Principles of single-channel recording.
Yoshikami, D., University of Utah. Slow synaptic potentials.
Stevens, C., Yale University School of Medicine. Fluctuation analysis of the acetylcholine post synaptic
response.
Dionne, V., University of California, San Diego. Kinetics of the acetylcholine channel.
Kado, R., CNRS. Voltage induced membrane conductance changes in crayfish and tunicate oocyte.
Stevens, C., Yale University School of Medicine. Molecular basis for endplate current time course and its
voltage sensitivity.
. Reverse voltage dependence of response amplitudes for nerve released and ontophorectically ap-
plied ACh.
Ohmori, H., Tokyo University. Properties of Ca" channels in CH cells-evidence from whole cell
voltage clamp and single channel recording.
Palatta, B., University of Miami. Studies of Ca" activated K channels using the single channel recording
method.
Lindstrom, J., Salk Institute. Structure and biosynthesis of acetycholine receptors.
. Myasthenia gravis, EAMG and the use of monoclonal antibodies to study acetylcholine receptors.
Rotundo, R., Carnegie Institution of Washington. Structure and function of the acetylcholine estarase.
. Synthesis and assembly of acetylcholine estarase molecules.
Black, I., Cornell University. The catecholamine synapse.
. Postnatal development of the catecholamine synapse.
. Target regulation of the catecholamine system.
. Catecholamine embryogenesis-phenotypic expression.
. Catecholamine-neuropeptide relations.
Adams, P., State University of New York, Stony Brook. Slow synaptic potentials in the frog autonomic
ganglia: The properties of the Mcurrent.
Black, I. Cornell University. Pathophysiology of the catecholaminergic synapse: Parkinsonism,
hyperkinetic disorder, idiopathis orthostatic hypotension.
Jan, L., University of California, San Francisco. Methodology for the study of the role of peptides in the
nervous system: Eukephalin and substance P.
. Peptidergic transmission in autonomic ganglia.
Yellen, G., Yale University. The calcium channels in heart dissociated muscle cells.
Herbert, E., University of Oregon. Neuroactive peptides: Protein processing and secretion.
. Neuroactive peptides: Use of recombinant DNA and molecular biology techniques to study pep-
tide gene expression.
Landmesser, L., Yale University. Development of the motor pattern to muscle: Possible errors in connec-
tion and mechanism of removal.
. Pathway selection in contributing to appropriate connectivity.
Purves, D., Washington University. Specificity of neuronal connections: Qualitative aspects.
. Specificity of Neuronal connections: Quantitative aspects.
Patterson, P., Harvard Medical School. Migration of neural crest cells: Effects of European lineage and of
American influence of environment.
. External factors in determination of self in autonomic nervous system.
Rubin, L., Rockefeller University. Early events in nerve muscle synapse formation.
Regulation of acetylcholine receptor and acetylcholine esterase appearance at newly formed
synapses.
McMahan, U.J., Stanford University School of Medicine. Sequence of steps in muscle denervation and
reinnervation.
. Factors that influence regeneration of the neuromuscular junction.
Frank, E., Harvard Medical School. Structure and functional specificity of spinal sensory-motoneuronal
synapses.
Quantal transmission at spinal sensory motoneuronal synapses.
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Greenberg, A., State University of New York, Stony Brook. Development of AChR single channel proper-
ties in non-innervated embryonic Xenopus muscle.
Hudspeth, A.J., California Institute of Technology. Structure and connection of the retina.
. Cell biology of photoreceptor cells.
Kehoe, J.S., Ecole Normale Superieure. Diminution of membrane conductance by synaptic actions.Hudspeth, A.J., California Institute of Technology. Photochemistry and extracellular signals ofphotoreceptors.
Corye, D., Yale Medical School. Intracellular signals of photoreceptors.
Intermediate messengers in photoreceptors.
Hudspeth, A.J., California Institute of Technology. Structure and operation of the inner ear.
Stefani, E., Instituto Politesnico Nacional, Mexico City. Calcium channels in muscle membrane.
Corey, D., Yale Medical School. Responses of hair cells to hair-bundel defection.
. Ionic basis and kinetics of the hair-cell response.
Hudspeth, A.J., California Institute of Technology. Membrane conductancesand frequency tuning in hair
cells.
Electrophysiological Methods, joy 29-August 17
INSTRUCTORS
Kehoe, JacSue, Ph.D., Ecole Normale Superieure, Paris, France
Chiarandini, Dante, M.D., New York University, New York
Stefani, Enrique, M.D., Instituto Politecnico Nacional, Mexico City, Mexico
GUEST LECTURER
Kado, Ray, Ph.D., CNRS, France
This laboratory course focused on methods of introducing biologically active macromolecules into living
cells. Emphasis was placed on transferring DNA into cultured cells by transfection and by nuclear injection
using glass micropipettes. Laboratory exercises included (1) transfection of DNA containing viral and
cellular transforming genes; (2) microinjection and transfection of DNAscontaining selectable biochemical
markers; (3) introduction of proteins into cells by fusion with loaded red cell ghosts and liposomes.
These exercises were supplemented with group discussion and lectures by invited speakers who con-
sidered the application of these methods to the isolation and functional characterizationof structural genes
and their regulatory sequences, evaluation of in vitro mutagenesis, and analysis of the biological activity ofproteins and messenger RNAs.
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PARTICIPANTS
Duerr, Janet S., M.S., Princeton University, New Jersey
Fung, Sek-chung, M.S., University Laboratory of Physiology, Oxford, England
Holt, Christine E., Ph.D., University of California, San Diego
Luini, Alberto, M.D., Weizmann Institute, Rehovot, Israel
Malenka, Robert C., B.A., Stanford University, California
Moody-Corbett, Frances, Ph.D., Harvard Medical School, Boston, Massachusetts
Muller, Dominique, M.D., University of Geneva, Switzerland
Sonderegger, Peter, M.D., National Institutes of Health, Bethesda, Maryland
Storm, Johan, M.D., University of Oslo, Norway
Weiner, Joseph S., B.A., New York University, New York
Yeast Genetics, July 28-August 17
INSTRUCTORS
Sherman, Fred, Ph.D., University of Rochester, New York
Fink, Gerald, Ph.D., Cornell University, Ithaca, New York
Hicks, James, Ph.D., Cold Spring Harbor Laboratory, New York
ASSISTANT
Laiken, Robert, B.A., University of Rochester, New York
The major laboratory techniques used in the genetic analysis of yeast were studied, including the isolation
and characterization of chromosomal and mitochondria! mutants, tetrad analysis, chromosomal mapping,
mitotic recombination, and test of allelism and complementation. Micromanipulation used in tetrad
analysis were carried out by all students. Recombinant DNA techniques, including yeast transformation,
filter hydridization, and gel electrophoresis were applied to cloning and genetic analysis of yeast DNA. Lec-
tures on fundamental aspects of yeast genetics were presented along with seminars given by outside
speakers on topics of current interest.
PARTICIPANTS
Berman, Judith G., B.S., Weizmann Institute, Rehovot, Israel
Chakraburtty, Kalpana, Ph.D., Medical College of Wisconsin, Madison
Couto, Fernando, B.S., Massachusetts Institute of Technology, Cambridge
Hall, Barry G., Ph.D., University of Connecticut, Storrs
Margolin, Paul, Ph.D., Public Health Research Institute, Bethesda, Maryland
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Peebles, Craig L., Ph.D., University of Pittsburgh, Pennsylvania
Poso, Hannu J., Ph.D., State Alcohol Monopoly, Helsinki, Finland
Rosbash, Michael M., Ph.D., Brandeis University, Waltham, Massachusetts
Sancar, Gwendolyn B., Ph.D., Yale University, New Haven, Connecticut
Segall, Jacqueline M., Ph.D., University of Toronto, Canada
Silver, Pamela A., Ph.D., University of California, Los Angeles
Sugino, Akio, Ph.D., National Institutes of Health, Bethesda, Maryland
Tittawella, Ivor, Ph.D., University of Goteborg, Sweden
Witkin, Evelyn M., Ph.D., Rutgers University, New Brunswick, New Jersey
Yang, Elizabeth W., M.S., Stanford University, California
Zoller, Mark J., Ph.D., University of British Columbia, Vancouver, Canada
SEMINARS
Dutcher, S.K., Rockefeller University. Genetic analysis of the cell division cycle.
Botstein, D., Massachusetts Institute of Technology. Cloning of yeast genes.
Hicks, J., Cold Spring Harbor Laboratory. Regulation of mating type.
Broach, J., State University of New York, Stony Brook. Yeast plasmid 2 Am circle.
Sherman, F., University of Rochester. Evolution and regulation of iso-cytochromes c.
Warner, J., Albert Einstein College of Medicine. Yeast ribosomal protein genes and their regulation.
Guthrie, C., University of California, San Francisco. Genetics and biochemistry RNA biosynthesis in
yeast.
Szostak, J., Sidney Farber Cancer Institute. Structure and function of telomeres.
Hereford, L., Brandeis University. Regulation of histone gene expression.
Fink, G., Cornell University. Transposable elements and reiterated sequences.
Petes, T., University of Chicago. Genetic interactions among repeated yeast genes.
Klar, A., Cold Spring Harbor Laboratory. Mechanism of cell type switching in yeast.
Fox, T., Cornell University. Mitochondria! genetic codes.
Strathern, J., Cold Spring Harbor Laboratory. Mechanism of cell type switching in yeast (/1).
Grunstein, M., University of California, Los Angeles. Genetic approach to histone function.
Esposito, R., University of Chicago. Defining genes controlling meiotic exchange and segregation.
Bloom, K., University of California, Santa Barbara. The structure of yeast centromere.
Introduction of Macromolecules into Mammalian Cells
July 28-August 17
INSTRUCTORS
Capecchi, Mario, Ph.D., University of Utah, Salt Lake City
Mulligan, Richard, Ph.D., Massachusetts Institute of Technology, Cambridge
ASSISTANTS
Fraser, Laurie, B.S., University of Utah, Salt Lake City
Mann, Richard, Massachusetts Institute of Technology, Cambridge
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This laboratory course focused on methods of introducing biologically active macromolecules into living
cells. Emphasis was placed on transferring DNA into cultured mammalian cells by transfection, viral infec-
tion and microinjection. Laboratory exercises included:
Use of retrovirus vectors for the study of expression and transformation, transfection, and microinjection
of DNA containing selectable biochemical markers into cultured mammalian cells, introduction of proteins
into cells by fusion with loaded red cell ghosts, and introduction of DNA into plant cells using liposomes.
These exercises were supplemented with group discussions and lectures by invited speakers who con-
sidered the application of these methods to problems in cellular and developmental biology.
PARTICIPANTS
Avivi, Abraham, Ph.D., Weizmann Institute, Rehovot, Israel
Baldacci, Patricia A., M.S., Institut Pasteur, Paris, France
Beckingham, Kathleen M., Ph.D., Rice University, Houston, Texas
Brennand, John, Ph.D., Baylor College of Medicine, Houston, Texas
Clegg, Christopher H., B.A., University of Washington, Seattle
Daubas, Philippe, Ph.D., Pasteur Institute, Paris, France
Flores-Menendez, Carlos, Ph.D., University of El Salvador, San Salvador
Gottlieb, Ellen, B.A., Yale University, New Haven, Connecticut
Kondor-Koch, Claudia, Ph.D., EMBO, Heidelberg, Federal Republic of Germany
Lupski, James R., B.A., New York University, New York
Korman, Allen, Harvard University, Cambridge, Massachusetts
Nagamine, Yoshikuni, Rockefeller University, New York, New York
Post, Leonard E., Ph.D., Upjohn Company, Kalamazoo, Michigan
Seiler, Anne F., Ph.D., National Cancer Institute, Bethesda, Maryland
Steinmetz, Michael, Ph.D., California Institute of Technology, Pasadena
Tramontano, Donatella, M.D., University of Naples, Italy
SEMINARS
McKnight, S., Fred Hutchinson Cancer Research Center. Transcription control signals of a constituitively
expressed eukaryotic protein-coding gene.
Botchan, M., University of California, Berkeley. Enhancer sequences of 5V40 and BPV.
Axel, R., Columbia University. Expression and regulation of cloned genes introduced into mammalian
cells via DNA transformation.
Maniatis, T., Harvard University. The expression of normal and abnormal globingenes in cells in culture.
Gluzman, Y., Cold Spring Harbor Laboratory. Helper independent adeno vectors.
Gething, M.J., Cold Spring Harbor Laboratory. Expression of the influenza hemagglutinate protein in
mammalian cells.
Hager, G., National Cancer Institute. Characterization of the hormone-inducible promoter of MMTV.
Howley, P., National Cancer Institute. BPV as a cell replicating eukaryotic vector.
Szostak, J., Sidney Farber Cancer Institute. On the mechanism of recombination in yeast.
Bishop, M., University of California, San Francisco. Retroviruses and cancer.
Rechsteiner, M., University of Utah. On the mechanism of protein degradation in cultured mammalian
cells.
DiMaio, D., Harvard University. BPV vectors.
Khoury, G., National Cancer Institute. On the mechanism of SV40 enhancer sequences.
Sorge, J., Cold Spring Harbor Laboratory. Retroviruses as a eukaryotic vector.
Wigler, M., Cold Spring Harbor Laboratory. Human transforming genes.
Ruddle, F., Yale University. Introduction of new genetic information into the germ line of mice.
Rubin, G., Carnegie Institution of Washington. P elements as transformation vectors in Drosophila.
Molecular Approaches to the Nervous System, August 9-August 15
INSTRUCTORS
Brockes, Jeremy, California Institute of Technology, Pasadena
McKay, Ronald, Cold Spring Harbor Laboratory, New York
Lecturers in the course considered a variety of topics in cellular and molecular neurobiology. These includ-
ed fundamental studies on receptors and in channels, the diversity and lineages of cell types in the nervous
system, and the molecular organization of synapses and possible mechanisms involved in synaptic
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specificity. A particular focus was the application of recombinant DNA methodology and monoclonal an-
tibodies to these and other issues. This included studies on gene expression in the vertebrate CNS, the
genetic organization of peptides, and recent progress in cloning genes for the subunits of the acetylcholine
receptor. Monoclonal antibodies were considered as probes for extracellular and intracellular components
at the neuromuscular junction and other synapses, as labels for discrete classes of neurons or neuronal pro-
cesses in vertebrate and invertebrate nervous systems, and as markers for morphogenetic patterns such as
gradients. The continued application of these techniques clearly promises to have considerable impact in
molecular neurobiology.
PARTICIPANTS
Bernhardt, Robert, M.S., Friedrich Miescher Institute, Tubingen, Federal Republic of Germany
Botticelli, Lawrence J., Ph.D., Stanford Medical School, California
Buonanno, Andres L., M.S., IVIC, Caracas, Venezuela
Early, Philip, Ph.D., University of California, Berkeley
Flaster, Murray S., Ph.D., Cold Spring Harbor Laboratory, New York
Fukada, Keiko, Ph.D., Harvard Medical School, Cambridge, Massachusetts
Johnson, Carl D., Ph.D., University of Wisconsin, Madison
Kanazir, Selma D., M.S., Yale University, New Haven, Connecticut
Lo, Mathew, MS., Ph.D., Johns Hopkins University, Baltimore, Maryland
Macagno, Eduardo R., Ph.D., Columbia University, New York, New York
O'Donohue, Thomas L., Ph.D., National Institutes of Health, Bethesda, Maryland
Sommer, Ernst W., Ph.D., Columbia University, New York, New York
Zipursky, Stephen, Ph.D., California Institute of Technology, Pasadena
SEMINARS
Fundamental Studies on Receptors and Channels
Stevens, C.F., Yale University
Karlin, A., Columbia University
Davidson, N., California Institute of Technology
Balivet, M., Salk Institute
Heinemann, S., Salk Institute
Catteral, W., University of Washington Medical School
Schwartz, J., Columbia University of Physicians and Surgeons
Spitzer, N.C., University of California
Goldin, S., Harvard Medical School
Genetic Organization of Neuropeptides
Roberts, J., Columbia University College of Physicians and Surgeons
Scheller, R., Columbia University College of Physicians and Surgeons
Specificity and Heterogeneity in the Nervous System
Zipser, B., Cold Spring Harbor Laboratory
Nirenberg, M., National Institutes of Health
Karten, H.J., State University of New York, Stony Brook
Hockfield, S., Cold Spring Harbor Laboratory
Jessel, T., Harvard Medical School
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General Features of Gene Expression in the Vertebrate CNS
Hahn, W.E., University of Colorado Medical Center
Sutcliffe, G., Scripps Clinic
The Neuromuscular Junction
Burden, S., Harvard Medical School
Fambrough, D.M., Carnegie institution of Washington
Sanes, J., Washington University
Rubin, L., Rockefeller University
Anderson, D., Rockefeller University
Mechanisms of Steroid Function
Kurtz, D., Cold Spring Harbor Laboratory
De Vellis, J., University of California
Gurney, M., University of Chicago Medical School
Neural Lineages
Horvitz, R., Massachusetts Institute of Technology
Goodman, C., Stanford University
Patterson, P., Harvard Medical School
Raff, Martin, University College London
Growth Factors
Gurney, M., University of Chicago Medical School
Patterson, P., Harvard Medical School
Villa-Komarov, L., University of Massachusetts
Axonal Extension and Guidance
Lasek, R.J., Case Western Reserve University
Reichardt, L., University of California
Rutishauser, U., Rockefeller University
Goodman, C., Stanford University
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UNDERGRADUATE SUMMER
RESEARCH PROGRAM
An important aspect of the summer program at the Laboratory is the participation of college undergraduate
students in active research projects under the supervision of full-time laboratory staff members. The pro-
gram was initiated in 1959. Since that year, 239 students have completed the course, and many have gone
on to creative careers in biological science.
The objectives of the program are to provide (1) a greater understanding of the fundamental principles of
biology, (2) an increased awareness of major problem areas under investigation, (3) better understanding of
the physical and intellectual tools for modern research and the pertinence of this information to future train-
ing, and (4) a personal acquaintance with research, research workers, and centers for study.
The following students, selected from a large number of applicants, took part in the program, which was
supported by The Camille and Henry Dreyfus Foundation, Inc. They are listed below with their laboratory
sponsors and topics of research.
Tania Ann Baker, University of Wisconsin
Research Advisor: A.I. Bukhari
David Campanelli, Wesleyan University
Research Advisor: L. Chow
Brad Cookson, University of Utah
Research Advisor: M. Wig ler
Andrew Gray, Princeton University
Research Advisor: P. Thomas
Jill Heemskerk, University of California, Berkeley
Research Advisor: M. So
Eva Nozik, University of Colorado
Research Advisor: D. Kurtz
Philip Starr, Princeton University
Research Advisor: T. Gingeras
Nick Theodorakis, Washington University
Research Advisor: J. Feramisco
Peter Weinstein, University of Michigan
Research Advisor: L. Silver
Olney Fellow
Kenneth Howard, University of Cambridge
Research Advisor: J. Fiddes
Cloning of the Mu A gene
Gene expression of human papilloma virus type 1
Construction of a transforming gene under control of
a metallothionein promoter
Genomic clones of human heat shock genes
DNA rearrangement and pathogenicity in
N. gonorrhoeae
Hormones and methylation patterns in gene
expression
Cloning bacterial restriction/modification genes
Analysis of structural proteins in non-muscle cells
Mapping of an MMTV provirus on mouse
chromosome 7
Aspects of expression of the multigene family for the
beta subunit of human chorionic gonadotropin
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IN-HOUSE SEMINARS
Cold Spring Harbor In-House Seminars were ini-
tiated to provide a semiformal avenue for com-
munication between the various research groups at
the laboratory. They are particularly useful for
research personnel who have joined the laboratory
during the summer. The seminars also afford a
necessary opportunity for the graduate students and
post-graduate staff to develop their skills in defend-
ing, organizing, and presenting their research. In ad-
dition to those listed below, seminars were given by
many others involved in research at this laboratory.
1981-1982
Lee Silver
October
Lindley C. Blair, University of California, Berkeley: Processing and secretion of yeast sex factors.
Roberto Weinmann, Wistar Institute, Philadelphia, Pennsylvania: Mechanism of initiation of transcrip-
tion by RNA polymerase II.
November
Seymour Fogel, University of California, Berkeley: Repetitive DNA and its relationship to metal
resistance in yeast.
Martin Marinus, University of Massachusetts Medical Center, Amherst: The deoxyadenosine methylase
(dam) function of E. coll.
Nancy Hoag, Imperial Cancer Research Fund, London, England: Human monocytes have a role in
coagulation.
Mary Jane Gething, Imperial Cancer Research Fund, London, England: Expression of a cloned copy of
the influenza hemagglutinin gene in prokaryotes and eukaryotes.
January
Janice Chow, National Institutes of Health, Bethesda, Maryland: Study of liver differentiation in vitro
with SV40 tsA mutant transformed cells.
Andrei Laszlo, Lawrence Berkeley Laboratory, Berkeley, California: Tumor promoter-induced alterations
in gene expression and protein phosphorylation in avian cells.
Jack Szostak, Sidney Farber Cancer Center, Boston, Massachusetts: The structure of the ends of
chromosomes-Analysis of cloned yeast telomeres.
Frank Stahl, University of Oregon, Eugene: Recombination in fungi.
Ihor Lemischky, Massachusetts Institute of Technology, Cambridge: The structure and evolution of rat
alpha-tubulin genes.
Mark Cochran, Queens University, Kingston, Canada: The molecular biology of baculoviruses.
February
Miercio Pereira, Tufts New England Medical Center, Boston, Massachusetts: Lectin receptors as tools for
studying the developmental stages of T. cruzi.
Judy White, Yale University, New Haven, Connecticut: Virus-mediated cell fusion.
David Anderson, Rockefeller University, New York, New York: Biosynthesis of acetylcholine receptors
in cell-free systems.
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March
Edward Wagner, University of California, Irvine: Overlapping mRNA families in herpes simplex virus
type I.
April
Mike Fried, Imperial Cancer Research Fund, London, England: The annual lecture on integration and ex-
pression of polyoma virus.
Lincoln T. Potter, University of Miami, Florida: Two populations of muscarine receptors.
Paolo Dotto, Rockefeller University, New York, New York: Functional dissection of the replication
origins of bacteriophage Fl.
Nick Proudfoot, University of Oxford, England: Structure and expression of normal and mutant
hemoglobin genes.
John Gordon, Yale University, New Haven, Connecticut: Gene transfer into mouse embryos.
David Ward, Yale University, New Haven, Connecticut: Immunological methods for in situ localization
of nucleic acids.
June
Mike Leffak, Wright State University, Dayton, Ohio: Chromatin assembly.
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NATURE STUDY PROGRAM
The Nature Study Program gives elementary and high school students the opportunity to acquire a greater
understanding of their environment. Through a series of specialized field courses, students can engage in
such introductory programs as Nature Detectives, Seashore Life, and Pebble Pups, as well as more ad-
vanced program programs such as Marine Biology, Nature Photography, and the Geology of Long Island.
During the summer of 1982 a new high total of 450 students participated in the Nature Study Program.
Most classes were held outdoors, when weather permitted, or at the Uplands Farm Nature Preserve of the
Long Island Chapter of the Nature Conservancy. The Laboratory has equipped and maintains a darkroom
and classroom-laboratories at Uplands Farm for the study of field specimens collected by the students. Field
classes are also held on Laboratory grounds, St. John's Preserve, Shu Swamp Preserve, Montauk Point State
Park, and in the Long Island pine barrens.
In addition to the four-week courses, a series of one-day marine biology workshops was offered to
students. Studies on the marine ocology of Long Island Sound were conducted aboard the 66-foot schooner
J.N. Carter chartered from Schooner, Inc. of New Haven, Connecticut. Students were able to study the
sound chemically, physically, and biologically using the ship's instrumentation. The three-day Adventure
Education class took children on an 18-mile bike hike to Caumsett State Park, a six-mile canoe trip on the
Nissequogue River, and a day of sailing on the J.W. Carter.
PROGRAM DIRECTOR
Edward Tronolone, M.S., P.D., Science Curriculum Associates, East Williston Public Schools
INSTRUCTORS
Kathryn Bott, M.S., science teacher, Friends Academy
Ruth Burgess, B.A., naturalist, Nassau County BOCES
Gail Claydon, B.S., teacher, United Methodist Church of Huntington, Cold Spring Harbor
Robert Jaeger, M.S., science teacher, Mineola High School
Fred Maasch, M.Ed., science teacher, Islip High School
Linda Payoski, B.A., naturalist, Nassau County BOCES
Debra Peters, B.S., naturalist, Nassau County BOCES
James Romansky, M.S., science teacher, Bay Shore High School
COURSES
Nature Bugs
Nature Detectives
Advanced Nature Study
Pebble Pups
Geology of Long Island
They Swim, Crawl, and Walk
Seashore Life
Marine Biology
Nature Photography I & II
Fresh Water Life
Frogs, Flippers, and Fins
Bird Study
Adventure Education
Marine Biology Workshop
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LABORATORY STAFF
DIRECTOR ADMINISTRATIVE ASSISTANT DIRECTOR DIRECTOR-
J.D. Watson DIRECTOR FOR RESEARCH BANBURY CENTER
William R. Udry Joseph Sambrook Michael Shodell
RESEARCH SCIENTISTS POSTDOCTORAL FELLOWS
Stephen Blose
Susan Bonitz
Thomas Broker
Ahmad Bukhari
Louise Chow
Fevzi Daldal
James Feramisco
John Fiddes
James Garrels
Mary-Jane Gething
Thomas Gingeras
Yakov Gluzman
Mitchell Goldfarb
Terri Grodzicker
Edward Harlow
Rasika Harshey
Fred Heffron
James Hicks
Susan Hockfield
Stephen Hughes
Amar Klar
David Kurtz
Jim Lin
Russell Malmberg
Michael Mathews
Fumio Matsumura
Ronald McKay
Richard Roberts
Mara Rossini
Lee Silver
Magdalene So
Bruce Stillman
Jeffrey Strathern
Fuyuhiko Tamanoi
William Topp
Michael Wig ler
Birgit Zipser
VISITING
SCIENTISTS
Jorgen Johansen
Yoshiki Katoh
Jin-Zhao Li
Pei-Mao Lin
Kenji Shimizu
Staff as of December 1982
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Judith Abraham
William Addison
David Beach
Ashok Bhagwat
Daniel Birnbaum
Janet Brandsma
Joan Brooks
Carolyn Deal
Stephen Dellaporta
Ottavio Fasano
Thomas Flanagan
Murray Flaster
Michele Francoeur
Robert Franza
Greg Freyer
Richard Guilfoyle
Mary Harper
David Helfman
William Huse
John Ivy
Tohru Kamata
Prasad Koka
Thomas Kost
Michael Krangel
Chao-Hung Lee
John Lewis
Janet Maclnnes
Catherine Monaghan
Michael Roth
Earl Ruley
Joseph Sorge
Yolande Suard
Olof Sundin
Karen Talmadge
Elizabeth Taparowsky
G. Paul Thomas
William Welch
Stuart Weisbrod
Masao Yamada
GRADUATE
STUDENTS
Carolyn Doyle
Douglas Hanahan
Margaret Kelly
Richard Kostricken
Michele Manos
Zarina Manzoor
Kent Matlack
Robert O'Malley
Nora Sarvetnick
Ellyn Segal
Carmella Stephens
Kevin Van Doren
RESEARCH ASSISTANTS
Barbara Ahrens
Elizabeth Billyard
Georgia Binns
Gladys Blose
Angela Ca lasso
Lynn Cascio
Terrance Chisum
Lois Cisek
Barbara Daniels
Deborah Danna
Mark Deluca
Dermody-Weisbrod
Anne Devine
Louise Edlund
Jane Emanuele
Deborah Foster
Cecilia Fraser
Rachel Galli
Laurel Garbarini
Nadia Gural
Nancy Haffner
Marie Hallaran
Christine Herrmann
Deborah Keller
Lynn Kleina
Elaine Kosik
Deborah Kwak
Patricia Lalik
Geraldine LoFranco
Diana Matkovich
Carolyn McGill
Robert McGuirk
Jean Mclndoo
Mary Merle
Doris Moll
Janet Monnier
Carolyn Moomaw
Phyllis Myers
Maureen O'Halloran
Diana O'Loane
Kathy O'Neill
Wendy Osheroff
Karen Pantina
Diana Pascucci
Anthony Pelletier
Gina Penzi
Doris Prudente
Stephen Raps
William Ricci
Michael Riggs
Linda Rodgers
Mary Ann Ruley
Jan Scal
Carol Schley
Patricia Smith
Deborah Taylor
Jane Uman
Linda Van der Wal
Bruce Vogel
Martin Walsh
Elizabeth Waldvogel
Margaret Wallace
Jeanne Wiggins
Jonathan Wood
ADMINISTRATIVE
AND GENERAL STAFF
Charlaine Apsel
Deon Baker
Guy Cozza
Sandra D'Arcangelo
Joan Doherty
Ann Felten
Douglas Gensel
Patrick Hickey
Eric Kaufman
William Keen
Stephen Kron
Patricia Kurfess
Dorrine Lonardo
John Maroney
Carlos Mendez
David Mick los
Neil Penn
June Polistina
James Sabin
Roberta Salant
Susan Schultz
Martin Spiegel
Jacqueline Terrence
Barbara Terry
GENETICS RESEARCH UNIT
CARNEGIE INSTITUTION
OF WASHINGTON
Alfred D. Hershey
Barbara McClintock
SUPPORTING STAFF
Michael Balamuth
Deborah Balke
Patricia Barkley
Maureen Berejka
Robert Borruso
Arthur Brings
Louisa Dalessandro
Joanne Dellaporta
August Dulis
Marilyn Goodwin
Catherine Jackson
Christopher Keller
Gladys Kist
Eric Lockhart
Deborah Lukralle
Raymond Mickus
Patrick Nevins
Michael Ockler
Constance Parra
Patricia Pugliese
Herb Parsons
Philip Renna
Marlene Rubino
Regina Schwarz
Lorine Seyffarth
Andrea Stephenson
Clifford Sutkevich
Madeline Szadkowski
Barbara Ward
PUBLICATIONS
DEPARTMENT
Dorothy Brown
Elizabeth Cattaneo
Michaela Cooney
Judith Cuddihy
Nadine Dumser
Nancy Ford
Annette Kirk
Douglas Owen
Elizabeth Ritcey
Karen Sundin
LIBRARY STAFF/
MARKETING
Carol Aznakian
Jennifer Carri
Ellen DeWeerdt
Cynthia Elwell
Genemary Falvey
Elaine Gaveglia
Susan Gensel
Amy Gibson
David Gibson
Karen Herrmann
Laura Hyman
Colleen Lanahan
Ronald Letta
Audrey Powers
BUILDINGS AND
GROUNDS DEPARTMENT
John Bach
Joseph Brodawchuk
Carol Caldarelli
Joseph Canner
Vincent Carey
Ronald Chambers
Barbara Cuff
Warren Eddy
Joseph Ellis
Bruce Fahlbusch
Willie Gardner
Louis Gruebel
Douglas Haskett
Mary Hill
Thomas Lyden
Charles Marshall
Christopher McEvoy
John Meyer
Alfred Nickel
Dirk Peterson
Alfred Pfeiffer
Joseph Pirnak
Gerald Reichert
Peter Rice
Jack Richards
Donald Rose
Diamond Scarduzio
Charles Schneider
Lane Smith
Peter Stahl
Owen Stewart
Mark Strazay
Patrick Sullivan
Peter Tierney
Hans Trede
Archibald Walker
Dorothy Youngs
BANBURY CENTER
Christine Dacier
Katya Davey
Margaret McEvoy
Lynda Moran
Beatrice Toliver
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First row: T. Lyden, J. Meyer; M. Balamuth, I. Dellaporta; W. Keen; C. Mendez, P. Kurfess, S. Kron
Second row: D. Lonardo; D. Gensel, S. Gensel; J.D. Watson, E. Watson; L. Moran, M. Shodell, B. To liver
Third row: D. Mick los, R. Wilson; C. Keller, L. Dalessandro; C. Schneider, B. Cuff; N. Ford, D. Brown, E. Cattaneo,
E. Ritcey
Fourth row: S. D'Arcangelo, A. Felten; M. Goodwin, P. Barkley; M. Berejka, M. Simkins, B. Ward, G. Kist; D. Baker,
B. Terry
First row: A. Brings; E. Kaufman, J. Maroney; M. Szadowski; L. Gruebel
Second row: J. Pirnak; J. Terrence; D. Owen; 0. Stewart; G. Cozza
Third row: A. Kirk, N. Dumser, K. Sundin, M. Cooney, J. Cuddihy; H. Parsons; L. Hyman, K. Herrmann, G. Falvey,
E. Deweerdt, A. Gibson, E. Gaveglia, A. Powers
Fourth row: M. Speigel; J. Doherty; J. Sabin; R. Sa lant; A. Stephenson
FINANCIAL SUPPORT
OF THE LABORATORY
The Cold Spring Harbor Laboratory is a publicly supported educational institution chartered by the Univer-
sity of the State of New York and may receive contributions which are tax exempt under the provisions of
the Internal Revenue Code, particularly Section 501C. In addition, the Laboratory has been formally
designated a "public charity" by the Internal Revenue Service. Accordingly, it is an acceptable recipient of
funds which would result from the termination of "private" foundations.
The Laboratory depends upon the generous contributions of its sponsors, participating institutions, and
friends for central institutional needs and capital improvements. In addition, the development of any new
programs, such as year-round research in neurobiology or the marine sciences, can be undertaken only
with substantial support from private sources.
Methods of Contributing to Cold Spring Harbor Laboratory
Gifts of money can be made directly to Cold Spring Harbor Laboratory.
Securities
You can generally deduct the full amount of the gift on your income tax return, if the appreciation
would have been a long-term gain, to the extent of 50% of your adjusted gross income and you need
pay no capital gains tax on the stock's appreciation.
We recommend either of the following methods:
(1) Deliver the stock certificates to your broker with instructions to him to open an account for Cold
Spring Harbor Laboratory and hold the securities in that account pending instructions from Cold
Spring Harbor Laboratory.
(2) Send the unendorsed stock certificates directly to the Laboratory: Comptroller, Cold Spring
Harbor Laboratory, Box 100, Cold Spring Harbor, New York 11724. In a separate envelope send
an executed stock power.
Bequests
Probably most wills need to be updated. Designating Cold Spring Harbor Laboratory as beneficiary en-
sures that a bequest will be utilized as specified for continuing good.
Appreciated real estate or personal property
Sizable tax benefits can result from such donations; the Laboratory can use some in its program and
can sell others.
Life insurance and charitable remainder trusts can be structured to suit the donor's specific desires as to ex-
tent, timing, and tax needs.
Conversion of private foundation to "public" status on termination
This may be done by creating a separate fund within Cold Spring Harbor Laboratory whereby the
assets of the private foundation could be accounted for as a separate fund and used for the purposes
specified by the donor. Alternatively, the private foundation can be established as a "supporting
organization of Cold Spring Harbor Laboratory."
For additional information, please contact the Administrative Director, Cold Spring Harbor Laboratory,
Box 100, Cold Spring Harbor, N.Y. 11724, or call 516-367-8300.
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CONTRIBUTORS
to the Cold Spring Harbor Laboratory
Dr. Bruce Alberts
Ande, Inc.
Mr. & Mrs. C.V. Angadi
Mr. & Mrs. E. Bench
Biogen, S.A.
Bristol-Myers Fund
Mr. & Mrs. S.R. Callaway
Patricia Casentini
Cetus Corp.
Chevron Fund
Dr. Bayard Clarkson
Columbia University
Conoco, Inc.
Cunningham Family
Dr. Bernard Davis
Mr. & Mrs. Charles F. Dolan
Dow Chemical Co.
Dr. Lester Dubnick
Duke University
E.I. du Pont de Nemours & Co.
Eli Lilly and Co.
Exxon Corp.
Exxon Research & Engineering Co.
Walter N. Frank, Jr.
Getty Oil Co.
Dr. & Mrs. H. Bentley Glass
Glenmede Trust Co.
Dr. & Mrs. Richard L. Golden
Grace Foundation, Inc.
Oliver R. Grace Charitable Trust
Dr. Alfred D. Hershey
Dr. Ira Herskowitz
Hoffman-La Roche, Inc.
Dr. Alexander Hollaender
Laura J. Ingraham
International Business Machine Corp.
Antonio Jimenez
Arthur Landy
Mr. & Mrs. Richard Leckerling
Mr. & Mrs. George Lindsay
Mr. & Mrs. Robert V. Lindsay
Mrs. V.S. Littauer
Mr. & Mrs. Michael Luckey
Massachusetts Institute of Technology
Leila McKnight
Merck Sharp & Dohme Research Laboratories
Arthur Merrill
Mrs. Anges Meyer & Family
Miles Laboratory
Morgan Guaranty Trust
R.V. Myers
New York Life Foundation
New York University Medical Center
Linda Peyton
Mr. & Mrs. Michael G. Pfeifer
Pamela P. Post
Rockwell International Corp. Trust
Marjorie Robertson Rose
Schering-Plough Corp.
Dr. T. Schopf
Searle Research and Development
Dr. & Mrs. W. Shropshire, Jr.
Dr. & Mrs. Robert Smirnow
Squibb Institute for Medical Research
Dr. A.R. Srinivasan
Stauffer Chemical Co.
Mr. & Mrs. Stuart Symington
Mrs. Robert W. Tilney, Jr.
University of Wisconsin
Upjohn Co.
Mr. & Mrs. Colton P. Wagner
Mr. & Mrs. Kenneth Wagner
Robert A. Weisberg
Yale University
Yeshiva University
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FINANCIAL STATEMENT
BALANCE SHEET
year ended December 31, 1982
with comparative figures for year ended December 31, 1981
ASSETS
CURRENT FUNDS
Unrestricted
1982 1981
LIABILITIES AND
CURRENT FUNDS
Unrestricted
FUND BALANCES
1982 1981
Cash and Short-term investments $ 2,658,863 $ 1,062,039 Accounts payable $ 171,326 $ 438,074
Accounts Receivable 464,261 267,888 Mortgage payable 33,300 66,600
Prepaid expenses and other assets 258,587 349,506 Due to plant fund 961,628 30,850
Inventory of books 203,899 131,461 Due to restricted fund - 110,702
Due from restricted fund 286,290 Fund balance 2,990,276 1,311,041
Due from Banbury Center 284,630 146,373 Total unrestricted 4,156,530 1,957,267
Total unrestricted 4,156,530 1,957,267
Restricted
Restricted Due to unrestricted fund 286,290 -
Grants and contracts receivable 4,615,780 2,845,237 Fund balance 4,329,490 2,955,939
Due from unrestricted fund 110,702
Total restricted 4,615,780 2,955,939 Total restricted 4,615,780 2,955,939
Total current funds $ 8,772,310 4,913,206 Total current funds $ 8,772,310 $ 4,913,206
ENDOWMENT FUNDS
Robertson Research Fund
Cash 508,041 395,840
Marketable securities
(quoted market 1982-$13,987,572;
1981-$11,111,405) 11,585,922 10,507,785
Total Robertson Research Fund 12,093,963 10,903,625
Olney Memorial Fund
Cash 1,420 90-
Marketable Securities
(quoted market 1982-$23,284;
1981-$20,355) 27,538 27,538
Total Olney Memorial Fund 28,958 27628
Total endowment funds $ 12,122,921 $ 10,931,253 Fund balance $ 12,122,921 $ 10,931,253
PLANT FUNDS PLANT FUNDS
Investments $ 461,239 $ 517,021
Due from unrestricted fund 961,628 30,850
Land and improvements 1,111,213 966,110
Buildings 7,307,583 6,513,210
Furniture, fixtures and equipment 1,647,248 1,408,503
Books and periodicals 365,630 365,630
Construction in progress 727,245 585,779
12,581,786 10,387,103
Less allowance for depreciation
and amortization 3,371,273 2,865,421
Total plant funds $ 9,210,513 $ 7,521,682 Fund balance $ 9,210,513 $ 7,521,682
BANBURY CENTER BANBURY CENTER
Current funds Current funds
Unrestricted Unrestricted
Cash $ 700 $ 700 Accounts payable $ 11,376 $ 85,406
Prepaid and deferred expenses 70,001 8,101 Due to CSHL unrestricted fund 284,630 146,373
Inventory of books 25,777 47,419 Fund balance (163,529) (133,245)
Due from Banbury restricted fund 35,999 42,314 Total unrestricted 132,477 98,534
Total unrestricted 132,477 98,534 Restricted
Due to Banbury unrestricted 35,999 42,314
Restricted Fund balance 55,047 71,126
Grants and contracts receivable 91,046 113,440 Total restricted 91,046 113,440
Total restricted 91,046 113,440 Total current funds 223,523 211,974
Total current funds 223,523 211,974
Endowment Funds Endowment funds
Robertson Maintenance Fund
Cash 89,768 21,660
Marketable securities
(quoted market 1982-
$2,385,039; 1981-$1,937,629) 1,971,628 1,882,356
co
r, Plant funds Plant funds
m Land $ 772,500 $ 772,500
Buildings 846,028 792,757
Furniture, fixtures and equipment 176,284 176,285
Construction in progress 1,386 1,386
1,796,198 1,742,928
Less allowance for depreciation 275,311 221,356
Total plant funds 1,520,887 1,521,572 Plant funds balance 1,520,887 1,521,572
Total Banbury Center $ 3,805,806 $ 3,637,562 Total Banbury Center $ 3,805,806 3,637,562
Total-All funds $33,911,550 $27,003,703 Total-All funds $33,911,550 $27,003,703
CURRENT REVENUES, EXPENSES AND TRANSFERS
year ended December 31, 1982
with comparative figures for year ended December 31, 1981
COLD SPRING HARBOR
REVENUES
LABORATORY
1982 1981
BANBURY CENTER
REVENUES
1982 1981
Grants and contracts $ 7,689,982 $ 5,691,966 Endowment income $ 99,000 $ 90,000
Indirect cost allowances on grants and Grants & contributions 288,226 277,003
contracts 3,381,795 2,402,569 Indirect cost allowances on
Contributions grants and contracts 19,880 -
Unrestricted 30,682 51,273 Rooms and apartments 46,353 40,196
Restricted and capital 225,000 33,367 Publications 136,391 139,455
Long Island Biological Association 46,500 - Conference fees 20,375 -
Robertson Research Fund Distribution 453,000 412,000 Dining hall 6,484 -
Summer programs 433,188 363,967 Transfer from Cold
Laboratory rental 20,732 20,732 Spring Harbor Laboratory 60,264
Marina rental 53,192 48,401 Total revenues 616,709 606,918Investment income 376,587 266,752
Publications sales 1,650,263 838,687
Dining Hall 469,196 387,436
Rooms and apartments 269,061 235,798 EXPENSES
Other sources 12,347 26,211 Conferences 151,631 118,715
Publications 168,011 182,079$15,111,525 $10,779,148Total revenues Operation and maintenance of plant 109,474 109,199
Program administration 163,312 183,610
EXPENSES Depreciation 53,954 48,537
Research* 5,716,197 4,616,825 Capital plant 53,271 13,315
Summer programs* 759,832 747,519 Total expenditures 699,653 655,455Library 191,344 182,990
Operation and maintenance of plant 1,719,729 1,378,817 Excess (deficit) of
General and Administrative 1,409,112 1,100,037 revenues over expenses $ (82,944) $ (48,537)
Depreciation 505,252 475,136
Publications sales* 1,132,856 655,911
Dining hall* 508,560 425,887
Total expenses $11,942,882 $ 9,583,122
va TRANSFERS
,oo Capital building projects 2,003,518 1,115,471
Banbury Center - 60,264
Total transfers 2,003,518 1,175,735
Total expenses and transfers 13,946,400 10,758,857
Excess (deficit) of revenues
over expenses and transfers $ 1,165,125 20,291
*Reported exclusive of an allocation for operation and maintenance of plant, general
and administrative, library, and depreciation expenses.
Note: Copies of our complete, audited financial statements, certified by our independent auditors, Peat, Marwick, Mitchell & Co., are available upon request
from the Comptroller, Cold Spring Harbor Laboratory.
COLD SPRING HARBOR LABORATORY
SOURCES OF REVENUE
Year End December, 31, 1982
Federal Grants and Contracts
55.2%
Endowments
3.6%
Auxiliary Activities
19.3%
Non-Federal Grants Private Contributions
18.9% .5%
Interest and Miscellaneous
2.5%
GRANTS
January 1-December 31, 1982
NEW GRANTS
COLD SPRING HARBOR LABORATORY
Grantor
Principal Investigator
and Program Total Award
Duration
of Grant
National Institutes of Health Dr. Watson-General Research $ 104,822 4/1/82-3/31/83
Support
Dr. Watson-Summer Workshops 657,174 6/1/82-12/31/86
Dr. Brandsma-Fellowship 17,040
Dr. Flaster-Fellowship 34,776 9/15/82-8/14/84
Dr. Hockfield-Research 282,400 2/1/82-1/31/82
Dr. Krangel-Fellowship 55,156 10/1/82-9/30/85
Dr. Lin-Research 290,636 9/24/82-8/31/85
Dr. Silver-Research 625,803 2/1/82-1/31/85
Dr. So-Research 379,182 9/1/82-8/31/85
Dr. Taparowsky-Fellowship 55,156 10/16/82-10/15/85
Dr. Topp-Research 279,134 3/1/82-2/28/84
Dr. Welch-Fellowship 57,156 9/1/82-8/31/85
Dr. B. Zipser-Neurobiology 331,891 5/1/82-4/30/85
Course Support
Dr. B. Zipser-Neurobiology 473,925 4/1/82-3/31/87
Course Support
1982 Papilloma Virus Meeting 9,500 7/23/82-6/30/83
Dr. Broker
1982 RNA Processing Meeting 10,000 4/15/82-3/31/83
Dr. Matthews
1982 Heat Shock Meeting 8,000 4/15/82-3/31/83
Dr. Watson
National Science Foundation Dr. Bukhari-Research 60,000 7/1/82-6/30/83
Dr. Harshey-Research 115,000 1 /1 /82 -12/31 /83
Drs. Hicks/Malmberg/Strathern/ 165,682 7/1/82-6/30/83
Klar-Research
Dr. So-Research 217,000 7/1/82-6/30/85
Drs. Stillman/Tamanoi 88,000 7/1/82-6/30/84
1982 Herpes Virus Workshop 4,000 7/15/82-6/30/83
-Dr. Watson
1982 Symposium-Dr. Watson 5,000 6/1/82-5/31/83
1982 Heat Shock Induction 7,000 5/1/82-4/30/83
Conference-Dr. Watson
1982 In Vitro Mutagenesis 5,000 5/1/82-4/30/83
Meeting-Dr. Watson
1982 Phycomyces Meeting 2,000 6/1/82-5/31/83
-Dr. Watson
1982 Papilloma Virus Conference 3,000 7/15/82-12/31/82
-Dr. Broker
1982 RNA Processing Meeting 5,000 5/15/82-4/30/83
-Dr. Mathews
A.B.C. Foundation Dr. Wigler-Research 600,000 5/1/82-4/30/87
Abbott Laboratories 1982 Papilloma Virus 500
Meeting Support
1982 In Vitro Mutagenesis 500
Meeting Support
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NEW GRANTS
COLD SPRING HARBOR LABORATORY
American Cancer Society Dr. Chow-Research 150,000 1 /1 /82 -12/31 /83
Dr. Rossini-Research 110,000 1 /1 /82 -12/31 /83
Dr. Topp-lnstitutional 50,000 7/1/82-6/30/84
Applied Molecular Genetics 1982 Papilloma Virus 500
Meeting Support
1982 In Vitro Mutagenesis 1,000
Meeting Support
Biogen, Inc. 1982 Papilloma Virus 500
Meeting Support
Cell Biology Corporation Dr. Sambrook-Research 394,100 1 /1 /82 -12/31 /82
Dr. Topp-Research 53,646 6/1/82-12/31/82
Cetus Corporation 1982 Papilloma Virus 1,000
Meeting Support
1982 In Vitro Mutagenesis 1,000
Support
Jane Coffin Childs Dr. Sundin-Fellowship 32,000 7/1/82-6/30/84
Ciba-Geigy 1982 Papilloma Virus 500
Meeting Support
Columbia University Dr. Fiddes-Research Subcontract 20,000 1 /1 /82 -12/31 /82
Council for Tobacco 1982 Papilloma Virus 3,500
Research-USA Meeting Support
Department of Energy 1982 Symposium Support 9,000 9/15/82-8/31/83
Exxon Research 7,500,000 1/1/82-12/31/86
Foundation for Microbiology 1982 Phycomyces Meeting 5,000
Support
Genentech 1982 Papilloma Virus 500
Meeting Support
Esther A. and Joseph Year round neurobiology support 150,000 1982-1984
Klingenstein Fund
Leukemia Society of America, Dr. Kost-Fellowship 37,000 7/1/82-6/30/84
Inc.
Eli Lilly & Co. 1982 In Vitro Mutagenesis 500
Meeting Support
1982 Papilloma Virus 500
Meeting Support
Merck & Co. 1982 In Vitro Mutagenesis 1,000
Meeting Support
Monsanto-External Research 1982 Heat Shock Meeting 1,000
& Development Division Support
Agricultural Products 1982 Heat Shock Meeting 2,000
Co-Research Division Support
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NEW GRANTS
COLD SPRING HARBOR LABORATORY
New England Biolabs 1982 In Vitro Mutagenesis 2,000
Meeting Support
New England Nuclear 1982 In Vitro Mutagenesis 100
Meeting Support
Pfizer Inc. 1982 In Vitro Mutagenesis 5,000
Meeting Support
Schleicher & Schuell, Inc. 1982 In Vitro Mutagenesis 100
Meeting Support
Alfred P. Sloan Foundation Neurobiology Workshop Support 20,000 1/6/82-12/31/82
Smith Kline & French 1982 Phycomyces Meeting 500
Support
State University of New York,
Stony Brook
Dr. Topp-Research
Sub-contract
7,267 8/1/82-7/31/83
Stauffer Chemical Dr. Hicks-Research 15,000 1982
Damon Runyon-Walter Dr. Bhagwat-Fellowship 35,000 7/1/82-6/30/84
Winchell Cancer Fund Dr. Roth-Fellowship 35,000 9/1/82-8/31/84
BANBURY CENTER
Duration
Grantor Program Total Award of Grant
National Institutes of Health 1982 Recombinant DNA $ 18,200 9/22/82-8/31/83
Applications Meeting Support
1982 Conference on Biological 30,672 9/30/82-8/31/83
Aspects of Alzheimer's Disease
March of Dimes 1982 Recombinant DNA 15,000 7/1/82-12/31/82
Applications Meeting Support
Henry J. Kaiser
Family Foundation
1982 Gene Therapy Meeting
and Publication Support
60,000 1 /1 /82 -12/31 /82
Burroughs Wellcome Fund 1982 Recombinant DNA 15,000 1 /1 /82 -12/31 /82
Applications Meeting Support
American Petroleum Institute 1982 Genotoxic Indicators 12,500 1/1/82-12/31/82
Meeting Support
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CONTINUING GRANTS
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Grantor
National Institutes of Health
Principal Investigator
and Program
Dr. Watson-Gene Organization
Dr. Watson-General Research
Support
Dr. Watson-Summer Workshops
Dr. Watson-Symposium Support
Dr. Watson-Neurobiology
Course Support
Total Award
$ 5,626,997
104,513
470,340
187,433
258,500
Duration
of Grant
4/1/81-3/31/86
4/1/81-3/31/82
4/1/77-3/31/82
4/1/79-3/31/84
6/1/79-3/31/82
Mr. Udry-Cancer Research 1,411,011 9/15/77-indefinite
Facility
Dr. Albrecht-Buehler-Research 67,014 5/1/81-4/30/82
Dr. Blose-Research 326,982 12/1/81-11/30/84
Dr. Bukhari-Genetics Program 1,661,439 6/1/80-5/31/83
Project
Dr. Feramisco-Research 214,758 7/1/80-6/30/83
Dr. Garrels-Research 323,073 4/1/79-3/31/82
Drs. G ingeras/Roberts-Research 408,085 3/1/80-2/28/83
Dr. Grodzicker-Fellowship 852,578 7/1/78-6/30/83
Training
Dr. Hicks-Advanced Bacterial 97,081 4/1/80-3/31/83
Genetics Course
Dr. Hicks-Research 1,196,529 7/1/81-6/30/86
Dr. Ivy-Fellowship 38,776 1/27/82-1/26/84
Dr. Klar-Research 876,786 7/1/81-6/30/86
Dr. Kurtz-Research 179,542 4/1/80-3/31/83
Dr. Lemaster-Fellowship 34,681 6/1/81-2/15/83
Dr. Mathews-Research 266,570 4/1/80-3/31/83
Dr. McKay-Research 288,546 7/1/81-6/30/84
Dr. Sambrook-Cancer 18,604,426 1/1/82-12/31/86
Research Center
Dr. So-Research 124,370 9/1/80-8/31/82
Dr. Sorge-Fellowship 58,332 6/1/81-1/31/83
Dr. Topp-Research 303,452 7/1/80-6/30/83
Dr. Welch-Fellowship 57,156 9/14/82-9/13/85
Dr. B. Zipser-Research 299,219 12/1/81-11/30/84
National Science Foundation Dr. Bukhari-Research 330,000 6/15/79-5/30/82
Dr. Garrels-Research 140,000 9/1/80-8/31/82
Dr. Heffron-Research 147,000 2/15/81-1/31/83
Dr. Hicks-Research 99,600 5/15/81-4/30/84
Dr. Roberts-Research 345,000 8/15/80-7/31/83
Dr. Roberts-Research 210,000 12/15/79-11/30/82
Dr. Strathern-Equipment 64,845 5/15/81-4/30/82
Dr. B. Zipser-Neurobiology 60,000 7/1/79-12/31/82
Course Support
Dr. D. Zipser-Research 157,000 5/15/80-4/30/83
Dr. D. Zipser-Research 100,000 1 /1 /81 -12/31 /82
American Cancer Society Dr. Topp-Research 15,000 2/1 /81 -1 /31 /82
Rita Allen Foundation Dr. Hockfield-Research 30,000 7/1/81-6/30/82
Cystic Fibrosis Dr. Garrels-Research 87,230 7/1/80-6/30/82
Grass Foundation Dr. B. Zipser-Neurobiology 25,790 1980-1982
Scholarship
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CONTINUING GRANTS
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The Camille and Henry
Dreyfus Foundation
Dr. D. Zipser-1982 Under-
graduate Research Participation
20,000 1 /1 /82 -12/31 /82
Department of Energy 1981 Symposium Support 9,000 5/1/81-4/30/82
Esther A. and Joseph Dr. Watson-Neurobiology 60,000 5/1/79-4/30/82
Klingenstein Fund Course Support
1982 Advanced Neuro- 45,000
Anatomical Course and
Single-Channel Recording
Workshop
Leukemia Society of Dr. Engler-Fellowship 18,000 7/1/81-6/30/82
America, Inc.
Merck & Co. Dr. So-Research 5,000
Muscular Dystrophy Dr. Carrels- Research 40,000 1 /1 /81 -12/31 /82
Association Dr. Lin-Research 58,743 1/1 /81-12/31/83
Dr. Matsumura-Fellowship 36,000 1 /1 /81 -12/31 /83
Dr. Welch-Fellowship 32,000 1 /1 /81 -12/31 /82
New England Biolabs, Inc. Dr. Roberts-Research 14,000
Alfred P. Sloan Foundation Dr. D. Zipser-Computer 31,000 6/1/79-12/31/82
Workshop
Volkswagen Foundation Dr. Watson-Neurobiology 78,696 1980-1982
Scholarships
Whitehall Foundation Dr. B. Zipser-Research 135,000 10/1/80-9/30/83
Damon Runyon-Walter Dr. Abraham-Fellowship 35,000 8/1/81-7/31/83
Winchell Cancer Fund Dr. B. Anderson-Fellowship 25,250 10/1/80-3/31/82
Dr. Brandsma-Fellowship 35,000 9/1/81-8/31/83
Dr. GoLdfarb-Fellowship 35,000 10/1/80-9/30/82
Yamasa Shoyo Co., Ltd. Dr. Katoh-Research 94,480 10/1/81-9/30/83
BANBURY CENTER
Duration
Grantor Program Total Award of Grant
National Institutes of Health 1981 Gene Amplification 31,120 9/1/81-8/31/82
Conference
1981 Nitrosamines Conference 32,320 9/30/81-8/31/82
Environmental Protection 1981 Meeting on Response of the 50,000 9/1/81-8/31/82
Agency Developing Organism to
Environmental Risks
Alfred P. Sloan Foundation Public Information Workshops 100,000 1/1/80-12/31/82
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THE LONG ISLAND
BIOLOGICAL ASSOCIATION
THE LONG ISLAND BIOLOGICAL ASSOCIATION (LIBA)
and Its Relation to the Cold Spring Harbor Laboratory
Biological research at Cold Spring Harbor began in
1890 when the Brooklyn Institute of Arts and
Sciences was looking for a place to set up a summer
laboratory as the headquarters of its Department of
Zoology. Representatives of the Institute were in-
vited by Eugene S. Blackford, at that time the First
Commissioner of the State of New York, to inspect a
site on Bungtown Road across Northern Boulevard
(25A) from the Fish Hatchery. The site was found to
be ideal, and so the original Laboratory was
organized with Mr. Blackford as president of the
Board of Trustees. The land was leased from Mr.
John D. Jones, whose family since 1819 had
operated various industries including shipbuilding,
coopering, and textile manufacture hater whaling,
also) at the head of Cold Spring Harbor. Bungtown
Road, which runs through the Lab property, got its
name from the factory that specialized in making
bungs-or stoppers-for barrels.
In 1892 the Laboratory's land was leased for a
dollar a year from the Wawepex Society, which Mr.
Jones had organized as a corporation for holding
real estate and for investing funds for the propaga-
tion of fishes and for scientific research. In 1904 the
Wawepex Society leased additional land to the Car-
negie Institution of Washington, which wanted to
locate a Department of Experimental Evolution in
the Cold Spring Harbor area. Charles B. Davenport,
who had been directing the Laboratory since 1896,
assumed the additional duties of director of the
Carnegie Institution's experimental station. It is in-
teresting to note that Mr. Davenport lived in what
came to be known later as the Carnegie Dormitory,
the Victorian house on 25A built by John D. Jones
before the turn of the century, and recently re-
painted in its original colors.
The Long Island Biological Association was
established in 1924 when the Brooklyn Institute
decided to discontinue its research at Cold Spring
Harbor and offered its laboratory to two univer-
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sities. Fortunately, a local group of interested
neighbors decided to assume responsibility for the
Lab, and thus LIBA came into being. For 38 years
LIBA actually operated the Laboratory in conjunc-
tion with the Carnegie Institution, but in 1962 it
seemed advisable for the Laboratory to be reor-
ganized as an independent unit. Therefore, the
property on which it now stands was conveyed to it
by LIBA, which, however, still retains reversionary
rights. Today LIBA is one of twelve institutions par-
ticipating in the support of the Laboratory, each in-
stitution being represented on the Laboratory's
Board of Trustees.
What has happened, in effect, is that LIBA has
become an expanding group of local "Friends of the
Laboratory" who help support it through annual
contributions. Also, from time to time, the Associa-
tion undertakes campaigns to finance special impor-
tant projects for which the Lab cannot obtain funds
from the Federal Government or from other
sources. For instance, in 1974, LIBA made possible
building the James Laboratory Annex and the
renovation of Blackford Hall; and in 1976 the re-
building of Williams House.
The affairs of LIBA are handled by a board of 28
directors who are elected to office by the member-
ship at an annual meeting. At least twice a year LIBA
members are invited to bring their friends to a lec-
ture or an open house at the Lab.
Membership in LIBA requires a minimum an-
nual contribution (tax deductible) of $25 for a
husband and wife, $15 for a single adult, $5 for
a junior member (under 21). Further informa-
tion can be obtained from the Long Island
Biological Association, Box 100, Cold Spring
Harbor, N.Y. 11724, or by telephoning the
Laboratory's administrative director, Mr.
William R. Udry, at (516) 367-8300.
OFFICERS
Chairman
Vice-Chairman
Treasurer
Secretary
Asst. Secretary-Treasurer
EXECUTIVE COMMITTEE
The Officers, also
Mrs. Charles 0. Ames
Mrs. Henry U. Harris, Jr.
Mrs. Richardson Pratt
DIRECTORS
Mrs. Charles 0. Ames
Dr. Alfred A. Azzoni
Mrs. Gilbert A. Ball
Mr. Edmund Bartlett
Mr. Samuel R. Callaway
Mrs. John P. Campbell
Mr. David C. Clark
Mrs. Miner D. Crary, Jr.
Mr. Roderick H. Cushman
Mr. Norris W. Darrell, Jr.
Mr. Edward Pulling
Mr. George J. Hossfeld, Jr.
Mr. James A. Eisenman
Mrs. James J. Pirtle, Jr.
Mr. William R. Udry
Mr. Joseph C. Dey, Jr.
Mr. Charles Dolan
Mr. James A. Eisenman
Mr. Walter N. Frank, Jr.
Mr. Clarence E. Galston
Mr. Charles S. Gay
Mrs. Henry U. Harris, Jr.
Mr. George J. Hossfeld, Jr.
Mr. Grinnell Morris
Mr. William Parsons, Jr.
Mrs. James J. Pirtle, Jr.
Mrs. Richardson Pratt
Mr. Edward Pulling
Mr. John R. Reese
Mr. Stanley S. Trotman, Jr.
Mrs. Stephen Ulman
Dr. James D. Watson
Mrs. Alex M. White
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REPORT OF THE CHAIRMAN FOR 1982
The big event for LIBA in 1982 was the launching of
another major project, this time to raise $500,000
from our members over a two-year period to help
the Lab finance the construction of an urgently
needed new auditorium.
As stated in the appeal brochure, the Cold Spring
Harbor Laboratory has become the world center for
the exchange and distribution of information about
the latest discoveries in molecular biology. As the
number of molecular biologists from all over the
world who apply for participation in the Sym-
posium and other seminar meetings continues to in-
crease, the need for an auditorium large enough to
accommodate them has become increasingly ur-
gent. In 1982 eleven meetings were held attended
by 2,400 scientists from many countries.
Of special interest to LIBA members and to all
North Shore residents is the fact that the new
auditorium has been planned to make it suitable for
concerts, lectures and other appropriate community
functions during the off-season for Laboratory
meetings.
I am happy to report that the response to our ap-
peal has been very generous. As of February 15,
1983 we have already passed the halfway mark
toward our goal.
As usual, members and their guests were invited
to two lectures during the year. At the first, the an-
nual Dorcas Cummings Memorial Lecture, on May
9th, our speaker was Robert D. Ballard, of the
Woods Hole Oceanographic Institution. He
fascinated his audience by an account of explora-
tions on the ocean floor.
Then at the Annual Meeting, held on December
12th, we were addressed by Professor Bob Brier,
chairman of the Philosophy Department at C.W.
Post College. He pointed out ways in which ethical
dilemmas created by modern science can be
delineated and clarified for making moral decisions.
A lively question and answer period took place after
Professor Brier had concluded his lecture.
At the directors' meeting on April 4th an informal
talk was given by Jeff Strathern, a member of the
Laboratory's scientific staff, who explained the
Architect's sketch of new auditorium
298
technical and complicated process and the implica-
tions of his work on molecular genetics.
The custom of giving dinner parties during the
June Symposium for visiting scientists was suc-
cessfully continued in 1982. It is a custom enjoyed
equally by the scientists and by their hosts and
hostesses. This year's parties were given by
Mrs. Frank R. Berman
Mrs. J. Sedgwick Browne
Mr. and Mrs. Sidney M.G. Butler
Mr. and Mrs. Roderick H. Cushman
Mr. and Mrs. George W. Cutting, Jr.
Mr. and Mrs. Norris W. Darrell, Jr.
Mr. and Mrs. James A. Eisenman
Mrs. Mario A. Fog
Mr. and Mrs. Henry U. Harris, Jr.
Mr. and Mrs. George J. Hossfeld, Jr.
Mr. and Mrs. George N. Lindsay, Jr.
Mr. and Mrs. Angus P. McIntyre
Mr. and Mrs. Walter H. Page
Mr. and Mrs. James J. Pirtle, Jr.
Mrs. E.W. Taylor
Mr. and Mrs. Stanley S. Trotman, Jr.
Mr. and Mrs. Stephen Ulman
Mr. and Mrs. Robert P. Walton
Mrs. Ethelbert Warfield
Mr. and Mrs. R. Ray Weeks
Mr. and Mrs. Richard J. Weghorn
At the annual meeting regret was expressed that
the terms of office as directors for Messrs. J.A.
McCurdy II, Walter H. Page, Edward Everett Post,
and Richard J. Weghorn had terminated after eight
years of faithful service. Mr. Clarence E. Galston,
chairman of the Nominating Committee, placed in
nomination to fill the vacant places: Mrs. Gilbert A.
Ball, Mrs. John P. Campbell, Mr. Grinnell Morris,
and Mr. John R. Reese, who were then duly elected
to the Board.
Edward Pulling, Chairman
Long Island Biological Association
February 1, 1983
LIRA members tour Laboratory facilities at Annual Open House Dr. Jeffrey Strathern at Director's
Meeting
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MEMBERS
of the Long Island Biological Association
Mr. & Mrs. Thomas Ackerman
Mr. & Mrs. Amyas Ames
Mrs. Charles E. Ames
Mrs. Charles 0. Ames
Mr. & Mrs. Hoyt Ammidon
Drs. Harold & Shirley Andersen
Mr. Robert W. Anthony
Mr. & Mrs. J.S. Armentrout
Mrs. Donald Arthur
Dr. & Mrs. Joseph T. August
Mrs. Robert W. Ayer
Dr. & Mrs. Alfred Azzoni
Mr. Henry D. Babcock, Jr.
Mr. & Mrs. Benjamin H. Balkind
Mrs. Gilbert Ball
Miss Marion S. Bannard
Mrs. George C. Barclay
Dr. & Mrs. Henry H. Bard
Mrs. Lila Barnes
Mr. & Mrs. D.R. Barr
Mr. & Mrs. Edmund Bartlett
Mrs. Robert E. Belknap, Jr.
Dr. & Mrs. Stephen Belman
Miss Linda Bennetta
Dr. & Mrs. Alan Bernheimer
Mr. & Mrs. Loren C. Berry
Mr. & Mrs. R. Beuerlein
Mr. & Mrs. Nicholas Biddle, Jr.
Mr. & Mrs. William Binnian
Mr. F. Roberts Blair
Miss Mary Lenore Blair
Mr. & Mrs. Bache Bleecker
Mrs. Margery Blumenthal
Mr. & Mrs. Elito Bongarzone
Mr. & Mrs. A.L. Boorstein
Dr. & Mrs. George Bowen
Mr. & Mrs. William Braden
Dr. & Mrs. Arik Brissenden
Mrs. Horace Brock
Mr. F. Sedgwick Browne
Mr. & Mrs. G. Morgan Browne, Jr.
Mr. & Mrs. Frank Bruder
Mr. & Mrs. James Bryan, Jr.
Mr. & Mrs. Julian Buckley
Mr. & Mrs. Vincent Burns
Mrs. R.P. Burr
Mr. & Mrs. John Busby
Mr. & Mrs. Albert Bush-Brown
Mr. & Mrs. Sidney G. Butler
Mr. & Mrs. T.J. Calabrese, Jr.
Mr. & Mrs. S.R. Callaway
Mr. & Mrs. John P. Campbell
Mr. & Mrs. Ward C. Campbell
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Martha Worth Carder
Mr. & Mrs. John Carr
Mr. & Mrs. T.C. Cattrall, Jr.
Mr. & Mrs. Lionel Chaikin
Mr. & Mrs. Beverly C. Chew
Mr. & Mrs. Charles M. Clark
Mr. & Mrs. David C. Clark
Dr. & Mrs. Bayard Clarkson
Mr. & Mrs. Thomas N. Cochran
Dr. & Mrs. Peter Cohn
Mrs. C. Payson Coleman
Mr. & Mrs. Francis X. Coleman, Jr.
Mr. & Mrs. John H. Coleman
Mrs. John K. Colgate
Mr. & Mrs. Emilio G. Collado
Mr. Bradley Collins
Mr. & Mrs. Patrick Collins
Mrs. Ralph C. Colyer
Mr. & Mrs. Kingsley Colton
Dr. & Mrs. Crispin Cooke
Mr. & Mrs. Howard Corning, Jr.
Mr. Duncan B. Cox
Mr. & Mrs. Charles L. Craig
Mr. & Mrs. Miner D. Crary, Jr.
Mr. & Mrs. Arthur M. Crocker
Mr. & Mrs. Robert Cuddeback
Mr. Robert L. Cummings
Mr. Robert L. Cummings Ill
Mr. & Mrs. Richard T. Cunniff
Dr. & Mrs. Paul Cushman, Jr.
Mr. & Mrs. Roderick H. Cushman
Mr. & Mrs. George W. Cutting, Jr.
Mrs. Howard Dana
Mr. Theodore H. Danforth
Mr. & Mrs. Van Ness Darling
Mr. & Mrs. Norris Darrell, Jr.
Mr. & Mrs. A. George Dartt
Miss Katya Davey
Mr. & Mrs. Lawrence Davis
Mrs. F. Trubee Davison
Mr. & Mrs. Jay DeBow
Mr. & Mrs. Raymond DeClairville
Mr. & Mrs. Donald L. Deming
Mr. & Mrs. Douglas Despard, Jr.
Mr. & Mrs. Joseph C. Dey, Jr.
Mr. & Mrs. Charles Dolan
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